PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Do, H; Healey, JF; Waller, EK; Lollar, P				Do, H; Healey, JF; Waller, EK; Lollar, P			Expression of factor VIII by murine liver sinusoidal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; FULMINANT HEPATIC-FAILURE; PROCOAGULANT ANTIGEN; HEMOPHILIA-A; MESSENGER-RNA; FACTOR GENE; LOCALIZATION; SEQUENCE; TISSUES; MOUSE	Factor VIII (MTI) is the procoagulant plasma glycoprotein that is missing or decreased in hemophilia A. The cellular origin of fVIII synthesis is controversial. Liver transplantation cures hemophilia A, demonstrating that the liver is a major site of fVIII synthesis. We detected fVIII mRNA in purified populations of murine liver sinusoidal endothelial cells (LSECs) and hepatocytes, but not Kupffer cells. LSECs and hepatocytes contained comparable numbers of fVIII mRNA (40 and 70 transcripts per cell, respectively) by quantitative competitive reverse transcriptase-polymerase chain reaction analysis. There was not detectable mRNA for factor IX,a hepatocyte marker, in the LSEC preparation, nor was there detectable mRNA for von Willebrand factor, an endothelial cell marker, in the hepatocyte preparation. This excludes the possibility that detectable fVIII mRNA is due to cross-contamination in the hepatocyte or LSEC preparations, Primary cultures of LSECs were established in which fVIII mRNA levels were indistinguishable from purified LSECs, LSECs secreted active fVIII into the culture medium. This finding represents the first demonstration of homologous expression of fVIII mRNA and protein in cell culture and should facilitate studies of fVIII gene regulation. Additionally, LSECs potentially are targets for a fVIII transgene during gene therapy of hemophilia A.	Emory Univ, Div Hematol Oncol, Dept Med, Atlanta, GA 30322 USA	Emory University	Lollar, P (corresponding author), Emory Univ, Div Hematol Oncol, Dept Med, Rm 1003,Woodruff Mem Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.		Wilson, Matthew H/K-3193-2013; Waller, Edmund K/AAP-3055-2020		NHLBI NIH HHS [R01 HL40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM AL, 1979, CLIN HAEMATOL, V8, P53; BONTEMPO FA, 1987, BLOOD, V69, P1721; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; Cardier JE, 1997, HEPATOLOGY, V26, P165; CORNU P, 1963, BRIT J HAEMATOL, V9, P189, DOI 10.1111/j.1365-2141.1963.tb05457.x; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; ELDER B, 1993, GENOMICS, V16, P374, DOI 10.1006/geno.1993.1200; FIGUEIREDO MS, 1995, J BIOL CHEM, V270, P11828, DOI 10.1074/jbc.270.20.11828; FIORE L, 1990, HEPATOLOGY TXB LIVER, P546; HATHAWAY WE, 1969, TRANSPLANTATION, V7, P73; HELLMAN L, 1989, BRIT J HAEMATOL, V73, P348, DOI 10.1111/j.1365-2141.1989.tb07751.x; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KADHOM N, 1988, THROMB HAEMOSTASIS, V59, P289; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kaufman RJ, 1999, BLOOD, V93, P193, DOI 10.1182/blood.V93.1.193.401k43_193_197; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KELLY DA, 1984, BRIT J HAEMATOL, V56, P535, DOI 10.1111/j.1365-2141.1984.tb02178.x; Koene R A, 1977, Proc Eur Dial Transplant Assoc, V14, P401; Kuiper Johan, 1994, P791; LANGLEY PG, 1985, THROMB HAEMOSTASIS, V54, P693; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LIU DL, 1995, ARCH SURG-CHICAGO, V130, P33; LIU LX, 1994, TRANSPLANT INT, V7, P201, DOI 10.1111/j.1432-2277.1994.tb01291.x; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; MARCHIORO TL, 1969, SCIENCE, V163, P188, DOI 10.1126/science.163.3863.188; NICHOLS WC, 1994, BLOOD, V83, P3225; NORMAN JC, 1968, SURGERY, V64, P1; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; POWELL EE, 1992, J LIPID RES, V33, P609; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; SCHAFFNER F, 1985, BOCKUS GASTROENTEROL, P2625; SCHARRER I, 1988, LANCET, V2, P800; SHIMA M, 1988, BRIT J HAEMATOL, V70, P63, DOI 10.1111/j.1365-2141.1988.tb02435.x; STEL HV, 1983, NATURE, V303, P530, DOI 10.1038/303530a0; Stirling D, 1998, THROMB HAEMOSTASIS, V79, P74; STORB R, 1972, BLOOD-J HEMATOL, V40, P234, DOI 10.1182/blood.V40.2.234.234; VANDERKWAST TH, 1986, BLOOD, V67, P222; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEBSTER WP, 1971, AM J PHYSIOL, V220, P1147, DOI 10.1152/ajplegacy.1971.220.5.1147; WEBSTER WP, 1976, AM J PHYSIOL, V230, P1342, DOI 10.1152/ajplegacy.1976.230.5.1342; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; WU SM, 1990, GENE, V86, P275, DOI 10.1016/0378-1119(90)90290-8; Yamamoto K, 1998, BLOOD, V92, P2791, DOI 10.1182/blood.V92.8.2791.420k24_2791_2801; ZELECHOWSKA MG, 1985, NATURE, V317, P729, DOI 10.1038/317729a0	47	149	156	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19587	19592		10.1074/jbc.274.28.19587	http://dx.doi.org/10.1074/jbc.274.28.19587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391893	hybrid			2022-12-25	WOS:000081377300013
J	Huang, J; Kleinberg, ME				Huang, J; Kleinberg, ME			Activation of the phagocyte NADPH oxidase protein p47(phox) - Phosphorylation controls SH3 domain-dependent binding to p22(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; CELL-FREE SYSTEM; KINASE-C; FUNCTIONAL DOMAIN; SUBUNIT P47(PHOX); FLAVOCYTOCHROME B(558); COMPONENT P47(PHOX); IN-VITRO; P67(PHOX)	Activation of phagocyte NADPH oxidase requires interaction between p47(phox) and p22(phox), p47(phox);, resting phagocytes does not bind p22(phox). Phosphorylation of serines in the p47(phox) C terminus enables binding to the p22(phox) C terminus by inducing a conformational change in p47(phox) that unmasks the SH3(A) domain. We report that an arginine/lysine-rich region in the p47phox C terminus binds the p47(phox) SH3 domains expressed in tandem (SH3(AB)) but does not bind the individual N-terminal SH3(A) and C-terminal SH3(B) domains. Peptides matching amino acids 301-320 and 314-335 of the p47(phox) arginine/lysine-rich region block the p47(phox) SH3(AB)/p22(phox) C-terminal and p47(phox) SH3(AB)/p47(phox) C-terminal binding and inhibit NADPH oxidase activity in vitro, Peptides with phosphoserines substituted for serines 310 and 328 do not block binding and are poor inhibitors of oxidase activity. Mutated full-length p47(phox) with aspartic acid substitutions to mimic the effects of phosphorylations at serines 310 and 328 bind the p22(phox) proline-rich region in contrast to wild-type p47(phox), We conclude that the p47(phox) SH3(A) domain-binding site is blocked by an interaction between the p47(phox) SH3(AB) domains and the C-terminal arginine/lysine-rich region. Phosphorylation of serines in the p47(phox) C terminus disrupts this interaction leading to exposure of the SH3(A) domain, binding to p22(phox) and activation of the NADPH oxidase.	Univ Maryland, Sch Med, Vet Affairs Med Ctr, Res Serv, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore	Kleinberg, ME (corresponding author), Dept Vet Affairs Med Ctr, Res Serv, Rm 3B-183,10 N Greene St, Baltimore, MD 21201 USA.				NIAID NIH HHS [AI32220, AI40007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032220] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Faris SL, 1998, BIOCHEM BIOPH RES CO, V247, P271, DOI 10.1006/bbrc.1998.8775; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; Huang J, 1995, BIOCHEMISTRY-US, V34, P16753, DOI 10.1021/bi00051a024; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Labadia ME, 1996, J LEUKOCYTE BIOL, V59, P116, DOI 10.1002/jlb.59.1.116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MENARD L, 1993, BIOCHEMISTRY-US, V32, P13357, DOI 10.1021/bi00211a050; MILLER RA, 1995, J INVEST MED, V43, P39; Morozov I, 1998, J BIOL CHEM, V273, P15435, DOI 10.1074/jbc.273.25.15435; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; Park HS, 1998, BBA-PROTEIN STRUCT M, V1387, P406, DOI 10.1016/S0167-4838(98)00152-6; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; Park JW, 1997, J BIOL CHEM, V272, P11035; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; Wallach TM, 1996, BIOCHEM J, V320, P33, DOI 10.1042/bj3200033; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185	42	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19731	19737		10.1074/jbc.274.28.19731	http://dx.doi.org/10.1074/jbc.274.28.19731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391914	hybrid			2022-12-25	WOS:000081377300034
J	Sokal, I; Otto-Bruc, AE; Surgucheva, I; Verlinde, CLMJ; Wang, CK; Baehr, W; Palczewski, K				Sokal, I; Otto-Bruc, AE; Surgucheva, I; Verlinde, CLMJ; Wang, CK; Baehr, W; Palczewski, K			Conformational changes in guanylyl cyclase-activating protein 1 (GCAP1) and its tryptophan mutants as a function of calcium concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONE DYSTROPHY; RECOVERIN; CLONING; BINDING; VISION	Guanylyl cyclase-activating proteins (GCAPs are 23-kDa Ca2+-binding proteins belonging to the calmodulin superfamily, Ca2+-free GCAPs are responsible for activation of photoreceptor guanylyl cyclase during light adaptation. In this study, we characterized GCAP1 mutants in which three endogenous nonessential Trp residues were replaced by Phe residues, eliminating intrinsic fluorescence. Subsequently, hydrophobic amino acids adjacent to each of the three functional Ca2+-binding loops were replaced by reporter Trp residues. Using fluorescence spectroscopy and biochemical assays, we found that binding of Ca2+ to GCAP1 causes a major conformational change especially in the region around the EF3-hand motif, This transition of GCAP1 from an activator to an inhibitor of Ge requires an activation energy E-a = 9.3 kcal/mol, When Tyr(99) adjacent to the EF3-hand motif was replaced by Cys, a mutation linked to autosomal dominant cone dystrophy in humans, Cys(99) is unable to stabilize the inactive GCAP1-Ca2+ complex. Stopped-flow kinetic measurements indicated that GCAP1 rapidly loses its bound Ca2+ (k(-1) = 72 s(-1) at 37 degrees C) and was estimated to associate with Ca2+ at a rate (k(1) > 2 x 10(8) M-1 s(-1)) close to the diffusion limit, Thus, GCAP1 displays thermodynamic and kinetic properties that are compatible with its involvement early in the phototransduction response.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	VERLINDE, CHRISTOPHE LMJ/J-5796-2013	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203	NEI NIH HHS [EY08061, EY08123] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008123, R01EY008061, R29EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; NICKOLDS CE, 1972, P NATL ACAD SCI USA, V69, P581, DOI 10.1073/pnas.69.3.581; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Parker C. A., 1968, PHOTLUMINESCENCE SOL; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WANG CK, 1992, BIOCHEMISTRY-US, V31, P4289, DOI 10.1021/bi00132a020	31	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19829	19837		10.1074/jbc.274.28.19829	http://dx.doi.org/10.1074/jbc.274.28.19829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391927	hybrid			2022-12-25	WOS:000081377300047
J	Dublet, B; Vernet, T; van der Rest, M				Dublet, B; Vernet, T; van der Rest, M			Schmid's metaphyseal chondrodysplasia mutations interfere with folding of the C-terminal domain of human collagen X expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLOBULAR DOMAIN; ALPHA-1(X) NC1; IN-VITRO; GENE; PROCOLLAGEN; COMPLEMENT; CARTILAGE; C1Q; SEQUENCE	Human collagen X contains a highly conserved 161-amino acid C-terminal non-triple helical domain that is homologous to the C-terminal domain of collagen VIII and to the Clq module of the human C1 enzyme. We have expressed this domain (residues 545-680) in Escherichia coli as a glutathione S-transferase fusion protein, The purified fusion protein trimerizes spontaneously in vitro, and after thrombin cleavage, the purified C-terminal domain trimer (46.2 kDa) is extremely stable and trypsin-resistant. Mutations within the C terminal domain have been observed in patients with Schmid's metaphyseal chondrodysplasia (SMCD), Some of these mutations (Y598D, G618V, W651X, or H669X; X is the stop codon) were constructed by site directed mutagenesis. Each mutation had identical consequences regarding the fusion protein: 1) absence of trimeric formation, 2) copurification of the similar to 60-kDa GroEL chaperone protein, and 3) sensitivity of the monomeric fusion protein to trypsin digestion. These results show that the C-terminal domain of collagen X is sufficient to produce a very stable and compact trimer in the absence of collagen Gly-X-Y repeats. Moreover, mutations causing SMCD interfere in this system with the correct folding of the C-terminal domain. The existence of a similar mechanism in chondrocytes might explain the relative homogeneity of phenotypes in SMCD despite the diversity of mutations.	Inst Biol Struct Jean Pierre Ebel, Lab Ingenierie Macromol, CEA, CNRS,UPR 9015, F-38027 Grenoble 01, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dublet, B (corresponding author), Inst Biol Struct Jean Pierre Ebel, Lab Ingenierie Macromol, CEA, CNRS,UPR 9015, 41 Rue Jules Horowitz, F-38027 Grenoble 01, France.	dublet@ibs.fr	Vernet, Thierry/G-1118-2012					APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Chan D, 1998, MATRIX BIOL, V17, P169, DOI 10.1016/S0945-053X(98)90056-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; DAVIS JG, 1995, SCIENCE, V267, P1031, DOI 10.1126/science.7863331; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GRANT WT, 1985, J BIOL CHEM, V260, P3798; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Hegyi H, 1997, J PROTEIN CHEM, V16, P545, DOI 10.1023/A:1026382032119; HOYLAND JA, 1991, BONE MINER, V15, P151, DOI 10.1016/0169-6009(91)90005-K; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KAVETY B, 1994, MOL BRAIN RES, V27, P152, DOI 10.1016/0169-328X(94)90196-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTOSH I, 1994, HUM MOL GENET, V3, P303, DOI 10.1093/hmg/3.2.303; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; VANDERMARK K, 1992, ARTHRITIS RHEUM, V35, P806; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508	35	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18909	18915		10.1074/jbc.274.27.18909	http://dx.doi.org/10.1074/jbc.274.27.18909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383388	hybrid			2022-12-25	WOS:000081196300011
J	Befort, K; Zilliox, C; Filliol, D; Yue, SY; Kieffer, BL				Befort, K; Zilliox, C; Filliol, D; Yue, SY; Kieffer, BL			Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; 3RD INTRACELLULAR LOOP; TERNARY COMPLEX MODEL; GAMMA-S BINDING; SIGNAL-TRANSDUCTION; BETA(2)-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR; LIGAND RECOGNITION; ADENOSINE RECEPTOR	We have investigated whether transmembrane amino acid residues Asp(128) (domain III), Tyr(129) (domain II), and Tyr(308) (domain VII) in the mouse delta opioid receptor play a role in receptor activation. To do so, we have used a [S-35]GTP gamma S (where GTP gamma S is guanosine 5'-3-O-(thio)triphosphate) binding assay to quantify the activation of recombinant receptors transiently expressed in COS cells and compared functional responses of D128N, D128A, Y129F, Y129A, and Y308F point-mutated receptors to that of the wild-type receptor. In the absence of ligand, [S-35]GTP gamma S binding was increased for every mutant receptor under study (1.6-2.6-fold), suggesting that all mutations are able to enhance constitutive activity at the receptor. In support of this finding, the inverse agonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu (where Aib represents cu-aminobutyric acid) efficiently reduced basal [S-35]GTP gamma S binding in the mutated receptor preparations. The potent agonist BW373U86 stimulated [S-35]GTP gamma S binding above basal levels with similar (D128N, Y129F, and Y129A) or markedly increased (Y308F) efficacy compared with wildtype receptor. BW373U86 potency was maintained or increased, In conclusion, our results demonstrate that the mutations under study increase functional activity of the receptor. Three-dimensional modeling suggests that Asp(128) (III), and Tyr(308) (VII) interact with each other and that Tyr(129) (III) undergoes H bonding with His(278) (VI). Thus, Asp(128), Tyr(129), and Tyr(308) may be involved in a network of interhelical bonds, which contributes to maintain the delta receptor under an inactive conformation. We suggest that the mutations weaken helix-helix interactions and generate a receptor state that favors the active conformation and/or interacts with heterotrimeric G proteins more effectively.	ESBS, CNRS, URR 9050, F-67400 Illkirch Graffenstaden, France; Astra Res Ctr Montreal, Dept Chem, Montreal, PQ H4S 1Z9, Canada; Astra Res Ctr Montreal, Dept Mol Biol, Montreal, PQ H4S 1Z9, Canada	Centre National de la Recherche Scientifique (CNRS)	Kieffer, BL (corresponding author), ESBS, CNRS, URR 9050, Parc Innovat,Blvd S Brandt, F-67400 Illkirch Graffenstaden, France.							Alkorta I, 1996, PROTEIN ENG, V9, P573, DOI 10.1093/protein/9.7.573; Befort K, 1996, NEUROCHEM RES, V21, P1301, DOI 10.1007/BF02532371; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; Befort K, 1996, MOL PHARMACOL, V49, P216; CHILDERS SR, 1993, MOL PHARMACOL, V44, P827; CHILDERS SR, 1993, HDB EXPT PHARM, V104, P189; Chiu TT, 1996, MOL PHARMACOL, V50, P1651; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COTTON R, 1984, EUR J PHARMACOL, V97, P331, DOI 10.1016/0014-2999(84)90470-9; Cox B.M., 1993, HDB EXPT PHARM, V104, P145, DOI [10.1007/978-3-642-77460-7_8, DOI 10.1007/978-3-642-77460-7_8]; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Dondio G, 1997, BIOORG MED CHEM LETT, V7, P2967, DOI 10.1016/S0960-894X(97)10119-6; Fong TM, 1996, CELL SIGNAL, V8, P217; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HabibiNezhad B, 1996, J MOL MODEL, V2, P362, DOI 10.1007/s0089460020362; Jin JG, 1997, BRIT J PHARMACOL, V121, P317, DOI 10.1038/sj.bjp.0701121; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KIM JH, 1995, J BIOL CHEM, V270, P13987, DOI 10.1074/jbc.270.23.13987; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MARIE J, 1994, J BIOL CHEM, V269, P20815; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NORTH RA, 1993, HDB EXP PHARM, V104, P773; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Perez DM, 1996, MOL PHARMACOL, V49, P112; Poda G, 1998, LETT PEPT SCI, V5, P193, DOI 10.1023/A:1008826904230; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Strahs D, 1997, PROTEIN ENG, V10, P1019, DOI 10.1093/protein/10.9.1019; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; YUE SY, 1997, J MOL GRAPH MODEL, V15, P403; Zhorov BS, 1998, J BIOMOL STRUCT DYN, V15, P631, DOI 10.1080/07391102.1998.10508980; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; Zuscik MJ, 1998, J BIOL CHEM, V273, P3401, DOI 10.1074/jbc.273.6.3401	56	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18574	18581		10.1074/jbc.274.26.18574	http://dx.doi.org/10.1074/jbc.274.26.18574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373467	Green Published, hybrid			2022-12-25	WOS:000081056700059
J	Fujikawa, K; Kamiya, H; Yakushiji, H; Fujii, Y; Nakabeppu, Y; Kasai, H				Fujikawa, K; Kamiya, H; Yakushiji, H; Fujii, Y; Nakabeppu, Y; Kasai, H			The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED NUCLEOTIDES; HUMAN MTH1 PROTEIN; ESCHERICHIA-COLI; DEGENERATIVE DISEASES; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; 8-OXO-DGTPASE; TAUTOMERISM; HYDROLYZES; EXPRESSION	The possibility that Escherichia coli MutT and human MTH1 (hMTH1) hydrolyze oxidized DNA precursors other than 8-hydroxy-dGTP (8-OH-dGTP) was investigated. We report here that hMTH1 hydrolyzed 2-hydroxy-dATP (2-OH-dATP) and 8-hydroxy-dATP (8-OH-dATP), oxidized forms of dATP, but not (R)-8,5'-cyclod-dATP, 5-hydroxy-dCTP, and 8-formyl-dUTP. The kinetic parameters indicated that 2-OH-dATP was hydrolyzed more efficiently and with higher affinity than 8-OH-dGTP. 8-OH-dATP was hydrolyzed as efficiently as 8-OH-dGTP. The preferential hydrolysis of 2-OH-dATP over 8-OH-dGTP was observed at all of the pH values tested (pH 7.2 to pH 8.8). In particular, a 5-fold difference in the hydrolysis efficiencies for 2-OH-dATP over 8-OH-dGTP was found at pH 7.2. However, E. coli MutT had no hydrolysis activity for either 2-OH-dATP or 8-OH-dATP. Thus, E. coli MutT is an imperfect counterpart for hMTH1. Furthermore, we found that 2-hydroxy-dADP and 8-hydroxy-dGDP competitively inhibited both the 8-OH-dATP hydrolase and 8-OH-dGTP hydrolase activities of hMTH1. The inhibitory effects of 2-hydroxy-dADP were S-fold stronger than those of 8-hydroxy-dGDP, These results suggest that the three damaged nucleotides share the same recognition site of hMTH1 and that it is a more important sanitization enzyme than expected thus far.	Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Biochem, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Japan Science & Technology Agency (JST); Kyushu University	Kasai, H (corresponding author), Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.		Kamiya, Hiroyuki/G-2383-2019; Nakabeppu, Yusaku/A-8902-2011	Kamiya, Hiroyuki/0000-0001-6866-5322; Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bialkowski K, 1998, NUCLEIC ACIDS RES, V26, P3194, DOI 10.1093/nar/26.13.3194; Cai JP, 1997, NUCLEIC ACIDS RES, V25, P1170, DOI 10.1093/nar/25.6.1170; CHENG KC, 1992, J BIOL CHEM, V267, P166; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Inoue M, 1998, J BIOL CHEM, V273, P11069, DOI 10.1074/jbc.273.18.11069; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; LEONARD GA, 1992, BIOCHEMISTRY-US, V31, P8415, DOI 10.1021/bi00151a004; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MurataKamiya N, 1997, J RADIAT RES, V38, P121, DOI 10.1269/jrr.38.121; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Saenger W., 1988, PRINCIPLES NUCL ACID; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SEELA F, 1992, HELV CHIM ACTA, V75, P2298, DOI 10.1002/hlca.19920750716; SEELA F, 1995, HELV CHIM ACTA, V78, P1843, DOI 10.1002/hlca.19950780718; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; UESUGI S, 1977, J AM CHEM SOC, V99, P2313, DOI 10.1021/ja00449a049; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	28	191	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18201	18205		10.1074/jbc.274.26.18201	http://dx.doi.org/10.1074/jbc.274.26.18201			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373420	hybrid			2022-12-25	WOS:000081056700012
J	Wakasugi, M; Sancar, A				Wakasugi, M; Sancar, A			Order of assembly of human DNA repair excision nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; ULTRAVIOLET-DAMAGED DNA; ANTICANCER DRUG CISPLATIN; HUMAN MISMATCH REPAIR; GROUP-C PROTEIN; BINDING-PROTEIN; PREFERENTIAL BINDING; TRANSCRIPTION FACTOR; PYRIMIDINE DIMERS; XPG PROTEIN	Human excision nuclease removes DNA damage by concerted dual incisions bracketing the lesion. The dual incisions are accomplished by sequential and partly overlapping actions of six repair factors, RPA, XPA, XPC, TFIIH, XPG, and XPF.ERCC1. Of these, RPA, XPA, and XPC have specific binding affinity for damaged DNA, To learn about the role of these three proteins in damage recognition and the order of assembly of the excision nuclease, we measured the binding affinities of XPA, RPA, and XPC to a DNA fragment containing a single (6-4) photoproduct and determined the rate of damage excision under a variety of reaction conditions. We found that XPC has the highest affinity to DNA and that RPA has the highest selectivity for damaged DNA. Under experimental conditions conducive to binding of either XPA + RPA or XPC to damaged DNA, the rate of damage removal was about 5-fold faster for reactions in which XPA + RPA was the first damage recognition factor presented to DNA compared with reactions in which XPC was the first protein that had the opportunity to bind to DNA, We conclude that RPA and XPA are the initial damage sensing factors of human excision nuclease.	Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Sch Med, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.		Wakasugi, Mitsuo/D-8417-2015	Wakasugi, Mitsuo/0000-0001-9593-0566	NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASASHINA H, 1994, MUTAT RES, V315, P229; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Coin F, 1998, MOL CELL BIOL, V18, P3907, DOI 10.1128/MCB.18.7.3907; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; GUNTZ D, 1996, J BIOL CHEM, V271, P25089; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MATSUTANI C, 1996, MOL CELL BIOL, V17, P6915; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Rodriguez K, 1998, J BIOL CHEM, V273, P34180, DOI 10.1074/jbc.273.51.34180; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V93, P6443; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	56	170	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18759	18768		10.1074/jbc.274.26.18759	http://dx.doi.org/10.1074/jbc.274.26.18759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373492	Green Published, hybrid			2022-12-25	WOS:000081056700084
J	Corrette-Bennett, SE; Parker, BO; Mohlman, NL; Lahue, RS				Corrette-Bennett, SE; Parker, BO; Mohlman, NL; Lahue, RS			Correction of large mispaired DNA loops by extracts of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-DIRECTED REPAIR; SMALL HETEROLOGOUS SEQUENCES; SINGLE-STRANDED LOOPS; SIMPLE REPETITIVE DNA; BASE-PAIR MISMATCHES; HETERODUPLEX DNA; MAMMALIAN-CELLS; ESCHERICHIA-COLI; GENE CONVERSION; MEIOTIC RECOMBINATION	Single base mispairs and small loops are corrected by DNA mismatch repair, but little is known about the corrrection of large loops. In this paper, large loop repair was examined in nuclear extracts of yeast, Biochemical assays showed that repair activity occurred on loops of 16, 27, and 216 bases, whereas a G-T mispair and an 8-base loop were poorly corrected under these conditions. Two modes of loop repair were revealed by comparison of heteroduplexes that contained a site-specific nick or were covalently closed. A nick-stimulated repair mode directs correction to the discontinuous strand, regardless of which strand contains the leap. An alternative mode is nick-independent and preferentially removes the loop. Both outcomes of repair were largely eliminated when DNA replication was inhibited, suggesting a requirement for repair synthesis. Excision tracts of 100-200 nucleotides, spanning the position of the loop, were observed on each strand under conditions of limited DNA repair synthesis. Both repair modes were independent of the mismatch correction genes 2MSH2, MSH3, MLH1, and PMS1, as judged by activity in mutant extracts. Together the loop specificity and mutant results furnish evidence for a large loop repair pathway in yeast that is distinct from mismatch repair.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Lahue, RS (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,600 S 42nd St, Omaha, NE 68198 USA.	rlahue@unmc.edu		Lahue, Robert/0000-0002-8870-5616	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018922] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727] Funding Source: Medline; NIGMS NIH HHS [GM18922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BOLLAG RJ, 1992, MOL CELL BIOL, V12, P1546, DOI 10.1128/MCB.12.4.1546; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 1999, METH MOL B, V113, P121; CROUSE GF, 1996, DNA DAMAGE REPAIR, V1, P411; DENG WP, 1994, MOL CELL BIOL, V14, P400, DOI 10.1128/MCB.14.1.400; DETLOFF P, 1992, MOL CELL BIOL, V12, P1805, DOI 10.1128/MCB.12.4.1805; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FINK GR, 1974, GENETICS, V77, P231; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; GASC AM, 1987, MOL GEN GENET, V210, P369, DOI 10.1007/BF00325708; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Luhr B, 1998, MOL GEN GENET, V257, P362, DOI 10.1007/s004380050658; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1991, GENETICS, V129, P669; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROSE MD, 1988, METHODS YEAST GENETI; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; Taghian DG, 1998, GENETICS, V148, P1257; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1996, GENETICS, V143, P1579; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17605	17611		10.1074/jbc.274.25.17605	http://dx.doi.org/10.1074/jbc.274.25.17605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364197	hybrid			2022-12-25	WOS:000080974300033
J	Jayaraman, G; Kumar, TKS; Yu, C				Jayaraman, G; Kumar, TKS; Yu, C			Binding of nucleotide triphosphates to cardiotoxin analogue II from the Taiwan cobra venom (Naja naja atra) - Elucidation of the structural interactions in the dATP-cardiotoxin analogue II complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHEMICAL MODIFICATION; NMR; DYNAMICS; SPECTROSCOPY; INHIBITION; RESIDUES; MOTIFS; CHAIN	Snake venom cardiotoxins have been recently shown to block the enzymatic activity of phospholipid protein kinase and Na+,K+-ATPase. To understand the molecular basis for the inhibitory effects of cardiotoxin on the action of these enzymes, the nucleotide triphosphate binding ability of cardiotoxin analogue II (CTX II) from the Taiwan cobra (Naja naja atra) venom is investigated using a variety of spectroscopic techniques such as fluorescence, circular dichroism, and two-dimensional NMR. CTX II is found to bind to all the four nucleotide triphosphates (ATP, UTP, GTP, and CTP) with similar affinity, Detailed studies of the binding of dATP to CTX II indicated that the toxin molecule is significantly stabilized in the presence of the nucleotide, Molecular modeling, based on the NOEs observed for the dATP.CTX II complex, reveals that dATP binds to the CTX II molecule at the groove enclosed between the Nand C-terminal ends of the toxin molecule. Based on the results obtained in the present study, a molecular mechanism to account for the inhibition of the enzymatic activity of the phospholipid-sensitive protein kinase and Na+,K+-ATPase is also proposed.	Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan	National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan.		Jayaraman, G./AAA-6219-2019; Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Jayaraman, G./0000-0001-5729-2719; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BHASKARAN R, 1994, J BIOL CHEM, V269, P23500; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHIOU SH, 1993, BIOCHEMISTRY-US, V32, P2062, DOI 10.1021/bi00059a025; DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321; GARIN J, 1988, FEBS LETT, V242, P172; GRISHAM CM, 1988, METHOD ENZYMOL, V156, P353; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; Jang JY, 1997, BIOCHEMISTRY-US, V36, P14635, DOI 10.1021/bi971107a; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kobayashi N, 1997, NAT STRUCT BIOL, V4, P6, DOI 10.1038/nsb0197-6; Kumar TKS, 1997, J BIOMOL STRUCT DYN, V15, P431, DOI 10.1080/07391102.1997.10508957; Kumar TKS, 1998, J TOXICOL-TOXIN REV, V17, P183, DOI 10.3109/15569549809009249; KUMAR TKS, 1996, NAT TOXINS, P114; KUMAR TKS, 1999, P NATL SCI COUNC ROC, V23, P1; KUO JF, 1983, FEBS LETT, V153, P183, DOI 10.1016/0014-5793(83)80144-6; Lee CS, 1998, BIOCHEMISTRY-US, V37, P155, DOI 10.1021/bi971979c; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; ROUMESTAND C, 1994, J MOL BIOL, V243, P719, DOI 10.1016/0022-2836(94)90043-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHIAU SYL, 1976, J PHARMACOL EXP THER, V196, P758; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Ubbink M, 1997, BIOCHEMISTRY-US, V36, P6326, DOI 10.1021/bi963199u; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG CC, 1981, TOXICON, V19, P645, DOI 10.1016/0041-0101(81)90102-1	29	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17869	17875		10.1074/jbc.274.25.17869	http://dx.doi.org/10.1074/jbc.274.25.17869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364232	hybrid			2022-12-25	WOS:000080974300068
J	Li, B; Holloszy, JO; Semenkovich, CF				Li, B; Holloszy, JO; Semenkovich, CF			Respiratory uncoupling induces delta-aminolevulinate synthase expression through a nuclear respiratory factor-1-dependent mechanism in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSCRIPTION FACTOR; DNA-BINDING PROTEIN; SKELETAL-MUSCLE; GENE; NRF-1; RAT; ACTIVATION; EXERCISE; PHOSPHORYLATION; INITIATION	Nuclear respiratory factor (NRF)-1 appears to be important for the expression of several respiratory genes, but there is no direct evidence that NRF-1 transduces a physiological signal into the production of an enzyme critical for mitochondrial biogenesis. We generated HeLa cells containing plasmids allowing doxycycline-inducible expression of uncoupling protein (UCP)-1. In the absence of doxycycline, UCP-1 mRNA and protein were undetectable. In the presence of doxycycline, UCP-1 was expressed and oxygen consumption doubled. This rise in oxygen consumption was associated with an increase in NRF-1 mRNA. It was also associated with an increase in NRF-1 protein binding activity as determined by electrophoretic mobility shift assay using a functional NRF-1 binding site from the delta-aminolevulinate (ALA) synthase promoter, Respiratory uncoupling also caused a time-dependent increase in protein levels of ALA synthase, an early marker for mitochondrial biogenesis. ALA synthase induction by respiratory uncoupling was prevented by transfecting cells with an oligonucleotide antisense to the region of the NRF-1 initiation codon; a scrambled oligonucleotide with the same base composition had no effect. Respiratory uncoupling increases oxygen consumption and lowers energy reserves. In HeLa cells, uncoupling also increases ALA synthase, an enzyme critical for mitochondrial respiration, but only if translatable mRNA for NRF-1 is available. These data suggest that the transcription factor NRF-1 plays a key role in cellular adaptation to energy demands by translating physiological signals into an increased capacity for generating energy.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8046, St Louis, MO 63110 USA.	semenkov@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R37AG000425, R56AG000425] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG00425] Funding Source: Medline; NIDDK NIH HHS [DK53198] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESSIG DA, 1990, AM J PHYSIOL, V259, pC310, DOI 10.1152/ajpcell.1990.259.2.C310; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; HAYASHI N, 1980, J BIOCHEM-TOKYO, V88, P921, DOI 10.1093/oxfordjournals.jbchem.a133079; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; KAPPAS A, 1989, METABOLIC BASIS INHE, V6, P1305; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LEE YP, 1965, J BIOL CHEM, V240, P1427; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; MAY BK, 1986, CURR TOP CELL REGUL, V28, P233; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Murakami T, 1998, BBA-GEN SUBJECTS, V1381, P113, DOI 10.1016/S0304-4165(98)00018-X; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Quaggin SE, 1997, J CLIN INVEST, V99, P718, DOI 10.1172/JCI119216; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	35	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17534	17540		10.1074/jbc.274.25.17534	http://dx.doi.org/10.1074/jbc.274.25.17534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364186	hybrid			2022-12-25	WOS:000080974300022
J	Saleh, A; Srinivasula, SM; Acharya, S; Fishel, R; Alnemri, ES				Saleh, A; Srinivasula, SM; Acharya, S; Fishel, R; Alnemri, ES			Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASES; APOPTOSIS; DEATH; CED-4	To elucidate the mechanism of activation of procaspase-9 by Apaf-1, we produced recombinant full-length Apaf-1 and purified it to complete homogeneity, Here we show using gel filtration that full-length Apaf-1 exists as a monomer that can be transformed to an oligomeric complex made of at least eight subunits after binding to cytochrome c and dATP, Apaf-1 binds to cytochrome c in the absence of dATP but does not form the oligomeric complex. However, when dATP is added to the cytochrome c-bound Apaf-1 complex, complete oligomerization occurs, suggesting that oligomerization is driven by hydrolysis of dATP, This was supported by the observation that ATP, but not the nonhydrolyzable adenosine 5'-O-(thiotriphosphate), can induce oligomerization of the Apaf-1-cytochrome c complex. Like the spontaneously oligomerizing Apaf-530, which lacks its WD-40 domain, the oligomeric full-length Apaf-1-cytochrome c complex can bind and process procaspase-9 in the absence of additional dATP or cytochrome c, However, unlike the truncated Apaf-530 compiler, the full-length Apaf-1 complex can release the mature caspase-9 after processing. Once released, mature caspase-9 can process procaspase-3, setting into motion the caspase cascade. These observations indicate that cytochrome c and dATP are required for oligomerization of Apaf-1 and suggest that the WD-40 domain plays an important role in oligomerization of full-length Apaf-1 and the release of mature caspase-9 from the Apaf-1 oligomeric complex.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, 904 Bluemle Life Sci Bldg,233 S 10th, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010	Saleh, Ayman M/0000-0003-1126-6018	NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	16	398	427	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17941	17945		10.1074/jbc.274.25.17941	http://dx.doi.org/10.1074/jbc.274.25.17941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364241	hybrid			2022-12-25	WOS:000080974300077
J	Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K				Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K			BAG-1 accelerates cell motility of human gastric cancer cells	ONCOGENE			English	Article						BAG-1; gastric adenocarcinoma; cell migration; membrane ruffles; cytoskeleton	HEAT-SHOCK PROTEINS; INTERMEDIATE FILAMENTS; INDUCED APOPTOSIS; MELANOMA-CELLS; DEATH ACTIVITY; HGF RECEPTOR; EXPRESSION; VIMENTIN; COEXPRESSION; ASSOCIATION	BAG-1 is a Hsp70/Hsc70-binding protein that interacts with Bcl-2, Raf-1, steroid hormone receptors, Siah-1, and hepatocyte growth factor (HGF) receptors, implying multiple functions for the BAG-1 protein, Here, we provide evidence that gene transfer-mediated overexpression of BAG-1 markedly enhances the motility of human gastric cancer cells, Two independent in vitro migration assays showed that the BAG-1-expressing MKN74 cells exhibited more active migration compared with control transfectants or parent MKN74 cells, In MKN74 cells, the overexpression of BAG-1 affected neither cell adhesion capability nor migration responses to HGF, The promotive effect of BAG-1 on cell migration was similarly observed in transfectants of another human gastric cancer MKN45 cell line, In BAG-1 transfected gastric cancer MKN74 cells, BAG-1 colocalized with cytokeratin as well as actin filaments, and was concentrated at membrane ruffles induced by lysophosphatidic acid (LPA), Taken together, these studies demonstrate that BAG-1 has a novel function as promoter of cell migration in human gastric cancer cells, possibly through cooperation with cytoskeletal proteins.	Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Pathol, Inst Canc Res, Sapporo, Hokkaido 0608543, Japan; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sapporo Medical University; Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Chu YW, 1996, AM J PATHOL, V148, P63; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; Hohfeld J, 1998, BIOL CHEM, V379, P269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SHARON LS, 1998, CELL DEATH DIFFER, V5, P372; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUART J, 1998, IN PRESS J BIOL CHEM; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1998, IN PRESS CANC RES; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; [No title captured]	34	45	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3244	3251		10.1038/sj.onc.1202661	http://dx.doi.org/10.1038/sj.onc.1202661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359530				2022-12-25	WOS:000080523800007
J	Ventura, S; Villegas, V; Sterner, J; Larson, J; Vendrell, J; Hershberger, CL; Aviles, FX				Ventura, S; Villegas, V; Sterner, J; Larson, J; Vendrell, J; Hershberger, CL; Aviles, FX			Mapping the pro-region of carboxypeptidase B by protein engineering - Cloning, overexpression, and mutagenesis of the porcine proenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROCARBOXYPEPTIDASE A2; ACTIVATION PATHWAY; 3-DIMENSIONAL STRUCTURE; FOLDING PROCESS; INHIBITION; DOMAIN; TRANSITION; MECHANISM; CHAPERONE; ZYMOGEN	The proteolytic processing of pancreatic procarboxypeptidase B to a mature and functional enzyme is much faster than that of procarboxypeptidase A1. This different behavior has been proposed to depend on specific conformational features at the region that connects the globular domain of the pro-segment to the enzyme and at the contacting surfaces on both moieties, A cDNA coding for porcine procarboxypeptidase B was cloned, sequenced, and expressed at high yield (250 mg/liter) in the methylotrophic yeast Pichia pastoris, To test the previous hypothesis, different mutants of the pro-segment at the putative tryptic targets in its connecting region and at some of the residues contacting the active enzyme were obtained. Moreover, the complete connecting region was replaced by the homologous sequence in procarboxypeptidase A1. The detailed study of the tryptic processing of the mutants shows that limited proteolysis of procarboxypeptidase B is a very specific process, as Arg-SS is the only residue accessible to tryptic attach in the proenzyme, A fast destabilization of the connecting region after the first tryptic cut allows subsequent proteolytic processing and the expression of carboxypeptidase B activity. Although all pancreatic procarboxypeptidases have a preformed active site, only the A forms show intrinsic activity. Mutational substitution of Asp-41 in the globular activation domain, located at the interface with the enzyme moiety, as well as removal of the adjacent 3(10) helix allow the appearance of residual activity in the mutated procarboxypeptidase B, indicating that the interaction of both structural elements with the enzyme moiety prevents the binding of substrates and promotes enzyme inhibition. In addition, the poor heterologous expression of such mutants indicates that the mutated region is important for the folding of the whole proenzyme.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Spain; Lilly Corp Ctr, Indianapolis, IN 46285 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; Eli Lilly	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain.		Villegas, Sandra/ABF-8206-2021; Ventura, Salvador/C-7021-2008; Avilés, Francesc Xavier/A-2664-2015; Villegas, Sandra/D-8789-2011; Vendrell, Josep/A-6731-2010; Ventura, Salvador/AAY-3170-2021; Aviles, Francesc Xavier/F-3482-2019	Villegas, Sandra/0000-0001-8644-4304; Ventura, Salvador/0000-0002-9652-6351; Avilés, Francesc Xavier/0000-0002-1399-6789; Villegas, Sandra/0000-0001-8644-4304; Vendrell, Josep/0000-0002-9378-4742; Ventura, Salvador/0000-0002-9652-6351; Aviles, Francesc Xavier/0000-0002-1399-6789				Aloy P, 1998, BIOL CHEM, V379, P149, DOI 10.1515/bchm.1998.379.2.149; AULD DS, 1987, NEW COMPR BIOCH, V16, P201; AVILES FX, 1993, EUR J BIOCHEM, V211, P391; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4092; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; COLL M, 1991, EMBO J, V9, P1; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1988, J BIOL CHEM, V263, P17929; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HO NS, 1989, GENE, V77, P51; Khan AR, 1998, PROTEIN SCI, V7, P815; LACKO AG, 1970, BIOCHEMISTRY-US, V9, P4680; Laethem RM, 1996, ARCH BIOCHEM BIOPHYS, V332, P8, DOI 10.1006/abbi.1996.0310; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REECK GR, 1972, BIOCHEMISTRY-US, V11, P3947, DOI 10.1021/bi00771a018; Reverter D, 1997, FEBS LETT, V420, P7, DOI 10.1016/S0014-5793(97)01476-2; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRA MA, 1995, THESIS U AUTONOMA BA; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, NATURE, V341, P362; VENDRELL J, 1986, J CHROMATOGR, V358, P401, DOI 10.1016/S0021-9673(01)90354-1; VENDRELL J, 1991, EMBO J, V10, P11, DOI 10.1002/j.1460-2075.1991.tb07915.x; VENDRELL J, 1990, J BIOL CHEM, V265, P6949; VILLEGAS V, 1995, BIOCHEMISTRY-US, V34, P15105, DOI 10.1021/bi00046a017; Villegas V, 1998, J MOL BIOL, V283, P1027, DOI 10.1006/jmbi.1998.2158; VILLEGAS V, 1995, PROTEIN SCI, V4, P1792, DOI 10.1002/pro.5560040914; VILLEGAS V, 1995, THESIS U AUTONOMA BA; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	37	46	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19925	19933		10.1074/jbc.274.28.19925	http://dx.doi.org/10.1074/jbc.274.28.19925			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391940	hybrid			2022-12-25	WOS:000081377300060
J	Alvarez-Fernandez, M; Barrett, AJ; Gerhartz, B; Dando, PM; Ni, JA; Abrahamson, M				Alvarez-Fernandez, M; Barrett, AJ; Gerhartz, B; Dando, PM; Ni, JA; Abrahamson, M			Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; EGG-WHITE CYSTATIN; RAY CRYSTAL-STRUCTURE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; CHICKEN CYSTATIN; ASPARAGINYL ENDOPEPTIDASE; GEL ELECTROPHORESIS; STEFIN-A; CLONING	We have investigated the inhibition of the recently identified family C13 cysteine peptidase, pig legumain, by human cystatin C, The cystatin was seen to inhibit enzyme activity by stoichiometric 1:1 binding in competition with substrate. The K-i value for the interaction was 0.20 nM, i.e. cystatin C had an affinity for legumain similar to that for the papain-like family C1 cysteine peptidase, cathepsin B, However, cystatin C variants with alterations in the N-terminal region and the "second hairpin loop" that rendered the cystatin inactive against cathepsin B, still inhibited legumain with K-i values 0.2-0.3 nM. Complexes between cystatin C and papain inhibited legumain activity against benzoyl-Asn-NHPhNO2, as efficiently as did cystatin C alone, Conversely, cystatin C inhibited papain activity against benzoyl-Arg-NHPhNO2 whether or not the cystatin had been incubated with legumain, strongly indicating that the cystatin inhibited the two enzymes with non-overlapping sites. A ternary complex between legumain, cystatin C, and papain was demonstrated by gel filtration supported by immunoblotting. Screening of a panel of cystatin superfamily members showed that type 1 inhibitors (cystatins A and B) and low M-r kininogen (type 3) did not inhibit pig legumain, Of human type 2 cystatins, cystatin D was non-inhibitory, whereas cystatin E/M and cystatin F displayed strong (K-i 0.0016 nM) and relatively weak (K-i 10 nM) affinity for legumain, respectively. Sequence alignments and molecular modeling led to the suggestion that a loop located on the opposite side to the papain-binding surface, between the alpha-helix and the first strand of the main beta-pleated sheet of the cystatin structure, could be involved in legumain binding. This was corroborated by analysis of a cystatin C variant with substitution of the Asn(39) residue in this loop (N39K-cystatin C); this variant showed a slight reduction in affinity for cathepsin B (K-i 1.5 nM) but much greater than 5,000-fold lower affinity for legumain (K-i much greater than 1,000 nM) than wild-type cystatin C.	Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden; Babraham Inst, MRC, Mol Enzymol Lab, Cambridge CB2 4AT, England; Human Genome Sci Inc, Rockville, MD 20850 USA	Lund University; Skane University Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; GlaxoSmithKline; Human Genome Sciences Inc	Abrahamson, M (corresponding author), Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden.	Magnus.Abrahamson@klinkem.lu.se	Abrahamson, Magnus/CAG-9507-2022; Barrett, Alan J/G-8970-2013	Barrett, Alan J/0000-0002-6082-4437				ABE Y, 1993, J BIOL CHEM, V268, P3525; Abola EE, 1997, METHOD ENZYMOL, V277, P556, DOI 10.1016/S0076-6879(97)77031-9; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; Bjarnadottir M, 1998, J CLIN PATHOL-MOL PA, V51, P317, DOI 10.1136/mp.51.6.317; BJORK I, 1989, BIOCHEM J, V260, P61; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; Gerhartz B, 1998, BIOCHEMISTRY-US, V37, P17309, DOI 10.1021/bi980873u; Glazer A., 1971, ENZYMES, P501; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Guex N., 1996, Experientia (Basel), V52, pA26; Halfon S, 1998, J BIOL CHEM, V273, P16400, DOI 10.1074/jbc.273.26.16400; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HARANISHIMURA T, 1998, HDB PROTEOLYTIC ENZY, P746; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; MACHLEIDT W, 1983, H-S Z PHYSIOL CHEM, V364, P1481, DOI 10.1515/bchm2.1983.364.2.1481; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MARTIN JR, 1995, J MOL BIOL, V246, P331, DOI 10.1006/jmbi.1994.0088; MIN W, 1994, STRUCT BIOL, V1, P502; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNITTGER S, 1993, GENOMICS, V16, P50, DOI 10.1006/geno.1993.1139; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Woessner J. F., 1998, HDB PROTEOLYTIC ENZY, P749; [No title captured]	55	233	241	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19195	19203		10.1074/jbc.274.27.19195	http://dx.doi.org/10.1074/jbc.274.27.19195			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383426	hybrid			2022-12-25	WOS:000081196300049
J	Dong, MQ; Wang, Y; Hadac, EM; Pinon, DI; Holicky, E; Miller, LJ				Dong, MQ; Wang, Y; Hadac, EM; Pinon, DI; Holicky, E; Miller, LJ			Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE (PTH)/PTH-RELATED PEPTIDE; AGONIST-BINDING; VIP RECEPTOR; CHOLECYSTOKININ RECEPTOR; EXTRACELLULAR DOMAIN; PROTEIN-RECEPTOR; CROSS-LINKING; FAMILY; SITE	Photoaffinity labeling is a powerful tool for the characterization of the molecular basis of ligand binding. We recently used this technique to demonstrate the proximity between a residue within the carboxyl-terminal half of a secretin-like ligand and the amino-terminal domain of the secretin receptor (Dong, M,, Wang, Y,, Pinon, D, I., Hadac, E. M., and Miller, L. J, (1999) J. Biol, Chem. 274, 903-909), In this work, we have developed another novel radioiodinatable secretin analogue ([Bpa(6),Tyr(10)]rat secretin-27) that incorporates a photolabile p-benzoyl-L-phenylalanine (Bpa) residue into position 6 of the amino terminal half of the ligand and used this to identify a specific receptor residue proximate to it, This probe specifically bound to the secretin receptor with high affinity (IC50 = 13.2 +/- 2.5 nM) and was a potent stimulant of cAMP accumulation in secretin receptor-bearing Chinese hamster ovary-SecR cells (EC50 = 720 +/- 230 pM). It covalently labeled the secretin receptor in a saturable and specific manner. Cyanogen bromide cleavage of this molecule yielded a single labeled fragment that migrated on an SDS-polyacrylamide gel at M-r = 19,000 that shifted to 10 after deglycosylation, most consistent with either of two glycosylated fragments within the aminoterminal tail. By immunoprecipitation with antibody directed to epitope tags incorporated into each of the two candidate fragments, the most distal fragment at the amino terminus was identified as the domain of labeling. The labeled domain was further refined to the first 16 residues by endoproteinase Lys-C cleavage and by cyanogen bromide cleavage of another receptor construct in which Val(16) was mutated to Met. Radiochemical sequencing of photoaffinity-labeled secretin receptor fragments established that Val(4) was the specific site of covalent attachment. This provides the first residue-residue contact between a secretin Ligand and its receptor and will contribute substantially to the molecular understanding of this interaction.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Guggenheim 17, Rochester, MN 55905 USA.				NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577, R56DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BODANSZKY M, 1986, PEPTIDES, V7, P43, DOI 10.1016/0196-9781(86)90162-2; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CLORE GM, 1988, EUR J BIOCHEM, V171, P479, DOI 10.1111/j.1432-1033.1988.tb13814.x; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; GRONENBORN AM, 1987, FEBS LETT, V215, P88, DOI 10.1016/0014-5793(87)80119-9; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; ROBBERECHT P, 1984, BIOCHIM BIOPHYS ACTA, V773, P271, DOI 10.1016/0005-2736(84)90091-9; ROBINSON RM, 1982, BIOPOLYMERS, V21, P1217, DOI 10.1002/bip.360210615; ROLAND PE, 1994, HUMAN BRAIN MAPPING, V2, P1; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 1997, ANN NY ACAD SCI, V812, P71, DOI 10.1111/j.1749-6632.1997.tb48147.x; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Strader CD, 1996, J MED CHEM, V39, P1; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	38	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19161	19167		10.1074/jbc.274.27.19161	http://dx.doi.org/10.1074/jbc.274.27.19161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383421	hybrid			2022-12-25	WOS:000081196300044
J	Raychaudhuri, S; Niu, LH; Conrad, J; Lane, BG; Ofengand, J				Raychaudhuri, S; Niu, LH; Conrad, J; Lane, BG; Ofengand, J			Functional effect of deletion and mutation of the Escherichia coli ribosomal RNA and tRNA pseudouridine synthase RluA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE CENTER; NUCLEOTIDE RESOLUTION; MIAA GENE; 16S RNA; RESIDUES; MUTAGENESIS; CLONING; SUBUNIT; K-12	The Escherichia coli gene rluA, coding for the pseudouridine synthase RIuA that forms 23 S rRNA pseudouridine 746 and tRNA pseudouridine 32, was deleted in strains MG1655 and BL21/DE3. The rluA deletion mutant failed to form either 23 S RNA pseudouridine 746 or tRNA pseudouridine 32. Replacement of rluA in trans on a rescue plasmid restored both pseudouridines. Therefore, RluA is the sole protein responsible for the in vivo formation of 23 S RNA pseudouridine 746 and tRNA pseudouridine 32, Plasmid rescue of both rluA(-) strains using an rluA gene carrying asparagine or threonine replacements for the highly conserved aspartate 64 demonstrated that neither mutant could form 23 S RNA pseudouridine 746 or tRNA pseudouridine 32 in vivo, showing that this conserved aspartate is essential for enzyme-catalyzed formation of both pseudouridines. In vitro assays using overexpressed wild-type and mutant synthases confirmed that only the wild-type protein was active despite the overexpression of mild-type and mutant syntheses in approximately equal amounts. There was no difference in exponential growth rate between wild-type and MG1655(rluA(-)) either in rich or minimal medium at 24, 37, or 42 degrees C, but when both strains were grown together, a strong selection against the deletion strain was observed.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Miami; University of Toronto	Ofengand, J (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058879] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58879] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKIN A, 1994, NUCLEIC ACIDS RES, V22, P3681, DOI 10.1093/nar/22.18.3681; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Bakin AV, 1998, METH MOL B, V77, P297; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; COHN WE, 1960, J BIOL CHEM, V235, P1488; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Conrad J, 1999, RNA, V5, P751, DOI 10.1017/S1355838299990167; Conrad J, 1998, J BIOL CHEM, V273, P18562, DOI 10.1074/jbc.273.29.18562; DEUTSCHE.MP, 1974, J BACTERIOL, V118, P621, DOI 10.1128/JB.118.2.621-627.1974; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Horie N, 1999, BIOCHEMISTRY-US, V38, P207, DOI 10.1021/bi981865g; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; KING TC, 1983, J BIOL CHEM, V258, P2034; Massenet S, 1999, MOL CELL BIOL, V19, P2142; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; Miller J. H., 1992, SHORT COURSE BACTERI, P357; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; OFENGAND J, 1993, TRANSLATIONAL APPARATUS, P489; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; SANTER M, 1993, BIOCHEMISTRY-US, V32, P5539, DOI 10.1021/bi00072a007; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; WRZESINSKI J, 1995, RNA, V1, P437; ZYSKIND JW, 1992, RECOMBINANT DNA LAB, P187	32	75	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18880	18886		10.1074/jbc.274.27.18880	http://dx.doi.org/10.1074/jbc.274.27.18880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383384	hybrid			2022-12-25	WOS:000081196300007
J	Yamagata, K; Andreasson, KI; Sugiura, H; Maru, E; Dominique, M; Irie, Y; Miki, N; Hayashi, Y; Yoshioka, M; Kaneko, K; Kato, H; Worley, PF				Yamagata, K; Andreasson, KI; Sugiura, H; Maru, E; Dominique, M; Irie, Y; Miki, N; Hayashi, Y; Yoshioka, M; Kaneko, K; Kato, H; Worley, PF			Arcadlin is a neural activity-regulated cadherin involved in long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER TRANSCRIPTION FACTOR; CELL-CELL INTERACTIONS; FACTOR MESSENGER-RNAS; SYNAPTIC PLASTICITY; ADHESION MOLECULE; BRAIN NEURONS; GROWTH-FACTOR; RAT-BRAIN; PROTEIN; NCAM	Neural activity results in long term changes that underlie synaptic plasticity. To examine the molecular basis of activity-dependent plasticity, we have used differential cloning techniques to identify genes that are rapidly induced in brain neurons by synaptic activity. Here, we identify a novel cadherin molecule Arcadlin (activity-regulated cadherin-like protein), arcadlin mRNA is rapidly and transiently induced in hippocampal granule cells by seizures and by N-methyl-D-aspartate-dependent synaptic activity in long term potentiation. The extracellular domain of Arcadlin is most homologous to protocadherin-8; however, the cytoplasmic region is distinct from that of any cadherin family member. Arcadlin protein is expressed at the synapses and shows a homophilic binding activity in a Ca2+-dependent manner. Furthermore, application of Arcadlin antibody reduces excitatory postsynaptic potential amplitude and blocks long term potentiation in hippocampal slices. Its close homology with cadherins, its rapid inducibility by neural activity, and its involvement in synaptic transmission suggest that Arcadlin may play an important role in activity-induced synaptic reorganization underlying long term memory.	Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Fuchu, Tokyo 183, Japan; Johns Hopkins Univ, Sch Med, Dept Neurol & Neurosci, Baltimore, MD 21205 USA; Nippon Med Univ, Sch Med, Dept Physiol 2, Tokyo 113, Japan; Ctr Med Univ Geneva, Dept Pharmacol, CH-1211 Geneva 4, Switzerland; Osaka Univ, Sch Med, Dept Pharmacol 1, Suita, Osaka 565, Japan; Nagano Nursing Univ, Komagane 39941, Japan; Yamagata Univ, Sch Med, Dept Physiol 2, Yamagata 99023, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Johns Hopkins University; Nippon Medical School; University of Geneva; Osaka University; Yamagata University	Yamagata, K (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, 2-6 Musashidai, Fuchu, Tokyo 183, Japan.							Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DESMOND NL, 1986, J COMP NEUROL, V253, P466, DOI 10.1002/cne.902530404; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MARU E, 1989, BRAIN RES, V478, P112, DOI 10.1016/0006-8993(89)91482-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SCHACHER S, 1993, NEURON, V10, P1079, DOI 10.1016/0896-6273(93)90056-W; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; THIEL G, 1994, J BIOL CHEM, V269, P15294; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yamagata K, 1994, Learn Mem, V1, P140	36	134	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19473	19479		10.1074/jbc.274.27.19473	http://dx.doi.org/10.1074/jbc.274.27.19473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383464	hybrid			2022-12-25	WOS:000081196300087
J	Davison, TS; Vagner, C; Kaghad, M; Ayed, A; Caput, D; Arrowsmith, CH				Davison, TS; Vagner, C; Kaghad, M; Ayed, A; Caput, D; Arrowsmith, CH			p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; OLIGOMERIZATION DOMAIN; HUMAN CANCERS; GENE-THERAPY; TETRAMERIZATION; MUTATIONS; PROTEIN; HOMOLOG; MUTANT	Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human cancers, Recent identification of two human homologues of p53 has raised the prospect of functional interactions between family members via a conserved oligomerization domain. Here we report in vitro and in vivo analysis of homo- and hetero-oligomerization of p53 and its homologues, p63 and p73, The oligomerization domains of p63 and p73 can independently fold into stable homotetramers, as previously observed for p53, However, the oligomerization domain of p53 does not associate with that of either p73 or p63, even when p53 is in 15-fold excess. On the other hand, the oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro, In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63, These data suggest that mutant p53 in cancer cells will not interact with endogenous or exogenous p63 or p73 via their respective oligomerization domains. It also establishes that the multiple isoforms of p63 as well as those of p73 are capable of interacting via their common oligomerization domain.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Sanofi Rech, F-31280 Labege, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sanofi-Aventis; Sanofi France	Arrowsmith, CH (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN JY, 1993, ONCOGENE, V8, P2159; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Nielsen LL, 1998, CLIN CANCER RES, V4, P835; Nielsen LL, 1998, CANCER GENE THER, V5, P52; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Sambrook J., 1989, MOL CLONING, pA1; SchreiberAgus N, 1997, CURR TOP MICROBIOL, V224, P159; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	27	140	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18709	18714		10.1074/jbc.274.26.18709	http://dx.doi.org/10.1074/jbc.274.26.18709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373484	hybrid			2022-12-25	WOS:000081056700076
J	Fishburn, CS; Herzmark, P; Morales, J; Bourne, HR				Fishburn, CS; Herzmark, P; Morales, J; Bourne, HR			G beta gamma and palmitate target newly synthesized G alpha(z) to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; LIPID MODIFICATIONS; POLYBASIC DOMAIN; TYROSINE KINASE; PALMITOYLATION; CELLS; MYRISTOYLATION; LOCALIZATION	The subcellular location of a signaling protein determines its ability to transmit messages accurately and efficiently. Three different lipid modifications tether heterotrimeric G proteins to membranes: alpha subunits are myristoylated and/or palmitoylated, and gamma subunits are prenylated, In a previous study, we examined the role of lipid modifications in maintaining the membrane attachment of a G protein alpha subunit, alpha(z), which is myristoylated and palmitoylated (Morales, J., Fishburn, C. S., Wilson, P. T., and Bourne, H. R. (1998) Mel. Biol. Cell 9, 1-14), Now we extend this analysis by characterizing the mechanisms that target newly synthesized alpha(z) to the plasma membrane (PM) and analyze the role of lipid modifications in this process. In comparison with newly synthesized alpha(s), which is palmitoylated but not myristoylated, alpha(z) moves more rapidly to the membrane fraction following synthesis in the cytosol, Newly synthesized alpha(z) associates randomly with cellular membranes, but with time accumulates at the PM. Palmitoylated alpha(z) is present only in PM-enriched fractions, whereas a nonpalmitoylated mutant of alpha(z) (alpha(z) C3A) associates less stably with the PM than does wild-type alpha(z). Expression of a C-terminal fragment of the beta-adrenoreceptor kinase, which sequesters free beta gamma, impairs association of both alpha(z) and alpha(z) C3A with the PM, suggesting that the alpha subunit must bind beta gamma in order to localize at the PM. Based on these findings, we propose a model in which, following synthesis on soluble ribosomes, myristoylated a, associates randomly and reversibly with membranes; upon association with the PM, alpha(z) binds beta gamma, which promotes its palmitoylation, thus securing it in the proper place for transmitting the hormonal signal.	Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, S-1212,Box 0450, San Francisco, CA 94143 USA.							Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JONES TLZ, 1994, G PROTEINS, P49; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	47	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18793	18800		10.1074/jbc.274.26.18793	http://dx.doi.org/10.1074/jbc.274.26.18793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373496	hybrid			2022-12-25	WOS:000081056700088
J	Hong, Y; Ohishi, K; Watanabe, R; Endo, Y; Maeda, Y; Kinoshita, T				Hong, Y; Ohishi, K; Watanabe, R; Endo, Y; Maeda, Y; Kinoshita, T			GPI1 stabilizes an enzyme essential in the first step of glycosylphosphatidylinositol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; ANCHORED MEMBRANE-PROTEINS; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; PHOSPHATIDYLINOSITOL; YEAST; MUTANTS; CLONING; IDENTIFICATION	Attachment of glycosylphosphatidylinositol (GPI) is essential for the surface expression of many proteins. Biosynthesis of glycosylphosphatidylinositol is initiated by the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol. In mammalian cells, this reaction is mediated by a complex of PIG-A, PIG-H, PIG-C, and GPI1. This complexity may be relevant for regulation and for usage of a particular phosphatidylinositol. However, the functions of the respective components have been unclear. Here we cloned the mouse GPI1 gene and disrupted it in F9 embryonal carcinoma cells. Disruption of the GPI1 gene caused a severe but not complete defect in the generation of glycosylphosphatidylinositol-anchored proteins, indicating some residual biosynthetic activity. A complex of PIG-A, PIG-H, and PIG-C decreased to a nearly undetectable level, whereas a complex of PIG-A and PIG-H was easily detected. A lack of GPI1 also caused partial decreases of PIG-C and PIG-H. Therefore, GPI1 stabilizes the enzyme by tying up PIG-C with a complex of PIG-A and PIG-H.	Microbial Dis Res Inst, Dept Immunol Regulat, Suita, Osaka 5650871, Japan; Fukushima Med Coll, Dept Biochem, Fukushima 9601295, Japan	Fukushima Medical University	Kinoshita, T (corresponding author), Microbial Dis Res Inst, Dept Immunol Regulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.		Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702				BESSLER M, 1994, HUM MOL GENET, V3, P751, DOI 10.1093/hmg/3.5.751; Blake JA, 1998, NUCLEIC ACIDS RES, V26, P130, DOI 10.1093/nar/26.1.130; Colussi PA, 1997, YEAST, V13, P139, DOI 10.1002/(SICI)1097-0061(199702)13:2<139::AID-YEA69>3.3.CO;2-J; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Inoue N, 1996, BIOCHEM BIOPH RES CO, V226, P193, DOI 10.1006/bbrc.1996.1332; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MORAN P, 1991, J BIOL CHEM, V266, P1250; Nozaki M, 1999, LAB INVEST, V79, P293; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGITA Y, 1993, J BIOCHEM-TOKYO, V114, P473, DOI 10.1093/oxfordjournals.jbchem.a124202; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tiede A, 1998, BIOCHEM J, V334, P609, DOI 10.1042/bj3340609; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18582	18588		10.1074/jbc.274.26.18582	http://dx.doi.org/10.1074/jbc.274.26.18582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373468	hybrid			2022-12-25	WOS:000081056700060
J	Steimle, PA; Hoffert, JD; Adey, NB; Craig, SW				Steimle, PA; Hoffert, JD; Adey, NB; Craig, SW			Polyphosphoinositides inhibit the interaction of vinculin with actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; TALIN-BINDING; TAIL DOMAINS; PROTEIN; MUSCLE; SITES; HEAD; PHOSPHORYLATION; DISRUPTION	Binding of vinculin to adhesion plaque proteins is restricted by an intramolecular association of vinculin's head and tail regions. Results of previous work suggest that polyphosphoinositides disrupt this interaction and thereby promote binding of vinculin to both talin and actin. However, data presented here show that phosphatidylinositol 4,5-bisphosphate (PI4,5P(2)) inhibits the interaction of purified tail domain with F-actin. Upon re-examining the effect of PI4,5P(2) on the actin and talin-binding activities of intact vinculin, we find that when the experimental design controls for the effect of magnesium on aggregation of PI4,5P(2) micelles, polyphosphoinositides promote interactions with the talin-binding domain, but block interactions of the actin-binding domain. In contrast, if vinculin is trapped in an open confirmation by a peptide specific for the talin-binding domain of vinculin, actin binding is allowed. These results demonstrate that activation of the actin-binding activity of vinculin requires steps other than or in addition to the binding of PI4,5P(2).	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Myriad Genet, Salt Lake City, UT 84108 USA	Johns Hopkins University; Myriad Genetics, Inc	Steimle, PA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	pas5@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adey NB, 1997, BIOCHEM J, V324, P523, DOI 10.1042/bj3240523; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 1996, J MUSCLE RES CELL M, V17, P1, DOI 10.1007/BF00140319; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RA, 1995, ENVIRONMETRICS, V6, P341, DOI 10.1002/env.3170060403; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; Schwienbacher C, 1996, FEBS LETT, V384, P71, DOI 10.1016/0014-5793(96)00286-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; VOLBERG T, 1995, J CELL SCI, V108, P2253; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; WEIMING X, 1998, J CELL SCI, V111, P1535; WEIMING X, 1998, DEVELOPMENT, V125, P327; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042	37	94	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18414	18420		10.1074/jbc.274.26.18414	http://dx.doi.org/10.1074/jbc.274.26.18414			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373448	hybrid, Green Submitted			2022-12-25	WOS:000081056700040
J	Stolz, J; Sauer, N				Stolz, J; Sauer, N			The fenpropimorph resistance gene FEN2 from Saccharomyces cerevisiae encodes a plasma membrane H+-pantothenate symporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ERGOSTEROL BIOSYNTHESIS; CATABOLITE REPRESSION; TRANSPORT PROTEIN; BAKERS-YEAST; WILD-TYPE; EXPRESSION; CLONING	The product of the FEN2 gene of Saccharomyces cerevisiae has previously been described as a protein conferring sensitivity to the antifungal agent fenpropimorph, Fen2p was postulated to act as a common regulator of carbon and nitrogen catabolite repression and of amino acid and ergosterol biosynthesis. In this paper, we present experimental evidence characterizing Fen2p as a plasma membrane-localized transporter for the vitamin pantothenate. The high affinity transport system (K-m = 3.5 mu M) is sensitive to uncouplers, suggesting a H+-pantothenate cotransport, Pantothenate transport rates in yeast are modulated by extracellular pantothenate, being maximal at low pantothenate concentrations. It is demonstrated that beta-alanine can suppress the growth defect of FEN2 wild-type and fen2 mutant cells on pantothenate-free medium. Evidence is presented that p-alanine is transported by the general amino acid permease Gap1p. The relation among pantothenate transport, nitrogen catabolite repression, and sensitivity to the antifungal agent fenpropimorph is discussed.	Univ Erlangen Nurnberg, Lehrstuhl Bot 2, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Bot 2, Staudtstr 5, D-91058 Erlangen, Germany.	nsauer@biologie.uni-erlangen.de						ANDRE B, 1993, MOL GEN GENET, V237, P17; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; BLATTNA J, 1965, VITAMINE CHEMIE BIOC, P1232; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; CARBONE MLA, 1992, YEAST, V8, P805, DOI 10.1002/yea.320080915; CROWLEY JH, 1994, ANTIMICROB AGENTS CH, V38, P1004, DOI 10.1128/AAC.38.5.1004; Engels AJG, 1998, CURR GENET, V33, P145, DOI 10.1007/s002940050320; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRENSON M, 1972, BIOCHEM BIOPH RES CO, V48, P749, DOI 10.1016/0006-291X(72)90670-5; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KELLY DE, 1994, FEMS MICROBIOL LETT, V122, P223, DOI 10.1016/0378-1097(94)00326-2; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; Leonian LH, 1942, AM J BOT, V29, P459, DOI 10.2307/2437311; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; Marcireau C, 1996, YEAST, V12, P531, DOI 10.1002/(SICI)1097-0061(199605)12:6<531::AID-YEA934>3.3.CO;2-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nielsen N, 1938, BIOCHEM Z, V295, P211; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Opekarova M, 1996, FEBS LETT, V386, P181, DOI 10.1016/0014-5793(96)00434-6; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REIZER J, 1990, RES MICROBIOL, V141, P1069, DOI 10.1016/0923-2508(90)90080-A; REVARDEL E, 1995, BIOCHIM BIOPHYS ACTA, V19, P261; Sajbidor J, 1998, J PHARM PHARMACOL, V50, P297, DOI 10.1111/j.2042-7158.1998.tb06864.x; SARETT HP, 1945, J BACTERIOL, V49, P31, DOI 10.1128/JB.49.1.31-39.1945; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERVOUSE M, 1986, BIOCHEM J, V240, P541, DOI 10.1042/bj2400541; Silve S, 1996, MOL CELL BIOL, V16, P2719; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; WALLER JR, 1970, APPL MICROBIOL, V20, P857, DOI 10.1128/AEM.20.6.857-860.1970; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	42	46	48	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18747	18752		10.1074/jbc.274.26.18747	http://dx.doi.org/10.1074/jbc.274.26.18747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373490	hybrid			2022-12-25	WOS:000081056700082
J	Tsukamoto, N; Hattori, M; Yang, HL; Bos, JL; Minato, N				Tsukamoto, N; Hattori, M; Yang, HL; Bos, JL; Minato, N			Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-LYMPHOCYTES; DISSOCIATION STIMULATOR; DEPENDENT ACTIVATION; GENE-PRODUCT; CYCLIC-AMP; MAP KINASE; RAS; FAMILY; RHO; CRK	Rap1 GTPase is activated by a variety of stimulations in many types of cells, but its exact functions remain unknown. In this study we have shown that SPA-1 interferes with Rap1 activation by membrane-targeted C3G, C3G-F, in 293T cells through the GTPase activating protein (GAP) activity. SPA-1 transiently expressed in HeLa cells was mostly localized at the cortical cytoskeleton and induced rounding up of the cells, whereas C3G-F conversely induced extensive cell spreading. Conditional SPA-1 overexpression in HeLa cells by tetracycline-regulative system suppressed Rap1 activation upon plating on dishes coated with fibronectin and resulted in the reduced adhesion. When SPA-1 was conditionally induced after the established cell adhesion, the cells gradually rounded up and detached from the dish. Both effects were counteracted by exogenous fibronectin in a dose-dependent manner. Retroviral overexpression of SPA-1 in promyelocytic 32D cells also inhibited both activation of Rap1 and induction of cell adhesion by granulocyte colony stimulating factor without affecting differentiation. These results have indicated that Rap1 GTP is required for the cell adhesion induced by both extracellular matrix and soluble factors, which is negatively regulated by SPA-1.	Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan; Univ Utrecht, Physiol Chem Lab, NL-2584 CG Utrecht, Netherlands	Kyoto University; Utrecht University	Minato, N (corresponding author), Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan.	minato@med.kyoto-u.ac.jp						ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; Gao QS, 1999, MOL CELL BIOL, V19, P733; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Woodside DG, 1998, J EXP MED, V188, P1211, DOI 10.1084/jem.188.7.1211; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	37	144	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18463	18469		10.1074/jbc.274.26.18463	http://dx.doi.org/10.1074/jbc.274.26.18463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373454	hybrid			2022-12-25	WOS:000081056700046
J	Biemesderfer, D; Nagy, T; DeGray, B; Aronson, PS				Biemesderfer, D; Nagy, T; DeGray, B; Aronson, PS			Specific association of megalin and the Na+/H+ exchanger isoform NHE3 in the proximal tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; NEPHRITIS ANTIGENIC COMPLEX; CAMP-MEDIATED INHIBITION; HEYMANN NEPHRITIS; H+ EXCHANGER; MOLECULAR-CLONING; EPITHELIAL-CELLS; GROWTH-FACTOR; CDNA CLONING; GENE FAMILY	We investigated whether the renal brush border Na+/H+ exchanger NHE3 exists in assemblies with other proteins in native kidney membranes. To this end we generated monoclonal antibodies (mAbs) against affinity purified NHE3 protein complexes. Hybridomas were selected based on ability to immunoprecipitate NHE3, One of the resulting mAbs (10A3) labeled a high molecular mass (>200 kDa) protein and stained primarily the coated pit region of the proximal tubule in a manner similar to that described for megalin (gp330). We then confirmed that both mAb 10A3 and a known anti-megalin mAb immunoprecipitated and immunoblotted the same protein, namely megalin. mAb 10A3 specifically co-precipitated NHE3 but not villin or NaPi-2 from solubilized renal membranes, indicating specificity of the NHE3-megalin interaction. When immunoprecipitations were performed using either 10A3 or anti-NHE3 mAb 2B9 after separation of solubilized renal proteins by sucrose velocity gradient centrifugation, we found that NHE3 exists in two states with distinct sedimentation coefficients, a 9.6 S megalin-free form and a 21 S megalin-bound form, and that when NHE3 assembles with megalin, epitopes within the carboxyl-terminal 131 amino acids of NHE3 are blocked. Taken together, these findings indicate that a significant pool of NHES exists as a multimeric complex with megalin in the brush border of the proximal tubule.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033793, R01DK033793] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33793] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BAUM M, 1995, AM J PHYSIOL, V268, pC815; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1997, CURR OPIN NEPHROL HY, V6, P20; COLLAZO R, 1998, J AM SOC NEPHROL, V9, P4; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FARQUHAR MG, 1995, J CLIN INVEST, V96, P1184, DOI 10.1172/JCI118149; Griffith O. M., 1983, TECHNIQUES PREPARATI; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; KERJASCHKI D, 1984, J CELL BIOL, V98, P1505, DOI 10.1083/jcb.98.4.1505; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; Orlando RA, 1998, J AM SOC NEPHROL, V9, P1759; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PENG Y, 1998, J AM SOC NEPHROL, V9, P10; Pizzonia JH, 1998, AM J PHYSIOL-RENAL, V275, pF510, DOI 10.1152/ajprenal.1998.275.4.F510; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; Rutherford PA, 1997, EXP NEPHROL, V5, P490; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	51	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17518	17524		10.1074/jbc.274.25.17518	http://dx.doi.org/10.1074/jbc.274.25.17518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364184	hybrid			2022-12-25	WOS:000080974300020
J	Bucher, EA; Dhoot, GK; Emerson, MM; Ober, M; Emerson, CP				Bucher, EA; Dhoot, GK; Emerson, MM; Ober, M; Emerson, CP			Structure and evolution of the alternatively spliced fast troponin T isoform gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; REPEAT-1 CR-1 ELEMENTS; AVIAN SKELETAL-MUSCLE; METAL-BINDING CLUSTER; PRE-MESSENGER-RNA; SINGLE GENE; HYPERTROPHIC CARDIOMYOPATHY; FUNCTIONAL DIFFERENCES; COMPUTER METHODS; ACID SEQUENCES	The vertebrate fast skeletal muscle troponin T gene, TnTf, produces a complexity of isoforms through differential mRNA splicing. The mechanisms that regulate splicing and the physiological significance of TnTf isoforms are poorly understood. To investigate these questions, we have determined the complete sequence structure of the quail TnTf gene, and we have characterized the developmental expression of alternatively spliced TnTf mRNAs in quail embryonic muscles. We report the following: 1) the quail TnTf gene is significantly larger than the rat TnTf gene and has 8 non-homologous exons, including a pectoral muscle-specific set of alternatively spliced exons; 2) specific sequences are implicated in regulated exon splicing; 3) a 900-base pair sequence element, composed primarily of intron sequence flanking the pectoral muscle-specific exons, is tandemly repeated 4 times and once partially, providing direct evidence that the pectoral-specific TnT exon domain arose by intragenic duplications; 4) a chicken repeat 1 retrotransposon element resides upstream of this repeated intronic/pectoral exon sequence domain Emd is implicated in transposition of this element into an ancestral genome; and 5) a large set of novel isoforms, produced by regulated exon splicing, is expressed in quail muscles, providing insights into the developmental regulation, physiological function, and evolution of the vertebrate TnTf isoforms.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Bucher, EA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.							ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; Ashiya M, 1997, RNA, V3, P996; BIRD IM, 1985, EUR J BIOCHEM, V150, P517, DOI 10.1111/j.1432-1033.1985.tb09052.x; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; BRIGGS MM, 1990, DEV BIOL, V140, P253, DOI 10.1016/0012-1606(90)90075-T; Briggs MM, 1996, AM J PHYSIOL-CELL PH, V270, pC298, DOI 10.1152/ajpcell.1996.270.1.C298; BUCHER EA, 1989, J BIOL CHEM, V264, P12482; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8443, DOI 10.1093/nar/16.17.8443; COOPER TA, 1985, J BIOL CHEM, V260, P1140; Davis MB, 1998, GENETICS, V150, P1105; DHOOT GK, 1988, J MUSCLE RES CELL M, V9, P446, DOI 10.1007/BF01774070; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Haas NB, 1997, GENE, V197, P305, DOI 10.1016/S0378-1119(97)00276-X; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOCHACHAKA PW, 1984, THESIS PRINCETON; HOLLAND SK, 1987, BIOSYSTEMS, V20, P181, DOI 10.1016/0303-2647(87)90044-X; IMAI H, 1986, J BIOCHEM, V99, P923, DOI 10.1093/oxfordjournals.jbchem.a135554; Innis MA, 1990, PCR PROTOCOLS GUIDE; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LECUYER TJ, 1991, PEDIATR RES, V30, P232, DOI 10.1203/00006450-199109000-00006; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGILVERY RW, 1985, METABOLIC ADAPTATION; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; Ohshima K, 1996, MOL CELL BIOL, V16, P3756; PAN BS, 1992, J BIOL CHEM, V267, P23052; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perez I, 1997, RNA, V3, P764; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHAT F, 1995, DEV BIOL, V171, P233, DOI 10.1006/dbio.1995.1274; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SILVA R, 1989, MOL CELL BIOL, V9, P3563, DOI 10.1128/MCB.9.8.3563; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; STADEN R, 1984, BIOCHEM SOC T, V12, P1005, DOI 10.1042/bst0121005; Standiford DM, 1997, GENETICS, V147, P725; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; VANDERGON TL, 1994, MOL BIOL EVOL, V11, P886; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; WU QL, 1995, GENE, V155, P225, DOI 10.1016/0378-1119(94)00846-K; YAO Y, 1992, DEV BIOL, V151, P531, DOI 10.1016/0012-1606(92)90191-I; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	65	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17661	17670		10.1074/jbc.274.25.17661	http://dx.doi.org/10.1074/jbc.274.25.17661			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364205	hybrid			2022-12-25	WOS:000080974300041
J	Doran, KS; Helinski, DB; Konieczny, I				Doran, KS; Helinski, DB; Konieczny, I			A critical DnaA box directs the cooperative binding of the Escherichia coli DnaA protein to the plasmid RK2 replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE; CHROMOSOMAL REPLICATION; NUCLEOTIDE-SEQUENCE; INITIATION PROTEIN; BACILLUS-SUBTILIS; REGION; TRFA; REPLICON; INVITRO; INCOMPATIBILITY	The requirement of DnaA protein binding for plasmid RK2 replication initiation the Escherichia coli was investigated by constructing mutations in the plasmid replication origin that scrambled or deleted each of the four upstream DnaA boxes, Altered origins were analyzed for replication activity in vivo and in vitro and for binding to the E. coli DnaA protein using a gel mobility shift assay and DNase I footprinting. Most strikingly, a mutation in one of the boxes, box 4, abolished replication activity and eliminated stable DnaA protein binding to all four boxes. Unlike DnaA binding to the E. coli origin, oriC, DnaA binding to two of the boxes (boxes 4 and 3) in the RK2 origin, oriV, is cooperative with box 4 acting as the "organizer" for the formation of the DnaA-oriV nucleoprotein complex, Interestingly, the inversion of box 4 also abolished replication activity, but did not result in a loss of binding to the other boxes. However, DnaA binding to this mutant origin was no longer cooperative. These results demonstrate that the sequence, position, and orientation of box 4 are crucial for cooperative DnaA binding and the formation of a nucleoprotein structure that is functional for the initiation of replication.	Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, PL-80822 Gdansk, Poland	University of California System; University of California San Diego; Fahrenheit Universities; University of Gdansk	Helinski, DB (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dhelinski@ucsd.edu		Konieczny, Igor/0000-0002-1588-5601	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; COWAN P, 1982, PLASMID, V8, P164, DOI 10.1016/0147-619X(82)90054-3; CROSS MA, 1986, PLASMID, V15, P132, DOI 10.1016/0147-619X(86)90049-1; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; FUJITA MQ, 1989, MOL GEN GENET, V215, P381, DOI 10.1007/BF00427033; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; Giraldo R, 1998, EMBO J, V17, P4511, DOI 10.1093/emboj/17.15.4511; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Kaguni JM, 1997, MOL CELLS, V7, P145; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; Toukdarian AE, 1998, GENE, V223, P205, DOI 10.1016/S0378-1119(98)00370-9; VOCKE C, 1983, P NATL ACAD SCI-BIOL, V80, P6557, DOI 10.1073/pnas.80.21.6557; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; WICKNER S, 1990, J BIOL CHEM, V265, P11622; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17918	17923		10.1074/jbc.274.25.17918	http://dx.doi.org/10.1074/jbc.274.25.17918			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364238	hybrid			2022-12-25	WOS:000080974300074
J	Kikuchi, A; Sagami, H; Ogura, K				Kikuchi, A; Sagami, H; Ogura, K			Evidence for covalent attachment of diphytanylglyceryl phosphate to the cell-surface glycoprotein of Halobacterium halobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAPONICA STRAIN TR-1; DOLICHYL PHOSPHATE; POLAR LIPIDS; RAT-LIVER; PROTEIN; LAYER; VOLCANII; CLONING; GENE	In a previous study, we demonstrated the occurrence of novel proteins modified with a diphytanylglyceryl group in thioether linkage in Halobacterium halobium (Sagami, H,, Kikuchi, A., and Ogura, K, (1995) J. Biol, Chem. 270, 14851-14854), In this study, we further investigated protein isoprenoid modification in this halobacterium using several radioactive tracers such as [H-3]geranylgeranyl diphosphate. One of the radioactive bands observed on SDS-polyacrylamide gel electrophoresis corresponded to a periodic acid-Schiff stain-positive protein (200 kDa), Radioactive and periodic acid-Schiff stain-positive peptides (28 kDa) were obtained by trypsin digestion of the labeled proteins. The radioactive materials released by acid treatment of the? peptides showed a similar mobility to dolichyl (C-55) phosphate on a normal-phase thin-layer plate. However, radioactive hydrolysates obtained by acid phosphatase treatment co-migrated not with dolichol (C55-65), but with diphytanylglycerol on both reverse- and normal-phase thin-layer plates, The mass spectrum of the hydrolysate was also coincident with that of diphytanylglycerol, The partial amino acid sequences of the 28-kDa peptides were found in a fragment (amino acids 731-816) obtainable by trypsin cleavage of the known cell-surface glycoprotein of this halobacterium, These results indicate that the cell-surface glycoprotein (200 kDa) is modified with diphytanylglyceryl phosphate.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, H (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.							BAUMEISTER W, 1992, J BIOENERG BIOMEMBR, V24, P567, DOI 10.1007/BF00762349; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHAUDHARY N, 1982, LIPIDS, V17, P558, DOI 10.1007/BF02535384; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Hjertman M, 1997, FEBS LETT, V416, P235, DOI 10.1016/S0014-5793(97)01208-8; HORIKOSHI K, 1993, EXPERIENTIA, V49, P497, DOI 10.1007/BF01955151; KESSEL M, 1988, EMBO J, V7, P1549, DOI 10.1002/j.1460-2075.1988.tb02974.x; Kobayashi T, 1997, BBA-GEN SUBJECTS, V1334, P1, DOI 10.1016/S0304-4165(96)00099-2; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; KUSHWAHA SC, 1975, BIOCHIM BIOPHYS ACTA, V398, P303, DOI 10.1016/0005-2760(75)90146-0; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LECHNER J, 1985, J BIOL CHEM, V260, P860; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mescher M F, 1977, Prog Clin Biol Res, V17, P459; MESCHER MF, 1974, J BACTERIOL, V120, P945, DOI 10.1128/JB.120.2.945-954.1974; MESCHER MF, 1976, P NATL ACAD SCI USA, V73, P2687, DOI 10.1073/pnas.73.8.2687; MESCHER MF, 1976, J BIOL CHEM, V251, P20025; MINNIKIN DE, 1975, J GEN MICROBIOL, V88, P200, DOI 10.1099/00221287-88-1-200; MOLDOVEANU N, 1988, BIOCHIM BIOPHYS ACTA, V960, P164, DOI 10.1016/0005-2760(88)90062-8; NORBERG P, 1969, J GEN MICROBIOL, V55, P251, DOI 10.1099/00221287-55-2-251; SAGAMI H, 1994, BIOCHEM BIOPH RES CO, V203, P972, DOI 10.1006/bbrc.1994.2277; SAGAMI H, 1995, J BIOL CHEM, V270, P14851, DOI 10.1074/jbc.270.25.14851; SCOTT JE, 1968, HISTOCHEMISTRY, V14, P215, DOI 10.1007/BF00306317; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; THELIN A, 1991, EUR J BIOCHEM, V195, P755, DOI 10.1111/j.1432-1033.1991.tb15763.x; Wakai H, 1997, EXTREMOPHILES, V1, P29, DOI 10.1007/s007920050012; Warren C D, 1978, Methods Enzymol, V50, P122; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	32	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18011	18016		10.1074/jbc.274.25.18011	http://dx.doi.org/10.1074/jbc.274.25.18011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364251	hybrid			2022-12-25	WOS:000080974300087
J	Klingenberg, O; Wiedlocha, A; Olsnes, S				Klingenberg, O; Wiedlocha, A; Olsnes, S			Effects of mutations of a phosphorylation site in an exposed loop in acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CELL-CYCLE; FACTOR-I; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; HEPARIN-BINDING; PROTEIN-KINASE; DIRECTED MUTAGENESIS; FACTOR MUTANT	Acidic fibroblast growth factor (aFGF) contains a phosphorylation site recognized by protein kinase C. A non-mitogenic mutant growth factor is devoid of this phosphorylation site. We have changed amino acids in and close to the phosphorylation site and studied the consequences of this for binding of the growth factor to high affinity receptors as well as to heparin. We have also studied the ability of the mutants to stimulate DNA synthesis and cell proliferation as well as phosphorylation of mitogen-activated protein kinase and the ability of the growth factor mutants to be transported to the nucleus. The results indicate that while the mutations strongly affect the ability of the growth factor to bind to heparin, they do not affect much the binding to the specific FGF receptors, activation of mitogen-activated protein kinase or transport of the growth factor to the nucleus. The mutations affect to various extents the ability of the growth factor to stimulate DNA synthesis and to induce cell multiplication. We find that phosphorylation of aFGF is not required for mitogenic activity. The data suggest that altered interaction of the growth factor with a cellular component different from the receptor, possibly a component in the nucleus, is the reason for the different mitogenicity of the different growth factor mutants.	Norwegian Radium Hosp, Canc Res Inst, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Klingenberg, O (corresponding author), Norwegian Radium Hosp, Canc Res Inst, Dept Biochem, N-0310 Oslo, Norway.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P576; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; Heldin CH, 1996, CANCER SURV, V27, P7; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zalecki P, 1998, EXP CELL RES, V244, P61, DOI 10.1006/excr.1998.4187; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	46	22	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18081	18086		10.1074/jbc.274.25.18081	http://dx.doi.org/10.1074/jbc.274.25.18081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364261	hybrid			2022-12-25	WOS:000080974300097
J	Moncrieffe, MC; Eaton, S; Bajzer, Z; Haydock, C; Potter, JD; Laue, TM; Prendergast, FG				Moncrieffe, MC; Eaton, S; Bajzer, Z; Haydock, C; Potter, JD; Laue, TM; Prendergast, FG			Rotational and translational motion of troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-FREE CALMODULIN; NMR SOLUTION STRUCTURE; X-RAY-SCATTERING; MUSCLE-CONTRACTION; FLUORESCENCE ANISOTROPY; HYDRODYNAMIC PROPERTIES; ANGSTROM RESOLUTION; DYNAMICS; COMPLEX; PROTEIN	Time resolved fluorescence anisotropy and sedimentation velocity has been used to study the rotational and translational hydrodynamic behavior of two mutants of chicken skeletal troponin C bearing a single tryptophan residue at position 78 or 154 in the metal-free-, metal-bound-, and troponin I peptide (residues 96-116 of troponin I)-ligated states. The fluorescence anisotropy data of both mutants were adequately described by two rotational correlation times, and these are compared with the theoretically expected values based on the rotational diffusion of an idealized dumbbell. These data imply that the motion of the N- and C-terminal domains of troponin C are independent. They also suggest that in the metal-free, calcium-saturated and calcium-saturated troponin I peptide-bound states, troponin C is elongated, having an axial ratio of 4-5, Calcium or magnesium binding to the high affinity sites alone reduces the axial ratio to approximately 3. However, with calcium bound to sites III and IV and in the presence of a 1:1 molar ratio of the troponin I peptide, troponin C is approximately spherical. The metal ion and troponin I peptide-induced length changes in troponin C may play a role in the mechanism by which the regulatory function of troponin C is effected.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ New Hampshire, Dept Biochem, Durham, NH 03824 USA	Mayo Clinic; University of Miami; University System Of New Hampshire; University of New Hampshire	Prendergast, FG (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034847] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37701] Funding Source: Medline; NIGMS NIH HHS [GM34847] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akima H., 1978, ACM Transactions on Mathematical Software, V4, P148, DOI 10.1145/355780.355786; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAJZER Z, 1992, METHOD ENZYMOL, V210, P200; BAJZER Z, 1995, BIOPHYS J, V69, P1148, DOI 10.1016/S0006-3495(95)79989-1; BELFORD GG, 1972, P NATL ACAD SCI USA, V69, P1392, DOI 10.1073/pnas.69.6.1392; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CATTERALL T, 1983, TIME RESOLVED FLUOES, P173; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHUANG TJ, 1972, J CHEM PHYS, V57, P5094, DOI 10.1063/1.1678194; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DELATORRE JG, 1977, BIOPOLYMERS, V16, P1747, DOI DOI 10.1002/BIP.1977.360160811; DOSTER W, 1983, BIOPHYS CHEM, V17, P97, DOI 10.1016/0301-4622(83)80002-7; EHRENBER.M, 1972, CHEM PHYS LETT, V14, P539, DOI 10.1016/0009-2614(72)87202-6; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; HAYDOCK C, 1993, J CHEM PHYS, V98, P8199, DOI 10.1063/1.464525; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; HUBBARD SR, 1988, J BIOL CHEM, V263, P4151; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAUE TM, 1993, ULTRASENSITIVE CLIN, V1895; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; O'Connor D. V., 1984, TIME CORRELATED SING; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; Shaw GS, 1996, BIOCHEMISTRY-US, V35, P7429, DOI 10.1021/bi9528006; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SMALL EW, 1988, BIOCHEMISTRY-US, V27, P419, DOI 10.1021/bi00401a063; SMALL EW, 1977, BIOPOLYMERS, V16, P1907, DOI 10.1002/bip.1977.360160907; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; VANGUNSTEREN WF, 1980, J COMPUT CHEM, V1, P266, DOI 10.1002/jcc.540010308; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WANG CK, 1993, J BIOL CHEM, V268, P14671; WANG CK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P16, DOI 10.1016/0167-4838(92)90331-7; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; [No title captured]	54	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17464	17470		10.1074/jbc.274.25.17464	http://dx.doi.org/10.1074/jbc.274.25.17464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364176	hybrid			2022-12-25	WOS:000080974300012
J	Nakamura, M; Tanigawa, Y				Nakamura, M; Tanigawa, Y			Biochemical analysis of the receptor for ubiquitin-like polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPECIFIC SUPPRESSOR FACTOR; CELL-SURFACE RECEPTORS; INDUCED 15-KDA PROTEIN; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; ACCEPTOR PROTEINS; ALPHA-CHAIN; FACTOR MNSF; ACTIVATION; EXPRESSION	Monoclonal nonspecific suppressor factor (MNSF), a lymphokine produced by murine T cell hybridoma, possesses pleiotrophic antigen-nonspecific suppressive functions. A cDNA clone encoding MNSF-beta, an isoform of the MNSF, has been isolated and characterized. MNSF-beta cDNA encodes a fusion protein consisting of a ubiquitin-like segment (Ubi-L) and ribosomal protein S30. Ubi-L appears to be cleaved from the ribosomal protein and released extracellularly in association with T cell receptor-like polypeptide. In the current study we have characterized the biochemical nature of the Ubi-L receptor on D.10 G4.1, a murine T helper clone type 2. Biotinylated Ubi-L bound preferentially to concanavalin A-stimulated but not to unstimulated D.10 cells. Detergent-extracted membrane proteins were applied to an immobilized Ubi-L column. SDS-polyacrylamide gel electrophoresis of eluted fraction revealed a band of M-r = 82,000. Biotinylated Ubi-L specifically recognized this band, confirming that the 82-kDa protein is the Ubi-L receptor, A complex of M-r = 90,000 was visualized by immunoprecipitation of I-125-Ubi-L cross-linked to the purified receptor followed by SDS-polyacrylamide gel electrophoresis and autoradiography. In addition, a 105-kDa protein was coimmunoprecipitated by anti-Ubi-L receptor (82-kDa polypeptide) antibody, indicative of the association of this protein with the Ubi-L receptor complex. Amino acid sequence analysis of the 82-kDa polypeptide revealed that the Ubi-L receptor may be a member of a cytokine receptor family.	Shimane Med Univ, Dept Biochem, Izumo, Shimane 693, Japan	Shimane University	Nakamura, M (corresponding author), Shimane Med Univ, Dept Biochem, 89-1 Enya Cho, Izumo, Shimane 693, Japan.			Nakamura, Morihiko/0000-0003-1079-9787				ARMITAGE RJ, 1992, BLOOD, V79, P1738; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BUSHKINHARAV I, 1995, J BIOL CHEM, V270, P13422, DOI 10.1074/jbc.270.22.13422; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DORF ME, 1989, PROGR IMMUNOLOGY, V7, P874; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREEN NM, 1965, BIOCHEM J, V94, P23; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; JENSON J, 1980, BIOCHIM BIOPHYS ACTA, V624, P378, DOI 10.1016/0005-2795(80)90079-3; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KNIGHT E, 1991, J IMMUNOL, V146, P2280; Kondoh T, 1999, IMMUNOBIOLOGY, V200, P140, DOI 10.1016/S0171-2985(99)80039-4; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MORI S, 1992, J BIOL CHEM, V267, P6429; Nagata T, 1998, BBA-MOL CELL RES, V1401, P319, DOI 10.1016/S0167-4889(97)00131-6; NAKAMURA M, 1995, EUR J IMMUNOL, V25, P2417, DOI 10.1002/eji.1830250844; NAKAMURA M, 1990, CELL IMMUNOL, V130, P281, DOI 10.1016/0008-8749(90)90271-R; Nakamura M, 1996, J Immunol, V156, P532; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 1996, INT IMMUNOL, V8, P1659, DOI 10.1093/intimm/8.11.1659; NAKAMURA M, 1986, J IMMUNOL, V136, P2904; NAKAMURA M, 1987, J IMMUNOL, V138, P1799; Nakamura M, 1998, IMMUNOLOGY, V94, P142, DOI 10.1046/j.1365-2567.1998.00501.x; NAKAMURA M, 1992, CELL IMMUNOL, V139, P131, DOI 10.1016/0008-8749(92)90106-Y; Nakamura M, 1998, BIOCHEM J, V330, P683, DOI 10.1042/bj3300683; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PANCRE V, 1986, J IMMUNOL, V137, P585; PANCRE V, 1991, EUR J IMMUNOL, V21, P2735, DOI 10.1002/eji.1830211113; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; Suzuki K, 1996, IMMUNOBIOLOGY, V195, P187, DOI 10.1016/S0171-2985(96)80038-6; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	40	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18026	18032		10.1074/jbc.274.25.18026	http://dx.doi.org/10.1074/jbc.274.25.18026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364253	hybrid			2022-12-25	WOS:000080974300089
J	Nibbs, RJB; Yang, JY; Landau, NR; Mao, JH; Graham, GJ				Nibbs, RJB; Yang, JY; Landau, NR; Mao, JH; Graham, GJ			LD78 beta, a non-allelic variant of human MIP-1 alpha (LD78 alpha), has enhanced receptor interactions and potent HIV suppressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-CHEMOKINE RECEPTOR; MOLECULAR-CLONING; T-CELLS; INFECTION; RANTES; CHEMOATTRACTANT; INHIBITION; IDENTIFICATION; INDIVIDUALS	Chemokines play diverse roles in inflammatory and non-inflammatory situations via activation of heptahelical G-protein-coupled receptors. Also, many chemokine receptors can act as cofactors for cellular entry of human immunodeficiency virus (HIV) in vitro. CCR5, a receptor for chemokines MLP-1 alpha (LD78 alpha), MIP-1 beta, RAN-TES, and MCP2, is of particular importance in vivo as polymorphisms in this gene affect HIV infection and rate of progression to APDS. Moreover, the CCR5 ligands can prevent HIV entry through this receptor and likely contribute to the control of HIV infection. Here we show that a non-allelic isoform of human MIP-1 alpha (LD78 alpha), termed LD78 beta or MIP-1 alpha P, has enhanced receptor binding affinities to CCR5 (similar to 6-fold) and the promiscuous beta-chemokine receptor, D6 (similar to 15-20-fold). We demonstrate that a proline residue at position 2 of MIP-1 alpha P is responsible for this enhanced activity. Moreover, MIP-1 alpha P is by far the most potent natural CCR5 agonist described to date, and importantly, displays markedly higher HIV1 suppressive activity than all other human MIP-1 alpha isoforms examined. In addition, while RANTES has been described as the most potent inhibitor of CCR5-mediated HIV entry, MIP-1 alpha P was as potent as, if not more potent than, RANTES in HIV-1 suppressive assays. This property suggests that MLP-1 alpha P may be of importance in controlling Viral spread in HN-infected individuals.	CRC, Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Beatson Institute; Beatson Institute; Rockefeller University	Graham, GJ (corresponding author), CRC, Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Graham, Gerard/D-1240-2009; Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Nibbs, Robert/0000-0002-8150-0044; Graham, Gerard/0000-0002-7801-204X	NATIONAL CANCER INSTITUTE [R01CA072149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036057, R01AI036057] Funding Source: NIH RePORTER; NCI NIH HHS [CA72149] Funding Source: Medline; NIAID NIH HHS [AI1384, AI36057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BERTINI R, 1995, AIDS RES HUM RETROV, V11, P155, DOI 10.1089/aid.1995.11.155; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bonini JA, 1997, DNA CELL BIOL, V16, P1023, DOI 10.1089/dna.1997.16.1023; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Clapham PR, 1997, TRENDS CELL BIOL, V7, P264, DOI 10.1016/S0962-8924(97)01075-1; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUNLOP DJ, 1992, BLOOD, V79, P2221; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Graham GJ, 1992, GROWTH FACTORS, V7, P151, DOI 10.3109/08977199209046404; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; IRVING SG, 1990, NUCLEIC ACIDS RES, V18, P3261, DOI 10.1093/nar/18.11.3261; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Meyer A, 1996, J BIOL CHEM, V271, P14445, DOI 10.1074/jbc.271.24.14445; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAKAO M, 1990, MOL CELL BIOL, V10, P3646, DOI 10.1128/MCB.10.7.3646; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; VOLUND A, 1978, BIOMETRICS, V34, P357, DOI 10.2307/2530598; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857	45	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17478	17483		10.1074/jbc.274.25.17478	http://dx.doi.org/10.1074/jbc.274.25.17478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364178	hybrid			2022-12-25	WOS:000080974300014
J	Ruttimann-Johnson, C; Staples, CR; Rangaraj, P; Shah, VK; Ludden, PW				Ruttimann-Johnson, C; Staples, CR; Rangaraj, P; Shah, VK; Ludden, PW			A vanadium and iron cluster accumulates on VnfX during iron-vanadium-cofactor synthesis for the vanadium nitrogenase in Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; STRUCTURAL GENES; FIXATION SYSTEM; NIFB COFACTOR; VFE PROTEIN; PURIFICATION; DINITROGENASE	The vnf-encoded nitrogenase from Azotobacter vinelandii contains an iron-vanadium cofactor (FeV-co) in its active site. Little is known about the synthesis pathway of FeV-co, other than that some of the gene products required are also involved in the synthesis of the iron-molybdenum cofactor (FeMo-co) of the widely studied molybdenum-dinitrogenase. We have found that VnfX, the gene product of one of the genes contained in the vnf-regulon, accumulates iron and vanadium in a novel V-Fe cluster during synthesis of FeV-co. The electron paramagnetic resonance (EPR) and metal analyses of the V-Fe cluster accumulated on VnfX are consistent with a VFe7-8SX precursor of FeV-co. The EPR spectrum of VnfX with the V-Fe cluster bound strongly resembles that of isolated FeV-co and a model VFe3S4 compound. The V-Fe cluster accumulating on VnfX does not contain homocitrate. No accumulation of V-Fe cluster on VnfX was observed in strains with deletions in genes known to be involved in the early steps of FeV-co synthesis, suggesting that it corresponds to a precursor of FeV-co, VnfX purified from a nifB strain incapable of FeV-co synthesis has a different electrophoretic mobility in native anoxic gels than does VnfX, which has the V-Fe cluster bound. NifB-co, the Fe and S precursor of FeMo-co (and presumably FeV-co), binds to VnfX purified from the nifB strain, producing a shift in its electrophoretic mobility on anoxic native gels. The data suggest that a precursor of FeV-co that contains vanadium and iron accumulates on VnfX, and thus, VnfX is involved in the synthesis of FeV-co.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BISHOP PE, 1980, P NATL ACAD SCI-BIOL, V77, P7342, DOI 10.1073/pnas.77.12.7342; BISHOP PE, 1982, J BACTERIOL, V150, P1244, DOI 10.1128/JB.150.3.1244-1251.1982; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; Butler A, 1998, CURR OPIN CHEM BIOL, V2, P279, DOI 10.1016/S1367-5931(98)80070-7; CARNEY MJ, 1987, INORG CHEM, V26, P719, DOI 10.1021/ic00252a016; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; EADY RR, 1991, ADV INORG CHEM, V36, P77, DOI 10.1016/S0898-8838(08)60037-9; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GOSINK MM, 1990, J BACTERIOL, V172, P1441, DOI 10.1128/jb.172.3.1441-1447.1990; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; RUPP H, 1979, BIOCHIM BIOPHYS ACTA, V548, P16, DOI 10.1016/0005-2728(79)90183-X; Schneider K, 1997, EUR J BIOCHEM, V244, P789, DOI 10.1111/j.1432-1033.1997.t01-1-00789.x; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; Slebodnick C, 1997, STRUCT BOND, V89, P51; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; Tittsworth RC, 1996, BIOCHEMISTRY-US, V35, P479, DOI 10.1021/bi951430i; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	36	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18087	18092		10.1074/jbc.274.25.18087	http://dx.doi.org/10.1074/jbc.274.25.18087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364262	hybrid			2022-12-25	WOS:000080974300098
J	Silverman, E; Eimerl, S; Orly, J				Silverman, E; Eimerl, S; Orly, J			CCAAT enhancer-binding protein beta and GATA-4 binding regions within the promoter of the steroidogenic acute regulatory protein (StAR) gene are required for transcription in rat ovarian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; FOLLICLE-STIMULATING-HORMONE; LIPOID ADRENAL-HYPERPLASIA; MESSENGER-RIBONUCLEIC-ACID; LEYDIG TUMOR-CELLS; BOVINE CYP11A GENE; GRANULOSA-CELLS; C/EBP-BETA; CONSTITUTIVE EXPRESSION; 3-BETA-HYDROXYSTEROID DEHYDROGENASE	Steroidogenic acute regulatory protein (StAR) is a vital accessory protein required for biosynthesis of steroid hormones from cholesterol. The present study shows that in primary granulosa cells from prepubertal rat ovary, StAR transcript and protein are acutely induced by gonadotropin (FSH). To determine the sequence elements required for hormone inducibility of the StAR promoter, truncated regions of the -1002/+6 sequence of the mouse gene were ligated to pCAT-Basic plasmid and transfected by electroporation to freshly prepared cells. FSH inducibility determined over a 6-h incubation was 10-40-fold above basal levels of chloramphenicol acetyltransferase activity. These functional studies, supported by electrophoretic mobility shift assays indicated that two sites were sufficient for transcription of the StAR promoter constructs: a non-consensus binding sequence (-81/-72) for CCAAT enhancer-binding protein beta (C/EBP beta) and a consensus motif for GATA-4 binding (-61/-66). Western analyses showed that GATA-4 is constitutively expressed in the granulosa cells, while all isoforms of C/EBP beta were markedly inducible by FSH. Site-directed mutations of both binding sequences practically ablated both basal and hormone-driven chloramphenicol acetyltransferase activities to less than 5% of the parental -96/+6 construct. Unlike earlier notions, elimination of potential binding sites for steroidogenic factor-1, a well known tissue-specific transcription factor, did not impair StAR transcription. Consequently, we propose that C/EBP beta and GATA-4 represent a novel combination of transcription factors capable of conferring an acute response to hormones upon their concomitant binding to the StAR promoter.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Orly, J (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	orly@vms.huji.ac.il						Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; AUSUBEL FM, 1988, CURRENT PROTOXOLS MO; Berrier A, 1998, J IMMUNOL, V161, P2267; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Carlone DL, 1997, J STEROID BIOCHEM, V61, P223, DOI 10.1016/S0960-0760(97)80016-7; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; Furukawa A, 1998, J NEUROCHEM, V71, P2231; HALL PF, 1986, STEROIDS, V48, P133; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HONDA S, 1993, J BIOL CHEM, V268, P7494; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; LaVoie HA, 1999, ENDOCRINOLOGY, V140, P146, DOI 10.1210/en.140.1.146; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Luo LD, 1998, BIOL REPROD, V59, P263, DOI 10.1095/biolreprod59.2.263; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; Narita N, 1997, DEVELOPMENT, V124, P3755; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; ORLY J, 1994, ENDOCRINOLOGY, V134, P2336, DOI 10.1210/en.134.6.2336; Orly J, 1996, BIOL REPROD, V54, P208, DOI 10.1095/biolreprod54.1.208; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Parker KL, 1998, MOL CELL ENDOCRINOL, V140, P59, DOI 10.1016/S0303-7207(98)00030-6; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Pescador N, 1997, BIOL REPROD, V57, P660, DOI 10.1095/biolreprod57.3.660; Pescador N, 1996, BIOL REPROD, V55, P485, DOI 10.1095/biolreprod55.2.485; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PON LA, 1986, J BIOL CHEM, V261, P3309; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RONEN FT, 1998, ENDOCRINOLOGY, V139, P303; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1978, J BIOL CHEM, V253, P3135; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; STEVENS VL, 1993, EUR J BIOCHEM, V216, P557, DOI 10.1111/j.1432-1033.1993.tb18174.x; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 1997, STEROIDS, V62, P29, DOI 10.1016/S0039-128X(96)00155-9; Stocco DM, 1997, BIOL REPROD, V56, P328, DOI 10.1095/biolreprod56.2.328; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	72	159	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17987	17996		10.1074/jbc.274.25.17987	http://dx.doi.org/10.1074/jbc.274.25.17987			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364248	hybrid			2022-12-25	WOS:000080974300084
J	Summers, SA; Kao, AW; Kohn, AD; Backus, GS; Roth, RA; Pessin, JE; Birnbaum, MJ				Summers, SA; Kao, AW; Kohn, AD; Backus, GS; Roth, RA; Pessin, JE; Birnbaum, MJ			The role of glycogen synthase kinase 3 beta in insulin-stimulated glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ISOLATED RAT ADIPOCYTES; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE/THREONINE KINASE; GLUT4 TRANSLOCATION; SIGNALING PATHWAYS; POTENTIAL ROLE	To characterize the contribution of glycogen synthase kinase 3 beta (GSK3 beta) inactivation to insulin-stimulated glucose metabolism, wild-type (WT-GSK), catalytically inactive (KM-GSK), and uninhibitable (SSA-GSK) forms of GSK3 beta were expressed in insulin-responsive 3T3-L1 adipocytes using adenovirus technology, WT-GSK but not KM-GSK, reduced basal and insulin-stimulated glycogen synthase activity without affecting the -fold stimulation of the enzyme by insulin. S9A-GSK similarly decreased cellular glycogen synthase activity, but also partially blocked insulin stimulation of the enzyme. SSA-GSK expression also markedly inhibited insulin stimulation of IRS-1-associated phosphatidylinositol 3-kinase activity, but only weakly inhibited insulin-stimulated Akt/PKB phosphorylation and glucose uptake, with no effect on GLUT4 translocation, To further evaluate the role of GSK3 beta in insulin signaling, the GSK3 beta inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3 beta inactivation. Although lithium stimulated the incorporation of glucose into glycogen and glycogen synthase enzyme activity, the inhibitor was without effect on GLUT4 translocation and pp70 S6 kinase, Lithium stimulation of glycogen synthesis was insensitive to wortmannin, which is consistent with its acting directly on GSK3 beta downstream of phosphatidylinositol 3-kinase. These data support the hypothesis that GSK3 beta contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport.	Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Iowa; Stanford University	Birnbaum, MJ (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.		/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39615, DK33823, DK34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R01DK039615, R37DK033823, R37DK034926, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BOSCH F, 1986, J BIOL CHEM, V261, P6927; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; CHENG K, 1983, MOL CELL BIOCHEM, V56, P177; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P66, DOI 10.1016/0005-2736(68)90009-6; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; Furnsinn C, 1997, AM J PHYSIOL-ENDOC M, V273, pE514, DOI 10.1152/ajpendo.1997.273.3.E514; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; RAMAKRISHNA S, 1985, J BIOL CHEM, V260, P2280; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SMITH RL, 1985, J BIOL CHEM, V260, P273; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	47	179	184	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17934	17940		10.1074/jbc.274.25.17934	http://dx.doi.org/10.1074/jbc.274.25.17934			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364240	hybrid			2022-12-25	WOS:000080974300076
J	Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE				Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE			Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGF alpha expression in transgenic mice	ONCOGENE			English	Article						tetracycline; skin; hair follicle	GROWTH-FACTOR RECEPTOR; HAIR FOLLICLE DEVELOPMENT; CANCER CELL-LINE; NEU-ONCOGENE; EGF RECEPTOR; TARGETED EXPRESSION; KERATIN PROMOTER; EPIDERMAL EXPRESSION; GENE-EXPRESSION; OWN RECEPTOR	The ErbB2 receptor tyrosine kinase (RTK) is expressed in basal cells of squamous epithelia and the outer root sheath of hair follicles. We previously showed that constitutive expression of activated ErbB2 directed to these sites in the skin by the keratin 14 (K14) promoter produces prominent hair follicle abnormalities and striking skin hyperplasia in transgenic mice. However, perinatal lethality precluded the establishment of a transgenic line for analysis of ErbB2 function in adult animals. To investigate the significance of ErbB2 signaling in epithelial tissues during and post development, we developed a K14-rtTA/TetRE-ErbB2 'Tet-On' bitransgenic mouse system. These mice were normal until the ErbB2 transgene mas induced by exposure to doxycycline (Dox). Prenatal induction resulted in perinatal death. Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. In adults, as in the neonates, prolonged ErbB2 induction caused prominent skin and hair follicle hyperplasias. Severe hyperplasias in the cornea, eye lids, tongue and esophagus mere also observed. ErbB2 transgene induction was accompanied by increased expression of TGF alpha, a ligand of epidermal growth factor receptor (EGFR), and to a lesser extent, EGFR, further enhancing RTK signal transduction. We conclude that ErbB2 plays important roles in both development and maintenance of hair follicles and diverse squamous epithelia and that this ligand-inducible and tissue-specific 'Tet-On' transgenic mouse system provides a means to study transgenes with perinatal toxicity.	Univ Alabama, Dept Med Endocrinol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med Endocrinol, 1808 7th Ave S,Room 756, Birmingham, AL 35294 USA.		Xie, Wen/M-1768-2016		NCI NIH HHS [CA36200] Funding Source: Medline; NIDDK NIH HHS [DK43652, DK48882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652, R01DK048882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS BM, 1993, NEUROSCIENCE, V56, P789, DOI 10.1016/0306-4522(93)90127-2; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1986, J BIOL CHEM, V261, P4777; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PRESS MF, 1990, ONCOGENE, V5, P953; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SHIH C, 1981, NATURE, V290, P621; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Tanaka S, 1997, CANCER RES, V57, P28; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P9710, DOI 10.1073/pnas.91.21.9710; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Xie W, 1997, ANTICANCER RES, V17, P2627; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	46	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3593	3607		10.1038/sj.onc.1202673	http://dx.doi.org/10.1038/sj.onc.1202673			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380881				2022-12-25	WOS:000080891700005
J	Farjot, G; Sergeant, A; Mikaelian, I				Farjot, G; Sergeant, A; Mikaelian, I			A new nucleoporin-like protein interacts with both HIV-1 Rev nuclear export signal and CRM-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ORDER CHROMOSOME STRUCTURE; RESPONSE ELEMENT; ACTIVATION DOMAIN; PORE COMPLEX; VIRION EXPRESSION; GENE-EXPRESSION; MESSENGER-RNAS; IMPORTIN-BETA; LEPTOMYCIN-B	The HTV-1 Rev is a shuttling protein required for the nuclear export of unspliced and partially spliced viral mRNA. In this study, we have identified a new Rev-interacting protein, that specifically interacts with the Rev nuclear export signal both in yeast and mammalian cells. This protein has features found in nucleoporins including many phenylalanine-glycine repeats, a very high serine content, a putative zinc finger, and a coiled-coil domain; we thus called it NLP-1 (nucleoporin-like protein 1). In addition, gene expression analysis and wheat germ agglutinin chromatography experiments suggested that NLP-1 is an ubiquitous O-glycosylated nuclear protein. Recently, a cellular factor called CRM-1 has been shown to be an essential nuclear export factor interacting directly with nuclear export signals including the Rev nuclear export signal in a RanGTP-dependent manner. We show here that NLP-1, like the previously described Rev-interacting protein hRIP/Rab and several nucleoporins, also interacts with CRM-1 both in yeast and mammalian cells.	Ecole Normale Super Lyon, Virol Lab, INSERM, U 412, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mikaelian, I (corresponding author), Ecole Normale Super Lyon, Virol Lab, INSERM, U 412, 42 Allee Italie, F-69364 Lyon 07, France.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALIM MH, 1989, J VIROL, V63, P1959; Manet Evelyne, 1993, Gene Expression, V3, P49; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MIKAELIAN I, 1993, J VIROL, V67, P734; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stutz F, 1996, MOL CELL BIOL, V16, P7144; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Van Laer L, 1997, EUR J HUM GENET, V5, P397, DOI 10.1159/000484798; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	52	33	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17309	17317		10.1074/jbc.274.24.17309	http://dx.doi.org/10.1074/jbc.274.24.17309			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358091	hybrid			2022-12-25	WOS:000080780400090
J	Wood, SJ; Wypych, J; Steavenson, S; Louis, JC; Citron, M; Biere, AL				Wood, SJ; Wypych, J; Steavenson, S; Louis, JC; Citron, M; Biere, AL			alpha-synuclein fibrillogenesis is nucleation-dependent - Implications for the pathogenesis of Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; IN-VITRO; PROTEIN; MUTATION; INCLUSIONS; BINDING; NUCLEI	Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major components of which are filaments consisting of alpha-synuclein, Two recently identified point mutations in a-synuclein are the only known genetic causes of PD, alpha-Synuclein fibrils similar to the Lewy body filaments can be formed in vitro, and we have shown recently that both PD-linked mutations accelerate their formation. This study addresses the mechanism of alpha-synuclein aggregation: we show that (i) it is a nucleation-dependent process that can be seeded by aggregated alpha-synuclein functioning as nuclei, (ii) this fibril growth follows first-order kinetics with respect to alpha-synuclein concentration, and (iii) mutant alpha-synuclein can seed the aggregation of wild type alpha-synuclein, which leads us to predict that the Lewy bodies of familial PD patients with a-synuclein mutations will contain both, the mutant and the wild type protein. Finally (iv), we show that wild type and mutant forms of alpha-synuclein do not differ in their critical concentrations. These results suggest that differences in aggregation kinetics of alpha-synucleins cannot be explained by differences in solubility but are due to different nucleation rates, Consequently, alpha-synuclein nucleation may be the rate-limiting step for the formation of Lewy body alpha-synuclein fibrils in Parkinson's disease.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Biere, AL (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	abiere@amgen.com						ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hashimoto I, 1999, NEUROREPORT, V10, P3201, DOI 10.1097/00001756-199910190-00014; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Walsh D, 1897, Br Med J, V2, P272; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j	27	585	605	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19509	19512		10.1074/jbc.274.28.19509	http://dx.doi.org/10.1074/jbc.274.28.19509			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391881	hybrid			2022-12-25	WOS:000081377300001
J	Kakizawa, T; Miyamoto, T; Ichikawa, K; Kaneko, A; Suzuki, S; Hara, M; Nagasawa, T; Takeda, T; Mori, J; Kumagai, R; Hashizume, K				Kakizawa, T; Miyamoto, T; Ichikawa, K; Kaneko, A; Suzuki, S; Hara, M; Nagasawa, T; Takeda, T; Mori, J; Kumagai, R; Hashizume, K			Functional interaction between Oct-1 and retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; OCTAMER TRANSCRIPTION FACTORS; NUCLEAR-RECEPTOR; POU DOMAIN; HISTONE ACETYLTRANSFERASE; RESPONSE ELEMENTS; GLUCOCORTICOID RECEPTOR; ACTIVATION FUNCTION; BINDING ACTIVITY; N-COR	The retinoid X receptor (RXR) is a member of the nuclear hormone receptor superfamily and heterodimerizes with a variety of other family members such as the thyroid hormone receptor (TR),(1) retinoic acid receptor, vitamin D receptor, and peroxisome proliferator-activated receptor. Therefore, RXR is supposed to play a key role in a ligand-dependent regulation of gene transcription by nuclear receptors. In this study, we have identified the octamer-binding transcription factor-1 (Oct-1) as a novel interaction factor of RXR. In vitro pull-down assays using RXR deletion mutants showed that the interaction surfaces were located in the region encompassing the DNA binding domain (C domain) and the hinge domain (D domain) of RXR, We also showed that RXR interacted with the POU homeodomain but not with the POU-specific domain of Oct-1. Gel shift analysis revealed that Oct-1 reduced the binding of TR/RXR heterodimers to the thyroid hormone response element (TRE), In transient transfection assays using COS1 cells, Oct-1 repressed the T3-dependent transcriptional activity of TR/RXR heterodimers, consistent with in vitro DNA binding data; however, transcriptional activation by Gal4-TR(LBD) (LBD, ligand binding domain), which lacks its own DNA binding domain but retains responsiveness to T3, was not influenced by Oct-1. These results suggest that Oct-1 functionally interacts with RXR and negatively regulates the nuclear receptor signaling pathway by altering the DNA binding ability of the receptors.	Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, Matsumoto, Nagano 3908621, Japan	Shinshu University	Kakizawa, T (corresponding author), Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tkaki@hsp.md.shinshu-u.ac.jp						BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P3027, DOI 10.1210/endo-129-6-3027; Miyamoto T, 1997, J BIOL CHEM, V272, P7752, DOI 10.1074/jbc.272.12.7752; MIYAMOTO T, 1994, MOL CELL ENDOCRINOL, V102, P111, DOI 10.1016/0303-7207(94)90104-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Shah PC, 1997, EMBO J, V16, P7105, DOI 10.1093/emboj/16.23.7105; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	61	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19103	19108		10.1074/jbc.274.27.19103	http://dx.doi.org/10.1074/jbc.274.27.19103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383413	hybrid			2022-12-25	WOS:000081196300036
J	Zeng, FY; Wess, J				Zeng, FY; Wess, J			Identification and molecular characterization of m3 muscarinic receptor dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; ACETYLCHOLINE-RECEPTOR; CHOLINERGIC RECEPTOR; ANTAGONIST BINDING; FUNCTIONAL RESCUE; DIMERIZATION; INTERNALIZATION; COEXPRESSION	Several studies suggest, but do not prove directly, that muscarinic receptors may be able to form dimeric or oligomeric arrays. To address this issue in a more direct fashion, we designed a series of biochemical experiments using a modified version of the rat m3 muscarinic receptor (referred to as m3') as a model system. When membrane lysates prepared from m3' receptor-expressing COS-7 cells were subjected to Western blot analysis under non-reducing conditions, several immunoreactive species were observed corresponding in size to putative receptor monomers, dimers, and oligomers, However, under reducing conditions, the monomeric receptor species represented the only detectable immunoreactive protein, consistent with the presence of disulfide-linked m3 receptor complexes. Similar results were obtained when native m3 muscarinic receptors present in rat brain membranes were analyzed. Control experiments carried out in the presence of high concentrations of the SH group alkylating agent, N-ethylmaleimide, suggested that disulfide bond formation did not occur artifactually during the preparation of cell lysates, The formation of m3' receptor dimers/multimers was confirmed in coimmunoprecipitation studies using differentially epitope-tagged m3' receptor constructs. In addition, these studies showed that m3' receptors were also able to form non-covalently associated receptor dimers and that m3' receptor dimer formation was receptor subtype-specific, Immunological studies also demonstrated that m3' receptor dimers/multimers were abundantly expressed on the cell surface. Site-directed mutagenesis studies indicated that two conserved extracellular Cys residues (Cys-140 and Cys-220) play key roles in the formation of disulfide-linked m3' receptor dimers. These results provide the first direct evidence for the existence of muscarinic receptor dimers and highlight the specificity and molecular diversity of G protein-coupled receptor dimerization/oligomerization.	NIDDKD, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDKD, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov						Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; HAGA K, 1985, J BIOL CHEM, V260, P7927; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEVEY AI, 1991, J NEUROSCI, V11, P3218; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; OHARA K, 1990, EUR J PHARM-MOLEC PH, V189, P341, DOI 10.1016/0922-4106(90)90030-2; POTTER LT, 1991, MOL PHARMACOL, V39, P211; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WATSON S, 1994, G PROTEIN LINKED REC, P1; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	42	205	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19487	19497		10.1074/jbc.274.27.19487	http://dx.doi.org/10.1074/jbc.274.27.19487			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383466	hybrid			2022-12-25	WOS:000081196300089
J	Blostein, R; Dunbar, L; Mense, M; Scanzano, R; Wilczynska, A; Caplan, MJ				Blostein, R; Dunbar, L; Mense, M; Scanzano, R; Wilczynska, A; Caplan, MJ			Cation selectivity of gastric H,K-ATPase and Na,K-ATPase chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; ALPHA-SUBUNIT; NA+,K+-ATPASE; SODIUM; SUBSTITUTES; ACTIVATION; RETICULUM; PROTONS; DOMAIN; IONS	Chimeras of the catalytic subunits of the gastric H,K-ATPase and Na,K-ATPase were constructed and expressed in LLC-PK1 cells. The chimeras included the following: (i) a control, H85N (the first 85 residues comprising the cytoplasmic N terminus of Na,K-ATPase replaced by the analogous region of H,K-ATPase); (ii) H85N/H356 -519N (the N-terminal half of the cytoplasmic M4-M5 loop also replaced); and (iii) H519N (the entire front half replaced). The latter two replacements confer a decrease in apparent affinity for extracellular K+. The 356-519 domain and, to a greater extent, the H519N replacement confer increased apparent selectivity for protons relative to Na+ at cytoplasmic sites as shown by the persistence of K+ influx when the proton concentration is increased and the Naf concentration decreased. The pH and Kf dependence of ouabain-inhibitable ATPase of membranes derived from the transfected cells indicate that the H519N and, to a lesser extent, the H356-519N substitution decrease the effectiveness of K+ to compete for protons at putative cytoplasmic H+ activation sites, Notable pH-independent behavior of H85N/H356-519N at low Na+ suggests that as pH is decreased, Na+/K+. exchange is replaced largely by (Na+ + H+)/K+ exchange. With H519N, the pH and Naf dependence of pump and ATPase activities suggest relatively active H+/K+ exchange even at neutral pH. Overall, this study provides evidence for important roles in cation selectivity for both the N-terminal half of the M4-M5 loop and the adjacent transmembrane helice(s).	McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Yale Univ, Sch Med, Dept Cell & Mol Physiol, New Haven, CT 06510 USA	McGill University; McGill University; Yale University	Blostein, R (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave,Rm L11-132, Montreal, PQ H3G 1A4, Canada.			Caplan, Michael/0000-0001-5768-4405	NIGMS NIH HHS [GM42136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BLOSTEIN R, 1992, ACTA PHYSIOL SCAND, V146, P105; BOVER PD, 1988, TRENDS BIOCHEM SCI, V12, P5; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; Canfield VA, 1998, BIOCHEMISTRY-US, V37, P7509, DOI 10.1021/bi980174h; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HARA Y, 1986, J BIOL CHEM, V261, P2655; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; PICK U, 1982, J BIOL CHEM, V257, P6111; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POLVANI C, 1989, J BIOL CHEM, V264, P17854; Post R.L., 1967, METHODS ENZYMOLOGY, P762; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	28	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18374	18381		10.1074/jbc.274.26.18374	http://dx.doi.org/10.1074/jbc.274.26.18374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373442	hybrid			2022-12-25	WOS:000081056700034
J	Kruip, J; Karapetyan, NV; Terekhova, IV; Rogner, M				Kruip, J; Karapetyan, NV; Terekhova, IV; Rogner, M			In vitro oligomerization of a membrane protein complex - Liposome-based reconstitution of trimeric photosystem I from isolated monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SPIRULINA-PLATENSIS; SYNECHOCOCCUS SP; STRUCTURAL CHARACTERIZATION; FLUORESCENCE SPECTROSCOPY; SYNECHOCYSTIS PCC-6803; CORE COMPLEXES; ORGANIZATION; SUBUNIT; CHLOROPHYLLS; ELONGATUS	Many membrane proteins can be isolated in different oligomeric forms. Photosystem I (PSI), for example, exists in cyanobacteria either as a monomeric or as a trimeric complex. Neither the factors responsible for the specific trimerization process nor its biological role are known at present. In the filamentous cyanobacterium Spirulina platensis, trimers in contrast to monomers show chlorophyll fluorescence emission at 760 nm. To investigate the oligomerization process as well as the nature of the long wavelength chlorophylls, we describe here an in vitro reconstitution procedure to assemble trimeric PS I from isolated purified PS I monomers. Monomers (and trimers) were extracted from S. platensis with n-dodecyl p-D-maltoside and further purified by perfusion chromatography steps. The isolated complexes had the same polypeptide composition as other cyanobacteria (PsaA-PsaF and PsaI-PsaM), as determined from high resolution gels and immunoblotting. They were incorporated into proteoliposomes, which had been prepared by the detergent absorption method, starting from a phosphatidylcholine:phosphatidic acid mixture solubilized by octylglucoside. After the addition of monomeric PSI (lipid:chlorophyll, 25:1), octylglucoside was gradually removed by the stepwise addition of Biobeads. The 77 K fluorescence emission spectrum of these proteoliposomes displays a long wavelength emission at 760 nm that is characteristic of PS I trimers, which indicates for the first time the successful in vitro reconstitution of PS I trimers, In addition, a high performance liquid chromatography analysis of complexes extracted from these proteoliposomes confirms the formation of structural trimers, We also could show with this system 1) that at least one of the stromal subunits PsaC, -D, and -E is necessary for trimer formation and 2) that the extreme long wavelength emitting chlorophyll is formed as a result of trimer formation.	Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany; Russian Acad Sci, AN Bakh Biochem Inst, Moscow 117071, Russia	Ruhr University Bochum; Research Center of Biotechnology RAS; Russian Academy of Sciences	Rogner, M (corresponding author), Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany.							[Anonymous], 1989, PLANT BIOL; BOEKEMA EJ, 1987, FEBS LETT, V217, P283, DOI 10.1016/0014-5793(87)80679-8; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Cladera J, 1996, J BIOENERG BIOMEMBR, V28, P503, DOI 10.1007/BF02110440; Dorra D, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P587; FORD RC, 1988, EMBO J, V7, P2287, DOI 10.1002/j.1460-2075.1988.tb03071.x; FREY TG, 1994, J MOL BIOL, V237, P275, DOI 10.1006/jmbi.1994.1231; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; GOBETS B, 1994, BBA-BIOENERGETICS, V1188, P75, DOI 10.1016/0005-2728(94)90024-8; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; Gourovskaya KN, 1997, FEBS LETT, V414, P193, DOI 10.1016/S0014-5793(97)00994-0; HLADIK J, 1991, PHOTOSYNTH RES, V29, P171, DOI 10.1007/BF00036220; HOFF WD, 1995, BIOPHYS CHEM, V56, P193, DOI 10.1016/0301-4622(95)00033-T; HOSHINA S, 1987, PLANT CELL PHYSIOL, V28, P599; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JEKOW P, 1995, BBA-BIOENERGETICS, V1229, P115, DOI 10.1016/0005-2728(94)00201-F; Karapetyan NV, 1997, BIOCHEMISTRY-US, V36, P13830, DOI 10.1021/bi970386z; Koehne B, 1998, BIOCHEMISTRY-US, V37, P5494, DOI 10.1021/bi9727500; KRUIP J, 1994, PHOTOSYNTH RES, V40, P279, DOI 10.1007/BF00034777; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kruip J, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P405; KRUIP J, 1993, J BIOL CHEM, V268, P23353; Kuhl H, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1001; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; Palsson LO, 1996, PHOTOSYNTH RES, V48, P239, DOI 10.1007/BF00041014; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROGNER M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P415, DOI 10.1016/0005-2728(90)90074-E; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHUBIN VV, 1993, FEBS LETT, V334, P79, DOI 10.1016/0014-5793(93)81685-S; SHUBIN VV, 1991, BIOCHIM BIOPHYS ACTA, V1060, P28, DOI 10.1016/S0005-2728(05)80115-X; SHUBIN VV, 1992, FEBS LETT, V309, P340, DOI 10.1016/0014-5793(92)80803-O; SHUBIN VV, 1995, J PHOTOCH PHOTOBIO B, V30, P153, DOI 10.1016/1011-1344(95)07173-Y; SMITH SO, 1994, BIOCHEMISTRY-US, V33, P6327, DOI 10.1021/bi00186a036; TRISSL HW, 1993, PHOTOSYNTH RES, V35, P247, DOI 10.1007/BF00016556; TSIOTIS G, 1995, EUR J BIOCHEM, V231, P823, DOI 10.1111/j.1432-1033.1995.tb20767.x; VONGRONDELLE R, 1994, BIOCHIM BIOPHYS ACTA, V1187, P1; WENK SO, 1998, PHOTOSYNTHESIS MECH, V3, P1637	43	57	61	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18181	18188		10.1074/jbc.274.26.18181	http://dx.doi.org/10.1074/jbc.274.26.18181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373417	hybrid			2022-12-25	WOS:000081056700009
J	Oya, T; Hattori, N; Mizuno, Y; Miyata, S; Maeda, S; Osawa, T; Uchida, K				Oya, T; Hattori, N; Mizuno, Y; Miyata, S; Maeda, S; Osawa, T; Uchida, K			Methylglyoxal modification of protein - Chemical and immunochemical characterization of methylglyoxal-arginine adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAILLARD REACTION INTERMEDIATE; GLYCATION END-PRODUCT; GLYOXALASE SYSTEM; DIABETIC COMPLICATIONS; IN-VIVO; IMMUNOHISTOCHEMICAL DETECTION; MITOCHONDRIAL RESPIRATION; LIPID-PEROXIDATION; ALDOSE REDUCTASE; SERUM-ALBUMIN	Methylglyoxal (MG), an endogenous metabolite that increases in diabetes and is a common intermediate in the Maillard reaction(glycation), reacts with proteins and forms advanced-glycation end products. In the present study, we identify a novel MG-arginine adduct and also characterize the structure of a major fluorescent adduct, In addition we describe the immunochemical study on the MG-arginine addicts using monoclonal antibody directed to MG-modified protein. Upon incubation of N(alpha)-acetyl-L-arginine with MG at 37 degrees C, two non-fluorescent products and one-fluorescent product were detected as the-major products, The nonfluorescent products were identified as the N(delta)-(5-hydro-5-methyl-4-imidazolon-2-yl)-L-ornithine derivatives (5-hydro-5-methylimidazolone) and a novel MG-arginine adduct having a tetra-hydropyrimidine -moiety; N(delta)-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2 -L-ornithine). On the basis of the following chemical and spectroscopic evidence; the-major fluorescent product, putatively identified as N(delta)-(5-methylimidazolon-2-yl)-L-ornithithine (5-methylimidazolone), was found to-be identical to N(delta)-(5-hydroxy4,6-dimethylpyrimidine-2-yl)-L-ornithine (argpyrimidine): (i) the low and-high resolution fast atom bombardment mass spectrometry gave a molecular ion peak at m/z of 297 (M+H) and:a molecular formula of C(10)H(25)O(6)N(4), respectively, which coincided with pyrimidine; (ii) the (1)H NMR spectrum of this product in. d6-Me(2)SO showed a singlet at 2.10 ppm corresponding to six protons; (iii) the peak corresponding to the 5-methylimidazolone derivative was not detected by the liquid chromatography-mass spectrometry with the mode of selected ion monitoring; (iv) incubation of 5-hydro-5-methylimidazolone, a putative precursor of 5 methylimidazolone, at 37 degrees C for 14 days scarcely generated 5-methylimidazolone. On the other hand, ras an immunochemical approach to the-detection-of these MG adducts, we raised the monoclonal antibodies (mAb3C and mAb6B) directed to the MG-modified protein and found that they specifically recognized the major, fluorescent product, argpyrimidine; as the dominant epitope, The immunohistochemical analysis of-the kidneys from diabetic patients revealed the localization of argpyrimidine in intima and media of small artery walls. Furthermore, the accumulation of argpyrimidine was also observed in some arterial walls of the rat brain after middle cerebral artery occlusion followed by reperfusion. These results suggest that argpyrimidine may contribute to the progression of not only long term diabetic complications, such as nephropathy and atherosclerosis, but also the tissue injury caused by ischemia/reperfusion.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 113, Japan; Kobe Univ, Sch Med, Dept Internal Med 2, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Pathol 2, Kobe, Hyogo 6500017, Japan	Nagoya University; Juntendo University; Kobe University; Kobe University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	OYA-ITO, Tomoko/M-8906-2014	Uchida, Koji/0000-0003-3894-5299				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; Baynes JW., 1989, PROG CLIN BIOL RES, V304, P1; Biswas S, 1997, BIOCHEM J, V323, P343, DOI 10.1042/bj3230343; BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6; BRINKMANN E, 1995, J CHEM SOC P2, V2, P1; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Che WY, 1997, J BIOL CHEM, V272, P18453, DOI 10.1074/jbc.272.29.18453; Cordeiro C, 1996, ANAL BIOCHEM, V234, P221, DOI 10.1006/abio.1996.0076; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; HALDER J, 1993, INT J CANCER, V54, P443, DOI 10.1002/ijc.2910540315; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1965, DOI 10.1080/00021369.1986.10867692; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1959, DOI 10.1080/00021369.1986.10867691; KATO H, 1986, J NUTR SCI VITAMINOL, V32, P55, DOI 10.3177/jnsv.32.55; KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953; LO TWC, 1994, J BIOL CHEM, V269, P32299; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MONNIER VM, 1990, ADV LIF SCI, P393; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; SELWOOD T, 1993, BIOCHEM SOC T, V21, P170; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; SHINODA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1826, DOI 10.1271/bbb.57.1826; SHINOHARA M, 1996, DIABETES, V45, pA126; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P403, DOI 10.1093/oxfordjournals.jbchem.a131472; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; URABE T, 1996, J NEUROCHEM, V67, P256; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Yoshino H, 1997, BRAIN RES, V767, P81, DOI 10.1016/S0006-8993(97)00616-1	44	314	346	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18492	18502		10.1074/jbc.274.26.18492	http://dx.doi.org/10.1074/jbc.274.26.18492			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373458	hybrid			2022-12-25	WOS:000081056700050
J	Zitzer, H; Richter, D; Kreienkamp, HJ				Zitzer, H; Richter, D; Kreienkamp, HJ			Agonist-dependent interaction of the rat somatostatin receptor subtype 2 with cortactin-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; LOCALIZATION; BRAIN; EXPRESSION; CLONING; SUBUNIT; SYSTEM; SST2A	We report here an interaction between the C terminus of the rat somatostatin receptor subtype 2 (SSTR2) and a protein that has recently been identified as contactin-binding protein 1 (CortBP1). Interaction is mediated by the PDZ (PSD-95/discs large/ZO-1) domain of CortBP1. As shown by in situ hybridization, SSTR2 and cortactin-binding protein are coexpressed in the rat brain. The association between SSTR2 and the PDZ-domain of CortBP1 was verified by overlay assays and by coprecipitation after transfection in human embryonic kidney (HEK) cells. Analysis by confocal microscopy indicates that CortBP1 is distributed diffusely throughout the cytosol in transfected cells and that it becomes concentrated at the plasma membrane when SSTR2 is present. This process is largely increased when the receptor is stimulated by somatostatin; as CortBP1 interacts with the C terminus of SSTR2, our data suggest that the binding of agonist to the receptor increase the accessibility of the receptor C terminus to the PDZ domain of CortBP1. Our data for the first time establish a link between a G-protein coupled receptor and constituents of the cytoskeleton.	Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Boehm S, 1997, J NEUROSCI, V17, P4066; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Dournaud P, 1998, J NEUROSCI, V18, P1056; Dournaud P, 1996, J NEUROSCI, V16, P4468; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Helboe L, 1998, J NEUROSCI, V18, P4938; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; PEREZ J, 1995, NEUROSCIENCE, V64, P241, DOI 10.1016/0306-4522(94)00364-B; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182	24	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18153	18156		10.1074/jbc.274.26.18153	http://dx.doi.org/10.1074/jbc.274.26.18153			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373412	hybrid			2022-12-25	WOS:000081056700004
J	Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T; Tamura, K; Oue, S; Iizuka, T; Ogura, T; Esumi, H				Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T; Tamura, K; Oue, S; Iizuka, T; Ogura, T; Esumi, H			Characterization of mouse nNOS2, a natural variant of neuronal nitric-oxide synthase produced in the central nervous system by selective alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; L-ARGININE BINDING; MESSENGER-RNA; CYTOCHROME P-450-CAM; SUBSTRATE-ANALOGS; OXYGENASE DOMAIN; ESCHERICHIA-COLI; PROXIMAL LIGAND; HEME ENZYMES; EXPRESSION	Mouse neuronal nitric-oxide synthase 2 (nNOS2) is a unique natural variant of constitutive neuronal nitric-oxide synthase (nNOS) specifically expressed in the central nervous system having a 105-amino acid deletion in the heme-binding domain as a result of in-frame mutation by specific alternative splicing. The mouse nNOS2 cDNA gene was heterologously expressed in Escherichia coli, and the resultant product was characterized spectroscopically in detail. Purified recombinant nNOS2 contained heme but showed no L-arginine- and NADPH-dependent citrulline-forming activity in the presence of Ca2+-promoted calmodulin, elicited a sharp electron paramagnetic resonance (EPR) signal at g = 6.0 indicating the presence of a high spin ferriheme as isolated and showed a peak at around 420 nm in the CO difference spectrum, instead of a 443-nm peak detected with the recombinant wild-type nNOS1 enzyme. Thus, although the heme domain of nNOS2 is capable of binding heme, the heme coordination geometry is highly abnormal in that it probably has a proximal non-cysteine thiolate ligand both in the ferric and ferrous states. Moreover, negligible spectral perturbation of the nNOS2 ferriheme was detected upon addition of either L-arginine or imidazole. These provide a possible rational explanation for the inability of nNOS2 to catalyze the cytochrome P450-type monooxygenase reaction.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; RIKEN, Inst Phys & Chem Res, Biophys Chem Lab, Wako, Saitama 3510198, Japan; Natl Canc Ctr, Res Inst E, Investigat Treatment Div, Kashiwa, Chiba 2770882, Japan	Nippon Medical School; RIKEN; National Cancer Center - Japan	Nishino, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ANDERSSON LA, 1991, STRUCT BOND, V74, P1; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DAWSON TM, 1994, PROG BRAIN RES, V103, P365; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hori H, 1997, BIOCHEM BIOPH RES CO, V234, P476, DOI 10.1006/bbrc.1997.6664; Ignarro LJ, 1996, KIDNEY INT, pS2; Iwasaki T, 1999, J BIOL CHEM, V274, P7705, DOI 10.1074/jbc.274.12.7705; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OGURA T, 1994, P 3 INT M BIOL NITR; Palmer G., 1979, PORPHYRINS, P313; Possee RD., 1992, BACULOVIRUS EXPRESSI; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; Rietjens IMCM, 1996, J BIOL INORG CHEM, V1, P372, DOI 10.1007/s007750050068; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, BIOCHEMISTRY-US, V36, P11821, DOI 10.1021/bi963003q; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Summers MD, 1987, TEXAS AGR EXPT STATI; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang Y, 1997, J BIOL CHEM, V272, P11392; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	69	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17559	17566		10.1074/jbc.274.25.17559	http://dx.doi.org/10.1074/jbc.274.25.17559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364190	hybrid			2022-12-25	WOS:000080974300026
J	Liu, ZX; Yu, YJ; Dennert, G				Liu, ZX; Yu, YJ; Dennert, G			A cell surface ADP-ribosyltransferase modulates T cell receptor association and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ANTIGEN-RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; TYROSINE KINASE; PROTEIN-KINASE; LYMPHOCYTES-T; EXPRESSION; CD45; PHOSPHORYLATION; STIMULATION	ART-1, a cell surface ADP-ribosyltransferase, is imbedded in the membrane by a glycosylphosphatidylinositol anchor. Function of this enzyme in mouse T lymphocytes is to transfer ADP-ribose groups from NAD to arginine residues, exposed on the extracellular domain of cell surface molecules. As a consequence, T cell responses are modulated. To explore the precise action of the enzyme, the T cell lymphoma EL-4 was transfected with the ART-1 gene, and its effects were examined. It is shown that ART-1 ADP-ribosylates distinct cell surface molecules, causing inhibition of T cell receptor signaling, concomitant to suppression of p56(lck) kinase activation. These effects are explained by failure of T cell receptors and co-receptors to associate into a contiguous and functional receptor cluster.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Dennert, G (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol, POB 33800,1441 Eastlake Ave,M-S 73, Los Angeles, CA 90033 USA.	dennert@hsc.usc.edu			NCI NIH HHS [CA37706] Funding Source: Medline; NIAID NIH HHS [AI43954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; BOLEN JB, 1991, ADV CANCER RES, V57, P103; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Nemoto E, 1996, J IMMUNOL, V156, P85; Okamoto S, 1998, J IMMUNOL, V160, P4190; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Poggi A, 1996, INT IMMUNOL, V8, P1947, DOI 10.1093/intimm/8.12.1947; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235	18	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17399	17401		10.1074/jbc.274.25.17399	http://dx.doi.org/10.1074/jbc.274.25.17399			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364166	hybrid			2022-12-25	WOS:000080974300002
J	Popov, M; Reithmeier, RAF				Popov, M; Reithmeier, RAF			Calnexin interaction with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger 1 (band 3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TCR-ALPHA-PROTEINS; ASPARAGINE-LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONES CALNEXIN; VIRUS-G-PROTEIN; EXTRACYTOSOLIC LOOPS; GLUCOSE-TRANSPORTER; SURFACE EXPRESSION; P-GLYCOPROTEIN; RIBONUCLEASE-B	The interaction of the endoplasmic reticulum chaperone calnexin with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger (AE1), was characterized by cell-free translation and in transfected HEK293 cells, followed by co-immunoprecipitation using anti-calnexin antibody. AE1 contains 12-14 transmembrane segments and has a single site of N-glycosylation at Asn-642 in the fourth extracytosolic loop. This site was mutated (N642D) to create a nonglycosylated protein. Calnexin showed a preferential interaction with N-glycosylated AE1 relative to nonglycosylated AE1 both in vitro and in vivo. This interaction could be blocked by inhibition of glucosidases I and II with castanospermine. Calnexin had access to novel N-glycosylated sites created in other extracytosolic loops in AE1 by site-directed or insertional mutagenesis. The interaction with AE1 was enhanced when multiple sites were introduced into the same loop or into two different loops. An association of calnexin with truncated versions of N-glycosylated AE1 was detected after release of the nascent chains from ribosomes with puromycin. The results show that the interaction of calnexin with the polytopic membrane glycoprotein AE1 was dependent on the presence but not the location of the oligosaccharide. Furthermore, calnexin was associated with AE1 after release of AE1 from the translocation machinery.	Univ Toronto, Dept Med, MRC Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, MRC Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Reithmeier, RAF (corresponding author), Univ Toronto, Dept Med, MRC Grp Membrane Biol, Rm 7344,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	r.reithmeier@utoronto.ca						Andersson H, 1996, FEBS LETT, V397, P321, DOI 10.1016/S0014-5793(96)01207-0; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Chevet E, 1998, MOL BIOL CELL, V9, p345A; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Flura T, 1997, GLYCOBIOLOGY, V7, P617, DOI 10.1093/glycob/7.5.617; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; Groves JD, 1998, FEBS LETT, V433, P223, DOI 10.1016/S0014-5793(98)00909-0; Groves JD, 1998, BIOCHEM J, V332, P161, DOI 10.1042/bj3320161; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hentges A, 1997, BIOL CHEM, V378, P1031, DOI 10.1515/bchm.1997.378.9.1031; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEPKE S, 1976, J MEMBRANE BIOL, V29, P147, DOI 10.1007/BF01868957; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PIND S, 1994, J BIOL CHEM, V269, P12784; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; Tam LY, 1996, BIOCHEM J, V318, P645, DOI 10.1042/bj3180645; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WADA I, 1994, J BIOL CHEM, V269, P7464; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	79	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17635	17642		10.1074/jbc.274.25.17635	http://dx.doi.org/10.1074/jbc.274.25.17635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364201	hybrid			2022-12-25	WOS:000080974300037
J	Qiu, JZ; Qian, Y; Chen, V; Guan, MX; Shen, BH				Qiu, JZ; Qian, Y; Chen, V; Guan, MX; Shen, BH			Human exonuclease 1 functionally complements its yeast homologues in DNA recombination, RNA primer removal, and mutation avoidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; NUCLEOTIDE EXCISION-REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; HUMAN FLAP ENDONUCLEASE-1; DOUBLE-STRAND BREAKS; MISMATCH REPAIR; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; POLYMERASE-I	Yeast exonuclease 1 (Exo1) is induced during meiosis and plays an important role in DNA homologous recombination and mismatch correction pathways. The human homolog, an 803-amino acid protein, shares 55% similarity to the yeast Exo1. In this report, we show that the enzyme functionally complements Saccharomyces cerevisiae Exo1 in recombination of direct repeat DNA fragments, UV resistance, and mutation avoidance by in vivo assays. Furthermore, the human enzyme suppresses the conditional lethality of a rad27 Delta mutant, symptomatic of defective RNA primer removal. The purified recombinant enzyme not only displays 5'-3' double strand DNA exonuclease activity, hut also shows an RNase H activity. This result indicates a back-up function of exonuclease 1 to flap endonuclease-1 in RNA primer removal during lagging strand DNA synthesis.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope; California Institute of Technology	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Binghui/0000-0002-4408-407X; Guan, Min-Xin/0000-0001-5067-6736	NCI NIH HHS [CA82468] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BOYER JC, 1995, CANCER RES, V55, P6063; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1995, DNA REPAIR MUTATGENE; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; Kornberg A., 1992, DNA REPLICATION; LEHMAN IR, 1978, ENZYME, V14, P15; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Murante RS, 1998, P NATL ACAD SCI USA, V95, P2244, DOI 10.1073/pnas.95.5.2244; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; Okinaka RT, 1997, MUTAT RES-DNA REPAIR, V385, P107, DOI 10.1016/S0921-8777(97)00031-1; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Qiu JZ, 1998, NUCLEIC ACIDS RES, V26, P3077, DOI 10.1093/nar/26.13.3077; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Schmutte C, 1998, CANCER RES, V58, P4537; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Sherman F., 1986, METHODS YEAST GENETI; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; States JC, 1998, HUM MUTAT, V12, P103, DOI 10.1002/(SICI)1098-1004(1998)12:2<103::AID-HUMU5>3.0.CO;2-6; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TAKAYAMA K, 1995, CANCER RES, V55, P5656; THOMAS BJ, 1989, GENETICS, V123, P725; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v	62	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17893	17900		10.1074/jbc.274.25.17893	http://dx.doi.org/10.1074/jbc.274.25.17893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364235	hybrid, Green Accepted			2022-12-25	WOS:000080974300071
J	Sachsenmaier, C; Sadowski, HB; Cooper, JA				Sachsenmaier, C; Sadowski, HB; Cooper, JA			STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation	ONCOGENE			English	Article						Src; STAT; PDGF; receptor tyrosine kinase; juxtamembrane	EPIDERMAL GROWTH-FACTOR; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; BETA-RECEPTOR; V-SRC; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; PROTEIN-KINASES; GENE-REGULATION	Activation of the platelet-derived growth factor (PDGF) receptor tyrosine kinase induces tyrosine phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins. Since the PDGF receptor also activates the Src tyrosine kinase, it is possible that Src mediates tyrosine phosphorylation of STATs in PDGF-treated cells. Consistent with a role for Src in STAT activation, we found that a PDGF receptor juxtamembrane tyrosine residue required for Src activation is necessary and sufficient for activation of STATs 1 and 3. To test the Src requirement further, we made other mutations in the PDGF receptor juxtamembrane region that increased or decreased Src binding. In epithelial and fibroblast cells, PDGF activated STAT1, 3 and 6 in the absence of detectable binding and activation of Src. In addition, PDGF induced C-myc RNA expression and DNA synthesis even though Src was not detectably activated. The activation of MAP kinase and the induction of c-fos gene expression both correlated with STAT but not Src activation by the receptor. We conclude that juxtamembrane tyrosine phosphorylation is necessary for both Src tyrosine kinase and STAT activation by the beta PDGF receptor, but that both processes are regulated independently by this region.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Fred Hutchinson Cancer Center; Cold Spring Harbor Laboratory	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A2-025,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA54786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELM MH, 1995, SCIENCE, V267, P1347; HERBST R, 1995, ONCOGENE, V10, P369; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Novak U, 1996, ONCOGENE, V13, P2607; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3583	3592		10.1038/sj.onc.1202694	http://dx.doi.org/10.1038/sj.onc.1202694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380880				2022-12-25	WOS:000080891700004
J	Stickeler, E; Kittrell, F; Medina, D; Berget, SM				Stickeler, E; Kittrell, F; Medina, D; Berget, SM			Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis	ONCOGENE			English	Article						SR splicing factors; alternative splicing; CD44; mammary tumorigenesis; mouse model	HUMAN BREAST-CANCER; MESSENGER-RNA; VARIANT ISOFORMS; PREMESSENGER RNA; OVARIAN-CANCER; SITE SELECTION; PROTEIN FAMILY; CD44 ISOFORMS; CELL-LINES; IN-VIVO	Using a mouse model of mammary gland development and tumorigenesis ne examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference nas observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Berget, SM (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA.		Stickeler, Elmar/AHE-9022-2022		NCI NIH HHS [CA 47112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1995, RNA, V1, P763; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, MAMMALIAN PRE MRNA S, P174; CANNISTRA SA, 1995, J CLIN ONCOL, V13, P1912, DOI 10.1200/JCO.1995.13.8.1912; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; EAST JA, 1993, EUR J CANCER, V29A, P1921, DOI 10.1016/0959-8049(93)90442-I; FOX SB, 1994, CANCER RES, V54, P4539; FRIEDRICHS K, 1995, LANCET, V345, P1237, DOI 10.1016/S0140-6736(95)92018-8; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; Heider KH, 1995, EUR J CANCER, V31A, P2385, DOI 10.1016/0959-8049(95)00420-3; JERRY DJ, 1993, CANCER RES, V53, P3374; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KITTRELL FS, 1992, CANCER RES, V52, P1924; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lee MP, 1997, CANCER RES, V57, P3131; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; Moore M., 1993, RNA WORLD, P303; Muller W, 1997, J PATHOL, V183, P222, DOI 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; NORTON PA, 1994, J CELL SCI, V107, P1; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stickeler E, 1997, ANTICANCER RES, V17, P1871; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Tran TA, 1997, HUM PATHOL, V28, P809, DOI 10.1016/S0046-8177(97)90154-4; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WANG J, 1995, RNA, V1, P335; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhu X, 1997, INT J CANCER, V72, P574, DOI 10.1002/(SICI)1097-0215(19970807)72:4<574::AID-IJC4>3.3.CO;2-Y	54	160	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3574	3582		10.1038/sj.onc.1202671	http://dx.doi.org/10.1038/sj.onc.1202671			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380879				2022-12-25	WOS:000080891700003
J	Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB				Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB			The EWS TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator	ONCOGENE			English	Article						EWS TEC; chondrosarcomas; fusion proteins; nuclear receptors; EWS; transcriptional activation	ORPHAN NUCLEAR RECEPTOR; EWINGS-SARCOMA TRANSLOCATION; NGFI-B; MALIGNANT-MELANOMA; DNA-BINDING; SOFT PARTS; MYXOID CHONDROSARCOMA; GENE FUSION; FAMILY; IDENTIFICATION	The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the full-length TEC receptor can efficiently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less efficiently the NBRE, Addition of the aminoterminal domain of EWS to either isoforms does not alter significantly their DNA-binding properties to the NBRE, Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.	CHUQ, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada; Univ Laval, Fac Med, Ste Foy, PQ G1K 7P4, Canada; Beth Israel Deaconess Med Ctr, Harvard Inst Med, Boston, MA 02115 USA	Laval University; Laval University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Labelle, Y (corresponding author), CHUQ, Unite Rech Genet Humaine & Mol, Pavillon St Francois dAssise, Quebec City, PQ G1L 3L5, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Buono P, 1997, BIOCHEM J, V323, P245, DOI 10.1042/bj3230245; CALVIO C, 1995, RNA, V1, P724; Castillo SO, 1997, GENOMICS, V41, P250, DOI 10.1006/geno.1997.4677; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3303	3308		10.1038/sj.onc.1202675	http://dx.doi.org/10.1038/sj.onc.1202675			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359536				2022-12-25	WOS:000080523800013
J	Patterson, C; Ruef, J; Madamanchi, NR; Barry-Lane, P; Hu, ZY; Horaist, C; Ballinger, CA; Brasier, AR; Bode, C; Runge, MS				Patterson, C; Ruef, J; Madamanchi, NR; Barry-Lane, P; Hu, ZY; Horaist, C; Ballinger, CA; Brasier, AR; Bode, C; Runge, MS			Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin - Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ENDOTHELIAL GROWTH-FACTOR; SUPEROXIDE ANION RELEASE; NECROSIS-FACTOR-ALPHA; NADPH OXIDASE; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; CYTOSOLIC COMPONENT	Thrombin is a potent vascular smooth muscle cell (VSMC) mitogen, Because recent evidence implicates reactive oxygen intermediates (ROI) in VSMC proliferation in general and atherogenesis in particular, we investigated whether ROI generation is necessary for thrombin-induced mitogenesis, Treatment of human aortic smooth muscle cells with thrombin increased DNA synthesis, an effect that was antagonized by diphenyleneiodonium but not by other inhibitors of cellular oxidase systems. This effect of thrombin was accompanied by increased O-2(.) and H2O2 generation and NADH/NADPH consumption, ROI generation in response to thrombin pretreatment could also be blocked by diphenyleneiodonium, suggesting that the NAD(P)H oxidase was necessary for ROI generation and thrombin-induced mitogenesis, Because of observed differences between the VSMC and neutrophil oxidase, we examined whether the cytosolic components of the phagocytic NAD(P)H oxidase were present in VSMC. p47(phox) and Rac2 were present in VSMC, Furthermore, thrombin increased expression of p47(phox) and Rac2 and stimulated their translocation to the cell membrane. We examined whether p47(phox) might be similarly regulated in vivo in a rat aorta balloon injury model and found that p47(phox) protein was increased after injury. Immunocytochemistry localized expression of p47(phox) to the neointima and media of injured arteries. Our data demonstrate that generation of O-2(.) and H2O2 is required for thrombin-mediated mitogenesis in VSMC and that p47(phox) is regulated by thrombin in vitro and is associated with vascular lesion formation in vivo.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Cardiol, Galveston, TX 77555 USA; Univ Heidelberg, Div Cardiol, D-69115 Heidelberg, Germany	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Ruprecht Karls University Heidelberg	Runge, MS (corresponding author), Univ Texas, Med Branch, Div Cardiol, 9-138 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.			Madamanchi, Nageswara/0000-0003-0590-0908	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003658, R01HL057352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG015234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57352, HL03658] Funding Source: Medline; NIA NIH HHS [AG15234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; Auclair C., 1985, CRC HDB METHODS OXYG, P123, DOI DOI 10.1201/9781351072922; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CLOWES AW, 1983, LAB INVEST, V49, P327; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Dieter P, 1995, BIOL SIGNAL, V4, P331; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FAGER G, 1995, CIRC RES, V77, P645, DOI 10.1161/01.RES.77.4.645; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; KACHIGIAN L, 1995, J BIOL CHEM, V270, P27679; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MATSUBARA T, 1986, J CELL PHYSIOL, V127, P207, DOI 10.1002/jcp.1041270203; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; Offermann M K, 1994, Heart Dis Stroke, V3, P52; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Rao GN, 1996, ONCOGENE, V13, P713; REIDY MA, 1992, CIRCULATION, V86, P43; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruef J, 1997, CIRC RES, V81, P24, DOI 10.1161/01.RES.81.1.24; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Sellmayer A, 1996, CELL SIGNAL, V8, P397, DOI 10.1016/0898-6568(96)00077-0; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; Tsai JC, 1996, J BIOL CHEM, V271, P3667; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Yamaguchi M, 1996, BIOCHEM BIOPH RES CO, V220, P891, DOI 10.1006/bbrc.1996.0501	62	284	291	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19814	19822		10.1074/jbc.274.28.19814	http://dx.doi.org/10.1074/jbc.274.28.19814			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391925	hybrid			2022-12-25	WOS:000081377300045
J	Slatter, DA; Paul, RG; Murray, M; Bailey, AJ				Slatter, DA; Paul, RG; Murray, M; Bailey, AJ			Reactions of lipid-derived malondialdehyde with collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CROSS-LINK; THIOBARBITURIC ACID; BIOLOGICAL-MATERIALS; KINETIC-ANALYSIS; GLYCATION; PEROXIDATION; PLASMA; MALONALDEHYDE; FLUORESCENCE	Malondialdehyde is a product of fatty acid oxidation (e.g. from low density lipoprotein) implicated in the damage of proteins such as collagen in the cardiovascular system (Chio, K. J., and Tappel, A. L. (1969) Biochemistry 8, 2821-2827), Its concentration is raised in diabetic subjects probably as a side effect of increased protein glycation, Collagen has enzyme-catalyzed cross-links formed between its individual molecules that are essential for maintaining the structure and flexibility of the collagen fiber. The cross-link dehydro-hydroxylysinonorleucine reacts irreversibly with 10 mM malondialdehyde at least 3 orders of magnitude faster than glucose reactions with lysine or arginine, such that there is little cross-link left after 1 h at 37 degrees C, Other cross-links and glycated elements of collagen are also vulnerable. Several possible products of malondialdehyde with collagen cross-links are proposed, and the potential involvement of collagenous histidine in these reactions is discussed. We have also isolated N-delta-(2-pyrimidyl)-L-ornithine from collagenous arginine reacted with malondialdehyde, The yields of this product were considerably higher than those from model reactions, being approximately 2 molecules/collagen molecule after 1 day at 37 degrees C in 10 mM malondialdehyde, Collagenous lysine-derived malondialdehyde products may have been present but were not protected from protein acid hydrolysis by standard reduction techniques, thus resulting in a multitude of fragmented products.	Univ Bristol, Div Mol & Cellular Biol, Collagen Grp, Langford BS40 5DS, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Bristol; University of Bristol	Bailey, AJ (corresponding author), Univ Bristol, Div Mol & Cellular Biol, Collagen Grp, Langford BS40 5DS, England.		Slatter, David/AAV-5771-2020; Slatter, David/AAW-6938-2021					BAILEY AJ, 1980, NATURE, V288, P408, DOI 10.1038/288408a0; BAILEY AJ, 1968, BIOCHEM BIOPH RES CO, V33, P812, DOI 10.1016/0006-291X(68)90233-7; BAX A, 1985, J MAGN RESON, V63, P230, DOI 10.1016/0022-2364(85)90176-3; BERNSTEIN PH, 1980, J BIOL CHEM, V255, P414; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; GOMEZSANCHEZ A, 1990, CARBOHYD RES, V200, P167, DOI 10.1016/0008-6215(90)84188-Z; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; HIGGINS PJ, 1981, J BIOL CHEM, V256, P5204; Kedziora-Kornatowska K, 1998, BIOCHEM MOL BIOL INT, V46, P577; LI XY, 1994, LIPIDS, V29, P73, DOI 10.1007/BF02537094; LIGHT ND, 1982, METHOD ENZYMOL, V82, P360; LOWREY CH, 1985, J BIOL CHEM, V260, P1611; MECHANIC GL, 1987, BIOCHEMISTRY-US, V26, P3500, DOI 10.1021/bi00386a038; NAIR V, 1986, LIPIDS, V21, P6, DOI 10.1007/BF02534294; NAIR V, 1988, TETRAHEDRON, V44, P2793; NOBERASCO G, 1991, BIOMED PHARMACOTHER, V45, P193, DOI 10.1016/0753-3322(91)90107-5; Paul RG, 1998, BIOCHEM J, V330, P1241, DOI 10.1042/bj3301241; Paul RG, 1997, INT J BIOCHEM CELL B, V29, P211, DOI 10.1016/S1357-2725(96)00134-3; PAUL RG, 1920, IN PRESS INT J BIOCH; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; RICHARD MJ, 1992, J CHROMATOGR-BIOMED, V577, P9, DOI 10.1016/0378-4347(92)80593-F; RICHARD MJ, 1992, CLIN CHEM, V38, P704; ROBINS SP, 1972, BIOCHEM BIOPH RES CO, V48, P76, DOI 10.1016/0006-291X(72)90346-4; SCHLEICHER E, 1986, BIOCHIM BIOPHYS ACTA, V884, P199, DOI 10.1016/0304-4165(86)90244-8; SHILTON BH, 1993, EUR J BIOCHEM, V213, P567; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6; Sims TJ, 1996, DIABETOLOGIA, V39, P946; SIMS TJ, 1999, METHODS MOL BIOL EXT; Slatter DA, 1998, FEBS LETT, V421, P180, DOI 10.1016/S0014-5793(97)01554-8; SUMMERFIELD FW, 1981, ANAL BIOCHEM, V111, P77, DOI 10.1016/0003-2697(81)90231-1; SUMMERFIELD FW, 1984, ANAL BIOCHEM, V143, P265, DOI 10.1016/0003-2697(84)90662-6; SUMMERFIELD FW, 1978, BIOCHEM BIOPH RES CO, V82, P547, DOI 10.1016/0006-291X(78)90909-9; TATUM VL, 1990, LIPIDS, V25, P226, DOI 10.1007/BF02535752; Volpi N, 1998, J CHROMATOGR B, V713, P433, DOI 10.1016/S0378-4347(98)00195-9; YAMAUCHI M, 1987, J BIOL CHEM, V262, P11428; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355	42	60	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19661	19669		10.1074/jbc.274.28.19661	http://dx.doi.org/10.1074/jbc.274.28.19661			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391905	hybrid			2022-12-25	WOS:000081377300025
J	Farber, SA; Olson, ES; Clark, JD; Halpern, ME				Farber, SA; Olson, ES; Clark, JD; Halpern, ME			Characterization of Ca(2+)-dependent phospholipase A(2) activity during zebrafish embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A(2); P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; CALCIUM IONOPHORE; RAT-BRAIN; CELLS; IDENTIFICATION; INHIBITION	We have developed a simple fluorescent assay for detection of phospholipase A(2) (PLA(2)) activity in zebrafish embryos that utilizes a fluorescent phosphatidylcholine substrate. By using this assay in conjunction with selective PLA(2) inhibitors and Western blot analysis, we identified the principal activity in zebrafish embryogenesis as characteristic of the Ca(2+)-dependent cytosolic PLA(2) (cPLA(2)) subtype. Embryonic cPLA(2) activity remained constant from the 1-cell stage until the onset of somitogenesis, at which time it increased sharply. This increase was preceded by the expression of a previously identified zebrafish cPLA(2) homologue (Nalefski, E., Sultzman, L., Martin, D., Kriz, R., Towler, P., Knopf, J., and Clark, J. (1994) J. Biol. Chem. 269, 18239-18249). By using a quenched BODIPY-labeled phosphatidylcholine that fluoresces only upon cleavage by PLA(2), lipase activity was visualized in the cells of living embryos where it localized to perinuclear membranes.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Genet Inst Inc, Cambridge, MA 02140 USA	Carnegie Institution for Science	Farber, SA (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	Farber@mail1.ciwemb.edu	Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; Clark, James D./0000-0002-4801-0123	NINDS NIH HHS [F32 NS10326] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010326] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEPENIK KP, 1984, CALCIFIED TISSUE INT, V36, P175, DOI 10.1007/BF02405314; CHEPENIK KP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P192, DOI 10.1016/0005-2760(92)90290-C; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gallagher ML, 1998, J FISH BIOL, V52, P1218, DOI 10.1111/j.1095-8649.1998.tb00967.x; GAY SW, 1984, J EXP ZOOL, V232, P317, DOI 10.1002/jez.1402320219; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KAWASAKI M, 1993, MOL BRAIN RES, V19, P39, DOI 10.1016/0169-328X(93)90146-G; Kim TS, 1997, J BIOL CHEM, V272, P2542; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MESHULAM T, 1992, J BIOL CHEM, V267, P21465; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Navas JM, 1997, J FISH BIOL, V51, P760, DOI 10.1006/jfbi.1997.0484; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Piddington R, 1996, DIABETOLOGIA, V39, P915; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Secombes C.J., 1996, Fish Physiology, V15, P63; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tocher Douglas R., 1995, Biochemistry and Molecular Biology of Fishes, V4, P119; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WALDMAN SA, 1984, INT J BIOCHEM, V16, P593, DOI 10.1016/0020-711X(84)90027-2; Watkins BA, 1996, IFT BAS SYM, V11, P71; Westerfield M, 1995, ZEBRAFISH BOOK; YOSHIHARA Y, 1992, BIOCHEM BIOPH RES CO, V185, P350, DOI 10.1016/S0006-291X(05)80992-1	50	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19338	19346		10.1074/jbc.274.27.19338	http://dx.doi.org/10.1074/jbc.274.27.19338			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383445	hybrid			2022-12-25	WOS:000081196300068
J	Izzo, MW; Strachan, GD; Stubbs, MC; Hall, DJ				Izzo, MW; Strachan, GD; Stubbs, MC; Hall, DJ			Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAR UPSTREAM ELEMENT; INSULIN PROMOTER; ADENOVIRUS E1A; BINDING; GENE; MAZ; CELLS; ACTIVATION; SEQUENCES; DOMAIN	ZF87/MAZ is a zinc finger-containing transcription factor that was cloned based on its ability to bind to a site within the c-myc P2 promoter. However, its role in the control of c-myc transcription has not yet been well established. Here we have analyzed the effect of ZF87/ MAZ overexpression on transcription from the murine c-myc P2 promoter. It was found that when overexpressed in COS cells, ZF87/MAZ significantly represses transcription from P2. The repression is mediated through the ME1a2 element, located at position -86 relative to the P2 transcriptional start site, and is not mediated through either the E2F or the ME1a1 sites. ZF87/ MAZ functions as a true transcriptional repressor since it can repress transcription independently of the c-myc promoter, as part of a fusion with the GAL4 protein. The repressive domain within ZF87/MAZ is located in the amino-terminal half of the protein, a region rich in proline and alanine residues. ZF87/MAZ therefore shares features (i.e. a Pro/Ala-rich region) with those of known transcriptional repressor proteins.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA	Jefferson University	Hall, DJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, Room 501 Curtis,1015 Walnut St, Philadelphia, PA 19107 USA.	hall@hendrix.jci.tju.edu		, Matthew/0000-0003-3771-7083	NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER; NCI NIH HHS [CA67032] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASSELIN C, 1989, ONCOGENE, V4, P549; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; HALL DJ, 1990, ONCOGENE, V5, P47; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HAY N, 1987, GENE DEV, V3, P293; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Kawasaki H, 1996, ARTIF ORGANS, V20, P836, DOI 10.1111/j.1525-1594.1996.tb04556.x; KENNEDY GC, 1993, BIOCHEM SOC T, V21, P178, DOI 10.1042/bst0210178; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LA RF, 1994, MOL CELL BIOL, V14, P1039; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; LOGAN T, 1993, BIOCHEM BIOPH RES CO, V192, P1204, DOI 10.1006/bbrc.1993.1544; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marcu KB, 1997, CURR TOP MICROBIOL, V224, P47; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432; WEINBERG RA, 1989, CANCER RES, V49, P3713; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	51	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19498	19506		10.1074/jbc.274.27.19498	http://dx.doi.org/10.1074/jbc.274.27.19498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383467	hybrid			2022-12-25	WOS:000081196300090
J	Reyland, ME; Anderson, SM; Matassa, AA; Barzen, KA; Quissell, DO				Reyland, ME; Anderson, SM; Matassa, AA; Barzen, KA; Quissell, DO			Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; ULTRAVIOLET-RADIATION; SIGNAL-TRANSDUCTION; SJOGRENS-SYNDROME; GAMMA-RADIATION; CANCER CELLS; JUN; DNA; INHIBITOR	We have previously shown that parotid C5 salivary acinar cells undergo apoptosis in response to etoposide treatment as indicated by alterations in cell morphology, caspase-3 activation, DNA fragmentation, sustained activation of c-Jun N-terminal kinase, and inactivation of extracellular regulated kinases 1 and 2, Here we report that apoptosis results in the caspase-dependent cleavage of protein kinase C-delta (PKC delta) to a 40-kDa fragment, the appearance of which correlates with a 9-fold increase in PKC delta activity. To understand the function of activated PKC delta in apoptosis, we have used the PKC delta-specific inhibitor, rottlerin, Pretreatment of parotid C5 cells with rottlerin prior to the addition of etoposide blocks the appearance of the apoptotic morphology, the sustained activation of c-Jun N-terminal kinase, and inactivation of extracellular regulated kinases 1 and 2, Inhibition of PKC delta also partially inhibits caspase-3 activation and DNA fragmentation. Immunoblot analysis shows that the PKC delta cleavage product does not accumulate in parotid C5 cells treated with rottlerin and etoposide together, suggesting that the catalytic activity of PKC delta may be required for cleavage. PKC alpha and PKC beta 1 activities also increase during etoposide-induced apoptosis, Inhibition of these two isoforms with Go6976 slightly suppresses the apoptotic morphology, caspase-3 activation, and DNA fragmentation, but has no effect on the sustained activation of c-Jun N-terminal kinase or inactivation of extracellular regulated kinase 1 and 2, These data demonstrate that activation of PKC delta is an integral and essential part of the apoptotic program in parotid C5 cells and that specific activated isoforms of PKC may have distinct functions in cell death.	Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Dent, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Dent, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.	mary.reyland@UCHSC.edu	Prada-Arismendy, Jeanette/GLR-4134-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE012422] Funding Source: NIH RePORTER; NCI NIH HHS [CA4541] Funding Source: Medline; NIDCR NIH HHS [DE12422] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Freemerman AJ, 1996, MOL PHARMACOL, V49, P788; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kong LP, 1997, ARTHRITIS RHEUM, V40, P87, DOI 10.1002/art.1780400113; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; Liem IH, 1996, EUR J NUCL MED, V23, P1485, DOI 10.1007/BF01254473; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; MANSSONRAHEMTULLA B, 1992, ORAL SURG ORAL MED O, V73, P35, DOI 10.1016/0030-4220(92)90151-F; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsumura R, 1996, CLIN EXP RHEUMATOL, V14, P309; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PONGRACZ J, 1995, EXP CELL RES, V218, P430, DOI 10.1006/excr.1995.1176; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; SOLARY E, 1993, BLOOD, V81, P1359; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	57	233	238	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19115	19123		10.1074/jbc.274.27.19115	http://dx.doi.org/10.1074/jbc.274.27.19115			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383415	hybrid			2022-12-25	WOS:000081196300038
J	Roobol, A; Grantham, J; Whitaker, HC; Carden, MJ				Roobol, A; Grantham, J; Whitaker, HC; Carden, MJ			Disassembly of the cytosolic chaperonin in mammalian cell extracts at intracellular levels of K+ and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-BINDING DOMAINS; T-COMPLEX POLYPEPTIDE-1; CYTOPLASMIC CHAPERONIN; MOLECULAR CHAPERONE; CHROMOBINDIN-A; IN-VITRO; MITOCHONDRIAL CHAPERONIN-60; EUKARYOTIC CHAPERONIN; THERMUS-THERMOPHILUS; SUBUNIT COMPOSITION	The eukaryotic, cytoplasmic chaperonin, CCT, is essential for the biogenesis of actin- and tubulin-based cytoskeletal structures. CCT purifies as a doubly toroidal particle containing two eight-membered rings of similar to 60-kDa ATPase subunits, each encoded by an essential and highly conserved gene. However, immunofluorescence detection with subunit-specific antibodies has indicated that in cells CCT subunits do not always colocalize. We report here that CCT ATPase activity is highly dependent on K+ ion concentration and that in cell extracts, at physiological levels of K+ and ATP, there is considerable dissociation of CCT to a smaller oligomeric structure and free subunits. This dissociation is consequent to ATP hydrolysis and is readily reversed on removal of ATP. The ranking order for ease with which subunits can exit the chaperonin particle correlates well with the length of a loop structure, identified by homology modeling, in the intermediate domain of CCT subunits. K+-ATP-induced disassembly is not an intrinsic property of purified CCT over a 80-fold concentration range and requires the presence of additional factor(s) present in cell extracts.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Kent	Roobol, A (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.		Carden, Martin/D-4135-2019; Grantham, Julie/A-5002-2009	Carden, Martin/0000-0002-0609-4605; 				BAIN G, 1994, BIOESSAYS, V16, P342; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CHATELLIER J, 1998, P NATL ACAD SCI USA, V95, P15024; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CREUTZ CE, 1994, J BIOL CHEM, V269, P32035; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis R. John, 1996, P1; ELLIS RJ, 1994, CURR BIOL, V4, P633; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRANTHAM J, 1998, STUDIES CHAPERONIN C; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; Horwich AL, 1998, NAT STRUCT BIOL, V5, P333, DOI 10.1038/nsb0598-333; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX CR, 1986, BIOCHEM SOC T, V14, P9, DOI 10.1042/bst0140009; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MARTIN WH, 1987, J BIOL CHEM, V262, P2803; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; Nielsen KL, 1998, MOL CELL, V2, P93, DOI 10.1016/S1097-2765(00)80117-3; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; QUAITERANDALL E, 1995, J BIOL CHEM, V270, P28818, DOI 10.1074/jbc.270.48.28818; Roobol A, 1999, J BIOL CHEM, V274, P2408, DOI 10.1074/jbc.274.4.2408; Roobol A, 1999, EUR J CELL BIOL, V78, P21, DOI 10.1016/S0171-9335(99)80004-1; ROOBOL A, 1993, J NEUROCHEM, V60, P2327, DOI 10.1111/j.1471-4159.1993.tb03524.x; ROOBOL A, 1995, J CELL SCI, V108, P1477; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROY H, 1988, PLANT PHYSIOL, V86, P50, DOI 10.1104/pp.86.1.50; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; Taguchi H, 1997, J BIOL CHEM, V272, P18155, DOI 10.1074/jbc.272.29.18155; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WEISSMAN JS, 1997, GUIDEBOOK MOL CHAPER, P173; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	57	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19220	19227		10.1074/jbc.274.27.19220	http://dx.doi.org/10.1074/jbc.274.27.19220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383429	hybrid			2022-12-25	WOS:000081196300052
J	Weber, J; Dunn, SD; Senior, AE				Weber, J; Dunn, SD; Senior, AE			Effect of the epsilon-subunit on nucleotide binding to Escherichia coli F-1-ATPase catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; F0F1 ATP SYNTHASE; COUPLING FACTOR; GAMMA-SUBUNIT; BETA-SUBUNIT; F1-ATPASE; HYDROLYSIS; F1; RECONSTITUTION; COOPERATIVITY	The influence of the epsilon-subunit on the nucleotide binding affinities of the three catalytic sites of Escherichia coli F-1-ATPase was investigated, using a genetically engineered Trp probe in the adenine-binding subdomain (beta-Trp-331). The interaction between epsilon and F-1 was not affected by the mutation. K-d for binding of epsilon to beta Y331W mutant F-1 was similar to 1 nM, and epsilon inhibited ATPase activity by 90%. The only nucleotide binding affinities that showed significant differences in the epsilon-depleted and epsilon-replete forms of the enzyme were those for MgATP and MgADP at the high-affinity catalytic site 1. K-d1(MgATP) and K-d1(MgADP) were an order of magnitude higher in the absence of epsilon than in its presence. In contrast, the binding affinities for MgATP and MgADP at sites 2 and 3 were similar in the epsilon-depleted and epsilon-replete enzymes, as were the affinities at all three sites for free ATP and ADP. Comparison of MgATP binding and hydrolysis parameters showed that in the presence as well as the absence of epsilon, K-m equals K-d3. Thus, in both cases, all three catalytic binding sites have to be occupied to obtain rapid (V-max) MgATP hydrolysis rates.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Rochester; Western University (University of Western Ontario)	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Alan_Senior@urmc.rochester.edu	Dunn, Stanley/D-3418-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COX GB, 1993, J MOL BIOL, V229, P1159, DOI 10.1006/jmbi.1993.1113; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; Gruber G, 1996, BIOCHEMISTRY-US, V35, P3875, DOI 10.1021/bi952949h; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Licher T, 1998, FEBS LETT, V431, P419, DOI 10.1016/S0014-5793(98)00807-2; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; RAO R, 1988, J BIOL CHEM, V263, P5569; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; STERNWEIS PC, 1978, J BIOL CHEM, V253, P3123; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P3474; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	42	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19124	19128		10.1074/jbc.274.27.19124	http://dx.doi.org/10.1074/jbc.274.27.19124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383416	hybrid			2022-12-25	WOS:000081196300039
J	Druey, KM; Ugur, O; Caron, JM; Chen, CK; Backlund, PS; Jones, TLZ				Druey, KM; Ugur, O; Caron, JM; Chen, CK; Backlund, PS; Jones, TLZ			Amino-terminal cysteine residues of RGS16 are required for palmitoylation and modulation of G(i)- and G(q)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PLASMA-MEMBRANE LOCALIZATION; ACTIVITY IN-VITRO; ALPHA-SUBUNITS; CORE DOMAIN; TRANSITION-STATE; GAIP; PHOSPHORYLATION; REGULATOR; RECEPTOR	RGS proteins (Regulators of G protein Signaling) are a recently discovered family of proteins that accelerate the GTPase activity of heterotrimeric G protein a subunits of the i, q, and 12 classes. The proteins share a homologous core domain but have divergent amino-terminal sequences that are the site of palmitoylation for RGS-GAIP and RGS4. We investigated the function of palmitoylation for RGS16, which shares conserved amino-terminal cysteines with RGS4 and RGS5. Mutation of cysteine residues at residues 2 and 12 blocked the incorporation of [H-3]palmitate into RGS16 in metabolic labeling studies of transfected cells or into purified RGS proteins in a cell-free palmitoylation assay. The purified RGS16 proteins with the cysteine mutations were still able to act as GTPase-activating protein for G(i)alpha. Inhibition or a decrease in palmitoylation did not significantly change the amount of protein that was membrane-associated. However, palmitoylation-defective RGS16 mutants demonstrated impaired ability to inhibit both G(i)-and G(q)-linked signaling pathways when expressed in HEK293T cells. These findings suggest that the aminoterminal region of RGS16 may affect the affinity of these proteins for Ga subunits in vivo or that palmitoylation localizes the RGS protein in close proximity to Ga subunits on cellular membranes.	NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Connecticut; California Institute of Technology	Jones, TLZ (corresponding author), NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.		Ugur, Özlem/J-3169-2019	Ugur, Özlem/0000-0002-5404-5242	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; *GEN COMP GROUP, 1998, WISC PACK GCG SOFTW; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	55	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18836	18842		10.1074/jbc.274.26.18836	http://dx.doi.org/10.1074/jbc.274.26.18836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373502	Green Accepted, hybrid			2022-12-25	WOS:000081056700094
J	Lin, CY; Anders, J; Johnson, M; Sang, QXA; Dickson, RB				Lin, CY; Anders, J; Johnson, M; Sang, QXA; Dickson, RB			Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; LDL-RECEPTOR; PLASMA PREKALLIKREIN; LIPOPROTEIN RECEPTOR; NUCLEOTIDE-SEQUENCE; CELL-ADHESION; GROWTH-FACTOR; GENE	A major protease from human breast cancer cells was previously detected by gelatin zymography and proposed to play a role in breast cancer invasion and metastasis, To structurally characterize the enzyme, we isolated a cDNA encoding the protease, Analysis of the cDNA reveals three sequence motifs: a carboxyl-terminal region with similarity to the trypsin-like serine proteases, four tandem cysteine-rich repeats homologous to the low density lipoprotein receptor, and two copies of tandem repeats originally found in the complement subcomponents Clr and Cls, By comparison with other serine proteases, the active-site triad was identified as His-484, Asp-539, and Ser-633. The protease contains a characteristic Arg-Val-Val-Gly-Gly motif that may serve as a proteolytic activation site. The bottom of the substrate specificity pocket was identified to be Asp-627 by comparison with other trypsin-like serine proteases, In addition, this protease exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the PI site. Thus, the protease is a mosaic protein with broad spectrum cleavage activity and two potential regulatory modules. Given its ability to degrade extracellular matrix and its trypsin-like activity, the name matriptase is proposed for the protease.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R44CA058158, R43CA058158, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [1P50CA58158, P30-CA51008, P30-CA51005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; Cseh S, 1996, MOL IMMUNOL, V33, P351, DOI 10.1016/0161-5890(95)00160-3; EMI M, 1986, GENE, V41, P305; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; HARTLEY BS, 1965, NATURE, V207, P1157, DOI 10.1038/2071157a0; HARTLEY BS, 1966, BIOCHEM J, V101, P229, DOI 10.1042/bj1010229; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KINOSHITA H, 1989, FEBS LETT, V250, P411, DOI 10.1016/0014-5793(89)80766-5; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nielsen BS, 1996, LAB INVEST, V74, P168; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; PYKE C, 1993, CANCER RES, V53, P1911; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SATO T, 1994, INT IMMUNOL, V6, P655; SHI YE, 1993, CANCER RES, V53, P1409; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	39	195	238	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18231	18236		10.1074/jbc.274.26.18231	http://dx.doi.org/10.1074/jbc.274.26.18231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373424	hybrid			2022-12-25	WOS:000081056700016
J	Lin, CY; Anders, J; Johnson, M; Dickson, RB				Lin, CY; Anders, J; Johnson, M; Dickson, RB			Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; TRYPSIN-INHIBITOR; FACTOR ACTIVATOR; PROTEINS; IDENTIFICATION; INVASION; MEMBRANE; SEQUENCE	Matriptase, a trypsin-like serine protease with two potential regulatory modules (low density lipoprotein receptor and complement C1r/s domains), was initially purified from T-47D breast cancer cells, Given its plasma membrane localization, extracellular matrix-degrading activity, and expression by breast cancer cells, this protease may be involved in multiple aspects of breast tumor progression, including cancer invasion. In breast cancer cells, matriptase was detected mainly as an uncomplexed form; however, low levels of matriptase were detected in complexes. In striking contrast, only the complexed matriptase was detected in human milk, The complexed matriptase has now been purified. Amino acid sequences obtained from the matriptase-associated proteins reveal that they are fragments of a Kunitz-type serine protease inhibitor that was previously reported to be an inhibitor of the hepatocyte growth factor activator. In addition, matriptase and its complexes were detected in milk-derived, SV40 T-antigen-immortalized mammary luminal epithelial cell lines, but not in human foreskin fibroblasts or in HT-1080 fibrosarcoma cells. These results suggest that the milk-derived matriptase complexes are likely to be produced by the epithelial components of the lactating mammary gland in vivo and that the activity and function of matriptase may be differentially regulated by its cognate inhibitor, comparing breast cancer with the lactating mammary gland.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [1P50CA58158, P30-CA51008, P30-CA51005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R44CA058158, R43CA058158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KOBAYASHI H, 1994, CANCER RES, V54, P844; KRAMER KK, 1994, J BIOL CHEM, V269, P7255; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	19	227	254	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18237	18242		10.1074/jbc.274.26.18237	http://dx.doi.org/10.1074/jbc.274.26.18237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373425	hybrid			2022-12-25	WOS:000081056700017
J	Tanner, KG; Trievel, RC; Kuo, MH; Howard, RM; Berger, SL; Allis, CD; Marmorstein, R; Denu, JM				Tanner, KG; Trievel, RC; Kuo, MH; Howard, RM; Berger, SL; Allis, CD; Marmorstein, R; Denu, JM			Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; FUNCTION IN-VIVO; CRYSTAL-STRUCTURE; YEAST GCN5P; ACETYLATION; ACTIVATION; SUPERFAMILY; CHROMATIN; PROTEIN; BINDING	Within chromatin, reversible acetylation of core histones is critical for transcriptional activation of eukaryotic target genes. The recent identification of intrinsic histone acetyltransferase (HAT) catalytic activity from a number of transcriptional co-activators (including yeast GCN5, p300/CBP, P/CAF, and TAFII250), has underscored the importance of protein acetylation in transcriptional control. The GCN5 family is the prototype for a diverse group of at least four distinct human HATs families. Although there is now a clear link between in vivo HAT catalytic activity and gene activation, little is known about the molecular mechanisms of histone acetylation. Herein, we report the first detailed biochemical study that probes the catalytic mechanism and the function of invariant glutamic acid 173 within the GCNB family of HATs, Our results suggest that the HAT reaction involves the formation of a ternary complex (histones, acetyl-CoA and enzyme) where the E-amino group of histone lysine residues directly attacks the bound acetyl-CoA, The acetylation reaction requires deprotonation of the E-amino group prior to nucleophilic attack. Employing site-directed mutagenesis, chemical modification, steady-state, and pH-dependent rate analysis, it is demonstrated that glutamic acid 173 is an essential catalytic residue, acting as a general base catalyst by deprotonating the histone substrate.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Oregon Health & Science University; University of Pennsylvania; The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Virginia	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Berger, Shelley/0000-0001-5398-4400	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jencks W. P., 1976, HDB BIOCH MOL BIOL, P305; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Segel IH, 1993, ENZYME KINETICS, P506; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; WIKTOROWICZ JE, 1982, J BIOL CHEM, V257, P2893; WIKTOROWICZ JE, 1981, BIOCHEMISTRY-US, V20, P1464, DOI 10.1021/bi00509a009; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	28	188	191	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18157	18160		10.1074/jbc.274.26.18157	http://dx.doi.org/10.1074/jbc.274.26.18157			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373413	hybrid			2022-12-25	WOS:000081056700005
J	Luo, X; Zeng, WZ; Xu, X; Popov, S; Davignon, I; Wilkie, TM; Mumby, SM; Muallem, S				Luo, X; Zeng, WZ; Xu, X; Popov, S; Davignon, I; Wilkie, TM; Mumby, SM; Muallem, S			Alternate coupling of receptors to G(s) and G(i) in pancreatic and submandibular gland cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ADENYLYL-CYCLASE; ACINAR-CELLS; BETA(2)-ADRENERGIC RECEPTOR; CALCIUM CHANNELS; CYCLIC-AMP; CA2+; BINDING; ANTIBODIES	Many G(s)-coupled receptors can activate both cAMP and Ca2+ signaling pathways. Three mechanisms for dual activation have been proposed. One is receptor coupling to both G(S) and G(15) (a G(q) class heterotrimeric G protein) to initiate independent signaling cascades that elevate intracellular levels of cAMP and Ca2+, respectively. The other two mechanisms involve cAMP-dependent protein kinase-mediated activation of phospholipase C beta either directly or by switching receptor coupling from G(S) to G(i). These mechanismswere primarily inferred from studies with transfected cell lines, In native cells we found that two G(S)-coupled receptors (the vasoactive intestinal peptide and beta-adrenergic receptors) in pancreatic acinar and submandibular gland duct cells, respectively, evoke a Ca2+ signal by a mechanism involving both G(S) and G(i). This inference was based on the inhibitory action of antibodies specific for Get,, Gari, and phosphatidylinositol 4,5-bisphosphate, pertussis toxin, RGS4, a fragment of beta-adrenergic receptor kinase and inhibitors of cAMP-dependent protein kinase. By contrast, Ca2+ signaling evoked by G(S)-coupled receptor agonists was not blocked by G(q) class-specific antibodies and was unaffected in G alpha(15) -/- knockout mice. We conclude that sequential activation of G(S) and G(i), mediated by caMP-dependent protein kinase, may represent a general mechanism in native cells for dual stimulation of signaling pathways by G(S)-coupled receptors.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5325 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047890, R01DK038939] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK47890, DK38939] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1984, J BIOL CHEM, V259, P9351; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; XIAO RP, 1995, MOL PHARMACOL, V47, P322; XIN X, 1998, J BIOL CHEM, V273, P27275; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	41	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17684	17690		10.1074/jbc.274.25.17684	http://dx.doi.org/10.1074/jbc.274.25.17684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364208	hybrid			2022-12-25	WOS:000080974300044
J	Potsch, S; Lendzian, F; Ingemarson, R; Hornberg, A; Thelander, L; Lubitz, W; Lassmann, G; Graslund, A				Potsch, S; Lendzian, F; Ingemarson, R; Hornberg, A; Thelander, L; Lubitz, W; Lassmann, G; Graslund, A			The iron-oxygen reconstitution reaction in protein R2-tyr-177 mutants of mouse ribonucleotide reductase - EPR and electron nuclear double resonance studies on a new transient tryptophan radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPIN-RESONANCE; 3-DIMENSIONAL STRUCTURE; ENDOR SPECTROSCOPY; R2; MECHANISM; COFACTOR; SITE; RESIDUES; SUBUNIT	The ferrous iron/oxygen reconstitution reaction in protein R2 of mouse and Escherichia coli ribonucleotide reductase (RNR) leads to the formation of a stable protein-linked tyrosyl radical and a mu-oxo-bridged diferric iron center, both necessary for enzyme activity. We have studied the reconstitution reaction in three protein R2 mutants Y177W, Y177F, and Y177C of mouse RNR to investigate if other residues at the site of the radical forming Tyr-177 can harbor free radicals. In Y177W we observed for the first time the formation of a tryptophan radical in protein R2 of mouse RNR with a Lifetime of several minutes at room temperature. We assign it to an oxidized neutral tryptophan radical on Trp-177, based on selective deuteration and EPR and electron nuclear double resonance spectroscopy in H2O and D2O solution. The reconstitution reaction at 22 degrees C in both Y177F and Y177C leads to the formation of a so-called intermediate X which has previously been assigned to an oxo (hydroxo)-bridged Fe(III)/Fe(IV) cluster. Surprisingly, in both mutants that do not have successor radicals as Trp' in Y177W, this cluster exists on a much longer time scale (several seconds) at room temperature than has been reported for X in E. coli Y122F or native mouse protein R2. All three mouse R2 mutants were enzymatically inactive, indicating that only a tyrosyl radical at position 177 has the capability to take part in the reduction of substrates.	Univ Stockholm, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10623 Berlin, Germany; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Stockholm University; Technical University of Berlin; Umea University	Graslund, A (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden.							ABERG A, 1993, BIOCHEMISTRY-US, V26, P5541; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BAUGHER JF, 1977, J PHYS CHEM-US, V81, P1349, DOI 10.1021/j100529a002; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRUDVIG GW, 1995, METHOD ENZYMOL, V246, P536; Davydov A, 1996, BIOCHEM BIOPH RES CO, V219, P213, DOI 10.1006/bbrc.1996.0207; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; GESSNER C, 1997, THESIS TU BERLIN; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Katterle B, 1997, J BIOL CHEM, V272, P10414; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LUBITZ W, 1995, ADV PHOTOSYNTHESIS, V3, P255; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NELSON DJ, 1977, J CHEM SOC PERK T 2, P2005, DOI 10.1039/p29770002005; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; PRUTZ WA, 1979, INT J RADIAT BIOL, V36, P513, DOI 10.1080/09553007914551301; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sjoberg BM, 1997, STRUCT BOND, V88, P139; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tong W, 1998, BIOCHEMISTRY-US, V37, P5840, DOI 10.1021/bi9728811; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Wertz J.E., 1986, ELECT SPIN RESONANCE; ZWEYGART W, 1994, J MAGN RESON SER A, V109, P172, DOI 10.1006/jmra.1994.1151	49	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17696	17704		10.1074/jbc.274.25.17696	http://dx.doi.org/10.1074/jbc.274.25.17696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364210	hybrid			2022-12-25	WOS:000080974300046
J	Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K				Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K			Mutations in the RAD54 recombination gene in primary cancers	ONCOGENE			English	Article						RAD54; cancer; mutation	NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; REPAIR PROTEIN; DNA; RESISTANCE; CLONING; COMPLEX; BREAST; SNF2	Association of a recombinational repair protein RAD51 with tumor suppressors BRCA1 and BRCA2 suggests that defects in homologous recombination are responsible for tumor formation. Also recent findings that a protein associated with the MRE11/RAD50 repair complex is mutated in Nijmegen breakage syndrome characterized by increased cancer incidence and ionizing radiation sensitivity strongly support this idea. However, the direct roles of BRCA proteins and the protein responsible for NBS in recombinational repair are not clear though they are associated with the recombinational repair complexes. Since RAD51 forms a complex with other members of the RAD52 epistasis group and with BRCA proteins, it is reasonable to ask if alterations of members of the RAD52 epistasis group lead to tumor development. Here we describe missense mutations at functional regions of RAD54 and the absence of the wild-type RAD54 expression resulting from aberrant splicing in primary cancers. Since RAD54 is a recombinational protein associated with RAD51, this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Surg 2, Minami Ku, Hiroshima 734, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; Kindai University (Kinki University)	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, 1-2-3 Kasumi, Hiroshima 734, Japan.							BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Rasio D, 1997, CANCER RES, V57, P2378; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SUGIMOTO K, 1991, BLOOD, V77, P1153; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	22	68	79	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3427	3430		10.1038/sj.onc.1202692	http://dx.doi.org/10.1038/sj.onc.1202692			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362365				2022-12-25	WOS:000080589300015
J	Casini, T; Pelicci, PG				Casini, T; Pelicci, PG			A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest	ONCOGENE			English	Article						APL; cell cycle; p21; PML/RAR alpha; RA	RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RAR-ALPHA; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; DEPENDENT KINASES; FUSION PROTEINS; EXPRESSION; P21(CIP1/WAF1); P21(WAF1/CIP1)	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukemias (APL) by triggering differentiation of neoplastic cells. Differentiation is mediated by the APL-specific transforming protein PML/RAR alpha and involves its activity as ligand-dependent enhancer factor on RA-target genes. We report here the identification of p21 as a transcriptional target of PML/RAR alpha during RA-induced differentiation of APL cells. We found that RA-treated APL cells undergo two rounds of cell division before entering post mitotic G1, that progression through the G1-S is indispensable for differentiation and coincides with the duration of commitment. RA-treatment induced two peaks of p21 synthesis: early (from the 2nd to the 6th hour), dependent on PML/RAR alpha expression and associated with G1-S transition and high CDK activity; late (from 3rd to the 4th day), independent from PML/RAR alpha and associated with G1 block and low CDK activity, Increased p21 in PML/RAR alpha cells during G1-S had no effect on the cell cycle while an antisense p21 prevented RA-induced differentiation without altering G1-S transition and the late ct block. These results demonstrate that p21 is an effector of the activity of PML/RAR alpha on differentiation and suggest that p21 exerts a function in G1-S connected to differentiation-commitment and uncoupled from cell cycle and CDK inhibition.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020					Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1996, FASEB J, V10, P954; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DYNLACHT B, 1997, CELL CYCLE CONTROL 2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; GRIGNANI F, 1998, CANC RES, V58; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIZHEN H, 1997, PNAS, V94, P5302; LUBBERT M, 1991, BLOOD, V77, P909; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRIGGS LL, 1992, BIOCHEM CELL BIOL, V70, P555, DOI 10.1139/o92-086; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1996, CANCER RES, V56, P2945; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3235	3243		10.1038/sj.onc.1202630	http://dx.doi.org/10.1038/sj.onc.1202630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359529				2022-12-25	WOS:000080523800006
J	Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C				Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C			The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; transactivation	NUCLEOTIDE EXCISION-REPAIR; DNA-BINDING PROTEIN; X-GENE PRODUCT; HUMAN FIBROBLASTS; HELA-CELLS; APOPTOSIS; TRANSCRIPTION; ACTIVATION; EXPRESSION; INTERACTS	The role of hepatitis B virus carcinogenesis associated with chronic, viral infection remains ill-defined. Indeed, pleiotropic effects have been ascribed to HBx: in addition to its well-documented ability to indirectly stimulate transcription, the protein has been reported to affect cell growth, signal transduction, DNA repair and apoptosis, In this work, we generated Chang (CCL-13)-derived cell lines constitutively expressing wild type or mutant HBx, as a model of HBx-host cell interaction closer to the chronic infection setting, than the classically used transient expression systems, We document the potentiation by HBx of the apoptotic cell death pathway in the recipient cells. This effect is unlikely to rely on p53 activity since the protein is functionally inactivated in CCL-13, In addition, antioxidants and cyclosporin A failed to reduce the apoptotic response back to the normal level, suggesting that production of reactive oxygen species and calcineurin activation are not directly involved in the proapoptotic effect of HBx. In contrast, our data show that transactivation and stimulation of apoptosis are tightly linked HBx activities. Finally, expression of transactivation-active protein did not result in detectable change in the pattern of MAP kinases phosphorylation nor did it affect the ability of the host cell to repair in vitro irradiated plasmid DNA.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Hop Necker Enfants Malad, INSERM, U370, Paris, France; Inst Rech Canc, Mol Genet Lab, UPR42 CNRS IFC1, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Transy, C (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.							ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FRITSCH A, 1978, CR ACAD SCI D NAT, V287, P1453; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAVAPPA KS, 1976, NATURE, V259, P211, DOI 10.1038/259211a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LOCK RB, 1994, CANCER RES, V54, P4933; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASON WS, 1981, VIRAL HEPATITIS, P107; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; SMITH ML, 1995, ONCOGENE, V10, P1053; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG XW, 1995, CANCER RES, V55, P6012; Weeda G, 1997, AM J HUM GENET, V60, P320; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	51	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2860	2871		10.1038/sj.onc.1202643	http://dx.doi.org/10.1038/sj.onc.1202643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362257				2022-12-25	WOS:000080125100009
J	Lum, PL; Schildbach, JF				Lum, PL; Schildbach, JF			Specific DNA recognition by F factor TraY involves beta-sheet residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARC REPRESSOR; GENE-PRODUCT; CRYSTAL-STRUCTURE; OPERATOR DNA; HELICASE-I; ORIT; MUTATIONS; PROTEINS; NICKING; BINDING	The F Factor TraY protein is a sequence-specific DNA-binding protein required for efficient conjugal transfer. Genetic and biochemical studies indicate that TraY has two functional roles in conjugation. TraY binds to the P-Y promoter to up-regulate transcription of tra genes. TraY also binds to the plasmid origin of transfer (oriT), serving as an accessory protein in the nicking of F Factor in preparation for transfer. TraY is thought to belong to the ribbon-helix-helix family of transcription factors. These proteins contact DNA using residues of an antiparallel beta-sheet. We engineered and characterized six TraY mutants each having a single potential beta-sheet DNA contact residue replaced with Ala. Most TraY mutants had significantly reduced affinity for the TraY oriT binding site while possessing near wild-type stability and nonspecific DNA recognition. These results indicate that TraY beta-sheet residues participate in DNA recognition, and support inclusion of TraY in the ribbon-helix-helix family.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, 235 Mudd Hall,3400 N Charles St, Baltimore, MD 21218 USA.			Schildbach, Joel/0000-0002-3038-9745				BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CARTER JR, 1991, J BACTERIOL, V173, P1027, DOI 10.1128/jb.173.3.1027-1034.1991; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; HOWARD MT, 1995, J BIOL CHEM, V270, P28381; Maneewannakul K, 1996, MOL MICROBIOL, V22, P197, DOI 10.1046/j.1365-2958.1996.00087.x; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; NELSON HCM, 1986, J MOL BIOL, V192, P27, DOI 10.1016/0022-2836(86)90461-4; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; NELSON WC, 1995, J BIOL CHEM, V270, P28374; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; Nelson WC, 1996, MOL MICROBIOL, V20, P1179, DOI 10.1111/j.1365-2958.1996.tb02638.x; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; RAUMANN BE, 1994, CURR OPIN STRUC BIOL, V4, P36, DOI 10.1016/S0959-440X(94)90057-4; Sambrook J., 2002, MOL CLONING LAB MANU; Schildbach JF, 1999, P NATL ACAD SCI USA, V96, P811, DOI 10.1073/pnas.96.3.811; Schildbach JF, 1998, J BIOL CHEM, V273, P1329, DOI 10.1074/jbc.273.3.1329; Silverman PM, 1996, J BACTERIOL, V178, P5787, DOI 10.1128/jb.178.19.5787-5789.1996; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19644	19648		10.1074/jbc.274.28.19644	http://dx.doi.org/10.1074/jbc.274.28.19644			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391902	hybrid			2022-12-25	WOS:000081377300022
J	Segawa, H; Fukasawa, Y; Miyamoto, K; Takeda, E; Endou, H; Kanai, Y				Segawa, H; Fukasawa, Y; Miyamoto, K; Takeda, E; Endou, H; Kanai, Y			Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; EXPRESSION CLONING; HEAVY-CHAIN; FAMILY; SYSTEM; CELLS; ANTIGEN; PROTEIN; CD98	We have isolated a cDNA from rat small intestine that encodes a novel Na+-independent neutral amino acid transporter with distinctive characteristics in substrate selectivity and transport property. The encoded protein, designated L-type amino acid transporter-2 (LAT-2), shows amino acid sequence similarity to the system L Na+-independent neutral amino acid transporter LAT-1 (Kanai, Y., Segawa, H., Miyamoto, K., Uchino, H., Takeda, E., and Endou, H.(1998) J. Biol. Chem. 273, 23629-23632) (50% identity) and the system y(+)L transporters y(+)LAT-1 (47%) and KIAA0245/y(+)LAT-2 (45%) (Torrents, D., Estevez, R., Pineda, M., Fernandez, E., Lloberas, J., Shi, Y.-B., Zorzano, A. and Palacin, M. (1998) J. Biol. Chem. 273, 32437-32445). LAT-2 is a nonglycosylated membrane protein. It requires 4F2 heavy chain, a type II membrane glycoprotein, for its functional expression in Xenopus oocytes. LAT-2-mediated transport is not dependent on Na+ or Cl- and is inhibited by a system L-specific inhibitor, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), indicating that LAT-2 is a second isoform of the system L transporter. Compared with LAT-1, which prefers large neutral amino acids with branched or aromatic side chains, LAT-2 exhibits remarkably broad substrate selectivity. It transports all of the L-isomers of neutral cu-amino acids. LAT-2 exhibits higher affinity (K-m = 30-50 mu M) to Tyr, Phe, Trp, Thr, Asn, Ile, Cys, Ser, Leu, Val, and Gin and relatively lower affinity (K-m = 180-300 mu M) to His, Ale, Met, and Gly. In addition, LAT-P mediates facilitated diffusion of substrate amino acids, as distinct from LAT-1, which mediates amino acid exchange. LAT-2-mediated transport is increased by lowering the pH level, with peak activity at pH 6.25, because of the decrease in the K-m value without changing the V-max value. Because of these functional properties and a high level of expression of LAT-S in the small intestine, kidney, placenta, and brain, it is suggested that the heterodimeric complex of LAT-2 and 4F2 heavy chain is involved in the trans-cellular transport of neutral amino acids in epithelia and blood-tissue barriers.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 7708503, Japan	Kyorin University; Tokushima University								ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; ENDERS RH, 1976, AM J PHYSIOL, V230, P706, DOI 10.1152/ajplegacy.1976.230.3.706; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Gallardo MA, 1996, J MEMBRANE BIOL, V152, P57, DOI 10.1007/s002329900085; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HARGREAVES KM, 1988, J BIOL CHEM, V263, P19392; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JAMES JH, 1981, PHARMACOLOGY, V22, P1; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MITSUMOTO Y, 1986, J BIOL CHEM, V261, P4549; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; RAMAMOORTHY S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P181, DOI 10.1016/0167-4889(92)90255-A; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; Wright E M, 1981, Ann N Y Acad Sci, V372, P626, DOI 10.1111/j.1749-6632.1981.tb15510.x	44	409	425	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19745	19751		10.1074/jbc.274.28.19745	http://dx.doi.org/10.1074/jbc.274.28.19745			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391916	hybrid			2022-12-25	WOS:000081377300036
J	Takasuga, S; Katada, T; Ui, M; Hazeki, O				Takasuga, S; Katada, T; Ui, M; Hazeki, O			Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; POTENTIAL ROLE; ADIPOSE-CELLS; CYCLIC-AMP; SENSITIVITY; SUFFICIENT	The role of adenosine receptor in regulation of insulin-induced activation of phosphoinositide S-kinase (PI 3-kinase) and protein kinase B was studied in isolated rat adipocytes. Rat adipocytes are known to spontaneously release adenosine, which in turn binds and stimulates the adenosine A, receptors on the cells. In the present study, we observed that degradation of this adenosine by adenosine deaminase attenuated markedly the insulin-induced accumulation of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), a product of PI 3-kinase. p-Aminophenylacetyl xanthine amine congener (PAPA-XAC), an inhibitor of the adenosine A(1) receptor, also inhibited the insulin-induced PtdIns(3,4,5)P-3 accumulation, When extracellular adenosine was inactivated by adenosine deaminase, phenylisopropyladenosine, an adenosine A(1) receptor agonist, potentiated the insulin-induced accumulation of PtdIns(3,4,5)P-3, Insulin-induced activation of protein kinase B, the activity of which is controlled by the lipid products of PI 3-kinase, was also potentiated by adenosine. Prostaglandin E-2, another activator of a pertussis toxin-sensitive GTP-binding protein in these cells, potentiated the insulin actions. Thus, the receptors coupling to the GTP-binding protein were found to positively regulate the production of PtdIns(3,4,5)P-3, a putative second messenger for insulin actions, in physiological target cells of insulin.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Dept Physiol Chem,Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan	Hiroshima University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Hazeki, O (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Dept Physiol Chem,Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GAWLER D, 1987, NATURE, V327, P224; GREEN A, 1987, J BIOL CHEM, V262, P15702; GREEN A, 1979, BIOCHEM J, V180, P365, DOI 10.1042/bj1800365; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; HONNOR RC, 1992, CELL SIGNAL, V4, P87, DOI 10.1016/0898-6568(92)90010-6; JOOST HG, 1982, MOL PHARMACOL, V22, P614; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KURODA M, 1987, J BIOL CHEM, V262, P245; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LANOUE KF, 1994, FASEB J, V8, P72, DOI 10.1096/fasebj.8.1.8299893; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOXAM CM, 1996, NATURE, V379, P840; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1977, BIOCHEM BIOPH RES CO, V75, P271, DOI 10.1016/0006-291X(77)91039-7; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520	29	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19545	19550		10.1074/jbc.274.28.19545	http://dx.doi.org/10.1074/jbc.274.28.19545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391887	hybrid			2022-12-25	WOS:000081377300007
J	Ahlgren, R; Suske, G; Waterman, MR; Lund, J				Ahlgren, R; Suske, G; Waterman, MR; Lund, J			Role of Sp1 in cAMP-dependent transcriptional regulation of the bovine CYP11A gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; ACTIVATION DOMAINS; PROMOTER ACTIVITY; RESPONSE ELEMENT; GRANULOSA-CELLS; P-450SCC GENE; LUTEAL CELLS; EXPRESSION	The pituitary peptide hormone ACTH regulates transcription of the cholesterol side chain cleavage cytochrome P450 (CYP11A) gene via cAMP and activation of cAMP-dependent protein kinase. A G-rich sequence element conferring cAMP-dependent regulation has been found to reside within region -118 to -100 of the bovine CYP11A promoter. Previous studies have suggested that it binds a protein antigenically related to the transcription factor Sp1. We now report that the -118/-100 element binds both Sp1 and Sp3, members of the Sp family of transcription factors. me have made use of Drosophila SL2 cells, which lack endogenous Sp factors, to dissect the possible functional roles of Sp1, Sp3, and Sp4. All factors stimulated the activity of cotransfected reporter constructs in which the promoter of the bovine CYP11A gene regulates luciferase expression. Sp3 did not repress Sp1-dependent activation, as has previously been shown for other G-rich promoters. Mutation of the -118/-100 element of CYP11A abolished Sp1-mediated activation of a CYP11A reporter gene in SL2 cells as well as cAMP responsiveness in human H295R cells. Furthermore, cotransfection of SL2 cells with the catalytic subunit of cAMP-dependent protein kinase together with Sp1 and a CYP11A reporter construct enhanced Sp1-dependent activation of the reporter 4.2-fold, demonstrating that Sp1 confers cAMP responsiveness in these cells. Thus, we show that introduction of Sp1 alone in an Sp-negative cell such as SL2 is sufficient to achieve the cAMP-dependent regulation observed using the -118/ -100 element of CYP11A in adrenocortical cells.	Univ Bergen, Sch Med, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	University of Bergen; Philipps University Marburg; Vanderbilt University	Lund, J (corresponding author), Univ Bergen, Sch Med, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.			Suske, Guntram/0000-0002-4807-0513	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; Grimaldi P, 1996, MOL CELL ENDOCRINOL, V117, P167, DOI 10.1016/0303-7207(95)03744-6; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jacob AL, 1998, J BIOL CHEM, V273, P13391, DOI 10.1074/jbc.273.22.13391; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUND J, 1990, J BIOL CHEM, V265, P3304; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; OONK RB, 1990, J BIOL CHEM, V265, P22392; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RICE DA, 1990, J BIOL CHEM, V265, P11713; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	50	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19422	19428		10.1074/jbc.274.27.19422	http://dx.doi.org/10.1074/jbc.274.27.19422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383457	hybrid			2022-12-25	WOS:000081196300080
J	Blanpain, C; Lee, B; Vakili, J; Doranz, BJ; Govaerts, C; Migeotte, I; Sharron, M; Dupriez, V; Vassart, G; Doms, RW; Parmentier, M				Blanpain, C; Lee, B; Vakili, J; Doranz, BJ; Govaerts, C; Migeotte, I; Sharron, M; Dupriez, V; Vassart, G; Doms, RW; Parmentier, M			Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-DIRECTED MUTAGENESIS; LINE-TROPIC HIV-1; RECEPTOR GENE; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; DIVERSE HUMAN; INFECTION; ENTRY	CCR5 is the major coreceptor for macrophage-tropic human immunodeficiency virus type I (HIV-1). For most G-protein-coupled receptors that have been tested so far, the disulfide bonds linking together the extracellular loops (ECL) are required for maintaining the structural integrity necessary for ligand binding and receptor activation, A natural mutation affecting Cys(20), which is thought to form a disulfide bond with Cys(269), has been described in various human populations, although the consequences of this mutation for CCR5 function are not known. Using site-directed mutagenesis, we mutated the four extracellular cysteines of CCR5 singly or in combination to investigate their role in maintaining the structural conformation of the receptor, its ligand binding and signal transduction properties, and its ability 60 function as a viral coreceptor. Alanine substitution of any single Cys residue reduced surface expression levels by 40-70%. However, mutation of Cys(101) or Cys(178), predicted to link ECL1 and ECL2 of the receptor, abolished recognition of CCR5 by a panel of conformation sensitive anti-CCR5 antibodies. The effects of the mutations on receptor expression and conformation were partially temperature-sensitive, with partial restoration of receptor expression and conformation achieved by incubating cells at 32 degrees C. All cysteine mutants were unable 60 bind detectable levels of MIP-1 beta, and did not respond functionally to CCR5 agonists. Surprisingly, all cysteine mutants did support infection by R5 strains of HIV, though at reduced levels. These results indicate that both disulfide bonds of CCR5 are necessary for maintaining the structural integrity of the receptor necessary for ligand binding and signaling. Env binding and the mechanisms of HIV entry appear much less sensitive to alterations of CCR5 conformation.	Free Univ Brussels, Inst Rech Interdisciplinaire, IRIBHN, B-1070 Brussels, Belgium; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Euroscreen, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania	Parmentier, M (corresponding author), Free Univ Brussels, Inst Rech Interdisciplinaire, IRIBHN, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709; Migeotte, Isabelle/0000-0002-8972-8211; Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [R01 AI40880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; FRASER CM, 1989, J BIOL CHEM, V264, P9266; Genoud S, 1999, J VIROL, V73, P1645, DOI 10.1128/JVI.73.2.1645-1648.1999; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; NODA K, 1994, J BIOL CHEM, V269, P6743; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	59	105	112	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18902	18908		10.1074/jbc.274.27.18902	http://dx.doi.org/10.1074/jbc.274.27.18902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383387	hybrid			2022-12-25	WOS:000081196300010
J	Blom, AM; Webb, J; Villoutreix, BO; Dahlback, B				Blom, AM; Webb, J; Villoutreix, BO; Dahlback, B			A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN C4-BINDING PROTEIN; HUMAN-COMPLEMENT SYSTEM; AMYLOID-P COMPONENT; HUMAN FACTOR-H; MOLECULAR-CLONING; REGULATORY COMPONENT; STREPTOCOCCUS-PYOGENES; CLASSICAL PATHWAY; C3B INACTIVATOR	C4b-binding protein (C4BP) is a regulator of the classical complement pathway, acting as a cofactor to factor I in the degradation of C4b. Computer modeling and structural analysis predicted a cluster of positively charged amino acids at the interface between complement control protein modules 1 and 2 of the C4BP cu-chain to be involved in C4b binding. Three C4BP mutants, R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q, were ex pressed and assayed for their ability to bind Gib and to function as factor I cofactors. The apparent affinities of R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q for immobilized Gib were 15-, 50-, and 140-fold lower, respectively, than that of recombinant wild type C4BP. The Gib binding site demonstrated herein was also found to be a specific heparin binding site. In C4b degradation, the mutants demonstrated decreased ability to serve as factor I cofactors. In particular, the R39Q/R64Q/R66Q mutant was inefficient as cofactor for cleavage of the Arg(937)-Thr(938) peptide bond in Gib. In contrast, the factor I mediated cleavage of Arg(1317)-Asn(1318) bond was less affected by the C4BP mutations. In conclusion, we identify a cluster of amino acids that is part of a C4b binding site involved in the regulation of the complement system.	Univ Lund, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				Accardo P, 1996, J IMMUNOL, V157, P4935; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blom AM, 1998, BBA-PROTEIN STRUCT M, V1388, P181, DOI 10.1016/S0167-4838(98)00178-2; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; BUDZKO DB, 1970, IMMUNOCHEMISTRY, V7, P227, DOI 10.1016/0019-2791(70)90158-8; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; CHUNG LP, 1985, BIOSCIENCE REP, V5, P855, DOI 10.1007/BF01119897; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DE FRUTOS PG, 1995, BBA-GENE STRUCT EXPR, V1261, P285, DOI 10.1016/0167-4781(95)00019-D; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1985, J IMMUNOL, V134, P3320; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GIGLI I, 1977, BIOCHEM J, V165, P439, DOI 10.1042/bj1650439; Hardig Y, 1997, BIOCHEM J, V323, P469; HARDIG Y, 1995, BIOCHEM J, V308, P795; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HESSING M, 1990, J IMMUNOL, V144, P204; HESSING M, 1990, FEBS LETT, V271, P131, DOI 10.1016/0014-5793(90)80389-Z; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; Hillarp A, 1997, J IMMUNOL, V158, P1315; HILLARP A, 1988, J BIOL CHEM, V263, P12759; HILLARP A, 1994, J IMMUNOL, V153, P4190; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; KUHN S, 1995, J IMMUNOL, V155, P5663; LAW SK, 1980, J IMMUNOL, V125, P634; Mackay D.H.J., 1989, PREDICTION PROTEIN S, P317; Makrides SC, 1998, PHARMACOL REV, V50, P59; MATSUGUCHI T, 1989, BIOCHEM BIOPH RES CO, V165, P138, DOI 10.1016/0006-291X(89)91045-0; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Mikata S, 1998, MOL IMMUNOL, V35, P537, DOI 10.1016/S0161-5890(98)00046-7; NAGASAWA S, 1982, J BIOCHEM-TOKYO, V92, P1329, DOI 10.1093/oxfordjournals.jbchem.a134052; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGATA RT, 1993, J IMMUNOL, V150, P2273; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PATRICK RA, 1970, IMMUNOCHEMISTRY, V7, P217, DOI 10.1016/0019-2791(70)90157-6; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Prodinger WM, 1998, J IMMUNOL, V161, P4604; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHREIBER RD, 1974, J EXP MED, V140, P1324, DOI 10.1084/jem.140.5.1324; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEYA T, 1995, MOL IMMUNOL, V32, P355, DOI 10.1016/0161-5890(94)00157-V; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; THERN A, 1995, J IMMUNOL, V154, P375; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; Villoutreix BO, 1999, IMMUNOPHARMACOLOGY, V42, P121, DOI 10.1016/S0162-3109(99)00022-3; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; ZABERN I, 1982, J IMMUNOL, V128, P1433; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	61	97	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19237	19245		10.1074/jbc.274.27.19237	http://dx.doi.org/10.1074/jbc.274.27.19237			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383431	hybrid			2022-12-25	WOS:000081196300054
J	McVey, M; Hill, J; Howlett, A; Klein, C				McVey, M; Hill, J; Howlett, A; Klein, C			Adenylyl cyclase, a coincidence detector for nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; NEUROBLASTOMA-CELLS; INHIBITION; STIMULATION; CALMODULIN; ACTIVATION; DISCOIDEUM; DIVERSITY; BINDING; CGMP	Nitric oxide (NO) donors inhibit hormone- and forskolin-stimulated adenylyl cyclase activity in purified plasma membrane preparations from N18TG2 neuroblastoma cells. Northern blot analyses indicate that the predominant isoform of adenylyl cyclase in N18TG2 cells is the type VI. Our experiments eliminate all the known regulatory proteins for this isoform as possible targets of NO. NO decreases the V-max of the enzyme without altering the K-m for ATP. Occupancy of the substrate-binding site protects the enzyme from the inhibitory effects of NO, suggesting that the conformation of the enzyme determines its sensitivity. The inhibition is reversed by reducing agents, implicating a Cys residue(s) as the target for nitric oxide and an S-nitrosylation as the underlying modification. These findings implicate NO as a novel cellular regulator of the type VI isoform of adenylyl cyclase.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Klein, C (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	KleinC@slu.edu		Howlett, Allyn/0000-0002-2810-0164				BIDAUTRUSSELL M, 1987, NEUROCHEM INT, V11, P287, DOI 10.1016/0197-0186(87)90048-9; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HOWLETT AC, 1982, MOL PHARMACOL, V21, P664; IYENGAR R, 1981, J BIOL CHEM, V256, P1036; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MATSUZAWA H, 1975, P NATL ACAD SCI USA, V72, P3472, DOI 10.1073/pnas.72.9.3472; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SIEGEL LI, 1986, ANAL BIOCHEM, V159, P82, DOI 10.1016/0003-2697(86)90310-6; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tao YP, 1998, J PHARMACOL EXP THER, V286, P298; TAO YP, 1992, FEBS LETT, V314, P49, DOI 10.1016/0014-5793(92)81459-Y; Tao YP, 1996, CELL SIGNAL, V8, P27, DOI 10.1016/0898-6568(95)02011-X; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALZ MA, 1987, J NEUROSCI RES, V17, P291, DOI 10.1002/jnr.490170314; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	30	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18887	18892		10.1074/jbc.274.27.18887	http://dx.doi.org/10.1074/jbc.274.27.18887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383385	hybrid			2022-12-25	WOS:000081196300008
J	Chen, Y; Schindler, M; Simon, SM				Chen, Y; Schindler, M; Simon, SM			A mechanism for tamoxifen-mediated inhibition of acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; DEFECTIVE ACIDIFICATION; PHOSPHOLIPID-VESICLES; CHLORIDE CHANNELS; LOCAL-ANESTHETICS; PROTON TRANSPORT; CYSTIC-FIBROSIS; RESISTANT CELLS; BONE-RESORPTION; H+-ATPASE	Tamoxifen has been reported to inhibit acidification of cytoplasmic organelles in mammalian cells. Here, the mechanism of this inhibition is investigated using in vitro assays on isolated organelles and liposomes. Tamoxifen inhibited ATP-dependent acidification in organelles from a variety of sources, including isolated microsomes from mammalian cells, vacuoles from Saccharomyces cerevisiae, and inverted membrane vesicles from Escherichia coli. Tamoxifen increased the ATPase activity of the vacuolar proton ATPase but decreased the membrane potential (V-m) generated by this proton pump, suggesting that tamoxifen may act by increasing proton permeability. In liposomes, tamoxifen increased the rate of pH dissipation. Studies comparing the effect of tamoxifen on pH gradients using different salt conditions and with other known ionophores suggest that tamoxifen affects transmembrane pH through two independent mechanisms. First, as a lipophilic weak base, it partitions into acidic vesicles, resulting in rapid neutralization. Second, it mediates coupled, electroneutral transport of proton or hydroxide with chloride. An understanding of the biochemical mechanism(s) for the effects of tamoxifen that are independent of the estrogen receptor could contribute to predicting side effects of tamoxifen and in designing screens to select for estrogen-receptor antagonists without these side effects.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Rockefeller University; Michigan State University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10021 USA.	simon@rockvax.rockefeller.edu		Simon, Sanford/0000-0002-8615-4224	NATIONAL CANCER INSTITUTE [R01CA081257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81257] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Altan N, 1999, P NATL ACAD SCI USA, V96, P4432, DOI 10.1073/pnas.96.8.4432; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BERMAN E, 1995, LEUKEMIA, V9, P1631; BERMAN E, 1991, BLOOD, V77, P818; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; CHATTERJEE M, 1990, BRIT J CANCER, V62, P712, DOI 10.1038/bjc.1990.365; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; Goulian M, 1998, BIOPHYS J, V74, P328, DOI 10.1016/S0006-3495(98)77790-2; GREENBERG DA, 1987, CANCER RES, V47, P70; GRUNER SM, 1991, ANN NY ACAD SCI, V625, P685, DOI 10.1111/j.1749-6632.1991.tb33902.x; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; JORDAN VC, 1995, P SOC EXP BIOL MED, V208, P144; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kellen J. A., 1996, TAMOXIFEN ANTIESTROG; Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rostovtseva TK, 1998, BIOPHYS J, V75, P1783, DOI 10.1016/S0006-3495(98)77620-9; SATO K, 1977, TOHOKU J EXP MED, V123, P185, DOI 10.1620/tjem.123.185; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; SEELIG A, 1988, BIOCHIM BIOPHYS ACTA, V939, P267, DOI 10.1016/0005-2736(88)90070-3; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Song JB, 1996, J PHARMACOL EXP THER, V277, P1444; SUN XC, 1992, J BIOL CHEM, V267, P19147; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Weinlander G, 1997, J CANCER RES CLIN, V123, P452, DOI 10.1007/BF01372550; Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488; Williams JP, 1997, J CELL BIOCHEM, V66, P358, DOI 10.1002/(SICI)1097-4644(19970901)66:3<358::AID-JCB8>3.3.CO;2-K; WISEMAN H, 1993, FEBS LETT, V330, P53, DOI 10.1016/0014-5793(93)80918-K; WISEMAN H, 1994, TRENDS PHARMACOL SCI, V15, P83, DOI 10.1016/0165-6147(94)90283-6; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	48	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18364	18373		10.1074/jbc.274.26.18364	http://dx.doi.org/10.1074/jbc.274.26.18364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373441	hybrid			2022-12-25	WOS:000081056700033
J	Dharmawardana, KR; Olson, ST; Bock, PE				Dharmawardana, KR; Olson, ST; Bock, PE			Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; PEPTIDE CHLOROMETHYL KETONES; MACROMOLECULAR SUBSTRATE RECOGNITION; AMINO-ACID SEQUENCE; CLOTTING FACTOR-V; ACTIVE-SITE; ALPHA-THROMBIN; FACTOR-XA; CATALYZED ACTIVATION; HEAVY-CHAIN	The blood coagulation proteinase, thrombin, converts factor V into factor Va through a multistep activation pathway that is regulated by interactions with thrombin exosites, Thrombin exosite interactions with human factor V and its activation products were quantitatively characterized in equilibrium binding studies based on fluorescence changes of thrombin covalently labeled with 2-anilinonaphthalene-6-sulfonic acid (ANS) linked to the catalytic site histidine residue by N-alpha-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl ([ANS]FPR-thrombin). Exosite I was shown to play a predominant role in the binding of factor V and factor Va from the effect of the exosite I-specific ligand, hirudin(54-65), on the interactions. Factor V and factor Va bound to exosite I of [ANS]FPR-thrombin with similar dissociation constants of 3.4 +/- 1.3 and 1.1 +/- 0.4 mu M and fluorescence enhancements of 182 +/- 41 and 127 +/- 17%, respectively. Native thrombin and labeled thrombin bound with similar affinity to factor Va. Among factor V activation products, the factor Va heavy chain was shown to contain the site of exosite I binding, whereas exosite I-independent, lower affinity interactions were observed for activation fragments E and C1, and no detectable binding was observed for the factor Va light chain. The results support the conclusion that the factor V activation pathway is initiated by exosite I-mediated binding of thrombin to a site in the heavy chain region of factor V that facilitates the initial cleavage at Arg(709) to generate the heavy chain of factor Va. The results further suggest that binding of thrombin through exosite I to factor V activation intermediates may regulate their conversion to factor Va and that similar binding of thrombin to the factor Va produced may reflect a mode of interaction involved in the regulation of prothrombin activation.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL039888, R37HL039888, R29HL038779, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02832, HL-38779, HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1998, THROMB HAEMOSTASIS, V79, P1157, DOI 10.1055/s-0037-1615033; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KANE WH, 1981, J BIOL CHEM, V256, P1002; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; MIHALYI E, 1968, J CHEM ENG DATA, V13, P179, DOI 10.1021/je60037a011; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	52	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18635	18643		10.1074/jbc.274.26.18635	http://dx.doi.org/10.1074/jbc.274.26.18635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373475	hybrid			2022-12-25	WOS:000081056700067
J	Enkemann, SA; Pavur, KS; Ryazanov, AG; Berger, SL				Enkemann, SA; Pavur, KS; Ryazanov, AG; Berger, SL			Does prothymosin alpha affect the phosphorylation of elongation factor 2?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; HL-60 CELLS; HISTONE H1; IN-VITRO; C-MYC; GENE; EXPRESSION; PROTEIN; PROLIFERATION; THYMOSIN-ALPHA-1	Prothymosin alpha is a small, acidic, essential nuclear protein that plays a poorly defined role in the proliferation and survival of mammalian cells. Recently, Vega et al. proposed that exogenous prothymosin alpha can specifically increase the phosphorylation of eukaryotic elongation factor 2 (eEF-2) in extracts of NIH3T3 cells (Vega, F. V., Vidal, A., Hellman, U., Wernstedt, C., and Dominguez, F. (1998) J. Biol. Chem. 273, 10147-10152). Using similar lysates prepared by four methods (detergent lysis, Dounce homogenization, digitonin permeabilization, and sonication) and three preparations of prothymosin alpha, one of which was purified by gentle means (the native protein, and a histidine-tagged recombinant prothymosin alpha expressed either in bacteria or in COS cells), we failed to find a response. A reconstituted system composed of eEF-2, recombinant eEF-2 kinase, calmodulin, and calcium was also unaffected by prothymosin alpha. However, unlike our optimized buffer, Vega's system included a phosphatase inhibitor, 50 mM fluoride, which when evaluated in our laboratories severely reduced phosphorylation of all species. Under these conditions, any procedure that decreases the effective fluoride concentration will relieve the inhibition and appear to activate. Our data do not support a direct relationship between the function of prothymosin a and the phosphorylation of eEF-2.	NCI, Sect Genes & Genes Prod, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Dept Pharmacol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Med & Canc Inst, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Berger, SL (corresponding author), NCI, Sect Genes & Genes Prod, Natl Inst Hlth, Bldg 37,Rm 5D-10,37 Convent Dr, Bethesda, MD 20892 USA.	bergers@pop.nci.nih.gov	ryazanov, alexey/J-8081-2017					BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CASTRO A, 1995, APPL OPTICS, V34, P3218, DOI 10.1364/AO.34.003218; CELIS JE, 1990, P NATL ACAD SCI USA, V87, P4231, DOI 10.1073/pnas.87.11.4231; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; CORDERO OJ, 1992, BIOCHEM INT, V28, P1117; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOSIL M, 1990, FEBS LETT, V269, P373, DOI 10.1016/0014-5793(90)81196-U; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P85; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOLDEMBERG AL, 1973, BIOCHIM BIOPHYS ACTA, V291, P489, DOI 10.1016/0005-2736(73)90500-2; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1987, FEBS LETT, V218, P107, DOI 10.1016/0014-5793(87)81028-1; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HARWOOD JP, 1973, J BIOL CHEM, V248, P4901; HELLUNGLARSEN P, 1969, BIOCHIM BIOPHYS ACTA, V190, P434, DOI 10.1016/0005-2787(69)90092-6; JOHNSON RA, 1973, J BIOL CHEM, V248, P5114; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MORI M, 1993, ONCOGENE, V8, P2821; NAIRN AC, 1996, TRANSLATIONAL CONTRO, P295; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; ROSON E, 1993, HISTOCHEM J, V25, P497, DOI 10.1007/BF00159285; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; RYAZANOV AG, 1993, TRANSLATIONAL REGULA, V2, P433; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SMITH MR, 1993, BLOOD, V82, P1127; SZABO P, 1992, CLIN IMMUNOL IMMUNOP, V65, P195, DOI 10.1016/0090-1229(92)90146-F; Tao L, 1999, J CELL PHYSIOL, V178, P154, DOI 10.1002/(SICI)1097-4652(199902)178:2<154::AID-JCP4>3.0.CO;2-V; Trumbore MW, 1998, PROTEIN EXPRES PURIF, V13, P383, DOI 10.1006/prep.1998.0909; Trumbore MW, 1997, J BIOL CHEM, V272, P26394, DOI 10.1074/jbc.272.42.26394; Vega FV, 1998, J BIOL CHEM, V273, P10147, DOI 10.1074/jbc.273.17.10147; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405; Warburg O., 1942, BIOCHEM Z, V310, P384; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6	52	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18644	18650		10.1074/jbc.274.26.18644	http://dx.doi.org/10.1074/jbc.274.26.18644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373476	hybrid			2022-12-25	WOS:000081056700068
J	Ramos, CHI				Ramos, CHI			Mapping subdomains in the C-terminal region of troponin I involved in its binding to troponin C and to thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SMALL-ANGLE SCATTERING; SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; PHOSPHORYLASE-KINASE; REGULATORY DOMAIN; CROSS-LINKING; CATALYTIC SUBUNIT; RABBIT	Troponin I (TnI) is the inhibitory component of troponin, the ternary complex that regulates skeletal and cardiac muscle contraction. Previous work showed that the C-terminal region of TnI, when linked to the "inhibitory region" (residues 98-116), possesses the major regulatory functions of the molecule (Farah, C. S., Miyamoto, C. A., Ramos, C. H. I., Silva, A. C. R., Quaggio, R. B., Fujimori, K., Smillie, L. B., and Reinach, F. C. (1994) J. Biol. Chem. 269, 5230-5240). To investigate these functions in more detail, serial deletion mutants of the C-terminal region of TnI were constructed. These experiments showed that longer C-terminal deletions result in lower inhibition of the actomyosin ATPase activity and weaken the interaction with the N-terminal domain of troponin C (TnC), consistent with the antiparallel model for the interaction between these two proteins. The conclusion is that the whole C-terminal region of TnI is necessary for its full regulatory activity. The region between residues 137 and 144, which was shown to have homology with residues 108-115 in the inhibitory region (Farah, C. S., and Reinach, F. C. (1995) FASEB J. 9, 755-767), is involved in the binding to TnC. The region between residues 98 and 129 is involved in modulating the affinity of TnC for calcium. The C-terminal residues 166-182 are involved in the binding of TnI to thin filament. A model for the function of TnI is discussed.	Ctr Biol Mol Estructural, Lab Nacl Luz Sincroton, BR-13083970 Campinas, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade de Sao Paulo	Ramos, CHI (corresponding author), Ctr Biol Mol Estructural, Lab Nacl Luz Sincroton, CP 6192, BR-13083970 Campinas, SP, Brazil.		Ramos, CH/C-1571-2012	Ramos, CH/0000-0002-7246-9081				ALDELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEDMAN JR, 1977, J BIOL CHEM, V252, P2437; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEINOHEN JK, 1987, ANAL BIOCHEM, V113, P313; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KOBAYASHI T, 1995, BIOCHEMISTRY-US, V34, P10946, DOI 10.1021/bi00034a029; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEVIT S, 1976, J BIOL CHEM, V251, P1333; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; NGAI SM, 1992, J BIOL CHEM, V267, P15715; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	53	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18189	18195		10.1074/jbc.274.26.18189	http://dx.doi.org/10.1074/jbc.274.26.18189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373418	hybrid			2022-12-25	WOS:000081056700010
J	Rouard, M; Bass, J; Grigorescu, F; Garrett, TPJ; Ward, CW; Lipkind, G; Jaffiole, C; Steiner, DF; Bell, GI				Rouard, M; Bass, J; Grigorescu, F; Garrett, TPJ; Ward, CW; Lipkind, G; Jaffiole, C; Steiner, DF; Bell, GI			Congenital insulin resistance associated with a conformational alteration in a conserved beta-sheet in the insulin receptor L1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; LIGAND-BINDING DOMAIN; FACTOR-I RECEPTOR; FIRST 3 DOMAINS; GROWTH-FACTOR; ALPHA-SUBUNIT; CROSS-LINKING; IDENTIFICATION; DETERMINANTS; SPECIFICITY	The hormone binding site of members of the insulin receptor family is contained within a highly conserved extracellular region of the receptor. Recent crystallization of the N-terminal region of the binding site revealed two large domains (L1, L2), each organized as a single-stranded right-handed beta-helix, connected by a rod-shaped cysteine-rich domain. Here, we analyze two new naturally occurring mutations in a single p-sheet within L1, D59G and L62P, that we previously identified in a young woman with classic congenital insulin resistance (type A). Substitution of D59G, a beta-sheet connecting loop residue, caused decreased hormone binding but did not disrupt overall folding, assembly, or movement to the cell surface. In contrast, replacement of the adjacent residue L62P, which is located within the beta-sheet, and positioned in a hormone binding surface, completely disrupted intracellular folding, oligomerization, and trafficking and resulted in aberrant proteolytic degradation. Immunohistochemistry in combination with biosynthetic studies showed that misfolded receptors were retained in an incorrect cellular location and that they colocalized with the resident endoplasmic reticulum chaperone calnexin, This study, together with other mutagenesis data, shows that formation of beta-sheet elements within the L1 beta-helix are critical for the folding of the entire extracellular domain of the receptor and that the hormone contact site is composed in part by residues in this domain.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Inst Univ Rech, Mol Endocrinol Lab, F-34093 Montpellier, France; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Bass, J (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.		Grigorescu, Florin/Q-3728-2019; GRIGORESCU, FLORIN/C-2238-2013	Grigorescu, Florin/0000-0002-3095-5639; GRIGORESCU, FLORIN/0000-0002-3095-5639				ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P110; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; KRAULIS P, 1991, J APP CRYST A, V47, P110; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; KUROSE T, 1994, J BIOL CHEM, V269, P29190; McKern NM, 1997, PROTEIN SCI, V6, P2663; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; OLSON TS, 1988, J BIOL CHEM, V263, P7342; Rouard M, 1997, BIOCHEM BIOPH RES CO, V234, P764, DOI 10.1006/bbrc.1997.6695; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR S, 1994, ENDOCR REV, V2, P58; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WERTHEIMER E, 1994, J BIOL CHEM, V269, P7587; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	27	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18487	18491		10.1074/jbc.274.26.18487	http://dx.doi.org/10.1074/jbc.274.26.18487			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373457	hybrid			2022-12-25	WOS:000081056700049
J	Chaudhuri, J; Chowdhury, D; Maitra, U				Chaudhuri, J; Chowdhury, D; Maitra, U			Distinct functions of eukaryotic translation initiation factors eIF1A and eIF3 in the formation of the 40 S ribosomal preinitiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; RABBIT RETICULOCYTES; DISSOCIATION FACTOR; MOLECULAR-CLONING; CALF LIVER; FACTOR-III; PURIFICATION; SUBUNIT; ASSOCIATION; MECHANISM	We have used an in vitro translation initiation assay to investigate the requirements for the efficient transfer of Met-tRNA(f) (as Met-tRNA(f).eIF2.GTP ternary complex) to 40 S ribosomal subunits in the absence of mRNA (or an AUG codon) to form the 40 S preinitiation complex. We observed that the 17-kDa initiation factor eIF1A is necessary and sufficient to mediate nearly quantitative transfer of Met-tRNA(f) to isolated 40 S ribosomal subunits. However, the addition of 60 S ribosomal subunits to the 40 S preinitiation complex formed under these conditions disrupted the 40 S complex resulting in dissociation of Met-tRNA(f) from the 40 S subunit. When the eIF1A-dependent preinitiation reaction was carried out with 40 S ribosomal subunits that had been preincubated with eIF3, the 40 S preinitiation complex formed included bound eIF3 (40 S.eIF3.Met-tRNA(f).eIF2.GTP). In contrast to the complex lacking eIF3, this complex was not disrupted by the addition of 60 S ribosomal subunits, These results suggest that in vivo, both eIF1A and eIF3 are required to form a stable 40 S preinitiation complex, eIF1A catalyzing the transfer of Met-tRNA(f).eIF2.GTP to 40 S subunits, and eIF3 stabilizing the resulting complex and preventing its disruption by 60 IS ribosomal subunits.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; RAYCHAUDHURI P, 1986, J BIOL CHEM, V261, P7723; RUSSELL DW, 1979, J BIOL CHEM, V254, P8796; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; SMITH KE, 1975, J BIOL CHEM, V250, P6880; SRIVASTAVA S, 1992, J MOL BIOL, V226, P301, DOI 10.1016/0022-2836(92)90946-H; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712	27	78	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17975	17980		10.1074/jbc.274.25.17975	http://dx.doi.org/10.1074/jbc.274.25.17975			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364246	hybrid			2022-12-25	WOS:000080974300082
J	Hendriks, J; Hoff, WD; Crielaard, W; Hellingwerf, KJ				Hendriks, J; Hoff, WD; Crielaard, W; Hellingwerf, KJ			Protonation deprotonation reactions triggered by photoactivation of photoactive yellow protein from Ectothiorhodospira halophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-COUMARIC ACID; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; PURPLE PHOTOTROPHIC BACTERIUM; PHOTOCYCLE INTERMEDIATE; ACTIVE-SITE; FLUORESCENCE; SPECTROSCOPY; DENATURATION; DEPENDENCE; RHODOPSIN	Light-dependent pH changes were measured in unbuffered solutions of wild type photoactive yellow protein (PYP) and its H108F and E46Q variants, using two independent techniques: transient absorption changes of added pH indicator dyes and direct readings with a combination pH electrode. Depending on the absolute pH of the sample, a reversible protonation as well as a deprotonation can be observed upon formation of the transient, blue-shifted photocycle intermediate (pB) of this photoreceptor protein. The latter is observed at very alkaline pH, the former at acidic pH values. At neutral pH, however, the formation of the pB state is not paralleled by significant protonation/deprotonation of PYP, as expected for concomitant protonation of the chromophore and deprotonation of Glu-46 during pB formation. We interpret these results as further evidence that a proton is transferred from Glu-46 to the coumaric acid chromophore of PYP, during pB formation. One cannot exclude the possibility, however, that this transfer proceeds through the bulk aqueous phase. Simultaneously, an amino acid side chain(s) (e.g. His108) changes from a buried to an exposed position. These results, therefore, further support the idea that PYP significantly unfolds in the pB state and resolve the controversy regarding proton transfer during the PYP photocycle.	Univ Amsterdam, Microbiol Lab, EC Slater Inst, Bioctr, NL-1018 WS Amsterdam, Netherlands	University of Amsterdam	Hellingwerf, KJ (corresponding author), Nieuwe Achtergracht 127, NL-1018 WS Amsterdam, Netherlands.	K.Hellingwerf@chem.uva.nl						BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Changenet P, 1998, CHEM PHYS LETT, V282, P276, DOI 10.1016/S0009-2614(97)01334-1; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hoff WD, 1996, BIOCHEMISTRY-US, V35, P1274, DOI 10.1021/bi951755z; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hoff WD, 1997, BBA-BIOENERGETICS, V1322, P151, DOI 10.1016/S0005-2728(97)00082-0; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; KRAAYENHOF R, 1982, ANAL BIOCHEM, V127, P93, DOI 10.1016/0003-2697(82)90149-X; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1993, ARCH BIOCHEM BIOPHYS, V306, P515, DOI 10.1006/abbi.1993.1545; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MILLER A, 1993, BIOCHIM BIOPHYS ACTA, V1141, P190, DOI 10.1016/0005-2728(93)90042-E; OESTERHELT D, 1973, EUR J BIOCHEM, V37, P316, DOI 10.1111/j.1432-1033.1973.tb02990.x; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; RENTHAL R, 1977, BIOCHEM BIOPH RES CO, V77, P155, DOI 10.1016/S0006-291X(77)80177-0; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; XE A, 1996, BIOCHEMISTRY-US, V35, P14671	38	62	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17655	17660		10.1074/jbc.274.25.17655	http://dx.doi.org/10.1074/jbc.274.25.17655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364204	hybrid			2022-12-25	WOS:000080974300040
J	Inoue, T; Nishio, N; Suzuki, S; Kataoka, K; Kohzuma, T; Kai, Y				Inoue, T; Nishio, N; Suzuki, S; Kataoka, K; Kohzuma, T; Kai, Y			Crystal structure determinations of oxidized and reduced pseudoazurins from Achromobacter cycloclastes - Concerted movement of copper site in redox forms with the rearrangement of hydrogen bond at a remote histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS S-6; AMINO-ACID-SEQUENCE; NITRITE REDUCTASE; X-RAY; THIOSPHAERA-PANTOTROPHA; PH VALUES; PROTEIN; REFINEMENT; RESOLUTION; AMICYANIN	The crystal structures of oxidized and reduced pseudoazurins from a denitrifying bacterium, Achromobacter cycloclastes IAM1013, have been determined at 1.35- and 1.6-Angstrom resolutions, respectively. The copper site in the oxidized state exhibits a distorted tetrahedral structure like those of other pseudoazurins. However, not only a small change of the copper geometry, but concerted peptide bond flips are identified. The imidazole ring of remote His(6) has a hydrogen bonding distance of 2.73 Angstrom between N-delta 1(His(6)) and O-gamma 1(Thr(36)) in the oxidized protein. When the protein is reduced at pH 6.0, the imidazole ring rotates by 30.3 degrees and moves 1.00 Angstrom away from the position of the oxidized state. A new hydrogen bond between N-epsilon 2(His(6)) and O-epsilon 1(Glu(4)) is formed with a distance of 3.03 Angstrom, while the hydrogen bond between N-delta 1(His(6))-O-gamma 1(Thr(36)) is maintained with an interatomic distance of 2.81 Angstrom. A concomitant peptide bond flip of main chain between Ile(34) and Thr(36) occurs.	Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Ibaraki Univ, Fac Sci, Dept Chem, Ibaraki 3108512, Japan	Osaka University; Osaka University; Ibaraki University	Kai, Y (corresponding author), Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan.		Kohzuma, Takamitsu/U-2966-2019; KATAOKA, Kunishige/J-8457-2015					Adman E., 1985, METALLOPROTEINS, V1, P1; ADMAN ET, 1989, J BIOL CHEM, V264, P87; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; AMBLER RP, 1997, EVOLUTION METALLOENZ, P100; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAN C, 1995, BIOCHEM J, V308, P585, DOI 10.1042/bj3080585; Chen JY, 1996, BIOCHEM BIOPH RES CO, V219, P423, DOI 10.1006/bbrc.1996.0249; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DENNISON C, 1994, J CHEM SOC DALTON, P437, DOI 10.1039/dt9940000437; DENNISON C, 1994, J CHEM SOC CHEM COMM, P581, DOI 10.1039/c39940000581; DENNISON C, 1994, INORG CHEM, V33, P3299, DOI 10.1021/ic00093a017; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HORMEL S, 1986, FEBS LETT, V197, P301, DOI 10.1016/0014-5793(86)80346-5; INOUE T, 1994, ACTA CRYSTALLOGR D, V50, P317, DOI 10.1107/S0907444994000260; INOUE T, 1993, J BIOCHEM-TOKYO, V114, P761, DOI 10.1093/oxfordjournals.jbchem.a124251; IWASAKI H, 1973, J BIOCHEM, V73, P659, DOI 10.1093/oxfordjournals.jbchem.a130125; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; Kohzuma T, 1997, J ELECTROANAL CHEM, V438, P49, DOI 10.1016/S0022-0728(97)00056-9; KOHZUMA T, 1993, CHEM LETT, P149, DOI 10.1246/cl.1993.149; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Libeu CAP, 1997, BIOCHEMISTRY-US, V36, P13160, DOI 10.1021/bi9704111; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; PETRATOS K, 1987, FEBS LETT, V218, P209, DOI 10.1016/0014-5793(87)81048-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SYKES AG, 1993, BIOINORGANIC CHEM CO, V1, P78; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; VAKOUFARI E, 1994, FEBS LETT, V347, P203, DOI 10.1016/0014-5793(94)00544-3; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975	45	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17845	17852		10.1074/jbc.274.25.17845	http://dx.doi.org/10.1074/jbc.274.25.17845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364229	hybrid			2022-12-25	WOS:000080974300065
J	Layton, JE; Shimamoto, G; Osslund, T; Hammacher, A; Smith, DK; Treutlein, HR; Boone, T				Layton, JE; Shimamoto, G; Osslund, T; Hammacher, A; Smith, DK; Treutlein, HR; Boone, T			Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor - evidence that Glu(19) of G-CSF interacts with Arg(288) of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; GROWTH-HORMONE RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; HUMAN INTERLEUKIN-6; CONFORMATIONAL-CHANGES; SIGNAL TRANSDUCER; CRYSTAL-STRUCTURE; ALPHA-CHAIN; COMPLEX	Granulocyte colony-stimulating factor (G-CSF) forms a tetrameric complex with its receptor, comprising two G-CSF and two receptor molecules. The structure of the complex is unknown, and it is unclear whether there are one or two binding sites on G-CSF and the receptor. The immunoglobulin-like domain and the cytokine receptor homologous module of the receptor are involved in G-CSF binding, and Arg(288) in the cytokine receptor homologous module is particularly important. To identify residues in G-CSF that interact with Arg(288), selected charged residues in G-CSF were mutated to Ale. To clarify whether there are two binding sites, a chimeric receptor was created in which the Ig domain was replaced with that of the related receptor gp130, This chimera bound G-CSF but could not transduce a signal, consistent with failure of dimerization and loss of one binding site, The G-CSF mutants had reduced mitogenic activity on cells expressing wild-type receptor. When tested with the chimeric receptor, all G-CSF mutants except one (E46A) showed reduced binding, suggesting that Glu(46) is important for interaction with the Ig domain, On cells expressing R288A receptor, all the G-CSF mutants except E19A showed reduced mitogenic activity, indicating that Glu(19) of G-CSF interacts with Arg(288) of the receptor.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Amgen Inc, Thousand Oaks, CA 91320 USA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Amgen	Layton, JE (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, POB 2008, Parkville, Vic 3050, Australia.		Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Smith, David/0000-0003-3608-0586				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CAMPBELL IK, 1991, J IMMUNOL, V147, P1238; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1997, J BIOCHEM-TOKYO, V121, P370; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LAYTON JE, 1997, GROWTH FACTORS CYTOK, P557; Li TS, 1997, BIOCHEMISTRY-US, V36, P8849, DOI 10.1021/bi962713t; LOVEJOY B, 1993, J MOL BIOL, V234, P640, DOI 10.1006/jmbi.1993.1617; Mellado M, 1997, J BIOL CHEM, V272, P9189; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLA NA, 1990, COLONY STIMULATING F, P77; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Rowlinson SW, 1998, J BIOL CHEM, V273, P5307, DOI 10.1074/jbc.273.9.5307; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; WERNER JM, 1994, BIOCHEMISTRY-US, V33, P7184, DOI 10.1021/bi00189a022; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Young DC, 1997, PROTEIN SCI, V6, P1228, DOI 10.1002/pro.5560060611; ZINK T, 1994, BIOCHEMISTRY-US, V33, P8453, DOI 10.1021/bi00194a009; ZSEBO KM, 1986, IMMUNOBIOLOGY, V172, P175, DOI 10.1016/S0171-2985(86)80097-3	43	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17445	17451		10.1074/jbc.274.25.17445	http://dx.doi.org/10.1074/jbc.274.25.17445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364174	hybrid			2022-12-25	WOS:000080974300010
J	McCollum, D; Feoktistova, A; Gould, KL				McCollum, D; Feoktistova, A; Gould, KL			Phosphorylation of the myosin-II light chain does not regulate the timing of cytokinesis in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; HEAVY-CHAIN; CONTRACTILE RING; CULTURED-CELLS; GENE; DICTYOSTELIUM; EXPRESSION; IDENTIFICATION; LOCALIZATION; EFFICIENCY	Proper coordination of cytokinesis with chromosome separation during mitosis is crucial to ensure that each daughter cell inherits an equivalent set of chromosomes. It has been proposed that one mechanism by which this is achieved is through temporally regulated myosin regulatory light chain (RLC) phosphorylation (Satterwhite, L. L., and Pollard, T. D. (1992) Curr. Opin. Cell Biol, 4, 43-52), A variety of evidence is consistent with this model. A direct test of the importance of RLC phosphorylation in vivo has been done only in Dictyostelium and Drosophila; phosphorylation of the RLC is essential in Drosophila (Jordan, P., and Karess, R. (1997) J. Cell Biol, 139, 1805-1819) but not essential in Dictyostelium (Ostrow, B, D,, Chen, P,, and Chisholm, R, L, (1994) J, Cell Biol, 127, 1945-1955), The Schizosaccharomyces pombe myosin light chain Cdc4p is essential for cytokinesis, but it was unknown whether phosphorylation played a role in its regulation. Here we show that the S, pombe myosin light chain Cdc4p is phosphorylated in vivo on either serine 2 or 6 but not both. Mutation of either or both of these sites to alanine did not effect the ability of Cdc4p to bind the type II myosin Myo2p, and cells expressing only these mutated versions of Cdc4p grew and divided normally. Similarly, mutation of Ser-2, Ser-6, or both residues to aspartic acid did not affect growth or division of cells. Thus we conclude that phosphorylation of Cdc4p is not essential in vivo for the function of the protein.	Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	kathy.gould@mcmail.vanderbilt.edu		Gould, Kathleen/0000-0002-3810-4070	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016145] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16145] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1998, GENETICS, V149, P1265; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHEN TLL, 1995, J CELL SCI, V108, P3207; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HAMMER JA, 1994, J CELL BIOL, V127, P1779, DOI 10.1083/jcb.127.6.1779; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; MARKS J, 1985, EUR J CELL BIOL, V39, P27; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; May KM, 1997, CELL MOTIL CYTOSKEL, V38, P385, DOI 10.1002/(SICI)1097-0169(1997)38:4<385::AID-CM8>3.0.CO;2-2; May KM, 1998, CELL MOTIL CYTOSKEL, V39, P195, DOI 10.1002/(SICI)1097-0169(1998)39:3<195::AID-CM2>3.0.CO;2-4; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Motegi F, 1997, FEBS LETT, V420, P161, DOI 10.1016/S0014-5793(97)01510-X; Naqvi NI, 1999, EMBO J, V18, P854, DOI 10.1093/emboj/18.4.854; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17691	17695		10.1074/jbc.274.25.17691	http://dx.doi.org/10.1074/jbc.274.25.17691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364209	hybrid			2022-12-25	WOS:000080974300045
J	Sakurai, T; Moriguchi, T; Furuya, K; Kajiwara, N; Nakamura, T; Yanagisawa, M; Goto, K				Sakurai, T; Moriguchi, T; Furuya, K; Kajiwara, N; Nakamura, T; Yanagisawa, M; Goto, K			Structure and function of human prepro-orexin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATERAL HYPOTHALAMIC AREA; TRANSGENIC MICE; EXPRESSION; PEPTIDES; BEHAVIOR; PROTEIN; NEURONS	Orexin-A and -B are recently identified potent orexigenic peptides that are derived from the same precursor peptide and are highly specifically localized in neurons located in the lateral hypothalamic area, a region classically implicated in feeding behavior. We cloned the whole length of the human prepro-orexin gene and corresponding cDNA. The human prepro-orexin mRNA was predicted to encode a 131-residue precursor peptide (prepro-orexin). The human prepro-orexin gene consists of two exons and one intron distributed over 1432 base pairs. The 143-base pair first exon includes the 5'-untranslated region and a small part of the coding region that encodes the first seven residues of the secretory signal sequence. The second exon contains the remaining portion of the open reading frame and 3'-untranslated region. The 3.2 kilobase pairs of the 5'-upstream region from a cloned human prepro-orexin gene promoter is sufficient to direct the expression of the Escherichia coli beta-galactosidase (lacZ) gene in transgenic mice to neurons in the lateral hypothalamic area and adjacent regions. The lacZ-positive neurons were positively stained with anti-orexin antibody but not with anti-melanin-concentrating hormone antibody. These findings suggest that this genomic fragment contains all the necessary elements for appropriate expression of the gene and will be useful for the targeted expression of the exogenous gene in orexin-containing neurons. These mice might also be useful for examining the molecular mechanisms by which orexin gene expression is regulated.	Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Res Ctr, Tsukuba, Ibaraki 3058575, Japan; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Tsukuba; University of Tsukuba; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sakurai, T (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan.							[Anonymous], [No title captured]; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MACGOWEN R, 1989, GENE DEV, V3, P1669; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Peyron C, 1998, J NEUROSCI, V18, P9996; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	20	151	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17771	17776		10.1074/jbc.274.25.17771	http://dx.doi.org/10.1074/jbc.274.25.17771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364220	hybrid			2022-12-25	WOS:000080974300056
J	Yeh, SR; Rousseau, DL				Yeh, SR; Rousseau, DL			Ligand exchange during unfolding of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING KINETICS; CIRCULAR-DICHROISM; PATHWAYS; SPECTROSCOPY; NUCLEATION; LEVINTHAL; SECONDARY; EVENTS; STATE; VIEW	The productive folding pathway of cytochrome c passes through an obligatory HW intermediate in which the heme is coordinated by a solvent water molecule and a native ligand, His-18, prior to the formation of the folded HM state with both the native His-18 and Met-80 heme coordination. Two off pathway intermediates, a five-coordinated state (5C) and a bis-histidine state (HH), were also identified during the folding reaction, In the present work, the thermodynamics and the kinetics of the unfolding reaction of cytochrome c were investigated with resonance Raman scattering, tryptophan fluorescence spectroscopy, and circular dichroism, The objective of these experiments was to determine if the protein opens up and diverges into the differing heme ligation states through a many pathway mechanism or if it passes through intermediate states analogous to those observed during the folding reaction. Equilibrium unfolding results indicate that, in contrast to 5C, the stability of HH with respect to HW decreases as the concentration of GdnHCl increases. The difference in their response to the denaturant indicates that the polypeptide structure of 5C is relatively loose as compared with HH in which the polypeptide is misfolded. Time-resolved resonance Raman measurements show that strikingly similar ligand exchange reactions occur during unfolding as were observed during folding Combined with fluorescence data, a kinetic model is proposed in which local structural rearrangements controlled by heme ligand exchange reactions appear prior to the global relaxation of the polypeptide chain.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Yeh, SR (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	SYEH@AECOM.YU.EDU		Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54812, GM-54806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; Bhuyan AK, 1998, BIOCHEMISTRY-US, V37, P9147, DOI 10.1021/bi980470u; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; Englander SW, 1998, ACCOUNTS CHEM RES, V31, P737, DOI 10.1021/ar970085h; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; JORDAN T, 1995, PROTEIN SCI, V4, P716; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Laurents DV, 1998, BIOPHYS J, V75, P428, DOI 10.1016/S0006-3495(98)77530-7; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ptitsyn OB, 1998, BIOCHEMISTRY-MOSCOW+, V63, P367; Shakhnovich EI, 1996, FOLD DES, V1, pR50, DOI 10.1016/S1359-0278(96)00027-2; Shakhnovich EI, 1998, FOLD DES, V3, pR108, DOI 10.1016/S1359-0278(98)00056-X; Shastry MCR, 1998, ACCOUNTS CHEM RES, V31, P717; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Sosnick TR, 1996, PROTEINS, V24, P413; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1998, ACCOUNTS CHEM RES, V31, P755, DOI 10.1021/ar970078t; TSONG TY, 1976, BIOCHEMISTRY-US, V15, P5467, DOI 10.1021/bi00670a007; VEERARAGHAVAN S, 1995, BIOCHEMISTRY-US, V34, P12892, DOI 10.1021/bi00039a052; Xu YJ, 1998, NAT STRUCT BIOL, V5, P774, DOI 10.1038/1810; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yeh SR, 1998, ACCOUNTS CHEM RES, V31, P727, DOI 10.1021/ar970084p; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222	36	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17853	17859		10.1074/jbc.274.25.17853	http://dx.doi.org/10.1074/jbc.274.25.17853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364230	hybrid			2022-12-25	WOS:000080974300066
J	Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC				Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC			Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms	ONCOGENE			English	Article						c-Myc; transformation; tumor supressor; transcription	TUMOR-SUPPRESSOR BIN1; C-MYC; ORNITHINE DECARBOXYLASE; ACTIVATES TRANSCRIPTION; REPRESSOR SIN3; ADENOVIRUS E1A; GROWTH ARREST; PROTEIN; GENE; P53	The tumor suppressor Bin1 nas identified through its interaction with the N-terminal region of Myc which harbors its transcriptional activation domain. Here we show that Bin1 and Myc physically and functionally associate in cells and that Bin1 inhibits cell proliferation through both Myc-dependent and Myc-independent mechanisms. Bin1 specifically inhibited transactivation by Myc as assayed from artificial promoters or from the Myc target genes ornithine decarboxylase (ODC) and alpha prothymosin (pT). Inhibition of ODC but not pT required the presence of the Myc binding domain (MBD) of Bin1 suggesting two mechanisms of action. Consistent with this possibility, a non-MBD region of Bin1 was sufficient to recruit a repression function to DNA that was unrelated to histone deacetylase. Regions outside the MBD required for growth inhibition were mapped in Ras cotransformation or HepG2 hepatoma cell growth assays. Bin1 required the N-terminal BAR domain to suppress focus formation by Myc whereas the C-terminal U1 and SH3 domains were required to inhibit adenovirus E1A or mutant p53, respectively. All three domains contributed to Bin1 suppression or tumor cell growth but BAR-C was most crucial. These findings supported functional interaction between Myc and Bin1 in cells and indicated that Bin1 could inhibit malignant cell growth through multiple mechanisms.	Wistar Inst, Philadelphia, PA 19104 USA; Univ Marburg, Inst Mol Biol & Tumour Res IMT, D-35033 Marburg, Germany; Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA	The Wistar Institute; Philipps University Marburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.			Gaubatz, Stefan/0000-0001-8751-4191; Eilers, Martin/0000-0002-0376-6533				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DYSON N, 1992, CANCER SURV, V12, P161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E., ANTIBODIES LAB MANUA; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARUYAMA K, 1987, ONCOGENE, V1, P361; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YUAN ZM, 1996, J BIOL CHEM, V271, P26257; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	93	101	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3564	3573		10.1038/sj.onc.1202670	http://dx.doi.org/10.1038/sj.onc.1202670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380878				2022-12-25	WOS:000080891700002
J	Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B				Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B			Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments	ONCOGENE			English	Article						p53; DNA-p53 interaction; sc DNA; divalent cation; gel electrophoresis	TUMOR-SUPPRESSOR PROTEIN; ASTERISK-H-DNA; WILD-TYPE; STRUCTURAL ASPECTS; CELL-CYCLE; ZINC; DOMAIN; IONS; METALLOTHIONEIN; CONFORMATION	Recently we have shown that mild-type human p53 protein binds preferentially to supercoiled (sc) DNA in vitro in both the presence and absence of the p53 consensus sequence (p53CON). This binding produces a ladder of retarded bands on an agarose gel. Using immunoblotting with the antibody DO-1, me show that the bands obtained correspond to ethidium-stained DNA, suggesting that each band of the ladder contains a DNA-p53 complex. The intensity and the number of these bands are decreased by physiological concentrations of zinc ions. At higher zinc concentrations, binding of p53 to scDNA is completely inhibited. The binding of additional zinc ions to p53 appears much weaker than the binding of the intrinsic zinc ion in the DNA binding site of the core domain. In contrast to previously published data suggesting that 100 mu M zinc ions do not influence p53 binding to p53CON in a DNA oligonucleotide, we show that 5-20 mu M zinc efficiently inhibits binding of p53 to p53CON in DNA fragments. We also show that relatively low concentrations of dithiothreitol but not of 2-mercaptoethanol decrease the concentration of free zinc ions, thereby preventing their inhibitory effect on binding of p53 to DNA. Nickel and cobalt ions inhibit binding of p53 to scDNA and to its consensus sequence in linear DNA fragments less efficiently than zinc; cobalt ions are least efficient, requiring > 100 mu M Co2+ for full inhibition of p53 binding. Modulation of binding of p53 to DNA by physiological concentrations of zinc might represent a novel pathway that regulates p53 activity in vivo.	Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic; Masaryk Mem Canc Inst, Brno 65653, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Masaryk Memorial Cancer Institute	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CS-61265 Brno, Czech Republic.		Brazdova, Marie/H-1924-2014; Václav, Brázda/F-9582-2011; Vlk, Daniel/A-1413-2014; Brazda, Vaclav/ABH-9460-2020; Palecek, Emil/C-1075-2013; Černocká, Hana/H-1926-2014	Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Palecek, Emil/0000-0003-2561-8336; Cernocka, Hana/0000-0002-1673-1305				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; COFFER AI, 1994, BBA-PROTEIN STRUCT M, V1209, P279, DOI 10.1016/0167-4838(94)90197-X; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; EBADI M, 1994, GEN PHARMACOL-VASC S, V25, P1297, DOI 10.1016/0306-3623(94)90152-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1995, ONCOGENE, V10, P27; Han WH, 1997, P NATL ACAD SCI USA, V94, P10565, DOI 10.1073/pnas.94.20.10565; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P497; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Klevickis C, 1996, MET IONS BIOL SYST, V32, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAUNDON CH, 1987, BIOCHEMISTRY-US, V26, P3759, DOI 10.1021/bi00387a003; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; ORTIZLOMBARDIA M, 1995, BIOCHEMISTRY-US, V34, P14408, DOI 10.1021/bi00044a018; Palecek E, 1997, ELECTROANAL, V9, P990, DOI 10.1002/elan.1140091305; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Sabat M, 1996, MET IONS BIOL SYST, V33, P143; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Tomschik M, 1998, ELECTROANAL, V10, P403, DOI 10.1002/(SICI)1521-4109(199805)10:6<403::AID-ELAN403>3.3.CO;2-U; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VLK D, 1997, THESIS ACAD SCI CZEC; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791	48	53	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3617	3625		10.1038/sj.onc.1202710	http://dx.doi.org/10.1038/sj.onc.1202710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380883				2022-12-25	WOS:000080891700007
J	Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B				Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B			Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association	ONCOGENE			English	Article						mos oncogene; cytostatic factor; molecular chaperone; protein phosphorylation; enzyme regulation	MURINE SARCOMA-VIRUS; PROTEIN-KINASE ACTIVITY; V-MOS; C-MOS; XENOPUS-OOCYTES; MOLECULAR CHAPERONES; CYTOSTATIC FACTOR; ONCOGENE PRODUCT; CELL-CYCLE; MAP KINASE	c-Mos is a germ cell-specific MAP kinase kinase kinase (;MAPKKK) that plays an essential role during meiotic divisions of oocytes, c-Mos is a key component of an activity, cytostatic factor, required for metaphase II arrest of unfertilized eggs in vertebrates. To understand the regulation of c-Mos, we are investigating c-Mos-interacting proteins, We provide evidence that mouse c-Mos binds to Hsp70, a molecular chaperone. Hsp70 was found to associate with Mos ectopically expressed in COS-1 cells. Mos-Hsp70 complexes could be immunoprecipitated with both Mos and Hsp70 antibodies. Despite a low-abundance of Mos, the Hsp70 antibody immunoprecipitated Mos as the major protein. Of importance, the Mos protein present in anti-Hsp70 immunoprecipitates functioned as an active MAPKKK indicating that it is not grossly misfolded, It is known that c-Mos protein kinase activity in cell extracts of transfected COS-1 or NIH3T3 cells is labile, We found that the inclusion of adenosine triphosphate (ATP) in cell extracts protected against the loss of Mos kinase activity, In the absence of ATP from cell extracts, protein kinase activity of Mos was lost within 6 h on ice even though the Mos protein was not degraded and remained bound to Hsp70. Based on our identification of c-Mos-Hsp70 interaction, one of the roles of ATP may be to assist the regulation of c-Mos via ATP involvement in the protein-folding function of Hsp70 and possibly other molecular chaperones. We also detected by coimmunoprecipitation a physical association between endogenous c-Mos and Hsp70 in Xenopus eggs, To provide further evidence for the functional significance of Hsp70 interaction to Mos function, we show that the residue serine 3 in Mos, which is important for the regulation of protein kinase activity of Mos is also important for Hsp70 association.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1993, ONCOGENE, V8, P2207; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; Pennisi E, 1996, SCIENCE, V274, P1613, DOI 10.1126/science.274.5293.1613; Pham CD, 1997, INT J GYNECOL CANCER, V7, P314, DOI 10.1046/j.1525-1438.1997.00461.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE TW, 1995, J BIOL CHEM, V270, P585; SHIBUYA EK, 1989, DEVELOPMENT, V106, P799; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Singh RK, 1997, B MATER SCI, V20, P259, DOI 10.1007/BF02744896; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; UZAWA M, 1995, DEV BIOL, V171, P512; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	47	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3461	3470		10.1038/sj.onc.1202699	http://dx.doi.org/10.1038/sj.onc.1202699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376524				2022-12-25	WOS:000080850600004
J	Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D				Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D			Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer	ONCOGENE			English	Article						testis; germ cell tumor; chromosomal deletions; LOH; 5q14	TUMOR-SUPPRESSOR GENE; MOUSE CHROMOSOME-18; TESTIS CANCER; HUMAN GENOME; HETEROZYGOSITY; CARCINOMA; MUTATION; LUNG; SUSCEPTIBILITY; DEFICIENCY	Since the biologic behavior and molecular genetic changes observed in testicular germ cell cancer differ from those seen in more common epithelial tumors, it is likely that hitherto uncharacterized genes play a role in the development of germ cell tumors, Our previous work on testicular germ cell cancer suggested that chromosome 5q might contain one or more novel tumor suppressor genes that play a role in this malignancy. In this study, we performed a high resolution loss of heterozygosity (LOH) study of testicular cancer using 37 informative markers on chromosome 5, We detected allelic losses in 20/48 (42%) specimens and identified three common sites of loss on chromosome 5q14, 5q21 and 5q34-qter, defined respectively by minimal regions of deletion of less than or equal to 1 cM, 10 cM and similar to 20 (cM), Using an overlapping series of YACs and radiation hybrid mapping, we have constructed a physical map of the 5q14 deletion that should aid in the isolation and characterization of the putative tumor suppressor gene located therein.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med, 100 Coll St,Med Sci Bldg,Room 7238, Toronto, ON M5S 1A8, Canada.							ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Canzian F, 1996, CANCER RES, V56, P3331; DING SF, 1993, CANCER DETECT PREV, V17, P405; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; GREENWALD BD, 1992, CANCER RES, V52, P741; HAGEMEIJER A, 1996, LEUKEMIA, P131; HATTA Y, 1995, J UROLOGY, V154, P1954, DOI 10.1016/S0022-5347(01)66833-2; HOSOE S, 1994, CANCER RES, V54, P1787; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; King BL, 1997, CANCER RES, V57, P209; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; LOTHE RA, 1995, LAB INVEST, V73, P606; MIURA I, 1992, CANCER RES, V52, P1322; Murty VVVS, 1996, ONCOGENE, V12, P2719; MURTY VVVS, 1994, ONCOGENE, V9, P2245; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; NICHOLSON DMC, 1995, SURF REV LETT, V2, P71, DOI 10.1142/S0218625X95000078; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; OZAI A, 1993, CANCER, V71, P3873; PELTOMAKI P, 1990, CANCER GENET CYTOGEN, V48, P1, DOI 10.1016/0165-4608(90)90209-S; PENG HQ, 1993, CANCER RES, V53, P3574; PENG HQ, 1995, CANCER RES, V55, P2871; Rapley E, 1998, APMIS, V106, P64; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SCHERER SW, 1997, ADV TECHNIQUES CHROM, P37; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Tamura G, 1996, CANCER RES, V56, P612; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wieland I, 1996, ONCOGENE, V12, P97	34	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3277	3283		10.1038/sj.onc.1202662	http://dx.doi.org/10.1038/sj.onc.1202662			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359533				2022-12-25	WOS:000080523800010
J	Chen, CH; Seow, KT; Guo, K; Yaw, LP; Lin, SC				Chen, CH; Seow, KT; Guo, K; Yaw, LP; Lin, SC			The membrane association domain of RGS16 contains unique amphipathic features that are conserved in RGS4 and RGS5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ACTIVITY IN-VITRO; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; ALPHA-SUBUNITS; CORE DOMAIN; BINDING; GAIP; PHOSPHORYLATION	Regulators of G protein signaling (RGS proteins) modulate G protein-mediated signaling pathways by acting as GTPase-activating proteins for G(i), G(q), and G(12) alpha-subunits of heterotrimeric G proteins. Although it is known that membrane association is critical for the biological activities of many RGS proteins, the mechanism underlying this requirement remains unclear. We reported recently that the NH, terminus of RGS16 is required for its function in vivo. In this study, we show that RGS16 lacking the NH, terminus is no longer localized to the plasma membrane as is the wild type protein, suggesting that membrane association is important for biological function, The region of amino acids 7-32 is sufficient to confer the membrane-targeting activity, of which amino acids 12-30 are predicted to adopt an amphipathic alpha-helix. Site-directed mutagenesis experiments showed that the hydrophobic residues of the nonpolar face of the helix and the strips of positively charged side chains positioned along the polar/nonpolar interface of the helix are crucial for membrane association. Subcellular fractionation by differential centrifugation followed by conditions that distinguish peripheral membrane proteins from integral ones indicate that RGS16 is a peripheral membrane protein. We show further that RGS16 membrane association does not require palmitoylation, Our results, together with other recent findings, have defined a unique membrane association domain with amphipathic features. We believe that these structural features and the mechanism of membrane association of RGS16 are likely to apply to the homologous domains in RGS4 and RGS5.	Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lin, SC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		Lin, SC/G-4666-2010					Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wise A, 1997, BIOCHEMISTRY-US, V36, P10620, DOI 10.1021/bi9702997	25	89	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19799	19806		10.1074/jbc.274.28.19799	http://dx.doi.org/10.1074/jbc.274.28.19799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391923	hybrid			2022-12-25	WOS:000081377300043
J	Glockzin, S; von Knethen, A; Scheffner, M; Brune, B				Glockzin, S; von Knethen, A; Scheffner, M; Brune, B			Activation of the cell death program by nitric oxide involves inhibition of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; I ANTIGEN PRESENTATION; INDUCED APOPTOSIS; RAW-264.7 MACROPHAGES; MEDIATED APOPTOSIS; GENE-EXPRESSION; DOWN-REGULATION; P53 EXPRESSION; DEGRADATION; PROTEIN	The ubiquitin/proteasome pathway mediates the degradation of many short-lived proteins that are critically involved in the regulation of cell proliferation and cell death, including the tumor suppressor protein p53, Accumulation of p53 and induction of apoptosis in RAW 264.7 macrophages in response to nitric oxide are well established. However, the molecular mechanisms involved in nitric oxide-induced p53 accumulation are unknown. Here we show that, similar to nitric oxide, treatment of macrophages with specific proteasome inhibitors, including clastolactacystin-beta-lactone, induces p53 accumulation and apoptosis, suggesting that nitric oxide may affect the activity of the proteasome, In support of this hypothesis, both exposure of cells to S-nitrosoglutathione and stimulation of endogenous nitric oxide production by lipopolysaccharide/interferon-gamma treatment result in inhibition of proteasome activity as measured in vitro by the degradation of the proteasome-specific substrate succinyl-Leu-Leu-Val-Tyr-4-methylcoumarin-7-amide. Moreover, chemically diverse nitric oxide donors interfere with proteasome-mediated degradation of polyubiquitinated p53 in vitro. These data imply that nitric oxide-induced apoptosis and accumulation of p53 are, at least in part, mediated by inhibition of the proteasome.	Univ Erlangen Nurnberg, Dept Med, Fac Med, Expt Div 4, D-91054 Erlangen, Germany; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	University of Erlangen Nuremberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Brune, B (corresponding author), Univ Erlangen Nurnberg, Dept Med, Fac Med, Expt Div 4, Loschgestr 8, D-91054 Erlangen, Germany.	mfm423@rzmail.uni-erlangen.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Albina JE, 1998, CANCER METAST REV, V17, P39, DOI 10.1023/A:1005904704618; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; Brown JP, 1997, BBA-REV CANCER, V1332, pO1, DOI 10.1016/S0304-419X(96)00048-0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FigueiredoPereira ME, 1996, J BIOL CHEM, V271, P16455, DOI 10.1074/jbc.271.28.16455; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Haas AL, 1997, FASEB J, V11, P1257; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Kim YM, 1997, BIOCHEM BIOPH RES CO, V236, P655, DOI 10.1006/bbrc.1997.7031; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LePage C, 1996, IMMUNOLOGY, V89, P274, DOI 10.1046/j.1365-2567.1996.d01-728.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Lopez D, 1997, J IMMUNOL, V159, P5769; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; Maki CG, 1996, CANCER RES, V56, P2649; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; Messmer UK, 1997, BRIT J PHARMACOL, V121, P625, DOI 10.1038/sj.bjp.0701156; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sandau K, 1997, KIDNEY INT, V52, P378, DOI 10.1038/ki.1997.344; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SAVORY PJ, 1997, BIOCHEM J, V289, P45; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sekkai D, 1998, J BIOL CHEM, V273, P3895, DOI 10.1074/jbc.273.7.3895; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; VonKnethen A, 1997, FASEB J, V11, P887; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	61	98	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19581	19586		10.1074/jbc.274.28.19581	http://dx.doi.org/10.1074/jbc.274.28.19581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391892	hybrid			2022-12-25	WOS:000081377300012
J	Hollnagel, A; Oehlmann, V; Heymer, J; Ruther, U; Nordheim, A				Hollnagel, A; Oehlmann, V; Heymer, J; Ruther, U; Nordheim, A			Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR-BETA; IMMEDIATE-EARLY GENE; EARLY TOOTH DEVELOPMENT; EARLY XENOPUS EMBRYO; LOOP-HELIX PROTEINS; EXPRESSION PATTERNS; MOUSE GASTRULATION; HOMEOBOX-GENE; TRANSCRIPTION FACTORS; DIFFERENTIAL DISPLAY	Bone morphogenetic proteins (BMPs) are morphogenetic signaling molecules essential for embryonic patterning. To obtain molecular insight into the influence of BMPs on morphogenesis, we searched for new genes directly activated by BMP signaling. In vitro cultured mouse embryonic stem (ES) cells were used, cultivated in chemically defined growth medium (CDM), CDM-cultured ES cells responded very selectively to stimulation by various mesoderm inducers (BMP2/4, activin A, and basic fibroblast growth factor). BMP2/4 rapidly induced transcript levels of the homeobox genes Msx-1 and Msx-2 and the proto-oncogene JunB, whereas c-jun transcripts displayed delayed albeit prolonged increase. Using differential display cDNA cloning, six direct BMP target genes were identified. These include Id3, which showed strong mRNA induction, and the moderately induced Cyr61, DEK, and eIF4AII genes, as well as a gene encoding a GC-binding protein. Besides Id3, also the Id1 and Id2 genes were activated by BMP4 in both ES cells and a range of different cell lines. Id genes encode negative regulators of basic helix-loop-helix transcription factors. In vivo we observed local ectopic expression of Id3 and Msx-2 mRNAs in Ft/+ embryos at overlapping regions of ectopic Bmp4 misexpression, We therefore propose that the Mxs and Id genes are direct target genes of embryonic BMP4 signaling in vivo.	Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Tubingen, Interfak Inst Zellbiol, Mol Biol Abt, D-72076 Tubingen, Germany	Hannover Medical School; Eberhard Karls University of Tubingen	Nordheim, A (corresponding author), Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany.	alfred.nordheim@uni-tuebingen.de						ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BROWN JM, 1993, DEVELOPMENT, V119, P41; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALE L, 1992, DEVELOPMENT, V115, P573; DAVID JB, 1994, J BIOL CHEM, V269, P6259; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DESCHAMPS J, 1987, DIFFERENTIATION, V35, P21, DOI 10.1111/j.1432-0436.1987.tb00147.x; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARA E, 1994, J BIOL CHEM, V269, P2139; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Hogan B, 1994, MANIPULATING MOUSE E; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Janatpour M. J., 1994, Molecular Biology of the Cell, V5, p453A; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Jernvall J, 1998, DEVELOPMENT, V125, P161; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONES CM, 1992, DEVELOPMENT, V115, P639; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; JOWETT AK, 1993, DEVELOPMENT, V117, P461; Kaplan FS, 1996, BONE, V19, pS13, DOI 10.1016/S8756-3282(96)00129-9; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kim HJ, 1998, DEVELOPMENT, V125, P1241; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; KURABAYASHI M, 1994, J BIOL CHEM, V269, P31162; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liebermann DA, 1998, INT J ONCOL, V12, P685; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1991, DEVELOPMENT, V113, P601; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Shen MM, 1997, DEVELOPMENT, V124, P429; SIMONSON MS, 1993, NUCLEIC ACIDS RES, V21, P5767, DOI 10.1093/nar/21.24.5767; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Suzuki A, 1997, DEVELOPMENT, V124, P3037; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WILES MV, 1991, DEVELOPMENT, V111, P259; Wiles MV, 1999, EXP CELL RES, V247, P241, DOI 10.1006/excr.1998.4353; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhang HB, 1996, DEVELOPMENT, V122, P2977	102	400	418	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19838	19845		10.1074/jbc.274.28.19838	http://dx.doi.org/10.1074/jbc.274.28.19838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391928	hybrid			2022-12-25	WOS:000081377300048
J	Maturana, AD; Casal, AJ; Demaurex, N; Vallotton, MB; Capponi, AM; Rossier, MF				Maturana, AD; Casal, AJ; Demaurex, N; Vallotton, MB; Capponi, AM; Rossier, MF			Angiotensin II negatively modulates L-type calcium channels through a pertussis toxin-sensitive G protein in adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; ALDOSTERONE SECRETION; T-TYPE; ACTIVATION; CURRENTS; K+; INHIBITION; INFLUX; STEROIDOGENESIS; STIMULATION	In bovine adrenal glomerulosa cells, angiotensin II and extracellular K+ stimulate aldosterone secretion in a calcium-dependent manner. In these cells, physiological concentrations of extracellular potassium activate both T-type (low threshold) and L-type (high threshold) voltage-operated calcium channels. Paradoxically, the cytosolic calcium response to 9 mM K+ is inhibited by angiotensin II. Because K+-induced calcium changes observed in the cytosol are almost exclusively due to L-type channel activity, we therefore studied the mechanisms of L-type channel regulation by angiotensin II. Using the patch-clamp method in its perforated patch configuration, we observed a marked inhibition (by 63%) of L-type barium currents in response to angiotensin II. This effect of the hormone was completely prevented by losartan, a specific antagonist of the AT(1) receptor subtype, Moreover, this inhibition was strongly reduced when the cells were previously treated for I night with pertussis toxin. An effect of pertussis toxin was also observed on the modulation by angiotensin II of the K+ (9 mm)-induced cytosolic calcium response in fura-2-loaded cells, as well as on the angiotensin II-induced aldosterone secretion, at both low (3 mM) and high (9 mM) K+ concentrations. Finally, the expression of both G(o) and G(i) proteins in bovine glomerulosa cells was detected by immunoblotting, Altogether, these results strongly suggest that in bovine glomerulosa cells, a pertussis toxin-sensitive G protein is involved in the inhibition of L-type channel activity induced by angiotensin II.	Univ Hosp, Div Endocrinol & Diabetol, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Univ Hosp, Clin Chem Lab, Dept Pathol, CH-1211 Geneva, Switzerland; Univ Hosp, Dept Physiol, CH-1211 Geneva 14, Switzerland; Univ Hosp, Fondat Rech Med, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Rossier, MF (corresponding author), Univ Hosp, Div Endocrinol & Diabetol, Dept Internal Med, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Rossier, Michel/AAW-2895-2021	Demaurex, Nicolas/0000-0002-9933-6772				Ai T, 1998, PFLUG ARCH EUR J PHY, V436, P168, DOI 10.1007/s004240050619; AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; Aptel HB, 1996, MOL CELL ENDOCRINOL, V119, P105, DOI 10.1016/0303-7207(96)03805-1; BALLA T, 1991, MOL PHARMACOL, V40, P401; BALLA T, 1991, BIOCHEM J, V273, P399, DOI 10.1042/bj2730399; BARRETT PQ, 1995, AM J PHYSIOL-CELL PH, V268, pC985, DOI 10.1152/ajpcell.1995.268.4.C985; BARRETT PQ, 1988, ENDOCRINOLOGY, V122, P799, DOI 10.1210/endo-122-3-799; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1994, ENDOCRINE, V2, P579; CAPPONI AM, 1987, BIOCHEM J, V247, P335, DOI 10.1042/bj2470335; Capponi AM, 1996, CURR OPIN ENDOCRINOL, V3, P248, DOI [10.1097/00060793-199606000-00010, DOI 10.1097/00060793-199606000-00010]; COHEN CJ, 1988, P NATL ACAD SCI USA, V85, P2412, DOI 10.1073/pnas.85.7.2412; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; GALLOPAYET N, 1991, MOL CELL ENDOCRINOL, V81, P11, DOI 10.1016/0303-7207(91)90200-C; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABUCHI Y, 1995, AM J PHYSIOL-HEART C, V268, pH1053, DOI 10.1152/ajpheart.1995.268.3.H1053; HAUSDORFF WP, 1987, ENDOCRINOLOGY, V120, P1668, DOI 10.1210/endo-120-4-1668; HESCHELER J, 1988, EMBO J, V7, P619, DOI 10.1002/j.1460-2075.1988.tb02855.x; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu HK, 1996, AM J PHYSIOL-CELL PH, V271, pC1340, DOI 10.1152/ajpcell.1996.271.4.C1340; MATSUNAGA H, 1987, BIOCHEM BIOPH RES CO, V149, P1049, DOI 10.1016/0006-291X(87)90514-6; Maturana AD, 1999, J RECEPT SIGNAL TR R, V19, P509, DOI 10.3109/10799899909036668; Rossier MF, 1996, ENDOCR RES, V22, P579, DOI 10.1080/07435809609043750; Rossier MF, 1996, ENDOCRINOLOGY, V137, P4817, DOI 10.1210/en.137.11.4817; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Rossier MF, 1998, LOW VOLTAGE ACTIVATE, P176; WOODCOCK EA, 1986, ENDOCRINOLOGY, V119, P1697, DOI 10.1210/endo-119-4-1697; YAJIMA Y, 1993, MOL CELL ENDOCRINOL, V92, P143, DOI 10.1016/0303-7207(93)90001-Z	34	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19943	19948		10.1074/jbc.274.28.19943	http://dx.doi.org/10.1074/jbc.274.28.19943			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391942	hybrid, Green Published			2022-12-25	WOS:000081377300062
J	Pastorino, JG; Tafani, M; Farber, JL				Pastorino, JG; Tafani, M; Farber, JL			Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; PROTEIN-KINASE; APOPTOSIS; ACTIVATION; AKT; SURVIVAL; 3-KINASE; TNF; INHIBITOR	Tumor necrosis factor (TNF) induced the phosphorylation of BAD at serine 136 in HeLa cells under conditions that are not cytotoxic. BAD phosphorylation by TNF was dependent on phosphatidylinositide-3-OH kinase (PI3K) and was accompanied by the translocation of BAD from the mitochondria to the cytosol. Blocking the phosphorylation of BAD and its translocation to the cytosol with the PI3K inhibitor wortmannin activated caspase-3 and markedly potentiated the cytotoxicity of TNF. Transient transfection with a PI3K dominant negative mutant or a dominant negative mutant of the serine threonine kinase Akt, the downstream target of PI3K and the enzyme that phosphorylates BAD, similarly potentiated the cytotoxicity of TNF. By contrast, transfection with a constitutively active Akt mutant protected against the cytotoxicity of TNF in the presence of wortmannin. Phosphorylation of BAD prevents its interaction with the antiapoptotic protein Bcl-X-L. Transfection with a Bcl-X-L expression vector protected against the cytotoxicity of TNF in the presence of wortmannin. The mechanism by which the inhibition of the phosphorylation of BAD is likely linked to the induction of lethal mitochondrial damage in TNF-intoxicated cells is discussed.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 251,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	farber1@jeflin.tju.edu	Tafani, Marco/U-7230-2019; Tafani, Marco/C-3275-2017	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NIDDK NIH HHS [DK38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Durandy A, 1997, J IMMUNOL, V158, P2576; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Fujita E, 1998, CELL DEATH DIFFER, V5, P289, DOI 10.1038/sj.cdd.4400355; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jackson TR, 1996, J CELL SCI, V109, P289; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	24	121	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19411	19416		10.1074/jbc.274.27.19411	http://dx.doi.org/10.1074/jbc.274.27.19411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383455	hybrid			2022-12-25	WOS:000081196300078
J	Valentin, E; Koduri, RS; Scimeca, JC; Carle, G; Gelb, MH; Lazdunski, M; Lambeau, G				Valentin, E; Koduri, RS; Scimeca, JC; Carle, G; Gelb, MH; Lazdunski, M; Lambeau, G			Cloning and recombinant expression of a novel mouse-secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; AMINO-ACID-SEQUENCE; INTERFACIAL CATALYSIS; SCOOTING MODE; PORCINE PANCREAS; CELL-MEMBRANES; MESSENGER-RNA; BETA-CELLS; BINDING; GENE	Secreted phospholipases A(2) (sPLA(2)s) form a class of structurally related enzymes that are involved in a variety of physiological and pathological effects including inflammation and associated diseases, cell proliferation, cell adhesion, and cancer, and are now known to bind to specific membrane receptors. Here, we report the cloning and expression of a novel sPLA(2) isolated from mouse thymus, Based on its structural features, this sPLA(2) is most similar to the previously cloned mouse group ILA sPLA(2) (mGIIA sPLA(2)). As for mGIIA sPLA(2), the novel sPLA(2) is made up of 125 amino acids with 14 cysteines, is basic (pI = 8.71) and its gene has been mapped to mouse chromosome 4, However, the novel sPLA(2) has only 48% identity with mGIIA and displays similar levels of identity with the other mouse group IIC and V sPLA(2)s, indicating that the novel sPLA(2) is not an isoform of mGIIA sPLA(2). This novel sPLA(2) has thus been called mouse group IID (mGIID) sPLA(2). In further contrast with mGIIA, which is found mainly in intestine, transcripts coding for mGIID sPLA(2) are found in several tissues including pancreas, spleen, thymus, skin, lung, and ovary, suggesting distinct functions for the two enzymes. Recombinant expression of mGIID sPLA(2) in Escherichia coli indicates that the cloned sPLA(2) is an active enzyme that has much lower specific activity than mGIIA and displays a distinct specificity for binding to various phospholipid vesicles. Finally, recombinant mGIID sPLA(2) did not bind to the mouse M-type sPLA(2) receptor, while mGIIA was previously found to bind to this receptor with high affinity.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fac Med, Lab Etud Genome Murin, IAG, CNRS,UMR 6549, F-06107 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411,660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Carle, Georges/GWC-5240-2022; Lambeau, Gerard/GRJ-5624-2022; Scimeca, Jean-Claude/P-3830-2016	Scimeca, Jean-Claude/0000-0003-3773-6110; Carle, Georges/0000-0002-3901-1052; Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235, R01HL036235, R23HL036235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hara N, 1997, ADV EXP MED BIOL, V407, P109; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Kadam Shilpa, 1998, Indian Journal of Experimental Biology, V36, P553; Kennedy BP, 1998, CANCER RES, V58, P500; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kinkaid Adrian R., 1997, Biochemical Society Transactions, V25, p497S; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Kundu GC, 1997, J BIOL CHEM, V272, P2346; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; METZ S, 1991, FEBS LETT, V295, P110, DOI 10.1016/0014-5793(91)81397-Q; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; OGAWA M, 1991, RES COMMUN CHEM PATH, V74, P241; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Ohmachi H, 1996, INT J ONCOL, V9, P511; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGGINS GJ, 1995, CANCER RES, V55, P5184; SCHMITT JD, 1995, CHEM PHYS LIPIDS, V77, P131, DOI 10.1016/0009-3084(95)02461-Q; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WILLIAMSON P, 1995, MAMM GENOME, V6, P429, DOI 10.1007/BF00355646; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P3870, DOI 10.1021/bi961541x	64	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19152	19160		10.1074/jbc.274.27.19152	http://dx.doi.org/10.1074/jbc.274.27.19152			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383420	Green Published, hybrid			2022-12-25	WOS:000081196300043
J	Meacci, E; Vasta, V; Moorman, JP; Bobak, DA; Bruni, P; Moss, J; Vaughan, M				Meacci, E; Vasta, V; Moorman, JP; Bobak, DA; Bruni, P; Moss, J; Vaughan, M			Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; DIFFICILE TOXIN-B; BREFELDIN-A; GUANINE-NUCLEOTIDE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEPENDENT ACTIVATION; SELECTIVE-INHIBITION; HUMAN NEUTROPHILS; GOLGI-APPARATUS	Phospholipase D (PLD) has been implicated as a crucial signaling enzyme in secretory pathways. Two 20-kDa guanine nucleotide-binding proteins, Rho and ADP-ribosylation factor (ARF), are involved in the regulation of secretion and can activate PLD in vitro. We investigated in intact (human adenocarcinoma A549 cells) the role of RhoA and ARF in activation of PLD by phorbol 12-myristate 13-acetate, bradykinin, and/or sphingosine 1-phosphate, To express recombinant Clostridium botulinum C3 exoenzyme (using double subgenomic recombinant Sindbis virus C3), an ADP-ribosyltransferase that inactivates Rho, or dominant-negative Rho containing asparagine at position 19 (using double subgenomic recombinant Sindbis virus Rho19N), cells were infected with Sindbis virus, a novel vector that allows rapid, high level expression of heterologous proteins. Expression of C3 toxin or Rho19N increased basal and decreased phorbol 12-myristate 13-acetate-stimulated PLD activity. Bradykinin or sphingosine 1-phosphate increased PLD activity with additive effects that were abolished in cells expressing C3 exoenzyme or Rho19N, In cells expressing C3, modification of Rho appeared to be incomplete, suggesting the existence of pools that differed in their accessibility to the enzyme. Similar results were obtained with cells scrape-loaded in the presence of C3; however, results with virus infection were more reproducible. To assess the role of ARF, cells were incubated with brefeldin A (BFA), a fungal metabolite that disrupts Golgi structure and inhibits enzymes that catalyze ARF activation by accelerating guanine nucleotide exchange. BFA disrupted Golgi structure, but did not affect basal or agonist-stimulated PLD activity, i.e. it did not alter a rate limiting step in PLD activation, It also had no effect on Rho-stimulated PLD activity, indicating that RhoA action did not involve a BFA-sensitive pathway, A novel PLD activation mechanism, not sensitive to BFA and involving RhoA, was identified in human airway epithelial cells by use of a viral infection technique that preserves cell responsiveness.	NHLBI, Pulmonary Crit Care Med Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Florence; University of Virginia	Moss, J (corresponding author), NHLBI, Pulmonary Crit Care Med Branch, Natl Inst Hlth, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Bruni, Paola/A-1151-2008	Bruni, Paola/0000-0002-1151-3413	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000627, Z01HL000656, Z01HL000638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUADRADO A, 1993, ONCOGENE, V8, P2959; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6409; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Guillemain I, 1997, EUR J BIOCHEM, V249, P812, DOI 10.1111/j.1432-1033.1997.00812.x; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Huang HV, 1996, CURR OPIN BIOTECH, V7, P531, DOI 10.1016/S0958-1669(96)80057-7; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JinsiParimoo A, 1997, J BIOL CHEM, V272, P14556, DOI 10.1074/jbc.272.23.14556; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LI GP, 1995, ARCH BIOCHEM BIOPHYS, V316, P529, DOI 10.1006/abbi.1995.1070; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Moorman JP, 1996, J IMMUNOL, V156, P4146; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Ojio K, 1996, BIOCHEM BIOPH RES CO, V224, P591, DOI 10.1006/bbrc.1996.1069; Pan ZXK, 1998, J IMMUNOL, V160, P3038; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Singer WD, 1996, J BIOL CHEM, V271, P4504; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsai SC, 1998, J BIOL CHEM, V273, P20697, DOI 10.1074/jbc.273.33.20697; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; YAN JP, 1994, J CELL BIOL, V126, P65, DOI 10.1083/jcb.126.1.65; YEO EJ, 1994, J BIOL CHEM, V269, P27823	50	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18605	18612		10.1074/jbc.274.26.18605	http://dx.doi.org/10.1074/jbc.274.26.18605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373471	hybrid			2022-12-25	WOS:000081056700063
J	Barroso, I; Santisteban, P				Barroso, I; Santisteban, P			Insulin-induced early growth response gene (Egr-1) mediates a short term repression of rat melic enzyme gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; STIMULATED H-35 CELLS; RETINOID-X-RECEPTOR; MALIC ENZYME; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; 3T3 CELLS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FUNCTIONAL-ANALYSIS; UPSTREAM SEQUENCES	In this report we have studied insulin regulation of malic enzyme (ME) gene transcription in rat H-35 hepatoma cells and localized the insulin-responsive region of the ME promoter between positions -177 and -102. This region contains a putative insulin response element (IRE-II), When nuclear extracts from untreated or insulin-treated H-35 cells were incubated with IRE-II!, transcription factors Spl and Sp3 were observed to, bind constitutively to this element, whereas insulin induces the quick and transient binding of an insulin response factor. This induction requires de novo protein synthesis, Competition and supershift assays demonstrated that the insulin response factor is the immediate-early gene Egr-1. In vitro assays revealed that Egr-1 displaces Spl from its binding site in IRE-II. Insulin induces Egr-1 mRNA,with a time course pattern that corresponds perfectly to the Egr-1 binding to IRE-II. This induction depends on the activation of mitogen-activated protein (MAP) kinase, and it is phosphatidylinositol 3-kinase-independent, as demonstrated with specific inhibitors for both pathways. By cotransfecting the wild-type or a dominant negative Ras, an upstream regulator of MAP kinase, we show that Ras inhibits ME promoter activity. Furthermore, overexpression of Egr-1 in H-35 cells represses the ME gene promoter in a dose-dependent manner. These results suggest that insulin induces a quick, transient, and Ras/MAP kinase-dependent activation of Egr-1 which leads to a transient repression of ME gene transcription. On a late phase, insulin would activate a different, Egr-1-independent pathway, which would result in activation of the ME gene.	Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Consejo Super Invest Cient, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Consejo Super Invest Cient, Arturo Duperier 4, E-28029 Madrid, Spain.		Santisteban, Pilar/E-7829-2016	Santisteban, Pilar/0000-0002-2758-796X				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GARCIAJIMENEZ C, 1994, MOL ENDOCRINOL, V8, P1361, DOI 10.1210/me.8.10.1361; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KICKENS M, 1998, J BIOL CHEM, V273, P20144; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MANIATIS T, 1982, MOL CLONING LABORATO, P324; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REUBER MD, 1961, J NATL CANCER I, V26, P891; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Slieker LJ, 1998, BIOCHEM BIOPH RES CO, V251, P225, DOI 10.1006/bbrc.1998.9433; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Svaren J, 1996, MOL CELL BIOL, V16, P3545; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG ZY, 1992, J BIOL CHEM, V267, P21999	66	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17997	18004		10.1074/jbc.274.25.17997	http://dx.doi.org/10.1074/jbc.274.25.17997			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364249	hybrid			2022-12-25	WOS:000080974300085
J	Spanfo, S; Silletta, MG; Colanzi, A; Alberti, S; Fiucci, G; Valente, C; Fusella, A; Salmona, M; Mironov, A; Luini, A; Corda, D				Spanfo, S; Silletta, MG; Colanzi, A; Alberti, S; Fiucci, G; Valente, C; Fusella, A; Salmona, M; Mironov, A; Luini, A; Corda, D			Molecular cloning and functional characterization of brefeldin A-ADP-ribosylated substrate - A novel protein involved in the maintenance of the Golgi structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; GUANINE-NUCLEOTIDE; BINDING-PROTEIN; DROSOPHILA CTBP; E1A PROTEIN; TRANSFORMATION; EXCHANGE; DOMAIN; GTP	Brefeldin A (BFA) is a fungal metabolite that disassembles the Golgi apparatus into tubular networks and causes the dissociation of coatomer proteins from Golgi membranes. We have previously shown that an additional effect of BFA is to stimulate the ADP-ribosylation of two cytosolic proteins of 38 and 50 kDa (brefeldin A-ADP-riboslyated substrate (BARS)) and that this effect greatly facilitates the Golgi-disassembling activity of the toxin, In this study, BARS has been purified from rat brain cytosol and microsequenced, and the EARS cDNA has been cloned. BARS shares high homology with two known proteins, C-terminal-binding protein 1 (CtBP1) and CtBPS, It is therefore a third member of the CtBP family. The role of BARS in Golgi disassembly by BFA was verified in permeabilized cells. In the presence of dialyzed cytosol that had been previously depleted of BARS or treated with an anti-BARS antibody, BFA potently disassembled the Golgi, However, in cytosol complemented with purified BARS, or even in control cytosols containing physiological levels of BARS, the action of BFA on Golgi disassembly was strongly inhibited. These results suggest that BARS exerts a negative control on Golgi tubulation, with important consequences for the structure and function of the Golgi complex.	Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Ist Ric Farmacol Mario Negri, I-66030 Chieti, Italy; Dept Biochem & Mol Pharmacol, I-20157 Milan, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Corda, D (corresponding author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Ist Ric Farmacol Mario Negri, I-66030 Chieti, Italy.		Luini, Alberto/L-1372-2013; Alberti, Saverio/M-4511-2014; Colanzi, Antonino/D-6821-2012; Valente, Carmen/AAH-5261-2019; Spanò, Stefania/F-4951-2011; salmona, mario/AAA-7116-2020; Corda, Daniela/K-6385-2016; salmona, mario/ABI-4066-2020	Luini, Alberto/0000-0002-8729-2549; Alberti, Saverio/0000-0002-4647-6042; Colanzi, Antonino/0000-0002-5643-0216; Valente, Carmen/0000-0002-6244-9108; Spanò, Stefania/0000-0001-9154-7463; salmona, mario/0000-0002-9098-9873; Corda, Daniela/0000-0002-3614-751X; 	Telethon [E.0982] Funding Source: Medline	Telethon(Fondazione Telethon)		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAVO R, 1984, 2 DIMENSIONAL GEL EL; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P114; DIGIROLAMO M, 1995, P NATL ACAD SCI USA, V92, P7065, DOI 10.1073/pnas.92.15.7065; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mironov A, 1997, J CELL BIOL, V139, P1109, DOI 10.1083/jcb.139.5.1109; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200	22	81	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17705	17710		10.1074/jbc.274.25.17705	http://dx.doi.org/10.1074/jbc.274.25.17705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364211	hybrid			2022-12-25	WOS:000080974300047
J	Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y				Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y			Mutations in serines 15 and 20 of human p53 impair its apoptotic activity	ONCOGENE			English	Article						serine; phosphorylation; p53; transactivation; apoptosis	CASEIN KINASE-II; CELL-CYCLE PROGRESSION; DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; WILD-TYPE; TRANSACTIVATION DOMAIN; C-JUN; PROTEIN; GENE; MDM2	Phosphorylation of the p53 tumor suppressor protein is likely to play an important role in regulating its activity, To study the regulatory role of potential phosphorylation sites within the N-terminal transactivation domain of human p53 (hp53), a series of p53 serine mutants were evaluated for transcriptional transactivation and sequence specific DNA binding. The role of these mutations in regulating p53-mediated growth suppression and programmed cell death,vas examined. This mutational analysis comprised serine residues located at positions 6, 9, 15, 20, 33 and 37 of human p53. Substitution of serine for alanine, either at individual residues or at all sis residues together, did not affect the suppression of cell growth and cell transformation, or the ability to bind DNA specifically and to transactivate different promoters, nor did it alter p53 expression, However, the ability of p53 to induce apoptosis was impaired by specific serine substitutions. Mutations in all sis N-terminal serines together reduced the apoptotic activity of p53 in H1299 cells by 50%, Analysis of individual mutants revealed that mutations in serine 15 and 20 are primarily responsible for this impairment. Our results suggest that these serines play a role in the regulation of p53-mediated apoptosis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; NCI, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Unger, T (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172; Howley, Peter/0000-0002-8668-9579				ADDISON C, 1990, ONCOGENE, V5, P423; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1996, Behring Inst Mitt, P32; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAYR GA, 1995, CANCER RES, V55, P2410; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIETZ JA, 1997, EMBO J, V60, P1; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Momand J, 1997, J CELL BIOCHEM, V64, P343; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1998, SPRINGER SEMIN IMMUN, V19, P345, DOI 10.1007/BF00787230; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	58	174	176	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3205	3212		10.1038/sj.onc.1202656	http://dx.doi.org/10.1038/sj.onc.1202656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359526				2022-12-25	WOS:000080523800003
J	Mazur, DJ; Perrino, FW				Mazur, DJ; Perrino, FW			Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3 '-> 5 ' exonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; CYTOSINE-ARABINOSIDE MONOPHOSPHATE; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; 3'-5' EXONUCLEASE; CATALYTIC SUBUNIT; MISMATCH REPAIR; EPSILON-SUBUNIT; ACTIVE-SITE; RNASE-T	The 3'-->5' exonucleases catalyze the excision of nucleoside monophosphates from the 3' termini of DNA. We have identified the cDNA sequences encoding two 3'-->5' exonucleases (TREX1 and TREX2) from mammalian cells. The TREX1 and TREX2 proteins are 304 and 236 amino acids in length, respectively. Analysis of the TREX1 and TREX2 sequences identifies three conserved motifs that likely generate the exonuclease active site in these enzymes. The specific amino acids in these three conserved motifs suggest that these mammalian exonucleases are most closely related to the proofreading exonucleases of the bacterial replicative DNA polymerases and the RNase T enzymes. Expression of TREX1 and TREX2 in Escherichia coli demonstrates that these recombinant proteins are active 3'-->5' exonucleases, The recombinant TREX1 protein was purified, and exonuclease activity was measured using single-stranded, partial duplex, and mispaired oligonucleotide DNA substrates. The greatest activity of the TREX1 protein was detected using a partial duplex DNA containing five mispaired nucleotides at the 3' terminus. No activity was detected using single-stranded RNA or an RNA-DNA partial duplex. Identification of the TREX1 and TREX2 cDNA sequences provides the genetic tools to investigate the physiological roles of these exonucleases in mammalian DNA replication, repair, and recombination pathways.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Perrino, FW (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA12197, CA75350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075350, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRODY RS, 1986, J BIOL CHEM, V261, P7136; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HARRINGTON C, 1995, J BIOL CHEM, V270, P26664, DOI 10.1074/jbc.270.44.26664; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HOLLIS GF, 1981, J BIOL CHEM, V256, P8074; HOSS M, 1999, IN PRESS EMBO J; HUANG P, 1991, CANCER RES, V51, P6110; Huang YP, 1997, FEBS LETT, V400, P94, DOI 10.1016/S0014-5793(96)01361-0; Ito J, 1998, MOL MICROBIOL, V27, P235, DOI 10.1046/j.1365-2958.1998.00673.x; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KESTI T, 1993, J BIOL CHEM, V268, P10238; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PERRINO FW, 1999, IN PRESS CELL BIOCH, V30; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKARNES W, 1986, J BIOL CHEM, V261, P6629; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	53	193	220	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19655	19660		10.1074/jbc.274.28.19655	http://dx.doi.org/10.1074/jbc.274.28.19655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391904	hybrid			2022-12-25	WOS:000081377300024
J	Zhao, CM; Yu, DH; Shen, R; Feng, GS				Zhao, CM; Yu, DH; Shen, R; Feng, GS			Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE FAMILY; GRB2 BINDING-SITE; GROWTH-FACTOR; TYROSINE-PHOSPHATASE; PHOSPHOTYROSINE PROTEIN; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; DOCKING PROTEIN; EGF-RECEPTOR; TRANSDUCTION	We describe a novel human adapter molecule containing a pleckstrin homolgy (PH) domain at the N terminus that is closely related to human Grb2-associated binder 1, Gab1, and Drosophila daughter of sevenless, We designate this protein as Gab2. Northern blot analysis indicates that Gab2 is widely expressed and has an overlapping but distinctive expression pattern as compared with Gab1, with high levels of Gab2 mRNA detected in the heart, brain, placenta, spleen, ovary, peripheral blood leukocytes, and spinal cord. Upon tyrosine phosphorylation, Gab2 physically interacts with Shp2 tyrosine phosphatase and Grb2 adapter protein. Strikingly, Gab2 has an inhibitory effect on the activation of Elk-1-dependent transcription triggered by a dominant active Ras mutant (RasV12) or under growth factor stimulation, whereas Gab1 acts to potentiate slightly the Elk-1 activity in the same system. In contrast to the reciprocal effects of Gab1 and Gab2 in mediating Elk-1 induction, these two molecules have a similar function in extracellular signal-regulated kinase activation induced by either oncogenic Pas or growth factor stimulation. Taken together, these results argue that Gab1 and Gab2, two closely related PH-containing adapter proteins, might have distinct roles in coupling cytoplasmic-nuclear signal transduction, This is the first evidence that an intracellular molecule with a PH domain operates as a negative effector in signal relay to the regulation of gene expression.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Rm 302,1044 W Walnut St, Indianapolis, IN 46202 USA.	gfeng@iupui.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19649	19654		10.1074/jbc.274.28.19649	http://dx.doi.org/10.1074/jbc.274.28.19649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391903	hybrid			2022-12-25	WOS:000081377300023
J	Ma, LL; Xu, JY; Coulombe, PA; Wirtz, D				Ma, LL; Xu, JY; Coulombe, PA; Wirtz, D			Keratin filament suspensions show unique micromechanical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE SPONGE NEVUS; INTERMEDIATE FILAMENTS; MECHANICAL-PROPERTIES; TRANSGENIC MICE; ROD DOMAIN; ACTIN GELS; F-ACTIN; NETWORKS; VIMENTIN; EXPRESSION	All epithelial cells feature a prominent keratin intermediate filament (IF) network in their cytoplasm. Studies in transgenic mice and in patients with inherited epithelial fragility syndromes showed that a major function of keratin Ifs is to provide mechanical support to epithelial cell sheets. Yet the micromechanical properties of keratin Ifs themselves remain unknown. We used rheological methods to assess the properties of suspensions of epidermal type I and type II keratin Ifs and of vimentin, a type III LF polymer. We find that both types of Ifs form gels with properties akin to visco elastic solids. With increasing deformation they display strain hardening and yield relatively rapidly. Remarkably, both types of gels recover their preshear properties upon cessation of the deformation. Repeated imposition of small deformations gives rise to a progressively stiffer gel for keratin but not vimentin Ifs. The visco-elastic moduli of both gels show a weak dependence upon the frequency of the input shear stress and the concentration of the polymer, suggesting that both steric and nonsteric interactions between individual polymers contribute to the observed mechanical properties. In support of this, the length of individual polymers contributes only modestly to the properties of IF gels. Collectively these properties render Ifs unique among cytoskeletal polymers and have strong implications for their function in vivo.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Coulombe, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Wirtz, Denis/A-3257-2010		NIAMS NIH HHS [AR42047] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042047, R55AR042047] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1980, VISCOELASTIC PROPERT; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bousquet O, 1996, CURR BIOL, V6, P1563, DOI 10.1016/S0960-9822(02)70772-0; COULOMBE P.A., 1994, MOL B INT U, P259; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; Doi M., 1989, THEORY POLYM DYNAMIC; Eckes B, 1998, J CELL SCI, V111, P1897; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; IRVINE AD, 1997, NAT GENET, V12; ISHIKAWA H, 1968, J CELL BIOL, V38, P538, DOI 10.1083/jcb.38.3.538; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morse DC, 1998, MACROMOLECULES, V31, P7030, DOI 10.1021/ma9803032; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; RICHARD G, 1995, NAT GENET, V11, P453, DOI 10.1038/ng1295-453; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; RUGG EL, 1995, NAT GENET, V11, P450, DOI 10.1038/ng1295-450; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VENETIANER A, 1983, NATURE, V305, P730, DOI 10.1038/305730a0; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; Wiche G, 1998, J CELL SCI, V111, P2477; WITTEN TA, 1988, J PHYS-PARIS, V49, P1055, DOI 10.1051/jphys:019880049060105500; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570	55	116	116	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19145	19151		10.1074/jbc.274.27.19145	http://dx.doi.org/10.1074/jbc.274.27.19145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383419	hybrid			2022-12-25	WOS:000081196300042
J	Soutourina, J; Plateau, P; Delort, F; Peirotes, A; Blanquet, S				Soutourina, J; Plateau, P; Delort, F; Peirotes, A; Blanquet, S			Functional characterization of the D-Tyr-tRNA(Tyr) deacylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; D-AMINO ACIDS; METHIONYL; CLEAVAGE; MUTANTS; GENES; SITE; IDENTIFICATION; HYDROLASE; PROTEINS	The yihZ gene of Escherichia coli is shown to produce a deacylase activity capable of recycling misaminoacylated D-Tyr-tRNA(Tyr). The reaction is specific and, under optimal in vitro conditions, proceeds at a rate of 6 s(-1) with a K-m value for the substrate equal to 1 mu M. Cell growth is sensitive to interruption of the yihZ gene if D-tyrosine is added to minimal culture medium. Toxicity of exogenous D-tyrosine is exacerbated if, in addition to the disruption of yihZ, the gene of D-amino acid dehydrogenase (dadA) is also inactivated. Orthologs of the yihZ gene occur in many, but not all, bacteria. In support of the idea of a general role of the D-Tyr-tRNA(Tyr) deacylase function in the detoxification of cells, similar genes can be recognized in Saccharomyces cerevisiae, Caenorhabditis elegans, Arabidopsis thaliana, mouse, and man.	Ecole Polytech, CNRS, Unite Mixte Rech 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, Unite Mixte Rech 7654, Biochim Lab, F-91128 Palaiseau, France.	plateau@coli.polytechnique.fr	Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARKER DG, 1982, EUR J BIOCHEM, V125, P357, DOI 10.1111/j.1432-1033.1982.tb06691.x; BERG P, 1958, J BIOL CHEM, V233, P601; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BONNET J, 1972, EUR J BIOCHEM, V31, P335, DOI 10.1111/j.1432-1033.1972.tb02538.x; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BRUNI CB, 1977, J BACTERIOL, V130, P4, DOI 10.1128/JB.130.1.4-10.1977; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Callahan C, 1996, J BACTERIOL, V178, P7329, DOI 10.1128/jb.178.24.7329-7332.1996; CAPARROS M, 1991, RES MICROBIOL, V142, P345, DOI 10.1016/0923-2508(91)90050-K; CAPARROS M, 1992, J BACTERIOL, V174, P5549; CHAMPNEY WS, 1970, J BACTERIOL, V104, P107, DOI 10.1128/JB.104.1.107-116.1970; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; DAVIE JW, 1956, ARCH BIOCHEM BIOPHYS, V65, P21; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; JENSEN RA, 1972, ARCH MIKROBIOL, V87, P173, DOI 10.1007/BF00424998; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KUHN J, 1974, BIOCHIM BIOPHYS ACTA, V332, P298, DOI 10.1016/0005-2736(74)90382-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MARSH L, 1987, J BACTERIOL, V169, P1818, DOI 10.1128/jb.169.5.1818-1823.1987; MCFALL E, 1996, ESCHERICHIA COLI SAL, P358; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MELLOT P, 1989, J MOL BIOL, V208, P429, DOI 10.1016/0022-2836(89)90507-X; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; NORTON SJ, 1963, J BIOL CHEM, V238, P269; OHNISHI E, 1962, J BIOL CHEM, V237, P138; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SOURGOUTCHOV A, 1974, EUR J BIOCHEM, V46, P431, DOI 10.1111/j.1432-1033.1974.tb03636.x; UZAN M, 1978, MOL GEN GENET, V165, P21, DOI 10.1007/BF00270372; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001	40	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19109	19114		10.1074/jbc.274.27.19109	http://dx.doi.org/10.1074/jbc.274.27.19109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383414	hybrid			2022-12-25	WOS:000081196300037
J	Taylor, CT; Fueki, N; Agah, A; Hershberg, RM; Colgan, SP				Taylor, CT; Fueki, N; Agah, A; Hershberg, RM; Colgan, SP			Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION; E-SELECTIN; CELL-LINE; BARRIER FUNCTION; LIPOPOLYSACCHARIDE; PROMOTER; CREB; PERMEABILITY	Tissue hypoxia is intimately associated with a number of chronic inflammatory conditions of the intestine. In this study, we investigated the impact of hypoxia on the expression of a panel of inflammatory mediators by intestinal epithelia, Initial experiments revealed that epithelial (T84 cell) exposure to ambient hypoxia evoked a time-dependent induction of the proinflammatory markers tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), and major histocompatibility complex (MHC) class II (37 +/- 6.1-, 7 +/- 0.8-, and 9 +/- 0.9-fold increase over normoxia, respectively, each p < 0.01). Since the gene regulatory elements for each of these molecules contains an NF-kappa B binding domain, we investigated the influence of hypoxia on NF-kappa B activation. Cellular hypoxia induced a time dependent increase in nuclear p65, suggesting a dominant role for NF-kappa B in hypoxia-elicited induction of proinflammatory gene products. Further work, however, revealed that hypoxia does not influence epithelial intercellular adhesion molecule 1 (ICAM-1) or MHC class I, the promoters of which also contain NF-kappa B binding domains, suggesting differential responses to hypoxia, Importantly, the genes for TNF-alpha, IL-8, and MHC class II, but not ICAM-1 or MHC class I, contain cyclic AMP response element (CRE) consensus motifs, Thus, we examined the role of cAMP in the hypoxia-elicited phenotype, Hypoxia diminished CRE binding protein (CREB) expression. In parallel, T84 cell cAMP was diminished by hypoxia (83 +/- 13.2% decrease, p < 0.001), and pharmacologic inhibition of protein kinase A induced TNF-alpha and protein release (9 +/- 3.9-fold increase). Addback of cAMP resulted in reversal of hypoxia-elicited TNF-alpha release (86 +/- 3.2% inhibition with 3 mM 8-bromo-cAMP). Furthermore, overexpression of CREB but not mutated CREB by retroviral-mediated gene transfer reversed hypoxia-elicited induction of TNF-alpha defining a causal relationship between hypoxia-elicited CREB reduction and TNF-alpha induction. Such data indicate a prominent role for CREB in the hypoxia-elicited epithelial phenotype and implicate intracellular cAMP as an important second messenger in differential induction of proinflammatory mediators.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Virginia Mason Medical Center	Colgan, SP (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn 7,Rm 704,75 Francis St, Boston, MA 02115 USA.		Colgan, Sean P./B-4573-2009		NHLBI NIH HHS [HL60569] Funding Source: Medline; NIDDK NIH HHS [DK50189, DK09699] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009699, R37DK050189, R29DK050189, R01DK050189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; COLGAN SP, 1993, J CELL BIOL, V120, P785, DOI 10.1083/jcb.120.3.785; COLGAN SP, 1994, J IMMUNOL, V153, P2122; COLGAN SP, 1994, AM J PHYSIOL, V267, P402; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Crosson SM, 1996, BIOCHEM BIOPH RES CO, V227, P915, DOI 10.1006/bbrc.1996.1605; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, P204; DITTEL BN, 1993, BLOOD, V81, P2272; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; MADARA JL, 1990, AM J PATHOL, V137, P1273; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; OGAWA S, 1990, ADV EXP MED BIOL, V281, P303; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; POWELL DW, 1987, PHYSL GASTROINTESTIN, P1267; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; SPENGLER RN, 1989, INFECT IMMUN, V57, P2837, DOI 10.1128/IAI.57.9.2837-2841.1989; Stevens T, 1995, ENDOTHELIUM-J ENDOTH, V3, P1, DOI [10.3109/10623329509024653, DOI 10.3109/10623329509024653]; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; Taylor CT, 1998, J PHARMACOL EXP THER, V284, P568; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WIDNELL KL, 1994, P NATL ACAD SCI USA, V91, P10947, DOI 10.1073/pnas.91.23.10947; Widnell KL, 1996, J NEUROCHEM, V66, P1770; ZHONG WW, 1995, IMMUNOLOGY, V84, P446; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075; Zund G, 1996, J BIOL CHEM, V271, P7460; Zund G, 1997, AM J PHYSIOL-CELL PH, V273, pC1571, DOI 10.1152/ajpcell.1997.273.5.C1571	45	79	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19447	19454		10.1074/jbc.274.27.19447	http://dx.doi.org/10.1074/jbc.274.27.19447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383461	hybrid			2022-12-25	WOS:000081196300084
J	Dery, O; Thoma, MS; Wong, H; Grady, EF; Bunnett, NW				Dery, O; Thoma, MS; Wong, H; Grady, EF; Bunnett, NW			Trafficking of proteinase-activated receptor-2 and beta-arrestin-1 tagged with green fluorescent protein - beta-arrestin-dependent endocytosis of a proteinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; COUPLED RECEPTOR; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; THROMBIN RECEPTOR; MOLECULAR-CLONING; CHOLECYSTOKININ RECEPTOR; MEDIATED ENDOCYTOSIS; PLATELET ACTIVATION; SUBSTANCE-P	Proteases cleave proteinase-activated receptors (PARs) to expose N-terminal tethered ligands that bind and activate the cleaved receptors. The tethered ligand, once exposed, is always available to interact with its binding site. Thus, efficient mechanisms must prevent continuous activation, including receptor phosphorylation and uncoupling from G-proteins, receptor endocytosis, and lysosomal degradation. beta-Arrestins mediate uncoupling and endocytosis of certain neurotransmitter receptors, which are activated in a reversible manner. However, the role of beta-arrestins in trafficking of PARs, which are irreversibly activated, and the effects of proteases on the subcellular distribution of beta-arrestins have not been examined. We studied trafficking of PARS and beta-arrestin1 coupled to green fluorescent protein. Trypsin induced the following: (a) redistribution of beta-arrestin1 from the cytosol to the plasma membrane, where it co-localized with PAR2; (b) internalization of beta-arrestin1 and PARS into the same early endosomes; (c) redistribution of beta-arrestin1 to the cytosol concurrent with PARS translocation to lysosomes; and (d) mobilization of PARS from the Gels apparatus to the plasma membrane. Overexpression of a C-terminal fragment of beta-arrestin-(319-418), which interacts constitutively with clathrin but does not bind receptors, inhibited agonist-induced endocytosis of PARS. Our results show that p-arrestins mediate endocytosis of PARS and support a role for beta-arrestins in uncoupling of PARs.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; W Los Angeles Vet Affairs Med Ctr, CURE, Digest Dis Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.			Thoma, Mark/0000-0003-0332-7044; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK42307, DK39957] Funding Source: Medline; NINDS NIH HHS [NS21710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R01DK039957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1997, BIOCHEM J, V322, P1; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Caughey GH, 1995, MAST CELL PROTEASES, P305; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORVERA C, 1999, IN PRESS J PHYSL LON; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HEIN L, 1994, J BIOL CHEM, V269, P27719; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	54	143	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18524	18535		10.1074/jbc.274.26.18524	http://dx.doi.org/10.1074/jbc.274.26.18524			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373461	hybrid			2022-12-25	WOS:000081056700053
J	Hernandez-Sanchez, C; Ito, Y; Ferrer, J; Reitman, M; LeRoith, D				Hernandez-Sanchez, C; Ito, Y; Ferrer, J; Reitman, M; LeRoith, D			Characterization of the mouse sulfonylurea receptor 1 promoter and its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SENSITIVE K+ CHANNELS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC BETA-CELLS; INSULIN-SECRETION; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; ATP; TRANSCRIPTION; KIR6.2	The ATP-sensitive potassium channels (K-ATP(+) channels) are heteromultimeric structures formed by a member of the sulfonylurea receptor (SUR) family and a member of the inwardly rectifying potassium channel family (Kir6.x), The K+,, channels play an essential role in nutrient-induced insulin secretion from the pancreatic beta-cell, We have cloned and characterized the promoter region of the mouse SUR1 gene, and have shown that it lacks CAAT and TATA boxes or an initiator element. Studies of transcription initiation in several tissues showed that there is a common SUR1 promoter in brain, heart, and pancreas and in the pancreatic beta-cell line, PTC3, The SUR1 gene uses multiple transcription start sites with the major site located 54 base pairs 5'-upstream of the translation initiation site. Transient transfection experiments in pancreatic p-cell lines showed that the proximal promoter fragment -84/+54 is sufficient for significant transcriptional activity. The proximal promoter region contains multiple SP1-binding sites, and cotransfection experiments of the SUR1 promoter-luciferase vector with SP1 expression Vector in Drosophila SL2 cells demonstrated a stimulatory effect of SP1 on SUR1 transcriptional activity. The mobility shift assays confirmed the interaction of the SP1 transcription factor with the proximal promoter region of the SUR1 gene. Together, these results indicate that SP1 may mediate transcription initiation of the SUR1 gene. In addition, we have described the coordinate regulation of the gene expression of both K-ATP(+),, channel subunits by glucocorticoids. SUR1 and Kir6,2 mRNA levels are down-regulated by similar to 40-50% in response to glucocorticoid treatment. Interestingly, the extent of the inhibitory effect as well as the kinetics and sensitivity are very similar for both mRNAs, Studies of mRNA turnover demonstrate that glucocorticoids most likely decrease the transcriptional activity of both SUR1 and Kir6,2 genes since glucocorticoids failed to affect the stability of each mRNA, Likewise, the reduction in mRNA levels was correlated with a decrease in SUR1 and Kir6,2 protein levels.	NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA; Hosp Clin Barcelona, Dept Endocrinol, E-08036 Barcelona, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Barcelona; Hospital Clinic de Barcelona	Hernandez-Sanchez, C (corresponding author), NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Rm 8D12,Bldg 10,10 Ctr Dr,MSC 1758, Bethesda, MD 20892 USA.	catalinah@bdg10.niddk.nih.gov	Hernández-Sánchez, Catalina/N-1737-2014; Ferrer, Jorge/A-3176-2012; Reitman, Marc/B-4448-2013	Hernández-Sánchez, Catalina/0000-0002-0846-5019; Ferrer, Jorge/0000-0002-5959-5729; Reitman, Marc/0000-0002-0426-9475				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHEROFT FM, 1988, ANNU REV NEUROSCI, V11, P97; Ashfield R, 1998, DIABETES, V47, P1274, DOI 10.2337/diabetes.47.8.1274; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; CONN JW, 1956, METABOLISM, V5, P114; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P773; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FISCHER B, 1990, ENDOCRINOLOGY, V126, P2635, DOI 10.1210/endo-126-5-2635; HernandezSanchez C, 1997, ENDOCRINOLOGY, V138, P705, DOI 10.1210/en.138.2.705; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LANS MS, 1994, J BIOL CHEM, V269, P14170; MATTHES H, 1994, ENDOCRINOLOGY, V135, P476, DOI 10.1210/en.135.1.476; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18261	18270		10.1074/jbc.274.26.18261	http://dx.doi.org/10.1074/jbc.274.26.18261			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373428	hybrid			2022-12-25	WOS:000081056700020
J	Zhou, ZM; Lin, SH; Cotter, RJ; Raetz, CRH				Zhou, ZM; Lin, SH; Cotter, RJ; Raetz, CRH			Lipid a modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12 - Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; TEMPERATURE REQUIREMENT GENE; RESISTANT PMRA-MUTANTS; ABC FAMILY TRANSPORTER; ACID-DEFICIENT MUTANT; POLYMYXIN-RESISTANT; BACTERIAL-ENDOTOXINS; MULTICOPY SUPPRESSOR; CHEMICAL-STRUCTURE; OUTER-MEMBRANE	Two-thirds of the lipid A in wild-type Escherichia coli K12 is a hexa-acylated disaccharide of glucosamine in which monophosphate groups are attached at positions 1 and 4', The remaining lipid A contains a monophosphate substituent at position 4' and a pyrophosphate moiety at position 1, The biosynthesis of the l-pyrophosphate unit is unknown, Its presence is associated with lipid A translocation to the outer membrane (Zhou, Z,,White, K, A, Polissi, A., Georgopoulos, C,, and Raetz, C. R, H, (1998) J, Biol. Chem. 273, 12466-12475), To determine if a phosphatase regulates the amount of the lipid A 1-pyrophosphate, we grew cells in broth containing nonspecific phosphatase inhibitors. Na2WO4 and sodium fluoride increased the relative amount of the 1-pyrophosphate slightly. Remarkably, NH4VO3-treated cells generated almost no 1-pyrophosphate, but made six major new lipid A derivatives (EV1 to EV6). Matrix-assisted laser desorption ionization/time of flight mass spectrometry of purified EV1 to EV6 indicated that these compounds were lipid A species substituted singly or in combination with palmitoyl, phosphoethanolamine, and/or aminodeoxypentose residues. The aminodeoxypentose residue was released by incubation in chloroform/methanol (4:1, v/v) at 25 degrees C, and was characterized by H-1 NMR spectroscopy. The chemical shifts and vicinal coupling constants of the two anomers of the aminodeoxypentose released from EV3 closely resembled those of synthetic 4-amino-4-deoxy-L-arabinose. NH4VO3-induced lipid A modification did not require the PhoP/PhoQ two-component regulatory system, and also occurred in E. coli msbB or htrB mutants, The lipid A variants that accumulate in NH4VO3 treated E. coli K12 are the same as many of those normally found in untreated Salmonella typhimurium and Salmonella minnesota, demonstrating that E, coli K12 has latent enzyme systems for synthesizing these important derivatives.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM54882-01, GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babinski KJ, 1998, FASEB J, V12, pA1288; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BISHOP RE, 1999, IN PRESS FASEB J, V13; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COTTER RJ, 1987, BIOMED ENVIRON MASS, V14, P591, DOI 10.1002/bms.1200141103; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GEBB C, 1975, EUR J BIOCHEM, V54, P493, DOI 10.1111/j.1432-1033.1975.tb04161.x; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASE S, 1977, EUR J BIOCHEM, V75, P23, DOI 10.1111/j.1432-1033.1977.tb11500.x; HASIN M, 1982, J BIOL CHEM, V257, P2475; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KYOSSEV ZN, 1995, EUR J BIOCHEM, V228, P109, DOI 10.1111/j.1432-1033.1995.0109o.x; MEYERS E, 1974, ANN NY ACAD SCI, V235, P493, DOI 10.1111/j.1749-6632.1974.tb43286.x; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PETERSON AA, 1987, ANTIMICROB AGENTS CH, V31, P230, DOI 10.1128/AAC.31.2.230; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1984, HDB ENDOTOXIN, V1; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; STANKIEWICZ PJ, 1995, MET IONS BIOL SYST, V31, P287; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WANG R, 1992, J MICROBIOL METH, V15, P151, DOI 10.1016/0167-7012(92)90037-5; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	63	192	197	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18503	18514		10.1074/jbc.274.26.18503	http://dx.doi.org/10.1074/jbc.274.26.18503			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373459	hybrid			2022-12-25	WOS:000081056700051
J	Chan, JM; Ryle, MJ; Seefeldt, LC				Chan, JM; Ryle, MJ; Seefeldt, LC			Evidence that MgATP accelerates primary electron transfer in a Clostridium pasteurianum Fe protein-Azotobacter vinelandii MoFe protein nitrogenase tight complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; PARAMAGNETIC-RESONANCE; KLEBSIELLA-PNEUMONIAE; ADENOSINE 5'-TRIPHOSPHATE; NUCLEOTIDE-BINDING; SODIUM DITHIONITE; EPR SPECTROSCOPY; REDOX PROPERTIES; METAL CENTERS; P-CLUSTERS	The nitrogenase catalytic cycle involves binding of the iron (Fe) protein to the molybdenum-iron (MoFe) protein, transfer of a single electron from the Fe protein to the MoFe protein concomitant with the hydrollysis of at least two MgATP molecules, followed by dissociation of the two proteins. Earlier studies found that combining the Fe protein isolated from the bacterium Clostridium pasteurianum with the MoFe protein isolated from the bacterium Azotobacter vinelandii resulted in an inactive, nondissociating Fe protein-MoFe protein complex. In the present work, it is demonstrated that primary electron transfer occurs within this nitrogenase tight complex in the absence of MgATP (apparent first-order rate constant k = 0.007 s(-1)) and that MgATP accelerates this electron transfer reaction by more than 10,000-fold to rates comparable to those observed within homologous nitrogenase complexes (k = 100 s(-1)). Electron transfer reactions were confirmed by EPR spectroscopy. Finally, the midpoint potentials (E-m) for the Fe protein [4Fe-4S](2+/+) cluster and the MoFe protein p(2+/N) cluster were determined for both the uncomplexed and complexed proteins and with or without MgADP. Calculations from electron transfer theory indicate that the measured changes in E-m are not likely to be sufficient to account for the observed nucleotide-dependent rate accelerations for electron transfer.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Seefeldt, LC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	seefeldt@cc.usu.edu		Seefeldt, Lance/0000-0002-6457-9504				ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BUI PT, 1969, BIOCHEMISTRY-US, V8, P2462, DOI 10.1021/bi00834a031; Burgess B. K., 1985, MOLYBDENUM ENZYMES, P161; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CARNAHAN JE, 1958, J BACTERIOL, V75, P121, DOI 10.1128/JB.75.2.121-124.1958; CHRISTIANSEN J, 1995, J AM CHEM SOC, V117, P10017, DOI 10.1021/ja00145a012; CHROMY V, 1974, CLIN CHEM, V20, P1362; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Dutton P L, 1978, Methods Enzymol, V54, P411; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; EMERICH DW, 1978, BIOCHIM BIOPHYS ACTA, V527, P359, DOI 10.1016/0005-2744(78)90350-9; EMERICH DW, 1978, J BACTERIOL, V134, P936, DOI 10.1128/JB.134.3.936-943.1978; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; JACOBS BA, 1991, J AM CHEM SOC, V113, P4390, DOI 10.1021/ja00012a003; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P399, DOI 10.1021/bi971681m; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P16770, DOI 10.1021/bi962286j; LARSEN C, 1995, ARCH BIOCHEM BIOPHYS, V323, P215, DOI 10.1006/abbi.1995.9972; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MENSINK RE, 1992, EUR J BIOCHEM, V208, P289, DOI 10.1111/j.1432-1033.1992.tb17185.x; MORGAN TV, 1988, J INORG BIOCHEM, V33, P111, DOI 10.1016/0162-0134(88)80039-4; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PALMER G, 1972, ARCH BIOCHEM BIOPHYS, V153, P325, DOI 10.1016/0003-9861(72)90452-3; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; REES DC, 1998, BIOL NITROGEN FIXATI, P11; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; Spee JH, 1998, FEBS LETT, V432, P55, DOI 10.1016/S0014-5793(98)00827-8; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1975, BIOCHEM J, V145, P391, DOI 10.1042/bj1450391; THORNELEY RNF, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P103; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; WATT GD, 1989, BIOCHEMISTRY-US, V28, P1844, DOI 10.1021/bi00430a062; WATT GD, 1980, BIOCHEMISTRY-US, V19, P4926, DOI 10.1021/bi00562a035; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	56	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17593	17598		10.1074/jbc.274.25.17593	http://dx.doi.org/10.1074/jbc.274.25.17593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364195	hybrid			2022-12-25	WOS:000080974300031
J	Naim, HY; Joberty, G; Alfalah, M; Jacob, R				Naim, HY; Joberty, G; Alfalah, M; Jacob, R			Temporal association of the N- and O-linked glycosylation events and their implication in the polarized sorting of intestinal brush border sucrase-isomaltase, aminopeptidase N, and dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; PHLORIZIN HYDROLASE; GLYCAN INITIATION; MDCK CELLS; BIOSYNTHESIS; LOCALIZATION; OLIGOSACCHARIDES; PROTEIN	The temporal association between O-glycosylation and processing of N-linked glycans in the Golgi apparatus as well as the implication of these events in the polarized sorting of three brush border proteins has been the subject of the current investigation. O-Glycosylation of pro-sucrase-isomaltase (pro-SI), aminopeptidase N (ApN), and dipeptidyl peptidase IV (DPPIV) is drastically reduced when processing of the mannose-rich N-linked glycans is blocked by deoxymannojirimycin, an inhibitor of the Golgi-located mannosidase I. By contrast, O-glycosylation is not affected in the presence of swainsonine, an inhibitor of Golgi mannosidase II. The results indicate that removal of the outermost mannose residues by mannosidase I from the mannose-rich N-linked glycans is required before O-glycosylation can ensue. On the other hand, subsequent mannose residues in the core chain impose no sterical constraints on the progression of O-glycosylation. Reduction or modification of N- and O-glycosylation do not affect the transport of pro-SI, ApN, or DPPIV to the cell surface per se. However, the polarized sorting of two of these proteins, pro-SI and DPPIV, to the apical membrane is substantially altered when O-glycans are not completely processed, while the sorting of ApN is not affected. The processing of N-linked glycans, on the other hand, has no influence on sorting of all three proteins. The results indicate that O-linked carbohydrates are at least a part of the sorting mechanism of pro-SI and DPPIV, The sorting of ApN implicates neither O-linked nor N-linked glycans and is driven most likely by carbohydrate-independent mechanisms.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Al Falah, Dr. Marwan/C-6281-2011; Jacob, Ralf/B-8163-2011					DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, GASTROENTEROLOGY, V109, P1039, DOI 10.1016/0016-5085(95)90561-8; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELBEIN AD, 1983, METHOD ENZYMOL, V98, P135; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JACOB R, 1994, J BIOL CHEM, V269, P2712; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JOKINEN M, 1985, J BIOL CHEM, V260, P1314; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW SH, 1991, J BIOL CHEM, V266, P19710; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1994, FEBS LETT, V342, P302; NAIM HY, 1993, BIOCHEM J, V296, P607, DOI 10.1042/bj2960607; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; PILLER V, 1990, J BIOL CHEM, V265, P9264; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROUSSET M, 1979, CANCER RES, V39, P531; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	47	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17961	17967		10.1074/jbc.274.25.17961	http://dx.doi.org/10.1074/jbc.274.25.17961			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364244	hybrid			2022-12-25	WOS:000080974300080
J	Li, JR; Bombeck, CA; Yang, SF; Kim, YM; Billiar, TR				Li, JR; Bombeck, CA; Yang, SF; Kim, YM; Billiar, TR			Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; RAT HEPATOCYTES; IN-VIVO; INHIBITS APOPTOSIS; PROTEASES; NECROSIS; FAMILY; MECHANISMS	Nitric oxide (NO) is a potent inhibitor of apoptosis in many cell types, including hepatocytes. We and others have described NO-dependent decreases in caspase activity in cells undergoing apoptosis. However, previous work has not determined whether NO disrupts the proteolytic processing and thus the activation of pro-caspases, Here we report that NO suppresses proteolytic processing and activation of multiple pro-caspases in intact cells, including caspase-3 and caspase-8. We found that both exogenous NO as well as endogenously produced NO via adenoviral inducible NO synthase gene transfer protected hepatocytes from tumor necrosid factor (TNF) alpha plus actinomycin D (TNF alpha/ActD)-induced apoptosis. Affinity labeling with biotin-VAD-fmk of all active caspase species in TNF alpha-mediated apoptosis identified four newly labeled spots (activated caspases) present exclusively in TNF alpha/ActD-treated cells. Both NO and the caspase inhibitor, Ac-DEVD-CHO, prevented the appearance of the four newly labeled spots or active caspases. Immunoanalysis of affinity labeled caspases demonstrated that caspase-3 was the major effector caspase. Western blot analysis also identified the activation of caspase-8 in the TNF alpha/ActD-treated cells, and the activation was suppressed by NO. Furthermore, NO inhibited several other events associated with caspase activation in cells, including release of cytochrome c from mitochondria, decrease in mitochondrial transmembrane potential, and cleavage of poly(ADP-ribose) polymerase in TNF alpha/ActD-treated cells. These findings indicate the involvement of multiple caspases in TNF alpha-mediated apoptosis in hepatocytes and establish the capacity of NO to inhibit not only active caspases but also caspase activation.	Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA; Kangweon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kangwon National University	Billiar, TR (corresponding author), Univ Pittsburgh, Dept Surg, Sch Med, A1010 PUH, Pittsburgh, PA 15213 USA.		Li, Jianrong/C-4126-2011	Li, Jianrong/0000-0002-8232-9322	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044100, R29GM044100, R01GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19866, GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, CANCER RES, V58, P5201; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Estevez AG, 1998, J NEUROSCI, V18, P3708; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; *HOEF SCI INSTR, 1994, PROT EL APPL GUID, P65; Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEIST M, 1994, J IMMUNOL, V153, P1778; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Sweeney EA, 1998, FEBS LETT, V425, P61, DOI 10.1016/S0014-5793(98)00198-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	51	235	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17325	17333		10.1074/jbc.274.24.17325	http://dx.doi.org/10.1074/jbc.274.24.17325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358093	hybrid			2022-12-25	WOS:000080780400092
J	Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G				Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G			Evidence for a p23 caspase-cleaved form of p27([KIP1]) involved in G(1) growth arrest	ONCOGENE			English	Article						p27([KIP1]); caspase; cell cycle; CDK2; CDK4; growth arrest	DEPENDENT KINASE INHIBITOR; CELL-CYCLE; POLY(ADP-RIBOSE) POLYMERASE; CPP32-LIKE PROTEASES; PHASE PROGRESSION; P27(KIP1); APOPTOSIS; ACTIVATION; PROTEIN; CDK	p27([KIP1]) (p27) is a cyclin dependent kinase inhibitor, involved in the negative regulation of G(1) progression in response to a number of anti-proliferative signals, In this study we show, in growing mouse hybridoma (7TD1) and human myeloma (U266) cell lines, that p27 is highly expressed but slightly upregulated when cells are arrested, regardless to the phases of the cell cycle, In contrast, the specific blockade of these cells in early G(1) phase reveals the induction of a protein of 23 kDa (p23) specifically recognized by polyclonal anti-p27 antibodies raised against the NH2 terminal part of p27 but not by anti-p21([CIP1]) antibodies. Experiments using caspase inhibitors strongly suggest that p23 results from the proteolysis of p27 by a 'caspase-3-like' protease. This cleavage leads to the cytosolic sequestration of p23 but does not alter its binding properties to CDK2 and CDK4 kinases. Indeed, p23 associated in vivo with high molecular weight complexes and coprecipitated with CDK2 and CDK4. We demonstrate by transfection experiments in SaOS-2 cells that p23 induces a G(1) phase growth arrest by inhibition of cyclin/CDK2 activity. In summary we describe here a caspase-cleaved form of p27, induced in absence of detectable apoptosis and likely involved in cell cycle regulation.	Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, F-06107 Nice 02, France; Fac Med Nice, CJF INSERM 96 05, F-06107 Nice, France; Hop Cantonal Geneva, Clin Immunol Lab, Geneva 14, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva	Ponzio, G (corresponding author), Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016; AUBERGER, Patrick/G-1491-2013; ROCHET, Nathalie/N-1819-2018	ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; AUBERGER, Patrick/0000-0002-2481-8275; ROCHET, Nathalie/0000-0002-9995-6699; Turchi, Laurent/0000-0003-2020-5831				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; CASTEDO M, 1996, J IMMUNOL, V157, P515; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; HALL M, 1995, ONCOGENE, V11, P1581; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HULTNER L, 1989, IMMUNOLOGY, V67, P408; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LIU J, 1994, CELL IMMUNOL, V155, P428, DOI 10.1006/cimm.1994.1135; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REZZONICO R, 1995, ONCOGENE, V11, P1069; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TEROAKA H, 1996, EX CELL RES, V222, P218; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107	49	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3324	3333		10.1038/sj.onc.1202668	http://dx.doi.org/10.1038/sj.onc.1202668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362353				2022-12-25	WOS:000080589300003
J	Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S				Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S			Telomerase activity in ductal carcinoma in situ and invasive breast cancer	ONCOGENE			English	Article						telomerase; breast cancer; ductal carcinoma in situ; microdissection; cancer progression	REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; ALLELIC LOSS; IN-SITU; LESIONS; IMMORTALITY; EXPRESSION; TUMORS; MARKER; CELLS	The increasing number of breast carcinoma in situ detected by screening procedures makes it imperative to develop improved markers to stratify the risk of invasive cancer, Telomerase is detectable in invasive cancer, but not in normal tissues. We have microdissected frozen tissue blocks containing both DCIS and invasive cancer to assay the telomerase activity of these two lesions. The 46 available cases of concurrent DCIS and invasive breast cancer resulted in 43 DCIS samples and 38 invasive cancer samples adequate for analysis. Seventy per cent of the DCIS and all invasive cancer samples tested had detectable telomerase activity. In addition, we analysed telomerase activity in ten cases of DCIS that were not associated with invasive cancer, and detected telomerase activity in seven (70%). Mixing experiments showed no evidence of telomerase inhibitors in telomerase negative samples. Furthermore, periductal inflammatory infiltrates were shown to be a potential confounding source of telomerase activity. Since DCIS lesions appear to be heterogeneous with respect to telomerase activity, and telomerase activation appears to precede the development of invasive cancer, telomerase activity may be a useful adjunct in stratifying the risk of developing invasive breast cancer in patients with DCIS.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Duke Univ, Dept Surg, Durham, NC USA; Geron Corp, Menlo Park, CA USA	Johns Hopkins University; Johns Hopkins University; Duke University; Geron Corporation	Sukumar, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Ross Bldg 370,720 Rutland Ave, Baltimore, MD 21205 USA.		Dome, Jeffrey/AAH-7825-2019					BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bednenko J, 1997, EMBO J, V16, P2507, DOI 10.1093/emboj/16.9.2507; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carey LA, 1998, CLIN CANCER RES, V4, P435; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; FLINT J, 1994, AM J HUM GENET, V55, P505; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HAY R, 1994, ATCC CELL LINES HYBR; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Hoos A, 1998, INT J CANCER, V79, P8, DOI 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Klingelhutz AJ, 1997, J MOL MED-JMM, V75, P45, DOI 10.1007/s001090050085; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Landberg G, 1997, CANCER RES, V57, P549; Meeker AK, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1323; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Nawaz S, 1997, AM J CLIN PATHOL, V107, P542; Nelson NJ, 1996, J NATL CANCER I, V88, P1021, DOI 10.1093/jnci/88.15.1021; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Page DL, 1998, MODERN PATHOL, V11, P120; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Poremba C, 1998, INT J ONCOL, V12, P641; Sambrook J., 2002, MOL CLONING LAB MANU; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tsao JI, 1997, CLIN CANCER RES, V3, P627; Umbricht CB, 1997, CANCER RES, V57, P2144; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Yashima K, 1998, CLIN CANCER RES, V4, P229; ZHUANG A, 1995, AM J PATHOL, V146, P620; ZHUANG ZP, 1995, CANCER RES, V55, P467	38	46	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3407	3414		10.1038/sj.onc.1202714	http://dx.doi.org/10.1038/sj.onc.1202714			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362362	Bronze			2022-12-25	WOS:000080589300012
J	Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP				Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP			In vivo analysis of the state of the human uPA enhancer following stimulation by TPA	ONCOGENE			English	Article						urokinase; enhancer; transcription; DNase I; hypersensitivity; in vivo footprinting	PLASMINOGEN-ACTIVATOR GENE; UROKINASE GENE; TRANSCRIPTION FACTORS; PHORBOL-ESTER; PROMOTER; CELLS; AP-1; COOPERATION; EXPRESSION; INDUCTION	We have analysed in vivo the -2.0 kb enhancer of the human urokinase-type plasminogen activator (uPA) gene in HepG2 cells, in which gene expression can be induced by phorbol esters, The results reveal that, within the regulatory region, the enhancer, the silencer and the minimal promoter become hypersensitive to deoxyribonuclease I (DNase I) upon induction of transcription, The hypersensitivity of the enhancer can be reversed after removal of the inducer. In vivo footprinting analysis indicates that all the cis-acting elements of the enhancer, previously identified in vitro, are occupied in vivo upon 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimulation of HepG2 cells, Micrococcal nuclease (MNase) cleavage of this region fails to reveal discrete nucleosomal boundaries in vivo in close proximity of the enhancer, either before or after stimulation. Furthermore, this region does not lose its nucleosomal configuration after TPA induction of transcription. An approximately 600 bp long region around the enhancer becomes more, but not fully, accessible to restriction endonucleases upon stimulation. A time-course experiment shows that this accessibility reaches a plateau after a Ih TPA treatment suggesting the persistent presence of nucleosomes, These results indicate that TPA induces the binding of transcription factors to the uPA enhancer without chromatin remodelling of this region.	Hosp San Raffaele, DIBIT, Mol Genet Lab, I-20132 Milan, Italy; Univ Milan, Dept Genet & Microbial Biol, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan	Crippa, MP (corresponding author), Hosp San Raffaele, DIBIT, Mol Genet Lab, Via Olgettina 58, I-20132 Milan, Italy.		crippa, massimo/J-6514-2016	crippa, massimo/0000-0003-3214-9670; Blasi, Francesco/0000-0001-9406-1784				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; BESSER D, 1996, FIBRINOLYSIS, V10, P214; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; Guerrini L, 1996, FEBS LETT, V393, P69, DOI 10.1016/0014-5793(96)00854-X; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; Li GY, 1998, GENE, V209, P139, DOI 10.1016/S0378-1119(98)00039-0; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Quivy JP, 1996, J MOL BIOL, V256, P249, DOI 10.1006/jmbi.1996.0083; Quivy JP, 1997, METHODS, V11, P171, DOI 10.1006/meth.1996.0403; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WINTER H, 1990, DIFFERENTIATION, V43, P105, DOI 10.1111/j.1432-0436.1990.tb00436.x	27	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2836	2845		10.1038/sj.onc.1202644	http://dx.doi.org/10.1038/sj.onc.1202644			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362254				2022-12-25	WOS:000080125100006
J	Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD				Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD			Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma	ONCOGENE			English	Article						11q23; mediastinal large cell lymphoma with; sclerosis (MLCLS); lymphoma proprotein convertase (LPC); alpha 2 subunit of platelet activating factor; acetylhydrolase (Pafah1a2); gene duplication; LINEI element	ACUTE MYELOID-LEUKEMIA; NONLYMPHOID HEMATOLOGIC MALIGNANCIES; DIEKER LISSENCEPHALY GENE; BETA-SUBUNIT; TRANSLOCATION BREAKPOINT; HOMOLOGOUS RECOMBINATION; TANDEM DUPLICATION; EXPRESSION; PROTEIN; CLONING	A region of 150 kb has been analysed around a previously isolated, lymphoma associated, translocation breakpoint located at chromosome band 11q23. This balanced and reciprocal translocation, t(11;14)(q32;q23), has been shown to result in the fusion between chromosome 11 specific sequence and the switch gamma 4 region of the IGH locus, The LPC gene, encoding a novel proprotein convertase belonging to the furin family, has been identified in this region. In order to characterize further the region surrounding the translocation, we have determined the detailed structure of LPC, Here we show that LPC consists of at least 16 exons covering 25 kb, and that there is a partial duplication, involving mobile genetic elements and containing LPC exons 13-17 in a tail-tail configuration at 65 kb downstream. Since the chromosomal breakpoint lay between these two structures, the intervening region was further analysed and shown to contain at least two unrelated genes, The previously known SM22 gene was localized close to the 3' tail of LPC, Furthermore,,ve identified the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) at the chromosomal breakpoint, The position of another previously identified breakpoint was also located to within the first intron of this gene, Altogether, our results give evidence of a genomic instability of this area of 11q23 and show that Pafah1a2 and not LPC is the gene disrupted by the translocation, suggesting that deregulated Pafah1a2 may have a role in lymphomagenesis.	Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Young, BD (corresponding author), Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.							Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKAO Y, 1993, GENE CHROMOSOME CANC, V8, P167, DOI 10.1002/gcc.2870080305; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; Bennett SAL, 1997, MOL CARCINOGEN, V20, P366, DOI 10.1002/(SICI)1098-2744(199712)20:4<366::AID-MC6>3.0.CO;2-H; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BLANK ML, 1981, LIFE SCI, V29, P769, DOI 10.1016/0024-3205(81)90031-X; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; Brown MA, 1996, ONCOGENE, V12, P2507; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DENIZOT Y, 1995, LEUKEMIA, V9, P1982; DENIZOT Y, 1995, BLOOD, V85, P2992, DOI 10.1182/blood.V85.10.2992.bloodjournal85102992; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kurahashi H, 1998, HUM GENET, V103, P189, DOI 10.1007/s004390050805; LEHRACH H., 1990, GENOME ANAL, P39; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; MAEDA N, 1986, ANNU REV GENET, V20, P81; Meerabux J, 1996, CANCER RES, V56, P448; MEERABUX JM, 1994, ONCOGENE, V9, P893; MIKI Y, 1992, CANCER RES, V52, P643; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Moro F, 1998, GENOMICS, V51, P157, DOI 10.1006/geno.1998.5322; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Sambrook J., 2002, MOL CLONING LAB MANU; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WARD CJ, 1994, CELL, V77, P881; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	48	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2852	2859		10.1038/sj.onc.1202645	http://dx.doi.org/10.1038/sj.onc.1202645			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362256				2022-12-25	WOS:000080125100008
J	Liang, HY; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB				Liang, HY; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB			Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; TYROSINE PHOSPHORYLATION; OKADAIC ACID; CALCINEURIN; ACTIVATION; KINASE; RECEPTOR; SRC; DEPHOSPHORYLATION; TRANSCRIPTION	Ligand binding to the angiotensin II (Ang II) AT, receptor on vascular smooth muscle cells (VSMCs) activates the Janus-activated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway, We have shown previously that the JAK2 tyrosine kinase and the Src family p59 Fyn tyrosine kinase are required for Ang II-induced STAT1 tyrosine phosphorylation in VSMCs. The mitogen-activated protein kinase phosphatase, MKP-1, is required for STAT1 tyrosine dephosphorylation, In the present study, using specific enzyme inhibitors and antisense oligonucleotides, we show that Ang II-induced tyrosine phosphorylation and nuclear translocation of STATE in VSMCs is mediated by p60 c-Src, whereas tyrosine dephosphorylation is mediated by calcineurin, Calcineurin is activated in response to Ang II stimulation of VSMCs and is translocated to the nucleus. In addition, we show that Ang II-induced serine phosphorylation of STATE in VSMCs is mediated by mitogen-activated protein kinase and that dephosphorylation is mediated by protein phosphatase 2A (PP2A). PP2A translocates to the nucleus in response to Ang II stimulation of VSMCs and forms a complex with STATE in an Ang II-dependent manner.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Venema, RC (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.	rvenema@mail.mcg.edu; mmarrero@mail.mcg.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201, R29HL058139, R01HL058139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58139, HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHAN CP, 1986, J BIOL CHEM, V261, P9890; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin H, 1998, BLOOD, V91, P3734; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PALLEN CJ, 1985, BIOCHEMISTRY-US, V24, P4727, DOI 10.1021/bi00339a003; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	38	77	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19846	19851		10.1074/jbc.274.28.19846	http://dx.doi.org/10.1074/jbc.274.28.19846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391929	hybrid			2022-12-25	WOS:000081377300049
J	Medkova, M; Cho, WH				Medkova, M; Cho, WH			Interplay of C1 and C2 domains of protein kinase C-alpha in its membrane binding and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER-BINDING; CYTOSOLIC PHOSPHOLIPASE A(2); SITE-DIRECTED MUTAGENESIS; X-100 MIXED MICELLES; INTERFACIAL CATALYSIS; LIPID MONOLAYERS; HIGH-AFFINITY; DIACYLGLYCEROL; PHOSPHATIDYLSERINE; CALCIUM	The regulatory domain of conventional protein kinase C (PKC) contains two membrane-targeting modules, the C2 domain that is responsible for Ca2+-dependent membrane binding of protein, and the C1 domain composed of two cysteine-rich zinc fingers (Cla and Gib) that bind diacylglycerols and phorbol esters, To understand the individual roles and the interplay of the C1 and C2 domains in the membrane binding and activation of PKC, we functionally expressed isolated C1 and C2 domains of PKC-alpha and measured their vesicle binding and monolayer penetration. Results indicate that the C2 domain of PKC-alpha is responsible for the initial Ca2+- and phosphatidylserine-dependent electrostatic membrane binding of PKC-alpha, whereas the C1 domain is involved in subsequent membrane penetration and diacylglycerol binding, which eventually lead to enzyme activation. To determine the roles of individual zinc fingers in the C1 domain, we also mutated hydrophobic residues in the C1a (Trp(58) and Phe(60)) and C1b (Tyr(123) and Leu(125)) domains of the native PKC-alpha molecule and measured the effects of mutations on vesicle binding, enzyme activity and monolayer penetration. Results show that the hydrophobic residues in the C1a domain are essential for the membrane penetration and activation of PKC-alpha, whereas those in the C1b domain are not directly involved in these processes. Based on these results in conjunction with our previous structure-function studies of the C2 domain (Medkova, M., and Cho, W. (1998) J. Biol. Chem. 273, 17544-17552), we propose a mechanism for the in vitro membrane binding and activation of conventional PKC that accounts for the temporal and spatial sequences of PKC activation.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WH (corresponding author), Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERS DM, 1982, AM J PHYSIOL, V242, P404; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bogi K, 1998, CANCER RES, V58, P1423; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Dibble ARG, 1996, BIOPHYS J, V71, P1877, DOI 10.1016/S0006-3495(96)79387-6; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; GAINES JGL, 1966, INSOLUBLE MONOLAYERS, P208; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Lecompte MF, 1998, BIOCHEMISTRY-US, V37, P16165, DOI 10.1021/bi9813072; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOREAU H, 1988, BIOCHEMISTRY-US, V27, P2319, DOI 10.1021/bi00407a012; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1992, J BIOL CHEM, V267, P15263; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	56	144	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19852	19861		10.1074/jbc.274.28.19852	http://dx.doi.org/10.1074/jbc.274.28.19852			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391930	hybrid			2022-12-25	WOS:000081377300050
J	Quiram, PA; Jones, JJ; Sine, SM				Quiram, PA; Jones, JJ; Sine, SM			Pairwise Interactions between neuronal alpha(7) acetylcholine receptors and alpha-conotoxin ImI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; MOLECULAR DISSECTION; CURARIFORM ANTAGONISTS; CONSERVED TYROSINES; CONFER SELECTIVITY; MUTANT CYCLES; CHANNEL PORE; K+ CHANNEL; IDENTIFICATION; RESIDUES	The present work uses alpha-conotoxin ImI (CTx ImI) to probe the neurotransmitter binding site of neuronal alpha(7) acetylcholine receptors. We identify key residues in alpha(7) that contribute to CTx ImI affinity, and use mutant cycles analysis to identify pairs of residues that stabilize the receptor-conotoxin complex. We first mutated key residues in the seven known loops of alpha(7) that converge at the subunit interface to form the ligand binding site. The mutant subunits were expressed in 293 HEK cells, and CTx ImI binding was measured by competition against the initial rate of I-125-alpha-bungarotoxin binding. The results reveal a predominant contribution by Tyr-195 in alpha(7), accompanied by smaller contributions by Thr-77, Tyr-93, Asn-111, Gln-117, and Trp-149, Based upon our previous identification of bioactive residues in CTx ImI, we measured binding of receptor and toxin mutations and analyzed the results using thermodynamic mutant cycles. The results reveal a single dominant interaction between Arg-7 of CTx ImI and Tyr-195 of alpha(7) that anchors the toxin to the binding site. We also find multiple weak interactions between Asp-5 of CTx ImI and Trp-149, Tyr-151, and Gly-153 of alpha(7), and between Trp-10 of CTx ImI and Thr-77 and Asn-111 of alpha(7). The overall results establish the orientation of CTx ImI as it bridges the subunit interface and demonstrate close approach of residues on opposing faces of the alpha(7) binding site.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu			NINDS NIH HHS [NS-31744] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; ANDRUE D, 1994, METHODS MOL BIOL PEP, V35, P139; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; FU DX, 1994, J BIOL CHEM, V269, P26152; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; PRINCE RJ, 1997, NICOTINIC ACETYLCHOL, P31; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	29	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19517	19524		10.1074/jbc.274.28.19517	http://dx.doi.org/10.1074/jbc.274.28.19517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391883	hybrid			2022-12-25	WOS:000081377300003
J	Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Ludden, PW; Shah, VK				Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Ludden, PW; Shah, VK			In vitro biosynthesis of iron molybdenum cofactor and maturation of the nif-encoded apodinitrogenase - Effect of substitution for NifH with site-specifically altered forms of NifH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE REDUCTION PROPERTIES; APO-MOFE PROTEIN; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; ELECTRON-TRANSFER; FE-PROTEIN; SIGNAL-TRANSDUCTION; INVITRO SYNTHESIS; GENE-PRODUCT; NITROGENASE	has three different roles in the nitrogenase enzyme system. Apart from serving as the physiological electron donor to dinitrogenase, NifH is involved in iron-molybdenum cofactor (FeMo-co) biosynthesis and in maturation of the FeMo-co-deficient form of apodinitrogenase to a FeMo-co-activable form (apodinitrogenase maturation). The exact roles of NifH in these processes are not well understood. In the present study, the features of NifH required for the aforementioned processes have been investigated by the use of site-specifically altered forms of the enzyme, The ability of six altered forms of NifH inactive in substrate reduction (K15R, D39N, D43N, L127 Delta, D129E, and F135Y) to function in in vitro FeMo-co synthesis and apodinitrogenase maturation reactions was investigated. We report that the ability of NifH to bind and not hydrolyze MgATP is required for it to function in these processes. We also present evidence that the ability of NifH to function in these processes is not dictated by the properties known to be required for its function in electron transfer to dinitrogenase, Evidence toward the existence of separate, overlapping sites on NifH for each of its functions (substrate reduction, FeMo-co biosynthesis, and apodinitrogenase maturation) is presented.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; Utah State University	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; CHATTERJEE R, 1994, J BACTERIOL, V176, P2747, DOI 10.1128/JB.176.9.2747-2750.1994; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; DEAN DR, 1985, P NATL ACAD SCI USA, V82, P5720, DOI 10.1073/pnas.82.17.5720; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; PIERRARD J, 1993, BIOCHEM BIOPH RES CO, V192, P1223, DOI 10.1006/bbrc.1993.1547; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; Pulakat L, 1996, J BIOL CHEM, V271, P1884, DOI 10.1074/jbc.271.4.1884; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P9424, DOI 10.1021/bi9608572; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH PK, 1985, ANAL BIOCHEM, V150, P175; THORNELEY RNF, 1993, ACS SYM SER, V535, P290; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	54	26	27	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19778	19784		10.1074/jbc.274.28.19778	http://dx.doi.org/10.1074/jbc.274.28.19778			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391920	hybrid			2022-12-25	WOS:000081377300040
J	Yu, J; Wang, C; Palmieri, SJ; Haarer, BK; Field, J				Yu, J; Wang, C; Palmieri, SJ; Haarer, BK; Field, J			A cytoskeletal localizing domain in the cyclase-associated protein, CAP/Srv2p, regulates access to a distant SH3-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ADENYLYL-CYCLASE; SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; ACTIN CYTOSKELETON; GENE-PRODUCT; CDC25 GENE; CAP; BINDING; ACTIVATION; PATHWAY	In the yeast, Saccharomyces cerevisiae, adenylyl cyclase consists of a 800-kDa catalytic subunit (CYR1) and a 70-kDa subunit (CAP/SRV2). CAP/Srv2p assists the small G protein Pas to activate adenylyl cyclase, CAP also regulates the cytoskeleton through an actin sequestering activity and is directed to cortical actin patches by a proline-rich SHE-binding site (P-2). In this report we analyze the role of the actin cytoskeleton in Ras/cAMP signaling. Two alleles of CAP, L16P(Srv2) and R19T (SupC), first isolated in genetic screens for mutants that attenuate cAMP levels, reduced adenylyl cyclase binding, and cortical actin patch localization. A third mutation, L27F, also failed to localize but showed no loss of either cAMP signaling or adenylyl cyclase binding. However, all three N-terminal mutations reduced CAP-CAP multimer formation and SH3 domain binding, although the SHE-binding site is about 350 amino acids away. Finally, disruption of the actin cytoskeleton with latrun-culin-A did not affect the cAMP phenotypes of the hyperactive Ras2(Val19) allele, These data identify a novel region of CAP that controls access to the SH3-binding site and demonstrate that cytoskeletal localization of CAP or an intact cytoskeleton per se is not necessary for cAMP signaling.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Texas, Sect Cell & Dev Biol, Austin, TX 78712 USA	University of Pennsylvania; University of Texas System; University of Texas Austin	Field, J (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	field@pharm.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048241] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hubberstey A, 1996, J CELL BIOCHEM, V61, P459, DOI 10.1002/(SICI)1097-4644(19960601)61:3<459::AID-JCB13>3.0.CO;2-E; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MINATO T, 1994, J BIOL CHEM, V269, P20845; Mintzer KA, 1999, CELL SIGNAL, V11, P127, DOI 10.1016/S0898-6568(98)00044-8; MINTZER KA, 1994, CELL SIGNAL, V6, P681, DOI 10.1016/0898-6568(94)90050-7; MINTZER KA, 1995, METHOD ENZYMOL, V255, P468; Nishida Y, 1998, J BIOL CHEM, V273, P28019, DOI 10.1074/jbc.273.43.28019; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243	46	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19985	19991		10.1074/jbc.274.28.19985	http://dx.doi.org/10.1074/jbc.274.28.19985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391948	hybrid			2022-12-25	WOS:000081377300068
J	Hashimoto, T; Fujita, T; Usuda, N; Cook, W; Qi, C; Peters, JM; Gonzalez, FJ; Yeldandi, AV; Rao, MS; Reddy, JK				Hashimoto, T; Fujita, T; Usuda, N; Cook, W; Qi, C; Peters, JM; Gonzalez, FJ; Yeldandi, AV; Rao, MS; Reddy, JK			Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty Acyl-CoA oxidase - Genotype correlation with fatty liver phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; RAT-LIVER; CARNITINE PALMITOYLTRANSFERASE; 3-KETOACYL-COA THIOLASE; MOLECULAR-CLONING; PTS2 RECEPTOR; HUMAN PEX7; GENE; PURIFICATION; EXPRESSION	Fatty acid beta-oxidation occurs in both mitochondria and peroxisomes. Long chain fatty acids are also metabolized by the cytochrome P450 CYP4A omega-oxidation enzymes to toxic dicarboxylic acids (DCAs) that serve as substrates for peroxisomal beta-oxidation. Synthetic peroxisome proliferators interact with peroxisome proliferator activated receptor alpha (PPAR alpha) to transcriptionally activate genes that participate in peroxisomal, microsomal, and mitochondrial fatty acid oxidation. Mice lacking PPAR alpha (PPAR alpha(-/-)) fail to respond to the inductive effects of peroxisome proliferators, whereas those lacking fatty acyl-CoA oxidase (AOX(-/-)), the first enzyme of the peroxisomal beta-oxidation system, exhibit extensive microvesicular steatohepatitis, leading to hepatocellular regeneration and massive peroxisome proliferation, implying sustained activation of PPAR alpha by natural ligands. We now report that mice nullizygous for both PPAR alpha and AOX (PPAR alpha(-/-) AOX(-/-)) failed to exhibit spontaneous peroxisome proliferation and induction of PPAR alpha-regulated genes by biological ligands unmetabolized in the absence of AOX. In AOX-/- mice, the hyperactivity of PPAR alpha enhances the severity of steatosis by inducing CYP4A family proteins that generate DCAs and since they are not metabolized in the absence of peroxisomal beta-oxidation, they damage mitochondria leading to steatosis. Blunting of microvesicular steatosis, which is restricted to few liver cells in periportal regions in PPAR alpha(-/-) AOX(-/-) mice, suggests a role for PPAR alpha-induced genes, especially members of CYP4A family, in determining the severity of steatosis in livers with defective peroxisomal beta-oxidation. In age-matched PPAR alpha(-/-) mice, a decrease in constitutive mitochondrial beta-oxidation with intact constitutive peroxisomal beta-oxidation system contributes to large droplet fatty change that is restricted to centrilobular hepatocytes. These data define a critical role for both PPAR alpha and AOX in hepatic lipid metabolism and in the pathogenesis of specific fatty liver phenotype.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; FORMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZAI K, 1992, J BIOL CHEM, V267, P1027; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANNAERTS GP, 1982, ANN NY ACAD SCI, V386, P30, DOI 10.1111/j.1749-6632.1982.tb21405.x; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OCKNER RK, 1993, HEPATOLOGY, V18, P669, DOI 10.1002/hep.1840180327; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; OZASA H, 1983, J BIOCHEM-TOKYO, V94, P543, DOI 10.1093/oxfordjournals.jbchem.a134385; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1985, HDB CARCINOGEN TESTI, P482; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SHERLOCK S, 1995, LANCET, V345, P227; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TONSGARD JH, 1985, J CLIN INVEST, V76, P816, DOI 10.1172/JCI112039; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; USUDA N, 1988, LAB INVEST, V58, P100; YOKOTA S, 1985, HISTOCHEMISTRY, V82, P25, DOI 10.1007/BF00502087	49	203	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19228	19236		10.1074/jbc.274.27.19228	http://dx.doi.org/10.1074/jbc.274.27.19228			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383430	hybrid			2022-12-25	WOS:000081196300053
J	Linton, MF; Babaev, VR; Gleaves, LA; Fazio, S				Linton, MF; Babaev, VR; Gleaves, LA; Fazio, S			A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER ACCUMULATION; MOUSE PERITONEAL-MACROPHAGES; BONE-MARROW TRANSPLANTATION; ISOLATED HUMAN LYMPHOCYTES; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-E; KNOCKOUT MICE; CANINE BETA; LDL; SUSCEPTIBILITY	To evaluate the contribution of the macrophage low density lipoprotein receptor (LDLR) to atherosclerotic lesion formation, we performed bone marrow transplantation studies in different mouse strains. First, LDLR(-/-) mice were transplanted with either LDLR(+/+) marrow or LDLR(-/-) marrow and were challenged with an atherogenic Western type diet. The diet caused severe hypercholesterolemia of a similar degree in the two groups, and no differences in the aortic lesion area were detected. Thus, macrophage LDLR expression does not influence foam cell lesion formation in the setting of extreme LDL accumulation. To determine whether macrophage LDLR expression affects foam cell formation under conditions of moderate, non-LDL by. perlipidemia, we transplanted C57BL/6 mice with either LDLR(-/-) marrow (experimental group) or LDLR(+/+) marrow (controls). Cholesterol levels were not significantly different between the two groups at baseline or after 6 weeks on a butterfat diet, but were 40% higher in the experimental mice after 13 weeks, mostly due to accumulation of beta-very low density lipoprotein (beta-VLDL). Despite the increase in cholesterol levels, mice receiving LDLR(-/-) marrow developed 63% smaller lesions than controls, demonstrating that macrophage LDLR affects the rate of foam cell formation when the atherogenic stimulus is beta-VLDL. We conclude that the macrophage LDLR is responsible for a significant portion of lipid accumulation in foam cells under conditions of dietary stress.	Vanderbilt Univ, Sch Med, Div Endocrinol, Med Ctr,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Linton, MF (corresponding author), Vanderbilt Univ, Sch Med, Div Endocrinol, Med Ctr,Dept Med, 715 Med Res Bldg 2, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53989-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boisvert WA, 1997, ARTERIOSCL THROM VAS, V17, P340, DOI 10.1161/01.ATV.17.2.340; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; ELLSWORTH JL, 1987, J BIOL CHEM, V262, P2316; Fazio S, 1997, J LIPID RES, V38, P391; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; Herijgers N, 1997, ARTERIOSCL THROM VAS, V17, P1995, DOI 10.1161/01.ATV.17.10.1995; HO YK, 1976, J CLIN INVEST, V58, P1465, DOI 10.1172/JCI108603; HO YK, 1977, J EXP MED, V145, P1531, DOI 10.1084/jem.145.6.1531; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; KNIGHT BL, 1986, EUR J BIOCHEM, V156, P205, DOI 10.1111/j.1432-1033.1986.tb09569.x; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KOO C, 1986, J BIOL CHEM, V261, P1194; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; MAHLEY RW, 1980, J LIPID RES, V21, P970; NAGELKERKE JF, 1986, J BIOL CHEM, V261, P8909; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Weintraub MS, 1996, BRIT MED J, V312, P936; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	35	79	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19204	19210		10.1074/jbc.274.27.19204	http://dx.doi.org/10.1074/jbc.274.27.19204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383427	hybrid			2022-12-25	WOS:000081196300050
J	Poukka, H; Aarnisalo, P; Karvonen, U; Palvimo, JJ; Janne, OA				Poukka, H; Aarnisalo, P; Karvonen, U; Palvimo, JJ; Janne, OA			Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; RAT GLUCOCORTICOID RECEPTOR; STEROID-HORMONE RECEPTORS; CREB-BINDING-PROTEIN; NUCLEAR-PORE COMPLEX; SUMO-1 MODIFICATION; DNA-BINDING; DEOXYRIBONUCLEIC-ACID; TARGETING SIGNAL; DOMAIN	Ubc9, a homologue of the class E2 ubiquitin-conjugating enzymes, has recently been shown to catalyze conjugation of a small ubiquitin-like molecule-1 (SUMO-1) to a variety of target proteins. SUMO-1 modifications have been implicated in the targeting of proteins to the nuclear envelope and certain intranuclear structures and in converting proteins resistant to ubiquitin-mediated degradation, In the present work, we find that Ubc9 interacts with the androgen receptor (AR), a member of the steroid receptor family of ligand-activated transcription factors. In transiently transfected COS-1 cells, AR dependent but not basal transcription is enhanced by the coexpression of Ubc9. The N-terminal half of the AR hinge region containing the C-terminal part of the bipartite nuclear localization signal is essential for the interaction with Ubc9, Deletion of this part of the nuclear localization signal, which does not completely prevent the transfer of AR to the nucleus, abolishes the AR-Ubc9 interaction and attenuates the transcriptional response to cotransfected Ubc9, The C93S substitution of Ubc9, which prevents SUMO-1 conjugation by abrogating the formation of a thiolester bond between SUMO-1 and Ubc9, does not influence the capability of Ubc9 to stimulate AR-dependent transactivation, implying that Ubc9 is able to act as an AR coregulator in a fashion independent of its ability to catalyze SUMO-1 conjugation.	Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Janne, OA (corresponding author), Univ Helsinki, Inst Biomed, Dept Physiol, POB 9,Siltavuorenpenger 20 J, FIN-00014 Helsinki, Finland.			Palvimo, Jorma/0000-0003-2373-0578				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	48	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19441	19446		10.1074/jbc.274.27.19441	http://dx.doi.org/10.1074/jbc.274.27.19441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383460	hybrid			2022-12-25	WOS:000081196300083
J	Sun, J; Xu, W; Hervas, M; Navarro, JK; De La Rosa, MA; Chitnis, PR				Sun, J; Xu, W; Hervas, M; Navarro, JK; De La Rosa, MA; Chitnis, PR			Oxidizing side of the cyanobacterial photosystem I - Evidence for interaction between the electron donor proteins and a luminal surface helix of the PsaB subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; PHOTOSYNTHETIC REACTION-CENTER; FLASH ABSORPTION-SPECTROSCOPY; SP PCC 6803; CYTOCHROME C(6); SYNECHOCOCCUS-ELONGATUS; TARGETED INACTIVATION; MUTATIONAL ANALYSIS; PLASTOCYANIN; POLYPEPTIDES	Photosystem I (PSI) interacts with plastocyanin or cytochrome c(6) on the luminal side. To identify sites of interaction between plastocyanin/cytochrome c(6) and the PSI core, site-directed mutations were generated in the luminal J loop of the PsaB protein from Synechocystis sp, PCC 6803. The eight mutant strains differed in their photoautotrophic growth. Western blotting with subunit-specific antibodies indicated that the mutations affected the PSI level in the thylakoid membranes. PSI proteins could not be detected in the S600R/G601C/ N602I, N609K/S610C/T611I, and M614I/G615C/W616A mutant membranes. The other mutant strains contained different levels of PSI proteins. Among the mutant strains that contained PSI proteins, the H595C/L596I, Q627H/L628C/I629S, and N638C/N639S mutants showed similar levels of PSI-mediated electron transfer activity when either cytochrome c(6) or an artificial electron donor was used. In contrast, cytochrome c(6) could not function as an electron donor to the W622C/A623R mutant, even though the PSI activity mediated by an artificial electron donor was detected in this mutant. Thus, the W622C/A623R mutation affected the interaction of the PSI complex with cytochrome c(6). Biotin-maleimide modification of the mutant PSI complexes indicated that His-595, Trp-622, Leu-628, Tyr-632, and Asn-638 in wildtype PsaB may be exposed on the surface of the PSI complex. The results presented here demonstrate the role of an extramembrane loop of a PSI core protein in the interaction with soluble electron donor proteins.	Iowa State Univ, Dept Biochem & Biophys, Ames, IA 50011 USA; Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Iowa State University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	Chitnis, PR (corresponding author), Iowa State Univ, Dept Biochem & Biophys, Ames, IA 50011 USA.	chitnis@iastate.edu	navarro, jose a/B-6354-2015; Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014	navarro, jose a/0000-0002-0536-6074; Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; Xu, Wu/0000-0002-2982-3276				ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BOUSSIBA S, 1992, RES PHOTOSYNTHESIS, V3, P429; Chitnis PR, 1996, PLANT PHYSIOL, V111, P661, DOI 10.1104/pp.111.3.661; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DEISENHOFER J, 1991, ANNU REV CELL BIOL, V7, P1; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Furr HC, 1992, MODERN CHROMATOGRAPH, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAEHNEL W, 1980, BIOCHIM BIOPHYS ACTA, V593, P384, DOI 10.1016/0005-2728(80)90075-4; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V34, P339, DOI 10.1016/0003-9861(51)90012-4; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; Sun J, 1998, METHOD ENZYMOL, V297, P124; Sun J, 1997, J BIOL CHEM, V272, P21793, DOI 10.1074/jbc.272.35.21793; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU QA, 1994, J BIOL CHEM, V269, P3205; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	46	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19048	19054		10.1074/jbc.274.27.19048	http://dx.doi.org/10.1074/jbc.274.27.19048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383406	Green Published, hybrid			2022-12-25	WOS:000081196300029
J	Unkles, SE; Heck, IS; Appleyard, MVCL; Kinghorn, JR				Unkles, SE; Heck, IS; Appleyard, MVCL; Kinghorn, JR			Eukaryotic molybdopterin synthase - Biochemical and molecular studies of Aspergillus nidulans cnxG and cnxH mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI; NITRATE REDUCTASE; CHLORATE TOXICITY; CONVERTING FACTOR; GENE; CLONING; LOCUS; INVOLVEMENT; DEFICIENCY	We describe the primary structure of eukaryotic molybdopterin synthase small and large subunits and compare the sequences of the lower eukaryote, Aspergillus nidulans, and a higher eukaryote, Homo sapiens. Mutants in the A. nidulans cnxG (encoding small subunit) and cnxH (large subunit) genes have been analyzed at the biochemical and molecular level. Chlorate-sensitive mutants, all the result of amino acid substitutions, were shown to produce low levels of molybdopterin, and growth tests suggest that they have low levels of molybdoenzymes. In contrast, chlorate-resistant cnx strains have undetectable levels of molybdopterin, lack the ability to utilize nitrate or hypoxanthine as sole nitrogen sources, and are probably null mutations. Thus on the basis of chlorate toxicity, it is possible to distinguish between amino acid substitutions that permit a low level of molybdopterin production and those mutations that completely abolish molybdopterin synthesis, most likely reflecting molybdopterin synthase activity per se. Residues have been identified that are essential for function including the C-terminal Gly of the small subunit (CnxG), which is thought to be crucial for the sulfur transfer process during the formation of molybdopterin. Two independent alterations at residue Gly-148 in the large subunit, CnxH, result in temperature sensitivity suggesting that this residue resides in a region important for correct folding of the fungal protein. Many years ago it was proposed, from data showing that temperature-sensitive cnxH mutants had thermolabile nitrate reductase, that CnxH is an integral part of the molybdoenzyme nitrate reductase (MacDonald, D. W., and Cove, D. J. (1974) fur. J. Biochem. 47, 107-110). Studies of temperature-sensitive cnxH mutants isolated in the course of this study do not support this hypothesis. Homologues of both molybdopterin synthase subunits are evident in diverse eukaryotic sources such as worm, rat, mouse, rice, and fruit fly as well as humans as discussed in this article. In contrast, molybdopterin synthase homologues are absent in the yeast Saccharomyces cerevisiae. Precursor Z and molybdopterin are undetectable in this organism nor do there appear to be homologues of molybdoenzymes.	Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Univ St Andrews, Sch Biol, Div Environm & Evolut Biol, St Andrews KY16 9TH, Fife, Scotland; Inst Plant Biochem, D-72076 Tubingen, Germany	Monash University; University of St Andrews	Unkles, SE (corresponding author), Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia.							ABERG B, 1947, KUNGL LANTBRUKSHOGSK, V15, P37; ADELBERG EA, 1965, BIOCHEM BIOPH RES CO, V18, P788, DOI 10.1016/0006-291X(65)90855-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; ARST HN, 1997, MICROBIOLOGY, V143, P1437; BAL J, 1977, MUTAT RES, V56, P153, DOI 10.1016/0027-5107(77)90203-2; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COOLEY RN, 1985, BIOCHIM BIOPHYS ACTA, V831, P89, DOI 10.1016/0167-4838(85)90153-0; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1976, HEREDITY, V36, P191, DOI 10.1038/hdy.1976.24; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; COVE DJ, 1976, MOL GEN GENET, V146, P147, DOI 10.1007/BF00268083; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GARRETT RG, 1976, MOL GEN GENET, V147, P179; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; HECK IS, 1995, PHOTOCHEM PHOTOBIOL, V61, P54, DOI 10.1111/j.1751-1097.1995.tb09242.x; Herman C., 1966, ASPERGILLUS NEWS LET, V7, P13; Hughes EF, 1998, DEV MED CHILD NEUROL, V40, P57; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KETCHUM PA, 1970, P NATL ACAD SCI USA, V66, P1016, DOI 10.1073/pnas.66.3.1016; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; MACDONALD DW, 1974, EUR J BIOCHEM, V47, P107, DOI 10.1111/j.1432-1033.1974.tb03673.x; MACDONALD DW, 1974, EUR J BIOCHEM, V46, P169; MINAGAWA N, 1982, J BIOCHEM, V91, P761, DOI 10.1093/oxfordjournals.jbchem.a133763; MIZE C, 1995, J INHERIT METAB DIS, V18, P283, DOI 10.1007/BF00710416; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; UNKLES SE, 1992, APPL MOL GENETICS FI, P28; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	40	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19286	19293		10.1074/jbc.274.27.19286	http://dx.doi.org/10.1074/jbc.274.27.19286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383438	hybrid			2022-12-25	WOS:000081196300061
J	Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A				Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A			Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood - Relevance to atherogenesis caused by hemodialysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; ACCELERATED ATHEROSCLEROSIS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; LDL SUBFRACTION; GENERATION; PROTEINS; HYDROPEROXIDES; ERYTHROCYTES; SPECIFICITY	Human blood contains a form of minimally modified low density lipoprotein (LDL), termed LDL-, whose origin remains unknown. Exploring the mechanism of formation, we found that LDL- can be produced in plasma in the absence of oxygen following LDL incubation with oxidized hemoglobin species. A high degree of apolipoprotein B100 modification results from covalent association of hemoglobin with LDL involving dityrosine formation but not due to the malonaldehyde epitope formation. This was evidenced by the cross-reactivity of oxidized LDL with antibodies against hemoglobin that was accompanied by a 60-fold increase in dityrosine levels. In this study we found significantly higher LDL- levels in the blood of hemodialysis patients, perhaps contributing 60 their greatly increased risk of atherosclerosis. The mechanism of LDL- formation was studied during ex vivo blood circulation using a model system resembling clinical hemodialysis in terms of the induction of inflammatory responses. This circulation increased free hemoglobin and LDL- levels compared with non-circulated blood without appreciable lipid peroxidation, Pronounced increases in LDL- were found also during circulation of plasma supplemented with nanomolar hemoglobin levels. The increase in dityrosine content and presence of heme in LDL after blood circulation suggest that LDL is modified, in part, by hemoglobin-LDL conjugates containing heme, Thus, hemoglobin-mediated reactions leading to LDL oxidation in plasma can account for high LDL- levels in hemodialysis patients.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Div Nephrol, Los Angeles, CA 90033 USA; Bellco SPA, Clin & Lab Res Dept, I-41037 Mirandola, Italy; Washington Univ, Sch Med, St Louis, MO 63110 USA; Karl Franzens Univ Graz, A-8010 Graz, Austria	University of Southern California; University of Southern California; Washington University (WUSTL); University of Graz	Sevanian, A (corresponding author), 1985 Zonal Ave,PSC 612, Los Angeles, CA 90033 USA.	asevan@thevine.net	Ziouzenkova, Ouliana/B-3690-2012; Ziouzenkova, Ouliana/AAM-1971-2020; Jürgens, Günther/B-8818-2011	Ziouzenkova, Ouliana/0000-0003-2449-2591; 	FOGARTY INTERNATIONAL CENTER [F05TW005340] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050350] Funding Source: NIH RePORTER; FIC NIH HHS [1 F05 TW05340-01] Funding Source: Medline; NHLBI NIH HHS [HL50350] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Balagopalakrishna C, 1997, ADV EXP MED BIOL, V411, P337; Banni S, 1996, NEPHRON, V72, P177, DOI 10.1159/000188838; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bonomini M, 1997, NEPHRON, V75, P402, DOI 10.1159/000189577; CAZZOLATO G, 1991, FREE RADICAL BIO MED, V11, P247, DOI 10.1016/0891-5849(91)90120-R; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; DAUL AE, 1994, DEUT MED WOCHENSCHR, V119, P1263, DOI 10.1055/s-2008-1058831; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DELMASBEAUVIEUX MC, 1995, NEPHRON, V69, P404, DOI 10.1159/000188510; Demuth K, 1996, ARTERIOSCL THROM VAS, V16, P773, DOI 10.1161/01.ATV.16.6.773; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FORTIER N, 1988, BLOOD, V71, P1427; GIULIVI C, 1994, METHOD ENZYMOL, V231, P490; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Greilberger J, 1997, ARTERIOSCL THROM VAS, V17, P2721, DOI 10.1161/01.ATV.17.11.2721; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HATTORI A, 1978, ARCH HISTOL JAPON, V41, P205, DOI 10.1679/aohc1950.41.205; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HODIS HN, 1994, J LIPID RES, V35, P669; Kim JG, 1997, FREE RADICAL BIO MED, V23, P251, DOI 10.1016/S0891-5849(96)00615-6; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MAGGI E, 1994, KIDNEY INT, V45, P876, DOI 10.1038/ki.1994.115; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; MARESCA M, 1992, CELL BIOCHEM FUNCT, V10, P79, DOI 10.1002/cbf.290100203; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PAGANGA G, 1992, FEBS LETT, V303, P154, DOI 10.1016/0014-5793(92)80508-E; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RiceEvans C, 1996, FREE RADICAL RES, V25, P285, DOI 10.3109/10715769609149053; Sevanian A, 1997, J LIPID RES, V38, P419; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Taccone-Galluci M, 1994, ASAIO J, V40, pM663, DOI 10.1097/00002480-199407000-00081; TETTA C, 1991, NEPHROL DIAL TRANSPL, V6, P24; VANDENBERG JJM, 1992, FREE RADICAL BIO MED, V12, P487, DOI 10.1016/0891-5849(92)90102-M; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R; WONG SHY, 1987, CLIN CHEM, V33, P214; Yang CY, 1997, FREE RADICAL BIO MED, V23, P82, DOI 10.1016/S0891-5849(96)00624-7; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUKAWA S, 1995, NEPHROL DIAL TRANSPL, V10, P1	48	113	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18916	18924		10.1074/jbc.274.27.18916	http://dx.doi.org/10.1074/jbc.274.27.18916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383389	hybrid			2022-12-25	WOS:000081196300012
J	Chen, KD; Li, YS; Kim, M; Li, S; Yuan, S; Chien, S; Shyy, JYJ				Chen, KD; Li, YS; Kim, M; Li, S; Yuan, S; Chien, S; Shyy, JYJ			Mechanotransduction in response to shear stress - Roles of receptor tyrosine kinases, integrins, and Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; PROTEIN-1 GENE-EXPRESSION; GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; VASCULAR ENDOTHELIUM; MECHANICAL-STRESS; RAS PATHWAY; ACTIVATION; FLOW	Shear stress, the tangential component of hemodynamic forces, activates many signal transduction pathways in vascular endothelial cells. The conversion of mechanical stimulation into chemical signals is still unclear. We report here that shear stress (12 dynes/cm(2)) induced a rapid and transient tyrosine phosphorylation of Flk-1 and its concomitant association with the adaptor protein Shc; these are accompanied by a concurrent clustering of Flk-1, as demonstrated by confocal microscopy. Our results also show that shear stress induced an association of alpha(v)beta(3) and beta 1 integrins with Shc, and an attendant association of Shc with Grb2. These associations are sustained, in contrast to the transient Flk-1 Shc association in response to shear stress and the transient association between alpha(v)beta(3) integrin and Shc caused by cell attachment to substratum. Shc-SH2, an expression plasmid encoding the SH2 domain of Shc, attenuated shear stress activation of extracellular signal-regulated kinases and c-Jun N-terminal kinases, and the gene transcription mediated by the activator protein- 1/12-O-tetradecanoylphorbol-13-acetate-responsive element complex. Our results indicate that receptor tyrosine kinases and integrins can serve as mechanosensors to transduce mechanical stimuli into chemical signals via their association with Shc.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Biomed Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Shyy, JYJ (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019454, P01HL043026, R37HL044147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43026, HL19454, HL44147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CALALB MB, 1995, MOL CELL BIOL, V15, P954; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; Gotoh N, 1995, ONCOGENE, V11, P2525; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Hu YL, 1997, J HISTOCHEM CYTOCHEM, V45, P237, DOI 10.1177/002215549704500209; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRASAD ARS, 1993, CIRC RES, V72, P827, DOI 10.1161/01.RES.72.4.827; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEISS FU, 1997, CURR OPIN GENE DEV, V7, P880; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	60	451	473	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18393	18400		10.1074/jbc.274.26.18393	http://dx.doi.org/10.1074/jbc.274.26.18393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373445	hybrid			2022-12-25	WOS:000081056700037
J	Merry, CLR; Lyon, M; Deakin, JA; Hopwood, JJ; Gallagher, JT				Merry, CLR; Lyon, M; Deakin, JA; Hopwood, JJ; Gallagher, JT			Highly sensitive sequencing of the sulfated domains of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; IDURONATE 2-SULFATE RESIDUES; BINDING DOMAIN; PURIFIED ENZYME; BASIC FGF; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; PROTEOGLYCANS; POLYSACCHARIDES; BIOSYNTHESIS	The heparan sulfates (HS) are hypervariable linear polysaccharides that act as membrane co-receptors for growth factors, chemokines, and extracellular matrix proteins. In most instances, the molecular basis of protein recognition by HS is poorly understood. We have sequenced 75% of the sulfated domains (S-domains) of fibroblast HS, including all of the major ones. This analysis revealed tight coupling of N- and 2-O-sulfation and a low frequency but precise positioning of 6-O-sulfates, which are required functional groups for MS-mediated activation of the fibroblast growth factors. S-domain sequencing was conducted using a novel and highly sensitive method based on a new way of reading the sequence from high performance liquid chromatography separation profiles of metabolically labeled HS-saccharides following specific chemical and enzymatic scis-sion. The implications of the patterns seen in the sulfated domains for better understanding of the synthesis and function of HS are discussed.	Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, N Adelaide, SA 5006, Australia	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Gallagher, JT (corresponding author), Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England.			merry, catherine/0000-0002-3490-2809; Lyon, Malcolm/0000-0001-9575-6879				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIES J, 1995, DEVELOPMENT, V121, P1507; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; DWEK RA, 1995, J ANAT, V187, P2790; EDGE CJ, 1992, P NATL ACAD SCI USA, V89, P6338, DOI 10.1073/pnas.89.14.6338; FRANSSON LA, 1989, HEPARIN, P115; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gallagher JT, 1998, TRENDS GLYCOSCI GLYC, V10, P137, DOI 10.4052/tigg.10.137; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hacker U, 1997, DEVELOPMENT, V124, P3565; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINKER A, 1979, BIOCHEM J, V183, P711, DOI 10.1042/bj1830711; Litjens T, 1997, BIOCHEM J, V327, P89, DOI 10.1042/bj3270089; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RADOFF S, 1984, J BIOL CHEM, V259, P166; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; Rudd PM, 1997, NATURE, V388, P205, DOI 10.1038/40677; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1997, BIOMETHODS, V9, P261; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621	47	114	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18455	18462		10.1074/jbc.274.26.18455	http://dx.doi.org/10.1074/jbc.274.26.18455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373453	hybrid			2022-12-25	WOS:000081056700045
J	Stolz, J; Hoja, U; Meier, S; Sauer, N; Schweizer, E				Stolz, J; Hoja, U; Meier, S; Sauer, N; Schweizer, E			Identification of the plasma membrane H+-biotin symporter of Saccharomyces cerevisiae by rescue of a fatty acid-auxotrophic mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-CARBOXYLASE; ESCHERICHIA-COLI; ACETYL-COENZYME; YEAST-CELLS; TRANSCRIPTION; PANTOTHENATE; EXPRESSION; STRAINS; TRANSFORMATION; BIOSYNTHESIS	Bakers' yeast is auxotrophic for biotin (vitamin H) and depends on the efficient uptake of this compound from the environment. A mutant strain with strongly reduced biotin uptake and with reduced levels of protein biotinylation was identified. The strain was auxotrophic for long-chain fatty acids, and this auxotrophy could be suppressed with high levels of biotin in the medium. After transformation of this mutant with a yeast genomic library, the unassigned open reading frame YGR065C was identified to complement this mutation. This gene codes for a protein with 593 amino acids and 12 putative transmembrane helices, Northern blot analysis revealed that, in wild-type cells, the corresponding mRNA levels were increased at low biotin concentrations. Likewise, cellular biotin uptake was increased with decreasing biotin availability. Expression of YGR065C under the control of the constitutive ADH1 promoter resulted in very high biotin transport rates across the plasma membrane that were no longer regulated by the biotin concentration in the growth medium. We conclude that YGR065C encodes the first biotin transporter identified for a non-mammalian organism and designate this gene VHT1 for vitamin H transporter 1.	Univ Erlangen Nurnberg, Lehrstuhl Bot 1, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Lehrstuhl Biochem, D-91058 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Bot 1, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; Bayer E A, 1979, Methods Enzymol, V62, P371; BECKER JM, 1971, P NATL ACAD SCI USA, V68, P2604, DOI 10.1073/pnas.68.10.2604; BONJOUR JP, 1985, ANN NY ACAD SCI, V447, P97, DOI 10.1111/j.1749-6632.1985.tb18428.x; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V311, P62, DOI 10.1006/abbi.1994.1209; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; DAKSHINAMURTI K, 1985, ANN NY ACAD SCI, V447, P38, DOI 10.1111/j.1749-6632.1985.tb18424.x; Dyer DL, 1997, METHOD ENZYMOL, V279, P393; EISENBERG M, 1987, CELLULAR MOL BIOL, V1, P544; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRASSL SM, 1992, J BIOL CHEM, V267, P22902; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; Hablacher M, 1993, J BIOL CHEM, V268, P10946; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HERTZ R, 1943, P SOC EXP BIOL MED, V52, P14; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Leonian LH, 1942, AM J BOT, V29, P459, DOI 10.2307/2437311; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Menendez J, 1998, YEAST, V14, P647; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MORTIMER RK, 1986, GENETICS, V113, P35; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; PIFFETEAU A, 1985, BIOCHIM BIOPHYS ACTA, V816, P77, DOI 10.1016/0005-2736(85)90395-5; PRAKASH O, 1974, J BACTERIOL, V120, P785, DOI 10.1128/JB.120.2.785-791.1974; Prasad PD, 1997, PLACENTA, V18, P527, DOI 10.1016/0143-4004(77)90006-6; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SWANSON MS, 1992, GENETICS, V132, P325; TUROSCY V, 1987, J BACTERIOL, V169, P2598, DOI 10.1128/jb.169.6.2598-2600.1987; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1998, METHOD MICROBIOL, V26, P67; [No title captured]	48	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18741	18746		10.1074/jbc.274.26.18741	http://dx.doi.org/10.1074/jbc.274.26.18741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373489	hybrid			2022-12-25	WOS:000081056700081
J	Gohla, A; Offermanns, S; Wilkie, TM; Schultz, G				Gohla, A; Offermanns, S; Wilkie, TM; Schultz, G			Differential involvement of G alpha(12) and G alpha(13) in receptor-mediated stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; G-PROTEINS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; P115 RHOGEF; ACTIVATION; EXCHANGE; EXPRESSION; DIVERSITY	The ubiquitously expressed heterotrimeric guanine nucleotide-binding proteins (G-proteins) G(12) and G(13) have been shown to activate the small GTPase Rho. Rho stimulation leads to a rapid remodeling of the actin cytoskeleton and subsequent stress fiber formation. We investigated the involvement of G(12) or G(13) in stress fiber formation induced through a variety of G(q)/G(11)-coupled receptors. Using fibroblast cell lines derived from wildtype and G alpha(q)/G alpha(11)-deficient mice, we show that agonist-dependent activation of the endogenous receptors for thrombin or lysophosphatidic acid and of the heterologously expressed bradykinin B-2, vasopressin V-1A, endothelin ETA, and serotonin 5-HT2C receptors induced stress fiber formation in either the presence or absence of G alpha(q)/G alpha(11). Stress fiber assembly induced through the muscarinic M-1 and the metabotropic glutamate subtype 1 alpha receptors was dependent on G(q)/G(11) proteins. The activation of the G(q)/G(11)-coupled endothelin ETB and angiotensin AT,A receptors failed to induce stress fiber formation. Lysophosphatidic acid, B-2, and 5-HT2C receptor-mediated stress fiber formation was dependent on G alpha(13) and involved epidermal growth factor (EGF) receptors, whereas thrombin, ETA, and V-1A receptors induced stress fiber accumulation via G alpha(12) in an EGF receptor-independent manner. Our data demonstrate that many G(q)/G(11)-coupled receptors induce stress fiber assembly in the absence of G alpha(q) and G alpha(11) and that this involves either a G alpha(12) or a G alpha(13)/EGF receptor-mediated pathway.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Free University of Berlin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805; Gohla, Antje/0000-0002-7442-1487				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE E, 1992, J BIOL CHEM, V267, P1212; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAH V, 1996, J BIOL CHEM, V49, P31185; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WONG YH, 1994, METHOD ENZYMOL, V238, P81; YANG JT, 1993, DEVELOPMENT, V119, P1093	38	191	196	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17901	17907		10.1074/jbc.274.25.17901	http://dx.doi.org/10.1074/jbc.274.25.17901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364236	hybrid			2022-12-25	WOS:000080974300072
J	Grenert, JP; Johnson, BD; Toft, DO				Grenert, JP; Johnson, BD; Toft, DO			The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; N-TERMINAL FRAGMENT; RABBIT RETICULOCYTE LYSATE; STEADY-STATE ANALYSIS; DNA TOPOISOMERASE-II; GYRASE-B-PROTEIN; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; IN-VIVO; MOLECULAR CHAPERONE	The chaperone hsp90 is capable of binding and hydrolyzing ATP. Using information on a related ATPase, DNA gyrase B, we selected three conserved residues in hsp90's ATP-binding domain for mutation. Two off these mutations eliminate nucleotide binding, while the third retains nucleotide binding but is apparently deficient in ATP hydrolysis. We first analyzed how these mutations affect hsp90's binding to the co-chaperones p23 and Hop, and to the hydrophobic resin, phenyl-Sepharose. These experiments showed that ATP's effects, specifically, increased affinity for p23 and decreased affinity for Hop and phenyl-Sepharose, are brought on by ATP binding alone. We also tested the ability of hsp90 mutants to assist hsp70, hsp40, and Hop in the refolding of denatured firefly luciferase. While hsp90 is capable of participating in this process in a nucleotide-independent manner, the ability to hydrolyze ATP markedly potentiates hsp90's effect. Finally, we assembled progesterone receptor heterocomplexes with hsp70, hsp40, Hop, pas, and wild type or mutant hsp90. While neither ATP binding nor hydrolysis was necessary to bind hsp90 to the receptor, mature complexes containing p23 and capable of hormone binding were only obtained with wild type hsp90.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55906 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK46249] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Bartha BB, 1998, BIOPHYS CHEM, V72, P313, DOI 10.1016/S0301-4622(98)00114-8; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Csermely P, 1997, LIFE SCI, V61, P411, DOI 10.1016/S0024-3205(97)00398-6; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DITMAR KD, 1997, J BIOL CHEM, V272, P13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gerloff DL, 1997, PROTEINS, V27, P450, DOI 10.1002/(SICI)1097-0134(199703)27:3<450::AID-PROT12>3.3.CO;2-9; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; GRODY WW, 1980, J STEROID BIOCHEM, V12, P115, DOI 10.1016/0022-4731(80)90260-5; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; TOFT D, 1979, J STEROID BIOCHEM, V11, P413, DOI 10.1016/0022-4731(79)90060-8; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	66	191	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17525	17533		10.1074/jbc.274.25.17525	http://dx.doi.org/10.1074/jbc.274.25.17525			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364185	hybrid			2022-12-25	WOS:000080974300021
J	Juang, YT; Au, WC; Lowther, W; Hiscott, J; Pitha, PM				Juang, YT; Au, WC; Lowther, W; Hiscott, J; Pitha, PM			Lipopolysaccharide inhibits virus-mediated induction of interferon genes by disruption of nuclear transport of interferon regulatory factors 3 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED RESPONSE ELEMENT; ALPHA PROMOTER REGION; PROTEIN-KINASE-C; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; HUMAN-MONOCYTES; IFN-GAMMA; PERITONEAL-MACROPHAGES; ENDOGENOUS INTERFERON	We have studied the effects of lipopolysaccharide (LPS) on the Newcastle disease virus (NDV)-mediated induction of cytokine genes expression. Raw cells treated with LPS before or after virus infection showed down-regulation in the expression of interferon A and, to a lesser extent, interferon B genes. In contrast, induction of the interleukin (IL)-6 gene was enhanced. The effects of LPS were not a result of the suppression of virus replication, because the transcription of viral nucleocapsid gene was not affected. Consistent with these findings, LPS also suppressed the NDV-mediated induction of chloramphenicol acetyltransferase reporter gene driven by murine interferon A4 promoter in a transient transfection assay. Furthermore, LPS-inhibited virus-mediated phosphorylation of interferon regulatory factor (IRF)-3 and the consequent translocation of IRF-3 from cytoplasm to nucleus. The LPS-mediated inhibition of IFNA gene expression was much weaker in infected Raw cells that constitutively overexpressed IRF-5. The nuclear translocation of IRF-7 in infected cells was also inhibited by LPS. These data suggest that LPS down-regulates the virus-mediated induction of IFNA genes by post-translationally targeting the IRF-3 and IRF-7 proteins.	Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; McGill Univ, Dept Microbiol & Med, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Lady Davis Institute; McGill University	Pitha, PM (corresponding author), Johns Hopkins Univ, Ctr Oncol, 418 N Bond St, Baltimore, MD 21231 USA.				NIAID NIH HHS [AI19737] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An MR, 1996, MOL CELL BIOL, V16, P2295; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BAKOUCHE O, 1992, J IMMUNOL, V148, P84; BARBER SA, 1995, J IMMUNOL, V155, P1404; BELARDELLI F, 1987, J GEN VIROL, V68, P2203, DOI 10.1099/0022-1317-68-8-2203; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; CAMUSSI G, 1995, J IMMUNOL, V155, P316; CAVAILLON JM, 1985, IMMUNOL LETT, V10, P35, DOI 10.1016/0165-2478(85)90047-1; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEIST W, 1989, IMMUNOBIOLOGY, V179, P293, DOI 10.1016/S0171-2985(89)80036-1; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GESSANI S, 1987, J IMMUNOL, V139, P1991; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; JAKWAY JP, 1986, SCIENCE, V234, P743, DOI 10.1126/science.3095921; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KIELIAN TL, 1995, IMMUNOPHARMACOLOGY, V29, P187, DOI 10.1016/0162-3109(95)00003-C; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LIU MK, 1994, J IMMUNOL, V153, P2642; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; Nickolaus P, 1998, J INTERF CYTOK RES, V18, P187, DOI 10.1089/jir.1998.18.187; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OHMORI Y, 1995, J IMMUNOL, V155, P3593; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PITHA PM, 1988, J IMMUNOL, V141, P3611; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; REIMANN T, 1994, J IMMUNOL, V153, P5740; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TEBO JM, 1992, J IMMUNOL, V149, P2352; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; VEALS SA, 1991, BRIT J HAEMATOL, V79, P9, DOI 10.1111/j.1365-2141.1991.tb08110.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	55	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18060	18066		10.1074/jbc.274.25.18060	http://dx.doi.org/10.1074/jbc.274.25.18060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364258	hybrid			2022-12-25	WOS:000080974300094
J	Morinaga, N; Adamik, R; Moss, J; Vaughan, M				Morinaga, N; Adamik, R; Moss, J; Vaughan, M			Brefeldin A inhibited activity of the Sec7 domain of p200, a mammalian guanine nucleotide-exchange protein for ADP-ribosylation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GOLGI-APPARATUS; PHOSPHOLIPASE-D; HOMOLOGY DOMAINS; CHOLERA-TOXIN; ARF; COMPARTMENTS; CYTOHESIN-1; PLECKSTRIN; ACTIVATION; TRANSPORT	A brefeldin A (BFA)-inhibited guanine nucleotide-exchange protein (GEP) for ADP-ribosylation factors (ARF) was purified earlier from bovine brain cytosol. Cloning and expression of the cDNA confirmed that the recombinant protein (p200) is a PEA-sensitive ARF GEP. p200 contains a domain that is 50% identical in amino acid sequence to a region in yeast Sec7, termed the Sec7 domain. Sec7 domains have been identified also in other proteins with ARF GEP activity, some of which are not inhibited by BFA. To identify structural elements that influence GEP activity and its BFA sensitivity, several truncated mutants of p200 were made. Deletion of sequence C-terminal to the Sec7 domain did not affect GEP activity. A protein lacking 594 amino acids at the N terminus, as well as sequence following the Sec7 domain, also had high activity, The mutant lacking 630 N-terminal amino acids was, however, only 1% as active, as was the Sec7 domain itself (mutant lacking 697 N-terminal residues). It appears that the Sec7 domain of p200 contains the catalytic site but additional sequence (perhaps especially that between positions 595 and 630) modifies activity dramatically. Myristoylated recombinant ARFs were better than non-myristoylated as substrates; ARFs 1 and 3 were better than ARF5, and no activity was detected with ARF6. Physical interaction of the Sec7 domain with an ARF1 mutant was demonstrated, but it was much weaker than that of the cytohesin-1 Sec7 domain with the same ARF protein. Effects of BFA on p200 and all mutants with high activity were similar with similar to 50% inhibition at less than or equal to 50 mu M. The inactive BFA analogue B36 did not inhibit the Sec7 domain or p200. Thus, the Sec7 domain of p200, like that of Sec7 itself (Sata, M., Donaldson, J. G., Moss, J., and Vaughan, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4204-4208), plays a role in BFA inhibition as well as in GEP activity, although the latter is markedly modified by other structural elements.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Morinaga, N (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000627, Z01HL000638, ZIAHL000627, Z01HL000656] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305	30	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17417	17423		10.1074/jbc.274.25.17417	http://dx.doi.org/10.1074/jbc.274.25.17417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364170	hybrid			2022-12-25	WOS:000080974300006
J	Subramaniam, N; Treuter, E; Okret, S				Subramaniam, N; Treuter, E; Okret, S			Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; BOVINE PROLACTIN GENE; CREB-BINDING-PROTEIN; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSCRIPTION; MEDIATED REPRESSION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CROSS-TALK	Recent development in the field of gene regulation by nuclear receptors (NRs) have identified a role for cofactors in transcriptional control. While some of the NR-associated proteins serve as coactivators, the effect of the receptor interacting protein 140 (RIP140) on NR transcriptional responses is complex. In this report we have studied the effect of RIP140 on gene regulation by the glucocorticoid receptor (GR). We demonstrate that RIP140 antagonized all GR-mediated responses tested, which included activation through classical GRE, the synergistic effects of glucocorticoids on AP-1 and Pbx1/HOXB1 responsive elements, as well as gene repression through a negative GRE and cross-talk with NF-kappa B (RelA). This involved the ligand-binding domain of the GR and did not occur when the GR was bound to the antagonist RU486, The strong repressive effect of RIP140 was restricted to glucocorticoid-mediated responses in as much as it slightly increased signaling through the RelA and the Pit-1/Pbx proteins and only slightly repressed signaling through the Pbx1/HOXB1 and AP-1 proteins, excluding general squelching as a mechanism. Instead, this suggests that RIP140 acts as a direct inhibitor of GR function. In line with a direct effect of RIP140 on the GR, we demonstrate a GR-RIP140 interaction in vitro by a glutathione S-transferase-pull down assay. Furthermore, the repressive effect of RIP140 could partially be overcome by overexpression of the coactivator TIF2, which involved a competition between TIF2 and RIP140 for binding to the GR.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Ctr Biotechnol, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, F60 Novum, SE-14186 Huddinge, Sweden.	Sam.Okret@mednut.ki.se		Treuter, Eckardt/0000-0002-4147-8989				Akerblom I.W., 1991, NUCLEAR HORMONE RECE, P175; Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Delaunay F, 1996, EUR J BIOCHEM, V242, P839, DOI 10.1111/j.1432-1033.1996.0839r.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DROUIN J, 1998, NUCL HORMONE RECEPTO, P118; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; LIU W, 1995, MOL CELL BIOL, V15, P1005; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	54	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18121	18127		10.1074/jbc.274.25.18121	http://dx.doi.org/10.1074/jbc.274.25.18121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364267	hybrid			2022-12-25	WOS:000080974300103
J	Van Ryk, DI; Venkatesan, S				Van Ryk, DI; Venkatesan, S			Real-time kinetics of HIV-1 Rev-Rev response element interactions - Definition of minimal, binding sites on RNA and protein and stoichiometric analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE-PLASMON RESONANCE; STRUCTURAL GENE-EXPRESSION; NUCLEAR EXPORT SIGNAL; VIRAL MESSENGER-RNA; TYPE-1 REV; TRANS-ACTIVATOR; TARGET SEQUENCE; REGULATORY PROTEINS; FUNCTIONAL-ANALYSIS	The kinetics of interaction between the human immunodeficiency virus-1 Rev protein and its RNA target, Rev response element (RRE) RNA was determined in vitro using a biosensor technique. Our results showed that the primary Rev binding site is a core stem-loop RNA molecule of 30 nucleotides that bound Rev at a 1:1 ratio, whereas the 244-nucleotide full-length RRE bound four Rev monomers. At high Rev concentrations, additional binding of Rev to RRE was observed with ratios of more than 10:1. Because RRE mutants that lacked the core binding site and were inactive in vivo bound Rev nonspecifically at these concentrations, the real stoichiometric ratio of Rev-RRE is probably closer to 4:1. Binding affinity of Rev for RRE was approximately 10(-10) M, whereas the affinity for the core RNA was about 10(-11) M, the difference being due to the contribution of low affinity binding sites on the RRE. Mathematical analysis suggested cooperativity of Rev binding, probably mediated by the Rev oligomerization domains. C-terminal deletions of Rev had no effect on RRE binding, but truncation of the N terminus by as few as 11 residues significantly reduced binding specificity. This method was also useful to rapidly evaluate the potential of aminoglycoside antibiotics, to inhibit the Rev-RRE interaction.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Venkatesan, S (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 10,Rm 6A05,9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000528, Z01AI000528] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1989, P NATL ACAD SCI USA, V86, P6111, DOI 10.1073/pnas.86.16.6111; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BOHNLEIN E, 1991, J VIROL, V65, P7051; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COCHRANE AW, 1989, J VIROL, V63, P4438, DOI 10.1128/JVI.63.10.4438-4440.1989; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; DALY TJ, 1995, J MOL BIOL, V253, P243, DOI 10.1006/jmbi.1995.0549; DAYTON ET, 1992, J VIROL, V66, P1139, DOI 10.1128/JVI.66.2.1139-1151.1992; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1990, J VIROL, V64, P3734, DOI 10.1128/JVI.64.8.3734-3741.1990; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOLLAND SM, 1990, J VIROL, V64, P5966, DOI 10.1128/JVI.64.12.5966-5975.1990; HOLLAND SM, 1992, J VIROL, V66, P3699, DOI 10.1128/JVI.66.6.3699-3706.1992; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; *PHARM BIOS AB, 1994, BIAT HDB; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WINGFIELD PT, 1991, BIOCHEMISTRY-US, V30, P7527, DOI 10.1021/bi00244a023; WOOD SJ, 1993, MICROCHEM J, V47, P330, DOI 10.1006/mchj.1993.1051; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	82	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17452	17463		10.1074/jbc.274.25.17452	http://dx.doi.org/10.1074/jbc.274.25.17452			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364175	hybrid			2022-12-25	WOS:000080974300011
J	Espanel, X; Sudol, M				Espanel, X; Sudol, M			A single point mutation in a Group IWW domain shifts its specificity to that of Group IIWW domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; EPITHELIAL SODIUM-CHANNEL; WW DOMAIN; MISSENSE MUTATION; LIDDLES-SYNDROME; SOLID SUPPORTS; BETA-SUBUNIT; SH3 DOMAINS; PY MOTIF; IDENTIFICATION	WW domains can be divided into three groups based on their binding specificity. By random mutagenesis, we switched the specificity of the Yes-associated protein (YAP) WW1 domain, a Group I WW domain, to that of the FE65 WW domain, which belongs to Group II. We showed that a single mutation, leucine 190 (beta B5) to tryptophan, is required to switch from Group I to Group II. Although this single substitution in YAP WW1 domain is sufficient to precipitate the two protein isoforms of Mena, an in vivo ligand of FE65, we showed that an additional substitution, histidine 192 (beta B7) to glycine, significantly increased the ability of YAP to mimic FE65. This double mutant (L190W/H192G) precipitates eight of the nine protein bands that FE65 pulls down from rat brain protein lysates. Based on both our data and a sequence comparison between Group I and Group II WW domains, we propose that a block of three consecutive aromatic amino acids within the second beta-sheet of the domain is required, but not always sufficient, for a WW domain to belong to Group II. These data deepen our understanding of WW domain binding specificity and provide a basis for the rational design of modified WW domains with potential therapeutic applications.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.				NCI NIH HHS [CA45757, CA01605] Funding Source: Medline; NIDDK NIH HHS [DK50795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050795] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GERTLER GB, 1996, CELL, V87, P1; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HASSON JH, 1995, P NATL ACAD SCI USA, V92, P11495; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; WENG ZG, 1995, MOL CELL BIOL, V15, P5627	32	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17284	17289		10.1074/jbc.274.24.17284	http://dx.doi.org/10.1074/jbc.274.24.17284			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358088	hybrid			2022-12-25	WOS:000080780400087
J	Jayaraman, G; Srinivas, R; Duggan, C; Ferreira, E; Swaminathan, S; Somasundaram, K; Williams, J; Hauser, C; Kurkinen, M; Dhar, R; Weitzman, S; Buttice, G; Thimmapaya, B				Jayaraman, G; Srinivas, R; Duggan, C; Ferreira, E; Swaminathan, S; Somasundaram, K; Williams, J; Hauser, C; Kurkinen, M; Dhar, R; Weitzman, S; Buttice, G; Thimmapaya, B			p300/cAMP-responsive element-binding protein interactions with Ets-1 and Ets-2 in the transcriptional activation of the human stromelysin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; ONCOGENIC ACTIVITY; ADENOVIRUS E1A; FAMILY MEMBER; C-JUN; P300; CBP; CREB; COACTIVATOR	In this paper we show that transcription factors Ets-1 and Ets-2 recruit transcription adapter proteins p300 and CBP (cAMP-responsive element-binding protein) during the transcriptional activation of the human stromelysin promoter, which contains palindromic Ets-binding sites. Ets-2 and p300/CBP exist as a complex in vivo. Two regions of p300/CBP between amino acids (a.a.) 328 and 596 and a.a. 1678 and 2370 independently can interact with Ets-1 and Ets-2 in vitro and in vivo. Both these regions of p300/CBP bind to the transactivation domain of Ets-2, whereas the C-terminal region binds only to the DNA binding domain of Ets-2. The N- and the C-terminal regions of CBP (a.a. 1-1097 and 1678-2442, respectively) which lack histone acetylation activity independently are capable of coactivating Ets-2. Other Ets family transcription factors failed to cooperate with p300/CBP in stimulating the stromelysin promoter. The LXXLL sequence, reported to be important in receptor-coactivator interactions, does not appear to play a role in the interaction of Ets-2 with p300/CBP. Previous studies have shown that the stimulation of transcriptional activation activity of Ets-2 requires phosphorylation of threonine 72 by the Ras/mitogen-activated protein kinase signaling pathway. We show that mutation of this site does not affect its capacity to bind to and to cooperate with p300/CBP.	Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; CNRS, Inst Biol Lille, F-59021 Lille, France; Burnham Inst, La Jolla, CA 92037 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Centre National de la Recherche Scientifique (CNRS); Sanford Burnham Prebys Medical Discovery Institute; Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thimmapaya, B (corresponding author), Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol Oncol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Duggan, Catherine/AAE-9777-2020; Duggan, Catherine/F-9414-2015	Duggan, Catherine/0000-0001-7369-4021; Buttice', Giovanna/0000-0001-6550-5585; Swaminathan, Sathyamangalam/0000-0002-4388-2248	NATIONAL CANCER INSTITUTE [P20CA065764, R01CA074403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011536] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 1P20CA65764, CA74403] Funding Source: Medline; NIA NIH HHS [AG11536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BIRKENDELHANSON H, 1996, CRIT REV ORAL BIOL M, V4, P197; BIRNKERHOFF CE, 1991, ARTHRITIS RHEUM, V34, P1073; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURELY SK, 1996, ANNU REV BIOCHEM, V65, P769; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATRISIAN LM, 1992, MOL REPROD DEV, V32, P111, DOI 10.1002/mrd.1080320206; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NERLOV C, 1991, ONCOGENE, V6, P1583; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	76	117	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17342	17352		10.1074/jbc.274.24.17342	http://dx.doi.org/10.1074/jbc.274.24.17342			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358095	hybrid			2022-12-25	WOS:000080780400094
J	Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F				Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F			Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex	ONCOGENE			English	Article						human papillomavirus; cervical cancer; AP-1; negative regulation; cytokines	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-NECROSIS-FACTOR; UPSTREAM REGULATORY REGION; CERVICAL-CARCINOMA CELLS; C-FOS; HUMAN KERATINOCYTES; GENE-EXPRESSION; FORESKIN KERATINOCYTES; SELECTIVE SUPPRESSION; TRANSFORMING ACTIVITY	AP-1 represents a transcription factor, which plays a pivotal role in initiating and maintaining the expression of human papillomavirus (HPV) oncoproteins E6 and E7 during HPV-linked carcinogenesis of the uterine cervix. AP-1 stands as a synonym for different proteins such as c-Jun, JunB, JunD, c-Fos, FosB as well as the Fos-related antigens Fra-1 and Fra-2, which can either homo- or heterodimerize to build up a functional transcription complex, AP-1 is mainly considered as a positive regulator, which binds to cognate DNA sequences within the viral upstream regulatory region, By using nontumorigenic HeLa-fibroblast hybrids ('444'), their tumorigenic segregants ('CGL3') as well as HPV 18 positive HeLa cells as a experimental model system, evidence is provided that AP-1 composition differs considerably between these cell lines, In nuclear extracts obtained from non-tumorigenic cells, Jun-family members (in the order c-Jun > JunD > JunB) were mainly heterodimerized with Fra-1, a protein, known to be involved in the abrogation of AP-1 activity under certain experimental conditions, In contrast, Fra-1 concentration is low in extracts from tumorigenic cells, Conversely, c-Fos, the canonical dimerization partner of Jun proteins is expressed in substantial quantity in HeLa- and 'CGL3' cells, but it is completely absent in AP-1 complexes from non-tumorigenic '444' cells, Ectopical expression of c-fos under a heterologous promoter in '444'-cells induces tumorigenicity and a change of the Jun/Fra-1 ratio towards a constellation initially detected in 'CGL3'-and HeLa cells. Furthermore, conversion to tumorigenicity is accompanied with a resistance against TNF-alpha, a cytokine, capable to selectively suppress HPV 18 transcription in formerly non-malignant cells, These data propose a novel role for AP-1 as an essential component of an inter- and intracellular surveillance mechanism negatively controlling HPV transcription in non-tumorigenic cells.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Maulana Azad Med Coll, Inst Cytol & Prevent Oncol, Div Mol Oncol, New Delhi, India	Helmholtz Association; German Cancer Research Center (DKFZ); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cancer Prevention & Research (NICPR); Maulana Azad Medical College	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ATTIA MAM, 1966, CANCER RES, V26, P1787; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CRIPE T P, 1990, New Biologist, V2, P450; CRUM CP, 1989, AM J PATHOL, V134, P1183; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINZER P, 1999, UNPUB; FUJII M, 1991, ONCOGENE, V6, P1023; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1989, J VIROL, V63, P555, DOI 10.1128/JVI.63.2.555-563.1989; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KHAN MA, 1993, CANCER RES, V53, P905; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1994, J VIROL, V68, P2142; Rosl F, 1997, J VIROL, V71, P362; ROSL F, 1999, IN PRESS CHEMOKINES; ROSL F, 1997, MOL B INT U, P25; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SMITS PHM, 1992, EMBO J, V11, P4601, DOI 10.1002/j.1460-2075.1992.tb05562.x; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; ZURHAUSEN H, 1986, LANCET, V11, P489	81	82	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3187	3198		10.1038/sj.onc.1202765	http://dx.doi.org/10.1038/sj.onc.1202765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359524				2022-12-25	WOS:000080523800001
J	Diaz-Meco, MT; Lallena, MJ; Monjas, A; Frutos, S; Moscat, J				Diaz-Meco, MT; Lallena, MJ; Monjas, A; Frutos, S; Moscat, J			Inactivation of the inhibitory kappa B protein kinase nuclear factor kappa B pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYZING PHOSPHOLIPASE-C; ZETA-SUBSPECIES BLOCKS; XENOPUS-LAEVIS OOCYTES; SIGNAL-TRANSDUCTION; TNF-ALPHA; CELL-DEATH; PKC-ZETA; ACTIVATION; RAS; SUPPRESSION	Par-4 is a novel protein identified in cells undergoing apoptosis. The ability of Par-4 to promote apoptotic cell death is dependent on the binding and inactivation of the atypical protein kinases C (PKCs). This subfamily of kinases has been reported to control nuclear factor kappa B (NF-kappa B) through the regulation of the I kappa B kinase activity. NF-kappa B activation by tumor necrosis factor alpha (TNF alpha) provides a survival signal that impairs the TNF alpha-induced apoptotic response. We show here that expression of Par-4 inhibits the TNF alpha-induced nuclear translocation of p65 as well as the kappa B-dependent promoter activity. Interestingly, Par-4 expression blocks inhibitory kappa B protein (I kappa B) kinase activity, which leads to the inhibition of I kappa B phosphorylation and degradation, in a manner that is dependent on its ability to inhibit lambda/iota PKC. Of potential functional relevance, the expression of Par-4 allows TNF alpha to induce apoptosis in NIH-3T3 cells. In addition, the down-regulation of Par-4 levels by oncogenic Ras sensitizes cells to TNF alpha-induced NF-kappa B activation.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Lab Glaxo Wellcome, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); GlaxoSmithKline	Moscat, J (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Lab Glaxo Wellcome, Canto Blanco, Madrid 28049, Spain.		Moscat, Jorge/A-7011-2009	de Frutos, Sergio/0000-0002-1225-5911; Diaz-Meco, Maria/0000-0003-0147-0998				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Parrizas M, 1997, J BIOL CHEM, V272, P154; REGINER CH, 1997, CELL, V90, P373; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	51	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19606	19612		10.1074/jbc.274.28.19606	http://dx.doi.org/10.1074/jbc.274.28.19606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391896	hybrid			2022-12-25	WOS:000081377300016
J	Nasuhara, Y; Adcock, IM; Catley, M; Barnes, PJ; Newton, R				Nasuhara, Y; Adcock, IM; Catley, M; Barnes, PJ; Newton, R			Differential I kappa B kinase activation and I kappa B alpha degradation by Interleukin-1 beta and tumor necrosis factor-alpha in human U937 monocytic cells - Evidence for additional regulatory steps in kappa B-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; TNF-ALPHA; IKK-ALPHA; PHOSPHORYLATION; PROTEIN; FAMILY; BETA; INHIBITOR; COMPLEX; PROTEOLYSIS	The I kappa B kinases (IKKs) lie downstream of the NF-kappa B-inducing kinase (MK) and activate NF-kappa B by phosphorylation of I kappa B alpha, This leads to I kappa B alpha degradation and release of NF-kappa B, In U937 monocytic cells, interleukin (IL)-1 beta (1 ng/ml) and tumor necrosis factor (TNF)-alpha; 10 ng/ml) induced kappa B-dependent transcription equally. However, IKK activity was strongly induced by TNF-alpha but not by IL-1 beta. This was consistent with I kappa B alpha phosphorylation and degradation, yet TNF-alpha-induced NF-KB DNA binding was only 30-40% greater than for IL-1 beta. This was not explained by degradation of I kappa B beta, I kappa B epsilon, Or p105 nor nuclear translocation of NF-kappa B.I kappa B alpha complexes or degradation-independent release of NF-KB. Dominant negative (NIK) repressed TNF-alpha and IL-1 beta-induced kappa B-ependent transcription by similar to 60% and similar to 35%, respectively. These data reveal an imprecise relationship between IKK activation, I kappa B alpha degradation, and NF-kappa B DNA binding, suggesting the existence of additional mechanisms that regulate NF-kappa B activation. Finally, the lack of correlation between DNA binding and transcriptional activation plus the fact that PP1 and genistein both inhibited KB-dependent transcription without affecting DNA binding activity demonstrate the existence of regulatory steps downstream of NF-kappa B DNA binding. Therapeutically these data are important as inhibition of the NIK-IKK-I kappa B alpha cascade may not produce equivalent reductions in NF-kappa B-dependent gene expression.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Newton, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.		Nasuhara, Yasuyuki/G-1647-2012; Newton, Robert/C-6814-2012; Adcock, Ian/L-3217-2019	Newton, Robert/0000-0002-4919-8498; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; ALBERTELLA MR, 1994, HUM MOL GENET, V3, P793, DOI 10.1093/hmg/3.5.793; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fiedler MA, 1998, AM J RESP CELL MOL, V19, P259, DOI 10.1165/ajrcmb.19.2.3149; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MECO MTD, 1994, EMBO J, V13, P2842; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwarzer N, 1998, J IMMUNOL, V161, P3010; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	54	144	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19965	19972		10.1074/jbc.274.28.19965	http://dx.doi.org/10.1074/jbc.274.28.19965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391945	hybrid			2022-12-25	WOS:000081377300065
J	Verdoucq, L; Vignols, F; Jacquot, JP; Chartier, Y; Meyer, Y				Verdoucq, L; Vignols, F; Jacquot, JP; Chartier, Y; Meyer, Y			In vivo characterization of a thioredoxin h target protein defines a new peroxiredoxin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ESCHERICHIA-COLI; MIXED DISULFIDE; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; TRANSCRIPTION FACTOR; REDUCTASE; ACTIVATION; EXPRESSION	Disruption of the two thioredoxin genes in yeast dramatically affects cell viability and growth. Expression of Arabidopsis thioredoxin AtTRX3 in the Saccharomyces thioredoxin Delta strain EMY63 restores a wild-type cell cycle, the ability to grow on methionine sulfoxide, and H2O2 tolerance. In order to isolate thioredoxin targets related to these phenotypes, we prepared a C35S (Escherichia coli numbering) thioredoxin mutant to stabilize the intermediate disulfide bridged complex and we added a polyhistidine N-terminal extension in order to purify the complex rapidly. Expression of this mutant thioredoxin in the wild-type yeast induces a reduced tolerance to H2O2, but only limited change in the cell cycle and no change in methionine sulfoxide utilization. Expression in the Delta thioredoxin strain EMY63 allowed us to isolate a complex of the thioredoxin with YLR109, an abundant yeast protein related to PMP20, a peroxisomal protein of Candida, No function has so far been attributed to this protein or to the other numerous homologues described in plants, animals, fungi, and prokaryotes, On the basis of the complementation and of low similarity with peroxiredoxins, we produced YLR109 and one of its Arabidopsis homologues in E, coli to test their peroxiredoxins activity, We demonstrate that both recombinant proteins present a thioredoxin-dependent peroxidase activity in vitro. The possible functions of this new peroxiredoxin family are discussed.	Univ Perpignan, UMR 5545, Lab Physiol & Biol Mol Plantes, F-66025 Perpignan, France; Univ Nancy 1, Lab Biol Forestiere, INRA, Associe, F-54506 Vandoeuvre Les Nancy, France	Universite Perpignan Via Domitia; INRAE; Universite de Lorraine	Meyer, Y (corresponding author), Univ Perpignan, UMR 5545, Lab Physiol & Biol Mol Plantes, Ave Villeneuve, F-66025 Perpignan, France.	ymeyer@univ-perp.fr	VIGNOLS, Florence/ABD-3603-2020; Vignols, Florence/X-6276-2019; Jacquot, Jean-Pierre/A-1571-2012	VIGNOLS, Florence/0000-0002-2031-0407; Jacquot, Jean-Pierre/0000-0003-4975-8587				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; Berardi MJ, 1998, BIOCHEMISTRY-US, V37, P5849, DOI 10.1021/bi972924d; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; Buchanan Bob B., 1994, Seminars in Cell Biology, V5, P285, DOI 10.1006/scel.1994.1035; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P3633; Chamnongpol S, 1998, P NATL ACAD SCI USA, V95, P5818, DOI 10.1073/pnas.95.10.5818; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Klimowski L, 1997, MOL BIOCHEM PARASIT, V90, P297, DOI 10.1016/S0166-6851(97)00167-9; Laughner BJ, 1998, PLANT PHYSIOL, V118, P987, DOI 10.1104/pp.118.3.987; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; LI XM, 1995, PLANT J, V8, P133, DOI 10.1046/j.1365-313X.1995.08010133.x; Marre MT, 1998, PLANT PHYSIOL, V118, P1379, DOI 10.1104/pp.118.4.1379; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rea G, 1998, FEBS LETT, V437, P177, DOI 10.1016/S0014-5793(98)01219-8; Rey P, 1998, PLANT J, V13, P97, DOI 10.1046/j.1365-313X.1998.00015.x; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; SHERMAN F, 1991, P3; Stacy RAP, 1996, PLANT MOL BIOL, V31, P1205, DOI 10.1007/BF00040837; STEIN M, 1995, PLANT MOL BIOL, V28, P487, DOI 10.1007/BF00020396; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang PF, 1996, BIOCHEMISTRY-US, V35, P4812, DOI 10.1021/bi9526793; Willekens H, 1997, EMBO J, V16, P4806, DOI 10.1093/emboj/16.16.4806; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	58	195	202	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19714	19722		10.1074/jbc.274.28.19714	http://dx.doi.org/10.1074/jbc.274.28.19714			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391912	hybrid			2022-12-25	WOS:000081377300032
J	Adam-Stitah, S; Penna, L; Chambon, P; Rochette-Egly, C				Adam-Stitah, S; Penna, L; Chambon, P; Rochette-Egly, C			Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LIGAND-BINDING DOMAIN; N-TERMINAL KINASE; HA-RAS MUTATION; PROTEIN-KINASE; ACID RECEPTOR; TRANSCRIPTION FACTORS; NUCLEAR RECEPTORS; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION	The nuclear receptor mouse retinoid X receptor alpha (mRXR alpha) was shown to be constitutively phosphorylated in its NH2-terminal A/B region, which contains potential phosphorylation sites for proline-directed Ser/Thr kinases, Mutants for each putative site were generated and overexpressed in transfected COS-1 cells. Constitutively phosphorylated residues identified by tryptic phosphopeptide mapping included serine 22 located in the A1 region that is specific to the RXR alpha 1 isoform, Overexpression and UV activation of the stress-activated kinases, c-Jun NH2-terminal kinases 1 and 2 (JNK1 and JNK2), hyperphosphorylated RXR alpha, resulting in a marked decrease in its electrophoretic mobility. This inducible hyperphosphorylation involved three residues (serines 61 and 75 and threonine 87) in the B region of RXR alpha and one residue (serine 265) in the ligand binding domain (E region). Binding assays performed in vitro with purified recombinant proteins demonstrated that JNKs did not interact with RXR alpha but bound to its heterodimeric partners, retinoic acid receptors alpha and gamma (RAR alpha and RAR gamma). Hyperphosphorylation by JNKs did not affect the transactivation properties of either RXR alpha homodimers or RXR alpha/RAR alpha heterodimers in transfected cultured cells.	Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						BLOMHOFF R, 1994, NUTR REV, V52, P13; Bocco JL, 1996, ONCOGENE, V12, P1971; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brocard J, 1996, BIOCHEM BIOPH RES CO, V229, P211, DOI 10.1006/bbrc.1996.1782; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; DEGRAEVE F, 1999, IN PRESS ONCOGENE; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P., 1994, Vitamin A in health and disease., P189; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Maden M, 1998, DEVELOPMENT, V125, P4133; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mascrez B, 1998, DEVELOPMENT, V125, P4691; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	60	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18932	18941		10.1074/jbc.274.27.18932	http://dx.doi.org/10.1074/jbc.274.27.18932			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383391	hybrid			2022-12-25	WOS:000081196300014
J	Mordoch, SS; Granot, D; Lebendiker, M; Schuldiner, S				Mordoch, SS; Granot, D; Lebendiker, M; Schuldiner, S			Scanning cysteine accessibility of EmrE, an H+-coupled multidrug transporter from Escherichia coli, reveals a hydrophobic pathway for solutes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; TRANSLOCATION PATHWAY; PROTEIN; RESIDUES; CHANNEL; SEGMENT; IDENTIFICATION; MUTAGENESIS; CLONING; EFFLUX	EmrE is a 12-kDa Escherichia coli multidrug transporter that confers resistance to a wide variety of toxic reagents by actively removing them in exchange for hydrogen ions, The three native Cys residues in EmrE are inaccessible to N-ethylmaleimide (NEM) and a series of other sulfhydryls. In addition, each of the three residues can be replaced with Ser without significant loss of activity, A protein without all the three Cys residues (Cys-less) has been generated and shown to be functional. Using this Cys-less protein, we have now generated a series of 48 single Cys replacements throughout the protein. The majority of them (43) show transport activity as judged from the ability of the mutant proteins to confer resistance against toxic compounds and from in vitro analysis of their activity in proteoliposomes. Here we describe the use of these mutants to study the accessibility to NEM, a membrane permeant sulfhydryl reagent. The study has been done systematically so that in one transmembrane segment (TMS2) each single residue was replaced. In each of the other three transmembrane segments, at least four residues covering one turn of the helix were replaced. The results show that although the residues in putative hydrophilic loops readily react with NEM, none of the residues in putative transmembrane domains are accessible to the reagent, The results imply very tight packing of the protein without any continuous aqueous domain. Based on the findings described in this work, we conclude that in EmrE the substrates are translocated through a hydrophobic pathway.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	shimons@leonardo.ls.huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED M, 1994, J BIOL CHEM, V269, P28506; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; Means G.E., 1971, CHEM MODIFICATION PR; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; Mulholland SE, 1998, J AM CHEM SOC, V120, P10296, DOI 10.1021/ja981279a; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PUREWAL AS, 1990, FEMS MICROBIOL LETT, V68, P73; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S, 1997, J EXP BIOL, V200, P335; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	28	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19480	19486		10.1074/jbc.274.27.19480	http://dx.doi.org/10.1074/jbc.274.27.19480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383465	hybrid			2022-12-25	WOS:000081196300088
J	Nakamura, T; Iwakura, M				Nakamura, T; Iwakura, M			Circular permutation analysis as a method for distinction of functional elements in the M20 loop of Escherichia coli dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE TRANSCARBAMOYLASE; BACILLUS-STEAROTHERMOPHILUS; POLYPEPTIDE-CHAINS; CRYSTAL-STRUCTURE; TRANSITION-STATE; PROTEIN; CONSTRUCTION; MECHANISM; BINDING; ENZYME	A functional element of an enzyme can be defined as the smallest unit of the local peptide backbone of which the connectivity is crucial for the catalytic activity. In order to elucidate the distribution of functional elements in an active site flexible loop (the M20 loop) of Escherichia coli dihydrofolate reductase, systematic cleavage of main chain connectivity was performed using circular permutation. Our analysis is based on the assumption that a permutation within a functional element would significantly reduce enzyme function, whereas ones outside or at the boundaries of the elements would affect the function only slightly. Thus, a functional element would be assigned as the minimum peptide chain between the identified boundaries. Comparison of the activities of the circularly permuted variants revealed that the peptide chain around the M20 loop could be divided into four regions (regions 1-4). Region 1 was found to play an important role in overall tertiary fold because most variants permuted at region 1 did not accumulate in E, coli cells stably, A distinction between region 2 and region 3 was in agreement with the extent of movements calculated from the coordinates of a carbons, supporting the idea that the movement of peptide backbone is a key feature of enzyme function, The boundary between region 3 and region 4 coincided with that between the M20 loop and the following a helix. From equilibrium binding studies, region 2 was found to be involved in the binding of nicotinamide substrates, whereas region 4 appeared to be very important for the binding of pterin substrates.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Osaka Natl Res Inst, Osaka 5638577, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Iwakura, M (corresponding author), Natl Inst Biosci & Human Technol, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.	iwakura@nibh.go.jpl	Nakamura, Tsutomu/M-3412-2018	Nakamura, Tsutomu/0000-0002-5511-8087				BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; EDER J, 1992, BIOCHEMISTRY-US, V31, P3617, DOI 10.1021/bi00129a010; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P439, DOI 10.1021/bi00168a007; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; HAHN M, 1994, P NATL ACAD SCI USA, V91, P10417, DOI 10.1073/pnas.91.22.10417; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; Iwakura M, 1998, PROTEIN ENG, V11, P707, DOI 10.1093/protein/11.8.707; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; IWAKURA M, 1998, PROTEIN SCI S1, V7, P85; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; KOMMAR AA, 1995, FEBS LETT, V376, P195; KREITMAN RJ, 1994, P NATL ACAD SCI USA, V91, P6889, DOI 10.1073/pnas.91.15.6889; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; Miller GP, 1998, BIOCHEMISTRY-US, V37, P6327, DOI 10.1021/bi972922t; Miller GP, 1998, BIOCHEMISTRY-US, V37, P6336, DOI 10.1021/bi973065w; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; MULLINS LS, 1994, J AM CHEM SOC, V116, P5529, DOI 10.1021/ja00092a001; Ohmae E, 1998, J BIOCHEM, V123, P839; PROTASOVA NY, 1994, PROTEIN ENG, V7, P1373, DOI 10.1093/protein/7.11.1373; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; TOYAMA H, 1991, J BIOL CHEM, V266, P13634; VIGNAIS ML, 1995, PROTEIN SCI, V4, P994; VIGUERA AR, 1995, J MOL BIOL, V247, P670, DOI 10.1016/S0022-2836(05)80146-9; VOLTZ KW, 1982, J BIOL CHEM, V257, P2528; YANG YR, 1993, P NATL ACAD SCI USA, V90, P11980, DOI 10.1073/pnas.90.24.11980; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006	41	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19041	19047		10.1074/jbc.274.27.19041	http://dx.doi.org/10.1074/jbc.274.27.19041			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383405	hybrid			2022-12-25	WOS:000081196300028
J	Schmid, JA; Mach, L; Paschke, E; Glossl, J				Schmid, JA; Mach, L; Paschke, E; Glossl, J			Accumulation of sialic acid in endocytic compartments interferes with the formation of mature lysosomes - Impaired proteolytic processing of cathepsin B in fibroblasts of patients with lysosomal sialic acid storage disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; MANNOSE 6-PHOSPHATE RECEPTOR; N-ACETYLNEURAMINIC ACID; LATE ENDOSOMES; BETA-HEXOSAMINIDASE; PROCATHEPSIN-B; SALLA DISEASE; MULTIVESICULAR ENDOSOMES; PROTEIN-DEGRADATION; TERMINAL LYSOSOMES	The impact of an altered endocytic environment on the biogenesis of lysosomes was studied in fibroblasts of patients suffering from sialic acid storage disease (SASD). This inherited disorder is characterized by the accumulation of acidic monosaccharides in lysosomal compartments and a concomitant decrease of their buoyant density. We demonstrate that C-terminal trimming of the lysosomal cysteine proteinase cathepsin B is inhibited in SASD fibroblasts. This late event in the biosynthesis of cathepsin B normally takes place in mature lysosomes, suggesting an impaired biogenesis of these organelles in SASD cells. When normal fibroblasts are loaded with sucrose, which inhibits transport from late endosomes to lysosomes, C-terminal cathepsin B processing is prevented to the same extent. Further characterization of the terminal endocytic compartments of SASD cells revealed properties usually associated with late endosomes/prelysosomes. In addition to a decreased buoyant density, SASD "lysosomes" show a reduced acidification capacity and appear smaller than their normal counterparts. We conclude that the accumulation of small non-diffusible compounds within endocytic compartments interferes with the formation of mature lysosomes and that the acidic environment of the latter organelles is a prerequisite for C-terminal processing of lysosomal hydrolases.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Univ Agr Sci, Ctr Appl Genet, A-1190 Vienna, Austria; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Childrens Hosp, A-8036 Graz, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna; University of Western Australia	Glossl, J (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	Johannes.Schmid@univie.ac.at	Schmid, Johannes A./C-7659-2009; Glössl, Josef/H-8208-2013	Schmid, Johannes A./0000-0002-6586-3507; Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				ANBARI M, 1994, HEPATOLOGY, V19, P1034, DOI 10.1002/hep.1840190432; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BRAULKE T, 1988, BIOL CHEM H-S, V369, P441, DOI 10.1515/bchm3.1988.369.1.441; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Bright NA, 1997, J CELL SCI, V110, P2027; BUCKMASTER MJ, 1988, BIOCHEM J, V249, P921, DOI 10.1042/bj2490921; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; FIGURA KV, 1978, EXP CELL RES, V111, P15, DOI 10.1016/0014-4827(78)90231-8; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HANCOCK LW, 1988, BIOCHEM BIOPH RES CO, V152, P83, DOI 10.1016/S0006-291X(88)80683-1; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; JAHRAUS A, 1994, J CELL SCI, V107, P145; JOHNSON KF, 1991, BIOCHIM BIOPHYS ACTA, V1073, P120, DOI 10.1016/0304-4165(91)90191-I; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MCVEYWARD DM, 1995, J CELL BIOL, V129, P1229; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; POHL J, 1987, ANAL BIOCHEM, V165, P96, DOI 10.1016/0003-2697(87)90205-3; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; RENLUND M, 1986, J CLIN INVEST, V77, P568, DOI 10.1172/JCI112338; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; ROWAN AD, 1993, BIOCHEM J, V294, P923, DOI 10.1042/bj2940923; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Storrie Brian, 1996, Bioessays, V18, P895, DOI 10.1002/bies.950181108; TIETZE F, 1989, J BIOL CHEM, V264, P15316; Tjelle TE, 1996, J CELL SCI, V109, P2905; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	65	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19063	19071		10.1074/jbc.274.27.19063	http://dx.doi.org/10.1074/jbc.274.27.19063			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383408	hybrid			2022-12-25	WOS:000081196300031
J	Tanaka, N; Kaneko, K; Asao, H; Kasai, H; Endo, Y; Fujita, T; Takeshita, T; Sugamura, H				Tanaka, N; Kaneko, K; Asao, H; Kasai, H; Endo, Y; Fujita, T; Takeshita, T; Sugamura, H			Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; DNA-BINDING ACTIVITY; JAK-3 JANUS KINASE; C-MYC INDUCTION; IL-2 RECEPTOR; CELL-GROWTH; JAK-STAT5 PATHWAY; ADAPTER MOLECULE; TYROSINE KINASE	STAM containing an SH3 (Src homology 3) domain and an immunoreceptor tyrosine-based activation motif was previously revealed to be implicated in signaling pathways immediately downstream of Jak2 and Jak3 tyrosine kinases associated with cytokine receptors. We molecularly cloned a novel molecule interacting with the SH3 domain of STAM, which was named AMSH (associated molecule with the SH3 domain of STAM). AMSH contains a putative bipartite nuclear localization signal and a homologous region of a c-Jun activation domain-binding protein 1 (JAB1) subdomain in addition to a binding site for the SH3 domain of STAM. AMSH mutant deleted of the C-terminal half conferred dominant negative effects on signaling for DNA synthesis and c-myc induction mediated by interleukin 2 and granulocyte macrophage-colony-stimulating factor. These results suggest that AMSH plays a critical role in the cytokine-mediated intracellular signal transduction downstream of the Jak2/Jak3.STAM complex.	Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Fukushima Med Coll, Dept Biochem, Fukushima 96012, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	Tohoku University; Fukushima Medical University; Japan Science & Technology Agency (JST)	Sugamura, H (corresponding author), Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	sugamura@mail.cc.tohoku.ac.jp	Kasai, Hirotake/L-9668-2017; Takeshita, Toshikazu/AAL-1382-2021	Kasai, Hirotake/0000-0002-5808-0803; 				Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cooper CL, 1998, J CELL BIOCHEM, V71, P277, DOI 10.1002/(SICI)1097-4644(19981101)71:2<277::AID-JCB12>3.0.CO;2-I; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502	40	110	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19129	19135		10.1074/jbc.274.27.19129	http://dx.doi.org/10.1074/jbc.274.27.19129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383417	hybrid			2022-12-25	WOS:000081196300040
J	Wang, D; Zheng, F; Holmberg, S; Kohlhaw, GB				Wang, D; Zheng, F; Holmberg, S; Kohlhaw, GB			Yeast transcriptional regulator Leu3p - Self-masking, specificity of masking, and evidence for regulation by the intracellular level of Leu3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ISOPROPYLMALATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; LEUCINE BIOSYNTHESIS; S-ADENOSYLMETHIONINE; ACTIVATION DOMAIN; DNA-BINDING; GENE LEU3; PROTEIN; MULTIPLE; IDENTIFICATION	Recent work suggests that the masking of the activation domain (AD) of yeast transactivator Leu3p, observed in the absence of the metabolic signal alpha-isopropylmalate, is an intramolecular event. Much of the evidence came from the construction and analysis of a mutant form of Leu3p (Leu3-dd) whose AD is permanently masked (Wang, D,, Hu, Y,, Zheng, F,, Zhou, K,, and Kohlhaw, G, B, (1997) J, Biol, Chem, 272, 19383-19392). In a modified two-hybrid experiment, the ADs of both wild type Leu3p and Leu3-dd were shown to interact with the remainder of the Leu3 protein, in an alpha-isopropylmalate-dependent manner. The finding that masking and unmasking proceed apparently normally when full-length Leu3p is expressed in mammalian cells is also consistent with the notion of intramolecular masking. Here we report on the identification of nine missense mutations tall of them suppressors of the Leu3-dd phenotype) that cause permanent unmasking of Leu3p, The nine mutations map to three short segments located within a 140-residue-long region of the C-terminal part of the middle region of Leu3p, These segments may be part of a spatial trap for the AD. We also performed "domain swaps'" between Leu3p and Cha4p, a serine/threonine-responsive activator that, like Leu3p, belongs to the family of Zn(II),Cys, proteins, We show that AD masking and response to the appropriate metabolic signal only occur when a given AD remains attached to its own middle region; middle region swapping results in constitutively active proteins. Finally, we show that the extent to which Leu3p regulates reporter gene expression depends on the intracellular concentration of Leu3p, The possible physiological significance of this observation is discussed in light of the known regulation of Leu3p by Gcn4p.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Univ Copenhagen, Inst Mol Biol, Dept Genet, DK-1353 Copenhagen K, Denmark	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Copenhagen	Kohlhaw, GB (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Holmberg, Steen/N-1128-2014	Holmberg, Steen/0000-0002-0262-3207	NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BORNAES C, 1993, MOL CELL BIOL, V13, P7604, DOI 10.1128/MCB.13.12.7604; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; DRAIN P, 1988, GENETICS, V119, P13; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Guo H, 1996, FEBS LETT, V390, P191, DOI 10.1016/0014-5793(96)00653-9; HAMPSEY DM, 1981, J BIOL CHEM, V256, P3791; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; Holmberg S, 1996, GENETICS, V144, P467; HU Y, 1996, THESIS PURDUE U W LA; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; HU YM, 1995, J BIOL CHEM, V270, P5270, DOI 10.1074/jbc.270.10.5270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SZE JY, 1993, J BIOL CHEM, V268, P2505; SZE JY, 1993, MOL CELL BIOL, V13, P5702, DOI 10.1128/MCB.13.9.5702; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Voss H, 1997, YEAST, V13, P655, DOI 10.1002/(SICI)1097-0061(19970615)13:7<655::AID-YEA120>3.0.CO;2-I; Wade PA, 1996, MOL CELL BIOL, V16, P1641; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU K, 1991, THESIS PURDUE U W LA; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	36	38	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19017	19024		10.1074/jbc.274.27.19017	http://dx.doi.org/10.1074/jbc.274.27.19017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383402	hybrid			2022-12-25	WOS:000081196300025
J	Wesche, H; Gao, X; Li, XX; Kirschning, CJ; Stark, GR; Cao, ZD				Wesche, H; Gao, X; Li, XX; Kirschning, CJ; Stark, GR; Cao, ZD			IRAK-M is a novel member of the pelle/interleukin-1 receptor-associated kinase (IRAK) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASES; INTERLEUKIN-1 RECEPTOR; ACCESSORY PROTEIN; DROSOPHILA TOLL; SIGNALING PATHWAYS; MOLECULAR-CLONING; MYD88; COMPLEX	The interleukin-1 receptor-associated kinase (IRAK) was first described as a signal transducer for interleukin-1 (IL-1) and has later been implicated in signal transduction of other members of the Toll/IL-1 receptor family. We now report the identification and characterization of a novel IRAK-like molecule. In contrast to the ubiquitously expressed IRAK and IRAK-2, this new IRAK-like molecule is found mainly in cells of monomyeloic origin and is, therefore, designated IRAK-M. Although IRAK-M and IRAK-2 exhibit only a negligible autophosphorylation activity, they can reconstitute the IL-1 response in a 293 mutant cell line lacking IRAK. In addition, we show for the first time that members of the IRAK family are indispensable elements of lipopolysaccharide signal transduction, The discovery of IRAK-M adds another level of complexity to our understanding of signaling by members of the Toll/IL-1 receptor family.	Tularik Inc, San Francisco, CA 94080 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cao, ZD (corresponding author), Tularik Inc, 2 Corporate Dr, San Francisco, CA 94080 USA.							Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LI X, 1999, IN RPESS MOL CELL BI; LORD KA, 1990, ONCOGENE, V5, P1095; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; THOMA JA, 1999, IN PRESS J IMMUNOL; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	42	333	378	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19403	19410		10.1074/jbc.274.27.19403	http://dx.doi.org/10.1074/jbc.274.27.19403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383454	hybrid			2022-12-25	WOS:000081196300077
J	de Haard, HJ; van Neer, N; Reurs, A; Hufton, SE; Roovers, RC; Henderikx, P; de Bruine, AP; Arends, JW; Hoogenboom, HR				de Haard, HJ; van Neer, N; Reurs, A; Hufton, SE; Roovers, RC; Henderikx, P; de Bruine, AP; Arends, JW; Hoogenboom, HR			A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; POLYMERASE CHAIN-REACTION; BY-PASSING IMMUNIZATION; DISPLAY LIBRARIES; ESCHERICHIA-COLI; SYNTHETIC REPERTOIRES; LUTEINIZING-HORMONE; BETA-SUBUNITS; SELECTION; CELLS	We report the design, construction, and use of the first very large non-immunized phage antibody library in Fab format, which allows the rapid isolation and affinity analysis of antigen-specific human antibody fragments. Individually cloned heavy and light chain variable region libraries were combined in an efficient two-step cloning procedure, permitting the cloning of a total of 3.7 x 10(10) independent Fab clones. The performance of the library was determined by the successful selection of on average 14 different Fabs against 6 antigens tested. These include tetanus toroid, the hapten phenyl-oxazolone, the breast cancer-associated MUC1 antigen, and three highly related glycoprotein hormones: human chorionic gonadotropin, human luteinizing hormone, and human follicle-stimulating hormone. In the latter category, a panel of either homone-specific or crossreactive antibodies were identified. The design of the library permits the monitoring of selections with polyclonal phage preparations and to carry out large scale screening of antibody off-rates with unpurified Fab fragments on BIAcore. Antibodies with off-rates in the order of 10(-2) to 10(-4) s(-1) and affinities up to 2.7 nM were recovered. The kinetics of these phage antibodies are of the same order of magnitude as antibodies associated with a secondary immune response. This new phage antibody library is set to become a valuable source of antibodies to many different targets, and to play a vital role in target discovery and validation in the area of functional genomics.	Target Quest BV, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, NL-6202 AZ Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Hoogenboom, HR (corresponding author), Target Quest BV, POB 5800, NL-6202 AZ Maastricht, Netherlands.	hho@lpat.azm.nl	Hufton, Simon E/E-3949-2013; hufton, simon/AAA-8245-2019	hufton, simon/0000-0003-1756-0306; Roovers, Rob/0000-0002-9715-2136				BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; CAI XH, 1995, P NATL ACAD SCI USA, V92, P6537, DOI 10.1073/pnas.92.14.6537; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; Cole LA, 1997, CLIN CHEM, V43, P2233; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; de Haard HJW, 1998, CLIN DIAGN LAB IMMUN, V5, P636, DOI 10.1128/CDLI.5.5.636-644.1998; de Haard HJW, 1998, PROTEIN ENG, V11, P1267, DOI 10.1093/protein/11.12.1267; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Gargano N, 1996, J VIROL, V70, P7706, DOI 10.1128/JVI.70.11.7706-7712.1996; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Henderikx P, 1998, CANCER RES, V58, P4324; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Holliger P, 1998, NAT BIOTECHNOL, V16, P1015, DOI 10.1038/3460; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; Kazemier B, 1996, J IMMUNOL METHODS, V194, P201, DOI 10.1016/0022-1759(96)00086-5; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kortt AA, 1997, PROTEIN ENG, V10, P423, DOI 10.1093/protein/10.4.423; LARRICK JW, 1989, BIOCHEM BIOPH RES CO, V160, P1250, DOI 10.1016/S0006-291X(89)80138-X; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MARKS JD, 1993, BIO-TECHNOL, V11, P1145, DOI 10.1038/nbt1093-1145; MASURE HR, 1981, J CLIN ENDOCR METAB, V53, P1014, DOI 10.1210/jcem-53-5-1014; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; ORUM H, 1993, NUCLEIC ACIDS RES, V21, P4491, DOI 10.1093/nar/21.19.4491; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; PAPAPETROU PD, 1980, CANCER-AM CANCER SOC, V45, P2583, DOI 10.1002/1097-0142(19800515)45:10<2583::AID-CNCR2820451018>3.0.CO;2-W; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; ROIT IM, 1985, IMMUNOLOGY; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	52	405	566	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18218	18230		10.1074/jbc.274.26.18218	http://dx.doi.org/10.1074/jbc.274.26.18218			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373423	hybrid			2022-12-25	WOS:000081056700015
J	Mou, HM; Grazio, HJ; Cook, TA; Beavo, JA; Cote, RH				Mou, HM; Grazio, HJ; Cook, TA; Beavo, JA; Cote, RH			cGMP binding to noncatalytic sites on mammalian rod photoreceptor phosphodiesterase is regulated by binding of its gamma and delta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; OUTER SEGMENTS; G-PROTEIN; GMP PHOSPHODIESTERASE; VISUAL TRANSDUCTION; LIGHT ADAPTATION; TARGET ENZYME; PHOTORESPONSE; PURIFICATION; ACTIVATION	The binding of cGMP to the noncatalytic sites on two isoforms of the phosphodiesterase (PDE) from mammalian rod outer segments has been characterized to evaluate their role in regulating PDE during phototransduction. Nonactivated, membrane-associated PDE (PDE-M, alpha beta gamma(2)) has one exchangeable site for cGMP binding; endogenous cGMP remains nonexchangeable at the second site, Non-activated, soluble PDE (PDE-S, alpha beta gamma(2)delta) can release and bind cGMP at both noncatalytic sites; the delta subunit is likely responsible for this difference in cGMP exchange rates. Removal of the delta and/or gamma subunits yields a catalytic cup dimer with identical catalytic and binding properties for both PDE-M and PDE-S as follows: high affinity cGMP binding is abolished at one site (K-D > mu M); cGMP binding affinity at the second site (K-D similar to 60 nM) is reduced 3-4-fold compared with the nonactivated enzyme; the kinetics of cGMP exchange to activated PDE-M and PDE-S are accelerated to similar extents. The properties of nonactivated PDE can be restored upon addition of gamma subunit. Occupancy of the noncatalytic sites by cGMP may modulate the interaction of the gamma subunit with the alpha beta dimer and thereby regulate cytoplasmic cGMP concentration and the lifetime of activated PDE during visual transduction in photoreceptor cells.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University System Of New Hampshire; University of New Hampshire; University of Washington; University of Washington Seattle	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick/G-3363-2013	Cote, Rick/0000-0002-1573-6526	NEI NIH HHS [R01 EY005798, EY-08197, EY-05798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798, R01EY008197] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CERVETTO L, 1984, PHOTORECEPTORS, P159; COLES JA, 1975, J PHYSL, V247, P180; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; COTE RH, 1989, J BIOL CHEM, V264, P15384; COTE RH, 1999, IN PRESS METHODS ENZ, V316; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Gallagher S., 1998, CURRENT PROTOCOLS PR; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MIKI N, 1975, J BIOL CHEM, V250, P6320; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495	41	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18813	18820		10.1074/jbc.274.26.18813	http://dx.doi.org/10.1074/jbc.274.26.18813			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373499	Green Published, hybrid			2022-12-25	WOS:000081056700091
J	Sakamoto, H; Omata, Y; Palmer, G; Noguchi, M				Sakamoto, H; Omata, Y; Palmer, G; Noguchi, M			Ferric alpha-hydroxyheme bound to heme oxygenase can be converted to verdoheme by dioxygen in the absence of added reducing equivalents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX-ALPHA; COMPLEX; LIGAND; HISTIDINE-25; REQUIREMENT; DEGRADATION; CONVERSION; RADICALS; FORM; EPR	Whether or not reducing equivalents are indispensable for the conversion of ferric alpha-hydroxyheme bound to heme oxygenase-l to verdoheme remains controversial (Matera, R. M., Takahashi, S., Fujii, H., Zhou, H., Ishikawa, K., Yoshimura, T., Rousseau, D. L., Yoshida, T., and Ikeda-Saito, M. (1996) J. Biol. Chem. 271, 6618-6624; Liu, Y., Moenne-Loccoz, P., Loehr, T. M., and Ortiz de Montellano, P. R. (1997) J. Biol. Chem. 272, 6906-6917), To resolve this controversy, we have prepared a ferric alpha-hydroxyheme-heme oxygenase-l complex and titrated the complex with O-2, under strictly anaerobic conditions. The formation of verdoheme was monitored by optical and electron spin resonance spectroscopies. Electron spin resonance spectra of the complex showed that alpha-hydroxyheme exists as a mixture of resonance structures composed of the iron(III) porphyrin and the iron(II) porphyrin rr neutral radical. Upon addition of CO the latter species becomes dominant. The results obtained from these titration experiments indicate that alpha-hydroxyheme can be converted to verdoheme by an approximately equimolar amount of O-2, without any requirement for exogenous electrons. The verdoheme formed from alpha-hydroxyheme was shown to be in the ferrous oxidation state by the addition of CO or potassium ferricyanide to the resultant verdoheme-heme oxygenase-l complex.	Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77351 USA	Kurume University; Rice University	Noguchi, M (corresponding author), Kurume Univ, Sch Med, Dept Med Biochem, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	mnoguchi@med.kurume-u.ac.jp	Sakamoto, Hiroshi/A-3181-2011		NIGMS NIH HHS [GM 21337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG WE, 1971, ADV CHEM, V100, P271; Fajer J., 1979, PORPHYRINS, V4, P197; FUHRHOP JH, 1975, J AM CHEM SOC, V97, P7141, DOI 10.1021/ja00857a029; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MORISHIMA I, 1995, INORG CHEM, V34, P1528, DOI 10.1021/ic00110a035; MORISHIMA I, 1986, J AM CHEM SOC, V108, P3858, DOI 10.1021/ja00273a067; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; PALMER G, 1977, ANAL BIOCHEM, V83, P597, DOI 10.1016/0003-2697(77)90063-X; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	25	42	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18196	18200		10.1074/jbc.274.26.18196	http://dx.doi.org/10.1074/jbc.274.26.18196			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373419	hybrid			2022-12-25	WOS:000081056700011
J	Zabel, U; Hausler, C; Weeger, M; Schmidt, HHHW				Zabel, U; Hausler, C; Weeger, M; Schmidt, HHHW			Homodimerization of soluble guanylyl cyclase subunits - Dimerization analysis using a glutathione S-transferase affinity tag	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LUNG; RAT LUNG; MOLECULAR-CLONING; PURIFICATION; IDENTIFICATION; EXPRESSION; BINDING	Soluble guanylyl cyclase (sGC) is an alpha/beta-heterodimeric hemoprotein that, upon interaction with the intercellular messenger molecule NO, generates cGMP. Although the related family of particulate guanylyl cyclases (pGCs) forms active homodimeric complexes, it is not known whether homodimerization of sGC subunits occurs. We report here the expression in Sf9 cells of glutathione S-transferase-tagged recombinant human sGC alpha 1 and pi subunits, applying a novel and rapid purification method based on GSH-Sepharose affinity chromatography, Surprisingly, in intact Sf9 cells, both homodimeric GST alpha/alpha: and GST beta/beta complexes were formed that were catalytically inactive, Upon coexpression of the respective complementary subunits, GST alpha/beta or GST beta/alpha heterodimers were preferentially formed, whereas homodimers were still detectable, When subunits were mixed after expression, e,g, GST beta and beta or;GST alpha and beta, no dimerization was observed, In conclusion, our data suggest the previously unrecognized possibility of a physiological equilibrium between homo- and heterodimeric sGC complexes.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Zabel, U (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Schmidt, Harald HHW/B-1549-2008	Schmidt, Harald HHW/0000-0003-0419-5549				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KIM TD, 1994, J BIOL CHEM, V269, P15540; Koesling Doris, 1995, P43, DOI 10.1016/B978-012721985-1/50005-8; Lincoln T., 1996, BIOCH SMOOTH MUSCLE, P257; NAKANE M, 1990, J BIOL CHEM, V265, P16841; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2692; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	25	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18149	18152		10.1074/jbc.274.26.18149	http://dx.doi.org/10.1074/jbc.274.26.18149			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373411	hybrid			2022-12-25	WOS:000081056700003
J	Arneson, LS; Kunz, J; Anderson, RA; Traub, LM				Arneson, LS; Kunz, J; Anderson, RA; Traub, LM			Coupled inositide phosphorylation and phospholipase D activation initiates clathrin-coat assembly on lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; I PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASES; TRANS-GOLGI NETWORK; PLECKSTRIN HOMOLOGY DOMAINS; LIPID KINASE FAMILY; PHOSPHATIDIC-ACID; VESICLE FORMATION; PIT FORMATION; BREFELDIN-A; MEDIATED ENDOCYTOSIS	Adaptors appear to control clathrin-coat assembly by determining the site of lattice polymerization but the nucleating events that target soluble adaptors to an appropriate membrane are poorly understood. Using an in vitro model system that allows AP-2-containing clathrin coats to assemble on lysosomes, we show that adaptor recruitment and Goat initiation requires phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) synthesis. PtdIns(4,5)P-2 is generated on lysosomes by the sequential action of a lysosome-associated type II phosphalidylinositol 4-kinase and a soluble type I phosphatidylinositol I-phosphate B-kinase. Phosphatidic acid, which potently stimulates type I phosphatidylinositol 4-phosphate B-kinase activity, is generated on the bilayer by a phospholipase D1-like enzyme located on the lysosomal surface. Quenching phosphatidic acid function with primary alcohols prevents the synthesis of PtdIns(4,5)P-2 and blocks coat assembly. Generating phosphatidic acid directly on lysosomes with exogenous bacterial phospholipase D in the absence of ATP still drives adaptor recruitment and limited coat assembly, indicating that PtdIns(4,5)P-2 functions, at least in part, to activate the PtdIns(4,5)P-2-dependent phospholipase D1, These results provide the first direct evidence for the involvement of anionic phospholipids in clathrin-coat assembly on membranes and define the enzymes responsible for the production of these important lipid mediators.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison	Traub, LM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.			Traub, Linton/0000-0002-1303-0298; Anderson, Richard/0000-0001-6265-8359	NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; NIDDK NIH HHS [R01 DK53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NTURE, V347, P173; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Katayama K, 1998, BIOCHEM J, V329, P647, DOI 10.1042/bj3290647; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Ktistakis NT, 1998, BIOESSAYS, V20, P495; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHMID SL, 1991, J CELL BIOL, V114, P896; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Warren RA, 1997, J BIOL CHEM, V272, P2116; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	74	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17794	17805		10.1074/jbc.274.25.17794	http://dx.doi.org/10.1074/jbc.274.25.17794			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364223	hybrid, Green Submitted			2022-12-25	WOS:000080974300059
J	Iost, I; Dreyfus, M; Linder, P				Iost, I; Dreyfus, M; Linder, P			Ded1p, a DEAD-box protein required for translation initiation in Saccharomyces cerevisiae, is an RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; 23S RIBOSOMAL-RNA; COLI REP HELICASE; MESSENGER-RNA; ESCHERICHIA-COLI; SECONDARY STRUCTURE; MUTATIONAL ANALYSIS; DNA HELICASE; ATP HYDROLYSIS; HELA-CELLS	The Ded1 protein (Ded1p), a member of the DEAD-box family, has recently been shown to be essential for translation initiation in Saccharomyces cerevisiae. Here, we show that Ded1p purified from Escherichia coli has an ATPase activity, which is stimulated by various RNA substrates. Using an RNA strand-displacement assay, we show that Ded1p has also an ATP-dependent RNA unwinding activity. Hydrolysis of ATP is required for this activity: the replacement of ATP by a nonhydrolyzable analog or a mutation in the DEAD motif abolishing ATPase activity results in loss of RNA unwinding We find that cells harboring a Ded1 protein with this mutated DEAD motif are nonviable, suggesting that the ATPase and RNA helicase activities of this protein are essential to the cell. Finally, RNA binding measurements indicate that the presence of ATP, but not ADP, increases the affinity of Ded1p for duplex versus single-stranded RNA; we discuss how this differential effect might drive the unwinding reaction.	Univ Geneva, Ctr Med, Dept Biochim Med, CH-1211 Geneva 4, Switzerland; Ecole Normale Super, CNRS, UMR 8541, Genet Mol Lab, F-75230 Paris, France	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Iost, I (corresponding author), Univ Geneva, Ctr Med, Dept Biochim Med, CH-1211 Geneva 4, Switzerland.		Iost, Isabelle/M-7149-2014	Iost, Isabelle/0000-0001-9061-4177				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; Boddeker N, 1997, NUCLEIC ACIDS RES, V25, P537, DOI 10.1093/nar/25.3.537; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; CZAPLINSKI K, 1995, RNA, V1, P610; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Gururajan R, 1997, BBA-GENE STRUCT EXPR, V1350, P169, DOI 10.1016/S0167-4781(96)00155-8; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kaiser C., 1994, METHODS YEAST GENETI; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LANKER S, 1992, J BIOL CHEM, V267, P21167; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE CG, 1992, J BIOL CHEM, V267, P4398; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PANUSKA JR, 1980, J BIOL CHEM, V255, P5208; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WENG Y, 1993, RNA, V4, P205; Weng YM, 1996, MOL CELL BIOL, V16, P5477; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	58	164	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17677	17683		10.1074/jbc.274.25.17677	http://dx.doi.org/10.1074/jbc.274.25.17677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364207	hybrid			2022-12-25	WOS:000080974300043
J	Kwon, YT; Levy, F; Varshavsky, A				Kwon, YT; Levy, F; Varshavsky, A			Bivalent inhibitor of the N-end rule pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; RECOGNITION COMPONENT; SACCHAROMYCES-CEREVISIAE; UBIQUITIN SYSTEM; BINDING-SITES; G-ALPHA; YEAST; ASPARAGINE; SEQUENCE; RESIDUE	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. Ubr1p, the recognition (E3) component of the Saccharomyces cerevisiae N-end rule pathway, contains at least two substrate-binding sites. The type 1 site is specific for N-terminal basic residues Arg, Lys, and His. The type 2 site is specific for N-terminal bulky hydrophobic residues Phe, Leu, Trp, Tyr, and Ile. Previous work has shown that dipeptides bearing either type 1 or type 2 N-terminal residues act as weak but specific inhibitors of the N-end rule pathway. We took advantage of the two-site architecture of Ubr1p to explore the feasibility of bivalent N-end rule inhibitors, whose expected higher efficacy would result from higher affinity of the cooperative (bivalent) binding to Ubr1p. The inhibitor comprised mixed tetramers of beta-galactosidase that bore both N-terminal Arg (type 1 residue) and N-terminal Leu (type 2 residue) but that were resistant to proteolysis in vivo. Expression of these constructs in S. cerevisiae inhibited the N-end rule pathway much more strongly than the expression of otherwise identical beta-galactosidase tetramers whose N-terminal residues were exclusively Arg or exclusively Leu. In addition to demonstrating spatial proximity between the type 1 and type 2 substrate-binding sites of Ubr1p, these results provide a route to high affinity inhibitors of the N-end rule pathway.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	California Institute of Technology; Ludwig Institute for Cancer Research	Varshavsky, A (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd,147-75, Pasadena, CA 91125 USA.	avarsh@its.caltech.edu			NIDDK NIH HHS [DK39520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAGRAMAM K, 1995, MOL MICROBIOL, V15, P225, DOI 10.1111/j.1365-2958.1995.tb02237.x; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V87, P2374; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Grigoryev S, 1996, J BIOL CHEM, V271, P28521, DOI 10.1074/jbc.271.45.28521; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MADURA K, 1993, J BIOL CHEM, V268, P12046; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Ptashne M., 1992, A GENETIC SWITCH; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; REISS Y, 1988, J BIOL CHEM, V263, P2693; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sijts AJAM, 1997, J BIOL CHEM, V272, P19261, DOI 10.1074/jbc.272.31.19261; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; STEWART AE, 1995, J BIOL CHEM, V270, P25, DOI 10.1074/jbc.270.1.25; Taban CH, 1996, EXPERIENTIA, V52, P865, DOI 10.1007/BF01938871; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223	41	29	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18135	18139		10.1074/jbc.274.25.18135	http://dx.doi.org/10.1074/jbc.274.25.18135			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364269	hybrid, Green Accepted			2022-12-25	WOS:000080974300105
J	Rakovic, S; Cui, Y; Iino, S; Galione, A; Ashamu, GA; Potter, BVL; Terrar, DA				Rakovic, S; Cui, Y; Iino, S; Galione, A; Ashamu, GA; Potter, BVL; Terrar, DA			An antagonist of cADP-ribose inhibits arrhythmogenic oscillations of intracellular Ca2+ in heart cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; PIG VENTRICULAR MYOCYTES; CARDIAC PURKINJE-FIBERS; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; CONTRACTION; RAT; CHANNELS; NEURONS; MUSCLE	Oscillations of Ca2+ in heart cells are a major underlying cause of important cardiac arrhythmias, and it is known that Ca2+-induced release of Ca2+ from intracellular stores (the sarcoplasmic reticulum) is fundamental to the generation of such oscillations. There is now evidence that cADP-ribose may be an endogenous regulator of the Ca2+ release channel of the sarcoplasmic reticulum (the ryanodine receptor), raising the possibility that cADP-ribose may influence arrhythmogenic mechanisms in the heart. 8-Amino-cADP-ribose an antagonist of cADP-ribose, suppressed oscillatory activity associated with overloading of intracellular Ca2+ stores in cardiac myocytes exposed to high doses of the p-adrenoreceptor agonist isoproterenol or the Na+/K+-ATPase inhibitor ouabain, The oscillations suppressed by 8-amino-cADP-ribose included intracellular Ca2+ waves, spontaneous action potentials, after-depolarizations, and transient inward currents. Another antagonist of cADP-ribose, 8-bromo-cADP-ribose, was also effective in suppressing isoproterenol-induced oscillatory activity. Furthermore, in the presence of ouabain under conditions in which there was no arrhythmogenesis, exogenous cADP-ribose was found to be capable of triggering spontaneous contractile and electrical activity, Because enzymatic machinery for regulating the cytosolic cADP-ribose concentration is present within the cell, we propose that 8-amino-cADP-ribose and 8-bromo-cADP-ribose suppress cytosolic Ca2+ oscillations by antagonism of endogenous cADP-ribose, which sensitizes the Ca2+ release channels of the sarcoplasmic reticulum to Ca2+.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Bath, Sch Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Oxford; University of Bath	Terrar, DA (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Potter, Barry/AAX-4781-2020; Galione, Antony/E-5884-2011; Potter, Barry VL/A-1845-2012	Galione, Antony/0000-0002-4132-7646; Terrar, Derek/0000-0001-9408-6594				ARONSON RS, 1988, J PHYSIOL-LONDON, V400, P113, DOI 10.1113/jphysiol.1988.sp017114; BERS DM, 1991, EXCITATION CONTRACTI, P119; Chidambaram N, 1998, BIOCHEM MOL BIOL INT, V44, P1225; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; EISNER DA, 1984, J PHYSIOL-LONDON, V355, P251, DOI 10.1113/jphysiol.1984.sp015417; EISNER DA, 1986, J PHYSIOL-LONDON, V372, P539, DOI 10.1113/jphysiol.1986.sp016024; Empson RM, 1997, J BIOL CHEM, V272, P20967, DOI 10.1074/jbc.272.34.20967; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; FOZZARD HA, 1985, J AM COLL CARDIOL, V5, pA10, DOI 10.1016/S0735-1097(85)80458-7; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1996, RYANODINE RECEPTORS, P52; Guo XQ, 1997, J BIOL CHEM, V272, P16984, DOI 10.1074/jbc.272.27.16984; GUSE AH, 1995, J IMMUNOL, V155, P3353; HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517, DOI 10.1113/jphysiol.1992.sp019100; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; Iino S, 1997, CIRC RES, V81, P879; KIMURA J, 1988, J PHYSIOL-LONDON, V407, pP79; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEVI AJ, 1994, PROG BIOPHYS MOL BIO, V62, P1, DOI 10.1016/0079-6107(94)90005-1; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; MCGARRY SJ, 1993, BRIT J PHARMACOL, V108, P1043, DOI 10.1111/j.1476-5381.1993.tb13503.x; Meszaros LG, 1997, BIOCHEM BIOPH RES CO, V234, P252, DOI 10.1006/bbrc.1997.6620; MESZAROS V, 1995, BIOCHEM BIOPH RES CO, V210, P452, DOI 10.1006/bbrc.1995.1681; MITCHELL MR, 1984, BRIT J PHARMACOL, V81, P543, DOI 10.1111/j.1476-5381.1984.tb10107.x; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; SITSAPESAN R, 1994, J MEMBRANE BIOL, V137, P215; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WIER WG, 1984, J GEN PHYSIOL, V83, P395, DOI 10.1085/jgp.83.3.395	37	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17820	17827		10.1074/jbc.274.25.17820	http://dx.doi.org/10.1074/jbc.274.25.17820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364226	hybrid			2022-12-25	WOS:000080974300062
J	Srinivasula, SM; Ahmad, M; Lin, J; Poyet, JL; Fernandes-Alnemri, T; Tsichlis, PN; Alnemri, ES				Srinivasula, SM; Ahmad, M; Lin, J; Poyet, JL; Fernandes-Alnemri, T; Tsichlis, PN; Alnemri, ES			CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappa B activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; CYTOCHROME-C; CELL-DEATH; SIGNAL-TRANSDUCTION; KINASE COMPLEX; INTERACTING PROTEIN; MOLECULAR-CLONING; ADAPTER MOLECULE; TNF; MITOCHONDRIA	Molecules that regulate NF-kappa B activation play critical roles in apoptosis and inflammation. We describe the cloning of the cellular homolog of the equine herpesvirus-2 protein E10 and show that both proteins regulate apoptosis and NF-kappa B activation. These proteins were found to contain N-terminal caspase-recruitment domains (CARDs) and novel C-terminal domains (CTDs) and were therefore named CLAPs (CARD-like apoptotic proteins). The cellular and viral CLAPs induce apoptosis downstream of caspase-8 by activating the Apaf-1-caspase-9 pathway and activate NF-kappa B by acting upstream of the NF-kappa B-inducing kinase, NIK, and the IkB kinase, IKK alpha. Deletion of either the CARD or the CTD domain inhibits both activities, The CARD domain was found to be important for homo- and heterodimerization of CLAPs, Substitution of the CARD domain with an inducible FKBP12 oligomerization domain produced a molecule that can induce NF-kappa B activation, suggesting that the CARD domain functions as an oligomerization domain, whereas the CTD domain functions as the effector domain in the NF-kappa B activation pathway. Expression of the CARD domain of human CLAP abrogates tumor necrosis factor-cw-induced NF-kappa B activation, suggesting that cellular CLAP plays an essential role in this pathway of NF-kappa B activation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NIA NIH HHS [AG13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Meinl E, 1998, IMMUNOL TODAY, V19, P474, DOI 10.1016/S0167-5699(98)01309-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robertson NM, 1997, CANCER RES, V57, P43; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P13706; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	95	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17946	17954		10.1074/jbc.274.25.17946	http://dx.doi.org/10.1074/jbc.274.25.17946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364242	hybrid			2022-12-25	WOS:000080974300078
J	Kane, PM; Tarsio, M; Liu, JZ				Kane, PM; Tarsio, M; Liu, JZ			Early steps in assembly of the yeast vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ENDOPLASMIC-RETICULUM PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; SECRETORY PATHWAY; ADENOSINE TRIPHOSPHATASE; MEMBRANE GLYCOPROTEIN; CARBOXYPEPTIDASE-Y; 14-KDA SUBUNIT; IN-VITRO	Vacuolar proton-translocating ATPases are composed of a complex of integral membrane proteins, the V-0 sector, attached to a complex of peripheral membrane proteins, the V-1 sector. We have examined the early steps in biosynthesis of the yeast vacuolar ATPase by biosynthetically labeling wild-type and mutant cells for varied pulse and chase times and immunoprecipitating fully and partially assembled complexes under nondenaturing conditions. In wild-type cells, several V-1 subunits and the 100-bDa V-0 subunit associate within 3-5 min, followed by addition of other V-0 subunits with time. Deletion mutants lacking single subunits of the enzyme show a variety of partial complexes, including both com plexes that resemble intermediates in the assembly pathway of wild-type cells and independent V-1 and V-0, sectors that form without any apparent V1V0 subunit interaction. Two yeast sec mutants that show a temperature-conditional block. in export from the endoplasmic reticulum accumulate a complex containing several V-1 subunits and the 100-kDa V-0 subunit during incubation at elevated temperature. This complex can assemble with the 17-KDa V-0 subunit when the temperature block is reversed. We propose that assembly of the yeast V-ATPase can occur by two different pathways: a concerted assembly pathway involving early interactions between V-1 and V-0 subunits and an independent assembly pathway requiring full assembly of V-1 and V-0 sectors before combination of the two sectors. The data suggest that in wild-type cells, assembly occurs predominantly by the concerted assembly pathway, and V-ATPase complexes acquire the full complement of V-0 subunits during or after exit from the endoplasmic reticulum.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NIGMS NIH HHS [R01 GM050322, R01-GM50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1993, J BIOL CHEM, V268, P12749; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Li XH, 1998, PLANT CELL, V10, P119, DOI 10.1105/tpc.10.1.119; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1982, METHODS YEAST GENETI, P177; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	53	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17275	17283		10.1074/jbc.274.24.17275	http://dx.doi.org/10.1074/jbc.274.24.17275			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358087	hybrid			2022-12-25	WOS:000080780400086
J	Pineda, M; Fernandez, E; Torrents, D; Estevez, R; Lopez, C; Camps, M; Lloberas, J; Zorzano, A; Palacin, M				Pineda, M; Fernandez, E; Torrents, D; Estevez, R; Lopez, C; Camps, M; Lloberas, J; Zorzano, A; Palacin, M			Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; ALANINE TRANSPORT; SURFACE-ANTIGEN; PLASMA-MEMBRANE; SYSTEM L; METABOLISM; CELLS; CLONING; CYSTINE; VESICLES	We have identified a new human cDNA, L-amino acid transporter-2 (LAT-2), that induces a system L transport activity with 4F2hc (the heavy chain of the surface antigen 4F2, also named CD98) in oocytes, Human LAT-2 is the fourth member of the family of amino acid transporters that are subunits of 4F2hc, The amino acid transport activity induced by the co-expression of 4F2hc and LAT-2 was sodium-independent and showed broad specificity for small and large zwitterionic amino acids, as well as bulky analogs (e.g. BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid)). This transport activity was highly trans-stimulated, suggesting an exchanger mechanism of transport. Expression of tagged N-myc-LAT-2 alone in oocytes did not induce amino acid transport, and the protein had an intracellular location. Co-expression of N-myc-LAT-2 and 4F2hc gave amino acid transport induction and expression of N-myc-LAT-2 at the plasma membrane of the oocytes, These data suggest that LAT-S is an additional member of the family of 4F2 light chain subunits, which associates with 4F2hc to express a system L transport activity with broad specificity for zwitterionic amino acids, Human LAT-S mRNA is expressed in kidney >>> placenta >> brain, liver > spleen, skeletal muscle, heart, small intestine, and lung. Human LAT-2 gene localizes at chromosome 14q11.2-13 (13 cR or similar to 286 kb from marker D14S1349), The high expression of LAT-S mRNA in epithelial cells of proximal tubules, the basolateral location of 4F2hc in these cells, and the amino acid transport activity of LAT-2 suggest that this transporter contributes to the renal reabsorption of neutral amino acids in the basolateral domain of epithelial proximal tubule cells.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Fisiol, E-08028 Barcelona, Spain; Univ Barcelona, Serv Cient Tecn, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona; University of Barcelona	Palacin, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Zorzano, Antonio/R-5479-2018; Camps, Marta/F-6557-2016; Riu, Marta Pineda/I-1497-2015; Estevez, Raul/D-8610-2015; Lloberas, Jorge/D-4303-2014; Palacín, Manuel/G-9786-2015; Torrents, David/G-5785-2015	Camps, Marta/0000-0001-5392-1792; Riu, Marta Pineda/0000-0002-5403-5845; Estevez, Raul/0000-0003-1579-650X; Lloberas, Jorge/0000-0001-7075-4201; Torrents, David/0000-0002-6086-9037; Palacin, Manuel/0000-0002-8670-293X				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CRAWHALL JC, 1967, BIOCHEM J, V105, P891, DOI 10.1042/bj1050891; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; FELIG P, 1975, ANNU REV BIOCHEM, V44, P933, DOI 10.1146/annurev.bi.44.070175.004441; FEY YJ, 1995, BIOCHEMISTRY-US, V34, P8744; GANDOLFI SA, 1987, BIOCHIM BIOPHYS ACTA, V904, P29, DOI 10.1016/0005-2736(87)90083-6; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; HAUSSINGER D, 1992, ENZYME, V46, P72; HOELTZLI SD, 1989, AM J PHYSIOL, V256, pC630, DOI 10.1152/ajpcell.1989.256.3.C630; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LASH LH, 1984, AM J PHYSIOL, V247, pG394, DOI 10.1152/ajpgi.1984.247.4.G394; Liang V C, 1997, Cell Res, V7, P179; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MIRCHEFF AK, 1980, J MEMBRANE BIOL, V52, P83, DOI 10.1007/BF01869009; NEWSHOLME EA, 1994, GUT, V35, pS13, DOI 10.1136/gut.35.1_Suppl.S13; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; SEGAL S, 1969, P NATL ACAD SCI USA, V63, P926, DOI 10.1073/pnas.63.3.926; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; SMITH DW, 1988, HUM GENET, V80, P395, DOI 10.1007/BF00273660; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WELLS RG, 1992, J BIOL CHEM, V267, P15285; Yao SYM, 1998, BIOCHEM J, V330, P745	40	325	332	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19738	19744		10.1074/jbc.274.28.19738	http://dx.doi.org/10.1074/jbc.274.28.19738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391915	hybrid, Green Published			2022-12-25	WOS:000081377300035
J	Prince, RJ; Sine, SM				Prince, RJ; Sine, SM			Acetylcholine and epibatidine binding to muscle acetylcholine receptors distinguish between concerted and uncoupled models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; MOLECULAR DISSECTION; TORPEDO-MARMORATA; MOUSE FIBROBLASTS; AGONIST BINDING; LIGAND-BINDING; ALPHA-SUBUNIT; ION CHANNELS; BC3H-1 CELLS; UNIQUE SITE	The muscle acetylcholine receptor (AChR) has served as a prototype for understanding allosteric mechanisms of neurotransmitter-gated ion channels. The phenomenon of cooperative agonist binding is described by the model of Monod et al, (Monod, J., Wyman, J., and Changeux, J. P. (1965) J. Mol. Biol. 12, 88-118; MWC model), which requires concerted switching of the two binding sites between low and high affinity states. The present study examines binding of acetylcholine (ACh) and epibatidine, agonists with opposite selectivity for the two binding sites of mouse muscle AChRs, We expressed either fetal or adult AChRs in 293 HEK cells and measured agonist binding by competition against the initial rate of I-125-alpha-bungarotoxin binding. We fit predictions of the MWC model to epibatidine and ACh binding data simultaneously, taking as constants previously determined parameters for agonist binding and channel gating steps, and varying the agonist-independent parameters. We find that the MWC model describes the apparent dissociation constants for both agonists but predicts Hill coefficients that are far too steep. An Uncoupled model, which relaxes the requirement of concerted state transitions, accurately describes binding of both ACh and epibatidine and provides parameters for agonist-independent steps consistent with known aspects of AChR function.	Mayo Clin & Mayo Fdn, Receptor Biol Lab, Dept Physiol & Biophys, Rochester, MN 55905 USA; Univ Manchester, Sch Biol Sci, Physiol Pharmacol & Toxicol Div, Manchester M13 9PT, Lancs, England	Mayo Clinic; University of Manchester	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Receptor Biol Lab, Dept Physiol & Biophys, 200 1st St SW, Rochester, MN 55905 USA.				NINDS NIH HHS [NS 31744] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUERBACH A, 1993, J PHYSIOL-LONDON, V461, P339, DOI 10.1113/jphysiol.1993.sp019517; CHANGEUX JP, 1994, TRENDS BIOCHEM SCI, V19, P399, DOI 10.1016/0968-0004(94)90084-1; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DILGER JP, 1992, PFLUG ARCH EUR J PHY, V420, P479, DOI 10.1007/BF00374622; Eigen M, 1968, Q Rev Biophys, V1, P3; FRANKE C, 1993, BIOPHYS J, V64, P339, DOI 10.1016/S0006-3495(93)81374-2; HEIDMANN T, 1980, BIOCHEM BIOPH RES CO, V97, P889, DOI 10.1016/0006-291X(80)91460-6; JACKSON MB, 1994, TRENDS BIOCHEM SCI, V19, P396, DOI 10.1016/0968-0004(94)90083-3; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P364; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Prince RJ, 1998, BIOPHYS J, V75, P1817, DOI 10.1016/S0006-3495(98)77623-4; Prince RJ, 1998, J BIOL CHEM, V273, P7843, DOI 10.1074/jbc.273.14.7843; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; PRINZ H, 1992, BIOCHEMISTRY-US, V31, P6728, DOI 10.1021/bi00144a012; Raines DE, 1998, BIOCHEMISTRY-US, V37, P956, DOI 10.1021/bi971689w; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; Ruiz M, 1997, NATURE, V389, P389, DOI 10.1038/38744; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCUKA M, 1992, PROG NEUROBIOL, V38, P19, DOI 10.1016/0301-0082(92)90033-B; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496; SINE SM, 1982, J BIOL CHEM, V257, P8106; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Tierney ML, 1998, CURR OPIN STRUC BIOL, V8, P186, DOI 10.1016/S0959-440X(98)80036-5; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; ZHANG YN, 1995, J PHYSIOL-LONDON, V486, P189, DOI 10.1113/jphysiol.1995.sp020802	35	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19623	19629		10.1074/jbc.274.28.19623	http://dx.doi.org/10.1074/jbc.274.28.19623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391899	hybrid			2022-12-25	WOS:000081377300019
J	Rolli, M; Kotlyarov, A; Sakamoto, KM; Gaestel, M; Neininger, A				Rolli, M; Kotlyarov, A; Sakamoto, KM; Gaestel, M; Neininger, A			Stress-induced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BRONCHIAL EPITHELIAL-CELLS; INDUCED IL-8 EXPRESSION; MYELOID-LEUKEMIA CELLS; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; IONIZING-RADIATION; CELLULAR STRESSES; DEPENDENT PATHWAY; HYDROGEN-PEROXIDE	The p38/stress-activated protein kinases (p38/SAPK2) is activated by cellular stress and proinflammatory cytokines. Several transcription factors have been reported to be regulated by p38/SAPK2, and this kinase is involved in the control of expression of various genes. In human Jurkat T-cells, induction of the early growth response gene-1 (egr-1) by anisomycin is completely inhibited by SB203580, a specific inhibitor of p38/SAPK2a and -b. Northern blot and reporter gene experiments indicate that this block is at the level of mRNA biosynthesis. Using mutants of the egr-1 promoter, we demonstrate that a distal cAMP-responsive element (CRE; nucleotides -134 to -126) is necessary to control egr-1 induction by p38/SAPK2. Pull-down assays indicate that phospho-CRE binding protein (CREB) and phospho-activating transcription factor-1 (ATF1) bind to this element in a p38/SAPK2-dependent manner. In response to anisomycin, two known CREB kinases downstream to p38/SAPK2, MAPKAP kinase 2 (MK2) and mitogen- and stress-activated kinase 1 (MSK1), show increased activity. However, in MK2 -/- fibroblasts derived from mice carrying a disruption of the MK2 gene, the phosphorylation of CREB and ATF1 and the expression of egr-1 reach levels comparable with wild type cells. This finding excludes MK2 as an involved enzyme. We conclude that egr-1 induction by anisomycin is mediated by p38/SAPK2 and probably by MSK1. Phosphorylated CREB and ATF1 then bind to the CRE of the egr-1 promoter and cause a stress-dependent transcriptional activation of this gene.	Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, D-06120 Halle, Germany; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	Martin Luther University Halle Wittenberg; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gaestel, M (corresponding author), Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, Hoher Weg 8, D-06120 Halle, Germany.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Sakamoto, Kathleen/0000-0003-0494-8838				Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gon Y, 1998, BIOCHEM BIOPH RES CO, V249, P156, DOI 10.1006/bbrc.1998.9115; Guay J, 1997, J CELL SCI, V110, P357; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HUANG RP, 1995, ONCOGENE, V10, P467; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KASHER MS, 1986, MOL CELL BIOL, V6, P3117, DOI 10.1128/MCB.6.9.3117; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Matsumoto K, 1998, J ALLERGY CLIN IMMUN, V101, P825, DOI 10.1016/S0091-6749(98)70311-2; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Nick JA, 1996, J IMMUNOL, V156, P4867; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reiser COA, 1998, BIOCHEM J, V330, P1107; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; von der Kammer H, 1998, J BIOL CHEM, V273, P14538, DOI 10.1074/jbc.273.23.14538; WANG XZ, 1996, SCIENCE, V272, P13472; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; Wong A, 1995, J BIOL CHEM, V270, P30271, DOI 10.1074/jbc.270.51.30271; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	68	111	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19559	19564		10.1074/jbc.274.28.19559	http://dx.doi.org/10.1074/jbc.274.28.19559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391889	hybrid			2022-12-25	WOS:000081377300009
J	Ames, JB; Dizhoor, AM; Ikura, M; Palczewski, K; Stryer, L				Ames, JB; Dizhoor, AM; Ikura, M; Palczewski, K; Stryer, L			Three-dimensional structure of guanylyl cyclase activating protein-2, a calcium-sensitive modulator of photoreceptor guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONE DYSTROPHY; MYRISTOYLATED RECOVERIN; MOLECULAR-CLONING; RHODOPSIN KINASE; OUTER SEGMENTS; VERTEBRATE; NMR; SWITCH; GCAP-2; RETINA	Guanylyl cyclase activating protein-2 (GCAP-2) is a Ca2+-sensitive regulator of phototransduction in retinal photoreceptor cells. GCAP-2 activates retinal guanylyl cyclases at low Ca2+ concentration (<100 nM) and inhibits them at high Ca2+ (>500 nM). The light-induced lowering of the Ca2+ level from similar to 500 nM in the dark to similar to 50 nM following illumination is known to play a key role in visual recovery and adaptation. We report here the three-dimensional structure of unmyristoylated GCAP-2 with three bound Ca2+ ions as determined by nuclear magnetic resonance spectroscopy of recombinant, isotopically labeled protein. GCAP-2 contains four EF-hand motifs arranged in a compact tandem array like that seen previously in recoverin. The root mean square deviation of the main chain atoms in the EF-hand regions is 2.2 Angstrom in comparing the Ca2+-bound structures of GCAP-2 and recoverin. EF-1, as in recoverin, does not bind calcium because it contains a disabling Cys-Pro sequence. GCAP-2 differs from recoverin in that the calcium ion binds to EF-4 in addition to EF-2 and EF-3. A prominent exposed patch of hydrophobic residues formed by EF-1 and EF-2 (Leu(24), Trp(27), Phe(31), Phe(45) Phe(48), Phe(49), Tyr(81), Val(82), Leu(85), and Leu(89)) may serve as a target-binding site for the transmission of calcium signals to guanylyl cyclase.	Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, Rockville, MD 20850 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	University System of Maryland; University of Maryland Baltimore; Wayne State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University	Ames, JB (corresponding author), Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	james@carb.nist.gov		Dizhoor, Alexander/0000-0001-6770-9186; Ikura, Mitsuhiko/0000-0002-9524-1303	NEI NIH HHS [EY08061, EY12347, EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522, R01EY008061, R01EY012347, R29EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames BN, 1996, HUM ECOL RISK ASSESS, V2, P6, DOI 10.1080/10807039.1996.10387453; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Hughes RE, 1998, PROTEIN SCI, V7, P2675, DOI 10.1002/pro.5560071222; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; RATTO GM, 1988, J NEUROSCI, V8, P3240; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAP K, 1999, IN PRESS TRENDS BIOC; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19329	19337		10.1074/jbc.274.27.19329	http://dx.doi.org/10.1074/jbc.274.27.19329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383444	hybrid			2022-12-25	WOS:000081196300067
J	Hurt-Camejo, E; Rosengren, B; Sartipy, P; Elfsberg, K; Camejo, G; Svensson, L				Hurt-Camejo, E; Rosengren, B; Sartipy, P; Elfsberg, K; Camejo, G; Svensson, L			CD44, a cell surface chondroitin sulfate proteoglycan, mediates binding of interferon-gamma and some of its biological effects on human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; IFN-GAMMA; HEPARAN-SULFATE; IMMUNE INTERFERON; EXTRACELLULAR-MATRIX; TERMINAL SEQUENCE; ENDOTHELIAL-CELLS; ACCESSORY FACTOR; GENE-EXPRESSION	Several cytokines and growth factors act on cells after their association with the glycosaminoglycan (GAG) moiety of cell surface proteoglycans (PGs). Interferon-gamma (IFN-gamma) binds to GAG; however, the relevance of this interaction for the biological activity of IFN-gamma on human cells remains to be established. Human arterial smooth muscle cells (HASMC), the main cells synthesizing PG in the vascular wall, respond markedly to IFN-gamma. We found that treatment of HASMC with chondroitinase ABC, an enzyme that degrades chondroitin sulfate GAG, reduced IFN-gamma binding by more than 50%. This treatment increased the affinity of I-125-IFN-gamma for cells from a K-d value of about 93 nM to a K-d value of about 33 nM. However, the total binding was reduced from 9.3 +/- 0.77 pmol/mu g to 3.0 +/- 0.23 pmol/mg (n = 4). Interestingly, pretreatment with chondroitinase ABC reduced significantly the cellular response toward IFN-gamma. The interaction of IFN-gamma with chondroitin sulfate GAG was confirmed by affinity chromatography of isolated cell-associated S-35-, H-3-labeled PG on a column with immobilized IFN-gamma. The cell-associated PG that binds to IFN-gamma was a chondroitin sulfate PG (CSPG). This CSPG had a core protein of approximately 110 kDa that was recognized by anti-CD44 antibodies on Western blots. High molecular weight complexes between IFN-gamma and chondroitin 6-sulfate were observed in gel exclusion chromatography. Additions of chondroitin 6-sulfate to cultured HASMC antagonized the antiproliferative effect and expression of major histocompatibility complex II antigens induced by IFN-gamma. These results indicate that IFN-gamma binds with low affinity to the chondroitin sulfate GAG moiety of the cell surface CSPG receptor CD44. This interaction may increase the local concentration of IFN-gamma at the cell surface, thus facilitating its binding to high affinity receptors and modulating the ability of IFN-gamma to signal a cellular response.	Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Astra Hassle AB, S-43183 Molndal, Sweden	University of Gothenburg	Hurt-Camejo, E (corresponding author), Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden.	Eva.Hurt@wlab.wall.gu.se						AIYER RA, 1986, J IMMUNOL, V136, P3329; AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; Batra RK, 1997, J BIOL CHEM, V272, P11736, DOI 10.1074/jbc.272.18.11736; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EPPS DE, 1995, ANAL BIOCHEM, V227, P342, DOI 10.1006/abio.1995.1290; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FAGER G, 1988, EXP CELL RES, V176, P319, DOI 10.1016/0014-4827(88)90334-5; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINBLOOM DS, 1989, J IMMUNOL, V142, P2314; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; HURTCAMEJO E, 1995, ARTERIOSCLER THROMB, V15, P1456; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONASSON L, 1985, J CLIN INVEST, V76, P125, DOI 10.1172/JCI111934; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, CELL MOL BIOL, V37, P253; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; Lustig F, 1996, BIOCHEMISTRY-US, V35, P12077, DOI 10.1021/bi960118l; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN C, 1988, INFLAMMATION BASIC P, P229; Olsson U, 1997, ARTERIOSCL THROM VAS, V17, P149, DOI 10.1161/01.ATV.17.1.149; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEELIG GF, 1988, BIOCHEMISTRY-US, V27, P1981, DOI 10.1021/bi00406a026; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; THYBERG J, 1991, CELL CULTURE TECHNIQ, P315; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; VANLOON APGM, 1991, J LEUKOCYTE BIOL, V49, P462, DOI 10.1002/jlb.49.5.462; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	71	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18957	18964		10.1074/jbc.274.27.18957	http://dx.doi.org/10.1074/jbc.274.27.18957			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383394	hybrid			2022-12-25	WOS:000081196300017
J	Jeong, SY; Ahn, SG; Lee, JH; Kim, HS; Kim, JW; Rhim, H; Jeong, SW; Kim, IK				Jeong, SY; Ahn, SG; Lee, JH; Kim, HS; Kim, JW; Rhim, H; Jeong, SW; Kim, IK			3-deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF-kappa B regulation - Inhibition of NF-kappa B transcriptional activity and promotion of I kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; HL-60 CELLS; LEUKOCYTE ADHESION; C-MYC; ACTIVATION; APOPTOSIS; ANALOGS; KINASE; GENE	Previously we reported that 3 deazaadenosine (DZA), a potent inhibitor and substrate for 3-adenosylhomocysteine hydrolase inhibits bacterial lipopolysaccharide-induced transcription of tumor necrosis factor-alpha and interleukin-1 beta in mouse macrophage RAW 264.7 cells. In this study, we demonstrate the effects of DZA on nuclear factor-kappa B (NF-kappa B) regulation. DZA inhibits the transcriptional activity of NF-kappa B through the hindrance of p65 (Rel-A) phosphorylation without reduction of its nuclear translocation and DNA binding activity. The inhibitory effect of DZA on NF-kappa B transcriptional activity is potentiated by the addition of homocysteine. Taken together, DZA promotes the proteolytic degradation of I kappa B alpha, but not I kappa B beta, resulting in an increase of DNA binding activity of NF-kappa B in the nucleus in the absence of its transcriptional activity in RAW 264.7 cells. The reduction of I kappa B alpha by DZA is neither involved in I kappa B kinase complex activation nor modulated by the addition of homocysteine. This study strongly suggests that DZA may be a potent drug for the treatment of diseases in which NF-kappa B plays a central pathogenic role, as well as a useful tool for studying the regulation and physiological functions of NF-kappa B.	Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Res Inst Mol Genet, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Kim, IK (corresponding author), Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea.							AKSAMIT RR, 1982, J BIOL CHEM, V257, P621; ANTWERP DJV, 1996, SCIENCE, V274, P787; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BACKLUND PS, 1986, EUR J BIOCHEM, V160, P245, DOI 10.1111/j.1432-1033.1986.tb09963.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUERRE JA, 1992, BIOCHEM CELL BIOL, V70, P703, DOI 10.1139/o92-107; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ENDRESEN PC, 1993, BIOCHEM PHARMACOL, V46, P1893, DOI 10.1016/0006-2952(93)90629-B; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Jeong SY, 1996, IMMUNOLOGY, V89, P558, DOI 10.1046/j.1365-2567.1996.d01-781.x; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; Kim IK, 1997, J BIOMED SCI, V4, P83, DOI 10.1007/BF02255598; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KRENITSKY TA, 1986, J MED CHEM, V29, P138, DOI 10.1021/jm00151a022; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Loennechen T, 1997, PHARMACOL TOXICOL, V81, P199, DOI 10.1111/j.1600-0773.1997.tb00046.x; MAYERS DL, 1995, P NATL ACAD SCI USA, V92, P215, DOI 10.1073/pnas.92.1.215; MEDZIHRADSKY JL, 1982, J IMMUNOPHARMACOL, V4, P29, DOI 10.3109/08923978209031073; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220	46	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18981	18988		10.1074/jbc.274.27.18981	http://dx.doi.org/10.1074/jbc.274.27.18981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383397	hybrid			2022-12-25	WOS:000081196300020
J	Rogalla, T; Ehrnsperger, M; Preville, X; Kotlyarov, A; Lutsch, G; Ducasse, C; Paul, C; Wieske, M; Arrigo, AP; Buchner, J; Gaestel, M				Rogalla, T; Ehrnsperger, M; Preville, X; Kotlyarov, A; Lutsch, G; Ducasse, C; Paul, C; Wieske, M; Arrigo, AP; Buchner, J; Gaestel, M			Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress tumor necrosis factor alpha by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; INDUCED CELL-DEATH; MAP KINASE KINASE; NIH 3T3 CELLS; TNF-ALPHA; IN-VIVO; ACTIN POLYMERIZATION; MOLECULAR CHAPERONE; DYNAMIC CHANGES; B-CRYSTALLIN	The small heat shock proteins (sHsps) from human (Hsp27) and mouse (Hsp25) form large oligomers which can act as molecular chaperones in vitro and protect cells from heat shock and oxidative stress when overexpressed. In addition, mammalian sHsps are rapidly phosphorylated by MAPKAP kinase 2/3 at two or three serine residues in response to various extracellular stresses. Here we analyze the effect of sHsp phosphorylation on its quaternary structure, chaperone function, and protection against oxidative stress. We show that in vitro phosphorylation of recombinant sHsp as well as molecular mimicry of Hsp27 phosphorylation lead to a significant decrease of the oligomeric size. We demonstrate that both phosphorylated sHsps and the triple mutant Hsp27-S15D,S78D,S82D show significantly decreased abilities to act as molecular chaperones suppressing thermal denaturation and facilitating refolding of citrate synthase in vitro. In parallel, Hsp27 and its mutants were analyzed for their ability to confer resistance against oxidative stress when overexpressed in L929 and 13.S.1.24 cells. While wild type Hsp27 confers resistance, the triple mutant S15D,S78D,S82D cannot protect against oxidative stress effectively. These data indicate that large oligomers of sHsps are necessary for chaperone action and resistance against oxidative stress whereas phosphorylation down-regulates these activities by dissociation of sHsp complexes to tetramers.	Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, D-06120 Halle, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, F-69622 Villeurbanne, France	Martin Luther University Halle Wittenberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Regensburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gaestel, M (corresponding author), Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, Hoher Weg 8, D-06120 Halle, Germany.		Paul, Catherine/F-8376-2019; Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Preville, Xavier/0000-0002-1416-7405; Buchner, Johannes/0000-0003-1282-7737; Paul, Catherine/0000-0002-7657-5535				Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CAIRNS J, 1994, J BIOL CHEM, V269, P9176; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; Coronas V, 1997, J NEUROCHEM, V69, P1870; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1998, MOL CHAPERONES LIFE, P533; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LIM K, 1989, BIOTECHNIQUES, V7, P576; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NOVER L, 1983, MOL CELL BIOL, V3, P1648, DOI 10.1128/MCB.3.9.1648; Preville X, 1998, CELL STRESS CHAPERON, V3, P177, DOI 10.1379/1466-1268(1998)003<0177:PINEFP>2.3.CO;2; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; ROSSI JM, 1989, J CELL BIOL, V108, P425, DOI 10.1083/jcb.108.2.425; SANGER F, 1949, BIOCHEM J, V45, P563, DOI 10.1042/bj0450563; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Suzuki TC, 1998, PLANT PHYSIOL, V116, P1151, DOI 10.1104/pp.116.3.1151; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	57	611	635	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18947	18956		10.1074/jbc.274.27.18947	http://dx.doi.org/10.1074/jbc.274.27.18947			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383393	hybrid			2022-12-25	WOS:000081196300016
J	Xie, ZJ; Kometiani, P; Liu, J; Li, J; Shapiro, JI; Askari, A				Xie, ZJ; Kometiani, P; Liu, J; Li, J; Shapiro, JI; Askari, A			Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; FREE-RADICALS; RESPONSE GENES; REDOX STRESS; CELLS; TRANSCRIPTION; OUABAIN; CARDIOMYOCYTES; INHIBITION	We showed before that in cardiac myocytes partial inhibition of Na+/K+-ATPase by nontoxic concentrations of ouabain causes hypertrophy and transcriptional regulations of growth-related marker genes through multiple Ca2+-dependent signal pathways many of which involve Ras and p42/44 mitogen-activated protein kinases, The aim of this work was to explore the roles of intracellular reactive oxygen species (ROS) in these ouabain-initiated pathways. Ouabain caused a rapid generation of ROS within the myocytes that was prevented by preexposure of cells to N-acetyl-cysteine (NAC) or vitamin E, These antioxidants also blocked or attenuated the following actions of ouabain: inductions of the genes of skeletal alpha-actin and atrial natriuretic factor, repression of the gene of the alpha(3)-subunit of Na+/K+-ATPase, activation of mitogen-activated protein kinases, activation of Ras-dependent protein synthesis, and activation of transcription factor NF-kappa B. Induction of c-fos and activation of AP-I by ouabain were not sensitive to NAG. Ouabain-induced inhibition of active Rb+ uptake through Na+/K+-ATPase and the resulting rise in intracellular Ca2+ were also not prevented by NAG. A phorbol ester that also causes myocyte hypertrophy did not increase ROS generation, and its effects on marker genes and protein synthesis were not affected by NAG. We conclude the following: (a) ROS are essential second messengers within some but not all signal pathways that are activated by the effect of ouabain on Na+/K+-ATPase; (b) the ROS-dependent pathways are involved in ouabain-induced hypertrophy; (c) increased ROS generation is not a common response of the myocyte to all hypertrophic stimuli; and (d) it may be possible to dissociate the positive inotropic effect of ouabain from its growth-related effects by alteration of the redox state of the cardiac myocyte.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MohazzabH KM, 1997, CIRCULATION, V96, P614; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Perry G, 1997, NEW ENGL J MED, V336, P525; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEN P, 1993, J STEROID BIOCHEM, V47, P55, DOI 10.1016/0960-0760(93)90057-4; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; STEMMER P, 1988, BIOCHIM BIOPHYS ACTA, V940, P188, DOI 10.1016/0005-2736(88)90194-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497	35	262	270	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19323	19328		10.1074/jbc.274.27.19323	http://dx.doi.org/10.1074/jbc.274.27.19323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383443	hybrid			2022-12-25	WOS:000081196300066
J	Nair, S; Guerra, C; Satir, P				Nair, S; Guerra, C; Satir, P			A Sec7-related protein in Paramecium	FASEB JOURNAL			English	Article						guanine nucleotide exchange factor; GEF; IQ motifs; cilia	YEAST GOLGI-APPARATUS; EXCHANGE FACTOR; SIGNALING PROTEINS; SECRETORY PATHWAY; HOMOLOGY DOMAINS; LIGHT-CHAIN; SEC7 DOMAIN; DYNEIN; CYTOHESIN-1; PLECKSTRIN	We have cloned and sequenced a SEC7-related gene in Paramecium tetraurelia that contains an open reading frame for 1135 amino acids encoding a 133 kDa protein, PSec7. Sec7, first identified in vesicular trafficking mutants in yeast, and its phylogenetic homologues function as guanine-nucleotide exchange factors for small G-proteins such as ARF (ADP-ribosylation factor). The deduced amino acid sequence in PSec7 for the motifs that form the ARF binding site are more than 70% identical to yeast Sec7 and similarly identical to ARNO, the human ARF exchange factor, with correct positioning of the critical glutamic acid residue within the motif region, Overall, the identity of PSec7 to yeast Sec7 is 32%. The deduced amino acid sequence also has five sequences that resemble IQ motifs, EF hand binding domains found in all myosins, and two pleckstrin homology domains. Similar sequences are present in yeast Sec7 and other Sec7-related molecules. A protein kinase A phosphorylation site may also be present. Southern blots suggest that a single gene encodes PSec7, Northern blots show that the message encoding PSec7 is induced on deciliation, followed by ciliogenesis, which suggests a role for PSec7 in cilia such as transport or targeting of ciliary membrane components.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Satir, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	satir@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218, P01DK041918] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09875] Funding Source: Medline; NIDDK NIH HHS [DK07218, DK41918] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ASAI DJ, 1994, J CELL SCI, V107, P839; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BONINI NM, 1991, ADV SEC MESS PHOSPH, V23, P227; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GUERMEUR Y, 1999, IN PRESS BIOINFORMAT; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LEDIZET M, 1995, MOL BIOL CELL, V6, P713, DOI 10.1091/mbc.6.6.713; LEFEBVRE PA, 1980, CELL, V20, P469, DOI 10.1016/0092-8674(80)90633-9; Levin S, 1998, BIOINFORMATICS, V14, P374, DOI 10.1093/bioinformatics/14.4.374; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OTTER T, 1989, CELL MOVEMENT, V1, P281; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; SANDERS MA, 1989, J CELL BIOL, V108, P1751, DOI 10.1083/jcb.108.5.1751; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SUBRAMANIAN SV, 1994, P NATL ACAD SCI USA, V91, P9832, DOI 10.1073/pnas.91.21.9832; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	31	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1249	1257		10.1096/fasebj.13.10.1249	http://dx.doi.org/10.1096/fasebj.13.10.1249			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385615	Bronze			2022-12-25	WOS:000081264800013
J	Brauner-Osborne, H; Jensen, AA; Sheppard, PO; O'Hara, P; Krogsgaard-Larsen, P				Brauner-Osborne, H; Jensen, AA; Sheppard, PO; O'Hara, P; Krogsgaard-Larsen, P			The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA2+-SENSING RECEPTOR; EXTRACELLULAR DOMAIN; EXPRESSION; CLONING; PROTEINS; RAT; SELECTIVITY; CA2+	The calcium-sensing receptor (CaR) is a G-protein-coupled receptor that displays 19-25% sequence identity to the gamma-aminobutyric acid type B (GABA,) and metabotropic glutamate (mGlu) receptors, All three groups of receptors have a large amino-terminal domain (ATD), which for the mGlu receptors has been shown to bind the endogenous agonist, To investigate whether the agonist-binding domain of the CaR also is located in the ATD, we constructed a chimeric receptor named Ca/1a consisting of the ATD of CaR and the seven transmembrane region and C terminus of mGlu(1a). The Ca/1a receptor stimulated inositol phosphate production when exposed to the cationic agonists Ca2+, Mg2+, and Ba2+ in transiently transfected tsA cells (a transformed HEK 293 cell line). The pharmacological profile of Ca/1a (EC50 values of 3.3, 2.6, and 3.9 mM for these cations, respectively) was very similar to that of the wild-type CaR (EC50 values of 3.2, 4.7, and 4.1 mM, respectively). For the mGlu(1a) receptor, it has been shown that Ser-165 and Thr-188, which are located in the ATD, are involved in the agonist binding. An alignment of CaR with the mGlu receptors showed that these two amino acid residues have been conserved in CaR as Ser-147 and Ser-170, respectively. Each of these residues was mutated to alanines and tested pharmacologically using the endogenous agonist Ca2+. CaR-S147A showed an impaired function as compared with wild-type CaR both with respect to potency of Ca2+ (4-fold increase in EC50) and maximal response (79% of wild-type response). CaR-S170A showed no significant response to Ca2+ even at 50 mM concentration. In contrast, each of the two adjacent mutations, S169A and S171A, resulted in pharmacological profiles almost identical to that of the wild-type receptor. These data demonstrate that Ser-170 and to some extent Ser-147 are involved in the Ca2+ activation of the CaR, and taken together, our results reveal a close resemblance of the activation mechanism between the CaR and the mGlu receptors.	Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; Zymogenet Inc, Seattle, WA 98105 USA	Royal Danish School of Pharmacy; Zymogenet Inc.	Brauner-Osborne, H (corresponding author), Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, 2 Univ Pk, DK-2100 Copenhagen, Denmark.		Bräuner-Osborne, Hans/D-7260-2011; Jensen, Anders/AAJ-3335-2020	Bräuner-Osborne, Hans/0000-0001-9495-7388; Jensen, Anders/0000-0002-7927-5052				BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	24	141	148	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18382	18386		10.1074/jbc.274.26.18382	http://dx.doi.org/10.1074/jbc.274.26.18382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373443	hybrid			2022-12-25	WOS:000081056700035
J	Goodwin, RL; Pabon-Pena, LM; Foster, GC; Bader, D				Goodwin, RL; Pabon-Pena, LM; Foster, GC; Bader, D			The cloning and analysis of LEK1 identifies variations in the LEK centromere protein F mitosin gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DIFFERENTIATION; CENP-F; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; LEUCINE ZIPPERS; EXPRESSION; CYCLINS; MARKER	We report the cloning of a novel murine cDNA, LEK1, that is related to human CENP-F and mitosin and more distantly to chicken CMF1, The proteins from these three organisms have significant homology, yet differ in their temporal, spatial, and subcellular localizations. The human proteins bind the kinetochore in mitotic cells, whereas the chicken protein is found only in skeletal and cardiac muscle and is developmentally regulated. Mouse LEK1 is a single copy gene that codes for two developmentally regulated transcripts. The LEK1 protein is expressed early and ubiquitously in mouse development and is generally down-regulated as development proceeds in a manner that correlates to a cessation of mitosis, In adult tissues, the LEK1 protein is detected exclusively in the pronucleus of the oocyte and was not observed in other actively dividing tissues. Subcellular localization revealed that the LEK1 protein in mitotic cells does not bind the kinetochore, From these data, we hypothesize that chicken CMF1, human CENP-F, mitosin, and mouse LEK1 are members of an emerging family of genes that have important and functionally distinct roles in development and cell division.	Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA	Vanderbilt University	Bader, D (corresponding author), Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA.		Goodwin, Richard L./AAN-5007-2020; Goodwin, Richard/R-6169-2019	Goodwin, Richard/0000-0002-2537-2535	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL09916, HL37675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009916, R01HL037675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Ausubel FM., 1994, CURRENT PROTOCOLS; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHA GKT, 1998, J CELL BIOL, V143, P49; Clark GM, 1997, CANCER RES, V57, P5505; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; HOGAN B, 1921, MANIPULATING MOUSE E; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; Landberg G, 1996, CYTOMETRY, V25, P90, DOI 10.1002/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu SC, 1998, CANCER EPIDEM BIOMAR, V7, P597; Muro Y, 1997, BONE MARROW TRANSPL, V19, P951, DOI 10.1038/sj.bmt.1700764; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; Rattner JB, 1997, CLIN INVEST MED, V20, P308; SLIBESTEIN L, CELL, V1075, P86; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; WANG J, 1995, BIOCHEM BIOPH RES CO, V206, P82, DOI 10.1006/bbrc.1995.1012; Wei Y, 1996, DEVELOPMENT, V122, P2779; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zhu XL, 1997, J CELL BIOCHEM, V66, P441, DOI 10.1002/(SICI)1097-4644(19970915)66:4<441::AID-JCB3>3.0.CO;2-L	28	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18597	18604		10.1074/jbc.274.26.18597	http://dx.doi.org/10.1074/jbc.274.26.18597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373470	hybrid			2022-12-25	WOS:000081056700062
J	Liu, PQ; Liu, CE; Ames, GFL				Liu, PQ; Liu, CE; Ames, GFL			Modulation of ATPase activity by physical disengagement of the ATP-binding domains of an ABC transporter, the histidine permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; COMPLETE GENOME SEQUENCE; CYSTIC-FIBROSIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRAFFIC ATPASE; PERIPLASMIC PERMEASES; MULTIDRUG-RESISTANCE; CASSETTE TRANSPORTER; MEMBRANE	The membrane-bound complex of the prokaryotic histidine permease, a periplasmic protein-dependent ABC transporter, is composed of two hydrophobic subunits, HisQ and HisM, and two identical ATP-binding subunits, HisP, and is energized by ATP hydrolysis. The soluble periplasmic binding protein, HisJ, creates a signal that induces ATP hydrolysis by HisP. The crystal structure of HisP has been resolved and shown to have an "L" shape, with one of its arms (arm I) being involved in ATP binding and the other one (arm II) being proposed to interact with the hydrophobic subunits (Hung, L.-W., Wang, I. X., Nikaido, K., Liu, P.-Q., Ames, G. F.-L., and Kim, S.-H. (1998) Nature 396, 703-707). Here we study the basis for the defect of several HisP mutants that have an altered signaling pathway and hydrolyze ATP constitutively. We use biochemical approaches to show that they produce a loosely assembled membrane complex, in which the mutant HisP subunits are disengaged from HisQ and HisM, suggesting that the residues involved are important in the interaction between HisP and the hydrophobic subunits. In addition, the mutant HisPs are shown to have lower affinity for ADP and to display no cooperativity for ATP. All of the residues affected in these HisP mutants are located in arm II of the crystal structure of HisP, thus supporting the proposed function of arm II of HisP as interacting with HisQ and HisM, A revised model involving a cycle of disengagement and reengagement of HisP is proposed as a general mechanism of action for ABC transporters.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, GFL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	giovanna@uclink4.berkeley.edu			NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; AMES GFL, 1985, CURR TOP MEMBR TRANS, V23, P103; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bliss JM, 1997, J BACTERIOL, V179, P1400, DOI 10.1128/jb.179.4.1400-1403.1997; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; Gruis DB, 1997, BIOCHEMISTRY-US, V36, P7739, DOI 10.1021/bi9701585; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM YJ, 1994, CELL, V78, P845; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; Liu CE, 1999, J BIOL CHEM, V274, P739, DOI 10.1074/jbc.274.2.739; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; LIU CE, 1996, THESIS U CALIFORNIA; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; MCDONNELL PA, 1993, J MOL BIOL, V233, P447, DOI 10.1006/jmbi.1993.1523; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; OPELLA SJ, 1994, METHOD ENZYMOL, V239, P536; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; Qu BH, 1997, J BIOENERG BIOMEMBR, V29, P483, DOI 10.1023/A:1022439108101; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHNEIDER E, 1995, J BACTERIOL, V177, P5364, DOI 10.1128/jb.177.18.5364-5367.1995; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YIN Y, 1995, FEBS LETT, V366, P1, DOI 10.1016/0014-5793(95)00454-H; ZHANG F, 1995, BIOCHEMISTRY-US, V34, P4193, DOI 10.1021/bi00013a007	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18310	18318		10.1074/jbc.274.26.18310	http://dx.doi.org/10.1074/jbc.274.26.18310			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373434	hybrid			2022-12-25	WOS:000081056700026
J	Yoneda-Kato, N; Fukuhara, S; Kato, J				Yoneda-Kato, N; Fukuhara, S; Kato, J			Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein	ONCOGENE			English	Article						apoptosis; myelodysplastic syndrome; anti-apoptotic oncoprotein; NPM-MLF1 chimeric protein; subcellular localization; dimerization	NON-HODGKINS-LYMPHOMA; S-PHASE ENTRY; CELL-DEATH; EXPRESSION; LEUKEMIA; NUCLEOPHOSMIN; FUSION; E2F-1; FAMILY; BCL-2	The NPM-MLF1 chimeric protein is produced by the t(3;5)(q25.1;q34) chromosomal translocation, which is associated with myelodysplastic syndrome (MDS) prior to progression into acute myeloid leukemia (AML). Here we report that K562 human leukemia cells ectopically expressing NPM-MLF1, but not those with wild-type;MLF1, mere gradually eliminated from the culture by undergoing apoptosis. NIH3T3 mouse fibroblasts engineered to overexpress NPM-MLF1 grew normally but serum deprivation triggered apoptotic cell death with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1. Quantitative analysis of apoptotic induction confirmed that, neither NPM nor MLF1, but the NPM-RLF1 fusion protein was able to induce apoptosis. Analyses using a variety of deletion mutants of NPM-MLF1 revealed that induction of apoptosis required the N-terminal domain of MLF1 and the NPM domain containing nuclear localization signal and that removal of the NPM dimerization domain markedly impaired the ability to induce apoptosis. Go-expression of Bcl-2 rescued NIH3T3 fibroblasts from NPM-MLF1-mediated cell death without affecting the expression level or the subcellular localization of NPM-MLF1 and enabled cells to progress into S phase in low serum. These findings provide an NPM-MLF1-mediated novel mechanism of apoptotic induction and imply that NPM-MLF1 in collaboration with anti-apoptotic oncoproteins may play an important role in multi-step progression from MDS to AML.	Kansai Med Univ, Dept Internal Med 1, Osaka 5700074, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Kansai Medical University; Nara Institute of Science & Technology	Yoneda-Kato, N (corresponding author), Kansai Med Univ, Dept Internal Med 1, 10-15 Fumisono, Osaka 5700074, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLARK DM, 1990, LEUKEMIA LYMPHOMA, V2, P415, DOI 10.3109/10428199009069295; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gallagher A, 1997, HAEMATOLOGICA, V82, P191; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Koeffler HP, 1996, SEMIN HEMATOL, V33, P87; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rajapaksa R, 1996, BLOOD, V88, P4275; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YonedaKato N, 1996, ONCOGENE, V12, P265; YOSHIDA Y, 1993, LEUKEMIA, V7, P144; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	43	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3716	3724		10.1038/sj.onc.1202711	http://dx.doi.org/10.1038/sj.onc.1202711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391679				2022-12-25	WOS:000081140200005
J	Edwards, JS; Palsson, BO				Edwards, JS; Palsson, BO			Systems properties of the Haemophilus influenzae Rd metabolic genotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; LINEAR OPTIMIZATION; NETWORK ANALYSIS; GENOME SEQUENCE; GENES; FLUX; IDENTIFICATION; BIOINFORMATICS	Haemophilus influenzae Rd was the first free-living organism for which the complete genomic sequence was established. The annotated sequence and known biochemical information was used to define the H. influenzae Rd metabolic genotype. This genotype contains 488 metabolic reactions operating on 343 metabolites. The stoichiometric matrix was used to determine the systems characteristics of the metabolic genotype and to assess the metabolic capabilities of H. influenzae. The need to balance cofactor and biosynthetic precursor production during growth on mixed substrates led to the definition of six different optimal metabolic phenotypes arising from the same metabolic genotype, each with different constraining features. The effects of variations in the metabolic genotype were also studied, and it was shown that the H. influenzae Rd metabolic genotype contains redundant functions under defined conditions. We thus show that the synthesis of in silico metabolic genotypes from annotated genome sequences is possible and that systems analysis methods are available that can be used to analyze and interpret phenotypic behavior of such genotypes.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785	CSR NIH HHS [1RGM57089-01A1] Funding Source: Medline	CSR NIH HHS		Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Ash C, 1997, TRENDS MICROBIOL, V5, P135, DOI 10.1016/S0966-842X(97)01031-7; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; BUTLER LO, 1962, J GEN MICROBIOL, V27, P51, DOI 10.1099/00221287-27-1-51; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Casari G, 1996, TRENDS GENET, V12, P244, DOI 10.1016/0168-9525(96)30057-7; Chvatal V., 1983, LINEAR PROGRAMMING; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Edwards JS, 1998, BIOTECHNOL BIOENG, V58, P162, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<162::AID-BIT8>3.0.CO;2-J; EDWARDS JS, 1998, METABOLIC ENG; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endy D, 1997, BIOTECHNOL BIOENG, V55, P375, DOI 10.1002/(SICI)1097-0290(19970720)55:2<375::AID-BIT15>3.0.CO;2-G; FELL D, 1996, UNDERSTANDING CONTRO; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLEISCHMANN RD, 1995, SCIENCE, V269, P507; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Heinrich R., 1996, REGULATION CELLULAR; HERRIOTT RM, 1970, J BACTERIOL, V101, P513, DOI 10.1128/JB.101.2.513-516.1970; Huerta AM, 1998, NUCLEIC ACIDS RES, V26, P55, DOI 10.1093/nar/26.1.55; *I GEN RES, 1998, TIGR; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KLEIN RD, 1979, J GEN MICROBIOL, V113, P409, DOI 10.1099/00221287-113-2-409; Lee Y, 1996, NAT BIOTECHNOL, V14, P491, DOI 10.1038/nbt0496-491; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Macfadyen LP, 1996, RES MICROBIOL, V147, P541, DOI 10.1016/0923-2508(96)84010-1; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; PENFOUND T, 1996, ESCHERICHIA COLI SAL, V1, P721; Pennisi E, 1998, SCIENCE, V281, P148, DOI 10.1126/science.281.5374.148; PRAMANIK J, 1997, BIOTECHNOL BIOENG, V56, P399; REICH JG, 1981, ENERGY METABOLISM CE; Robison K, 1996, SCIENCE, V271, P1302; SAVINELL JM, 1992, J THEOR BIOL, V154, P421, DOI 10.1016/S0022-5193(05)80161-4; SAVINELL JM, 1992, J THEOR BIOL, V154, P455, DOI 10.1016/S0022-5193(05)80162-6; Schilling CH, 1998, P NATL ACAD SCI USA, V95, P4193, DOI 10.1073/pnas.95.8.4193; SCHUTZ EA, 1994, SPORTS MED ARTHROSC, V2, P165; SHULER ML, 1983, FDN BIOCH ENG, P101; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Strang G, 1988, LINEAR ALGEBRA ITS A; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; TALMADGE MB, 1960, BIOCHEM BIOPH RES CO, V2, P203, DOI 10.1016/0006-291X(60)90013-9; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trivedi B, 1998, NAT BIOTECHNOL, V16, P1316, DOI 10.1038/4280; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; VARMA A, 1995, BIOTECHNOL BIOENG, V45, P69, DOI 10.1002/bit.260450110; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1993, J THEOR BIOL, V165, P477, DOI 10.1006/jtbi.1993.1202; VARMA A, 1993, BIOTECHNOL BIOENG, V42, P59, DOI 10.1002/bit.260420109; Yada T, 1998, BIOINFORMATICS, V14, P317, DOI 10.1093/bioinformatics/14.4.317	57	263	335	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17410	17416		10.1074/jbc.274.25.17410	http://dx.doi.org/10.1074/jbc.274.25.17410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364169	hybrid			2022-12-25	WOS:000080974300005
J	Shaked, GM; Fridlander, G; Meiner, Z; Taraboulos, A; Gabizon, R				Shaked, GM; Fridlander, G; Meiner, Z; Taraboulos, A; Gabizon, R			Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE AGENT; PHYSICAL-PROPERTIES; TRANSGENIC MICE; CONGO RED; PRP; HAMSTERS; REPLICATION; STRAINS; ACCUMULATION	PrPSc, an abnormal isoform of PrPC, is the only known component of the prion, an agent causing fatal neurodegenerative disorders such as bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD). It has been postulated that prion diseases propagate by the conversion of detergent-soluble and protease-sensitive PrPC molecules into protease-resistant and insoluble PrPSc molecules by a mechanism in which PrPSc serves as a template. We show here that the chemical chaperone dimethyl sulfoxide (Me2SO) can partially inhibit the aggregation of either PrPSc or that of its protease-resistant core PrP27-30. Following; Me2SO removal by methanol precipitation, solubilized PrP27-30 molecules aggregated into small and amorphous structures that did not resemble the rod configuration observed when scrapie brain membranes were extracted with Sarkosyl and digested with proteinase K. Interestingly, aggregates derived from Me2SO-solubilized PrP27-30 presented less than 1% of the prion infectivity obtained when the same amount of PrP27-30 in rods was inoculated into hamsters. These results suggest that the conversion of PrPC into protease-resistant and detergent-insoluble PrP molecules is not the only crucial step in prion replication. Whether an additional requirement is the aggregation of newly formed proteinase K-resistant PrP molecules into uniquely structured aggregates remains to be established.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.	gabizonr@hadassah.org.il						Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1961, J COMP PATHOL THERAP, V71, P101, DOI 10.1016/S0368-1742(61)80013-1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; RAVID M, 1977, LANCET, V1, P730; SAFAR J, 1990, NEUROLOGY, V40, P503, DOI 10.1212/WNL.40.3_Part_1.503; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	44	57	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17981	17986		10.1074/jbc.274.25.17981	http://dx.doi.org/10.1074/jbc.274.25.17981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364247	hybrid			2022-12-25	WOS:000080974300083
J	Simonsson, T; Sjoback, R				Simonsson, T; Sjoback, R			DNA tetraplex formation studied with fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED POLYMORPHIC REGION; C-MYC GENE; TELOMERIC DNA; CHROMATIN STRUCTURE; QUARTET STRUCTURES; CRYSTAL-STRUCTURE; GUANINE TETRADS; FORM; HAIRPIN; THERMODYNAMICS	It is emerging that DNA tetraplexes are pivotal for many major cellular processes, and techniques that assess their structure and nature to the point are under development. Here we show how the structural conversion of largely unstructured single-stranded DNA molecules into compact intrastrand DNA tetraplexes can be monitored by fluorescence resonance energy transfer. We recently reported that intrastrand tetraplex formation takes place in a nuclease hypersensitive element upstream of the human c-myc proto-oncogene. Despite the highly repetitive guanine-rich sequence of the hypersensitive element, fluorescence resonance energy transfer measurements indicate that only one well defined tetraplex structure forms therein. The proposed structure, which is specifically stabilized by potassium ions in vitro, has a core of three stacked guanine tetrads that is capped by two intrastrand A-T base pairs.	Chalmers Univ Technol, Lundberg Inst, Dept Biochem, SE-40530 Gothenburg, Sweden	Chalmers University of Technology	Simonsson, T (corresponding author), Chalmers Univ Technol, Lundberg Inst, Dept Biochem, Box 462, SE-40530 Gothenburg, Sweden.	Tomas@bcbp.chalmers.se						AGRAWAL S, 1986, NUCLEIC ACIDS RES, V14, P6227, DOI 10.1093/nar/14.15.6227; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; Catasti P, 1996, J MOL BIOL, V264, P534, DOI 10.1006/jmbi.1996.0659; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GHOSH SS, 1994, NUCLEIC ACIDS RES, V22, P3155, DOI 10.1093/nar/22.15.3155; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; Hardin CC, 1997, BIOCHEMISTRY-US, V36, P15428, DOI 10.1021/bi970488p; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; Howell R, 1997, MOL BIOL EVOL, V14, P144, DOI 10.1093/oxfordjournals.molbev.a025747; Howell RM, 1996, J BIOL CHEM, V271, P5208; JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KENIRY MA, 1995, EUR J BIOCHEM, V233, P631, DOI 10.1111/j.1432-1033.1995.631_2.x; Kettani A, 1997, NAT STRUCT BIOL, V4, P382, DOI 10.1038/nsb0597-382; KUBISTA M, 1994, ANALYST, V119, P417, DOI 10.1039/an9941900417; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Pauling L., 1960, NATURE CHEM BOND, V3rd; PILCH DS, 1995, CURR OPIN STRUC BIOL, V5, P334, DOI 10.1016/0959-440X(95)80095-6; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shiber MC, 1996, NUCLEIC ACIDS RES, V24, P5004, DOI 10.1093/nar/24.24.5004; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Sjoback R, 1998, BIOPOLYMERS, V46, P445; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; Vorlickova M, 1998, NUCLEIC ACIDS RES, V26, P2679, DOI 10.1093/nar/26.11.2679; WANG Y, 1994, STRUCTURE, V2, P1141, DOI 10.1016/S0969-2126(94)00117-0; WANG Y, 1995, J MOL BIOL, V251, P76, DOI 10.1006/jmbi.1995.0417; YANG MS, 1994, BIOCHEMISTRY-US, V33, P15329, DOI 10.1021/bi00255a014	46	70	73	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17379	17383		10.1074/jbc.274.24.17379	http://dx.doi.org/10.1074/jbc.274.24.17379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358100	hybrid			2022-12-25	WOS:000080780400099
J	Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH				Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH			Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate	ONCOGENE			English	Article						C-CAM; androgen regulation; prostate	TRANSGENIC MICE; BILIARY GLYCOPROTEIN; HEPATOCELLULAR CARCINOMAS; MESSENGER-RNA; ANTIGEN GENE; ECTO-ATPASE; E-CADHERIN; CANCER; PROGRESSION; PROBASIN	C-CAM is an epithelial cell adhesion molecule with two major splice variants that differ in the length of the cytoplasmic domain. C-CAM1 (long (L)-form) strongly suppresses the tumorigenicity of human prostate carcinoma cells. In contrast, C-CAM2 (short (S)-form) does not exhibit tumor-suppressive activity. In the present study we have investigated the functional significance of L-form and S-form C-CAM in rat prostate by examining their expression and distribution in different prostate lobes and their response to androgen deprivation, RNase protection assays with a probe for both C-CAM isoforms detected high levels of C-CAM messages in the rat dorso-lateral prostate (DLP), L- and S-form proteins, localized by indirect immunofluorescence using isoform-specific antipeptide antibodies, were co-expressed on the apical surface of prostate epithelial cells in normal DLP, Androgen depletion did not significantly change the steady state levels of C-CAM message and protein expression in the DLP, although there was a change in the pattern of protein expression in these lobes, In contrast, C-CAM isoform messages and proteins were undetectable in normal ventral prostate (VP) but increased markedly in this lobe in response to castration, producing isoform ratios similar to those in DLP, These results demonstrate that coordinate expression of C-CAM isoforms is maintained in the VP following androgen depletion and suggest that androgen suppresses C-CAM expression in VP but not in DLP, These results suggest that balanced expression of L- and S-form C-CAM is important for normal prostate growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA	University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Lin, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.			PU, YEONG-SHIAU/0000-0002-2859-3966	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042714, R01CA064856] Funding Source: NIH RePORTER; NCI NIH HHS [CA64856, CA16672, CA42714] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Kasper S, 1998, LAB INVEST, V78, P319; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LEE C, 1981, PROSTATIC CELL STRUC, P145; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MATUO Y, 1985, BIOCHEM BIOPH RES CO, V130, P293, DOI 10.1016/0006-291X(85)90416-4; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; PARKER MG, 1979, P NATL ACAD SCI USA, V76, P1580, DOI 10.1073/pnas.76.4.1580; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PRICE D, 1963, NATL CANCER I MONOGR, V12, P351; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; Turbide C, 1997, CANCER RES, V57, P2781; UMBAS R, 1992, CANCER RES, V52, P5104; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Yan Y, 1997, PROSTATE, V32, P129	30	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3252	3260		10.1038/sj.onc.1202665	http://dx.doi.org/10.1038/sj.onc.1202665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359531				2022-12-25	WOS:000080523800008
J	Williams, AC; Collard, TJ; Paraskeva, C				Williams, AC; Collard, TJ; Paraskeva, C			An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis	ONCOGENE			English	Article						pH; apoptosis; colon; p53; pRb	WILD-TYPE P53; INTRACELLULAR PH; TGF-BETA(1)-INDUCED APOPTOSIS; CANCER-CELLS; CYCLE ARREST; TUMOR; ENDONUCLEASE; EXPRESSION; INHIBITION; GROWTH	As tumours are known to acidify their microenvironment and fluctuations in lumenal pH have been reported in a number of colonic disease conditions, we investigated whether lass of p53 function, commonly associated with the adenoma to carcinoma transition in human colorectal epithelium, was implicated in the cellular response to changes in extracellular pH, Human colonic adenoma and carcinoma derived cell lines were incubated at an inital pH range of 5.5-8.0 and the attached cell yield and apoptotic cell yield determined after 4 days. Exposure of all cell lines to an acidic growth environment was associated with a G1 arrest, down regulation of the retinoblastoma protein (pRb) protein and snitch to the hypophosphorylated form of the protein, and increased expression of the p21 protein, However, induction of apoptosis, associated with increased p53 protein expression but not,vith changes in Bcl-2 expression was only detected in the adenoma derived BH/C1 and AA/C1 cell lines which express wild type p53 activity. Furthermore, this induction of apoptosis Has inhibited in the transfected cell line AA/273p53/B, in which the wild type p53 function has been abrogated. These results suggest that acidification of the microenvironment would provide a selective growth advantage for cells that have lost wild type p53 function, leading to clonal expansion of aberrant cell populations.	Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Bristol BS8 1TD, Avon, England	University of Bristol	Williams, AC (corresponding author), Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Univ Walk, Bristol BS8 1TD, Avon, England.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEDI A, 1995, CANCER RES, V55, P1811; BRACEY TS, 1995, ONCOGENE, V10, P2391; Butt AJ, 1997, CELL DEATH DIFFER, V4, P725, DOI 10.1038/sj.cdd.4400293; Collins MKL, 1996, J CELL SCI, V109, P2393; DESOIGNIE R, 1994, GASTROENTEROLOGY, V107, P347, DOI 10.1016/0016-5085(94)90158-9; Elder DJE, 1996, CANCER RES, V56, P2273; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerweck LE, 1996, CANCER RES, V56, P1194; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1998, CARCINOGENESIS, V19, P1691, DOI 10.1093/carcin/19.9.1691; HALL PA, 1994, J CELL SCI, V107, P3569; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MANNING AM, 1991, ONCOGENE, V6, P1471; MORANA S, 1994, INT J ONCOL, V5, P153; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Sasaki Y, 1997, AM J GASTROENTEROL, V92, P114; SHEMTOV MM, 1995, J UROLOGY, V154, P269, DOI 10.1016/S0022-5347(01)67292-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vanderStappen JWJ, 1996, INT J CANCER, V67, P547, DOI 10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Wolf CM, 1997, CELL DEATH DIFFER, V4, P125, DOI 10.1038/sj.cdd.4400218; Zoran DL, 1997, NUTR CANCER, V27, P222, DOI 10.1080/01635589709514530	32	161	164	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3199	3204		10.1038/sj.onc.1202660	http://dx.doi.org/10.1038/sj.onc.1202660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359525				2022-12-25	WOS:000080523800002
J	Matsui, E; Kawasaki, S; Ishida, H; Ishikawa, K; Kosugi, Y; Kikuchi, H; Kawarabayashi, Y; Matsui, I				Matsui, E; Kawasaki, S; Ishida, H; Ishikawa, K; Kosugi, Y; Kikuchi, H; Kawarabayashi, Y; Matsui, I			Thermostable flap endonuclease from the archaeon, Pyrococcus horikoshii, cleaves the replication fork-like structure endo exonucleolytically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING RECBCD ENZYME; NUCLEOTIDE EXCISION-REPAIR; HOT-SPOT-CHI; ESCHERICHIA-COLI; DNA-REPLICATION; MAMMALIAN 5'-EXONUCLEASE; NUCLEIC-ACIDS; RECOMBINATION; STRAND; 3'-EXONUCLEASE	The flap endonuclease gene homologue from the hyperthermophilic archaeon, Pyrococcus horikoshii, was overexpressed in Escherichia coli and purified, The results of gel filtration indicated that this protein was a 41-kDa monomer. P. horikoshii flap endonuclease (phFEN) cleaves replication fork-like substrates (RF) and 5' double strand flap structures (DF) using both flap endonuclease and 5'-3'-exonuclease activities. The mammalian flap endonuclease (mFEN) is a single-strand flap-specific endonuclease (Harrington, J. J,, and Lieber, M, R, (1994) EMBO J, 13, 1235-1246), but the action patterns of phFEN appear to be quite different from those of mFEN at this point, The DF specific flap endonuclease ase and 5'-exonuclease activities have not yet been reported. Therefore, this is the first report of the specific endo/exonuclease activities of phFEN. The DF-specific 5'-exonuclease activity degraded the downstream primer of 3' single-flap structure and was 15 times higher than the activities against nicked substrates without 3' flap strand. DF-specific flap endonuclease cleaved the 5' double-flap strand in DF and the lagging strand in RF at the junction portion. Because the RF appears to be the intermediate structure, due to the arrest of the replication fork, the double strand breaks after the arrests of the replication forks are probably caused by phFEN.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; AIST, Natl Inst Technol & Evaluat, Tokyo 150, Japan; New Energy & Ind Technol Dev Org, Tokyo 170, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Biosci & Human Technol, Higashi 1-1, Tsukuba, Ibaraki 305, Japan.	imatsui@ccmail.nibh.go.jp						Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; COX SL, 1998, JIKKENIGAKU, V16, P1031; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROBB FT, 1996, ABSTR THERM 96, P85; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tracy RB, 1997, CELL, V90, P205, DOI 10.1016/S0092-8674(00)80328-1; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	35	25	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18297	18309		10.1074/jbc.274.26.18297	http://dx.doi.org/10.1074/jbc.274.26.18297			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373433	hybrid			2022-12-25	WOS:000081056700025
J	Niviere, V; Fieschi, F; Decout, JL; Fontecave, M				Niviere, V; Fieschi, F; Decout, JL; Fontecave, M			The NAD(P)H : Flavin oxidoreductase from Escherichia coli - Evidence for a new mode of binding for reduced pyridine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHTHALATE DIOXYGENASE REDUCTASE; VIBRIO-FISCHERI ATCC-7744; FERREDOXIN-NADP(+) REDUCTASE; RIBONUCLEOTIDE REDUCTASE; BIOLUMINESCENT BACTERIUM; SUBSTRATE-SPECIFICITY; SULFITE REDUCTASE; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; NADPH	The NAD(P)H:flavin oxidoreductase from Escherichia coli, named Fre, is a monomer of 26.2 kDa that catalyzes the reduction of free flavins using NADPH or NADH as electron donor. The enzyme does not contain any prosthetic group but accommodates both the reduced pyridine nucleotide and the flavin in a ternary complex prior to oxidoreduction. The specificity of the flavin reductase for the pyridine nucleotide was studied by steady-state kinetics using a variety of NADP analogs. Both the nicotinamide ring and the adenosine part of the substrate molecule have been found to be important for binding to the polypeptide chain. However, in the case of NADPH, the 2'-phosphate group destabilized almost completely the interaction with the adenosine moiety. Moreover, NADPH and NMNH are very good substrates for the flavin reductase, and we have shown that both these molecules bind to the enzyme almost exclusively by the nicotinamide ring. This provides evidence that the flavin reductase exhibits a unique mode for recognition of the reduced pyridine nucleotide. In addition, we have shown that the flavin reductase selectively transfers the pro-R hydrogen from the C-4 position of the nicotinamide ring and is therefore classified as an A-side-specific enzyme.	Univ J Fourier, CNRS, CEA,Ctr Redox Biol, DBMS,Lab Chim & Biochim, F-38054 Grenoble 9, France; Univ J Fourier, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Niviere, V (corresponding author), Univ J Fourier, CNRS, CEA,Ctr Redox Biol, DBMS,Lab Chim & Biochim, Batiment K,17 Ave Martyrs, F-38054 Grenoble 9, France.		Fieschi, Franck/W-2748-2019	Niviere, Vincent/0000-0002-5132-457X; FIESCHI, Franck/0000-0003-1194-8107				Adolph HW, 1997, BIOCHEMISTRY-US, V36, P8743, DOI 10.1021/bi970398k; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DALZIEL K, 1973, ENZYMES, V11, P2; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; FONTECAVE M, 1992, ADV ENZYMOL, V65, P145; Fromm H J, 1979, Methods Enzymol, V63, P467; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; GAUDU P, 1994, J BIOL CHEM, V269, P8182; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; HULTQUIST DE, 1993, AM J HEMATOL, V42, P13, DOI 10.1002/ajh.2830420105; INOUYE S, 1994, BIOCHEM BIOPH RES CO, V205, P275, DOI 10.1006/bbrc.1994.2661; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; MOSTAD SB, 1993, J CHEM EDUC, V70, P504, DOI 10.1021/ed070p504; Niviere V, 1996, J BIOL CHEM, V271, P16656, DOI 10.1074/jbc.271.28.16656; Niviere V, 1998, BIOCHEMISTRY-US, V37, P11879, DOI 10.1021/bi980396f; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; RUDOLPH FB, 1979, METHOD ENZYMOL, V63, P139; Segel I.H., 1975, ENZYME KINETICS; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; TRIMBOLI AJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P48, DOI 10.1006/abbi.1994.1469; YUBISUI T, 1979, J BIOCHEM, V85, P719; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	39	36	38	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18252	18260		10.1074/jbc.274.26.18252	http://dx.doi.org/10.1074/jbc.274.26.18252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373427	Green Submitted, hybrid			2022-12-25	WOS:000081056700019
J	Rabbani, A; Iskandar, M; Ausio, J				Rabbani, A; Iskandar, M; Ausio, J			Daunomycin-induced unfolding and aggregation of chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRACYCLINE ANTIBIOTICS; DEOXYRIBONUCLEIC-ACID; EQUILIBRIUM BINDING; MOLECULAR-STRUCTURE; HISTONE TAILS; DNA-BINDING; NUCLEOSOMES; ADRIAMYCIN; DAUNORUBICIN; D(CPGPTPAPCPG)	Using equilibrium dialysis and sedimentation velocity analysis, we have characterized the binding of the antitumor drug daunomycin to chicken erythrocyte chromatin before and after depletion of linker histones and to its constitutive DNA under several ionic strengths (5, 25, and 75 mM NaCl), The equilibrium dialysis experiments reveal that the drug binds cooperatively to both the chromatin fractions and to the DNA counterpart within the range of ionic strength used in this study. A significant decrease in the binding affinity was observed at 75 mM NaCl, At any given salt concentration, daunomycin exhibits higher binding affinity for DNA than for linker histone-depleted chromatin or chromatin (in decreasing order). Binding of daunomycin to DNA does not significantly affect the sedimentation coefficient of the molecule. This is in contrast to binding to chromatin and to its linker histone depleted counterpart. In these instances, preferential binding of the drug to the linker DNA regions induces an unfolding of the chromatin fiber that is followed by aggregation, presumably because of histone-DNA interfiber interactions.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Tehran, Inst Biochem & Biophys, Tehran 14174, Iran	University of Victoria; University of Tehran	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						Arcamone F., 1981, DOXORUBICIN ANTICANC; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; BARCELO F, 1991, INT J BIOL MACROMOL, V13, P235; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CERA C, 1991, NUCLEIC ACIDS RES, V19, P2309, DOI 10.1093/nar/19.9.2309; Chaires J. B., 1996, ADV DNA SEQUENCE SPE, V2, P141; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P284, DOI 10.1021/bi00271a009; DIMARCO A, 1974, ANTIBIOTICS; DORIGOTTI L., 1964, TUMORI, V50, P117; DORR RT, 1982, CURRENT CONCEPTS USE, P1; FRITZSCHE H, 1987, BIOCHEMISTRY-US, V26, P1996, DOI 10.1021/bi00381a032; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GELVAN D, 1986, BIOCHEM PHARMACOL, V35, P3267, DOI 10.1016/0006-2952(86)90423-5; GRAVES DE, 1983, BIOCHEMISTRY-US, V22, P3941, DOI 10.1021/bi00285a033; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Krajewski WA, 1997, J BIOMOL STRUCT DYN, V14, P641, DOI 10.1080/07391102.1997.10508164; KRIEBARDIS T, 1987, J BIOL CHEM, V262, P12632; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Maniatis T., 1982, MOL CLONING; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; NEIDLE S, 1979, FEBS LETT, V107, P348, DOI 10.1016/0014-5793(79)80405-6; Neidle S, 1979, Prog Med Chem, V16, P151, DOI 10.1016/S0079-6468(08)70188-7; PEARLMAN LF, 1986, CANCER RES, V46, P341; PHILLIPS DR, 1989, FEBS LETT, V246, P233, DOI 10.1016/0014-5793(89)80289-3; QUIGLEY GJ, 1980, P NATL ACAD SCI-BIOL, V77, P7204, DOI 10.1073/pnas.77.12.7204; RABBANI A, 1994, GEN PHARMACOL-VASC S, V25, P787, DOI 10.1016/0306-3623(94)90261-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID CW, 1971, BIOPOLYMERS, V10, P883, DOI 10.1002/bip.360100511; SEN D, 1986, BIOCHEMISTRY-US, V25, P1503, DOI 10.1021/bi00355a005; TATCHELL K, 1979, BIOCHEMISTRY-US, V18, P2870, DOI 10.1021/bi00580a031; THOMAS JO, 1980, J MOL BIOL, V144, P89, DOI 10.1016/0022-2836(80)90215-6; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; YAGER TD, 1984, J BIOL CHEM, V259, P4212; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561; ZUNINO F, 1980, BIOCHIM BIOPHYS ACTA, V607, P206, DOI 10.1016/0005-2787(80)90073-8	44	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18401	18406		10.1074/jbc.274.26.18401	http://dx.doi.org/10.1074/jbc.274.26.18401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373446	hybrid			2022-12-25	WOS:000081056700038
J	Ame, JC; Rolli, V; Schreiber, V; Niedergang, C; Apiou, F; Decker, P; Muller, S; Hoger, T; Murcia, JMD; de Murcia, G				Ame, JC; Rolli, V; Schreiber, V; Niedergang, C; Apiou, F; Decker, P; Muller, S; Hoger, T; Murcia, JMD; de Murcia, G			PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); CATALYTIC DOMAIN; CDNA SEQUENCE; PROTEIN; REPAIR; PURIFICATION; BINDING; CELLS; OVERPRODUCTION; NUCLEAR	Poly(ADP-ribosylation) is a post-translational modification of nuclear proteins in response to DNA damage that activates the base excision repair machinery. Poly(ADP-ribose) polymerase which we will now call PARP-1, has been the only known enzyme of this type for over 30 years. Here, we describe a cDNA encoding a 62-kDa protein that shares considerable homology with the catalytic domain of PARP-1 and also contains a basic DNA-binding domain. We propose to call this enzyme poly(ADP-ribose) polymerase 2 (PARP-2). The PARP-2 gene maps to chromosome 14C1 and 14q11.2 in mouse and human, respectively, Purified recombinant mouse PARP-2 is a damaged DNA-binding protein in vitro and catalyzes the formation of poly(ADP-ribose) polymers in a DNA-dependent manner. PARP-2 displays automodification properties similar to PARP-1. The protein is localized in the nucleus in vivo and may account for the residual poly(ADP-ribose) synthesis observed in PARP-1-deficient cells, treated with alkylating agents or hydrogen peroxide.	Ecole Super Biotechnol Strasbourg, Lab Conventionne Commissariat Energie Atom, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France; Inst Curie Rech, UMR 147, F-75248 Paris, France; BASF AG, Pharmaceut Res, D-67056 Ludwigshafen, Germany; CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67000 Strasbourg, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; BASF; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de Murcia, G (corresponding author), Ecole Super Biotechnol Strasbourg, Lab Conventionne Commissariat Energie Atom, CNRS, UPR 9003, Blvd Sebastien Brant, F-67400 Illkirch Graffenstaden, France.	demurcia@esbs.u-strasbg.fr	Decker, Patrice/AAD-8624-2022; Schreiber, Valérie/M-5007-2016; Muller, Sylviane/J-5319-2014	Schreiber, Valérie/0000-0003-0507-639X; Decker, Patrice/0000-0002-8155-2792				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN YM, 1994, EUR J BIOCHEM, V224, P135, DOI 10.1111/j.1432-1033.1994.tb20004.x; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DANG CV, 1989, J BIOL CHEM, V264, P18019; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DURKACZ BW, 1981, EUR J BIOCHEM, V121, P65, DOI 10.1111/j.1432-1033.1981.tb06430.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; JUNG S, 1994, J MOL BIOL, V244, P114, DOI 10.1006/jmbi.1994.1709; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; KEITH G, 1990, ANAL BIOCHEM, V191, P309, DOI 10.1016/0003-2697(90)90224-W; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; Mahajan PB, 1998, PLANT PHYSIOL, V118, P895, DOI 10.1104/pp.118.3.895; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; Miranda EA, 1997, BRAZ J MED BIOL RES, V30, P923, DOI 10.1590/S0100-879X1997000800002; Miwa M, 1982, Princess Takamatsu Symp, V12, P205; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; OFARRELL M, 1995, BIOCHIMIE, V77, P486, DOI 10.1016/0300-9084(96)88165-X; Ruf A, 1998, J MOL BIOL, V278, P57, DOI 10.1006/jmbi.1998.1673; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879	46	577	619	1	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17860	17868		10.1074/jbc.274.25.17860	http://dx.doi.org/10.1074/jbc.274.25.17860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364231	hybrid			2022-12-25	WOS:000080974300067
J	Bauer, B; Mirey, G; Vetter, IR; Garcia-Ranea, JA; Valencia, A; Wittinghofer, A; Camonis, JH; Cool, RH				Bauer, B; Mirey, G; Vetter, IR; Garcia-Ranea, JA; Valencia, A; Wittinghofer, A; Camonis, JH; Cool, RH			Effector recognition by the small GTP-binding proteins Ras and Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PLATELET GN-PROTEINS; C-FOS PROMOTER; PUTATIVE EFFECTOR; ACTIVATING PROTEIN; EXCHANGE FACTOR; PHOSPHOLIPASE-D; INTERACTING DOMAIN; SYNAPTIC VESICLES; ESCHERICHIA-COLI	The Ral effector protein RLIP76 (also called RIP/RalBP1) binds to Ral GTP via a region that shares no sequence homology with the Ras-binding domains of the Ser/Thr kinase c-Raf-1 and the Ral-specific guanine nucleotide exchange factors. Whereas the Res-binding domains have a similar ubiquitin-like structure, the Ral-binding domain of RLIP was predicted to comprise a coiled-coil region. In order to obtain more information about the specificity and the structural mode of the interaction between Ral and RLIP, we have performed a sequence space and a mutational analysis. The sequence space analysis of a comprehensive nonredundant assembly of Ras-like proteins strongly indicated that positions 36 and 37 in the core of the effector region are tree-determinant positions for all subfamilies off Ras-like proteins and dictate the specificity of the interaction of these GTPases with their effector proteins. Indeed, we could convert the specific interaction with Ras effecters and RLIP by mutating these residues in Res and Ral. We therefore conclude that positions 36 and 37 are critical for the discrimination between Ras and Ral effecters and that, despite the absence of sequence homology between the Ral-binding and the Ras-binding domains, their mode of interaction is most probably similar.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany; Inst Curie, INSERM, U248, F-75248 Paris 05, France; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Prot Design Grp, M-28049 Madrid, Spain	Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Cool, RH (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	robbert.cool@mpi-dortmund.mpg.de	Valencia, Alfonso/I-3127-2015; Mirey, Gladys/H-5676-2019	Valencia, Alfonso/0000-0002-8937-6789; Mirey, Gladys/0000-0002-0095-1864; Cool, Robbert/0000-0002-9845-2202; Garcia Ranea, Juan Antonio/0000-0003-0327-1837				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDRADE MA, 1999, GENOME SEQUENCE ANAL; Atrian S, 1998, J MOL EVOL, V47, P211, DOI 10.1007/PL00006378; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; CASARI G, 1995, PROTEIN FOLD DISTANC, P124; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4830; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; FRECH M, 1990, J BIOL CHEM, V265, P6353; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herberg JA, 1998, J MOL BIOL, V277, P839, DOI 10.1006/jmbi.1998.1637; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Murai H, 1997, J BIOL CHEM, V272, P10483; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; OLOFSSON B, 1988, ONCOGENE, V3, P231; Park SH, 1995, ONCOGENE, V11, P2349; Pazos F., 1997, BIOCOMPUTING EMERGEN, P132; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romero F, 1996, MOL CELL BIOL, V16, P37; Rose MD., 1990, METHODS YEAST GENETI; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schwartz MA, 1998, ONCOGENE, V17, P625, DOI 10.1038/sj.onc.1201977; Shirouzu M, 1998, J BIOL CHEM, V273, P7737, DOI 10.1074/jbc.273.13.7737; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	71	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17763	17770		10.1074/jbc.274.25.17763	http://dx.doi.org/10.1074/jbc.274.25.17763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364219	Green Published, hybrid			2022-12-25	WOS:000080974300055
J	Carballo, M; Conde, M; El Bekay, R; Martin-Nieto, J; Camacho, MJ; Monteseirin, J; Conde, J; Bedoya, FJ; Sobrino, F				Carballo, M; Conde, M; El Bekay, R; Martin-Nieto, J; Camacho, MJ; Monteseirin, J; Conde, J; Bedoya, FJ; Sobrino, F			Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; T-LYMPHOCYTES; CYTOKINE RECEPTORS; PHOSPHATASE INHIBITORS; DEPENDENT ACTIVATION; TRANSCRIPTION FACTOR; PHENYLARSINE OXIDE; HYDROGEN-PEROXIDE; INTERFERON-GAMMA	Oxidizing agents are powerful activators of factors responsible for the transcriptional activation of cytokine-encoding genes involved in tissue injury. In this study we show evidence that STAT3 is a transcription factor whose activity is modulated by H2O2 in human lymphocytes, in which endogenous catalase had previously been inhibited. H2O2-induced nuclear translocation of STAT3 to form sequence-specific DNA-bound complexes was evidenced by immunoblotting of nuclear fractions and electrophoretic mobility shift assays, and vanadate was found to strongly synergize with H2O2. Moreover, anti-STAT3 antibodies specifically precipitated a protein of 92 kDa that becomes phosphorylated on tyrosine upon lymphocyte treatment with H2O2. Phenylarsine oxide, a tyrosine phosphatase inhibitor, and genistein, a tyrosine kinase inhibitor, cooperated and cancelled, respectively, the H2O2-promoted STAT3 nuclear translocation, Evidence is also presented, using Fe2+/Cu2+ ions, that 'OH generated from H2O2 through Fenton reactions could be a candidate oxygen reactive species to directly activate STAT3, Present data suggest that H2O2 and vanadate are likely to inhibit the activity of intracellular tyrosine phosphatase(s), leading to enhanced STAT3 tyrosine phosphorylation and hence its translocation to the nucleus, These results demonstrate that the DNA binding activity of STAT3 can be modulated by oxidizing agents and provide a framework to understand the effects of oxidative stress on the JAK-STAT signaling pathway.	Univ Seville, Hosp Virgen Macarena, Dept Bioquim Med & Biol Mol, Fac Med, E-41009 Seville, Spain; Univ Seville, Hosp Virgen Macarena, Dept Med, Serv Reg Inmunol & Alergia, E-41009 Seville, Spain; Univ Alicante, Div Genet, E-03080 Alicante, Spain	Hospital Universitario Virgen Macarena; University of Sevilla; Hospital Universitario Virgen Macarena; University of Sevilla; Universitat d'Alacant	Sobrino, F (corresponding author), Fac Med, Dept Bioquim Med & Biol Mol, Avda Sanchex Pizjuan 4, Seville 41009, Spain.	fsobrino@cica.es	Bedoya, Francisco J/R-4871-2018; Bedoya, Francisco/AAX-8812-2021; Bekay, Rajaa El/AAZ-3959-2020; MARTÍN-NIETO, JOSÉ/R-5428-2018; El Bekay, RAJAA/AGN-6069-2022	Bedoya, Francisco J/0000-0003-0262-7029; Bedoya, Francisco/0000-0003-0262-7029; MARTÍN-NIETO, JOSÉ/0000-0002-7815-6887; El Bekay, RAJAA/0000-0003-3332-3431; Sobrino, Francisco/0000-0002-4503-5739				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Coligan J.E., 1993, CURRENT PROTOCOLS IM; CROSS AR, 1989, NEUTROPHIL CELLULAR, P97; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLESCHER E, 1994, J IMMUNOL, V153, P4880; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GUNTHER MR, 1995, ARCH BIOCHEM BIOPHYS, V316, P515, DOI 10.1006/abbi.1995.1068; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Jornot L, 1998, BIOCHEM J, V335, P85, DOI 10.1042/bj3350085; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; Liu BQ, 1996, J IMMUNOL, V157, P160; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STONE RL, 1994, J BIOL CHEM, V269, P31323; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	57	218	224	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17580	17586		10.1074/jbc.274.25.17580	http://dx.doi.org/10.1074/jbc.274.25.17580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364193	hybrid, Green Published			2022-12-25	WOS:000080974300029
J	Hecht, A; Litterst, CM; Huber, O; Kemler, R				Hecht, A; Litterst, CM; Huber, O; Kemler, R			Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; ACIDIC ACTIVATION DOMAINS; RNA-POLYMERASE-II; XENOPUS EMBRYOS; AXIS SPECIFICATION; FACTOR-TFIIB; IN-VITRO; DROSOPHILA; ARMADILLO; PLAKOGLOBIN	beta-Catenin, a member of the family of Armadillo repeat proteins, plays a dual role in cadherin-mediated cell adhesion and in signaling by Wnt growth factors, Upon Wnt stimulation beta-catenin undergoes nuclear translocation and serves as transcriptional coactivator of T cell factor DNA-binding proteins. Previously the transactivation potential of different portions of beta-catenin has been demonstrated, but the precise location of transactivating elements has not been established. Also, the mechanism of transactivation by beta-catenin and the molecular basis for functional differences between beta-catenin and the closely related proteins Armadillo and Plakoglobin are poorly understood. Here we have used a yeast system for the detailed characterization of the transactivation properties of beta-catenin. We show that its transactivation domains possess a modular structure, consist of multiple subelements that cover broad regions at its N and C termini, and extend considerably into the Armadillo repeat region. Compared with beta-catenin the N termini of Plakoglobin and Armadillo have different transactivation capacities that may explain their distinct signaling properties. Furthermore, transactivating elements of beta-catenin interact specifically and directly with the TATA-binding protein in vitro providing further evidence that a major function of beta-catenin during Wnt signaling is to recruit the basal transcription machinery to promoter regions of Wnt target genes.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Max Planck Society	Hecht, A (corresponding author), Max Planck Inst Immunobiol, Stuebeweg 51, D-79108 Freiburg, Germany.	hecht@immunbio.mpg.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747; Hecht, Andreas/0000-0003-2262-2575				ABERLE H, 1994, J CELL SCI, V107, P3655; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bierkamp C, 1999, DEVELOPMENT, V126, P371; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLEY JR, 1995, DNA CLONING PRACTICA, P169; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; Kobayashi N, 1998, MOL CELL BIOL, V18, P4023, DOI 10.1128/MCB.18.7.4023; Kofron M, 1997, DEVELOPMENT, V124, P1553; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	66	154	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18017	18025		10.1074/jbc.274.25.18017	http://dx.doi.org/10.1074/jbc.274.25.18017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364252	hybrid			2022-12-25	WOS:000080974300088
J	Kaliman, P; Canicio, J; Testar, X; Palacin, M; Zorzano, A				Kaliman, P; Canicio, J; Testar, X; Palacin, M; Zorzano, A			Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappa B and inducible nitric-oxide synthase define a common myogenic signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; TRANSCRIPTION FACTOR; DNA-BINDING; MYOBLAST DIFFERENTIATION; S6 KINASE; IGF-I; EXPRESSION; ACTIVATION; ALPHA	Insulin-like growth factors (IGFs) are potent inducers of skeletal muscle differentiation and plnosphatidylinositol (PI) 3-kinase activity is essential for this process. Here we show that IGF-II induces nuclear factor-kappa B (NF-kappa B) and nitric-oxide synthase (NOS) activities downstream from PI 3-kinase and that these events are critical for myogenesis. Differentiation of rat L6E9 myoblasts with IGF-II transiently induced NF-kappa B DNA binding activity, inducible nitric-oxide synthase (iNOS) expression, and nitric oxide (NO) production. IGF-II-induced iNOS expression and NO production were blocked by NF-kappa B inhibition. Both NF-kappa B and NOS activities were essential for IGF-II-induced terminal differentiation (myotube formation and expression of skeletal muscle proteins: myosin heavy chain, GLUT 4, and caveolin 3), which was totally blocked by NF-kappa B or NOS inhibitors in rat and human myoblasts. Moreover, the NOS substrate L-Arg induced myogenesis in the absence of IGFs in both rat and human myoblasts, and this effect was blocked by NOS inhibition. Regarding the mechanisms involved in IGF-II activation of NF-kappa B, PI S-kinase inhibition prevented NF-kappa B activation, iNOS expression, and NO production. Moreover, IGF-II induced, through a PI 3-kinase-dependent pathway, a decrease in I kappa B-alpha protein content that correlated with a decrease in the amount of I kappa B-alpha associated with p65 NF-kappa B.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Kaliman, P (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avinguda Diagonal 645, E-08028 Barcelona, Spain.		Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015	Palacin, Manuel/0000-0002-8670-293X				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BRENMAN JE, 1995, CELL, V82, P742; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; Canicio J, 1998, ENDOCRINOLOGY, V139, P5042, DOI 10.1210/en.139.12.5042; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GUO K, 1995, MOL CELL BIOL, V15, P3823; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LEE KH, 1994, J BIOL CHEM, V269, P14371; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PUJADES C, 1992, J CELL SCI, V102, P815; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	105	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17437	17444		10.1074/jbc.274.25.17437	http://dx.doi.org/10.1074/jbc.274.25.17437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364173	hybrid			2022-12-25	WOS:000080974300009
J	Monick, MM; Carter, AB; Hunninghake, GW				Monick, MM; Carter, AB; Hunninghake, GW			Human alveolar macrophages are markedly deficient in REF-1 and AP-1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-2; INTERSTITIAL LUNG-DISEASE; BLOOD MONOCYTES; ARACHIDONATE METABOLISM; TRANSCRIPTION FACTOR; MESSENGER-RNA; PROTEIN; EXPRESSION; FOS; JUN	Although many functions of human alveolar macrophages are altered compared with their precursor cell, the blood monocyte (monocyte), the reason(s) for these functional changes have not been determined. We recently reported that human alveolar macrophages do not express AP-1 DNA binding activity (Monick, M. RI., Carter, A B., Gudmundsson, G;., Geist, L, J,, and Hunninghake, G;. W, (1998) Am, J, Physiol, 275, L389-L397). To determine why alveolar macrophages do not express AP-1 DNA binding activity, we first showed that there was not a decrease in expression of the FOS and JUN proteins that make up the AP-1 complex. There was, however, a significant difference in the amounts of the nuclear protein, REF-1 (which regulates AP-1 DNA: binding by altering the redox status of FOS and JUN proteins), in alveolar macrophages compared with monocytes, In addition, in vitro differentiation of monocytes to a macrophage-like cell resulted in decreased amounts of REF-1, Finally, addition of REF-1 from activated monocytes to alveolar macrophage nuclear proteins resulted in a marked increase in AP-1 DNA binding, These studies strongly suggest that the process of differentiation of monocytes into alveolar macrophages is associated with a loss of REF-1 and AP-1 activity. This observation may explain, in part, some of the functional differences observed for alveolar macrophages compared with monocytes.	Univ Iowa, Coll Med, Dept Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Hunninghake, GW (corresponding author), Univ Iowa Hosp & Clin, Div Pulm, Rm 100 EMRB,200 Hawkins Dr, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL-03860, HL-37121] Funding Source: Medline; NIAID NIH HHS [AI-35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; BALTER MS, 1989, J IMMUNOL, V142, P602; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Bingisser P, 1996, AM J RESP CELL MOL, V15, P64, DOI 10.1165/ajrcmb.15.1.8679223; BROWN GP, 1988, AM J PHYSIOL, V254, pC809, DOI 10.1152/ajpcell.1988.254.6.C809; CAMPBELL DA, 1986, THORAX, V41, P429, DOI 10.1136/thx.41.6.429; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; ELIAS JA, 1985, J IMMUNOL, V135, P3198; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fung H, 1998, CANCER RES, V58, P189; Geist LJ, 1997, AM J RESP CELL MOL, V16, P31, DOI 10.1165/ajrcmb.16.1.8998076; Gillardon F, 1997, MOL BRAIN RES, V52, P194, DOI 10.1016/S0169-328X(97)00237-4; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HEMPEL SL, 1994, J BIOL CHEM, V269, P32979; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOOGSTEDEN HC, 1989, CHEST, V95, P574, DOI 10.1378/chest.95.3.574; Hopkins HA, 1995, AM J PHYSIOL-LUNG C, V269, pL849, DOI 10.1152/ajplung.1995.269.6.L849; Hopkins HA, 1996, J INFECT DIS, V174, P69, DOI 10.1093/infdis/174.1.69; HUNNINGHAKE GW, 1986, ANN NY ACAD SCI, V465, P82, DOI 10.1111/j.1749-6632.1986.tb18483.x; HUNNINGHAKE GW, 1980, METHOD CELL BIOL, P95; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLINE JN, 1993, CHEST, V104, P47, DOI 10.1378/chest.104.1.47; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; MONICK M, 1987, AM REV RESPIR DIS, V135, P72; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P4320; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Rothwell DG, 1997, ONCOL RES, V9, P275; STRIETER RM, 1990, AM J RESP CELL MOL, V2, P321, DOI 10.1165/ajrcmb/2.4.321; Suzuki S, 1998, BIOCHEM MOL BIOL INT, V44, P217; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	38	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18075	18080		10.1074/jbc.274.25.18075	http://dx.doi.org/10.1074/jbc.274.25.18075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364260	hybrid			2022-12-25	WOS:000080974300096
J	Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS				Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS			Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint	ONCOGENE			English	Article						p53; radiation; cell cycle; homologous recombination	WILD-TYPE P53; CELL-CYCLE ARREST; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; GENE AMPLIFICATION; RAD51 PROTEIN; MUTATION; CONFORMATION; DEFECTS	We report here a systematic analysis of the effects of different p53 mutations on both spontaneous and radiation-stimulated homologous recombination in mouse L cells. In order to monitor different recombination pathways, we used both direct and inverted repeat recombination substrates. In each line bearing one of these substrates, we expressed p53 proteins mutated at positions: 175, 248 or 273, p53 mutations leading to an increased spontaneous recombination rate also stimulate radiation-induced recombination. The effect on recombination may be partially related to the conformation of the p53 protein. Moreover, p53 mutations act on recombination between direct repeats as well as between inverted repeats indicating that strand invasion mechanisms are stimulated. Although all of the p53 mutations affect the p53 transactivation activity measured on the WAF1 and MDM2 gene promoters, no correlation between the transactivation activity and the extent of homologous recombination can be drawn. Finally, some p53 mutations do not affect the G1 arrest after radiation but stimulate radiation-induced recombination. These results show that the role of p53 on transactivation and G1 cell cycle checkpoint is separable from its involvement in homologous recombination. A direct participation of p53 in the recombination mechanism itself is discussed.	CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, F-92265 Fontenay Aux Roses, France; Inst Curie, F-75231 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, 60-68 Av Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Saintigny, Yannick/C-2697-2008; Lopez, Bernard S/O-7308-2017	Saintigny, Yannick/0000-0002-3839-3562; Lopez, Bernard S/0000-0001-5088-0155; soussi, thierry/0000-0001-8184-3293				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Arnheim N., 1983, P38; BALTIMORE D, 1981, CELL, V26, P295, DOI 10.1016/0092-8674(81)90196-3; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BENJAMIN MB, 1992, MOL CELL BIOL, V12, P2730, DOI 10.1128/MCB.12.6.2730; Bertini I, 1997, J BIOL INORG CHEM, V2, P1; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Ivanov EL, 1996, GENETICS, V142, P693; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1999, IN PRESS MUTATION RE; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; LIN FLM, 1987, MOL CELL BIOL, V7, P129, DOI 10.1128/MCB.7.1.129; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J., 2002, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TYLER J, 1996, NATURE, V381, P643; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	49	106	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3553	3563		10.1038/sj.onc.1202941	http://dx.doi.org/10.1038/sj.onc.1202941			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380877	Bronze, Green Published			2022-12-25	WOS:000080891700001
J	De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B				De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B			Role of the ATFa/JNK2 complex in Jun activation	ONCOGENE			English	Article						ATF; Jun; JNK SAPK	DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; HETERODIMER FORMATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; RESPONSE ELEMENT; MAMMALIAN-CELLS; MAP KINASES	The ATFa proteins, which are members of the CREB/ATF family of transcription factors, display quite versatile properties, We have previously shown that they interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity and heterodimerize with the Jun, Fos or related transcription factors, thereby modulating their DNA-binding specificity, In the present study, we report the sequence requirement of the N-terminal activation domain of ATFa and demonstrate the importance of specific threonine residues (Thr51 and Thr53) in addition to that of the metal-binding domain, in transcriptional activation processes. We also show that the N-terminal domain of ATFa which stably binds the Jun N-terminal kinase-2 (JNK2) (Bocco et al,, 1996), is not a substrate for this kinase in vivo but, instead, serves as a JNK2-docking site for ATFa-associated partners like JunD, allowing them to be phosphorylated by the bound kinase.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Kedinger, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Wagner, Erwin F/0000-0001-7872-0196; DE GRAEVE, Fabienne/0000-0002-3455-7507				ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bocco JL, 1996, ONCOGENE, V12, P1971; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE KAW, 1992, J CELL SCI, V103, P9; LEFF T, 1994, P NATL ACAD SCI USA, V81, P4381; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU F, 1993, NATURE, V366, P531; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang HL, 1996, ONCOGENE, V13, P2639; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	48	26	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3491	3500		10.1038/sj.onc.1202723	http://dx.doi.org/10.1038/sj.onc.1202723			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376527				2022-12-25	WOS:000080850600007
J	Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML				Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML			Repression of NF-kappa B impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators	ONCOGENE			English	Article						cell cycle; NF-kappa B; G1/S transition; p53; c-Myc; apoptosis	TRANSCRIPTION FACTOR; C-MYC; PROTEIN-KINASE; ALPHA PROTEOLYSIS; BREAST-CANCER; DNA-BINDING; IN-VIVO; ACTIVATION; PHOSPHORYLATION; GROWTH	NF-kappa B is an inducible transcription factor, which is regulated by interaction with inhibitory I kappa B proteins. Previous studies linked the activity of NF-kappa B to the proliferative state of the cell, Here we have analysed the function of NF-kappa B in the cell cycle. Inhibition of NF-kappa B in HeLa cells by stable overexpression of a transdominant negative I kappa B-alpha protein reduced cell growth. A kinetic analysis of the cell cycle revealed a retarded G1/S transition. The I kappa B-alpha overexpressing cell clones show ed a decreased percentage of cells in the S phase and an impaired incorporation of bromodeoxyuridine (BrdU), The amounts of cyclins A, B1, D1, D3, and E were unchanged, but the G1-specific proteins cyclin D2 and cdk2 were strongly elevated in the I kappa B-alpha overexpressing cell clones. These cell clones also displayed an increase in cyclin D1-dependent kinase activity, pointing to a cell ca de arrest at the late G1 phase. I kappa B-alpha overexpression crosstalked to cell cycle checkpoints via a reduction of transcription factor p53 and elevation of p21(WAF). Surprisingly, the I kappa B-alpha overexpressing cells showed an enrichment of c-Myc in the nucleoli, although the total amount of c-Myc protein was unchanged. These experiments identify an important contribution of the NF-kappa B/I kappa B system for the growth of HeLa cells.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Anat, Mol Neurobiol Lab, D-79104 Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLIGAN JE, 1997, CURRENT PROTOCOLS IM, V1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MICHIELI P, 1994, CANCER RES, V54, P3391; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Scheidereit C, 1996, J MOL MED-JMM, V74, P707, DOI 10.1007/s001090050075; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sharma HW, 1996, ANTICANCER RES, V16, P61; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	65	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3213	3225		10.1038/sj.onc.1202657	http://dx.doi.org/10.1038/sj.onc.1202657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359527				2022-12-25	WOS:000080523800004
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1/Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression, In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function, PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity, In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding, The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, R (corresponding author), Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3290	3302		10.1038/sj.onc.1202681	http://dx.doi.org/10.1038/sj.onc.1202681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359535				2022-12-25	WOS:000080523800012
J	Aguda, BD				Aguda, BD			Instabilities in phosphorylation-dephosphorylation cascades and cell cycle checkpoints	ONCOGENE			English	Article						cell cycle; phosphorylation-dephosphorylation cascades; G2-M checkpoint	DNA-DAMAGE CHECKPOINT; CDC2; MITOSIS; KINASE; EVENTS; MODEL	The G2-M checkpoint in the cell cycle is identified with a set of phosphorylation-dephosphorylation (PD) cycles involving Cdc25 and the maturation-promoting factor (MPF); these PD cycles are coupled in a way that generates an instability. This instability arises out of a transcritical bifurcation which could be exploited by the G2 DNA damage checkpoint pathway in order to arrest or delay entry into mitosis, The coupling between PD cycles involving Weel and MPF does not lead to an instability and therefore Weel may not be a crucial target of the checkpoint pathway, A set of PD cycles exhibiting transcritical bifurcation also possesses the integrative ability of a checkpoint for 'checking' that prerequisites are satisfied prior to the next cell cycle event. Such a set of coupled PD cycles is suggested to be a core mechanism of cell cycle checkpoints.	Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada	Laurentian University	Aguda, BD (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada.							BASI G, 1995, CELL CYCLE CONTROL, P106; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FURNARI B, 1996, SCIENCE, V274, P1495; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLES; NOVAK B, 1993, J CELL SCI, V106, P1153; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osmani SA, 1997, TRENDS CELL BIOL, V7, P283, DOI 10.1016/S0962-8924(97)01086-6; PINES J, 1995, CELL CYCLE CONTROL, P144; Poon RYC, 1997, CANCER RES, V57, P5168; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SHACHTER E, 1986, ENZYMES A, V17, P21; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; Thron CD, 1997, ONCOGENE, V15, P317, DOI 10.1038/sj.onc.1201190; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450	22	24	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2846	2851		10.1038/sj.onc.1202462	http://dx.doi.org/10.1038/sj.onc.1202462			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362255				2022-12-25	WOS:000080125100007
J	Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB				Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB			Cooperation of Spl and p300 in the induction of the CDK inhibitor p21(WAF1/CIP1) during NGF-mediated neuronal differentiation	ONCOGENE			English	Article						p21WAF1/CIP1; p300; Spl; NGF; neuronal differentiation; PC12	NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR SP1; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; CELL-CYCLE ARREST; NF-KAPPA-B; PC12 CELLS; HISTONE ACETYLTRANSFERASE; TERMINAL DIFFERENTIATION; TRANSACTIVATION DOMAIN	Addition of nerve growth factor (NGF) to PC12 cells promotes neuronal differentiation while inhibiting cell proliferation. In order to understand how NGF exerts its antimitogenic effect during differentiation, we have studied the mechanism by which this factor activates the promoter of the CDK inhibitor p21(WAF1/CIP1). The minimal region of the p21 promoter required for the NGF-induction was mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site, This GC-rich region was shown to interact specifically with the transcription factor Spl and the related protein Sp3, in either exponentially-growing or NGF-treated PC12 cells, The addition of NGF resulted in an accumulation of the transcriptional co-activator p300 in complexes associated with the NGF-responsive region, Transcriptional activity of Sp1, Sp3 and p300 was specifically induced by NGF in a Gal4-fusion assay, indicating that induction of p21 during neuronal differentiation may involve regulation of the activity of these factors by NGF, Furthermore, p300 was able to act as a co-activator for Sp1-mediated transcriptional activation in PC12 cells, suggesting that p300 and Spl may cooperate in activating p21 transcription during the withdrawal of neuronal precursors from the cell cycle. This hypothesis is supported by experiments showing that p300 and Spl form complexes in PC12 cells.	Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, F-69364 Lyon 07, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Duke University	Rudkin, BB (corresponding author), Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; Watt, Alanna/0000-0002-6371-6220; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4790; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V28, P743; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ECKNER R, 1996, GENE DEV, V7, P1933; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAMIREZ S, 1997, J BIOL CHEM, V272, P31013; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	63	120	121	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2872	2882		10.1038/sj.onc.1202712	http://dx.doi.org/10.1038/sj.onc.1202712			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362258				2022-12-25	WOS:000080125100010
J	Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA				Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA			The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases	ONCOGENE			English	Article						c-Cbl; Src; growth-factor-signaling; mitogenesis	PHOSPHOTYROSINE-BINDING DOMAIN; V-CBL; EGF RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; IN-VIVO; T-CELLS; SRC; ASSOCIATION; PATHWAY	In C, elegans, genetic and biochemical data indicate that the Cbl homolog Sli-1 attenuates Let-23 (EGFR) signaling. To investigate whether c-Cbl might have a role in mammalian growth factor-mediated mitogenic signaling, me microinjected NIH3T3 mouse fibroblasts with expression plasmids encoding wt and G306ECbl (a 'loss of function' mutant identified in C. elegans). We observed inhibition of PDGF BB- and EGF-induced DNA synthesis by wt Cbl but not the mutant. Microinjection of two different affinity purified polyclonal antisera against Cbl boosted a suboptimal PDGF-stimulated mitogenic response. The inhibition of both PDGF BB- and EGF-induced DNA synthesis by,rt Cbl was reversed by co-expression with Myc but not with Fos, DNA synthesis initiated by constitutively activated Src was also blocked by Cbl expression, but curiously by the G306E mutant as well. These data are all consistent with the proposition that Cbl negatively affects mitogenic signaling in mammalian fibroblasts.	SUGEN Inc, S San Francisco, CA 94080 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Pfizer; New York University	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, S San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; KEANE MM, 1995, ONCOGENE, V10, P2367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; YISHIMURA T, 1995, EMBO J, V14, P2816; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	31	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2908	2912		10.1038/sj.onc.1202873	http://dx.doi.org/10.1038/sj.onc.1202873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362262				2022-12-25	WOS:000080125100014
J	Jiang, B; Cyert, MS				Jiang, B; Cyert, MS			Identification of a novel region critical for calcineurin function in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; 1,3-BETA-D-GLUCAN SYNTHASE; AUTOINHIBITORY DOMAIN; CATALYTIC SUBUNIT; MEMBRANE-PROTEIN; ESCHERICHIA-COLI; SHUTTLE VECTORS	Calcineurin is a Ca2+/calmodulin-regulated protein phosphatase that plays critical functional roles in T cell activation and other Ca2+-mediated signal transduction pathways in mammalian cells. In Saccharomyces cerevisiae, calcineurin regulates the transcription of several genes involved in maintaining ion homeostasis (PMC1, PMR1, and PMR2) and cell wall synthesis (FKS2). In this paper, we report the identification and characterization of 11 single amino acid substitutions in the yeast calcineurin catalytic subunit Cna1p. We show that six substitutions (R177G, F211S, S232F, D258V, L259P, and A262P) affect the stability of calcineurin and that two substitutions (V385D and M400R) disrupt the interaction between Cna1p and the calcineurin regulatory subunit Cnb1p. We also identify three mutations (S373P, H375L, and L379S) that are clustered between the catalytic and the calcineurin B subunit-binding domains. These mutations do not significantly affect the ability of Cna1p to interact with Cnb1p, calmodulin, or Fkb1p (FK506-binding protein). However, these residue substitutions dramatically affect calcineurin activity both in vitro and in vivo. Thus, by using a random mutagenesis approach, we have shown for the first time that the linker region of the calcineurin catalytic subunit, as defined by the Ser(373), His(375), and Leu(379) residues, is crucial for its function as a phosphatase.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Cyert, MS (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Cyert, Martha/0000-0003-3825-7437				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1989, ADV EXP MED BIOL, V155, P347; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU XQ, 1993, ACTA PHARM SINIC, V14, P200; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MENDOZA I, 1994, J BIOL CHEM, V269, P2792; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NAKAMURA T, 1992, FEBS LETT, V309, P103, DOI 10.1016/0014-5793(92)80749-7; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Sherman F., 1986, METHODS YEAST GENETI; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SIKORSKI RS, 1989, GENETICS, V122, P19; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Withee JL, 1998, GENETICS, V149, P865; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18543	18551		10.1074/jbc.274.26.18543	http://dx.doi.org/10.1074/jbc.274.26.18543			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373463	hybrid			2022-12-25	WOS:000081056700055
J	Mochizuki, T; Kitanaka, C; Noguchi, K; Muramatsu, T; Asai, A; Kuchino, Y				Mochizuki, T; Kitanaka, C; Noguchi, K; Muramatsu, T; Asai, A; Kuchino, Y			Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase - Implications for the Pim-1-mediated activation of the c-Myc signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAGENESIS; TRANSGENIC MICE; INHIBITS APOPTOSIS; MESSENGER-RNA; MYELOID CELLS; BONE-MARROW; EXPRESSION; PROTEIN; INDUCTION	The pim-1 oncogene encodes a serine/threonine kinase (Pim-1) involved in the transduction of cytokine-triggered mitogenic signals. Pim-1 is unique in that it closely cooperates with c-Myc not only in oncogenesis, but also in apoptosis induction. However, the molecular basis of Pim-1 function remains poorly understood, largely because the downstream effector molecule(s) for Pim-1 kinase has not been identified. Here we provide several lines of evidence that Cdc25A cell cycle phosphatase, a direct transcriptional target for c-Myc, is a substrate for Pim-1 kinase and functions as an effector for Pim-1, We found that Pim-1 physically interacts with Cdc25A both in vitro and in vivo and phosphorylates Cdc25A. We also observed that Pim-1-mediated phosphorylation of Cdc25A increases its phosphatase activity. In addition, wild-type Pim-1, but not kinase-inactive Pim-1, enhanced Cdc25A-mediated cellular transformation and apoptosis, Our results indicate that Cdc25A might be a key molecule that links Pim-1 and c-Myc and that also ties Pim-1-mediated mitogenic signals to cell cycle machinery.	Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; University of Tokyo; Japan Science & Technology Agency (JST)	Kuchino, Y (corresponding author), Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.							ACTON D, 1992, MECH B CELL NEOPLASI, P293; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; ASKEW DS, 1991, ONCOGENE, V6, P1915; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hernandez S, 1998, CANCER RES, V58, P1762; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOOVER D, 1991, J BIOL CHEM, V266, P14018; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PADMA R, 1991, CANCER RES, V51, P2486; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHINTO Y, 1995, ONCOGENE, V11, P1729; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKAHASHI C, 1995, BIOCHEM BIOPH RES CO, V215, P538, DOI 10.1006/bbrc.1995.2498; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIPSCHNEIDER MT, 1995, BLOOD, V85, P3494, DOI 10.1182/blood.V85.12.3494.bloodjournal85123494; Zornig M, 1996, ONCOGENE, V12, P1789	49	198	217	4	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18659	18666		10.1074/jbc.274.26.18659	http://dx.doi.org/10.1074/jbc.274.26.18659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373478	hybrid			2022-12-25	WOS:000081056700070
J	Muramatsu, M; Sankaranand, VS; Anant, S; Sugai, M; Kinoshita, K; Davidson, NO; Honjo, T				Muramatsu, M; Sankaranand, VS; Anant, S; Sugai, M; Kinoshita, K; Davidson, NO; Honjo, T			Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; PRIMARY IMMUNE-RESPONSE; CATALYTIC SUBUNIT; CHROMOSOMAL LOCALIZATION; SOMATIC HYPERMUTATION; MOLECULAR-CLONING; PROTEIN; ENZYME; MATURATION; BINDING	We have identified a novel gene referred to as activation-induced deaminase (AID) by subtraction of cDNAs derived from switch-induced and uninduced murine B lymphoma CH12F3-2 cells, more than 80% of which switch exclusively to IgA upon stimulation. The amino acid sequence encoded by ALD cDNA is homologous to that of apolipoprotein B (apoB) mRNA-editing enzyme, catalytic polypeptide 1 (APOBEC-1), a type of cytidine deaminase that constitutes a catalytic subunit for the apoB mRNA-editing complex. In vitro experiments using a glutathione S-transferase AID fusion protein revealed significant cytidine deaminase activity that is blocked by tetrahydrouridine and by zinc chelation. However, AID alone did neither demonstrate activity in C to U editing of apoB mRNA nor bind to AU-rich RNA targets, AID mRNA expression is induced in splenic B cells that were activated in vitro or by immunizations with sheep red blood cells. In situ hybridization of immunized spleen sections revealed the restricted expression of AID mRNA in developing germinal centers in which modulation of immunoglobulin gene information through somatic hypermutation and class switch recombination takes place. Taken together, these findings suggest that AID is a new member of the RNA-editing deaminase family and may play a role in genetic events in the germinal center B cell.	Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan; Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA	Kyoto University; Kyoto University; Washington University (WUSTL)	Honjo, T (corresponding author), Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016; Muramatsu, Masamichi/C-4339-2015; Anant, Shrikant/AAF-8020-2020	Muramatsu, Masamichi/0000-0002-0153-3533; Sugai, Manabu/0000-0003-1668-7647	NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; George J, 1992, Semin Immunol, V4, P11; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; Kinoshita K, 1998, IMMUNITY, V9, P849, DOI 10.1016/S1074-7613(00)80650-0; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KRAAL G, 1985, ADV EXP MED BIOL, V186, P145; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; Lorenz M, 1996, CURR TOP MICROBIOL, V217, P151; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Nakamura T, 1998, GENOMICS, V54, P89, DOI 10.1006/geno.1998.5571; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; REDIES C, 1993, J COMP NEUROL, V333, P398, DOI 10.1002/cne.903330307; SABLITZKY F, 1985, EMBO J, V4, P345, DOI 10.1002/j.1460-2075.1985.tb03635.x; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; Smith HC, 1996, TRENDS GENET, V12, P418, DOI 10.1016/0168-9525(96)10042-1; Smith KGC, 1997, EMBO J, V16, P2996, DOI 10.1093/emboj/16.11.2996; Sugai M, 1998, NUCLEIC ACIDS RES, V26, P911, DOI 10.1093/nar/26.4.911; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	34	885	928	5	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18470	18476		10.1074/jbc.274.26.18470	http://dx.doi.org/10.1074/jbc.274.26.18470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373455	hybrid, Green Submitted			2022-12-25	WOS:000081056700047
J	Shimada, Y; Nakamura, M; Naito, Y; Nomura, K; Ohno-Iwashita, Y				Shimada, Y; Nakamura, M; Naito, Y; Nomura, K; Ohno-Iwashita, Y			C-terminal amino acid residues are required for the folding and cholesterol binding property of perfringolysin O, a pore-forming cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-ACTIVATED CYTOLYSIN; THETA-TOXIN; CLOSTRIDIUM-PERFRINGENS; STREPTOLYSIN-O; NUCLEOTIDE-SEQUENCE; LISTERIOLYSIN-O; TRYPTOPHAN RESIDUES; LIPOSOMAL MEMBRANES; ESCHERICHIA-COLI; PNEUMOLYSIN	Perfringolysin O (theta-toxin) is a pore-forming cytolysin whose activity is triggered by binding to cholesterol in the plasma membrane. The cholesterol binding activity is predominantly localized in the beta-sheet-rich C-terminal half. In order to determine the roles of the C-terminal amino acids in theta-toxin conformation and activity, mutants were constructed by truncation of the C terminus. While the mutant with a two-amino acid C-terminal truncation retains full activity and has similar structural features to native theta-toxin, truncation of three amino acids causes a 40% decrease in hemolytic activity due to the reduction in cholesterol binding activity with a slight change in its higher order structure. Furthermore, both mutants were found to be poor at in vitro refolding after denaturation in 6 M guanidine hydrochloride, resulting in a dramatic reduction in cholesterol binding and hemolytic activities. These activity losses were accompanied by a slight decrease in beta-sheet content. A mutant toxin with a five-amino acid truncation expressed in Escherichia coli is recovered as a further truncated form lacking the C-terminal 21 amino residues. The product retains neither cholesterol binding nor hemolytic activities and shows a highly disordered structure as detected by alterations in the circular dichroism and tryptophan fluorescence spectra. These results show that the C-terminal region of theta-toxin has two distinct roles; the last 21 amino acids are involved to maintain an ordered overall structure, and in addition, the last two amino acids at the C-terminal end are needed for protein folding in vitro, in order to produce the necessary conformation for optimal cholesterol binding and hemolytic activities.	Tokyo Metropolitan Inst Gerontol, Dept Prot Biochem, Itabashi Ku, Tokyo 1730015, Japan; Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 5310198, Japan	Tokyo Metropolitan Institute of Gerontology; RIKEN	Shimada, Y (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Prot Biochem, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	yshimada@tmig.or.jp; iwashita@tmig.or.jp						Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen YJ, 1996, PROTEINS, V26, P465; COOK RA, 1988, CRIT REV BIOTECHNOL, V8, P159, DOI 10.3109/07388558809147554; delosToyos JR, 1996, INFECT IMMUN, V64, P480, DOI 10.1128/IAI.64.2.480-484.1996; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Feil SC, 1996, FEBS LETT, V397, P290, DOI 10.1016/S0014-5793(96)01200-8; GEOFFROY C, 1990, J BACTERIOL, V172, P7301, DOI 10.1128/jb.172.12.7301-7305.1990; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; IWAMOTO M, 1990, EUR J BIOCHEM, V194, P25, DOI 10.1111/j.1432-1033.1990.tb19422.x; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; KEHOE MA, 1987, INFECT IMMUN, V55, P3228, DOI 10.1128/IAI.55.12.3228-3232.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER MM, 1961, KABAT MAYERS EXPT IM, P133; MENGAUD J, 1987, INFECT IMMUN, V55, P3225, DOI 10.1128/IAI.55.12.3225-3227.1987; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MITCHELL TJ, 1992, BACTERIAL PROTEIN TO, P429; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V554, P68, DOI 10.1016/0005-2736(79)90007-5; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; Nakayama H, 1996, J CHROMATOGR A, V730, P279, DOI 10.1016/0021-9673(95)00974-4; OHNOIWASHITA Y, 1986, BIOCHEMISTRY-US, V25, P6048, DOI 10.1021/bi00368a032; OHNOIWASHITA Y, 1988, EUR J BIOCHEM, V176, P95, DOI 10.1111/j.1432-1033.1988.tb14255.x; OWEN RHG, 1994, FEMS MICROBIOL LETT, V121, P217, DOI 10.1016/0378-1097(94)90129-5; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SAITO M, 1982, MECH AGEING DEV, V20, P53, DOI 10.1016/0047-6374(82)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SekinoSuzuki N, 1996, EUR J BIOCHEM, V241, P941, DOI 10.1111/j.1432-1033.1996.00941.x; SHIMIZU T, 1991, INFECT IMMUN, V59, P137, DOI 10.1128/IAI.59.1.137-142.1991; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugahara M, 1996, J CRYST GROWTH, V168, P288, DOI 10.1016/0022-0248(96)00334-X; TWETEN RK, 1988, INFECT IMMUN, V56, P3235, DOI 10.1128/IAI.56.12.3235-3240.1988; Voziyan PA, 1996, BIOCHEMISTRY-US, V35, P12526, DOI 10.1021/bi960562o; WALKER JA, 1987, INFECT IMMUN, V55, P1184, DOI 10.1128/IAI.55.5.1184-1189.1987	37	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18536	18542		10.1074/jbc.274.26.18536	http://dx.doi.org/10.1074/jbc.274.26.18536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373462	hybrid			2022-12-25	WOS:000081056700054
J	Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A				Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A			Mutational analysis of p51A/TAp63 gamma, a p53 homolog, in non-small cell lung cancer and breast cancer	ONCOGENE			English	Article						p51; non-small cell lung cancer; mutation; p53	P73 GENE; CARCINOMA; ADENOCARCINOMA; YEAST	p51, a novel family member of human p53, is a recently identified candidate tumor suppressor gene mapped at chromosome 3q28, Like p53, p51 was found to activate p21(Waf1/Cip1) and to induce apoptosis, Since the DNA loss at 3q is reported in several cancers including non-small cell lung cancer (NSCLC), we screened for mutations in p51A (TAp63 gamma), an isoform of p51 with short C-terminal region, in 80 NSCLCs as well as 85 breast cancers by RT-PCR single strand conformation polymorphism (SSCP) analysis and DNA sequencing. In NSCLCs, p51 was expressed in most tumors at variable levels and we found three missense and one silent mutations: Gln31His (transactivation domain) in two tumors, Ala148Pro (DNA-binding domain) and Leu248Leu (DNA-binding domain). In the tumor with Ala148Pro or the silent mutation, only the mutant gene appeared to be expressed. The modified FASAY method to test the ability of yeast expressing p51A cDNA to grow in medium lacking histidine has revealed that Ala148Pro results in a loss of function, while Gln31His does not, In contrast to NSCLC, no mutation was observed in all 85 breast cancers by the similar method. Our results suggest that, because of infrequent mutation, p51 may not be a Knudson type tumor suppressor in most NSCLCs and breast cancers. Nevertheless, in at least a part of NSCLC, p51 may play a certain role in carcinogenesis in a tissue-specific manner.	Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Chiba Univ, Sch Med, Inst Pulm Canc Res, Dept Surg, Chiba, Japan; Chiba Canc Ctr, Div Thorac Surg, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9800872, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan	Tokyo Medical & Dental University (TMDU); Chiba Cancer Center; Hokkaido University; Chiba University; Chiba Cancer Center; Tohoku University; Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan.		Kato, Shunsuke/F-7607-2014; 井川, 俊太郎/L-5911-2015	Ishioka, Chikashi/0000-0002-3023-1227				COLES C, 1992, CANCER RES, V52, P5291; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; ISHIOKA C, 1995, ONCOGENE, V10, P1485; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; IZUO M, 1989, JPN J SURG, V19, P612; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KISHIMOTO Y, 1990, CANCER RES, V52, P4799; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Petersen I, 1997, CANCER RES, V57, P2331; SATO S, 1994, CANCER RES, V54, P5652; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	22	52	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3761	3765		10.1038/sj.onc.1202972	http://dx.doi.org/10.1038/sj.onc.1202972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391684				2022-12-25	WOS:000081140200010
J	Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK				Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK			Binding of the human T-cell leukemia virus Tax protein to the coactivator CBP interferes with CBP-mediated transcriptional control	ONCOGENE			English	Article						transformation; c-jun; CBP/p300; leukemogenesis	ACUTE MYELOID-LEUKEMIA; I TAX; TRANSACTIVATOR TAX; DNA-BINDING; HISTONE ACETYLTRANSFERASE; 21-BASE-PAIR REPEATS; MOLECULAR MECHANISM; INDUCED STIMULATION; CREB PROTEIN; TYPE-1 TAX	The HTLV-I oncoprotein Tax is required for high level viral transcription and is strongly linked to HTLV-I associated malignant transformation. Tax stimulates HTLV-I transcription through high affinity binding to the KIX domain of CBP, a pleiotropic coactivator. Several cellular proteins, including c-jun, also bind to KIX and utilize CBP as a coactivator. To test whether Tax binding to KIX may disable cellular CBP function, we examined the potential interplay between Tax and c-jun for binding to KIX. We show that Tax represses the transcription function of c-jun in vivo and demonstrate that both transcription factors bind to an overlapping minimal region of KIX in vitro. c-jun binding to KIX is displaced by Tax, indicating that their binding is mutually exclusive and providing a molecular basis for the observed repression. The competition between Tax and cellular transcription factors for CBP represents a novel pathway for HTLV-I dependent deregulation of gene expression, and may have significant implications for cellular homeostasis and transformation in the HTLV-I infected T-cell.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.							ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIMLING P, 1992, ONCOGENE, V7, P257; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RADHAKRISHNAN I, 1997, CELL, V91, P7441; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Smits PHM, 1996, ONCOGENE, V12, P1529; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TAKE T, 1997, BLOOD, V89, P3945; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3766	3772		10.1038/sj.onc.1202703	http://dx.doi.org/10.1038/sj.onc.1202703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391685				2022-12-25	WOS:000081140200011
J	Herring, BP; Hoggatt, AM; Smith, AF; Gallagher, PJ				Herring, BP; Hoggatt, AM; Smith, AF; Gallagher, PJ			Targeted expression of SV40 large T-antigen to visceral smooth muscle induces proliferation of contractile smooth muscle cells and results megacolon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; NONMUSCLE MYOSIN; MOUSE EMBRYOGENESIS; ACTIN EXPRESSION; PROTEIN; RAT; PHENOTYPE; CALDESMON; KINASE; CYTOSKELETAL	Many pathological conditions result from the proliferation and de-differentiation of smooth muscle cells leading to impaired contractility of the muscle. Here we show that targeted expression of SV40 large T-antigen to visceral smooth muscle cells in vivo results in increased smooth muscle cell proliferation without de-differentiation or decreased contractility. These data suggest that the de-differentiation and proliferation of smooth muscle cells, seen in many pathological states, may be independently regulated. In the T-antigen transgenic mice the increased smooth muscle cell proliferation results in thickening of the distal colon. Consequently the distal colon becomes hyper-contractile and impedes the flow of digesta through the colon resulting in enlargement of the colon oral to the obstruction. These transgenic mice thus represent a novel model of megacolon that results from increased smooth muscle cell proliferation rather than altered neuronal innervation.	Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Physiol & Biophys, 635 Barnhill Dr, Indianapolis, IN 46202 USA.				NHLBI NIH HHS [R01 HL054118-03, R01 HL058571, R01 HL054118, HL 58571, HL 54118] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118, R01HL058571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1993, CIRC RES, V73, P1002; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; CHIAVEGATO A, 1993, EXP CELL RES, V207, P310, DOI 10.1006/excr.1993.1198; DeLeon H, 1997, CIRC RES, V80, P514, DOI 10.1161/01.RES.80.4.514; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GABELLA G, 1990, ANAT EMBRYOL, V182, P409; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gattuso JM, 1997, GUT, V41, P252, DOI 10.1136/gut.41.2.252; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; KIM YS, 1994, MOL CELL BIOCHEM, V131, P115, DOI 10.1007/BF00925947; LECLERC G, 1992, CIRCULATION, V85, P543, DOI 10.1161/01.CIR.85.2.543; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MALMQVIST U, 1991, AM J PHYSIOL, V260, pC1085, DOI 10.1152/ajpcell.1991.260.5.C1085; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sartore S, 1997, ARTERIOSCL THROM VAS, V17, P1210, DOI 10.1161/01.ATV.17.7.1210; Siegman MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1571, DOI 10.1152/ajpgi.1997.272.6.G1571; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SOBUE K, 1991, J BIOL CHEM, V266, P12115; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; Wartiovaara K, 1998, ANN MED, V30, P66, DOI 10.3109/07853899808999386; WOODCOCKMITCHELL J, 1993, AM J RESP CELL MOL, V8, P617, DOI 10.1165/ajrcmb/8.6.617	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17725	17732		10.1074/jbc.274.25.17725	http://dx.doi.org/10.1074/jbc.274.25.17725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364214	Green Accepted, hybrid			2022-12-25	WOS:000080974300050
J	Quinto, I; Mallardo, M; Baldassarre, F; Scala, G; Englund, G; Jeang, KT				Quinto, I; Mallardo, M; Baldassarre, F; Scala, G; Englund, G; Jeang, KT			Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappa B (I kappa B-alpha S32/36A) and the implications for vaccine development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; DYNAMICS IN-VIVO; EFFICIENT REPLICATION; CHEMOKINE RECEPTORS; INDUCED APOPTOSIS; SIV VACCINE; T-CELLS; ALPHA; TYPE-1; LIVE	Live-attenuated human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine. Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV. Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to prevent the emergence off virulent mutants. New strategies that attenuate via mechanisms distinct from loss-of-function are needed for enhancing the safety phenotype of viral genome. Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for attenuating HIV-1, We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-resistant nuclear factor-kappa B inhibitor (I kappa B-alpha S32/36A) in the nef region. HIV-1 expressing 1 kappa B-alpha S32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. We provide formal proof that the phenotypic and attenuating characteristics of I kappa B-alpha S32/36A permit its stable maintenance in a live, replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture. As compared with other open-reading frames embedded into HIV/SIV genome, this degree of stability is unprecedented. Thus, I kappa B-alpha S32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of live HIV-1, can be stable. These findings illustrate gain-of-function as a feasible strategy for developing safer live-attenuated HIVs to be tested as candidates for AIDS vaccine.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Magna Graecia University of Catanzaro	Quinto, I (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via Sergio Pansini 5, I-80131 Naples, Italy.	quinto@dbbm.unina.it	SCALA, GIUSEPPE/A-3280-2009; Jeang, Kuan-Teh/A-2424-2008	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Beer B, 1997, P NATL ACAD SCI USA, V94, P4062, DOI 10.1073/pnas.94.8.4062; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 1999, J VIROL, V73, P1138, DOI 10.1128/JVI.73.2.1138-1145.1999; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giavedoni LD, 1996, J VIROL, V70, P2247, DOI 10.1128/JVI.70.4.2247-2251.1996; Gundlach BR, 1997, J VIROL, V71, P2225, DOI 10.1128/JVI.71.3.2225-2232.1997; Ilyinskii PO, 1997, J VIROL, V71, P1880, DOI 10.1128/JVI.71.3.1880-1887.1997; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KESTLER HW, 1995, SCIENCE, V270, P1219; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marx PA, 1998, SEMIN IMMUNOL, V10, P215, DOI 10.1006/smim.1998.0135; MYERS G, 1996, HUMAN RETROVIRUSES A, P3; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pohlmann S, 1998, J VIROL, V72, P5589; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WRIGHT SC, 1988, J IMMUNOL, V141, P99; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Zhang JB, 1997, VIRUS RES, V49, P205, DOI 10.1016/S0168-1702(97)01462-7	45	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17567	17572		10.1074/jbc.274.25.17567	http://dx.doi.org/10.1074/jbc.274.25.17567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364191	hybrid			2022-12-25	WOS:000080974300027
J	Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM				Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM			Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice	ONCOGENE			English	Article						RET; transgenic; papillary thyroid carcinoma; mouse NIS; radioiodide uptake	RECEPTOR TYROSINE KINASE; SODIUM-IODIDE SYMPORTER; RET ONCOGENE; CARCINOMAS; EXPRESSION; PROTEIN; DIFFERENTIATION; ORGANIZATION; ACTIVATION; CLONING	The RET/PTC1 oncogene, a rearranged form of the RET proto-oncogene, has been reported to be associated with human papillary thyroid carcinomas. We have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid carcinomas in transgenic mice with histologic and cytologic similarities to human papillary thyroid carcinoma. To further investigate how RET/PTC1 expression contributes to the pathogenesis of papillary thyroid tumor, the time of tumor onset and the early phenotypic consequences of RET/PTC1 expression in thyrocytes were determined. All high copy transgenic mice developed bilateral thyroid tumors as early as 4 days of age. At embryological days 16-18, increased proliferation rate, distorted thyroid follicle formation and reduced radioiodide concentrating activity were identified in transgenic embryos. The reduced radioiodide concentrating activity was attributed to decreased expression of the sodium-iodide symporter. Our study showed that RET/PTC1 not only increased proliferation of thyrocytes, it also altered morphogenesis and differentiation. These findings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human papillary thyroid carcinoma.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [R29CA060074, R01CA060074] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHRACH LK, 1985, ENDOCRINOLOGY, V116, P1603, DOI 10.1210/endo-116-4-1603; BOND JA, 1994, ONCOGENE, V9, P281; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Klugbauer S, 1995, ONCOGENE, V11, P2459; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Tong Q, 1997, J BIOL CHEM, V272, P9043; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Yap AS, 1997, ENDOCRINOLOGY, V138, P2315, DOI 10.1210/en.138.6.2315; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185	21	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3659	3665		10.1038/sj.onc.1202709	http://dx.doi.org/10.1038/sj.onc.1202709			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380889				2022-12-25	WOS:000080891700013
J	Volloch, VZ; Sherman, MY				Volloch, VZ; Sherman, MY			Oncogenic potential of Hsp72	ONCOGENE			English	Article						Hsp72; oncogene; fibroblasts	HEAT-SHOCK PROTEINS; CELLS; THERMOTOLERANCE; GENE	Hsp72 is the major heat shock-inducible protein capable of protecting cells from a variety of stresses. In nontransformed cells at normal conditions Hsp72 is expressed at very low levels. It is, however, present at elevated levels in the major fraction of tumors and in many transformed cell lines. It is commonly assumed that in tumor cells the expression of Hsp72 at elevated levels is the consequence of oncogenic transformation. In the present study we addressed an alternative possibility that Hsp72 plays an active, role in the process of oncogenic transformation. We report hero that when Hsp72 was expressed in the Rat-1 fibroblasts either constitutively or from an adenovirus-based construct, cells become oncogenically transformed by the following criteria: loss of contact inhibition and formation of foci characteristic for oncogenically transformed cells; acquisition of the ability to grow in an anchorage-independent manner and to form colonies in soft agar; generation of tumors upon injection into mice. Furthermore, we also report that turning off the Hsp72 expression led to the reversal of the transformed phenotype. We also show that oncogenic potential of Hsp72 is confined in its peptide binding domain since the expression of this domain alone nas sufficient for oncogenic transformation of Rat-1 cells.	Tufts Univ, Ctr Biotechnol, Medford, MA 02155 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Tufts University; Boston Biomedical Research Institute	Volloch, VZ (corresponding author), Tufts Univ, Ctr Biotechnol, 4 Colby St,Room 142, Medford, MA 02155 USA.							AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; CLARK G, 1995, METHOD ENZYMOL, V225, P395; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; Jani A, 1997, J VIROL METHODS, V64, P111, DOI 10.1016/S0166-0934(96)02138-6; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103	15	100	125	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3648	3651		10.1038/sj.onc.1202525	http://dx.doi.org/10.1038/sj.onc.1202525			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380887				2022-12-25	WOS:000080891700011
J	Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE				Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE			NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways	ONCOGENE			English	Article						apoptosis; cell cycle; ErbB receptors; PKB; c-Src kinase	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR-RELATED PEPTIDES; TYROSINE KINASE; CANCER CELLS; EGF-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY	Neu differentiation factor (NDF)/heregulin activates ErbB2 via heterodimerization with the NDF receptors ErbB3 and ErbB4. Cells which express normal levels of these receptors are often growth stimulated by NDF, whereas SKBR3, and other ErbB2-overexpressing breast tumour cells are growth inhibited. We demonstrate here that in SKBR3 cells, NDF induces G1 progression but also causes a G2 delay from day 1 and apoptosis from days 2-3. G1 progression was associated with ErbB2 transactivation of ErbB3 and subsequent stimulation of the phosphatidylinositol 3-kinase (PI3K) whereas apoptosis was dependent on p38 MAPK. Inhibition of ERK1/ERK2 had no effect on cell cycle progression or apoptosis. Activation of ErbB3 and PI3K was also seen with betacellulin (BTC) but not epidermal growth factor (EGF) and. correlated with the growth effects of these ligands. All three ligands induced shortterm activation of p38 MAPK in a c-Src-dependent manner. However, only NDF caused a second, c-Src-independent increase in p38 MAPK activity which was required for apoptosis.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66,R-1066-206, CH-4058 Basel, Switzerland.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BERGER MS, 1988, CANCER RES, V48, P1238; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daly JM, 1997, CANCER RES, V57, P3804; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; Jannot CB, 1996, ONCOGENE, V13, P275; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAX I, 1991, J BIOL CHEM, V266, P13828; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lewis GD, 1996, CANCER RES, V56, P1457; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSBACH M, 1999, IN PRESS BONE; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Traxler PM, 1996, J MED CHEM, V39, P2285, DOI 10.1021/jm960118j; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	64	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3440	3451		10.1038/sj.onc.1202700	http://dx.doi.org/10.1038/sj.onc.1202700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376522				2022-12-25	WOS:000080850600002
J	Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S				Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S			Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity	ONCOGENE			English	Article						DAP kinase family; calcium/calmodulin-dependent kinase; apoptosis	SERINE THREONINE KINASE; JUN ACTIVATION DOMAIN; INDUCED CELL-DEATH; C-JUN; DAP-KINASE; IDENTIFICATION; INDUCTION; CASPASES; PHOSPHORYLATES; REQUIREMENT	We have identified and characterized a new calcium/calmodulin (Ca2+/CaM) dependent protein kinase termed death-associated protein kinase 2 (DAPK2) that contains an N-terminal protein kinase domain followed by a conserved CaM-binding domain with significant homologies to those of DAP kinase, a protein kinase involved in apoptosis, DAPK2 mRNA is expressed abundantly in heart, lung and skeletal muscle. The mapping results indicated that DAPK2 is located in the central region of mouse chromosome 9, bl vitro kinase assay revealed that DAPK2 is autophosphorylated and phosphorylates myosin light chain (MLC) as an exogenous substrate. DAPK2 binds directly to CaM and is activated in a Ca2+/CaM-dependent manner. A constitutively active DAPK2 mutant is generated by removal of the CaM-binding domain (Delta CaM). Treatment of agonists that elevate intracellular Ca2+-concentration led to the activation of DAPK2 and transfection studies revealed that DAPK2 is localized in the cytoplasm. Overexpression of DAPK2, but not the kinase negative mutant, significantly induced the morphological changes characteristic of apoptosis, These results indicate that DAPK2 is an additional member of DAP kinase family involved in apoptotic signaling.	Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Hyogo College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Hyogo Coll Med, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Hoshino, Katsuaki/AAE-2830-2022; Hoshino, Katsuaki/L-9162-2014; Akira, Shizuo/C-3134-2009	Hoshino, Katsuaki/0000-0003-0493-4815; Hoshino, Katsuaki/0000-0003-0493-4815; Kawai, Taro/0000-0001-7510-4662				ANDESON P, MICROBIOL MOL BIOL R, V61, P33; ASKEW DS, 1991, ONCOGENE, V6, P1915; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GIGUERE V, 1995, GENOMICS, V28, P596, DOI 10.1006/geno.1995.1197; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISSIL JL, 1997, ONCOGENE, V15, P405; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P2673; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	104	112	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3471	3480		10.1038/sj.onc.1202701	http://dx.doi.org/10.1038/sj.onc.1202701			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376525				2022-12-25	WOS:000080850600005
J	Chen, J; Song, JL; Zhang, S; Wang, Y; Cui, DF; Wang, CC				Chen, J; Song, JL; Zhang, S; Wang, Y; Cui, DF; Wang, CC			Chaperone activity of DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ESCHERICHIA-COLI; BOND FORMATION; PERIPLASMIC PROTEIN; FLUORESCEINTHIOCARBAMYL-INSULIN; SUBSTRATE; ENCODES; BINDING; ENZYME; ASSAY	DsbC, a periplasmic disulfide isomerase of Gram-negative bacteria, displays about 30% of the activities of eukaryotic protein disulfide isomerase (PDI) as isomerase and as thiol-protein oxidoreductase. However, DsbC shows more pronounced chaperone activity than does PDI in promoting the in vitro reactivation and suppressing aggregation of denatured D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) during refolding, Carboxymethylation of DsbC at Cys(98) decreases its intrinsic fluorescence, deprives of its enzyme activities, but lowers only partly its chaperone activity in assisting GAPDH reactivation, Simultaneous presence of DsbC and PDI in the refolding buffer shows an additive effect on the reactivation of GAPDH. The assisted reactivation of GAPDH and the protein disulfide oxidoreductase activity of DsbC can both be inhibited by scrambled and S-carboxymethylated RNases, but not by shorter peptides, including synthetic 10- and 14-mer peptides and S-carboxymethylated insulin A chain. In contrast, all the three peptides and the two nonnative RNases inhibit PDI-assisted GAPDH reactivation and the reductase activity of PDI. DsbC assists refolding of denatured and reduced lysozyme to a higher level than does PDI in phosphate buffer and does not show anti-chaperone activity in HEPES buffer. Like PDI, DsbC is also a disulfide isomerase with chaperone activity but may recognize different folding intermediates as does PDI.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Acad Sinica, Inst Biochem, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; CAI H, 1994, J BIOL CHEM, V269, P24550; Darby NJ, 1998, BIOCHEMISTRY-US, V37, P783, DOI 10.1021/bi971888f; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; Guddat LW, 1997, PROTEIN SCI, V6, P1148, DOI 10.1002/pro.5560060603; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rybin V, 1996, ACTA CRYSTALLOGR D, V52, P1219, DOI 10.1107/S0907444996008967; Sauvonnet N, 1998, MOL MICROBIOL, V27, P661, DOI 10.1046/j.1365-2958.1998.00722.x; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Sone M, 1997, J BIOL CHEM, V272, P10349; Song JL, 1997, BIOCHEM J, V328, P841, DOI 10.1042/bj3280841; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Wang C. H., 1997, Pan Pacific Microelectronics Symposium. Proceedings of the Technical Program, P315; Wang CC, 1998, FEBS LETT, V425, P382, DOI 10.1016/S0014-5793(98)00272-5; Wang CC, 1998, BIOCHEMISTRY-MOSCOW+, V63, P407; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	36	140	205	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19601	19605		10.1074/jbc.274.28.19601	http://dx.doi.org/10.1074/jbc.274.28.19601			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391895	hybrid			2022-12-25	WOS:000081377300015
J	Chen, XQ; Tan, I; Leung, T; Lim, L				Chen, XQ; Tan, I; Leung, T; Lim, L			The myotonic dystrophy kinase-related Cdc42-binding kinase is involved in the regulation of neurite outgrowth in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; NERVE GROWTH-FACTOR; NEURONAL DIFFERENTIATION; FOCAL ADHESIONS; STRESS FIBERS; ACTIVATION; RAC; REORGANIZATION; CYTOSKELETON; RETRACTION	The myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK alpha) has been implicated in the morphological activities of Cdc42 in nonneural cells. Both MRCK alpha and the kinase-related Rho-binding kinase (ROKa) are involved in nonmuscle myosin light-chain phosphorylation and associated actin cytoskeleton reorganization. We now show that in PC12 cells, overexpression of the kinase domain of MRCK alpha and ROK alpha resulted in retraction of neurites formed on nerve growth factor (NGF) treatment, as observed with RhoA. However, introduction of kinase-dead MRCK alpha did not result in NGF-independent neurite outgrowth as observed with dominant negative kinase-dead ROK alpha or the Rho inhibitor C3, Neurite outgrowth induced by NGF or kinase-dead ROK alpha was inhibited by dominant negative Cdc42(N17), Rac1(N17), and the Src homology 3 domain of c-Crk, indicating the participation of common downstream components. Neurite outgrowth induced by either agent was blocked by kinase-dead MRCK alpha lacking the pal-binding domain or by a minimal C-terminal regulatory region consisting of the cysteine-rich domain/pleckstrin homology domain plus a region with homology to citron, The latter region alone was an effective blocker of NGF-induced outgrowth. These results suggest that although ROK alpha is involved in neurite retraction promoted by RhoA, the related MRCK alpha is conversely involved in neurite outgrowth promoted by Cdc42 and Rac.	Inst Mol & Cell Biol, Glaxo IMCB Grp, Singapore 117609, Singapore; UCL, Neurol Inst, Dept Neurochem, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Leung, T (corresponding author), Inst Mol & Cell Biol, Glaxo IMCB Grp, 30 Med Dr, Singapore 117609, Singapore.							Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tigyi G, 1996, J NEUROCHEM, V66, P537; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	30	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19901	19905		10.1074/jbc.274.28.19901	http://dx.doi.org/10.1074/jbc.274.28.19901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391936	hybrid			2022-12-25	WOS:000081377300056
J	Yao, LB; Janmey, P; Frigeri, LG; Han, W; Fujita, J; Kawakami, Y; Apgar, JR; Kawakami, T				Yao, LB; Janmey, P; Frigeri, LG; Han, W; Fujita, J; Kawakami, Y; Apgar, JR; Kawakami, T			Pleckstrin homology domains interact with filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; RI CROSS-LINKING; BETA-GAMMA-SUBUNITS; SRC FAMILY KINASES; PH DOMAIN; INOSITOL PHOSPHATES; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BUNDLE FORMATION	A fraction of Bruton's tyrosine kinase (Btk) co-localizes with actin fibers upon stimulation of mast cells via the high affinity IgE receptor (Fc epsilon RI). In this study, a molecular basis of the Btk co-localization with actin fibers is presented. Btk and other Tec family tyrosine kinases have a pleckstrin homology (PH) domain at their N termini. The PH domain is a short peptide module frequently found in signal-transducing proteins and cytoskeletal proteins. Filamentous actin (F-actin) is shown to be a novel ligand for a subset of PH domains, including that of Btk. The actin-binding site was mapped to a 10-residue region of the N-terminal region of Btk. Basic residues in this short stretch are demonstrated to be involved in actin binding. Isolated PH domains induced actin filament bundle formation. Consistent with these observations, Btk binds F-actin in vitro and in vitro. Wild-type Btk protein is in part translocated to the cytoskeleton upon FceRI cross-linking, whereas Btk containing a mutated PH domain is not. Phosphatidylinositol 3,4,5-trisphosphate-mediated membrane translocation of Btk was enhanced in cytochalasin D-pretreated, Fc epsilon RI-stimulated mast cells. These data indicate that PH domain-mediated F-actin binding plays a role in Btk co-localization with actin filaments.	La Jolla Inst Allergy & Immunol, Div Allergy, San Diego, CA 92121 USA; Brigham & Womens Hosp, Div Expt Med, Boston, MA 02115 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 606, Japan	La Jolla Institute for Immunology; Harvard University; Brigham & Women's Hospital; Scripps Research Institute; Kyoto University	Kawakami, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Allergy, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Kawakami, Toshiaki/O-1616-2015		NIAID NIH HHS [AI38348, AI33617] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038348, R01AI033617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berne B. J., 1976, DYNAMIC LIGHT SCATTE, P14; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DATTA K, 1995, MOL CELL BIOL, V15, P2304; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Kawakami Y, 1999, J LEUKOCYTE BIOL, V65, P286, DOI 10.1002/jlb.65.3.286; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; Pollard Thomas D., 1993, P3; PRICE LS, 1995, CURR BIOL, V5, P8; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P2866; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; Tang JX, 1996, BER BUNSEN PHYS CHEM, V100, P796, DOI 10.1002/bbpc.19961000620; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	56	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19752	19761		10.1074/jbc.274.28.19752	http://dx.doi.org/10.1074/jbc.274.28.19752			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391917	hybrid			2022-12-25	WOS:000081377300037
J	Alvarez, M; Wouters, J; Maes, D; Mainfroid, V; Rentier-Delrue, F; Wyns, L; Depiereux, E; Martial, JA				Alvarez, M; Wouters, J; Maes, D; Mainfroid, V; Rentier-Delrue, F; Wyns, L; Depiereux, E; Martial, JA			Lys(13) plays a crucial role in the functional adaptation of the thermophilic triose-phosphate isomerase from Bacillus stearothermophilus to high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THERMOTOGA-MARITIMA; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; PHOSPHOGLYCERATE KINASE; ASPARAGINE RESIDUES; ANGSTROM RESOLUTION; PROTEIN STABILITY; ESCHERICHIA-COLI	The thermophilic triose-phosphate isomerases (TIMs) of Bacillus stearothermophilus (bTIM) and Thermotoga maritima (tTIM) have been found to possess a His(12)- Lys(13) pair instead of the Asn(12)-Gly(13) pair normally present in mesophilic TIMs. His(12) in bTIM was proposed to prevent deamidation at high temperature, while the precise role of Lys(13) is unknown. To investigate the role of the His(12) and Lys(13) pair in the enzyme's thermoadaptation, we reintroduced the "mesophilic residues" Asn and Gly into both thermophilic TIMs. Neither double mutant displayed diminished structural stability, but the bTIM double mutant showed drastically reduced catalytic activity. No similar behavior was observed with the tTIM double mutant, suggesting that the presence of the His(12) and Lys(13) cannot be systematically correlated to thermoadaptation in TIMs, We determined the crystal structure of the bTIM double mutant complexed with 2-phosphoglycolate to 2,4-Angstrom resolution. A molecular dynamics simulation showed that upon substitution of Lys(13) to, Gly an increase of the flexibility of loop 1 is observed, causing an incorrect orientation of the catalytic Lys(10). This suggests that Lys(13) in bTIM plays a crucial role in the functional adaptation of this enzyme to high temperature. Analysis of bTIM single mutants supports this assumption.	Univ Liege, Lab Biol Mol & Genie Genet, B-4000 Liege, Belgium; Fac Univ Notre Dame Paix, Lab Biol Mol Struct, B-5000 Namur, Belgium; Free Univ Brussels VIB, Ultrastruct Unit, B-1640 Rhode St Genese, Belgium	University of Liege; University of Namur; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Martial, JA (corresponding author), Univ Liege, Lab Biol Mol & Genie Genet, B6, B-4000 Liege, Belgium.	jmartial@ulg.ac.be		Wouters, Johan/0000-0002-4920-6857				AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; Alvarez M, 1998, J BIOL CHEM, V273, P2199, DOI 10.1074/jbc.273.4.2199; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASAL JI, 1987, BIOCHEMISTRY-US, V26, P1258, DOI 10.1021/bi00379a009; CHEN HM, 1994, BIOCHEM J, V301, P275, DOI 10.1042/bj3010275; DELBONI LF, 1995, PROTEIN SCI, V4, P2594, DOI 10.1002/pro.5560041217; FAHEY RC, 1971, BIOCHEM J, V124, pP77, DOI 10.1042/bj1240077P; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; GRACY RW, 1983, ALTERED PROTEINS AGI, P27; Grattinger M, 1998, J MOL BIOL, V280, P525, DOI 10.1006/jmbi.1998.1861; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMAL M, 1995, FEBS LETT, V374, P363, DOI 10.1016/0014-5793(95)01145-5; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; LEYVAVAZQUEZ MA, 1994, J BACTERIOL, V176, P3903, DOI 10.1128/JB.176.13.3903-3910.1994; LHOIR C, 1990, GENE, V89, P47, DOI 10.1016/0378-1119(90)90204-5; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; Maldonado E, 1998, J MOL BIOL, V283, P193, DOI 10.1006/jmbi.1998.2094; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MCCARTHY DJ, 1994, BIOCHEMISTRY-US, V33, P2815; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; NOBLE MEM, 1993, ACTA CRYSTALLOGR D, V49, P403, DOI 10.1107/S0907444993002628; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; Pfeil W, 1997, J MOL BIOL, V272, P591, DOI 10.1006/jmbi.1997.1278; Pfeil W., 1998, PROTEIN STABILITY FO; RENTIERDELRUE F, 1993, J MOL BIOL, V229, P85, DOI 10.1006/jmbi.1993.1010; Rice DW, 1996, FEMS MICROBIOL REV, V18, P105; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL RJM, 1995, CURR OPIN BIOTECH, V6, P370, DOI 10.1016/0958-1669(95)80064-6; SCHURIG H, 1995, EMBO J, V14, P442, DOI 10.1002/j.1460-2075.1995.tb07020.x; Shimizu T, 1997, INT J BIOCHEM CELL B, V29, P303, DOI 10.1016/S1357-2725(96)00088-X; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Tomizawa H, 1995, PROTEIN ENG, V8, P1023, DOI 10.1093/protein/8.10.1023; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Velanker SS, 1997, STRUCTURE, V5, P751, DOI 10.1016/S0969-2126(97)00230-X; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; Williams JC, 1999, PROTEIN ENG, V12, P243, DOI 10.1093/protein/12.3.243; Wouters J, 1998, PROTEIN SCI, V7, P2472, DOI 10.1002/pro.5560071127; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	60	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19181	19187		10.1074/jbc.274.27.19181	http://dx.doi.org/10.1074/jbc.274.27.19181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383424	hybrid			2022-12-25	WOS:000081196300047
J	Kawauchi, S; Takahashi, S; Nakajima, O; Ogino, H; Morita, M; Nishizawa, M; Yasuda, K; Yamamoto, M				Kawauchi, S; Takahashi, S; Nakajima, O; Ogino, H; Morita, M; Nishizawa, M; Yasuda, K; Yamamoto, M			Regulation of lens fiber cell differentiation by transcription factor c-Maf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CRYSTALLIN GENE; TISSUE-SPECIFIC EXPRESSION; ENHANCER ELEMENT; ENCODES; BINDING; MOUSE; RAT; DELTA-1-CRYSTALLIN; SEQUENCES; PROMOTER	To elucidate the regulatory mechanisms underlying lens development, we searched for members of the large Maf family, which are expressed in the mouse lens, and found three, c-Maf, MafB, and Nrl. Of these, the earliest factor expressed in the lens was c-Maf. The expression of c-Maf was most prominent in lens fiber cells and persisted throughout lens development. To examine the functional contribution of c-Maf to lens development, we isolated genomic clones encompassing the murine c-maf gene and carried out its targeted disruption. Insertion of the beta-galactosidase (lacZ) gene into the c-maf locus allowed visualization of c-Maf accumulation in heterozygous mutant mice by staining for LacZ activity. Homozygous mutant embryos and newborns lacked normal lenses. Histological examination of these mice revealed defective differentiation of lens fiber cells. The expression of crystallin genes was severely impaired in the c-maf-null mutant mouse lens. These results demonstrate that c-Maf is an indispensable regulator of lens differentiation during murine development.	Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Bunkyo Ku, Tokyo 1138549, Japan; Scripps Res Inst, La Jolla, CA 92037 USA; Nara Inst Sci & Technol, Ikoma 6300101, Japan	University of Tsukuba; University of Tsukuba; Tokyo Medical & Dental University (TMDU); Scripps Research Institute; Nara Institute of Science & Technology	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr TARA, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.		Ogino, Hajime/G-5279-2019; Yamamoto, Masayuki/A-4873-2010; Warfield, Simon/B-3352-2009	Ogino, Hajime/0000-0003-2707-2330; Yamamoto, Masayuki/0000-0002-9073-9436; Warfield, Simon/0000-0002-7659-3880				CARTIER M, 1992, NAT GENET, V2, P42, DOI 10.1038/ng0992-42; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Eichmann A, 1997, MECH DEVELOP, V65, P111, DOI 10.1016/S0925-4773(97)00063-4; FUNAHASHI J, 1991, NUCLEIC ACIDS RES, V19, P3543, DOI 10.1093/nar/19.13.3543; GINO H, 1998, SCIENCE, V280, P115; Graw J, 1997, BIOL CHEM, V378, P1331; HERIQUE D, 1995, NATURE, V375, P787; HOGAN B, 1994, MANIPULATING MOUSE E, P277; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Liu Q, 1996, ONCOGENE, V12, P207; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murata T, 1998, GENES CELLS, V3, P443, DOI 10.1046/j.1365-2443.1998.00204.x; MUTHUKKARUPPAN V, 1965, J EXP ZOOL, V159, P269, DOI 10.1002/jez.1401590210; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; ODA SI, 1980, EXP EYE RES, V31, P673, DOI 10.1016/S0014-4835(80)80051-0; OsumiYamashita N, 1997, DEV GROWTH DIFFER, V39, P53; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; SAX CM, 1993, NUCLEIC ACIDS RES, V21, P2633, DOI 10.1093/nar/21.11.2633; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; YAMAMOTO M, 1991, J BIOL CHEM, V266, P3317; YASUDA K, 1986, STRUCTURE EXPRESSION, P183; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	31	196	199	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19254	19260		10.1074/jbc.274.27.19254	http://dx.doi.org/10.1074/jbc.274.27.19254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383433	Green Submitted, hybrid			2022-12-25	WOS:000081196300056
J	Lin, S; Na, CL; Akinbi, HT; Apsley, KS; Whitsett, JA; Weaver, TE				Lin, S; Na, CL; Akinbi, HT; Apsley, KS; Whitsett, JA; Weaver, TE			Surfactant protein B (SP-B) -/- mice are rescued by restoration of SP-B expression in alveolar type II cells but not Clara cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; SECRETORY PROTEIN; STRUCTURAL REQUIREMENTS; NATURAL SURFACTANT; HUMAN-LUNG; IN-VIVO; GENE; LOCALIZATION; BRONCHIOLAR; DEFICIENCY	Surfactant protein B (SP-B) mRNA and protein are restricted to alveolar Type II and Clara cells in the respiratory epithelium. In order to investigate the function of SP-B in these distinct cell types, transgenic mice were generated in which SP-B expression was selectively restored in Type II cells or Clara cells of SP-B -/- mice. The 4.8-kilobase murine SP-C promoter was used to generate 3 transgenic lines which expressed human SP-B in Type II cells (mSP-C/hSP-B). Likewise, the 2.3-kilobase murine CCSP promoter was used to generate two transgenic lines which expressed human SP-B in Clara cells (mCCSP/hSP-B). mSP-C/hSP-B and mCCSP/hSP-B transgenic mice were subsequently bred to SP-B +/- mice in order to selectively express SP-B in Type II cells or Clara cells of SP-B -/- mice. Selective restoration of SP-B expression in Type II cells completely rescued the neonatal lethal phenotype in SP-B -/- mice. Expression of SP-B in some, but not all Type II cells of SP-B -/- mice, allowed postnatal survival, but resulted in significantly altered lung architecture and function. Selective restoration of SP-B expression in Clara cells of SP-B -/- mice resulted in respiratory dysfunction and invariable neonatal death, related to the complete absence of mature SP-B peptide in these mice. These results indicate that expression and processing of the SP-B proprotein to the mature peptide in Type II cells is absolutely required for lung function in vivo and that SP-B expression in Clara cells cannot substitute for this function.	Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Weaver, TE (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL056285, R01HL036055, R01HL056285] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56285, HL56285-S, HL36055] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V12, pL381; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DEMELLO DE, 1994, AM J RESP CELL MOL, V11, P230, DOI 10.1165/ajrcmb.11.2.8049084; ENHORNING G, 1995, AM J RESP CRIT CARE, V151, P554, DOI 10.1164/ajrccm.151.2.7842219; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; HAMVAS A, 1994, J PEDIATR-US, V125, P356, DOI 10.1016/S0022-3476(05)83276-7; HAWGOOD S, 1993, AM J PHYSIOL, V264, pL290, DOI 10.1152/ajplung.1993.264.3.L290; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MIZUNO K, 1995, PEDIATR RES, V37, P271, DOI 10.1203/00006450-199503000-00004; NOGEE LM, 1991, AM J RESP CELL MOL, V4, P102, DOI 10.1165/ajrcmb/4.2.102; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1987, J HISTOCHEM CYTOCHEM, V35, P1339, DOI 10.1177/35.11.3309049; PINKERTON KE, 1994, J APPL PHYSIOL, V77, P1953, DOI 10.1152/jappl.1994.77.4.1953; PLOPPER CG, 1983, AM REV RESPIR DIS, V128, pS37; PLOPPER CG, 1980, EXP LUNG RES, V1, P139, DOI 10.3109/01902148009069644; REVAK SD, 1988, J CLIN INVEST, V81, P826, DOI 10.1172/JCI113391; RIDER ED, 1993, AM REV RESPIR DIS, V147, P669, DOI 10.1164/ajrccm/147.3.669; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; STRIPP BR, 1994, GENOMICS, V20, P27, DOI 10.1006/geno.1994.1123; TOKIEDA K, 1999, IN PRESS AM J RESP C; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	36	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19168	19174		10.1074/jbc.274.27.19168	http://dx.doi.org/10.1074/jbc.274.27.19168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383422	hybrid			2022-12-25	WOS:000081196300045
J	Bouloumie, A; Marumo, T; Lafontan, M; Busse, R				Bouloumie, A; Marumo, T; Lafontan, M; Busse, R			Leptin induces oxidative stress in human endothelial cells	FASEB JOURNAL			English	Article						Jun kinase; MCP-1; AP-1; NF-kappa B; atherosclerosis; obesity	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ADHESION MOLECULE-1; OBESE GENE; ANTIOXIDANTS; ACTIVATION; KINASES; INDUCTION	Human umbilical vein endothelial cells (HUVEC) express functional receptors to leptin, the product of the ob gene. As human obesity is associated with atherosclerosis and hyperleptinemia, we investigated whether leptin, in addition to its angiogenic properties, exerts atherogenic effects through the generation of oxidative stress in endothelial cells. In HUVEC leptin increased the accumulation of reactive oxygen species (ROS), as assessed by the oxidation of 2',7'- dichlorodihydrofluorescein, in a time- and concentration-dependent manner. In addition, leptin activated the NH2-terminal c-Jun kinase/stress-activated protein kinase pathway as demonstrated by enhanced JNK activity and AP-1 DNA binding. Both effects were sensitive to antioxidant treatment with N-acetylcysteine, NF-KB, another redox-sensitive transcription factor, was also activated by leptin stimulation in an oxidant-dependent manner, Finally, activation of both AP-1 and NF-KB was associated with an enhanced expression of the monocyte chemoattractant protein-1 in HUVEC, These findings demonstrate that ROS are second messengers involved in leptin-induced signaling in endothelial cells. Thus, chronic oxidative stress in endothelial cells under hyperleptinemia may activate atherogenic processes and contribute to the development of vascular pathology.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany; CHU Rangueil, Inst Louis Bugnard, INSERM U317, F-31054 Toulouse, France	Goethe University Frankfurt; Goethe University Frankfurt Hospital; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bouloumie, A (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Bouloumie-Diehl, Anne/M-4446-2017	Bouloumie-Diehl, Anne/0000-0001-5496-8891				BENETT BD, 1996, CURR BIOL, V6, P1170; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cimino F, 1997, CURR TOP CELL REGUL, V35, P123, DOI 10.1016/S0070-2137(97)80005-2; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; delArco PG, 1996, J BIOL CHEM, V271, P26335; Faruqi RM, 1997, AM J PHYSIOL-HEART C, V273, pH817, DOI 10.1152/ajpheart.1997.273.2.H817; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Marumo T, 1998, HYPERTENSION, V32, P1083, DOI 10.1161/01.HYP.32.6.1083; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	36	560	600	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1231	1238		10.1096/fasebj.13.10.1231	http://dx.doi.org/10.1096/fasebj.13.10.1231			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385613				2022-12-25	WOS:000081264800011
J	Moalem, G; Monsonego, A; Shani, Y; Cohen, IR; Schwartz, M				Moalem, G; Monsonego, A; Shani, Y; Cohen, IR; Schwartz, M			Differential T cell response in central and peripheral nerve injury: connection with immune privilege	FASEB JOURNAL			English	Article						T lymphocytes; CNS; PNS; Fas ligand; major histocompatibility complex	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RAT OPTIC-NERVE; FAS LIGAND; ANTIGEN PRESENTATION; MULTIPLE-SCLEROSIS; MICROGLIAL CELLS; BRAIN-BARRIER; CD95 LIGAND; SYSTEM	The central nervous system (CNS), unlike the peripheral nervous system (PNS), is an immune-privileged site in which local immune responses are restricted. Whereas immune privilege in the intact CNS has been studied intensively, Little is known about its effects after trauma. In this study, we examined the influence of CNS immune privilege on T cell response to central nerve injury. Immunocytochemistry revealed a significantly greater accumulation of endogenous T cells in the injured rat sciatic nerve than in the injured rat optic nerve (representing PNS and CNS white matter trauma, respectively). Use of the in situ terminal deoxytransferase-catalyzed DNA nick end labeling (TUNEL) procedure revealed extensive death of accumulating T cells in injured CNS nerves as well as in CNS nerves of rats with acute experimental autoimmune encephalomyelitis, but not in injured PNS nerves, Although Fas ligand (FasL) protein was expressed in white matter tissue of both systems, it was more pronounced in the CNS, Expression of major histocompatibility complex (MHC) class II antigens was found to be constitutive in the PNS, but in the CNS was induced only after injury, Our findings suggest that the T cell response to central nerve injury is restricted by the reduced expression of MHC class II antigens, the pronounced Fast expression, and the elimination of infiltrating lymphocytes through cell death.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Cohen, Irun R/B-3542-2009; Moalem-Taylor, Gila/C-3116-2008	Moalem-Taylor, Gila/0000-0003-3828-9527				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNUN A, 1982, J IMMUNOL, V129, P303; BERGSTEINSDOTTIR K, 1992, J NEUROCYTOL, V21, P382, DOI 10.1007/BF01191706; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; FIERZ W, 1985, J IMMUNOL, V134, P3785; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Glass A, 1996, J IMMUNOL, V156, P3638; Gold R, 1997, TRENDS NEUROSCI, V20, P399, DOI 10.1016/S0166-2236(97)01079-5; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HIRSHFELD T, 1970, FEBS LETT, V7, P317; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KSANDER BR, 1994, CHEM IMMUNOL, V58, P117; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MONACO S, 1992, J NEUROCYTOL, V21, P623, DOI 10.1007/BF01191724; NAPARSTEK Y, 1983, EUR J IMMUNOL, V13, P418, DOI 10.1002/eji.1830130513; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; POLTORAK M, 1991, ANN NEUROL, V29, P377, DOI 10.1002/ana.410290408; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAO K, 1989, TRANSPLANTATION, V48, P1018, DOI 10.1097/00007890-198912000-00025; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Sabelko KA, 1997, J IMMUNOL, V159, P3096; SCHMIED M, 1993, AM J PATHOL, V143, P446; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Smith T, 1996, J AUTOIMMUN, V9, P167, DOI 10.1006/jaut.1996.0020; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Waldner H, 1997, J IMMUNOL, V159, P3100; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WUCHERPFENNIG KW, 1994, CLIN IMMUNOL IMMUNOP, V72, P293, DOI 10.1006/clin.1994.1145; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; YU LT, 1990, J NEUROIMMUNOL, V30, P121, DOI 10.1016/0165-5728(90)90095-5	58	130	136	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1207	1217		10.1096/fasebj.13.10.1207	http://dx.doi.org/10.1096/fasebj.13.10.1207			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385611				2022-12-25	WOS:000081264800009
J	Chapman, SC; Ayala, JE; Streeper, RS; Culbert, AA; Eaton, EM; Svitek, CA; Goldman, JK; Tavare, JM; O'Brien, RM				Chapman, SC; Ayala, JE; Streeper, RS; Culbert, AA; Eaton, EM; Svitek, CA; Goldman, JK; Tavare, JM; O'Brien, RM			Multiple promoter elements are required for the stimulatory effect of insulin on human collagenase-1 gene transcription - Selective effects on activator protein-1 expression may explain the quantitative difference in insulin and phorbol ester action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; MATRIX METALLOPROTEINASES; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PROLACTIN GENE; KINASE-C; 5'-FLANKING REGION; TISSUE INHIBITORS; DIABETES-MELLITUS; RESPONSE ELEMENT; MESANGIAL CELLS	Several of the complications seen in patients with both type I and type II diabetes mellitus are associated with alterations in the expression of matrix metalloproteinases. To identify the cis-acting elements that mediate the stimulatory effect of insulin on collagenase-1 (matrix metalloproteinase-1) gene transcription a series of collagenase-chloramphenicol acetyltransferase (CAT) fusion genes were transiently transfected into HeLa cells, Multiple promoter elements, including an Ets and activator protein-1 (AP-1) motif, were required for the effect of insulin. The AP-1 motif appears to be a target for insulin signaling because it is sufficient to mediate an effect of insulin on the expression of a heterologous fusion gene, whereas the data suggest that the Ets motif acts to enhance the effect of insulin mediated through the AP-1 motif. Multiple promoter elements were also required for the stimulatory effect of phorbol esters on collagenase-CAT gene transcription, and the AP-1 motif was also a target for phorbol ester signaling. However, the cis-acting elements required for the effects of insulin and phorbol esters were not identical. Moreover, phorbol esters were a much more potent inducer of collagenase-CAT gene transcription than insulin, a difference that may be explained by selective effects of insulin and phorbol esters on AP-1 expression.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Vanderbilt University; University of Bristol	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 761 MRB 2, Nashville, TN 37232 USA.			Tobin, Stacey/0000-0003-1674-9844	NIDDK NIH HHS [R01 DK52820] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052820] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1994, J AM SOC NEPHROL, V5, P1165; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARNQVIST HJ, 1988, AM J PHYSIOL, V254, pC411, DOI 10.1152/ajpcell.1988.254.3.C411; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BASAYEAUX JP, 1997, J BIOL CHEM, V272, P26188; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jiang Zhen Y., 1996, P719; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NAKAMURA T, 1994, RENAL PHYSIOL BIOCH, V17, P316; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OEMAR BS, 1991, J BIOL CHEM, V266, P2369; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Reaven GM, 1997, AM J KIDNEY DIS, V30, P928, DOI 10.1016/S0272-6386(97)90106-2; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SCHLEICHER ED, 1992, EUR J CLIN CHEM CLIN, V30, P635; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SHEHADEH A, 1995, CLIN CARDIOL, V18, P301, DOI 10.1002/clc.4960180604; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231	56	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18625	18634		10.1074/jbc.274.26.18625	http://dx.doi.org/10.1074/jbc.274.26.18625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373474	hybrid			2022-12-25	WOS:000081056700066
J	Fucini, RV; Okada, S; Pessin, JE				Fucini, RV; Okada, S; Pessin, JE			Insulin-induced desensitization of extracellular signal-regulated kinase activation results from all inhibition of Raf activity independent of Ras activation and dissociation of the Grb2-SOS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; SON-OF-SEVENLESS; PROTEIN-KINASE; ADAPTER PROTEIN; P21(RAS) DESENSITIZATION; DEPENDENT ACTIVATION; SOS-GRB2 COMPLEX; GROWTH-FACTORS; SH3 DOMAINS	Previous studies have suggested that the interaction between the small adaptor protein Grb2 with the Ras guanyl nucleotide exchange factor SOS is functionally important in the regulation of the Ras activation/inactivation cycle. To examine the relationship between the Grb2-SOS complex and Ras activation, we observed that insulin stimulation results in a rapid but transient activation of Ras and the extracellular-signal regulated kinase (ERK) followed by dissociation of the Grb2-SOS complex. Although treatment with the phorbol myristate acetate resulted in ERK activation and complete dissociation of the Grb2-SOS complex, there was no effect on subsequent insulin-stimulated Ras activation. Similarly, insulin stimulation followed by insulin removal resulted in a time-dependent restoration of the Grb2-SOS complex but which was significantly slower than the recovery of insulin-stimulated Ras activation. In addition, although insulin was able to activate Ras under these conditions, there was a complete desensitization of Raf and ERK activation. This apparent homologous desensitization of insulin action was specific for Raf and ERK as the insulin re-stimulation of insulin receptor autophosphorylation and protein kinase B activation were unaffected. Together, these data demonstrate the presence of a pathway independent of the Grb2-SOS complex that can lead to Ras activation but that the desensitization of Raf accounts for the homologous desensitization of ERK.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823, R01DK049781] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49781, DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Combettes-Souverain M, 1998, DIABETES METAB, V24, P477; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yuryev A, 1998, Cell Res, V8, P81; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18651	18658		10.1074/jbc.274.26.18651	http://dx.doi.org/10.1074/jbc.274.26.18651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373477	hybrid			2022-12-25	WOS:000081056700069
J	Jones, DR; Gonzalez-Garcia, A; Diez, E; Martinez-A, C; Carrera, AC; Merida, I				Jones, DR; Gonzalez-Garcia, A; Diez, E; Martinez-A, C; Carrera, AC; Merida, I			The identification of phosphatidylinositol 3,5-bisphosphate in T-lymphocytes and its regulation by interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; PHOSPHOINOSITIDE 3-KINASE; CELL PROLIFERATION; KINASE ACTIVATION; PROTEIN-KINASE; OSMOTIC-STRESS; GROWTH-FACTOR; C2 DOMAIN; PATHWAY; POLYPHOSPHOINOSITIDES	In recent times 3-phosphoinositides have emerged as important regulators of cell metabolism, survival, and proliferation. During the last year, the phospholipid phosphatidylinositol 3,5-bisphosphate (PtdIns3,5P(2)) was identified in yeast, fibroblasts, SV40-transformed kidney (COS-7) cells, and platelets. The discovery of this novel phospholipid has increased the complexity of the metabolism relating to the generation of biologically active inositol-containing lipids. We describe here the identification of PtdIns3,5P(2) in the CTLL-8 mouse T-lymphocyte cell line using two in vivo radiolabeling protocols. Treatment of the cells with UV radiation led to an increase in the cellular content of PtdIns3,5P(2). In contrast, preincubation of the cells with wortmannin or treatment with hypertonic medium (high concentration sorbitol) led to the opposite effect. Herein we demonstrate that interleukin-2 (IL-2), the growth factor required for CTLL-2 cell proliferation, was able to increase the level of PtdIns3,5P(2) with similar kinetics to that of the formation of phosphatidylinositol: 3,4-bisphosphate (PtdIns3,4P(2)). An increase in this novel 3-phosphorylated lipid in response to IL-2 seems to be a general property of this cytokine because a similar result was obtained when the pre-B cell line BaF/3 ex pressing the high affinity IL-2 receptor was used. Using a constitutively active regulatory subunit of type I phosphatidylinositol 3-kinase and cells expressing a deletion of the serine-rich domain of the IL-2 receptor beta chain, which is required for IL-2-stimulated type I phosphatidylinositol 3-kinase activation, we demonstrate that IL-2-induced generation of PtdIns3,5P(2) is related to the activation of this enzyme. The results show for the first time the identification of PtdIns3,5P(2) in both T- and B-lymphocytes and indicate its positive regulation by the mitogen IL-2.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Madrid 28760, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); GlaxoSmithKline	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Merida, Isabel/A-9713-2014; Gonzalez-Garcia, Ana/D-9736-2014	Merida, Isabel/0000-0003-2762-6241; Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; KANAZAWA T, 1994, CELL IMMUNOL, V156, P378, DOI 10.1006/cimm.1994.1183; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MILLS GB, 1986, J IMMUNOL, V136, P3019; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; VANHAESEBROCK B, 1997, TRENDS BIOCHEM SCI, V22, P355; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	39	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18407	18413		10.1074/jbc.274.26.18407	http://dx.doi.org/10.1074/jbc.274.26.18407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373447	hybrid			2022-12-25	WOS:000081056700039
J	Lee, SSK; Lehman, IR				Lee, SSK; Lehman, IR			The interaction of herpes simplex type 1 virus origin-binding protein (UL9 protein) with box I, the high affinity element of the viral origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ACTIVITY; DOMAIN	The herpes simplex type 1 (HSV-1) origin binding protein, the UL9 protein, exists in solution as a homodimer of 94-kDa monomers. It binds to Box I, the high affinity element of the HSV-I origin, Ori,, as a dimer. The UL9 protein also binds the HSV-I single strand DNA-binding protein, ICPS. Photocross-linking studies have shown that although the UL9 protein binds Box I as a dimer, only one of the two monomers contacts Box I. It is this form of the UL9 homodimer that upon interaction with ICP8, promotes the unwinding of Box I coupled to the hydrolysis of ATP to ADP and P-i. Photocross-linking studies have also shown that the amount of UL9 protein that interacts with Box I is reduced by its interaction with ICP8, Antibody directed against the C-terminal ten amino acids of the UL9 protein inhibits its Box I unwinding activity, consistent with the requirement for interaction of the C terminus of the UL9 protein with ICPS, Inhibition by the antibody is enhanced when the UL9 protein is first bound to Box I, suggesting that the C terminus of the UL9 protein undergoes a conformational change upon binding Box I.	Stanford Univ, Dept Biochem, Beckman Ctr, Stanford, CA 94305 USA	Stanford University	Lehman, IR (corresponding author), Stanford Univ, Dept Biochem, Beckman Ctr, B-400, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DODSON MS, 1993, J BIOL CHEM, V268, P1213; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; ELIAS P, 1992, J BIOL CHEM, V267, P17167; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; STABELL EC, 1993, NUCLEIC ACIDS RES, V21, P5203, DOI 10.1093/nar/21.22.5203	19	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18613	18617		10.1074/jbc.274.26.18613	http://dx.doi.org/10.1074/jbc.274.26.18613			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373472	hybrid			2022-12-25	WOS:000081056700064
J	Romaris, M; Coomans, C; Ceulemans, H; Bruystens, AM; Vekemans, S; David, G				Romaris, M; Coomans, C; Ceulemans, H; Bruystens, AM; Vekemans, S; David, G			Molecular polymorphism of the syndecans - Identification of a hypo-glycanated murine syndecan-1 splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; I COLLAGEN; SURFACE PROTEOGLYCAN; FINE-STRUCTURE; CORE PROTEINS; EXPRESSION; CLONING	We have identified a cDNA that encodes a variant form of murine syndecan-1, The variant cDNA lacks the sequence corresponding to the first 132 nucleotides of the third exon of the syndecan-1 gene. The corresponding message is rare. The alternative splice respects the reading frame and deletes 44 amino acids from the protein, joining the S(45)GS(47)GT sequence to a variant immediate downstream context. This sequence context initiates with alanine instead of glycine as residue 50, reducing the number of SGXG sequence motifs in the protein from two to one. Expression of this variant syndecan-1 in Madin-Darby canine kidney or MOLT-4 cells yielded a recombinant proteoglycan with a reduced number and clustering of the heparan sulfate chains, Both the conversions of Ala(50) and of Lys(53) into glycine enhanced the heparan sulfate substitution of the variant protein. These findings support the concept that serine glycine dipeptide signals for glycosaminoglycan/heparan sulfate synthesis depend on sequence context (Zhang, L., David, G.., and Esko, J. D. (1995) J. Biol. Chem, 270, 27127-27135) and imply that alternative splicing mechanisms may in part control the molecular polymorphism of syndecan-1 and, therefore, the efficiency and versatility of this protein in its co-receptor functions.	Univ Louvain, Lab Glycobiol & Dev Genet, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium		David, G (corresponding author), Univ Louvain, Lab Glycobiol & Dev Genet, Ctr Human Genet, Campus Gasthuisberg,0&N6,Herestr 49, B-3000 Louvain, Belgium.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HINKES MT, 1993, J BIOL CHEM, V268, P11440; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; KODA JE, 1985, J BIOL CHEM, V260, P8157; KODA JE, 1984, J BIOL CHEM, V259, P1763; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; LORIES V, 1989, J BIOL CHEM, V264, P7009; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RIDLEY RC, 1993, BLOOD, V81, P767; RODEN L, 1985, FED PROC, V44, P373; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	33	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18667	18674		10.1074/jbc.274.26.18667	http://dx.doi.org/10.1074/jbc.274.26.18667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373479	hybrid			2022-12-25	WOS:000081056700071
J	Schuler, B; Rachel, R; Seckler, R				Schuler, B; Rachel, R; Seckler, R			Formation of fibrous aggregates from a non-native intermediate: The isolated P22 tailspike beta-helix domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FOLDING MUTATIONS; INCLUSION-BODY FORMATION; HEAD-BINDING DOMAIN; TAIL-SPIKE PROTEIN; ALTERNATIVE CONFORMATIONS; AMYLOIDOGENIC PROTEINS; ELECTRON-MICROSCOPY; POLYPEPTIDE-CHAINS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS	In the assembly pathway of the trimeric P22 tailspike protein, the protein conformation critical for the partitioning between productive folding and off-pathway aggregation is a monomeric folding intermediate. The central domain of tailspike, a large right-handed parallel beta-helix, is essentially structured in this species, We used the isolated beta-helix domain (Bhx), expressed with a hexahistidine tag, to investigate the mechanism of aggregation without the two terminal domains present in the complete protein. Although Bhx has been shown to fold reversibly at low ionic strength conditions, increased ionic strength induced aggregation with a maximum at urea concentrations corresponding to the midpoint of urea-induced folding transitions. According to size exclusion chromatography, aggregation appeared to proceed via a linear polymerization mechanism. Circular dichroism indicated a secondary structure content of the aggregates similar to that of the native state, but at the same time their tryptophan fluorescence was largely quenched. Microscopic analysis of the aggregates revealed a variety of morphologies; among others, fibrils with fine structure were observed that exhibited bright green birefringence if viewed under cross-polarized light after staining with Congo red, These observations, together with the effects of folding mutations on the aggregation process, indicate the involvement of a partially structured intermediate distinct from both unfolded and native Bhx.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Regensburg, Inst Biochem Genet & Mikrobiol, D-93040 Regensburg, Germany; Univ Potsdam, D-14943 Luckenwalde, Germany	University of Regensburg; University of Regensburg; University of Potsdam	Schuler, B (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany.		Schuler, Benjamin/E-7342-2011	Schuler, Benjamin/0000-0002-5970-4251				Betts S, 1997, ADV PROTEIN CHEM, V50, P243, DOI 10.1016/S0065-3233(08)60323-X; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P1172; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; DILL KA, 1995, ADV PROTEIN CHEM, V46, P59, DOI 10.1016/S0065-3233(08)60332-0; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; HaasePettingell C, 1997, J MOL BIOL, V267, P88, DOI 10.1006/jmbi.1996.0841; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HEMKER DJ, 1990, MACROMOLECULES, V23, P4404, DOI 10.1021/ma00222a013; HERBST R, 1998, BIOCHEMISTRY-US, V37, P3253; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; Miller S, 1998, BIOCHEMISTRY-US, V37, P9160, DOI 10.1021/bi980190e; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; Pace C N, 1986, Methods Enzymol, V131, P266; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RACHEL R, 1986, ULTRAMICROSCOPY, V20, P305, DOI 10.1016/0304-3991(86)90194-4; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; SECKLER R, 1997, MOL CHAPERONES LIFE, P391; SMITH DH, 1980, GENETICS, V96, P331; Speed MA, 1997, PROTEIN SCI, V6, P99; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WETZEL R, 1997, ADV PROTEIN CHEM, V50, P243; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; [No title captured]	50	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18589	18596		10.1074/jbc.274.26.18589	http://dx.doi.org/10.1074/jbc.274.26.18589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373469	hybrid			2022-12-25	WOS:000081056700061
J	Haas, E; Grell, M; Wajant, H; Scheurich, P				Haas, E; Grell, M; Wajant, H; Scheurich, P			Continuous autotropic signaling by membrane-expressed tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; FACTOR TNF; FACTOR-ALPHA; CELL-DEATH; TRANSMEMBRANE FORM; FACTOR RECEPTOR; AUTOCRINE ROLE; INDUCTION; CYTOTOXICITY; PROTEIN	Tumor necrosis factor (TNF) exists in two bioactive forms, the membrane-integrated form and the proteolytically derived soluble cytokine. Cells that produce TNF are often responsive to TNF, allowing autocrine/juxtacrine feedback loops. However, whether the membrane form of TNF is involved in such regulatory circuits is unclear. Here we demonstrate that HeLa cells, expressing a permanently membrane-integrated mutant form of TNF, constitutively express TNF.TNF receptor complexes at their cell surface. These cells show a permanent activation of the transcription factor NF-kappa B, exert constitutive p38 mitogen-activated protein kinase activity, and produce high amounts of interleukin-6. In parallel, transmembrane TNF-expressing HeLa cells display high sensitivity to cycloheximide or interferon-gamma, similar to untransfected cells treated with these agents in combination with sTNF, Moreover, cycloheximide-induced apoptosis in transmembrane TNF transfectants can be blocked by the caspase inhibitor zVAD-fmk and does not necessarily need cell to cell contact, indicating a critical role of constitutive autotropic signaling of TNF . TNF receptor complexes. These data demonstrate that autotropic signaling loops of membrane TNF can exist, which may be of importance for cells that express both TNF and TNF receptors, such as T lymphocytes, macrophages, and endothelial cells.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Scheurich, P (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Decoster E, 1998, J BIOL CHEM, V273, P3271, DOI 10.1074/jbc.273.6.3271; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1997, GROWTH FACTORS CYTOK, P669; HELLER RA, 1992, CELL, V70, P47; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOPEZCEPERO M, 1994, J IMMUNOL, V152, P3333; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Moss ML, 1997, NATURE, V386, P738, DOI 10.1038/386738c0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; SCHEURICH P, 1986, INT J CANCER, V15, P127; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; SMITH DM, 1990, CANCER RES, V50, P3146; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; WALLACH D, 1988, J IMMUNOL, V140, P2994; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; WONG GHW, 1992, J IMMUNOL, V149, P3350	32	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18107	18112		10.1074/jbc.274.25.18107	http://dx.doi.org/10.1074/jbc.274.25.18107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364265	hybrid			2022-12-25	WOS:000080974300101
J	Ma, JX; Qu, W; Scarborough, PE; Tomer, KB; Moomaw, CR; Maronpot, R; Davis, LS; Breyer, MD; Zeldin, DC				Ma, JX; Qu, W; Scarborough, PE; Tomer, KB; Moomaw, CR; Maronpot, R; Davis, LS; Breyer, MD; Zeldin, DC			Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome p450 highly expressed in Kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; SPONTANEOUSLY HYPERTENSIVE RATS; EPOXYEICOSATRIENOIC ACIDS; HUMAN LIVER; MICROSOMAL CYTOCHROME-P450; ENANTIOFACIAL SELECTIVITY; FUNCTIONAL-SIGNIFICANCE; OMEGA-HYDROXYLATION; EPITHELIAL-CELLS; PROXIMAL TUBULE	A cDNA encoding a new cytochrome P450 was isolated from a mouse liver library. Sequence analysis reveals that this 1,886-base pair cDNA encodes a 501-amino acid polypeptide that is 69-74% identical to CYP2J subfamily P450s and is designated CYP2J5. Recombinant CYP2J5 was co-expressed with NADPH-cytochrome P450 oxidoreductase in Sf9 cells using a baculovirus system. Microsomal fractions of CYP2J5/NADPH-cytochrome P450 oxidoreductase-transfected cells metabolize arachidonic acid to 14,15-, 11,12-, and 8,9-epoxyeicosatrienoic acids and 11- and 15-hydroxyeicosatetraenoic acids (catalytic turnover, 4.5 nmol of product/nmol of cytochrome P450/min at 37 degrees C); thus CYP2J5 is enzymologically distinct. Northern analysis reveals that CYP2J5 transcripts are most abundant in mouse kidney and present at lower levels in liver. Immunoblotting using a polyclonal antibody against a CYP2J5-specific peptide detects a protein with the same electrophoretic mobility sis recombinant CYP2J5 most abundantly in mouse kidney microsomes. CYP2J5 is regulated during development in a tissue-specific fashion. In the kidney, CYP2J5 is present before birth and reaches maximal levels at 2-4 weeks of age. In the liver, CYP2J5 is absent prenatally and during the early postnatal period, first appears at 1 week, and then remains relatively constant. Immunohistochemical staining of kidney sections with anti-human CYP2J2 IBG reveals that CYP2J protein(s) are present primarily in the proximal tubules and collecting ducts, sites where the epoxyeicosatrienoic acids are known to modulate fluid/electrolyte transport and mediate hormonal action. In situ hybridization confirms abundant CYP2J5 mRNA within tubules of the renal cortex and outer medulla. Epoxyeicosatrienoic acids are endogenous constituents of mouse kidney thus providing direct evidence for the in vivo metabolism of arachidonic acid by the mouse renal epoxygenase(s). Based on these data, we conclude that CYP2J5 is an enzymologically distinct, developmentally regulated, protein that is localized to specific nephron segments and contributes to the oxidation of endogenous renal arachidonic acid pools. In light of the well documented effects of epoxyeicosatrienoic acids in modulating renal tubular transport processes, we postulate that CYP2J5 products play important functional roles in the kidney.	NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University	Zeldin, DC (corresponding author), NIEHS, Pulm Pathobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK38226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; BURKE MD, 1979, PHARMACOL THERAPEUT, V7, P549, DOI 10.1016/0163-7258(79)90042-1; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1996, ADV MOL CEL, V14, P317; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; DEES JH, 1982, CANCER RES, V42, P1423; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FORCE T, 1991, J BIOL CHEM, V266, P4295; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HARDWICK JP, 1991, METHOD ENZYMOL, V206, P273; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HENRICH WL, 1990, AM J PHYSIOL, V258, pE269, DOI 10.1152/ajpendo.1990.258.2.E269; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; IMAOKA S, 1993, J PHARMACOL EXP THER, V267, P1012; IMIG JD, 1993, HYPERTENSION, V22, P357, DOI 10.1161/01.HYP.22.3.357; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR, P311; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1993, J BIOL CHEM, V268, P13565; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; Kroetz DL, 1997, MOL PHARMACOL, V52, P362, DOI 10.1124/mol.52.3.362; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; LEVERE RD, 1990, J CLIN INVEST, V86, P213, DOI 10.1172/JCI114686; Ma JX, 1998, GENOMICS, V49, P152, DOI 10.1006/geno.1998.5235; MA YH, 1994, AM J PHYSIOL, V36, pR579; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MCGIFF JC, 1993, STEROIDS, V58, P573, DOI 10.1016/0039-128X(93)90098-8; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMATA K, 1993, J LIPID MEDIATOR, V6, P369; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; OMATA K, 1992, AM J PHYSIOL, V262, pF8, DOI 10.1152/ajprenal.1992.262.1.F8; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Pascual JMS, 1998, J PHARMACOL EXP THER, V286, P772; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; ROMAN RJ, 1987, HYPERTENSION, V9, P130; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schwartzman ML, 1996, NEPHRON, V73, P652; Stec DE, 1996, HYPERTENSION, V27, P564, DOI 10.1161/01.HYP.27.3.564; Stec DE, 1996, HYPERTENSION, V27, P1329, DOI 10.1161/01.HYP.27.6.1329; UMENO M, 1988, J BIOL CHEM, V263, P4956; UYEHARA CFT, 1993, AM J PHYSIOL, V34, pR943; Wang MH, 1996, ARCH BIOCHEM BIOPHYS, V336, P240, DOI 10.1006/abbi.1996.0554; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; Zeldin DC, 1997, MOL PHARMACOL, V51, P931, DOI 10.1124/mol.51.6.931; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922; Zou AP, 1996, AM J PHYSIOL-RENAL, V270, pF822, DOI 10.1152/ajprenal.1996.270.5.F822	82	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17777	17788		10.1074/jbc.274.25.17777	http://dx.doi.org/10.1074/jbc.274.25.17777			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364221	hybrid			2022-12-25	WOS:000080974300057
J	Verhamme, I; Kvassman, JO; Day, D; Debrock, S; Vleugels, N; Declerck, PJ; Shore, JD				Verhamme, I; Kvassman, JO; Day, D; Debrock, S; Vleugels, N; Declerck, PJ; Shore, JD			Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ESCHERICHIA-COLI; IDENTIFICATION; PURIFICATION; VITRONECTIN; PROTEIN; LOCALIZATION; INSERTION; COMPLEXES; MECHANISM	The serpin plasminogen activator inhibitor-1 (PAI-1) slowly converts to an inactive latent form by inserting a major part of its reactive center loop (RCL) into its beta-sheet A. A murine monoclonal antibody (MA-33B8), raised against the human plasminogen activator (tPA). PAI-1 complex, rapidly inactivates PAI-1, Results presented here indicate that MA-33B8 induces acceleration of the active-to-latent conversion. The antibody-induced inactivation of PAI-1 labeled with the fluorescent probe N,N'-dimethyl-N-(acetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylene diamine (NBD) at P9 in the RCL caused a fluorescence enhancement and shift identical to those accompanying the spontaneous conversion of the PS NBD PAI-1 to the latent form, Like latent PAI-1, antibody-inactivated PAI-1 was protected from cleavage by elastase, The rate constants for MA-33B8 binding, measured by NBD fluorescence or inactivation, were similar (1.3-1.8 x 10(4) M-1 s(-1)), resulting in a 4000-fold faster inactivation at 4.2 mu M antibody binding sites. The apparent antibody binding rate constant, at least 1000 times slower than one limited by diffusion, indicates that exposure of its epitope depends on an unfavorable equilibrium of PAI-1. Our observations are consistent with this idea and suggest that the equilibrium involves partial insertion of the RCL into sheet A: latent, RCL-cleaved, and tPA-complexed PAI-1, which are inactive loop-inserted forms, bound much faster than active PAI-1 to MA-33B8, whereas two loop-extracted forms of PAI-1, modified to prevent loop insertion, did not bind or bound much more weakly to the antibody.	Henry Ford Hlth Sci Ctr, Div Biochem Res, Detroit, MI 48202 USA; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital; KU Leuven	Shore, JD (corresponding author), Henry Ford Hlth Sci Ctr, Div Biochem Res, 1 Ford Pl,5D, Detroit, MI 48202 USA.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45930A07] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Creighton T. E., 1993, PROTEINS STRUCTURE M, P402; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Ngo TH, 1997, FEBS LETT, V416, P373, DOI 10.1016/S0014-5793(97)01242-8; OLSON ST, 1995, J BIOL CHEM, V270, P30007; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SHORE JD, 1996, ADV EXPT MED BIOL, V425, P300; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	28	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17511	17517		10.1074/jbc.274.25.17511	http://dx.doi.org/10.1074/jbc.274.25.17511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364183	hybrid			2022-12-25	WOS:000080974300019
J	Akiba, S; Mizunaga, S; Kume, K; Hayama, M; Sato, T				Akiba, S; Mizunaga, S; Kume, K; Hayama, M; Sato, T			Involvement of group VICa2+-independent phospholipase A(2) in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D(1) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; PHOSPHATIDATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; BROMOENOL LACTONE; INHIBITION; MOBILIZATION; RELEASE; ACTIVATION; MECHANISM; MEMBRANE	We investigated the possible involvement of group VI Ca2+-independent phospholipase A(2) (iPLA(2)) in arachidonic acid (AA) liberation in zymosan-stimulated macrophage-like P388D(1) cells. Zymosan-induced AA liberation was markedly inhibited by methyl arachidonoyl fluorophosphonate, a dual inhibitor of group IV cytosolic phospholipase A, (cPLA(2)) and iPLA(2). We found that a relatively specific iPLA(2) inhibitor, bromoenol lactone, significantly decreased the zymosan-induced AA liberation in parallel with the decrease in iPLA(2) activity, without an effect on diacylglycerol formation. Consistent with this, attenuation of iPLA(2) activity by a group VI iPLA(2) antisense oligonucleotide resulted in a decrease in zymosan-induced prostaglandin D, generation. These findings suggest that zymosan-induced AA liberation may be, at least in part, mediated by iPLA(2). A protein kinase C (PKC) inhibitor diminished zymosan-induced AA liberation, while a PKC activator, phorbol la-myristate 13-acetate (PMA), enhanced the liberation. Bromoenol lactone suppressed the PMA-enhanced AA liberation without any effect on PIMA-induced PKC activation. Down-regulation of PKC alpha on prolonged exposure to PMA also decreased zymosan-induced AA liberation. Under these conditions, the remaining AA liberation was insensitive to bromoenol lactone, Furthermore, the PKC depletion suppressed increases in iPLA(2) proteins and the activity in the membrane fraction of zymosan-stimulated cells. In contrast, the zymosan-induced increases in iPLA(2) proteins and the activity in the fraction were facilitated by simultaneous addition of PMA Although intracellular Ca2+ depletion prevented zymosan-induced AA liberation, the translocation of PKCa to membranes was also inhibited. Taken together, we propose that zymosan may stimulate iPLA(2)-mediated AA liberation, probably through a PKC-dependent mechanism.	Kyoto Pharmaceut Univ, Dept Pathol Biochem, Yamashima Ku, Kyoto 6078414, Japan	Kyoto Pharmaceutical University	Akiba, S (corresponding author), Kyoto Pharmaceut Univ, Dept Pathol Biochem, Yamashima Ku, Kyoto 6078414, Japan.							ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Derrickson BH, 1997, AM J PHYSIOL-RENAL, V272, pF781, DOI 10.1152/ajprenal.1997.272.6.F781; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HUWILER A, 1993, EUR J BIOCHEM, V217, P69, DOI 10.1111/j.1432-1033.1993.tb18219.x; Ishimoto T, 1996, J BIOCHEM-TOKYO, V120, P616; KARIMI K, 1995, J IMMUNOL, V155, P5786; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LANNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; LISTER MD, 1989, J BIOL CHEM, V264, P8520; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Ma ZM, 1997, J BIOL CHEM, V272, P11118; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; QUI ZH, 1998, J BIOL CHEM, V273, P8203; QUI ZH, 1994, J BIOL CHEM, V269, P19480; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WAITE M, 1985, J LIPID RES, V26, P1379; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522	43	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19906	19912		10.1074/jbc.274.28.19906	http://dx.doi.org/10.1074/jbc.274.28.19906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391937	hybrid			2022-12-25	WOS:000081377300057
J	Memon, RA; Holleran, WM; Uchida, Y; Moser, AH; Ichikawa, S; Hirabayashi, Y; Grunfeld, C; Feingold, KR				Memon, RA; Holleran, WM; Uchida, Y; Moser, AH; Ichikawa, S; Hirabayashi, Y; Grunfeld, C; Feingold, KR			Regulation of glycosphingolipid metabolism in liver during the acute phase response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN; PERMEABILITY BARRIER FUNCTION; LIPID-METABOLISM; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLCERAMIDE SYNTHASE; SPHINGOLIPID BIOSYNTHESIS; CHOLESTEROL-METABOLISM; SYRIAN-HAMSTERS; RAT-LIVER	The host response to infection is associated with multiple alterations in lipid and lipoprotein metabolism. We have shown recently that endotoxin (lipopolysaccharide (LPS)) and cytokines enhance hepatic sphingolipid synthesis, increase the activity and mRNA levels of serine palmitoyltransferase, the first committed step in sphingolipid synthesis, and increase the content of sphingomyelin, ceramide, and glucosylceramide (GlcCer) in circulating lipoproteins in Syrian hamsters, Since the LPS-induced increase in GlcCer content of lipoproteins was far greater than that of ceramide or sphingomyelin, we have now examined the effect of LPS and cytokines on glycosphingolipid metabolism. LPS markedly increased the mRNA level of hepatic GlcCer synthase, the enzyme that catalyzes the first glycosylation step of glycosphingolipid synthesis. The LPS-induced increase in GlcCer synthase mRNA levels was seen within 2 h, sustained for 8 h, and declined to base line by 24 h. LPS-induced increase in GlcCer synthase mRNA was partly accounted for by an increase in its transcription rate, LPS produced a 3-4-fold increase in hepatic GlcCer synthase activity and significantly increased the content of GlcCer (the immediate product of GlcCer synthase reaction) as well as ceramide trihexoside and ganglioside GM3 (products distal to the GlcCer synthase step) in the liver. Moreover, both tumor necrosis factor-cy and interleukin-1 beta, cytokines that mediate many of the metabolic effects of LPS, increased hepatic GlcCer synthase mRNA levels in vivo as well as in HepG2 cells in vitro, suggesting that these cytokines can directly stimulate glycosphingolipid metabolism. These results indicate that LPS and cytokines up-regulate glycosphingolipid metabolism in vivo and in vitro. An increase in GlcCer synthase mRNA levels and activity leads to the increase in hepatic GlcCer content and may account for the increased GlcCer content in circulating lipoproteins during the acute phase response.	Univ Calif San Francisco, Metab Sect 111F, Dept Vet Affairs Med Ctr, Med Serv,Dept Med, San Francisco, CA 94121 USA; Dept Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Metab Sect 111F, Dept Vet Affairs Med Ctr, Med Serv,Dept Dermatol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Feingold, KR (corresponding author), Univ Calif San Francisco, Metab Sect 111F, Dept Vet Affairs Med Ctr, Med Serv,Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.			Uchida, Yoshikazu/0000-0002-4980-3416; Hirabayashi, Yoshio/0000-0002-5774-7354	NIAMS NIH HHS [AR39448] Funding Source: Medline; NIDDK NIH HHS [DK 49448] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049448] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; CHATTERJEE S, 1976, LIPIDS, V11, P462, DOI 10.1007/BF02532836; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chujor CSN, 1998, J LIPID RES, V39, P277; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; DESHMUKH GD, 1994, J LIPID RES, V35, P1611; ElKhatib M, 1996, AM J PHYSIOL-RENAL, V270, pF476, DOI 10.1152/ajprenal.1996.270.3.F476; FEINGOLD KR, 1991, ARTERIOSCLER THROMB, V11, P495, DOI 10.1161/01.ATV.11.3.495; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; FEINGOLD KR, 1995, J LIPID RES, V36, P1474; FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267; Grunfeld C, 1999, J LIPID RES, V40, P245; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; GRUNFELD C, 1992, P SOC EXP BIOL MED, V200, P224; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hanley K, 1997, J LIPID RES, V38, P576; Hardardottir I, 1995, BIOCHEM SOC T, V23, P1013, DOI 10.1042/bst0231013; HARDARDOTTIR I, 1994, LYMPHOKINE CYTOK RES, V13, P161; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HOLLERAN WM, 1986, CANCER CHEMOTH PHARM, V17, P11, DOI 10.1007/BF00299859; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; HOLLERAN WM, 1991, J LIPID RES, V32, P1151; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KISILEVSKY R, 1992, LAB INVEST, V66, P778; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kushner I, 1991, Eur Cytokine Netw, V2, P75; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210, DOI 10.1152/ajpendo.1998.274.2.E210; MEMON RA, 1992, AM J PHYSIOL, V263, pE301, DOI 10.1152/ajpendo.1992.263.2.E301; MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Richards C, 1991, Eur Cytokine Netw, V2, P89; Sando GN, 1996, J BIOL CHEM, V271, P22044, DOI 10.1074/jbc.271.36.22044; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHUKLA A, 1992, AM J PHYSIOL, V262, pF24, DOI 10.1152/ajprenal.1992.262.1.F24; SU GL, 1994, J IMMUNOL, V153, P743; Su GL, 1995, CRIT REV IMMUNOL, V15, P201, DOI 10.1615/CritRevImmunol.v15.i3-4.10; Takami Yoshihiro, 1998, Journal of Dermatology (Tokyo), V25, P73; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; YAO JK, 1994, NEUROCHEM RES, V19, P31, DOI 10.1007/BF00966725; ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299	54	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19707	19713		10.1074/jbc.274.28.19707	http://dx.doi.org/10.1074/jbc.274.28.19707			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391911	hybrid			2022-12-25	WOS:000081377300031
J	Sturm, NR; Campbell, DK				Sturm, NR; Campbell, DK			The role of intron structures in trans-splicing and Cap 4 formation for the Leishmania spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; LEPTOMONAS-COLLOSOMA; MESSENGER-RNAS; SL RNA; TARENTOLAE; GENE; EXPRESSION; SEQUENCE; TRANSCRIPTION; REQUIREMENTS	A 39-nucleotide leader is trans-spliced onto all trypanosome nuclear mRNAs. The precursor spliced leader RNA was tested for trans-splicing function in vivo by mutating the intron. We report that in Leishmania tarentolae spliced leader RNA 5' modification is influenced by the primary sequence of stem-loop II, the Sm-binding site, and the secondary structure of stem-loop III. The sequence of stem-loop II was found to be important for cap 4 formation and splicing. As in Ascaris, mutagenesis of the bulge nucleotide in stem-loop II was detrimental to trans-splicing. Because restoration of the L. tarentolae stem-loop II structure was not sufficient to restore splicing, this result contrasts the findings in the kinetoplastid Leptomonas, where mutations that restored stem-loop II structure supported splicing. Methylation of the cap 4 structure and splicing was also dependent on both the Sm-binding site and the structure of stem-loop III and was inhibited by incomplete 3' end processing. The critical nature of the L. tarentolae Sm-binding site is consistent with its essential role in the Ascaris spliced leader RNA, whereas in Leptomonas mutation of the Sm-binding site and deletion of stem-loop III did not affect trans-splicing. A pathway for Leishmania spliced leader RNA processing and maturation is proposed.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Campbell, DK (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NIAID NIH HHS [2-T32-AI-07323, AI34536] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034536, T32AI007323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Denker JA, 1996, RNA, V2, P746; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Ferguson KC, 1999, MOL CELL BIOL, V19, P1892; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; Goncharov I, 1998, NUCLEIC ACIDS RES, V26, P2200, DOI 10.1093/nar/26.9.2200; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARRIS KA, 1995, RNA, V1, P351; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; Sturm NR, 1998, BBA-GENE STRUCT EXPR, V1442, P347, DOI 10.1016/S0167-4781(98)00150-X; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; ULLU E, 1996, MOL BIOL PARASITIC P, P115; Xie HY, 1998, P NATL ACAD SCI USA, V95, P4235, DOI 10.1073/pnas.95.8.4235; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	33	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19361	19367		10.1074/jbc.274.27.19361	http://dx.doi.org/10.1074/jbc.274.27.19361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383448	hybrid			2022-12-25	WOS:000081196300071
J	Kao, AW; Noda, Y; Johnson, JH; Pessin, JE; Saltiel, AR				Kao, AW; Noda, Y; Johnson, JH; Pessin, JE; Saltiel, AR			Aldolase mediates the association of F-actin with the insulin-responsive glucose transporter GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR SEQUESTRATION; INTERNALIZATION MOTIF; CYTOPLASMIC DOMAIN; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; PLASMA-MEMBRANE; TRANSLOCATION; TERMINUS	To identify potential proteins interacting with the insulin-responsive glucose transporter(GLUT4), we generated fusion proteins of glutathione S-transferase (GST) and the final 30 amino acids from GLUT4 (GST-G4) or GLUT1 (GST-G1). Incubation of these carboxyl-terminal fusion proteins with adipocyte cell extracts revealed a specific interaction of GLUT4 with fructose 1,6-bisphosphate aldolase. In the presence of aldolase, GST-G4 but not GST-G1 was able to co-pellet with filamentous (F)-actin. This interaction was prevented by incubation with the aldolase substrates, fructose 1,6-bisphosphate or glyceraldehyde 8-phosphate. Immunofluorescence confocal microscopy demonstrated a significant co-localization of aldolase and GLUT4 in intact 3T3L1 adipocytes, which decreased following insulin stimulation. Introduction into permeabilized 3T3L1 adipocytes of fructose 1,6-bisphosphate or the metabolic inhibitor P-deoxyglucose, two agents that disrupt the interaction between aldolase and actin, inhibited insulin-stimulated GLUT4 exocytosis without affecting GLUT4 endocytosis. Furthermore, microinjection of an aldolase-specific antibody also inhibited insulin-stimulated GLUT4 translocation. These data suggest that aldolase functions as a scaffolding protein for GLUT4 and that glucose metabolism may provide a negative feedback signal for the regulation of glucose transport by insulin.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Iowa; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	alan.saltiel@wl.com	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHENZION M, 1992, INT J BIOCHEM, V24, P821; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YANG J, 1993, J BIOL CHEM, V268, P4600	34	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17742	17747		10.1074/jbc.274.25.17742	http://dx.doi.org/10.1074/jbc.274.25.17742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364216	hybrid			2022-12-25	WOS:000080974300052
J	Millar, CA; Powell, KA; Hickson, GRX; Bader, MF; Gould, GW				Millar, CA; Powell, KA; Hickson, GRX; Bader, MF; Gould, GW			Evidence for a role for ADP-ribosylation factor 6 in insulin-stimulated glucose transporter-4 (GLUT4) trafficking in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTORS; REGULATED EXOCYTOSIS; CHROMAFFIN CELLS; SKELETAL-MUSCLE; PHOSPHOLIPASE-D; ARF PROTEINS; TRANSLOCATION; VESICLES	ADP-ribosylation factors (ARFs) play important roles in both constitutive and regulated membrane trafficking to the plasma membrane in other cells. Here we have examined their role in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. These cells express ARF5 and ARF6. ARF5 was identified in the soluble protein and intracellular membranes; in response to insulin some ARF5 was observed to re-locate to the plasma membrane. In contrast, ARF6 was predominantly localized to the plasma membrane and did not redistribute in response to insulin. We employed myristoylated peptides corresponding to the NH, termini of ARF5 and ARF6 to investigate the function of these proteins. Myr-ARF6 peptide inhibited insulin-stimulated glucose transport and GLUT4 translocation by similar to 50% in permeabilized adipocytes. In contrast, myr-BRF1 and myr-ARF5 peptides were without effect. Myr-ARF5 peptide also inhibited the insulin stimulated increase in cell surface levels of GLUT1 and transferrin receptors. Myr-ARF6 peptide significantly decreased cell surface levels of these proteins in both basal and insulin-stimulated states, but did not inhibit the fold increase in response to insulin. These data suggest an important role for ARF6 in regulating cell surface levels of GLUT4 in adipocytes, and argue for a role for both ARF5 and ARF6 in the regulation of membrane trafficking to the plasma membrane.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; INSERM, U 338, F-67084 Strasbourg, France	University of Glasgow; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gould, GW (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.W.Gould@bio.gla.ac.uk	Gould, Gwyn/AAF-6721-2019; Bader, Marie-France/O-2098-2016	Gould, Gwyn/0000-0001-6571-2875; Powell, Kate/0000-0002-1826-953X; Hickson, Gilles/0000-0001-7670-9815				Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Ralston E, 1996, J CELL SCI, V109, P2967; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Slot JW, 1997, J CELL BIOL, V137, P1243, DOI 10.1083/jcb.137.6.1243; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; YANG J, 1993, J BIOL CHEM, V268, P4600; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977; Zorzano A, 1996, DIABETES, V45, pS70, DOI 10.2337/diab.45.1.S70	47	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17619	17625		10.1074/jbc.274.25.17619	http://dx.doi.org/10.1074/jbc.274.25.17619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364199	hybrid			2022-12-25	WOS:000080974300035
J	Santalucia, T; Boheler, KR; Brand, NJ; Sahye, U; Fandos, C; Vinals, F; Ferre, J; Testar, X; Palacin, M; Zorzano, A				Santalucia, T; Boheler, KR; Brand, NJ; Sahye, U; Fandos, C; Vinals, F; Ferre, J; Testar, X; Palacin, M; Zorzano, A			Factors involved in GLUT-1 glucose transporter gene transcription in cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; POSTNATAL-DEVELOPMENT; CELL-DIFFERENTIATION; SP1-MEDIATED TRANSCRIPTION; REGULATE EXPRESSION; VESICLE POPULATIONS; BIOCHEMICAL ASPECTS; THYROID-HORMONE	Glucose constitutes a major fuel for the heart, and high glucose uptake during fetal development is coincident with the highest level of expression of the glucose transporter GLUT-1 during life. We have previously reported that GLUT-1 is repressed perinatally in rat heart, and GLUT-1, which shows a low level of expression in the fetal stage, becomes the main glucose transporter in the adult. Here, we show that the perinatal expression of GLUT-1 and GLUT-1 glucose transporters in heart is controlled directly at the level of gene transcription. Transient transfection assays show that the -99/-33 fragment of the GLUT-1 gene is sufficient to drive transcriptional activity in rat neonatal cardiomyocytes. Electrophoretic mobility shift assays demonstrate that the transcription factor Sp1, a trans-activator of GLUT-1 promoter, binds to the -102/-82 region of GLUT-2 promoter during the fetal state but not during adulthood. Mutation of the Sp1 site in this region demonstrates that Sp1 is essential for maintaining a high transcriptional activity in cardiac myocytes. Sp1 is markedly down-regulated both in heart and in skeletal muscle during neonatal life, suggesting an active role for Sp1 in the regulation of GLUT-1 transcription. In all, these results indicate that the expression of GLUT-1 and GLUT-I in heart during perinatal development is largely controlled at a transcriptional level by mechanisms that might be related to hyperplasia and that are independent from the signals that trigger cell hypertrophy in the developing heart. Furthermore, our results provide the first functional insight into the mechanisms regulating muscle GLUT-1 gene expression in a live animal.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; NIA, Gerontol Res Ctr, Mol Cardiol Unit, Cardiovasc Sci Lab,NIH, Baltimore, MD 21224 USA; Imperial Coll, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of Barcelona; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Diagonal 645, E-08028 Barcelona, Spain.		Vinals, Francesc/P-6278-2019; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Viñals, Francesc/F-5928-2016; Santalucia, Tomas/I-7411-2012; Santalucia, Tomas/B-6140-2012	Viñals, Francesc/0000-0002-9918-6751; Santalucia, Tomas/0000-0003-4604-9195; Santalucia, Tomas/0000-0003-4604-9195; Fandos, Cesar/0000-0001-7348-1376; Palacin, Manuel/0000-0002-8670-293X				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHALLICE CE, 1973, ULTRASTRUCTURE MAMMA, V6, P91; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHENG W, 1995, LAB INVEST, V72, P646; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CLARK CM, 1971, AM J PHYSIOL, V220, P583; CLAYCOMB WC, 1976, J BIOL CHEM, V251, P6082; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P3229; CLAYCOMB WC, 1983, ADV EXP MED BIOL, V161, P249; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gould G.W., 1997, FACILITATIVE GLUCOSE, P1; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Koban MU, 1998, CARDIOVASC RES, V37, P405, DOI 10.1016/S0008-6363(97)00276-9; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar HL, 1997, AM J CARDIOL, V80, pA90, DOI 10.1016/S0002-9149(97)00462-1; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIU ML, 1994, J BIOL CHEM, V269, P28514; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MCCULLY JD, 1988, BIOCHEM J, V256, P441, DOI 10.1042/bj2560441; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; NEWSHOLME EA, 1983, BIOCH MED SCI, P228; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; Paternostro G, 1996, J CLIN INVEST, V98, P2094, DOI 10.1172/JCI119015; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; REN JM, 1993, J BIOL CHEM, V268, P16113; RIBADEAUDUMAS A, 1999, IN PRESS CARDIOVASC; RICHARDSON JM, 1993, J BIOL CHEM, V268, P21021; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sadoshima J, 1997, CIRC RES, V80, P228, DOI 10.1161/01.RES.80.2.228; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; SHAO ZH, 1995, ONCOGENE, V10, P221; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1215, DOI 10.1210/en.138.3.1215; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WANG C, 1985, P NATL ACAD SCI USA, V82, P3621, DOI 10.1073/pnas.82.11.3621; WHITE MK, 1995, INT J ONCOL, V7, P701; Ye JP, 1996, MOL CELL BIOL, V16, P6178; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	67	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17626	17634		10.1074/jbc.274.25.17626	http://dx.doi.org/10.1074/jbc.274.25.17626			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364200	hybrid, Green Published			2022-12-25	WOS:000080974300036
J	Sonveaux, N; Vigano, C; Shapiro, AB; Ling, V; Ruysschaert, JM				Sonveaux, N; Vigano, C; Shapiro, AB; Ling, V; Ruysschaert, JM			Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein - A tryptophan fluorescence quenching analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; ATP-DEPENDENT TRANSPORT; DRUG-TRANSPORT; SITES; NUCLEOTIDE; MECHANISM; CYSTEINE	Ligand-dependent changes in accessibility of purified P-glycoprotein, functionally reconstituted in liposomes, were investigated by fluorescence measurements.. Trp quenching experiments provided evidence that P-glyeoprotein adopts different tertiary structures upon binding of drug substrates in the absence and presence of MgATP and its nonhydrolyzable analog, MgATP gamma S, Five anthracycline derivatives were tested as drug substrates: daunorubicin, 4'-epi-doxorubicin, iododoxorubicin, 4-demethoxy-daunorubicin, and methoxy-morpholino-doxorubicin. Among them, daunorubicin and 4'-epi-doxorubicin have been shown to be rejected outside the multidrug-resistant cells, whereas the three others have been shown to accumulate in multidrug-resistant cells overexpressing P-glycoprotein and therefore retain their cytotoxic activity. A small conformational change was associated with nucleotide 'binding and amplified after nucleotide hydrolysis, Different conformational states were adopted by P-glycoprotein upon the addition of the anthracycline derivatives in the absence and presence of MgATP or MgATP gamma S. These conformational changes are shown to be related to the nature of the antitumor agents and more precisely to their capacity to accumulate in resistant cells, These data also suggest that the cytotoxicity of iododoxorubicin and 4-demethoxy-daunorubicin is related to the fact they are not transported by P-glycoprotein, On the contrary, methoxy-morpholino-doxorubicin cytotoxicity may be explained in terms of its rapid reincorporation into the:plasma membrane after being transported by P-glycoprotein.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	Universite Libre de Bruxelles; Vrije Universiteit Brussel; British Columbia Cancer Agency	Ruysschaert, JM (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, CP 206-2,Bd Triomphe, B-1050 Brussels, Belgium.							BOSCH L, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF37; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Eytan GD, 1996, J BIOL CHEM, V271, P12897, DOI 10.1074/jbc.271.22.12897; FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Goldstein LJ, 1996, EUR J CANCER, V32A, P1039, DOI 10.1016/0959-8049(96)00100-1; GOTTESMAN MM, 1993, CANCER RES, V53, P747; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Praet M, 1996, BIOCHEM PHARMACOL, V51, P1341, DOI 10.1016/0006-2952(96)00042-1; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; Scala S, 1997, MOL PHARMACOL, V51, P1024, DOI 10.1124/mol.51.6.1024; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P115, DOI 10.1111/j.1432-1033.1997.00115.x; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SKACH WR, 1993, J BIOL CHEM, V268, P6903; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	35	84	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17649	17654		10.1074/jbc.274.25.17649	http://dx.doi.org/10.1074/jbc.274.25.17649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364203	hybrid			2022-12-25	WOS:000080974300039
J	Upadhyaya, AB; Lee, SH; DeJong, J				Upadhyaya, AB; Lee, SH; DeJong, J			Identification of a general transcription factor TFIIA alpha/beta homolog selectively expressed in testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TBP-DNA BINDING; ACTIVATED TRANSCRIPTION; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SMALL-SUBUNIT; 2 GENES	In this paper we describe the isolation of a cDNA that encodes a human TFIIA alpha/beta-like factor (ALF). The open reading frame of ALF predicts a protein of 478 amino acids that contains characteristic N- and C-terminal conserved domains separated by an internal nonconserved domain, In addition, a rare ALF-containing cDNA, which possesses an extended N terminus (Stoned B/TFIIA alpha/beta-like factor; SALF) has also been identified. The results of Northern and dot blot analyses show that ALF is expressed almost exclusively in testis; in contrast, TFIIA alpha/beta and TFIIA gamma are enriched in testis but are also widely expressed in other human tissues; Recombinant ALF (69 kDa) and TFIITA gamma (12 kDa) polypeptides produced in Escherichia coli form an ALF/gamma complex that can stabilize TBP-TATA interactions in an electrophoretic mobility shift assay. The ALF/gamma complex is also able to restore transcription from the adenovirus major late promoter using HeLa cell nuclear extracts that have been depleted of TFIIA, Overall, the data show that ALF is a functional homolog of human general transcription factor TFIIA alpha/beta that may be uniquely important to testis biology.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.							Andrews J, 1996, GENETICS, V143, P1699; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BERNSTEIN R, 1994, J BIOL CHEM, V269, P24361; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Eddy EM, 1995, REPROD FERT DEVELOP, V7, P695, DOI 10.1071/RD9950695; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Schmidt EE, 1997, DEV BIOL, V184, P138, DOI 10.1006/dbio.1997.8514; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50	61	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18040	18048		10.1074/jbc.274.25.18040	http://dx.doi.org/10.1074/jbc.274.25.18040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364255	hybrid			2022-12-25	WOS:000080974300091
J	Chen, HM; Wei, SQ; Engelman, A				Chen, HM; Wei, SQ; Engelman, A			Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRAL DNA INTEGRATION; PHOTO-CROSS-LINKING; HIV-1 INTEGRASE; CONCERTED INTEGRATION; PREINTEGRATION COMPLEXES; INVITRO; VITRO; PROTEIN; BINDING; MUTAGENESIS	Mu-mediated polymerase chain reaction footprinting was used to investigate the protein-DNA structure of human immunodeficiency virus type I (HIV-I) preintegration complexes. Preintegration complexes were partially purified from cells after using an established coculture infection technique as well as a novel technique using cell-free supernatant from transfected cells as the source of virus. Footprinting revealed that bound proteins protected the terminal 200-250 base pairs of each viral end from nuclease attack. Bound proteins also caused strong transpositional enhancements near each end of HIV-I. In contrast, regions of viral DNA internal to the ends did not show evidence of strong protein binding. The end regions of preintegrative HIV-I apparently form a unique nucleoprotein structure, which we term the intasome to distinguish it from the greater preintegration complex. Our novel system also allowed us to analyze the structure and function of preintegration complexes isolated from cells infected with integrase mutant viruses. Complexes were derived from viruses defective for either integrase catalysis, integrase binding to the viral DNA substrate, or an unknown function in the carboxyl-terminal domain of the integrase protein. None of these mutant complexes supported detectable integration activity. Despite the presence of the mutant integrase proteins in purified samples, none of these nucleoprotein complexes displayed the native intasome structure detected in wildtype preintegration complexes. We conclude that multiple integrase functions are required to form the native structure of the HIV-I intasome in infected cells.	Dana Farber Canc Inst, Dept Canc Immunol & Aids, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & Aids, 44 Binney St, Boston, MA 02115 USA.			Chen, Hongmin/0000-0002-8914-1875	NIAID NIH HHS [AI39394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039394, R01AI039394] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; Brown P. O., 1997, P161; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUJACZ G, 1995, J MOL BIOL, V253, P336; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Engelman A, 1997, J VIROL, V71, P3507, DOI 10.1128/JVI.71.5.3507-3514.1997; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gerton JL, 1998, J VIROL, V72, P5046, DOI 10.1128/JVI.72.6.5046-5055.1998; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Miyoshi I., 1982, GANN MONOGR, V28, P219; Nilsen BM, 1996, J VIROL, V70, P1580, DOI 10.1128/JVI.70.3.1580-1587.1996; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; RATNER L, 1985, NATURE, V313, P227; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Sambrook J., 2002, MOL CLONING LAB MANU; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; WEISS A, 1984, J IMMUNOL, V133, P123; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	40	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17358	17364		10.1074/jbc.274.24.17358	http://dx.doi.org/10.1074/jbc.274.24.17358			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358097	hybrid, Green Submitted			2022-12-25	WOS:000080780400096
J	Murayama, T; Oba, T; Katayama, E; Oyamada, H; Oguchi, K; Kobayashi, M; Otsuka, K; Ogawa, Y				Murayama, T; Oba, T; Katayama, E; Oyamada, H; Oguchi, K; Kobayashi, M; Otsuka, K; Ogawa, Y			Further characterization of the type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; BINDING-PROTEIN ISOFORMS; BULLFROG SKELETAL-MUSCLE; CA2+ RELEASE; ELECTRON-MICROSCOPY; FK506-BINDING PROTEIN; 3-DIMENSIONAL ARCHITECTURE; CRYOELECTRON MICROSCOPY; LOCALIZATION	We characterized type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm by immunoaffinity chromatography using a specific antibody. The purified receptor was free from 12-kDa FK506-binding protein, although it retained the ability to bind 12-kDa FK506-binding protein. Negatively stained images of RyR3 show a characteristic rectangular structure that was indistinguishable from RyR1. The location of the D2 segment, which exists uniquely in the RyR1 isoform, was determined as the region around domain 9 close to the corner of the square-shaped assembly, with use of D2-directed antibody as a probe. The RS RS homotetramer had a single class of high affinity [H-3]ryanodine-binding sites with a stoichiometry of 1 mol/mol. In planar lipid bilayers, RyR3 displayed cation channel activity that was modulated by several ligands including Ca2+, Mg2+, caffeine, and ATP, which is consistent with [H-3]ryanodine binding activity. RyR3 showed a slightly larger unit conductance and a longer mean open time than RyR1, Whereas RyR1 showed two classes of channel activity with distinct open probabilities (P-o), RyR3 displayed a homogeneous and steeply Ca2+-dependent activity with P-o similar to 1. RyR3 was more steeply affected in the channel activity by sulfhydryl-oxidizing and -reducing reagents than RyR1, suggesting that the channel activity of RyR3 may be transformed more precipitously by the redox state. This is also a likely explanation for the difference in the Ca2+ dependence of RyR3 between [H-3]ryanodine binding and channel activity.	Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan; Nagoya City Univ, Sch Med, Dept Physiol, Nagoya 4678601, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Tokyo 1088639, Japan; Showa Univ, Sch Med, Dept Pharmacol, Tokyo 1428555, Japan; Fujisawa Pharmaceut Co Ltd, Osaka 5418541, Japan	Juntendo University; Nagoya City University; University of Tokyo; Showa University; Astellas Pharmaceuticals	Ogawa, Y (corresponding author), Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 113, Japan.							AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; Copello JA, 1997, BIOPHYS J, V73, P141, DOI 10.1016/S0006-3495(97)78055-X; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KOBAYASHI M, 1993, TRANSPLANT P, V25, P655; KOSHITA M, 1989, CAN J PHYSIOL PHARM, V67, P890, DOI 10.1139/y89-139; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Oba T, 1997, AM J PHYSIOL-CELL PH, V273, pC1588, DOI 10.1152/ajpcell.1997.273.5.C1588; Oba T, 1998, AM J PHYSIOL-CELL PH, V274, pC914, DOI 10.1152/ajpcell.1998.274.4.C914; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Shirakata Y, 1995, TRANSPLANTATION, V60, P1582, DOI 10.1097/00007890-199560120-00035; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wagenknecht T, 1997, CURR OPIN STRUC BIOL, V7, P258, DOI 10.1016/S0959-440X(97)80034-6; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; YAMAMOTO K, 1985, J MOL BIOL, V183, P287, DOI 10.1016/0022-2836(85)90222-0; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069	52	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17297	17308		10.1074/jbc.274.24.17297	http://dx.doi.org/10.1074/jbc.274.24.17297			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358090	hybrid			2022-12-25	WOS:000080780400089
J	Huttunen, HJ; Fages, C; Rauvala, H				Huttunen, HJ; Fages, C; Rauvala, H			Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappa B require the cytoplasmic domain of the receptor but different downstream signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; DEVELOPING NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE; BINDING-PROTEIN; CELL-SURFACE; SOLUBLE RECEPTOR; OXIDANT STRESS; BLASTOMA CELLS; RHO; EXPRESSION	Receptor for advanced glycation end products (RAGE) mediates neurite outgrowth in vitro on amphoterin-coated substrates. Ligation of RAGE by two other ligands, advanced glycation end products or amyloid beta-peptide, is suggested to play a role in cell injury mechanisms involving cellular oxidant stress and activation of the transcription factor NF-kappa B, However, the RAGE signaling pathways in neurite outgrowth and cell injury are largely unknown. Here we show that transfection of RAGE to neuroblastoma cells induces extension of filopodia and neurites on amphoterin-coated substrates. Furthermore, ligation of RAGE in transfected cells enhances NF-kappa B-dependent transcription. Both the RAGE-mediated neurite outgrowth and activation of NF-kappa B are blocked by deletion of the cytoplasmic domain of RAGE. Moreover, dominant negative Rac and Cdc42 but not dominant negative Ras inhibit the extension of neurites induced by RAGE-amphoterin interaction In contrast, the activation of NF-kappa B is inhibited by dominant negative Ras but not Rac or Cdc42, These data suggest that distinct signaling pathways are used by RAGE to induce neurite outgrowth and regulate gene expression through NF-kappa B.	Univ Helsinki, Inst Biotechnol, Mol Neurobiol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Huttunen, HJ (corresponding author), Univ Helsinki, Inst Biotechnol, Mol Neurobiol Lab, POB 56 Viikinkaari 5, FIN-00014 Helsinki, Finland.			Rauvala, Heikki/0000-0001-7809-9811; Huttunen, Henri/0000-0002-9867-4438				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DASTON MM, 1994, J NEUROCYTOL, V23, P323, DOI 10.1007/BF01188500; DASTON MM, 1991, J CELL BIOL, V112, P1229, DOI 10.1083/jcb.112.6.1229; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DU Y.S., 1997, P NATL ACAD SCI USA, V94, P5296; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Nair SM, 1998, NEUROSCIENCE, V85, P759, DOI 10.1016/S0306-4522(97)00666-0; Nair SM, 1997, J NEUROCHEM, V68, P1286; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Passalacqua M, 1997, FEBS LETT, V400, P275, DOI 10.1016/S0014-5793(96)01402-0; Passalacqua M, 1998, NEUROSCIENCE, V82, P1021; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1984, J CELL BIOL, V98, P1010, DOI 10.1083/jcb.98.3.1010; Rauvala H, 1997, PROG NEUROBIOL, V52, P127, DOI 10.1016/S0301-0082(97)00007-5; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	51	537	573	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19919	19924		10.1074/jbc.274.28.19919	http://dx.doi.org/10.1074/jbc.274.28.19919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391939	hybrid			2022-12-25	WOS:000081377300059
J	Tanoue, T; Moriguchi, T; Nishida, E				Tanoue, T; Moriguchi, T; Nishida, E			Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; MAP KINASE; TYROSINE-PHOSPHATASE; PC12 CELLS; NEURONAL DIFFERENTIATION; HEAT-SHOCK; IN-VIVO; CASCADES	A group of dual specificity protein phosphatases negatively regulates members of the mitogen-activated protein kinase (MAPK) superfamily, which consists of three major subfamilies, MAPK/extracellular signal-regulated kinase (ERK), stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), and p38. Nine members of this group of dual specificity phosphatases have previously been cloned. They show distinct substrate specificities for MAPKs, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli. Here we have cloned and characterized a novel dual specificity phosphatase, which we have designated MKP-5, MKP-5 is a protein of 482 amino acids with a calculated molecular mass of 52.6 kDa and consists of 150 N-terminal amino acids of unknown function, two Cdc25 homology 2 regions in the middle, and a C-terminal catalytic domain. MKP-5 binds to p38 and SAPK/JNK, but not to MAPK/ERK, and inactivates p38 and SAPK/JNK, but not MAPK/ERK. p38 is a preferred substrate, The subcellular localization of MKP-5 is unique; it is present evenly in both the cytoplasm and the nucleus. MKP-5 mRNA is widely expressed in various tissues and organs, and its expression in cultured cells is elevated by stress stimuli. These results suggest that MKP-5 is a novel type of dual specificity phosphatase specific for p38 and SAPK/JNK.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dowd S, 1998, J CELL SCI, V111, P3389; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	44	190	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19949	19956		10.1074/jbc.274.28.19949	http://dx.doi.org/10.1074/jbc.274.28.19949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391943	hybrid			2022-12-25	WOS:000081377300063
J	Cartier, C; Sivard, P; Tranchat, C; Decimo, D; Desgranges, C; Boyer, V				Cartier, C; Sivard, P; Tranchat, C; Decimo, D; Desgranges, C; Boyer, V			Identification of three major phosphorylation sites within HIV-1 capsid - Role of phosphorylation during the early steps of infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VIRUS; PROTEIN-KINASE-C; VIRAL MATRIX PROTEIN; TYPE-1 VPU PROTEIN; NF-KAPPA-B; NUCLEAR IMPORT; CORE PROTEIN; REV PROTEIN; POSTTRANSLATIONAL MODIFICATIONS	We previously reported the presence of two cellular serine/threonine protein kinases incorporated in human immunodeficiency virus type 1 (HIV-1) particles. One protein kinase is MAPK ERK2 (mitogen-activated protein kinase), whereas the other one, a 53-kDa protein, still needs to be identified. Furthermore, we demonstrated that the capsid protein CAp24 is phosphorylated by one of those two virion-associated protein kinases (Cartier, C., Deckert, M., Grangeasse, C., Trauger, R., Jensen, F., Bernard, k, Cozzone, k, Desgranges, C., and Boyer, V. (1997) J. Virol. 71, 4832-4837). In this study, we showed that CAp24 is not a direct substrate of MAPK ERK2. Moreover, using site-directed mutagenesis of each of the 9 serine residues of CAp24, we demonstrated the phosphorylation of 3 serine residues (Ser-109, Ser-149, and Ser-178) in the CAp24. Substitution of each serine residue did not affect viral budding, nor viral structure. By contrast, substitution of Ser-109, Ser-149, or Ser-178 affects viral infectivity by preventing the reverse transcription process to be completely achieved. Our results suggest that CAp24 serine phosphorylation is essential for viral uncoating process.	INSERM, U271, F-69424 Lyon 03, France; Ecole Normale Super Lyon, INSERM, U412, LaboRetro,Unite Virol Humaine, F-69364 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cartier, C (corresponding author), INSERM, U271, 151 Cours A Thomas, F-69424 Lyon 03, France.		Boyer, Veronique/E-6122-2017	Decimo, Didier/0000-0002-0390-1205				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; Briant L, 1998, J IMMUNOL, V160, P1875; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; Bukrinskaya AG, 1996, MOL BIOL+, V30, P303; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COATES K, 1995, J GEN VIROL, V76, P837, DOI 10.1099/0022-1317-76-4-837; Coates K, 1997, J BIOL CHEM, V272, P12289, DOI 10.1074/jbc.272.19.12289; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; Duclos-Vallee JC, 1998, J GEN VIROL, V79, P1665, DOI 10.1099/0022-1317-79-7-1665; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fouts DE, 1997, BIOCHEMISTRY-US, V36, P13256, DOI 10.1021/bi971551d; Freed EO, 1997, CELL, V88, P171, DOI 10.1016/S0092-8674(00)81836-X; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; GARNIER L, 1998, AIDS SA, V12, P5; GERLICH WH, 1982, J VIROL, V42, P761, DOI 10.1128/JVI.42.3.761-766.1982; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KANN M, 1994, J VIROL, V68, P7993, DOI 10.1128/JVI.68.12.7993-8000.1994; Kau JH, 1998, J VIROL, V72, P3796, DOI 10.1128/JVI.72.5.3796-3803.1998; LIAO W, 1995, J VIROL, V69, P1025, DOI 10.1128/JVI.69.2.1025-1029.1995; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; Luo TC, 1997, J VIROL, V71, P2535, DOI 10.1128/JVI.71.3.2535-2539.1997; MACHIDA A, 1991, J VIROL, V65, P6024, DOI 10.1128/JVI.65.11.6024-6030.1991; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; Meggio F, 1996, BIOCHEM BIOPH RES CO, V226, P547, DOI 10.1006/bbrc.1996.1392; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Paul M, 1997, VIROLOGY, V232, P207, DOI 10.1006/viro.1997.8541; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SONG WH, 1995, NUCLEIC ACIDS RES, V23, P3609, DOI 10.1093/nar/23.17.3609; Spearman P, 1996, J VIROL, V70, P8187, DOI 10.1128/JVI.70.11.8187-8194.1996; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; Tiganos E, 1997, J VIROL, V71, P4452, DOI 10.1128/JVI.71.6.4452-4460.1997; Trono D, 1997, CELL, V88, P173, DOI 10.1016/S0092-8674(00)81837-1; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; Yin L, 1998, J VIROL, V72, P6430, DOI 10.1128/JVI.72.8.6430-6436.1998	62	65	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19434	19440		10.1074/jbc.274.27.19434	http://dx.doi.org/10.1074/jbc.274.27.19434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383459	hybrid			2022-12-25	WOS:000081196300082
J	Georges, D; Schwabe, C				Georges, D; Schwabe, C			Porcine relaxin, a 500 million-year-old hormone? The tunicate Ciona intestinalis has porcine relaxin	FASEB JOURNAL			English	Article						relaxin coding region; DNA polymerase; genomic potential hypothesis	MESSENGER-RNA; EXPRESSION; PURIFICATION; EVOLUTION; SEQUENCE; PEPTIDE	The fossil record of tunicates reaches back to the upper Cambrian period. Ascidians have mobile, tadpole-like juvenile forms with a notochord, which inspired the classification of tunicates as Urochordata, i.e., predecessors of vertebrates. The genome of the tunicate Ciona intestinalis contains a relaxin coding region that is organized like a mammalian gene, i.e., signal peptide, B-chain domain, connecting peptide domain, followed by the A-chain domain with a stop codon after cysteine A-22, RNA-derived cDNA encodes a relaxin that is identical to the circulating form of the porcine hormone. In contrast to the porcine gene, the ascidian gene has no intron in the C-peptide domain, and in that respect is similar to the bombyxin gene of the silkworm. During the spawning period, only enough relaxin could be extracted and isolated from gonads of C. intestinalis for a partial sequence analysis. Remarkable as it may be, these findings suggest that relaxin is identical in pigs, whales, and the tunicate C, intestinalis.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Grenoble 1, UFR Biol, Grenoble, France	Medical University of South Carolina; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHENCHIK A, 1995, CLONTECHNIQUES, V9, P9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GEORGES D, 1990, GEN COMP ENDOCR, V79, P429, DOI 10.1016/0016-6480(90)90073-U; GEORGES D, 1990, GEN COMP ENDOCR, V79, P423, DOI 10.1016/0016-6480(90)90072-T; GOWAN LK, 1981, FEBS LETT, V129, P80, DOI 10.1016/0014-5793(81)80760-0; HALEY J, 1987, J BIOL CHEM, V262, P11940; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; KIMURAKAWAKAMI M, 1992, GEN COMP ENDOCR, V86, P257, DOI 10.1016/0016-6480(92)90109-W; NEUWINGER J, 1990, ANDROLOGIA, V22, P335; Parry LJ, 1997, BIOL REPROD, V57, P119, DOI 10.1095/biolreprod57.1.119; REDDY GK, 1992, ARCH BIOCHEM BIOPHYS, V294, P579, DOI 10.1016/0003-9861(92)90728-F; Reinecke M, 1999, CELL TISSUE RES, V295, P331, DOI 10.1007/s004410051239; SCHWABE C, 1986, TRENDS BIOCHEM SCI, V11, P280, DOI 10.1016/0968-0004(86)90024-1; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1983, J BIOL CHEM, V258, P2778; SCHWABE C, 1990, COMPUT MATH APPL, V20, P287, DOI 10.1016/0898-1221(90)90334-G	17	15	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1269	1275		10.1096/fasebj.13.10.1269	http://dx.doi.org/10.1096/fasebj.13.10.1269			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385617				2022-12-25	WOS:000081264800015
J	Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor	ONCOGENE			English	Article						cytokine; proliferation; apoptosis; PKB; ERK; STAT	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; INDUCE TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GM-CSF; INTERLEUKIN-5 RECEPTOR; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN	Interleukin (IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) regulate proliferation, differentiation and apoptosis of target cells. Receptors for these cytokines consist of a cytokine-specific alpha subunit and a common shared beta c subunit, Tyrosine phosphorylation of the beta c is thought to play a critical role in mediating signal transduction events. We have examined the effect of mutation of beta c tyrosines on the activation of multiple signal transduction pathways. Activation of protein kinase B (PKB) required JAK2 and was inhibited by dominant-negative phosphatidylinositol 3-kinase (PI3K). Overexpression of JAK2 was sufficient to activate both protein kinase B (PKB) and extracellular regulated kinase-1 (ERK1). Tyrosine 577 and 612 were found to be critical for the activation of PKB and ERK1, but not activation of STAT transcription factors, Activation of both PKB and ERK have been implicated in the regulation of proliferation and apoptosis. We generated GM-CSFR stable cell lines expressing receptor mutants to evaluate their effect on these processes. Activation of both PKB and ERK was perturbed, while STAT activation remained unaffected. Tyrosines 577 and 612 were necessary for optimal proliferation, however, mutation of these tyrosine residues did not affect GM-CSF mediated rescue from apoptosis. These data demonstrate that while phosphorylation of beta c tyrosine residues 577 and 612 are important for optimal cell proliferation, rescue from apoptosis can be mediated bg alternative signalling routes apparently independent of PKB or ERK activation.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Koenderman, Leo/0000-0002-5636-6453; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEGROOT RP, 1998, IN PRESS CELL SIGNAL; delPeso L, 1997, SCIENCE, V278, P687; Durstin M, 1996, J IMMUNOL, V157, P534; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Iversen PO, 1997, BLOOD, V90, P4910, DOI 10.1182/blood.V90.12.4910.4910_4910_4917; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MULI AL, 1996, EMBO J, V15, P2425; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Wei S, 1996, J IMMUNOL, V157, P5155; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	68	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3334	3342		10.1038/sj.onc.1202678	http://dx.doi.org/10.1038/sj.onc.1202678			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362354	Bronze			2022-12-25	WOS:000080589300004
J	Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL				Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL			Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin	ONCOGENE			English	Article						Etk; tyrosine kinase; PI3-kinase; photodynamic therapy; thapsigargin; apoptosis; prostate cancer	MOUSE LYMPHOMA-CELLS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; POLY(ADP-RIBOSE) POLYMERASE; ENDOPLASMIC-RETICULUM; ACTIVATION; AKT; PHOSPHORYLATION; RESISTANCE	Prostate carcinoma (PCA) is the most frequently diagnosed malignancy in American men. PCA at advanced stages can both proliferate abnormally and resist apoptosis, Among the many known signal transduction pathways, phosphatidylinositide-3'OH kinase (PI3-kinase) has been shown to play an important role in cell survival and resistance to apoptosis, In this study, we investigate the involvement of Etk/Bmx, a newly discovered tyrosine kinase that is a substrate of PI3-kinase, in protection of prostate cancer cells from apoptosis, Parental LNCaP cells and tno derivative cell lines, one overexpressing mild type Etk (Etkwt) and the other expressing a dominant negative Etk (EtkDN), were used to study the function of Etk. The cells mere treated with photodynamic therapy (PDT), a newly approved cancer treatment which employs a photosensitizer and visible light to produce an oxidative stress in cells, often leading to apoptosis. Our results indicate that PDT induces apoptosis in LNCaP cells, as measured by DNA fragmentation and by cleavage of poly(ADP-ribose) polymerase (PARP), and moreover, the extent of apoptosis was much reduced in Etkwt cells as compared to LNCaP or EtkDN cells. Assay of overall cell viability confirmed that Etkwt cells mere considerably less sensitive to PDT than were the parental LNCaP or EtkDN cells. Similar results were found in response to thapsigargin (TG). A specific inhibitor of PI3-kinase, LY294002, abolished Etk activity and markedly increased TG-induced PARP cleavage. The results suggest that Etk/Bmx is an efficient effector of PI3-kinase and that the newly described PI3-kinase/Etk pathway is involved in the protection of prostate carcinoma cells from apoptosis in response to PDT or TG.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, P01 CA48735, CA57179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA039207, R01CA057179, R37CA039207, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fisher AMR, 1997, PHOTOCHEM PHOTOBIOL, V66, P265, DOI 10.1111/j.1751-1097.1997.tb08653.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GOMER CJ, 1991, CANCER RES, V51, P6574; Hasan T., 1997, PHOTODYNAMIC THERAPY, P739; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LI WWF, 1993, J BIOL CHEM, V268, P12003; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LIU H, 1997, J BIOL CHEM, V272, P21752; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; McConkey DJ, 1996, CANCER RES, V56, P5594; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang DG, 1997, PROSTATE, V32, P284; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Tenniswood M, 1997, BRIT J UROL, V79, P27, DOI 10.1111/j.1464-410X.1997.tb16918.x; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Xue LY, 1997, PHOTOCHEM PHOTOBIOL, V66, P105, DOI 10.1111/j.1751-1097.1997.tb03145.x	48	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3391	3398		10.1038/sj.onc.1202687	http://dx.doi.org/10.1038/sj.onc.1202687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362360				2022-12-25	WOS:000080589300010
J	Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA				Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA			p21(Waf1/Cip1/Sdi1) induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53	ONCOGENE			English	Article						p21(Waf1/Cip1/Sdi1); replicative senescence; EJ; tetracycline-regulatable expression system; mitomycin C	CYCLIN-DEPENDENT KINASES; NUCLEOTIDE EXCISION-REPAIR; INHIBITS DNA-REPLICATION; HUMAN FIBROBLASTS; P53-INDEPENDENT PATHWAY; WILD-TYPE; NUCLEAR ANTIGEN; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITORS	We have shown previously that wild type p53 can rapidly induce replicative senescence in EJ human bladder carcinoma cells lacking functional p53, A major effector of p53 functions is p21(Waf1/Cip1/Sdi1), a potent cyclin-dependent kinase inhibitor. p21(Waf1/Cip1/Sdi1) has been shown to be involved in both p53 dependent and independent control of cell proliferation, differentiation and death. To directly investigate the effects of p21(Waf1/Cip1/Sid1) in the p53 response observed in EJ tumor cells, we established p21(Waf1/Cip1/Sdi1) inducible lines using the tetracycline-regulatable vector system. p21(Waf1/Cip1/Sdi1) induction caused irreversible cell cycle arrest in both G1 and G2/M, and diminished Cdk2 kinase activity. In addition, p21(Waf1/Cip1/Sdi1) induction led to morphological alterations characteristic of cells undergoing replicative senescence with morphological, biochemical and ultrastructural markers of the senescent phenotype, Furthermore, sustained p21(Waf1/Cip1/Sdi1) induction sensitized EJ cells to apoptotic cell death induced by mitomycin C, a cross-linking DNA damaging agent, These findings support the function of p21(Waf1/Cip1/Sdi1) as an inducer of replicative senescence and a major mediator of this phenomenon in response to p53. Moreover, our results imply that therapeutic intervention in human cancers might be aimed at sustained elevation Of p21(Waf1/Cip1/Sid1) expression.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA066654, R01CA066271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812] Funding Source: NIH RePORTER; NCI NIH HHS [CA66654, CA66271-01] Funding Source: Medline; NIA NIH HHS [AG08812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GHADIALLY FN, 1975, ULTRASTRUCT PATHOL, P306; Gorospe M, 1996, CANCER RES, V56, P475; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pignolo RJ, 1998, EXP GERONTOL, V33, P67, DOI 10.1016/S0531-5565(97)00090-9; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAHARA H, 1995, ONCOGENE, V10, P835; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG E, 1995, CANCER RES, V55, P2284; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202; YU Y, 1998, ONCOGENE, V16, P705	65	157	164	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2789	2797		10.1038/sj.onc.1202615	http://dx.doi.org/10.1038/sj.onc.1202615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362249				2022-12-25	WOS:000080125100001
J	Ding, H; Benotmane, AM; Suske, G; Collen, D; Belayew, A				Ding, H; Benotmane, AM; Suske, G; Collen, D; Belayew, A			Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; BOX-BINDING-PROTEINS; SP1-LIKE PROTEINS; REGULATORY REGION; RESPONSE ELEMENT; PAI-1 GENE; PROMOTER; FAMILY; CELLS; CLONING	Basal expression of the human plasminogen activator inhibitor-1 (PAI-1) is mediated by a promoter element named B box that binds the helicase-like transcription factor (HLTF), homologous to SNF/SWI proteins. Electrophoretic mobility shift assays performed on a set of B box point mutants demonstrated two HLTF sites flanking and partially overlapping with a GT box binding Sp1 and Sp3. Mutations affecting either the Sp1/Sp3 or the two HLTF sites inhibited by 6- and 2.5-fold, respectively, transient expression in HeLa cells of a reporter gene fused to the PAI-1 promoter. In Sp1/Sp3-devoid insect cells, co-expression of PAI-1-lacZ with Sp1 or Sp3 led to a 14-26-fold induction while HLTF had no effect. Simultaneous presence of Sp1 or Sp3 and the short HLTF form (initiating at Met-123) provided an additional 2-3-fold synergistic activation suppressed by mutations that prevented HLTF binding. Moreover, a DNA-independent interaction between HLTFMet123 and Sp1/Sp3 was demonstrated by co-immunoprecipitation from HeLa cell extracts and glutathione S-transferase pull-down experiments. The interaction domains were mapped to the carboxyl-terminal region of each protein; deletion of the last 85 amino acids of HLTFMet123 abolished the synergy with Sp1. This is the first demonstration of a functional interaction between proteins of the Sp1 and SNF/SWI families.	Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Universite Catholique Louvain; Philipps University Marburg	Ding, H (corresponding author), Mt Sinai Hosp, Lunenfeld Inst, Toronto, ON M5G 1X5, Canada.		BELAYEW, Alexandra/D-5205-2013	BELAYEW, Alexandra/0000-0001-5115-2424; Benotmane, Rafi/0000-0002-8985-1578; Suske, Guntram/0000-0002-4807-0513				ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Benotmane AM, 1997, ANAL BIOCHEM, V250, P181, DOI 10.1006/abio.1997.2231; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CARMELIET PFM, 1995, BAILLIERE CLIN HAEM, V8, P329; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; COLLEN D, 1991, BLOOD, V78, P3114; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ding H, 1996, DNA CELL BIOL, V15, P429, DOI 10.1089/dna.1996.15.429; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gong XH, 1997, DEV BIOL, V183, P166, DOI 10.1006/dbio.1996.8486; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HaywardLester A, 1996, MOL ENDOCRINOL, V10, P1335, DOI 10.1210/me.10.11.1335; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kang SH, 1996, J BIOL CHEM, V271, P7330, DOI 10.1074/jbc.271.13.7330; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNUDSEN H, 1994, EUR J BIOCHEM, V220, P63, DOI 10.1111/j.1432-1033.1994.tb18599.x; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIJNEN H, 1996, EUR J BIOCHEM, V241, P940; Lijnen HR, 1996, CIRCULATION, V94, P2052, DOI 10.1161/01.CIR.94.9.2052; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PAPPOT H, 1995, BIOL CHEM H-S, V376, P259; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SAMBROOK J, 1989, MOL CLINING LAB MANU; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; SHERIDAN PL, 1995, J BIOL CHEM, V270, P4575, DOI 10.1074/jbc.270.9.4575; Shi YG, 1996, BIOCHEMISTRY-US, V35, P3845, DOI 10.1021/bi952384p; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Zhang Q, 1997, GENE, V202, P31, DOI 10.1016/S0378-1119(97)00446-0	62	64	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19573	19580		10.1074/jbc.274.28.19573	http://dx.doi.org/10.1074/jbc.274.28.19573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391891	hybrid			2022-12-25	WOS:000081377300011
J	Kawaminami, S; Takahashi, H; Ito, S; Arata, Y; Shimada, I				Kawaminami, S; Takahashi, H; Ito, S; Arata, Y; Shimada, I			A multinuclear NMR study of the active site of an endoglucanase from a strain of Bacillus - Use of Trp residues as structural probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRICHODERMA-REESEI; CATALYTIC CORE; SP KSM-330; CLOSTRIDIUM-THERMOCELLUM; 3-DIMENSIONAL STRUCTURE; BACTERIAL CELLULASE; ANGSTROM RESOLUTION; GLYCOSYL HYDROLASE; DOMAIN	In the hydrolytic reaction catalyzed by an endoglucanase from a Bacillus strain (endoglucanase K), 2 of 12 Trp residues, Trp(174) and Trp(243), are responsible for binding of the substrate and/or for the catalysis (Kawaminami, S., Ozaki, K., Sumitomo, N., Hayashi, Y., Ito, S., Shimada, I., and Arata, Y. (1994) J. Biol. Chem. 269, 28752-28756), Here we report results of a stable isotope-aided NMR analysis of the active site of endoglucanase K,using Trp(174) and Trp(243) as structural probes. Hydrogen-deuterium exchange experiments performed for the NH protons of main and side chains of Trp residues revealed that Trp(174) and Trp(243) are. located in the hydrophilic and hydrophobic microenvironments in the active site, respectively. We also carried out pH titration experiments for indole C2 proton resonances of Trp residues and measured the pH dependence of specific activities for wild-type endoglucanase K and its mutants in which Glu or Asp residues are replaced with their respective amide forms. On the basis of the results obtained from the present study, we conclude that (a) Glu(130) and Asp(191), which are in spatial proximity to Trp(174) and Trp(243) in the active site, play a crucial role in the enzymatic activity; (b) Glu(130) and Asp(191) interact with each other in the active site, leading to an increase in the pK(a) values to 5.5 for both amino acid residues; and (c) the pK(a) values of Glu(130) and Asp(191) would lead to an unusually narrow ps-activity profile of the endoglucanase K.	Kao Corp, Biol Sci Labs, Haga, Tochigi 3213497, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan; Water Res Inst, Tsukuba, Ibaraki 3050047, Japan	KAO Corporation; University of Tokyo	Kawaminami, S (corresponding author), Kao Corp, Biol Sci Labs, 2606 Akabane, Haga, Tochigi 3213497, Japan.							Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; BEGUIN P, 1985, J BACTERIOL, V162, P102; BOUDENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; DUCROS V, 1995, STRUCTURE, V3, P939, DOI 10.1016/S0969-2126(01)00228-3; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KAWAMINAMI S, 1995, BIOCHEM BIOPH RES CO, V212, P539, DOI 10.1006/bbrc.1995.2003; KAWAMINAMI S, 1994, J BIOL CHEM, V269, P28752; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; Kleywegt GJ, 1997, J MOL BIOL, V272, P383, DOI 10.1006/jmbi.1997.1243; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NORWOOD TJ, 1989, FEBS LETT, V255, P369, DOI 10.1016/0014-5793(89)81124-X; OZAKI K, 1991, J GEN MICROBIOL, V137, P41, DOI 10.1099/00221287-137-1-41; OZAKI K, 1991, J GEN MICROBIOL, V137, P2299, DOI 10.1099/00221287-137-10-2299; OZAKI K, 1994, BBA-PROTEIN STRUCT M, V1207, P159, DOI 10.1016/0167-4838(94)00060-3; PETTERSS.G, 1968, ARCH BIOCHEM BIOPHYS, V126, P776, DOI 10.1016/0003-9861(68)90471-2; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; SIDHU MS, 1986, FOLIA MICROBIOL, V31, P293, DOI 10.1007/BF02926954; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; SUMITOMO N, 1995, BIOSCI BIOTECH BIOCH, V59, P2172, DOI 10.1271/bbb.59.2172	28	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19823	19828		10.1074/jbc.274.28.19823	http://dx.doi.org/10.1074/jbc.274.28.19823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391926	hybrid			2022-12-25	WOS:000081377300046
J	Koshlukova, SE; Lloyd, TL; Araujo, MWB; Edgerton, M				Koshlukova, SE; Lloyd, TL; Araujo, MWB; Edgerton, M			Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHOTERICIN-B SUSCEPTIBILITY; HISTIDINE-RICH POLYPEPTIDES; HUMAN-PAROTID SECRETION; ORAL CANDIDA; PEPTIDES; MECHANISM; YEAST; KETOCONAZOLE; IMMUNITY; PROTEINS	Salivary histatins are potent in vitro antifungal proteins and have promise as therapeutic agents against oral candidiasis. We performed pharmacological studies directed at understanding the biochemical basis of list 5 candidacidal activity. Three inhibitors of mitochondrial metabolism: carbonyl cyanide p-chlorophenylhydrazone, dinitrophenol, and azide inhibited Hst 5 killing of Candida albicans, while not inhibiting cellular ATP production. In contrast, Hst 5 caused a drastic reduction of C, albicans intracellular ATP content, which was a result of an efflux of ATP, Carbonyl cyanide p-chlorophenylhydrazone, dinitrophenol, and azide inhibited Hst 5-induced ATP efflux, thus establishing a correlation between ATP release and cell killing. Furthermore, C, albicans cells were respiring and had polarized membranes at least 80 min after ATP release, thus implying a non-lytic exit of cellular ATP in response to Hst 5. Based on evidence that transmembrane ATP efflux can occur in the absence of cytolysis through a channel-like pathway and that released ATP can act as a cytotoxic mediator by binding to membrane purinergic receptors, we evaluated whether extracellular ATP released by Hst 5 may have further functional role in cell killing. Consistent with this hypothesis, purinergic agonists BzATP and adenosine 5'O-(thiotriphosphate) induced loss of C. albicans cell viability and purinergic antagonists prevented Hst 5 killing.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Dent Med, Dept Restorat Dent, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Edgerton, M (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 310 Foster Hall,Main St Campus,3435 Main St, Buffalo, NY 14214 USA.				NIDCR NIH HHS [DE10641, DE12159, R01 DE010641-07, R01 DE010641] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012159, R29DE010641] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBOTT AB, 1989, J ANTIMICROB CHEMOTH, V24, P905, DOI 10.1093/jac/24.6.905; ANSEHN S, 1984, ANTIMICROB AGENTS CH, V26, P22, DOI 10.1128/AAC.26.1.22; BEGGS WH, 1994, ANTIMICROB AGENTS CH, V38, P363, DOI 10.1128/AAC.38.2.363; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Boyum R, 1997, MICROBIOL-SGM, V143, P1901, DOI 10.1099/00221287-143-6-1901; Burnstock G, 1996, CIBA F SYMP, V198, P1; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CANNON RD, 1995, J DENT RES, V74, P1152, DOI 10.1177/00220345950740050301; Chowdhury B, 1997, EUR J BIOCHEM, V247, P673, DOI 10.1111/j.1432-1033.1997.00673.x; Clark FS, 1996, ANTIMICROB AGENTS CH, V40, P419, DOI 10.1128/AAC.40.2.419; COCKAYNE A, 1984, J GEN MICROBIOL, V130, P465; COLEMAN DC, 1993, CRIT REV MICROBIOL, V19, P61, DOI 10.3109/10408419309113523; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Guidotti G, 1996, CHEM BIOL, V3, P703, DOI 10.1016/S1074-5521(96)90244-6; Hickman SE, 1996, CIBA F SYMP, V198, P71; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1993, REV IMMUNOL, V5, P97; LOHMEIERVOGEL E, 1989, APPL ENVIRON MICROB, V55, P1974, DOI 10.1128/AEM.55.8.1974-1980.1989; MACKAY BJ, 1984, INFECT IMMUN, V44, P695, DOI 10.1128/IAI.44.3.695-701.1984; NOSHIRO A, 1987, J BIOL CHEM, V262, P14154; OLSON V, 1976, CAN J MICROBIOL, V23, P166; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; ORDONEZ JV, 1995, CYTOMETRY, V22, P154, DOI 10.1002/cyto.990220213; PERINPANAYAGAM HER, 1995, J DENT RES, V74, P345, DOI 10.1177/00220345950740011001; Peyron F, 1997, ANTIMICROB AGENTS CH, V41, P1537, DOI 10.1128/AAC.41.7.1537; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; PRASAD R, 1991, CANDIDA ALBICANS CEL, P215; RAJ PA, 1990, J BIOL CHEM, V265, P3898; Raj PA, 1998, BIOPOLYMERS, V45, P51, DOI 10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y; Raj PA, 1996, BIOCHEMISTRY-US, V35, P4314, DOI 10.1021/bi951681r; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; SABATINI LM, 1989, BIOCHEM BIOPH RES CO, V160, P495, DOI 10.1016/0006-291X(89)92460-1; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; SANTARPIA RP, 1988, ARCH ORAL BIOL, V33, P567, DOI 10.1016/0003-9969(88)90131-8; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tsai HY, 1996, INFECT IMMUN, V64, P5000, DOI 10.1128/IAI.64.12.5000-5007.1996; UNO J, 1982, ANTIMICROB AGENTS CH, V21, P912, DOI 10.1128/AAC.21.6.912; VANDENBOSSCHE H, 1987, CRIT REV MICROBIOL, V15, P57; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; ZUO Y, 1995, GENE, V161, P87, DOI 10.1016/0378-1119(95)00237-Z; [No title captured]	55	161	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18872	18879		10.1074/jbc.274.27.18872	http://dx.doi.org/10.1074/jbc.274.27.18872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383383	hybrid			2022-12-25	WOS:000081196300006
J	Sieradzki, R; Pinho, MG; Tomasz, A				Sieradzki, R; Pinho, MG; Tomasz, A			Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN-4; VANCOMYCIN; TEICOPLANIN; ANTIBIOTICS; STRAIN; GENE	Both vancomycin- and teicoplanin-resistant laboratory mutants of Staphylococcus aureus produce peptidoglycans of altered composition in which the proportion of highly cross-linked muropeptide species is drastically reduced with a parallel increase in the representation of muropeptide monomers and dimers (Sieradzki, K., and Tomasz, A. (1997) J. Bacteriol. 179, 2557-2566; and Sieradzki, K,, and Tomasz, A. (1998) Microb, Drug Resist. 4, 159-168). We now report that the distorted peptidoglycan composition is related to defects in penicillin-binding protein 4 (PBP4); no PBP4 was detectable by the fluorographic assay in membrane preparations from the mutants, and comparison of the sequence of pbp4 amplified from the mutants indicated disruption of the gene by two types of abnormalities, a 17-amino acid long duplication starting at position 305 of the pbp4 gene was detected in the vancomycin-resistant mutant, and a stop codon was found to be introduced into the pbp4 KTG motif at position 261 in the mutant selected for teicoplanin resistance. Additional common patterns of disturbances in the peptidoglycan metabolism of the mutants are indicated by the increased sensitivity of mutant cell walls to the M1 muramidase and decreased sensitivity to lysostaphin, which is a reversal of the susceptibility pattern of the parental cell walls. Furthermore, the results of high performance liquid chromatography analysis of lysostaphin digests of peptidoglycan suggest an increase in the average chain length of the glycan strands in the peptidoglycan of the glycopeptide-resistant mutants. The increased molar proportion of muropeptide monomers in the cell wall of the glycopeptide-resistant mutants should provide binding sites for the "capture" of vancomycin and teicoplanin molecules, which may be part of the mechanism of glycopeptide resistance in S. aureus.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Tomasz, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Pinho, Mariana/B-9192-2008	Pinho, Mariana/0000-0002-7132-8842; Tomasz, Alexander/0000-0003-1520-1983				BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P2; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P813; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P765; CURTIS NAC, 1980, FEMS MICROBIOL LETT, V9, P263; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Domanski TL, 1997, J BACTERIOL, V179, P2651, DOI 10.1128/jb.179.8.2651-2657.1997; GROVES P, 1994, STRUCTURE, V2, P747, DOI 10.1016/S0969-2126(94)00075-1; Henze UU, 1996, ANTIMICROB AGENTS CH, V40, P2121, DOI 10.1128/AAC.40.9.2121; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; KAATZ GW, 1990, J INFECT DIS, V162, P103, DOI 10.1093/infdis/162.1.103; KOZARICH JW, 1978, J BIOL CHEM, V253, P1272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LICHENSTEIN HS, 1990, GENE, V88, P81, DOI 10.1016/0378-1119(90)90062-V; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; NIETO M, 1971, BIOCHEM J, V123, P789, DOI 10.1042/bj1230789; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; Sieradzki K, 1998, ANTIMICROB AGENTS CH, V42, P100, DOI 10.1128/AAC.42.1.100; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Sieradzki K, 1998, MICROB DRUG RESIST, V4, P159, DOI 10.1089/mdr.1998.4.159; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; WYKE AW, 1981, EUR J BIOCHEM, V119, P389, DOI 10.1111/j.1432-1033.1981.tb05620.x; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073	26	100	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18942	18946		10.1074/jbc.274.27.18942	http://dx.doi.org/10.1074/jbc.274.27.18942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383392				2022-12-25	WOS:000081196300015
J	Wetsel, RA; Kildsgaard, J; Zsigmond, E; Liao, W; Chan, L				Wetsel, RA; Kildsgaard, J; Zsigmond, E; Liao, W; Chan, L			Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; APOLIPOPROTEIN-B; FAMILIAL HYPERCHOLESTEROLEMIA; C3A ANAPHYLATOXIN; PATHWAY; HYPERAPOB; ASP; ASSOCIATION; METABOLISM; ADIPOCYTES	The acylation stimulating protein (ASP) is a 76-amino acid peptide that has been proposed as a potent mediator of triglyceride synthesis and, when functionally impaired, as a major cause of hyperapobetalipoproteinemia (HyperapoB), Purification and sequence analysis of ASP from human sera have revealed that ASP is identical to the complement C3-derived activation peptide C3ades-Arg, Because C3 is the precursor for C3ades-Arg and therefore ASP, a deficiency in C3 would be predicted to result in a phenotype characteristic of HyperapoB. To test this hypothesis in vivo, the current study was undertaken in which ASP(C3ades-Arg)-deficient mice were used as a model system. No significant differences were found in the triglyceride, cholesterol, or free fatty acid concentrations in the plasma of fasted normal and ASP(C3ades-Arg)-deficient animals. In addition, plasma lipoprotein analyses indicated that the very low density lipoprotein, low density lipoprotein, and high density lipoprotein cholesterol and triglyceride concentrations as well as the apolipoprotein B-48 and B-100 levels were not significantly different in the plasma of ASP(C3ades-Arg)-deficient and wild type mice. Furthermore, when challenged with an oral fat load, the ASP(C3ades-Arg)-deficient mice showed no impaired ability to clear triglycerides and free fatty acids from their circulation when compared with their wild-type littermates, Collectively, these results indicate that ASP(C3ades-Arg) deficiency does not cause HyperapoB in mice and that the physiological importance of impaired ASP(C3ades-Arg) function as a cause of hyperapobetalipoproteinemia needs to be reevaluated.	Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Wetsel, RA (corresponding author), Inst Mol Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwetsel@imm2.imm.uth.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025011, R55AI025011] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51586] Funding Source: Medline; NIAID NIH HHS [AI25011] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; CABEZAS MC, 1993, J CLIN INVEST, V92, P160, DOI 10.1172/JCI116544; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Choy LN, 1996, OBES RES, V4, P521, DOI 10.1002/j.1550-8528.1996.tb00266.x; CIANFLONE K, 1988, CLIN INVEST MED, V11, P99; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; CIRCOLO A, 1999, IN RPESS IMMUNOPHARM; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; Murray I, 1997, J LIPID RES, V38, P2492; MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SINGER L, 1994, PATHOBIOLOGY, V62, P14, DOI 10.1159/000163873; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; Sniderman A., 1992, CURR OPIN LIPIDOL, V3, P137; SNIDERMAN AD, 1994, ANN MED, V26, P389, DOI 10.3109/07853899409148358; Sniderman AD, 1997, P NUTR SOC, V56, P703, DOI 10.1079/PNS19970070; Sniderman AD, 1997, DIABETOLOGIA, V40, pS152, DOI 10.1007/s001250051435; SNIDERMAN AD, 1995, INT J OBESITY, V19, pS27; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1988, CAN J PHYSIOL PHARM, V66, P239, DOI 10.1139/y88-040; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; Zhang XJ, 1998, EUR J CLIN INVEST, V28, P730	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19429	19433		10.1074/jbc.274.27.19429	http://dx.doi.org/10.1074/jbc.274.27.19429			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383458	hybrid			2022-12-25	WOS:000081196300081
J	Yang, XN; Rudolf, M; Carew, RA; Yoshida, M; Nerreter, V; Riley, AM; Chung, SK; Bruzik, KS; Potter, BVL; Schultz, C; Shears, SB				Yang, XN; Rudolf, M; Carew, RA; Yoshida, M; Nerreter, V; Riley, AM; Chung, SK; Bruzik, KS; Potter, BVL; Schultz, C; Shears, SB			Inositol 1,3,4-trisphosphate acts in vivo as a specific regulator of cellular signaling by inositol 3,4,5,6-tetrakisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ACTIVITY; RAT PANCREATOMA CELLS; D-MYO-INOSITOL; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; CHLORIDE SECRETION; AVIAN ERYTHROCYTES; POLYPHOSPHATE 4-PHOSPHATASE; MEMBRANE-PERMEANT; 1321N1 CELLS	Ca2+-activated Cl- channels are inhibited by inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4) (Xie, W. Haetzel, M. A., Bruzik, K. S., Dedman, J. R., Shears, S. B., and Nelson, D. J. (1996) J. Biol. Chem. 271, 14092-14097), a novel second messenger that is formed after stimulus-dependent activation of phospholipase C (PLC). In this study, we show that inositol 1,3,4-trisphosphate (Ins(1,3,4)P-3) is the specific signal that ties increased cellular levels of Ins(3,4,5,6)P-4 to changes in PLC activity. We first demonstrated that Ins(1,3,4)P-3 inhibited Ins(3,4,5,6)P-4 1-kinase activity that was either (i) in lysates of AR4-2J pancreatoma cells or (ii) purified 22,500-fold (yield = 13%) from bovine aorta. Next, we incubated [H-3]inositol-labeled AR4-2J cells with cell permeant and non-radiolabeled 2,5,6-tri-O-butyryl-myo-inositol 1,3,4-trisphosphate-hexakis(acetoxymethyl) ester. This treatment increased cellular levels of Ins(1,3,4)P-3 2.7-fold, while [H-3]Ins(3,4,5,6)P-4 levels increased a-fold; there were no changes to levels of other H-3-labeled inositol phosphates. This experiment provides the first direct evidence that levels of Ins(3,4,5,6)P-4 are regulated by Ins(1,3,4)P-3 in vivo, independently of Ins(1,3,4)P-3 being metabolized to Ins(3,4,5,6)P-4. In addition, we found that the Ins(1,3,4)P-3 metabolites, namely Ins(1,3)P-2 and Ins(3,4)P-2, were >100-fold weaker inhibitors of the 1-kinase compared with Ins(1,3,4)P-3 itself (IC50 = 0.17 mu M). This result shows that dephosphorylation of Ins(1,3,4)P-3 in vivo is an efficient mechanism to "switch-off" the cellular regulation of Ins(3,4,5,6)P-4 levels that comes from Ins(1,3,4)P-3-mediated inhibition of the 1-kinase. We also found that Ins(1,3,6)P-3 and Ins(1,4,6)P-3 were poor inhibitors of the 1-kinase (IC50 = 17 and >30 mu M, respectively). The non-physiological trisphosphates, D/L-Ins(1,2,4)P-3, inhibited 1-kinase relatively potently (IC50 = 0.7 mu M), thereby suggesting a new strategy for the rational design of therapeutically useful kinase inhibitors. Overall, our data provide new information to support the idea that Ins(1,3,4)P-3 acts in an important signaling cascade.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Bremen, Inst Organ Chem, D-28359 Bremen, Germany; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bremen; University of Bath; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Pohang University of Science & Technology (POSTECH)	Yang, XN (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	yang3@niehs.nih.gov	Shears, Stephen B/C-6335-2019; Potter, Barry/AAX-4781-2020; Riley, Andrew M/F-3526-2013; Potter, Barry VL/A-1845-2012	Shears, Stephen B/0000-0001-7309-8916; Riley, Andrew M/0000-0001-9003-3540; Schultz, Carsten/0000-0002-5824-2171	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Batty IH, 1998, BIOCHEM J, V330, P1069; BATTY IH, 1994, BIOCHEM J, V297, P529, DOI 10.1042/bj2970529; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHUNG SK, 1995, J CHEM SOC CHEM COMM, P11, DOI 10.1039/c39950000011; Chung SK, 1998, J CARBOHYD CHEM, V17, P369, DOI 10.1080/07328309808002898; Chung SK, 1996, CHEM COMMUN, P163, DOI 10.1039/cc9960000163; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; INHORN RC, 1987, J BIOL CHEM, V262, P15946; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Li WH, 1997, TETRAHEDRON, V53, P12017, DOI 10.1016/S0040-4020(97)00714-X; Maslanski J. A., 1990, METHODS INOSITIDE RE, P109; MCCONNELL FM, 1992, BIOCHEM J, V284, P447, DOI 10.1042/bj2840447; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MENNITI FS, 1991, BIOCHEM J, V274, P622, DOI 10.1042/bj2740622; Mills SJ, 1996, J ORG CHEM, V61, P8980, DOI 10.1021/jo961280x; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NOGIMORI K, 1990, BIOCHEM J, V269, P195, DOI 10.1042/bj2690195; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RILEY AM, 1994, J MED CHEM, V37, P3918, DOI 10.1021/jm00049a011; Rudolf MT, 1998, BIOORG MED CHEM LETT, V8, P1857, DOI 10.1016/S0960-894X(98)00322-9; Rudolf MT, 1997, LIEBIGS ANN-RECL, P1861; Rudolf MT, 1998, J MED CHEM, V41, P3635, DOI 10.1021/jm970781n; Schultz C, 1997, GASTROENTEROLOGY, V112, pA401; SHEARS SB, 1987, BIOCHEM J, V248, P977, DOI 10.1042/bj2480977; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shears SB, 1997, PRACT APPROACH SER, V176, P33; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; Tan Z, 1997, J BIOL CHEM, V272, P2285; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	48	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18973	18980		10.1074/jbc.274.27.18973	http://dx.doi.org/10.1074/jbc.274.27.18973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383396	hybrid			2022-12-25	WOS:000081196300019
J	Bornstein, SR; Tajima, T; Eisenhofer, G; Haidan, A; Aguilera, G				Bornstein, SR; Tajima, T; Eisenhofer, G; Haidan, A; Aguilera, G			Adrenomedullary function is severely impaired in 21-hydroxylase-deficient mice	FASEB JOURNAL			English	Article						21-OH deficiency; adrenal medulla; catecholamine synthesis	CONGENITAL ADRENAL-HYPERPLASIA; NEURAL CREST DERIVATIVES; CHROMAFFIN CELLS; ADRENOCORTICAL-CELLS; SPLANCHNIC NERVE; INTRAADRENAL INTERACTIONS; LEARNING-DISABILITIES; PRENATAL TREATMENT; CORTICAL-CELLS; GROWTH-FACTORS	Deficiency of 21-hydroxylase (21-OH), one of the most common genetic defects in humans, causes low glucocorticoid and mineralocorticoid production by the adrenal cortex, but the effect of this disorder on the adrenomedullary system is unknown. Therefore, we analyzed the development, structure, and function of the adrenal medulla in 21-OH-deficient mice, an animal model resembling human congenital adrenal hyperplasia, Chromaffin cells of el-OH-deficient mice exhibited ultrastructural features of neuronal transdifferentiation with reduced granules, increased rough endoplasmic reticulum and small neurite outgowth. Migration of chromaffin cells in the adrenal to form a central medulla was impaired. Expression of phenylethanolamine-N-methyltransferase (PNMT) was reduced to 27 +/- 9% (P<0.05), as determined by quantitative TaqMan polymerase chain reaction, and there was a significant reduction of cells staining positive for PNMT in the adrenal medulla of the 21-OH-deficient mice, Adrenal contents of epinephrine were decreased to 30 +/- 2% (P<0.01) whereas norepinephrine and dopamine levels were reduced to 57 +/- 4% (P<0.01) and 50 +/- 9% (P<0.05), respectively. 21-OH-deficient mice demonstrate severe adrenomedullary dysfunction, with alterations in chromaffin cell migration, development, structure, and catecholamine synthesis. This hitherto unrecognized mechanism may contribute to the frequent clinical, mental, and therapeutic problems encountered in humans with this genetic disease.	NICHD, Dev Endocrinol Branch, NIH, Sect Endocrine Physiol, Bethesda, MD 20892 USA; NINDS, NIH, Bethesda, MD 20892 USA; Univ Leipzig, Dept Internal Med, D-7010 Leipzig, Germany	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Leipzig University	Bornstein, SR (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Sect Endocrine Physiol, Bldg 10,Rm 10n262,10 Ctr Dr MSC 1862, Bethesda, MD 20892 USA.	Bornstes@mail.nih.gov	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000631] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000631] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMSTERDAM JD, 1987, PSYCHIAT RES, V21, P189, DOI 10.1016/0165-1781(87)90022-9; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BELLONI AS, 1994, BIOMED RES-TOKYO, V15, P95, DOI 10.2220/biomedres.15.95; BORNSTEIN SR, 1990, ENDOCRINOLOGY, V127, P900, DOI 10.1210/endo-127-2-900; BORNSTEIN SR, 1992, ENDOCRINOLOGY, V131, P3126, DOI 10.1210/en.131.6.3126; BORNSTEIN SR, 1995, CLIN ENDOCRINOL, V42, P215, DOI 10.1111/j.1365-2265.1995.tb01866.x; BORNSTEIN SR, 1994, J CLIN ENDOCR METAB, V78, P225, DOI 10.1210/jcem.78.1.7507122; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BORNSTEIN SR, 1991, CELL TISSUE RES, V265, P1, DOI 10.1007/BF00318133; Bosinski HAG, 1997, PSYCHONEUROENDOCRINO, V22, P361, DOI 10.1016/S0306-4530(97)00033-4; CALOGERO AE, 1992, METABOLISM, V41, P839, DOI 10.1016/0026-0495(92)90164-6; CUTLER GB, 1990, NEW ENGL J MED, V323, P1806; DALLMAN MF, 1985, ENDOCR RES, V10, P213, DOI 10.1080/07435808409036499; DALLMAN MF, 1976, AM J PHYSIOL, V231, P408, DOI 10.1152/ajplegacy.1976.231.2.408; Dijkstra I, 1996, ENDOCRINOLOGY, V137, P540, DOI 10.1210/en.137.2.540; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P214, DOI 10.1136/adc.70.3.214; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; EhrhartBornstein M, 1997, HORM METAB RES, V29, P30, DOI 10.1055/s-2007-978976; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Engeland WC, 1998, HORM METAB RES, V30, P311, DOI 10.1055/s-2007-978890; Eranko L, 1977, Adv Biochem Psychopharmacol, V16, P519; Eranko O, 1977, Adv Biochem Psychopharmacol, V16, P525; EVINGER MJ, 1992, CELL MOL NEUROBIOL, V12, P193, DOI 10.1007/BF00712926; Forest MG, 1998, TRENDS ENDOCRIN MET, V9, P284, DOI 10.1016/S1043-2760(98)00067-8; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FUKUSHI M, 1987, ADV NEONATAL SCREENI, P303; GONZALEZHERNANDEZ JA, 1995, CLIN EXP IMMUNOL, V99, P137; GONZALEZHERNANDEZ JA, 1994, CELL TISSUE RES, V278, P201, DOI 10.1007/BF00414161; GOODMAN R, 1978, J CELL BIOL, V78, pR1, DOI 10.1083/jcb.78.1.R1; GOTOH H, 1994, ENDOCRINOLOGY, V135, P1470, DOI 10.1210/en.135.4.1470; GOTOH H, 1988, ENDOCRINOLOGY, V123, P1923, DOI 10.1210/endo-123-4-1923; GUPTA P, 1992, ENDOCRINOLOGY, V130, P2129, DOI 10.1210/en.130.4.2129; Haidan A, 1998, ENDOCRINOLOGY, V139, P772, DOI 10.1210/en.139.2.772; Hanna GL, 1996, J CHILD ADOL PSYCHOP, V6, P63, DOI 10.1089/cap.1996.6.63; HARLAN RE, 1988, MOL NEUROBIOL, V2, P183, DOI 10.1007/BF02935345; HASBAK P, 1995, J HYPERTENS, V13, P235; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JASPER MS, 1994, NEUROENDOCRINOLOGY, V59, P97, DOI 10.1159/000126645; JERN S, 1991, HYPERTENSION, V18, P467, DOI 10.1161/01.HYP.18.4.467; JOHANSSON G, 1976, BIOL PSYCHOL, V4, P157, DOI 10.1016/0301-0511(76)90001-6; Krahenbuhl G S, 1975, J Sports Med, V3, P117; Lange DL, 1998, HYPERTENSION, V31, P403, DOI 10.1161/01.HYP.31.1.403; LEFEBVRE H, 1993, J CLIN ENDOCR METAB, V77, P1662, DOI 10.1210/jc.77.6.1662; LORIAUX DL, 1974, J CLIN ENDOCR METAB, V39, P627, DOI 10.1210/jcem-39-4-627; Marx C, 1998, NEUROIMMUNOMODULAT, V5, P5, DOI 10.1159/000026320; Marx C, 1997, J CLIN ENDOCR METAB, V82, P3136, DOI 10.1210/jc.82.9.3136; Marx C, 1998, HORM METAB RES, V30, P416, DOI 10.1055/s-2007-978907; MEFFORD IN, 1998, PROG NEUROPSYCHOPHAR, V12, P365; Merke DP, 1997, JAMA-J AM MED ASSOC, V277, P1073, DOI 10.1001/jama.277.13.1073; Miller WL, 1998, TRENDS ENDOCRIN MET, V9, P290, DOI 10.1016/S1043-2760(98)00068-X; Murray SA, 1997, MICROSC RES TECHNIQ, V36, P510; NASS R, 1991, J CHILD NEUROL, V6, P306, DOI 10.1177/088307389100600404; New MI, 1998, ANNU REV MED, V49, P311, DOI 10.1146/annurev.med.49.1.311; PHAMHUUTRUNG MT, 1973, ACTA ENDOCRINOL-COP, V73, P316; Plante E, 1996, DEV MED CHILD NEUROL, V38, P423; Remy-Jouet I, 1998, HORM METAB RES, V30, P341, DOI 10.1055/s-2007-978895; REMYJOUET I, 1994, J STEROID BIOCHEM, V50, P55, DOI 10.1016/0960-0760(94)90172-4; RITTMASTER RS, 1987, ANN INTERN MED, V106, P95, DOI 10.7326/0003-4819-106-1-95; RUDMAN D, 1981, J CLIN ENDOCR METAB, V53, P722, DOI 10.1210/jcem-53-4-722; SHIROISHI T, 1987, P NATL ACAD SCI USA, V84, P2819, DOI 10.1073/pnas.84.9.2819; SIPPELL WG, 1980, PEDIATR RES, V14, P39, DOI 10.1203/00006450-198014010-00010; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; VANZIJDERVELD GA, 1993, BIOL PSYCHOL, V36, P157, DOI 10.1016/0301-0511(93)90016-2; VERMES I, 1995, J CLIN ENDOCR METAB, V80, P1238, DOI 10.1210/jc.80.4.1238; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; WURTMAN RJ, 1972, PHARMACOL REV, P411	71	54	55	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1185	1194		10.1096/fasebj.13.10.1185	http://dx.doi.org/10.1096/fasebj.13.10.1185			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385609	Bronze			2022-12-25	WOS:000081264800007
J	Abbott, DW; Thompson, ME; Robinson-Benion, C; Tomlinson, G; Jensen, RA; Holt, JT				Abbott, DW; Thompson, ME; Robinson-Benion, C; Tomlinson, G; Jensen, RA; Holt, JT			BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; POLYMERASE-II HOLOENZYME; V(D)J RECOMBINATION; MEIOTIC CELLS; GENE BRCA1; BREAST; MUTATION; GROWTH; MOUSE; STRAND	The breast cancer predisposition genes, BRCA1 and BRCA2, are responsible for the vast majority of hereditary breast cancer. Although BRCA2 functions to help the cell repair double-stranded DNA breaks, the function of BRCA1 remains enigmatic. Here, we develop a human genetic system to study the role of BRCA1 in oxidative DNA damage. We show that human cancer cells containing mutated BRCA1 are hypersensitive to ionizing radiation. This hypersensitivity can be reversed by the expression of forms of BRCA1 that are not growth suppressing. Reversal of hypersensitivity requires the ring finger of BRCA1, its transactivation domain, and its BRCT domain. Lastly, we show that unlike BRCA2, BRCA1 does not function in the repair of double-stranded DNA breaks. Instead, it functions in transcription-coupled DNA repair (TCR). TCR ability correlated with radioresistance as cells containing BRCA1 showed both increased TCR and radioresistance, whereas cells without BRCA1 showed decreased TCR and radiosensitivity. These findings give physiologic significance to the interaction of BRCA1 with the basal transcription machinery.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Holt, JT (corresponding author), Vanderbilt Univ, Ingram Canc Ctr, Rm 659,MRB 2,2220 Pierce Ave S, Nashville, TN 37232 USA.		Tomlinson, Gail/AAR-9776-2020; Jensen, Roy A/B-9739-2011	Jensen, Roy A/0000-0003-4430-2281; Abbott, Derek/0000-0003-4387-8094	NCI NIH HHS [R01CA5175S1, R01CA51735, R29CA62161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051735, R29CA062161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Burke TF, 1998, ONCOGENE, V16, P1031, DOI 10.1038/sj.onc.1201623; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Errami A, 1996, MOL CELL BIOL, V16, P1519; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NAMBA M, 1977, JPN J EXP MED, V47, P263; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; WALTON DG, 1984, MUTAT RES, V129, P129, DOI 10.1016/0027-5107(84)90131-3; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YAGI T, 1982, MUTAT RES, V96, P89, DOI 10.1016/0027-5107(82)90019-7	43	201	209	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18808	18812		10.1074/jbc.274.26.18808	http://dx.doi.org/10.1074/jbc.274.26.18808			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373498	hybrid			2022-12-25	WOS:000081056700090
J	Chao, CF; Chuang, HC; Chiou, ST; Liu, TY				Chao, CF; Chuang, HC; Chiou, ST; Liu, TY			On the biosynthesis of alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid catalyzed by the sialyltransferase of Escherichia coli Bos-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; CAPSULAR POLYSACCHARIDE; NEISSERIA-MENINGITIDIS; COLOMINIC ACID; STRAIN BOS-12; POLYMERS; K92; K1	Escherichia coli Bos-la synthesizes a heteropolymer of sialic acids with alternating alpha-2,9/alpha-2,8 glycosidic linkages (1), In this study, we have shown that the polysialyltransferase of the E. coli Bos-12 recognizes an a-2,8 glycosidic linkage of sialic acid at the nonreducing end of an exogenous acceptor of either the alpha-2,8 homopolymer of sialic acid or the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid and catalyzes the transfer of Neu5Ac from CMP-Neu5Ac to this residue. When the exogenous acceptor is an alpha-a,8-linked oligomer of sialic acid, the main product synthesized is derived from the addition of a single residue of [C-14]Neu5Ac to form either an alpha-2,8 glycosidic linkage or an alpha-2,9 glycosidic linkage at the nonreducing end, at an alpha-2,8/alpha-2,9 ratio of approximately 2:1, When the acceptor is the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid, chain elongation takes place four to five times more efficiently than the alpha-2,8-linked homopolymer of sialic acid as an acceptor. It was found that the alpha-2,9-linked homopolymer of sialic acid and the alpha-2,8/alpha-2,9-linked hetero-oligomer of sialic acid with alpha-2,9 at the nonreducing end not only failed to serve as an acceptor for the E. coli Bos-la polysialyltransferase for the transfer of [C-14]Neu5Ac, but they inhibited the de novo synthesis of polysialic acid catalyzed by this enzyme. The results obtained in this study favor the proposal that the biosynthesis of the alpha-2,9/alpha-2,8 heteropolymer of sialic acid catalyzed by the E. coli Bos-la polysialyltransferase involves a successive transfer of a preformed alpha-2,8-linked dimer of sialic acid at the nonreducing terminus of the acceptor to form an alpha-2,9 glycosidic linkage between the incoming dimer and the acceptor. The glycosidic linkage at the nonreducing end of the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid produced by E, coli Bos-la should be an alpha-2,8 glycosidic bond and not an alpha-2,9 glycosidic linkage.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Liu, TY (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	dtl@gate.sinica.edu.tw						ADA GL, 1961, J GEN MICROBIOL, V24, P409, DOI 10.1099/00221287-24-3-409; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; EGAN W, 1977, BIOCHEMISTRY-US, V16, P3687, DOI 10.1021/bi00635a028; FERRERO MA, 1991, BIOCHEM J, V280, P575, DOI 10.1042/bj2800575; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KUNDIG FD, 1971, J BIOL CHEM, V246, P2543; KWIATKOWSKI B, 1987, METHOD ENZYMOL, V138, P786; LIFELY MR, 1985, CARBOHYD RES, V143, P191; LIU TY, 1971, J BIOL CHEM, V246, P4703; LIU TY, 1977, J INFECT DIS, V136, pS71, DOI 10.1093/infdis/136.Supplement.S71; REGLERO A, 1993, INT J BIOCHEM, V25, P1517, DOI 10.1016/0020-711X(93)90507-B; REUTER G, 1994, METHOD ENZYMOL, V230, P168; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1982, METHOD ENZYMOL, V83, P540; TROY FA, 1979, J BIOL CHEM, V254, P7377; TROY FA, 1975, J BIOL CHEM, V250, P156; VANN WF, 1978, J BACTERIOL, V133, P1300, DOI 10.1128/JB.133.3.1300-1306.1978; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIMR ER, 1992, J BACTERIOL, V174, P5127, DOI 10.1128/JB.174.15.5127-5131.1992; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985	21	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18206	18212		10.1074/jbc.274.26.18206	http://dx.doi.org/10.1074/jbc.274.26.18206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373421	hybrid			2022-12-25	WOS:000081056700013
J	Fujishige, K; Kotera, J; Michibata, H; Yuasa, K; Takebayashi, S; Okumura, K; Omori, K				Fujishige, K; Kotera, J; Michibata, H; Yuasa, K; Takebayashi, S; Okumura, K; Omori, K			Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; RECESSIVE JUVENILE PARKINSONISM; SMOOTH-MUSCLE; BINDING; EXPRESSION; PHOSPHORYLATION; RELAXATION; REGION; AORTA; SITES	cDNA encoding a novel phosphodiesterase (PDE) was isolated from a human fetal lung cDNA library and designated PDE10A, The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families. Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with K-m values of 0.26 and 7.2 mu M, respectively, and V-max with cGRIP was almost twice that with cAMP, Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 mu M for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 mu M, respectively. Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE, PDE10A transcripts were particularly abundant in the putamen and caudate nucleus regions of brain and in thyroid and testis, and in much lower amounts in other tissues. The PDE10A gene was located on chromosome 6q26 by fluorescent in situ hybridization analysis. PDE10A represents a new member of the PDE superfamily, exhibiting unique kinetic properties and inhibitor sensitivity.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan; Mie Univ, Fac Bioresources, Biol Chem Lab, Tsu, Mie 5148507, Japan	Mitsubishi Tanabe Pharma Corporation; Mie University	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358505, Japan.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAVO J, 1990, CYCLIC NUCLEOTIDE PH, V2; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; Hayashi M, 1998, BIOCHEM BIOPH RES CO, V250, P751, DOI 10.1006/bbrc.1998.9379; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; Jones AC, 1998, AM J HUM GENET, V63, P80, DOI 10.1086/301937; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P539; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MIYAHARA M, 1995, EUR J PHARMACOL, V284, P25, DOI 10.1016/0014-2999(95)00355-O; Okumura K, 1998, BIOSCI BIOTECH BIOCH, V62, P1640, DOI 10.1271/bbb.62.1640; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAEKI T, 1994, J PHARMACOL EXP THER, V284, P25; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; TAKAHASHI E, 1990, HUM GENET, V86, P4; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; Turko IV, 1998, BIOCHEM J, V329, P505; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; YAN C, 1994, J NEUROSCI, V14, P973; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x	32	338	415	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18438	18445		10.1074/jbc.274.26.18438	http://dx.doi.org/10.1074/jbc.274.26.18438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373451	hybrid			2022-12-25	WOS:000081056700043
J	Galsgaard, ED; Nielsen, JH; Moldrup, A				Galsgaard, ED; Nielsen, JH; Moldrup, A			Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells - Prolactin and growth hormone activate one of the rat PRLR gene promoters via STAT5a and STAT5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE STIMULATION THRESHOLD; BETA-CELL; PLACENTAL-LACTOGEN; HEPATIC RECEPTORS; PANCREATIC-ISLETS; INDUCTION; SECRETION; LIVER; PREGNANCY; INS-1	Expression of the prolactin receptor (PRLR) gene is increased in pancreatic islets during pregnancy and in vitro in insulin-producing cells by growth hormone (GH) and prolactin (PRL), The 5'-region of the rat PRLR gene contains at least three alternative first exons that are expressed tissue-specifically because of differential promoter usage. We show by reverse transcription-polymerase chain reaction analysis that both exon 1A- and exon 1C-containing PRLR transcripts are expressed in rat islets and that human (h)GH, ovine (o)PRL, and bovine (b)GH increase exon 1A expression 6.5 +/- 0.8-fold, 6.8 +/- 0.7-fold, and 3.9 +/- 0.7-fold and exon le expression 4.8 +/- 0.4-fold, 4.4 +/- 0.6-fold, and 2.5 +/- 0.7-fold, respectively. Expression of exon 1B was not detectable. The transcriptional activities of reporter constructs containing the 1A, 1B, or 1C promoter were found to be 22.8-fold, 2.7-fold, and 8.0-fold, respectively, above that of a promoterless reporter construct when transfected into the insulin-producing INS-1 cells. The transcriptional activity of the 1A promoter construct was increased 8.9 +/- 1.9-fold by 0.5 mu g/ml hGH. Responsiveness to hGH of the 1A promoter was localized to the region from -225 to +81 with respect to the transcription start site. This region contains the sequence TTCTAGGAA that by gel retardation experiments was shown to bind the transcription factors STAT5a and STAT5b in response to stimulation by hGH, oPRL, or bGH. Mutation of this gamma-activated sequence-like element completely abolished transcriptional induction of the 1A promoter by hGH, Our results suggest that GH and PRL increase the levels of exon 1A- and 1C-containing PRLR mRNA species and furthermore that the transcriptional activity of the 1A promoter is increased via activation of STAT5a and STAT5b.	Hagedorn Res Inst, Dept Cell Biol, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute	Galsgaard, ED (corresponding author), Hagedorn Res Inst, Dept Cell Biol, Niels Steensensvej 6, DK-2820 Gentofte, Denmark.			Nielsen, Jens Hoiriis/0000-0001-8252-3048				AMIT T, 1985, MOL CELL ENDOCRINOL, V39, P21, DOI 10.1016/0303-7207(85)90088-7; ASFARI M, 1995, MOL CELL ENDOCRINOL, V107, P209, DOI 10.1016/0303-7207(94)03445-Y; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARASH I, 1988, ENDOCRINOLOGY, V122, P1151, DOI 10.1210/endo-122-3-1151; BAXTER RC, 1984, ENDOCRINOLOGY, V115, P2009, DOI 10.1210/endo-115-5-2009; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Matsuda M, 1997, ZOOL SCI, V14, P159, DOI 10.2108/zsj.14.159; MOLDRUP A, 1990, J BIOL CHEM, V265, P8686; MOLDRUP A, 1993, ENDOCRINOLOGY, V133, P1165, DOI 10.1210/en.133.3.1165; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; Ormandy CJ, 1998, DNA CELL BIOL, V17, P761, DOI 10.1089/dna.1998.17.761; POLAK M, 1990, DIABETES, V39, P1045, DOI 10.2337/diabetes.39.9.1045; ROBERTSON JA, 1990, MOL ENDOCRINOL, V4, P1235, DOI 10.1210/mend-4-8-1235; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; SORENSON RL, 1987, PANCREAS, V2, P283, DOI 10.1097/00006676-198705000-00006; SORENSON RL, 1987, ENDOCRINOLOGY, V121, P1447, DOI 10.1210/endo-121-4-1447; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	30	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18686	18692		10.1074/jbc.274.26.18686	http://dx.doi.org/10.1074/jbc.274.26.18686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373481	hybrid			2022-12-25	WOS:000081056700073
J	Kowalczyk, AP; Hatzfeld, M; Bornslaeger, EA; Kopp, DS; Borgwardt, JE; Corcoran, CM; Settler, A; Green, KJ				Kowalczyk, AP; Hatzfeld, M; Bornslaeger, EA; Kopp, DS; Borgwardt, JE; Corcoran, CM; Settler, A; Green, KJ			The head domain of plakophilin-1 binds to desmoplakin and enhances its recruitment to desmosomes - Implications for cutaneous disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; PLAQUE PROTEIN; PEMPHIGUS-VULGARIS; MULTIGENE FAMILY; EMBRYONIC HEART; BAND-6 PROTEIN; PLAKOGLOBIN; CADHERIN; GENE; CONNECTION	The contribution of desmosomes to epidermal integrity is evident in the inherited blistering disorder associated with the absence of a functional gene for plakophilin-1. To define the function of plakophilin-1 in desmosome assembly, interactions among the desmosomal cadherins, desmoplakin, and the armadillo family members plakoglobin and plakophilin-1 were examined. In transient expression assays, plakophilin-1 formed complexes with a desmoplakin amino-terminal domain and enhanced its recruitment to cell-cell borders; this recruitment was not dependent on the equimolar expression of desmosomal cadherins. In contrast to desmoplakin-plakoglobin interactions, the interaction between desmoplakin and plakophilin-1 was not mediated by the armadillo repeat domain of plakophilin-1 but by the non-armadillo head domain, as assessed by yeast two-hybrid and recruitment assays. We propose a model whereby plakoglobin serves as a linker between the cadherins and desmoplakin, whereas plakophilin-1 enhances lateral interactions between desmoplakin molecules. This model suggests that epidermal lesions in patients lacking plakophilin-1 are a consequence of the loss of integrity resulting from a decrease in binding sites for desmoplakin and intermediate filaments at desmosomes.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Halle Wittenberg, Fac Med, Mol Biol Grp, D-06097 Halle, Germany	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Martin Luther University Halle Wittenberg	Green, KJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043380, K01AR002039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR43380, K01 AR02039] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Green KJ, 1997, SOC GEN PHY, V52, P123; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; MATHUR M, 1994, J BIOL CHEM, V269, P14075; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STANLEY JR, 1995, J EXP MED, V181, P1, DOI 10.1084/jem.181.1.1	32	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18145	18148		10.1074/jbc.274.26.18145	http://dx.doi.org/10.1074/jbc.274.26.18145			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373410	hybrid			2022-12-25	WOS:000081056700002
J	Tsai, LY; Tu, SL; Li, HM				Tsai, LY; Tu, SL; Li, HM			Insertion of atToc34 into the chloroplastic outer membrane is assisted by at least two proteinaceous components in the import system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE MEMBRANE; MACHINERY; BINDING; PATHWAY; TRANSPORT; TRANSLOCATION; PRECURSORS; APPARATUS; SIGNAL	Toc34 is a member of the outer membrane translocon complex that mediates the initial stage of protein import into chloroplasts. Toc34, like most outer membrane proteins, is synthesized in the cytosol at its mature size without a cleavable transit peptide. The majority of outer membrane proteins do not require thermolysin-sensitive components on the chloroplastic surface or ATP for their insertion into the outer membrane. However, different results have been obtained concerning the factors required for Toc34 insertion into the outer membrane, Using an Arabidopsis homologue of pea Toc34, atToc34, we show that the insertion of atToc34 was greatly reduced by thermolysin pretreatment of chloroplasts as assayed either by protease digestion or by alkaline extraction. The insertion was also dependent on the presence of ATP or GTP. A mutant of atToc34 with the GTP-binding domain deleted still required ATP for optimal insertion, indicating that ATP was used by other protein components in the import system. The ATP-supported insertion was observed even in thermolysin-pretreated chloroplasts, suggesting that the protein component responsible for ATP-stimulated insertion is a different protein from the thermolysin-sensitive component that assists atToc34 insertion.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Grad Inst Life Sci, Taipei 112, Taiwan; Natl Def Med Ctr, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Defense Medical Center	Li, HM (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbhmli@ccvax.sinica.edu.tw	Li, Hsou-min/AAZ-8011-2021; Tu, Shih-Long/ABF-5446-2021	Li, Hsou-min/0000-0002-0211-7339; Tu, Shih-Long/0000-0001-9436-278X				Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; CLINE K, 1985, J BIOL CHEM, V260, P3691; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; Fuks B, 1997, PLANT PHYSIOL, V114, P405, DOI 10.1104/pp.114.2.405; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1992, J BIOL CHEM, V267, P2986; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; Li HM, 1996, PLANT CELL, V8, P2117, DOI 10.1105/tpc.8.11.2117; Li HM, 1997, J BIOL CHEM, V272, P10968; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W	22	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18735	18740		10.1074/jbc.274.26.18735	http://dx.doi.org/10.1074/jbc.274.26.18735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373488	hybrid			2022-12-25	WOS:000081056700080
J	Ronca, F; Yee, KSY; Yu, VC				Ronca, F; Yee, KSY; Yu, VC			Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; CYTOPLASMIC SEQUESTRATION; MOUSE THYMOCYTES; DRUG-RESISTANCE; GENE-MUTATIONS; N-MYC; DEATH; INDUCTION; RECEPTOR; PATHWAY	Many cell lines derived from neuroblastoma (NB) carry the wild-type p53 gene with a p53-dependent apoptotic pathway that is responsive to DNA damaging agents. A recent study has demonstrated that retinoic acid (RA) pretreatment of NE cells promotes chemoresistance to apoptosis induced by chemotherapeutic agents. We examine here the possible contribution of the p53 pathway to the chemoresistance response associated with the RA treatment in NE cells. Upon treatment with RA (1-10 mu M) for 4 days, the human NE cells, SH-SY5Y, developed resistance selectively to p53-dependent apoptotic stimuli including gamma-irradiation, etoposide, and 1-(5-isoquinolinyl sulfonyl)-2-methylpiperazine (H-7). Interestingly, RA affected the ability of H-7 to induce nuclear accumulation of the p53 protein without altering its effect on elevating the steady-state level of p53, suggesting that drug-induced up-regulation and nuclear accumulation of the wild-type p53 protein are separable processes. The modulation of nuclear import of p53 protein by RA may thus represent a potential mechanism by which certain tumor cells with the wild-type p53 gene develop resistance to chemotherapeutic agents.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Yu, VC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015	Yu, Victor/0000-0003-3270-4734				Aboseif SR, 1997, PROSTATE, V31, P161; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIEDLER JL, 1994, CANCER RES, V54, P666; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; FRITSCHE M, 1993, ONCOGENE, V8, P307; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudas Lorraine J., 1994, P443; HAMMERLING U, 1987, ONCOGENE, V2, P73; HANADA M, 1993, CANCER RES, V53, P4978; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; IMAMURA J, 1993, CANCER RES, V53, P4053; Kaba SE, 1997, J NEURO-ONCOL, V34, P145, DOI 10.1023/A:1005743707803; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOMURO H, 1993, CANCER RES, V53, P5284; LASORELLA A, 1995, CANCER RES, V55, P4711; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304, DOI 10.1074/jbc.270.47.28304; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PONZONI M, 1995, CANCER RES, V55, P853; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; VOGAN K, 1993, CANCER RES, V53, P5269; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z	42	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18128	18134		10.1074/jbc.274.25.18128	http://dx.doi.org/10.1074/jbc.274.25.18128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364268	hybrid			2022-12-25	WOS:000080974300104
J	Zhang, SH; Liu, JP; Kobayashi, R; Tonks, NK				Zhang, SH; Liu, JP; Kobayashi, R; Tonks, NK			Identification of the cell cycle regulator VCP (p97/CDC48) as a substrate of the band 4.1-related protein-tyrosine phosphatase PTPH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; MAMMALIAN HOMOLOG; PHOSPHORYLATION; ASSOCIATION; FUSION; KINASE; CDC48	The human band 4.1-related protein-tyrosine phosphatase PTPH1 was introduced into NIH3T3 cells under the control of a tetracycline-repressible promoter. Ectopic expression of wild type PTPH1 dramatically inhibited cell growth, whereas a catalytically impaired mutant showed no effect. To identify the direct target of PTPH1 in the cell, we generated a substrate-trapping mutant, in which an invariant aspartate residue was changed to alanine (D811A in PTPH1), The PTPH1-D811A mutant trapped primarily a 97-kDa tyrosine-phosphorylated protein, which was determined to be VCP (also named p97 or yeast CDC48), from various cell lysates in vitro. However, when expressed in mammalian cells, the D811A mutant was observed to contain high levels of phosphotyrosine and did not trap substrates. Mutation of tyrosine 676 to phenylalanine (Y676F) in the PTPH1-D811A mutant led to a marked reduction in phosphotyrosine content. Furthermore, this double mutant specifically trapped VCP in vivo and recognized the C-terminal tyrosinesof VCP, whose phosphorylation is important for cell cycle progression in yeast. Like wild type PTPH1, this double mutant also inhibited cell proliferation. Moreover, induction of wild type PTPH1 resulted in specific dephosphorylation of VCP without changing the overall phosphotyrosine profile of the cells, VCP has been implicated in control of a variety of membrane functions, including membrane fusions, and is a regulator of the cell cycle. Our results suggest that PTPH1 may exert its effects on cell growth through dephosphorylation of VCP, thus implicating tyrosine phosphorylation as an important regulator of VCP function.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; APTEL SK, 1998, CELL, V92, P611; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Long AR, 1998, GENE, V208, P191, DOI 10.1016/S0378-1119(97)00652-5; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pennisi E, 1998, SCIENCE, V282, P1972, DOI 10.1126/science.282.5396.1972; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	26	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17806	17812		10.1074/jbc.274.25.17806	http://dx.doi.org/10.1074/jbc.274.25.17806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364224	hybrid			2022-12-25	WOS:000080974300060
J	Dubendorff, JW; Lipsick, JS				Dubendorff, JW; Lipsick, JS			Transcriptional regulation by the carboxyl terminus of c-Myb depends upon both the Myb DNA-binding domain and the DNA recognition site	ONCOGENE			English	Article						c-Myb; DNA-binding; v-Myb	V-MYB; GENE-EXPRESSION; FUNCTIONAL DOMAINS; PROTEIN SEQUENCES; COACTIVATOR CBP; LEUCINE-ZIPPER; IN-VITRO; A-MYB; ACTIVATION; TRANSACTIVATION	The c-Myb protein binds to DNA,can regulate transcription, and is required for normal hematopoiesis in vertebrates. Either amino- or carboxy-terminal truncation of this protein is required for efficient oncogenic activation. Previous studies have shown that the carboxyl terminus of c-Myb that is deleted in v-Myb contains negative regulatory domains. We now demonstrate that specific mutations within this carboxyl terminus result in greater transcriptional activation than truncation of the entire carboxyl terminus. Furthermore, this increased transcriptional activation depends upon the presence of the highly conserved Myb DNA-binding domain and is also dependent upon the nature of the Myb-binding sites within the target prompter. In a similar fashion, an activating mutation within the heptad leucine repeat region of c-Myb that, is also present in v-Myb functions only in conjunction,vith the Myb DNA-binding domain and with particular Myb-binding sites. These results suggest a model in which multiple domains of the c-Myb protein are highly interdependent for transcriptional regulation. These interactions are promoter-specific and are not web modeled by heterologous fusion proteins.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NCI NIH HHS [T32 CA09176, R01 CA56509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056509, T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUBENDORFF JW, 1997, METHOD MOL CELL BIOL, V5, P367; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FENG DF, 1990, METHOD ENZYMOL, V183, P375; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GANTER B, 1998, IN PRESS ADV CANC RE; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SENECA S, 1993, ONCOGENE, V8, P2335; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG X, 1995, MOL CELL BIOL, V15, P4735; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998	50	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3452	3460		10.1038/sj.onc.1202679	http://dx.doi.org/10.1038/sj.onc.1202679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376523				2022-12-25	WOS:000080850600003
J	Li, Q; Ahuja, N; Burger, PC; Issa, JPJ				Li, Q; Ahuja, N; Burger, PC; Issa, JPJ			Methylation and silencing of the Thrombospondin-1 promoter in human cancer	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; Thrombospondin-1 (THBS1); angiogenesis	ENDOTHELIAL GROWTH-FACTOR; NICKEL-TRANSFORMED CELLS; DNA METHYLATION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; HUMAN BREAST; CPG ISLAND; INDUCTION; FIBROBLASTS; INHIBITION	Neovascularization is a common feature of many human cancers, but relatively few molecular defects have been demonstrated in genes regulating angiogenesis. Decreased expression of Thrombospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human tumors, including glioblastoma multiforme (GBM). To study whether methylation-associated inactivation is involved in down-regulating THBS1 expression in cancer, we analysed the methylation status of THBS1 in several cell lines and primary tumors. Three cell lines (RKO, CEM and RAJI) were completely methylated at several CpG sites within the THBS1 5' CpG island, and had no detectable expression ba RT-PCR, THBS1 expression,vas readily reactivated using the methylation-inhibitor 5-deoxy-azacytidine in all three lines, Furthermore, THBS1 methylation was present in 33% (14/42) of primary GBMs, Thus, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [5UO1CA64928] Funding Source: Medline; NIA NIH HHS [AG05146] Funding Source: Medline; NIDDK NIH HHS [1-T32-DK07713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA064928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1997, CANCER RES, V57, P3370; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CANFIELD AE, 1995, J CELL SCI, V108, P797; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Furnari FB, 1995, CANCER SURV, V25, P233; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Guo NH, 1997, CANCER RES, V57, P1735; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsu SC, 1996, CANCER RES, V56, P5684; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1996, CANCER RES, V56, P2463; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; MEEHAN R, 1992, J CELL SCI, P9; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Stirzaker C, 1997, CANCER RES, V57, P2229; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	37	142	153	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3284	3289		10.1038/sj.onc.1202663	http://dx.doi.org/10.1038/sj.onc.1202663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359534				2022-12-25	WOS:000080523800011
J	Agou, F; Raveh, S; Mesnildrey, S; Veron, M				Agou, F; Raveh, S; Mesnildrey, S; Veron, M			Single strand DNA specificity analysis of human nucleoside diphosphate kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEASE-HYPERSENSITIVE ELEMENT; X-RAY STRUCTURE; C-MYC; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; ACID INTERACTIONS; GENE-EXPRESSION; NDP-KINASE; NM23 GENE; IN-VIVO	Nucleoside diphosphate kinases (NDP kinases) form a family of oligomeric enzymes present in all organisms, Eukaryotic NDP kinases are hexamers composed of identical subunits (approximate to 17 kDa), A distinctive property of human NDPK-B encoded by the gene nm23-H-2 is its ability to stimulate the gene transcription. This property is independent of its catalytic activity and is possibly related to the role of this protein in cellular events including differentiation and tumor metastasis. In this paper, we report the first characterization of human NDPK-B.DNA complex formation using a filter-binding assay and fluorescence spectroscopy. We analyzed the binding of several oligonucleotides mimicking the promoter region of the c-myc oncogene including variants in sequence, structure, and length of both strands, We show that NDPK-B binds to single-stranded oligonucleotides in a nonsequence specific manner, but that it exhibits a poor binding activity to double-stranded oligonucleotides. This indicates that the specificity of recognition to DNA is a function of the structural conformation of DNA rather than of its specific sequence. Moreover, competition experiments performed with all nucleotides provide evidence for the contribution of the six active sites in the DNA-protein complex formation. We propose a mechanism through which human NDPK-B could stimulate transcription of c-myc or possibly other genes involved in cellular differentiation.	Inst Pasteur, CNRS URA 1773, Unite Regualt Enzymat Activites Cellulaires, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Veron, M (corresponding author), Inst Pasteur, CNRS URA 1773, Unite Regualt Enzymat Activites Cellulaires, 25 Rue Docteur Roux, F-75724 Paris 15, France.	mveron@pasteur.fr	, AGOU/GXA-2760-2022					Agarwal R P, 1978, Methods Enzymol, V51, P376; Albert T, 1997, MOL CELL BIOL, V17, P4363, DOI 10.1128/MCB.17.8.4363; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; Lambeth DO, 1997, J BIOL CHEM, V272, P24604, DOI 10.1074/jbc.272.39.24604; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; Mesnildrey S, 1997, FEBS LETT, V418, P53, DOI 10.1016/S0014-5793(97)01292-1; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; Schaertl S, 1998, J BIOL CHEM, V273, P5662, DOI 10.1074/jbc.273.10.5662; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Tomonaga T, 1998, MOL CELL, V1, P759, DOI 10.1016/S1097-2765(00)80075-1; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	50	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19630	19638		10.1074/jbc.274.28.19630	http://dx.doi.org/10.1074/jbc.274.28.19630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391900	Green Published, hybrid			2022-12-25	WOS:000081377300020
J	Chidiac, P; Ross, EM				Chidiac, P; Ross, EM			Phospholipase C-beta 1 directly accelerates GTP hydrolysis by G alpha(q) and acceleration is inhibited by G beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; ACTIVATING PROTEIN; RGS PROTEINS; P115 RHOGEF; PURIFICATION; IDENTIFICATION; BINDING; SUBFAMILY; MECHANISM; RECEPTOR	Phospholipase C-beta, the principal effector protein regulated by G alpha(q), has been shown to increase the agonist-stimulated, steady-state GTPase activity of G(q) in proteoliposomes that contain both heterotrimeric G(q) and ml muscarinic receptor. We now use a moderately stable complex of R183C G alpha(q) bound to GTP to show that PLC-beta 1 acts directly as a GTPase-activating protein (GAP) for isolated G alpha(q) in a membrane-free system. PLC-beta 1 accelerated the hydrolysis of G alpha(qR183C).GTP up to 20-fold. The K-m was 1.5 nM, which is similar both to the EC50 with which R183C and wild type G alpha(q) activate PLC-beta 1 and to the EC50 with which PLC-beta 1 acts as a G(q) GAP in the vesicle-based assay. The G alpha(q) GAP activity of RGS4 can also be quantitated by this assay; it accelerated hydrolysis of bound GTP about 100-fold. The G(q) GAP activities of both PLC-beta 1 and RGS4 are blocked by G beta gamma subunits, probably by a competitive mechanism. These data suggest either that the G beta gamma subunits are not continuously required for receptor-catalyzed GDP/GTP exchange during steady-state GTP hydrolysis or that GAPs, either PLC-beta or RGS proteins, can substitute for G beta gamma in this set of reactions.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chidiac, P (corresponding author), Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada.	pchidiac@julian.uwo.ca	Chidiac, Peter/L-5906-2015	Chidiac, Peter/0000-0001-8365-6109	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLANK JL, 1991, J BIOL CHEM, V266, P18206; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; PANG IH, 1990, J BIOL CHEM, V265, P18707; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; POSNER BA, 1999, IN PRESS BIOCHEMISTR, V38; ROSS EM, 1994, INT CONGR SER, V1051, P211; Ross EM, 1999, CRC METH SIG TRANS, P123; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	29	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19639	19643		10.1074/jbc.274.28.19639	http://dx.doi.org/10.1074/jbc.274.28.19639			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391901	hybrid			2022-12-25	WOS:000081377300021
J	Codina, J; Pressley, TA; DuBose, TD				Codina, J; Pressley, TA; DuBose, TD			The colonic H+,K+-ATPase functions as a Na+-dependent K+(NH4+)-ATPase in apical membranes from rat distal colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; K+-ATPASE; GASTRIC H+,K+-ATPASE; EXPRESSION; LOCALIZATION; H,K-ATPASE; MECHANISM; TRANSPORT; KIDNEY	Recent studies have suggested that the colonic H+,K+ ATPase (HK alpha(2)) can secrete either Na+ or H+ in exchange for K+. If correct, this view would indicate that the transporter could function as either a Na+ or a H+ pump. To investigate this possibility a series of experiments was performed using apical membranes from rat colon which were enriched in colonic H+,K+-ATPase protein. An antibody specific for HK alpha(2) was employed to determine whether HK alpha(2), functions under physiological conditions as a Na+-dependent or Na+-independent K+-ATPase in this same membrane fraction. K+-ATPase activity was measured as [gamma-P-32]ATP hydrolysis, The Na+-dependent K+-ATPase accounted for approximately 80% of overall K+-ATPase activity and was characterized by insensitivity to Sch-28080 but partial sensitivity to ouabain. The Na+-independent K+-ATPase activity was insensitive to both Sch-28080 and ouabain, Both types of K+-ATPase activity substituted NH4+ for K+ in a similar manner. Furthermore, our results demonstrate that when incubated with native distal colon membranes, the blocking antibody inhibited dramatically Na+-dependent K+-ATPase activity. Therefore, these data demonstrate that HK alpha(2), can function in native distal colon apical membranes as a Na+-dependent K+-ATPase. Elucidation of the role of the pump as a transporter of Na+ versus H+ or NH4+ versus K+ in vivo will require additional studies.	Univ Texas, Sch Med, Div Renal Dis & Hypertens, Dept Internal Med, Houston, TX 77030 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Physiol, Lubbock, TX 79430 USA	University of Texas System; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	DuBose, TD (corresponding author), Univ Texas, Sch Med, Div Renal Dis & Hypertens, Dept Internal Med, 6431 Fannin St,Rm 4-148, Houston, TX 77030 USA.	tdubose@heart.med.uth.tmc.edu			NIDDK NIH HHS [DK-30603] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030603] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amlal H., 1998, Journal of the American Society of Nephrology, V9, p2A; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ASANO S, 1998, AM J PHYSIOL, V275, pG669; Codina J, 1998, J BIOL CHEM, V273, P7894, DOI 10.1074/jbc.273.14.7894; Codina J, 1997, AM J PHYSIOL-RENAL, V272, pF22, DOI 10.1152/ajprenal.1997.272.1.F22; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Codina J, 1998, AM J PHYSIOL-RENAL, V275, pF433, DOI 10.1152/ajprenal.1998.275.3.F433; Cougnon M., 1998, Journal of the American Society of Nephrology, V9, p4A; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DANTZIG AH, 1991, BIOCHEM PHARMACOL, V42, P2019, DOI 10.1016/0006-2952(91)90603-3; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DIAZDIAZ FD, 1986, AM J PHYSIOL, V251, pF297, DOI 10.1152/ajprenal.1986.251.2.F297; DUBOSE TD, 1939, AM J PHYSIOL, V269, pF500; GARVIN JL, 1985, AM J PHYSIOL, V249, pF784, DOI 10.1152/ajprenal.1985.249.5.F785; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Grishin AV, 1998, J BIOL CHEM, V273, P27772, DOI 10.1074/jbc.273.43.27772; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; Jaisser F, 1996, AM J PHYSIOL-CELL PH, V270, pC679, DOI 10.1152/ajpcell.1996.270.2.C679; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; Kraut JA, 1997, AM J PHYSIOL-RENAL, V272, pF744, DOI 10.1152/ajprenal.1997.272.6.F744; KURTZ I, 1986, AM J PHYSIOL, V250, pF497, DOI 10.1152/ajprenal.1986.250.3.F497; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; Nakamura S, 1998, AM J PHYSIOL-RENAL, V274, pF687, DOI 10.1152/ajprenal.1998.274.4.F687; POHL SL, 1971, J BIOL CHEM, V246, P4447; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Rajendran VM, 1998, AM J PHYSIOL-GASTR L, V274, pG424, DOI 10.1152/ajpgi.1998.274.2.G424; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SKOU JC, 1960, BIOCHIM BIOPHYS ACTA, V42, P6, DOI 10.1016/0006-3002(60)90746-0; Wall SM, 1998, AM J PHYSIOL-RENAL, V275, pF543, DOI 10.1152/ajprenal.1998.275.4.F543; WALL SM, 1994, AM J PHYSIOL-RENAL, V267, pF660, DOI 10.1152/ajprenal.1994.267.4.F660; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	36	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19693	19698		10.1074/jbc.274.28.19693	http://dx.doi.org/10.1074/jbc.274.28.19693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391909	hybrid			2022-12-25	WOS:000081377300029
J	Rivera-Nieves, J; Thompson, WC; Levine, RL; Moss, J				Rivera-Nieves, J; Thompson, WC; Levine, RL; Moss, J			Thiols mediate superoxide-dependent NADH modification of glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED ADP-RIBOSYLATION; NITRIC-OXIDE; S-NITROSYLATION; RELAXING FACTOR; ACID; RIBOSYLTRANSFERASE; PEROXYNITRITE; INVOLVEMENT; MECHANISM; OXIDATION	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is covalently modified by NAD in the presence of nitric oxide (NO) and dithiothreitol. Replacement of NAD with NADH in the presence of SIN-1 (3-morpholinosydnonimine) and dithiothreitol increased modification 25-fold. We now demonstrate that in contrast to NO-mediated attachment of NAD, covalent attachment of NADH to GAPDH proceeds in the presence of low molecular weight thiols, independent of NO. Removal of oxygen and transition metal ions inhibited modification, consistent with a role for reactive oxygen species; inhibition by superoxide dismutase, stimulation by xanthine oxidase/hypoxanthine, and the lack of an effect of catalase supported the hypothesis that superoxide, generated hom thiol oxidation, was involved. Electrospray mass spectrometry showed covalent Linkage of the NADH molecule to GAPDH Characterization of the product of phosphodiesterase cleavage demonstrated that linkage to GAPDH occurred through the nicotinamide of NADH. Lys-C digestion of GAPDH, followed by peptide isolation by high performance liquid chromatography, matrix-assisted laser desorption ionization time-of-flight analysis, and Ed-man sequencing, demonstrated that NADH attachment occurred at Cys-149, the active-site thiol. This thiol linkage was stable to HgCl2. Thus, linkage of GAPDH to NADH, in contrast to NAD, occurs in the presence of thiol, is independent of NO, and is mediated by superoxide.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Moss, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N-307,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.	JR3u@virginia.edu	Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002537] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; Babior B M, 1995, Curr Opin Hematol, V2, P55; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; BUCHANAN JD, 1978, INT J RADIAT BIOL, V33, P409, DOI 10.1080/09553007814550331; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; Halliwell B, 1996, PATHOL BIOL, V44, P6; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jocelyn P. C., 1972, BIOCH SH GROUP, P94; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LI J, 1993, J PHARMACOL EXP THER, V267, P371; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MISRA HP, 1974, J BIOL CHEM, V249, P2151; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MORAS D, 1975, J BIOL CHEM, V250, P9137; MOSS J, 1983, J BIOL CHEM, V258, P6466; Moss J, 1997, ADV EXP MED BIOL, V419, P25; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE KL, 1993, PRACTICAL GUIDE PROT, P55; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WEST RE, 1985, J BIOL CHEM, V260, P4428; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19525	19531		10.1074/jbc.274.28.19525	http://dx.doi.org/10.1074/jbc.274.28.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391884	hybrid			2022-12-25	WOS:000081377300004
J	Cypess, AM; Unson, CG; Wu, CR; Sakmar, TP				Cypess, AM; Unson, CG; Wu, CR; Sakmar, TP			Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HORMONE (PTH)/PTH-RELATED PEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; SITE-DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; MEMBRANE-GLYCOPROTEINS; CONSTITUTIVE ACTIVITY; CALCITONIN RECEPTORS; MUSCARINIC RECEPTOR; SEQUENCE ALIGNMENT	The glucagon receptor is a member of a distinct class of G protein-coupled receptors (GPCRs) sharing little amino acid sequence homology with the larger rhodopsin-like GPCR family. To identify the components of the glucagon receptor necessary for G-protein coupling, we replaced sequentially all or part of each intracellular loop (i1, i2, and i3) and the C-terminal tail of the glucagon receptor with the 11 amino acids comprising the first intracellular loop of the D4 dopamine receptor. When expressed in transiently transfected COS-1 cells, the mutant receptors fell into two different groups with respect to hormone-mediated signaling. The first group included the loop i1 mutants, which bound glucagon and signaled normally. The second group comprised the loop i2 and i3 chimeras, which caused no detectable adenylyl cyclase activation in COS-1 cells. However, when expressed in HEK 293T cells, the loop i2 or i3 chimeras caused very small glucagon-mediated increases in cAMP levels and intracellular calcium concentrations, with EC50 values nearly 100-fold higher than those measured for wild-type receptor. Replacement of both loops i2 and i3 simultaneously was required to completely abolish G protein signaling as measured by both cAMP accumulation and calcium flux assays. These results show that the i2 and i3 loops play a role in glucagon receptor signaling, consistent with recent models for the mechanism of activation of G proteins by rhodopsin-like GPCRs.	Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, Box 284,1230 York Ave, New York, NY 10021 USA.		Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054718, R01DK024039] Funding Source: NIH RePORTER; NCI NIH HHS [CA09673] Funding Source: Medline; NIDDK NIH HHS [DK24039, DK54718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; Buggy JJ, 1997, DIABETES, V46, P1400, DOI 10.2337/diabetes.46.9.1400; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; Cohen DP, 1997, ENDOCRINOLOGY, V138, P1400, DOI 10.1210/en.138.4.1400; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Heller RS, 1996, BIOCHEM BIOPH RES CO, V223, P624, DOI 10.1006/bbrc.1996.0945; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LO KM, 1984, P NATL ACAD SCI USA, V91, P2285; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; Tseng CC, 1997, BIOCHEM BIOPH RES CO, V232, P96, DOI 10.1006/bbrc.1997.6231; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349	68	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19455	19464		10.1074/jbc.274.27.19455	http://dx.doi.org/10.1074/jbc.274.27.19455			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383462	hybrid			2022-12-25	WOS:000081196300085
J	Diebold, SS; Kursa, P; Wagner, E; Cotten, M; Zenke, M				Diebold, SS; Kursa, P; Wagner, E; Cotten, M; Zenke, M			Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; GENE-TRANSFER; IN-VIVO; MAMMALIAN-CELLS; PLASMID DNA; HUMAN BLOOD; ADENOVIRUS; COMPLEXES	Cell surface-bound receptors represent suitable entry sites for gene delivery into cells by receptor-mediated endocytosis. Here we have taken advantage of the mannose receptor that is highly expressed on antigen-presenting dendritic cells for targeted gene transfer by employing mannosylpolyethylenimine (ManPEI) conjugates. Several ManPEI conjugates were synthesized and used for formation of ManPEI/DNA transfection complexes. Conjugates differed in the Linker between mannose and polyethylenimine (PEI) and in the size of the PEI moiety. We demonstrate that ManPEI transfection is effective in delivering DNA into mannose receptor-expressing cells. Uptake of ManPEI/DNA complexes is receptor-specific, since DNA delivery can be competed with mannosylated albumin, Additionally, incorporation of adenovirus particles into transfection complexes effectively enhances transgene expression. This is particularly important for primary immunocompetent dendritic cells. It is demonstrated here that dendritic cells transfected with ManPEI/DNA complexes containing adenovirus particles are effective in activating T cells of T cell receptor transgenic mice in an antigen-specific fashion.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Boehringer Ingelheim Austria, A-1121 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Cotten, Matthew/0000-0002-3361-3351				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Aicher A, 1997, EXP HEMATOL, V25, P39; Arthur JF, 1997, CANCER GENE THER, V4, P17; Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002; Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219; Baker A, 1997, NUCLEIC ACIDS RES, V25, P1950, DOI 10.1093/nar/25.10.1950; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1994, VIROLOGY, V205, P254, DOI 10.1006/viro.1994.1641; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; COTTEN M, 1994, GENE THER, V1, P239; COTTEN M, 1996, CURRENT PROTOCOLS HU; Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; Diebold SS, 1999, HUM GENE THER, V10, P775, DOI 10.1089/10430349950018535; Diebold SS, 1998, ADV EXP MED BIOL, V451, P449; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Erbacher P, 1996, HUM GENE THER, V7, P721, DOI 10.1089/hum.1996.7.6-721; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Ferkol T, 1996, P NATL ACAD SCI USA, V93, P101, DOI 10.1073/pnas.93.1.101; Girolomoni G, 1997, IMMUNOL TODAY, V18, P102, DOI 10.1016/S0167-5699(97)01030-X; HOQUIST KA, 1994, CELL, V76, P17; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LEMAY P, 1980, VIROLOGY, V101, P131, DOI 10.1016/0042-6822(80)90490-0; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Ribas A, 1997, CANCER RES, V57, P2865; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Westermann J, 1998, GENE THER, V5, P264, DOI 10.1038/sj.gt.3300568; WU GY, 1987, J BIOL CHEM, V262, P4429; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	54	212	251	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19087	19094		10.1074/jbc.274.27.19087	http://dx.doi.org/10.1074/jbc.274.27.19087			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383411	hybrid			2022-12-25	WOS:000081196300034
J	Lim, YP; Low, BC; Lim, J; Wong, ESM; Guy, GR				Lim, YP; Low, BC; Lim, J; Wong, ESM; Guy, GR			Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHATASE; PC12 CELLS; IN-VITRO; ACTIVATION; ZETA; RECEPTOR; SUBSTRATE; RAS; SNT	FRS2 is a docker protein that recruits signaling proteins to the plasma membrane in fibroblast growth factor signal transduction. We report here that FRS2 was associated with PKC lambda when Swiss 3T3 cells were stimulated with basic fibroblast growth factor. PKC zeta, the other member of the atypical PKC subfamily, could also bind FRS2. The association between FRS2 and PKC lambda is likely to be direct as shown by yeast two-hybrid analysis. The C-terminal fragments of FRS2 (amino acid residues 300-508) and SNT2 (amino acids 281-492), an isoform bearing 50% identity to FRS2, interacted with PKC lambda at a region (amino acids 240-562) that encompasses the catalytic domain. In vitro kinase assays revealed neither FRS2 nor SNT2 was a substrate of PKC lambda or zeta. Mutation of the alanine residue (Ala-120) to glutamate in the pseudo-substrate region of PKC lambda results in a constitutively active kinase that exhibited more than 2-fold greater binding to FRS2 in vitro than its "closed" wildtype counterpart. Tyrosine phosphorylation of FRS2 did not affect its binding to the constitutively active PRC lambda mutant, suggesting that the activation of PKC lambda is necessary and sufficient for its association with FRS2. It is likely that FRS2 serves as an anchoring protein for targeting activated atypical PKCs to the cell plasma membrane in signaling pathways.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Jormay/A-7257-2011; Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Lim, Jormay/0000-0001-7191-545X; Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; EDURNE B, 1995, EMBO J, V14, P6157; EDURNE B, 1993, CELL, V74, P555; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lim YP, 1997, J BIOL CHEM, V272, P29892, DOI 10.1074/jbc.272.47.29892; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PLUS A, 1997, P NATL ACAD SCI USA, V94, P6191; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSEN DM, 1991, P NATL ACAD SCI USA, V88, P3997; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Wang JK, 1996, ONCOGENE, V13, P721; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	34	30	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19025	19034		10.1074/jbc.274.27.19025	http://dx.doi.org/10.1074/jbc.274.27.19025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383403	hybrid			2022-12-25	WOS:000081196300026
J	Pece, S; Chiariello, M; Murga, C; Gutkind, JS				Pece, S; Chiariello, M; Murga, C; Gutkind, JS			Activation of the protein kinase Akt PKB by the formation of E-cadherin-mediated cell-cell junctions - Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TYROSINE PHOSPHORYLATION; ALPHA-CATENIN; DIMERIZATION; EXPRESSION; TRANSITION; CARCINOMA; RECEPTORS; PHENOTYPE; SURVIVAL	E-cadherins are surface adhesion molecules localized at the level of adherens junctions, which play a major role in cell adhesiveness by mediating calcium-dependent homophylic interactions at sites of cell-cell contacts. Recently, E-cadherins have been also implicated in a number of biological processes, including cell growth and differentiation, cell recognition, and sorting during developmental morphogenesis, as well as in aggregation-dependent cell survival. As phosphatidylinositol (PI) 3-kinase and Akt play a critical role in survival pathways in response to both growth factors and extracellular stimuli, these observations prompted us to explore whether E-cadherins could affect intracellular molecules regulating the activity of the PI 3-kinase/Akt signaling cascade. Using Madin-Darby canine kidney cells as a model system, we show here that engagement of E-cadherins in homophylic calcium-dependent cell cell interactions results in a rapid PI 3-kinase-dependent activation of Akt and the subsequent translocation of Akt to the nucleus. Moreover, we demonstrate that the activation of PI 3-kinase in response to cell-cell contact formation involves the phosphorylation of PI 3-kinase in tyrosine residues, and the concomitant recruitment of PI 3-kinase to E-cadherin-containing protein complexes. These findings indicate that E-cadherins can initiate outside-in signal transducing pathways that regulate the activity of PI 3-kinase and Akt, thus providing a novel molecular mechanism whereby the interaction among neighboring cells and their adhesion status may ultimately control the fate of epithelial cells.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Pece, Salvatore/B-9609-2013; Murga, Cristina/E-1965-2014	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482; Pece, Salvatore/0000-0003-1764-3929; Murga, Cristina/0000-0002-8964-4077				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; KINEH MS, 1995, J CELL BIOL, V130, P461; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Simard D, 1996, BIOCHEM BIOPH RES CO, V219, P122, DOI 10.1006/bbrc.1996.0192; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Toyoyama H, 1999, ONCOL REP, V6, P81; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	32	235	242	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19347	19351		10.1074/jbc.274.27.19347	http://dx.doi.org/10.1074/jbc.274.27.19347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383446	hybrid			2022-12-25	WOS:000081196300069
J	Racz, A; Barsony, J				Racz, A; Barsony, J			Hormone-dependent translocation of vitamin D receptors is linked to transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; 1,25-DIHYDROXYVITAMIN D-3 RECEPTOR; TRANSCRIPTION FACTOR IIB; GLUCOCORTICOID RECEPTOR; LIVING CELLS; ACTIVATION FUNCTION-2; NUCLEAR-LOCALIZATION; BASAL TRANSCRIPTION; DNA-BINDING; DOMAIN	Vitamin D receptor (VDR) acts as a transcription factor mediating genomic actions of calcitriol. Our earlier studies suggested that calcitriol induces translocation of cytoplasmic VDR, but the physiologic relevance of this finding remained uncertain. Previous studies demonstrated that the activation function 2 domain (AF-2) plays an essential role in VDR transactivation. To elucidate hormone-dependent VDR translocation and its role, we constructed green fluorescent protein (GFP) chimeras with full-length VDR (VDR-GFP), AF-2-truncated VDR (AF-2del-VDR-GFP), and ligand-binding domain LBD)-truncated VDR (LBDdel-VDR-GFP), COS-7 cells were transiently transfected with these constructs. Western blot analysis, fluorescent microscopy, and transactivation assays showed that the generated chimeras are expressed and fluoresce and that VDR-GFP is transcriptionally active. After hormone treatment, cytoplasmic VDR-GFP translocated to the nucleus in a concentration-, time-, temperature-, and analog-specific manner. Hormone dose-response relationships for translocation and for transactivation were similar. Truncation of LED and truncation of AF-2 each abolished hormone-dependent translocation and transactivation. Our data confirm a hormone-dependent VDR translocation, demonstrate that an intact AF-2 domain is required for this translocation, and indicate that translocation is part of the receptor activation process.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Barsony, J (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 422,8 Ctr Dr, Bethesda, MD 20892 USA.	jul@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060051, Z01DK060050] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BLIZIOTES M, 1988, J CLIN ENDOCR METAB, V66, P294, DOI 10.1210/jcem-66-2-294; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DeLuca H F, 1985, Soc Gen Physiol Ser, V39, P159; DeLuca HF, 1998, NUTR REV, V56, pS4; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Georget V, 1998, J CLIN ENDOCR METAB, V83, P3597, DOI 10.1210/jc.83.10.3597; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Hager GL, 1998, J STEROID BIOCHEM, V65, P125, DOI 10.1016/S0960-0760(97)00178-7; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; HSU SC, 1995, J BIOL CHEM, V270, P3359, DOI 10.1074/jbc.270.7.3359; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Johnson JA, 1996, HISTOCHEM CELL BIOL, V105, P7, DOI 10.1007/BF01450873; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Nayeri S, 1996, NUCLEIC ACIDS RES, V24, P4513, DOI 10.1093/nar/24.22.4513; Norman AW, 1996, J STEROID BIOCHEM, V56, P13, DOI 10.1016/0960-0760(95)00219-7; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SMITH CL, 1991, MOL ENDOCRINOL, V5, P867, DOI 10.1210/mend-5-6-867; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; WIESE RJ, 1993, MOL CELL ENDOCRINOL, V90, P197, DOI 10.1016/0303-7207(93)90152-A; Zanello SB, 1997, HORM METAB RES, V29, P231, DOI 10.1055/s-2007-979027; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	43	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19352	19360		10.1074/jbc.274.27.19352	http://dx.doi.org/10.1074/jbc.274.27.19352			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383447	hybrid			2022-12-25	WOS:000081196300070
J	Sarret, P; Nouel, D; Dal Farra, C; Vincent, JP; Beaudet, A; Mazella, J				Sarret, P; Nouel, D; Dal Farra, C; Vincent, JP; Beaudet, A; Mazella, J			Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; RAT NEUROTENSIN RECEPTOR; MESSENGER-RNA; TUMOR-CELLS; SIGNAL-TRANSDUCTION; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; DESENSITIZATION; SUBTYPE; ENDOCYTOSIS	The inhibitory effect of the neuropeptide somatostatin on the expression of growth hormone was measured by quantitative polymerase chain reaction in the pituitary cell line AtT-20. We demonstrate that this effect is dependent on the internalization of somatostatin-receptor complexes and that it is totally independent from the peptide-induced inhibition of adenylate cyclase. Indeed, the inhibitory effect of the peptide on growth hormone mRNA levels was totally insensitive to pertussis toxin treatment but was totally abolished under conditions which block somatostatin receptor internalization. Comparative confocal microscopic imaging of fluorescent somatostatin sequestration and fluorescence immunolabeling of sst1, sst2A, and sst5 receptors suggests that sst2A is most probably responsible of the inhibitory effect of somatostatin on growth hormone expression.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Mazella, Jean/A-6767-2012	Sarret, Philippe/0000-0002-7627-701X				Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dournaud P, 1998, J NEUROSCI, V18, P1056; Dournaud P, 1996, J NEUROSCI, V16, P4468; DRAZNIN B, 1985, ENDOCRINOLOGY, V117, P960, DOI 10.1210/endo-117-3-960; EPELBAUM J, 1994, CRIT REV NEUROBIOL, V8, P25; Garland AM, 1996, MOL PHARMACOL, V49, P438; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Girardin SE, 1998, FEBS LETT, V431, P333, DOI 10.1016/S0014-5793(98)00787-X; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Koenig JA, 1998, BIOCHEM J, V336, P291, DOI 10.1042/bj3360291; Koenig JA, 1997, BRIT J PHARMACOL, V120, P52, DOI 10.1038/sj.bjp.0700859; LAMBERTS SWJ, 1991, INT J CANCER, V48, P938, DOI 10.1002/ijc.2910480623; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LINZER DIH, 1985, J BIOL CHEM, V260, P9574; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; LUINI A, 1986, J NEUROSCI, V6, P3128; MOREL G, 1986, ENDOCRINOLOGY, V119, P1972, DOI 10.1210/endo-119-5-1972; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PATEL YC, 1990, METABOLISM, V39, P63, DOI 10.1016/0026-0495(90)90214-W; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PATEL YC, 1994, J BIOL CHEM, V269, P1506; Patel YC, 1996, METABOLISM, V45, P31, DOI 10.1016/S0026-0495(96)90076-1; PETEN EP, 1993, KIDNEY INT, V43, pS55; Reisine T, 1995, AM J PHYSIOL-GASTR L, V269, pG813, DOI 10.1152/ajpgi.1995.269.6.G813; REISINE T, 1990, METABOLISM, V39, P70, DOI 10.1016/0026-0495(90)90215-X; REISINE T, 1985, ENDOCRINOLOGY, V116, P2259, DOI 10.1210/endo-116-6-2259; REISINE T, 1995, NEUROSCIENCE, V67, P777, DOI 10.1016/0306-4522(95)00072-Q; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; Sarret P, 1998, NEUROENDOCRINOLOGY, V68, P37, DOI 10.1159/000054348; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; Souaze F, 1997, J BIOL CHEM, V272, P10087; STROH T, 1993, NEUROSCI LETT, V160, P145, DOI 10.1016/0304-3940(93)90399-6; SUGIHARA H, 1993, ENDOCRINOLOGY, V132, P1225, DOI 10.1210/en.132.3.1225; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THORNER MO, 1990, METABOLISM, V39, P40, DOI 10.1016/0026-0495(90)90207-S; WOOD DF, 1987, MOL CELL ENDOCRINOL, V52, P257, DOI 10.1016/0303-7207(87)90052-9; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMADA M, 1994, MOL PHARMACOL, V46, P470; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; YU SS, 1993, J BIOL CHEM, V268, P337	58	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19294	19300		10.1074/jbc.274.27.19294	http://dx.doi.org/10.1074/jbc.274.27.19294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383439	hybrid			2022-12-25	WOS:000081196300062
J	Lind, U; Greenidge, P; Gustafsson, JA; Wright, APH; Carlstedt-Duke, J				Lind, U; Greenidge, P; Gustafsson, JA; Wright, APH; Carlstedt-Duke, J			Valine 571 functions as a regional organizer in programming the glucocorticoid receptor for differential binding of glucocorticoids and mineralocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SINGLE AMINO-ACID; C-TERMINUS; CRYSTAL-STRUCTURE; POINT MUTATIONS; YEAST-CELLS; DOMAIN; TRANSACTIVATION; EXPRESSION; SPECIFICITY	The glucocorticoid receptor (GR) interacts specifically with glucocorticoids, whereas its closest relative, the mineralocorticoid receptor (MR), interacts with both glucocorticoids and mineralocorticoids, such as aldosterone. To investigate the mechanism underlying the glucocorticoid/mineralocorticoid specificity of the GR, we used a yeast model system to screen for GR ligand-binding domain mutants, substituted with MR residues in the segment 565-574, that can be efficiently activated by aldosterone. In all such increased activity mutants, valine 571 was replaced by methionine, even though most mutants also contained substitutions of other residues with their MR counterparts, Further analysis in yeast and COS-7 cells has revealed that the identity of residue 571 determines the behavior of other MR substituted residues in the 565-574 segment. Generally, MR substitutions in this region are only consistent with aldosterone binding if residue 571 is also replaced with methionine (MR conformation). If residue 571 is valine (GR conformation), most other MR substitution mutants drastically reduce interaction with both mineralocorticoid and glucocorticoid hormones. Eased on these functional data, we hypothesize that residue 571 functions as a regional organizer involved in discriminating between glucocorticoid and mineralocorticoid hormones, We have used a molecular model of the GR ligand-binding domain in an attempt to interpret our functional data in structural terms.	Huddinge Hosp, Karolinska Inst, Dept Med Nutr, Novum, S-14186 Huddinge, Sweden; Karo Bio AB, Novum, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Sodertorns Hogskola, S-14104 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodertorn University	Lind, U (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med Nutr, Novum, S-14186 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHEN DG, 1994, J BIOL CHEM, V269, P7914; CHEN DG, 1994, MOL ENDOCRINOL, V8, P422, DOI 10.1210/me.8.4.422; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KAISER P, 1993, BIOTECHNIQUES, V14, P552; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lind U, 1996, MOL ENDOCRINOL, V10, P1358, DOI 10.1210/me.10.11.1358; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MILHON J, 1994, J STEROID BIOCHEM, V51, P11, DOI 10.1016/0960-0760(94)90110-4; Miller WL., 1995, ENDOCRINOL METAB, P555; Parker MG, 1996, NAT STRUCT BIOL, V3, P113, DOI 10.1038/nsb0296-113; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; VELDHUIS HD, 1982, ENDOCRINOLOGY, V110, P2044, DOI 10.1210/endo-110-6-2044; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	36	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18515	18523		10.1074/jbc.274.26.18515	http://dx.doi.org/10.1074/jbc.274.26.18515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373460	hybrid			2022-12-25	WOS:000081056700052
J	Asano, K; Hama, C; Inoue, S; Moriwaki, H; Mizobuchi, K				Asano, K; Hama, C; Inoue, S; Moriwaki, H; Mizobuchi, K			The plasmid ColI-P9 antisense inc RNA controls expression of the repZ replication protein and its positive regulator repY with different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; RIBOSOME-BINDING; GENE-EXPRESSION; COLIB-P9; TRANSLATION; INITIATION; CLONING; PSEUDOKNOT; SEQUENCES; COLLB-P9	The autonomous replication region of plasmid CoIIb-P9 contains repZ encoding the RepZ replication protein, and inc and repY as the negative and positive regulators of repZ translation, respectively, inc encodes the anti-sense Inc RNA, and repY is a short open reading frame upstream of repZ. Translation of repY enables repZ translation by inducing formation of a pseudoknot containing stem-loop I, which base pairs with the sequence preceding the repZ start codon. Inc RNA inhibits both repY translation and formation of the pseudoknot by binding to the loop I. To investigate control of repY expression by Inc RNA, we isolated a number of mutations that express repY in the presence of Inc RNA One class of mutations delete a part of another stem-loop (II), which derepresses repY expression by initiating translation at codon 10 (CUG), located within this structure, Point mutations in stern-loop II can also derepress repY translation, and the introduction of compensatory base-changes restores control of repY translation. These results not only indicate that suppressing a cryptic Start codon by secondary structure is important for maintaining the translational control of repZ but also demonstrate that the position of start site for repY translation is critical for its control by Inc RNA. Thus, Inc RNA controls repY translation by binding in the vicinity of the start codon, in contrast to the control of repZ expression at the level of loop-loop interaction.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan; Univ Electrocommun, Dept Appl Phys & Chem, Tokyo 182, Japan	University of Tokyo; University of Electro-Communications - Japan	Asano, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan.							Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1998, J BIOL CHEM, V273, P11826, DOI 10.1074/jbc.273.19.11826; ASANO K, 1991, J BIOL CHEM, V266, P3774; Asano K, 1998, EMBO J, V17, P5201, DOI 10.1093/emboj/17.17.5201; ASANO K, 1991, J BIOL CHEM, V266, P24549; Asano K, 1998, J BIOL CHEM, V273, P11815, DOI 10.1074/jbc.273.19.11815; BLOMBERG P, 1994, MOL MICROBIOL, V12, P49, DOI 10.1111/j.1365-2958.1994.tb00994.x; BLOMBERG P, 1992, EMBO J, V11, P2675, DOI 10.1002/j.1460-2075.1992.tb05333.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; GUSSIN GN, 1966, COLD SPRING HARB SYM, V31, P257, DOI 10.1101/SQB.1966.031.01.034; HAMA C, 1990, J BACTERIOL, V172, P1983, DOI 10.1128/jb.172.4.1983-1991.1990; HAMA C, 1990, J BIOL CHEM, V265, P10666; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Kato A, 1994, DNA Res, V1, P201, DOI 10.1093/dnares/1.5.201; MA CK, 1994, MOL MICROBIOL, V14, P1033, DOI 10.1111/j.1365-2958.1994.tb01337.x; Malmgren C, 1997, J BIOL CHEM, V272, P12508, DOI 10.1074/jbc.272.19.12508; Malmgren C, 1996, RNA, V2, P1022; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick WC., 1996, TRANSLATION CONTROL, P31; Miller JH., 1972, EXPT MOL GENETICS; MORI A, 1995, MOL MICROBIOL, V17, P291, DOI 10.1111/j.1365-2958.1995.mmi_17020291.x; MURRAY NE, 1974, NATURE, V251, P476, DOI 10.1038/251476a0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PRASKIER J, 1991, J BACTERIOL, V161, P2393; SHIBA K, 1990, J BACTERIOL, V172, P1992, DOI 10.1128/jb.172.4.1992-1997.1990; SIEMERING KR, 1993, J BACTERIOL, V175, P2895, DOI 10.1128/JB.175.10.2895-2906.1993; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STEITZ JA, 1975, RNA PHAGES, P319; TANAKA K, 1992, NUCLEIC ACIDS RES, V20, P2705, DOI 10.1093/nar/20.11.2705; Voorma H. O., 1996, TRANSLATIONAL CONTRO, p[759, 759]; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WILSON IW, 1994, J BACTERIOL, V176, P6497, DOI 10.1128/JB.176.21.6497-6508.1994; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17924	17933		10.1074/jbc.274.25.17924	http://dx.doi.org/10.1074/jbc.274.25.17924			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364239	hybrid			2022-12-25	WOS:000080974300075
J	Costello, LC; Liu, YY; Zou, J; Franklin, RB				Costello, LC; Liu, YY; Zou, J; Franklin, RB			Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; EPITHELIAL-CELLS; CITRATE METABOLISM; GENE ENCODES; PROTEIN	The glandular epithelial cells of the human prostate gland have the unique capability and function of accumulating the highest zinc levels of any soft tissue in the body. Zinc accumulation in the prostate is regulated by prolactin and testosterone; however, little information is available concerning the mechanisms associated with zinc accumulation and its regulation in prostate epithelial cells. In the present studies the uptake and accumulation of zinc were determined in the human malignant prostate cell lines LNCaP and PC-3. The results demonstrate that LNCaP cells and PC-3 cells possess the unique capability of accumulating high levels of zinc. Zinc accumulation in both cell types is stimulated by physiological concentrations of prolactin and testosterone. The studies reveal that these cells contain a rapid zinc uptake process indicative of a plasma membrane zinc transporter. Initial kinetic studies demonstrate that the rapid uptake of zinc is effective under physiological conditions that reflect the total and mobile zinc levels in circulation. Correspondingly, genetic studies demonstrate the expression of a ZIP family zinc uptake transporter in both LNCaP and PC-3 cells. The rapid zinc uptake transport process is stimulated by treatment of cells with physiological levels of prolactin and testosterone, which possibly is the result of the regulation of the ZIP-type zinc transporter gene. These zinc-accumulating characteristics are specific for prostate cells. The studies support the concept that these prostate cells express a unique hormone-responsive, plasma membrane-associated, rapid zinc uptake transporter gene associated with their unique ability to accumulate high zinc levels.	Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Cellular & Mol Biol Sect, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Costello, LC (corresponding author), Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Cellular & Mol Biol Sect, 666 W Baltimore St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA071207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028015] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71207] Funding Source: Medline; NIDDK NIH HHS [DK 28015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; Costello LC, 1998, PROSTATE, V35, P285, DOI 10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F; COSTELLO LC, 1994, CELL MOL BIOL, V39, P515; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Franklin R. B., 1997, PROSTATE BASIC CLIN, P115; Franklin RB, 1997, MOL CELL ENDOCRINOL, V127, P19, DOI 10.1016/S0303-7207(96)03972-X; FRANKLIN RB, 1990, PROSTATE, V16, P137, DOI 10.1002/pros.2990160205; FRANKLIN RB, 1993, ENDOCR J, V3, P603; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; JUANG HH, 1995, J BIOL CHEM, V270, P12629, DOI 10.1074/jbc.270.21.12629; KAVANAGH JP, 1983, J REPROD FERTIL, V69, P359; LAO LX, 1993, PROSTATE, V22, P53, DOI 10.1002/pros.2990220108; LARUE JP, 1984, ENDOCR RES, V10, P183, DOI 10.3109/07435808409035418; LARUE JP, 1984, ENDOCR RES, V10, P171, DOI 10.3109/07435808409035417; Liu Y, 1997, PROSTATE, V30, P26, DOI 10.1002/(SICI)1097-0045(19970101)30:1<26::AID-PROS4>3.0.CO;2-J; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; ROSOFF B, 1981, PROSTATIC CELL STRUC, P447; Suhy DA, 1996, MET IONS BIOL SYST, V32, P557; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	24	186	188	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17499	17504		10.1074/jbc.274.25.17499	http://dx.doi.org/10.1074/jbc.274.25.17499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364181	hybrid			2022-12-25	WOS:000080974300017
J	Gibson, S; Tu, S; Oyer, R; Anderson, SM; Johnson, GL				Gibson, S; Tu, S; Oyer, R; Anderson, SM; Johnson, GL			Epidermal growth factor protects epithelial cells against Fas-induced apoptosis - Requirement for Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B C-AKT; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; BREAST-CANCER; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; PRIMARY CULTURE; DEATH; PHOSPHORYLATION; EXPRESSION	Chemotherapeutic drugs that damage DNA kill tumor cells, in part, by inducing the expression of a death receptor such as Fas or its ligand, FastL. Here, we demonstrate that epidermal growth factor (EGF) stimulation of T47D breast adenocarcinoma and embryonic kidney epithelial (HEK293) cells protects these cells from Fas-induced apoptosis. EGF stimulation of epithelial cells also inhibited Fas-induced caspase activation and the proteolysis of signaling proteins downstream of the EGF receptor, Cbl and Akt/protein kinase B (Akt), EGF stimulation of Akt kinase activity blocked Fas-induced apoptosis. Expression of activated Akt in MCF-7 breast adenocarcinoma cells was sufficient to block Fas-mediated apoptosis, Inhibition of EGF-stimulated extracellular signal-regulated kinase (ERK) activity did not affect EGF protection from Fas-mediated apoptosis. The findings indicate that EGF receptor stimulation of epithelial cells has a significant survival function against death receptor-induced apoptosis mediated by Akt.	Univ Colorado, Sch Med, Program Mol Signal Transduct, Div Basic Sci,Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gibson, S (corresponding author), Univ Colorado, Sch Med, Program Mol Signal Transduct, Div Basic Sci,Natl Jewish Med & Res Ctr, Denver, CO 80206 USA.	johnsonlab@nju.org		Tu, S. Sean/0000-0003-0391-8186; Gibson, Spencer/0000-0003-0119-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48845, DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson CNG, 1999, J NEUROSCI, V19, P664; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GRUBER J, 1994, INT ARCH ALLERGY IMM, V105, P368, DOI 10.1159/000236785; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hodge S, 1998, VIROLOGY, V252, P354, DOI 10.1006/viro.1998.9477; Ilio KY, 1995, J ANDROL, V16, P482; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; O'Connor Rosemary, 1998, V62, P137; Porras A, 1997, FEBS LETT, V416, P324, DOI 10.1016/S0014-5793(97)01204-0; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Rusch Valerie, 1996, Cytokine and Growth Factor Reviews, V7, P133, DOI 10.1016/1359-6101(96)00016-0; Sterle M, 1997, BIOL CELL, V89, P263, DOI 10.1016/S0248-4900(97)82314-3; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Walker PR, 1998, CURR OPIN IMMUNOL, V10, P564, DOI 10.1016/S0952-7915(98)80225-2; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	42	226	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17612	17618		10.1074/jbc.274.25.17612	http://dx.doi.org/10.1074/jbc.274.25.17612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364198	hybrid			2022-12-25	WOS:000080974300034
J	Hikita, C; Takito, J; Vijayakumar, S; Al-Awqati, Q				Hikita, C; Takito, J; Vijayakumar, S; Al-Awqati, Q			Only multimeric hensin located in the extracellular matrix can induce apical endocytosis and reverse the polarity of intercalated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELL; URINARY ACIDIFICATION; FIBRONECTIN MATRIX; SRCR SUPERFAMILY; DOMAIN; RECEPTORS; PROTEINS	When an intercalated epithelial cell line was seeded at low density and allowed to reach confluence, it located the anion exchanger band 3 in the apical membrane and an H+-ATPase in the basolateral membrane, The same clonal cells seeded at high density targeted these proteins to the reverse location. Furthermore, high density cells had vigorous apical endocytosis, and low density cells had none. The extracellular matrix of high density cells was capable of inducing apical endocytosis and relocation of band 3 to the basolateral membrane in low density cells. A 230-kDa extracellular matrix (ECM) protein termed hensin, when purified to near-homogeneity, was able to reverse the phenotype of the low density cells. Antibodies to hensin prevented this effect, indicating that hensin is necessary for conversion of polarity. We show here that hensin was synthesized by both low density and high density cells. Whereas both phenotypes secreted soluble hensin into their media, only high density cells localized it in their ECM, Analysis of soluble hensin by sucrose density gradients showed that low density cells secreted monomeric hensin, and high density cells secreted higher order multimers, When S-35-labeled monomeric hensin was added to high density cells, they induced its aggregation suggesting that the multimerization was catalyzed by surface events in the high density cells. Soluble monomeric or multimeric hensin did not induce apical endocytosis in low density cells, whereas the more polymerized hensin isolated from insoluble ECM readily induced it. These multimers could be disaggregated by sulfhydryl reagents and by dimethylmaleic anhydride, and treatment of high density ECM by these reagents prevented the induction of endocytosis. These results demonstrate that hensin, like several ECM proteins, needs to be precipitated in the ECM to be functional.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Al-Awqati, Q (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NCRR NIH HHS [RR10506] Funding Source: Medline; NIDDK NIH HHS [DK-39532, DK-20999] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020999, R01DK039532, R37DK020999] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Awqati Q, 1998, AM J PHYSIOL-RENAL, V275, pF183, DOI 10.1152/ajprenal.1998.275.2.F183; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; Kadler KE, 1996, BIOCHEM J, V316, P1; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; MEANS GE, 1971, CHEM MODIFICATION PR, P76; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Sanderson IR, 1996, P NATL ACAD SCI USA, V93, P7717, DOI 10.1073/pnas.93.15.7717; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; TAKITO J, 1999, IN PRESS AM J PHYSL; TAKITO J, 1996, J CLIN INVEST, V98, P2325; VANADELSBERG J, 1994, CELL, V76, P1053, DOI 10.1016/0092-8674(94)90382-4; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; Vijayakumar S, 1999, J CELL BIOL, V144, P1057, DOI 10.1083/jcb.144.5.1057; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	27	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17671	17676		10.1074/jbc.274.25.17671	http://dx.doi.org/10.1074/jbc.274.25.17671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364206	hybrid			2022-12-25	WOS:000080974300042
J	Pond, L; Watts, C				Pond, L; Watts, C			Functional early endosomes are required for maturation of major histocompatibility complex class II molecules in human B lymphoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-II; INVARIANT CHAIN COMPLEXES; ENDOCYTIC PATHWAY; SUBCELLULAR COMPARTMENTS; LYSOSOMAL COMPARTMENTS; INTRACELLULAR PATHWAY; PEPTIDE COMPLEXES; CYTOPLASMIC TAIL; GOLGI-COMPLEX; HLA ANTIGENS	Major histocompatibility complex (MHC) class II molecules are targeted together with their invariant chain (Ii) chaperone from the secretory pathway to the endocytic pathway. Within the endosome/lysosome system, Ii must be degraded to enable peptide capture by MHC class II molecules. It remains controversial exactly which route or routes MHC class II/Ii complexes take to reach the sites of Ii processing and peptide loading. We have asked whether early endosomes are required for successful maturation of MHC class II molecules by using an in situ peroxidase/diaminobenzidine compartment ablation technique. Cells whose early endosomes were selectively ablated using transferrin-horseradish peroxidase conjugates fail to mature their newly synthesized MHC class II molecules. We show that whereas transport of secretory Ig through the secretory pathway is virtually normal in the ablated cells, newly synthesized MHC class II/Ii complexes never reach compartments capable of processing Ii. These results strongly suggest that the transport of the bulk of newly synthesized MHC class II molecules through early endosomes is obligatory and that direct input into later endosomes/lysosomes does not take place.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bldg, Dundee DD1 4HN, Scotland.			Watts, Colin/0000-0001-6183-2087				AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KOCH N, 1991, J IMMUNOL, V147, P2643; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MORTON PA, 1995, J IMMUNOL, V154, P137; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1993, J CELL SCI, V106, P831; Pond L, 1997, J IMMUNOL, V159, P543; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; QUARANTA V, 1984, J IMMUNOL, V132, P1900; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; Saudrais C, 1998, J IMMUNOL, V160, P2597; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18049	18054		10.1074/jbc.274.25.18049	http://dx.doi.org/10.1074/jbc.274.25.18049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364256	hybrid			2022-12-25	WOS:000080974300092
J	Wang, MY; Lee, Y; Unger, RH				Wang, MY; Lee, Y; Unger, RH			Novel form of lipolysis induced by leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LEPTIN; NORMAL RATS; ADIPOCYTES; EXPRESSION	Hyperleptinemia causes disappearance of body fat without a rise in free fatty acids (FFA) or ketones, suggesting that leptin can deplete adipocytes of fat without releasing FFA. To test this, we measured FFA and glycerol released from adipocytes obtained from normal lean Zucker diabetic fatty rats (+/+) and incubated for 0, 3, 6, or 24 h in either 20 ng/ml recombinant leptin or 100 nM norepinephrine (NE). Whereas NE increased both FFA and glycerol release from adipocytes of +/+ rats, leptin increased glycerol release in +/+ adipocytes without a parallel increase in FFA release. In adipocytes of obese Zucker diabetic fatty rats (fa/fa) with defective leptin receptors, NE increased both FFA and glycerol release, but leptin had no effect on either. Leptin significantly lowered the mRNA of leptin and fatty acid synthase of adipocytes (FAS) (P < 0.05), and up-regulated the mRNA of peroxisome proliferator-activated receptor (PPAR)-alpha, carnitine palmitoyl transferase-1, (CPT-P), and acyl CoA oxidase (ACO) (p < 0.05). NE (100 nM) also lowered leptin mRNA (p < 0.05) but did not affect FAS, PPAR alpha, AGO, or CPT-1 expression. We conclude that in normal adipocytes leptin directly decreases FAS expression, increases PPAR alpha and the enzymes of FFA oxidation, and stimulates a novel form of lipolysis in which glycerol is released without a proportional release of FFA.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Adm Med Ctr, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Runger@mednet.SWmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002700, R37DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; RODBELL M, 1964, J BIOL CHEM, V239, P375; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sivitz WI, 1998, METABOLISM, V47, P584, DOI 10.1016/S0026-0495(98)90244-X; SLAVIN BG, 1994, J LIPID RES, V35, P1535; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tasaka Y, 1997, ENDOCR J, V44, P671, DOI 10.1507/endocrj.44.671; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	17	282	294	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17541	17544		10.1074/jbc.274.25.17541	http://dx.doi.org/10.1074/jbc.274.25.17541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364187	hybrid			2022-12-25	WOS:000080974300023
J	Woulfe, DS; Stadel, JM				Woulfe, DS; Stadel, JM			Structural basis for the selectivity of the RGS protein, GAIP, for G alpha(i) family members - Identification of a single amino acid determinant for selective interaction of G alpha(i) subunits with GAIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; G-ALPHA PROTEINS; SIGNAL-TRANSDUCTION; IN-VITRO; TRANSITION-STATE; PHOSPHOLIPASE-C; POINT MUTATION; CORE DOMAIN; INHIBITION	GAIP is a regulator of G protein signaling (RGS) that accelerates the rate of GTP hydrolysis by some G protein alpha subunits, In the present studies, we have examined the structural basis for the ability of GAIP to discriminate among members of the G alpha(i) family. G alpha(il), G alpha(i3), and G alpha(o) interacted strongly with GAIP, whereas G alpha(i2), interacted weakly and G alpha(S) did not interact at all. A chimeric: G: protein composed of a G alpha(i2), N terminus and a G alpha(il) C terminus interacted as strongly with GAIP as native G alpha(il), whereas a chimeric N-terminal G alpha(il), with a G alpha(i2), C terminus did not interact. These results suggest that the determinants responsible for GAIP selectivity between these two G alpha(i)S reside within the C-terminal GTPase domain of the G protein. To further localize residues contributing to G protein-GAIP selectivity, a panel of 15 site-directed G alpha(il) and G alpha(i2) mutants were assayed. Of the Gcu,, mutants tested, only that containing a mutation at aspartate 229 located at the N terminus of Switch 3 did not interact with GAIP. Furthermore, the only Gar, variant that interacted strongly with GAIP contained a replacement of the corresponding G alpha(i2) Switch 3 residue (Ala(230)) with aspartate. To determine whether GAIP showed lRmetional preferences for Gac subunits that correlate with the binding data, the ability of GALP to enhance the GTPase activity of purified cu subunits was tested. GAIP catalyzed a 3-5-fold increase in the rate of GTP hydrolysis by Get,, and G alpha(i2)(A230D) but no increase in the rate of G alpha(i2) and less than a 2-fold increase in the rate of G alpha(il)(D229A) under the same conditions, Thus, GAIP was able to discriminate between G alpha(il) and G alpha(i2) in both binding and functional assays, and in both Gases residue 229/230 played a critical role in selective recognition.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	University of Pennsylvania; GlaxoSmithKline	Woulfe, DS (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2,Rm 913, Philadelphia, PA 19104 USA.							Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HUNT TW, 1996, NATURE, V383, P176; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miller JH., 1972, EXPT MOL GENETICS; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; STADEL JM, 1997, TRENDS PHARMACOL SCI, V11, P190; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	37	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17718	17724		10.1074/jbc.274.25.17718	http://dx.doi.org/10.1074/jbc.274.25.17718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364213	Green Submitted, hybrid			2022-12-25	WOS:000080974300049
J	Davies, J; Badiani, P; Weston, K				Davies, J; Badiani, P; Weston, K			Cooperation of Myb and Myc proteins in T cell lymphomagenesis	ONCOGENE			English	Article						myb; myc; lymphoma	TRANSGENIC MICE; LEUKEMIA-VIRUS; C-MYC; INFECTION; ONCOGENE; REARRANGEMENT; RETROVIRUSES; SENSITIVITY; EXPRESSION; INVITRO	The v-Myb oncogene causes late onset T cell lymphomas when expressed in the T cell lineage of transgenic mice. In order to define the cellular mutations cooperating with v-Myb to cause lymphomas, we have infected v-Myb transgenic mice with Moloney murine leukemia virus (M-MuLV). Tumor formation is significantly accelerated from a mean age of onset of 60 weeks in uninfected vMyb transgenics to 13 weeks in infected vMyb transgenics. We studied the loci into which the M-MuLV had inserted, and found that in 73% of animals, either the c-myc or the N-myc genes had been disrupted and deregulated. Therefore, v-myb and c-myb can cooperate to induce T cell lymphomas.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Badiani PA, 1996, ONCOGENE, V13, P2205; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GISSELBRECHT S, 1978, INT J CANCER, V21, P626, DOI 10.1002/ijc.2910210513; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; HARTLEY JW, 1983, J EXP MED, V158, P16, DOI 10.1084/jem.158.1.16; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SHINTO Y, 1995, ONCOGENE, V11, P1729; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VILLENEUVE L, 1993, J VIROL, V67, P5733, DOI 10.1128/JVI.67.10.5733-5739.1993; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	28	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3643	3647		10.1038/sj.onc.1202956	http://dx.doi.org/10.1038/sj.onc.1202956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380886				2022-12-25	WOS:000080891700010
J	Jones, FE; Stern, DF				Jones, FE; Stern, DF			Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation	ONCOGENE			English	Article						ErbB2; dominant negative receptor mutant; transgenic mice; mammary gland development	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; FACTOR RECEPTOR FAMILY; EGF RECEPTOR; DUCTAL MORPHOGENESIS; KINASE-ACTIVITY; NEU ONCOGENE; DIFFERENTIATION; ACTIVATION; PROTEIN	Overexpression of the receptor tyrosine kinase ErbB2/HER2/Neu (ErbB2) occurs in 15-40% of human breast cancers. To determine the function of ErbB2 signaling during normal mouse mammary gland development, me expressed a carboxyl-terminal truncated dominant negative allele of ErbB2 (ErbB2 Delta IC) in the developing mouse mammary gland. Despite ErbB2 Delta IC expression within mammary glands of pubescent virgin and pregnant mice, a phenotype was not observed until late in pregnancy. At 1 day post-partum, lactationally active, distended lobuloalveoli failed to form. This phenotype was exaggerated in multiparous females expressing ErbB2 Delta IC. Immunohistochemical staining for ErbB2 Delta IC revealed a concordance between high levels of ErbB2 Delta IC protein expression and the absence of lactational products within the lumens of ErbB2 Delta IC stained lobuloalveoli. These results demonstrate that ErbB2 signaling is required for proper mammary development and lactation at parturition.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, BML-342,POB 208023, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DiAugustine RP, 1997, J MAMMARY GLAND BIOL, V2, P109, DOI 10.1023/A:1026395513038; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vonderhaar B, 1984, CONTROL CELL GROWTH, P11; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yoo JY, 1998, MOL CELL ENDOCRINOL, V138, P163, DOI 10.1016/S0303-7207(98)00004-5	53	89	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3481	3490		10.1038/sj.onc.1202698	http://dx.doi.org/10.1038/sj.onc.1202698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376526				2022-12-25	WOS:000080850600006
J	Huang, CS; Ma, WY; Dong, ZG				Huang, CS; Ma, WY; Dong, ZG			The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells	ONCOGENE			English	Article						UV; Erks; JNKs; AP-1	GROWTH-FACTOR RECEPTORS; C-JUN; COUPLED RECEPTORS; TYROSINE KINASES; MAP KINASES; TRANSFORMATION; PHOSPHORYLATION; TRANSDUCTION; PATHWAYS; SPHINGOMYELINASE	Mitogen activated protein (MAP) kinase belongs to a large family of serine/threonine protein kinases, including extracellular-signal-regulated protein kinases (Erks), P38 kinase and c-Jun N-terminal kinases (JNKs), Although previous work has shown that both Erks and JNKs are activated in cells in response to ultraviolet (UV) irradiation, most studies have focused only on the role of JNKs in UV-induced AP-1 activation. Hence, the role of Erks in UV-induced AP-1 activity is not well defined. We here have investigated this issue by using MAP kinase kinase (MEK,) inhibitor PD098059 and a dominant negative Erk2, as a ell as wild-type Erk2, in a JB6 cell model. PD098059 inhibited UVB- or UVC-induced AP-1 activity and phosphorylation of MEK1, and Erks, but not JNKs, in JB6 Cl 41 cells. Overexpression of mild-type Erk2 in Cl 30.7b cells that contain small amounts of Erks caused a 46.6- or 138.1-fold increase of AP-1 activity by UVB and UVC, respectively; introduction of a dominant negative Erk2 into Cl 41 cells significantly blocked the UV-induced Erks activation as well as the AP-1 activation. In contrast, overexpression of wild-type Erk2 in Cl 30.7b cells and dominant negative Erk2 in Cl 41 cells did not show a marked influence on the phosphorylation of JNKs, These results demonstrate that activation of Erks, in addition to the previously reported JNKs, is required for UV-induced AP-1 activation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSCHER M, 1988, ONCOGENE, V3, P301; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; HUANG C, 1996, J BIOL CHEM, V49, P31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1996, INT J ONCOL, V8, P389; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEIVA E, 1993, J BIOL CHEM, V268, P2250; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATTS RG, 1998, IN PRESS ONCOGENE, V17; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2828	2835		10.1038/sj.onc.1202639	http://dx.doi.org/10.1038/sj.onc.1202639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362253				2022-12-25	WOS:000080125100005
J	Douziech, M; Forget, D; Greenblatt, J; Coulombe, B				Douziech, M; Forget, D; Greenblatt, J; Coulombe, B			Topological localization of the carboxyl-terminal domain of RNA polymerase II in the initiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRANSCRIPTION FACTORS IIE; LARGEST SUBUNIT; SACCHAROMYCES-CEREVISIAE; REPEAT DOMAIN; NONPHOSPHORYLATED FORM; PREINITIATION COMPLEX; HEPTAPEPTIDE REPEAT; CAPPING ENZYME; PHOSPHORYLATION	The carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAP II) functions at multiple stages of transcription and is involved in the coupling of transcription to pre-mRNA processing. We have used site-specific protein-DNA photocross-linking to determine the position of the CTD along promoter DNA in the transcriptional pre-initiation complex. Comparison of the promoter contacts made by RNAP II with or without the CTD indicate that the CTD approaches promoter DNA downstream of the transcriptional initiation site between positions +16 and +26. Incubation of pre-assembled initiation complexes with antibodies to the CTD prior to UV irradiation led to specific photocross-linking of the IgG heavy chain to nucleotide +17, indicating that the CTD is accessible for protein-protein interactions in a complex containing RNAP II and the general initiation factors. In conjunction with previously published observations, our structural data are fully compatible with the notion that DNA wrapping around RNAP II places the CTD and the RNA exit chan nel into juxtaposition and provide a rationale for contacts between the SRB-mediator complex and core RNAP II observed in the RNAP II holoenzyme.	Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Sherbrooke; University of Toronto	Coulombe, B (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.	b.coulom@courrier.usher-b.ca			Canadian Institutes of Health Research [14309-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kornberg RD, 1996, TRENDS BIOCHEM SCI, V21, P325, DOI 10.1016/0968-0004(96)20021-0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; ROBERT F, 1999, METHODS MOL BIOL PRO; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; WEST ML, 1995, GENETICS, V140, P1223; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	49	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19868	19873		10.1074/jbc.274.28.19868	http://dx.doi.org/10.1074/jbc.274.28.19868			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391932	hybrid, Green Accepted			2022-12-25	WOS:000081377300052
J	Lim, J; Pahlke, G; Conti, M				Lim, J; Pahlke, G; Conti, M			Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation - Identification and function of an inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMP-SPECIFIC PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; RAT SERTOLI-CELL; CATALYTIC ACTIVITY; CGMP PHOSPHODIESTERASE; HORMONAL-REGULATION; ROLIPRAM BINDING; EXPRESSION; GENE	Splicing variants of type 4 phosphodiesterases (PDE4) are regulated by phosphorylation. In these proteins, a conserved region is located between the amino-terminal domain, which is the target for phosphorylation, and the catalytic domain. Previous studies have indicated that nested deletions encompassing this region cause an increase in catalytic activity, suggesting this domain exerts an inhibitory constraint on catalysis, Here, we have further investigated the presence and function of this domain. A time-dependent increase in hydrolytic activity was observed when PDE4D3 from FRTL-5 cells was incubated with the endoproteinase Lys-C, The activation was abolished by protease inhibitors and was absent when a phosphorylated enzyme was used, Western blot analysis with PDE4D-specific antibodies indicated the Lys-C treatment separates the catalytic domain of PDE4D3 from the inhibitory domain. Incubation with antibodies recognizing an epitope within this domain caused a 3- to 6-fold increase in activity of native or recombinant PDE4D3, Again, PDE activation by these antibodies had properties similar to, and not additive with, the activation by protein kinase A phosphorylation. An interaction between the inhibitory domain and both regulatory and catalytic domains of PDE4D3 was detected by the yeast two-hybrid system. Mutations of Ser(54) to Ala in the regulatory domain decreased or abolished this interaction, whereas mutations of Ser(54) to the negatively charged Asp strengthened it. These data strongly support the hypothesis that an inhibitory domain is present in PDE4D and that phosphorylation of the regulatory domain causes activation of the enzyme by modulating the interaction between inhibitory and catalytic domains.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.			Lim, Jaeseung/0000-0003-0928-0259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahlstrom M, 1997, J BONE MINER RES, V12, P172, DOI 10.1359/jbmr.1997.12.2.172; ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Antaraki A, 1997, BRIT J PHARMACOL, V121, P991, DOI 10.1038/sj.bjp.0701228; BALL EH, 1980, J BIOL CHEM, V255, P2962; Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CORBIN JD, 1985, J BIOL CHEM, V260, P8731; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Ekholm D, 1997, BBA-MOL CELL RES, V1356, P64, DOI 10.1016/S0167-4889(96)00159-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; Madelian V, 1996, BIOCHEM PHARMACOL, V51, P1739, DOI 10.1016/0006-2952(96)00167-0; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; Salanova M, 1998, METHODS, V14, P55, DOI 10.1006/meth.1997.0565; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; SOUNESS JE, 1992, FEBS LETT, V302, P181, DOI 10.1016/0014-5793(92)80435-J; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TUCKER MM, 1981, J BIOL CHEM, V256, P9051	44	72	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19677	19685		10.1074/jbc.274.28.19677	http://dx.doi.org/10.1074/jbc.274.28.19677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391907	hybrid			2022-12-25	WOS:000081377300027
J	Fedi, P; Bafico, A; Soria, AN; Burgess, WH; Miki, T; Bottaro, DP; Kraus, MH; Aaronson, SA				Fedi, P; Bafico, A; Soria, AN; Burgess, WH; Miki, T; Bottaro, DP; Kraus, MH; Aaronson, SA			Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CDNA CLONING; BETA-CATENIN; TYROSINE KINASE; HEAD INDUCTION; CELL-LINE; FAMILY; PROTEIN; GROWTH; TRANSFORMATION; ACTIVATION	In an effort to isolate novel growth factors, we identified a human protein, designated Sk, that co-eluted with Neuregulin during chromatographic separation of conditioned medium from the SK-LMS-1 human leiomyosarcoma cell line. Degenerate oligonucleotides based on amino-terminal sequence analysis of the purified protein were used to isolate the corresponding cDNA from a library generated from this cell line. Sk is a novel 266-amino acid protein that contains a signal peptide sequence and two cysteine-rich domains with no similarity to other known growth factors. A single major 2-kilobase transcript was expressed in several embryonic tissues, Transfection of mammalian cells demonstrated that the protein was secreted and expressed as a doublet of approximately 35 kDa. In vitro translation and endoglycosylase analysis indicated that this doublet, which was also observed in cells expressing the endogenous protein, arises from posttranslational modification. A search of the GenBank(TM) data base revealed a match of Sk with Dkk-1, which is a novel secreted protein required for head induction in amphibian embryos and a potent Wnt inhibitor. When coexpressed with Wnt-2 in NIH3T3 cells, human Sk/Dkk-1 caused reversion of Wnt-2 induced morphological alterations and inhibited the Wnt-2 induced increase in uncomplexed beta-catenin levels. These results provide biochemical evidence that human Sk/Dkk-1 antagonizes Wnt signaling upstream of its effect on beta-catenin regulation.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA; NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS European Institute of Oncology (IEO)	Fedi, P (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	pfedi@smtplink.mssm.edu	Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	NCI NIH HHS [CA71672, CA71997] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA071672, R29CA071997, R55CA071997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Aravind L, 1998, CURR BIOL, V8, pR477, DOI 10.1016/S0960-9822(98)70309-4; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; LIN TP, 1992, CANCER RES, V52, P4413; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	38	226	271	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19465	19472		10.1074/jbc.274.27.19465	http://dx.doi.org/10.1074/jbc.274.27.19465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383463	hybrid, Green Submitted			2022-12-25	WOS:000081196300086
J	Sanders, SL; Klebanow, ER; Weil, PA				Sanders, SL; Klebanow, ER; Weil, PA			TAF25p, a non-histone-like subunit of TFIID and SAGA complexes, is essential for total mRNA gene transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; RNA-POLYMERASE; YEAST; COMPONENT; TAF(II)S; ENCODES; MUTANT; CELLS; TAFS	We demonstrate, utilizing a temperature conditional mutant allele of the gene encoding TAF25p, that this non-histone-like TBP-associated factor, which is shared between the TFIID and SAGA complexes, is required for hulk mRNA gene transcription by RNA polymerase II in vivo. Immunoblotting experiments indicate that at the restrictive temperature, inactivation of TAF25p function results in a reduction of the levels of numerous TFIID and SAGA subunits, indicating its loss of function, like the histone-like TAFs, causes degradation of the constituents of these two multisubunit complexes. These data suggest that TAF25p plays a key structural role in maintaining TFIID and SAGA complex integrity, This is the first demonstration that a non-histone-like TAF is required for continuous, high level RNA polymerase II-mediated mRNA gene transcription in living yeast cells.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	tony.weil@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052461, R56GM052461] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07563-09] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; Holstege FCP, 1999, P NATL ACAD SCI USA, V96, P2, DOI 10.1073/pnas.96.1.2; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; RAY BL, 1991, CURR GENET, V20, P25, DOI 10.1007/BF00312761; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schroeder SC, 1998, NUCLEIC ACIDS RES, V26, P4186, DOI 10.1093/nar/26.18.4186; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X	25	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18847	18850		10.1074/jbc.274.27.18847	http://dx.doi.org/10.1074/jbc.274.27.18847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383379	hybrid			2022-12-25	WOS:000081196300002
J	Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH				Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH			SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras MAP kinase pathway and chemotaxis	ONCOGENE			English	Article						PDGF beta-receptor; SHP-2; chemotaxis; Ras MAP kinase pathway	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA; TANDEM SH2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; REGULATED KINASE; CELL-ADHESION; 3T3 CELLS; SH-PTP2	Activation of the beta-receptor for platelet-derived growth factor (PDGF) by its ligand leads to autophosphorylation on a number of tyrosine residues. Here me show that Tyr763 in the kinase insert region is a novel autophosphorylation site, which after phosphorylation binds the protein tyrosine phosphatase SHP-2. SHP-2 has also previously been shown to bind to phosphorylated Tyr1009 in the PDGF beta-receptor. Porcine aortic endothelial (PAE) cells transfected with a PDGF beta-receptor in which Tyr763 and Tyr1009 were mutated to phenylalanine residues failed to associate with SHP-2 after ligand stimulation. Moreover, PDGF-BB-induced Ras GTP-loading and Erk2 activation were severely compromised in the receptor mutant. Whereas the mitogenic response to PDGF-BB remained at the same level as in cells expressing wild-type PDGF beta-receptor, chemotaxis induced by PDGF-BB was significantly decreased in the case of the Y763F/Y1009F mutant cells, suggesting an important role for SHP-2 in chemotactic signaling.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu XL, 1998, ONCOGENE, V17, P441, DOI 10.1038/sj.onc.1201988; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; WENNSTROM S, 1994, ONCOGENE, V9, P651; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	63	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3696	3702		10.1038/sj.onc.1202705	http://dx.doi.org/10.1038/sj.onc.1202705			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391677				2022-12-25	WOS:000081140200003
J	Altstein, M; Ben-Aziz, O; Daniel, S; Schefler, I; Zeltser, I; Gilon, C				Altstein, M; Ben-Aziz, O; Daniel, S; Schefler, I; Zeltser, I; Gilon, C			Backbone cyclic peptide antagonists, derived from the insect pheromone biosynthesis activating neuropeptide, inhibit sex pheromone biosynthesis in moths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOTHIS-PELTIGERA LEPIDOPTERA; C-TERMINAL HEXAPEPTIDE; AMINO-ACID-SEQUENCE; SUBSTANCE-P; LOCUSTA-MIGRATORIA; BIOLOGICAL-ACTIVITY; BUILDING UNITS; BOMBYX-MORI; SUBESOPHAGEAL GANGLION; NEUROENDOCRINE CONTROL	We describe an application of the backbone cyclization and cycloscan concept for the design and synthesis of pheromone biosynthesis activating neuropeptide (PBAN) antagonists capable of inhibiting sex pheromone biosynthesis in Heliothis peltigera female moths. Two backbone cyclic (BBC) sub-libraries were designed and synthesized. The structure of the first sub-library ([Arg(27)]PBAN27-33NH(2), termed the Ser sub-library) was based on the active C-terminal hexapeptide sequence (Tyr-Phe-Ser-Pro-Arg-Leu-NH2) of PBAN1-33NH(2), which was found to comprise its active core. The second sub-library ([Arg(27),D-Phe30]PBAN27-33NH(2), termed the D-Phe sub-library) was based on the sequence of the lead antagonist Arg-Tyr-Phe-(D)Phe-Pro-Arg-Leu-NH,. In both sub-libraries the Pro residue was replaced by an N-alpha(omega-amino-alkyl)Gly building unit having various lengths of the alkyl chain. All the cyclic peptides in each sub-library had the same primary sequence and the same location of the ring. The members of each library differed from each other by the bridge size and bridge chemistry. Screening of the two libraries for pheromonotropic antagonists resulted in the disclosure of four compounds that fully inhibited sex pheromone biosynthesis at 1 nmol and were devoid of agonistic activity. All antagonistic peptides originated from the D-Phe sub-library. Substitution of the D-Phe30 amino acid, with a Ser resulted in a loss of antagonistic activity, Agonistic activities were exhibited by peptides from both sub-libraries.	Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel; Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem	Altstein, M (corresponding author), Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel.							Altstein M, 1996, ARCH INSECT BIOCHEM, V31, P355, DOI 10.1002/(SICI)1520-6327(1996)31:4&lt;355::AID-ARCH1&gt;3.0.CO;2-V; ALTSTEIN M, 1993, ARCH INSECT BIOCHEM, V22, P153, DOI 10.1002/arch.940220113; ALTSTEIN M, 1996, INSECT PHEROMONE RES, P56; ALTSTEIN M, 1995, ARCH INSECT BIOCH PH, V30, P309; ALTSTEIN M, 1997, MODERN AGR ENV, P109; BAKER TC, 1989, EXPERIENTIA, V45, P248, DOI 10.1007/BF01951811; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Behrens S, 1996, INT J PEPT PROT RES, V48, P569; BITAN G, 1995, TETRAHEDRON, V51, P10513; Bitan G, 1997, J PEPT RES, V49, P421; Bitan G, 1997, J CHEM SOC PERK T 1, P1501, DOI 10.1039/a608389g; Byk G, 1996, J MED CHEM, V39, P3174, DOI 10.1021/jm960154i; DUNKELBLUM E, 1989, J CHEM ECOL, V15, P2233, DOI 10.1007/BF01014112; Friedler A, 1998, BIOCHEMISTRY-US, V37, P5616, DOI 10.1021/bi972878h; Gade G, 1997, PROG CH ORG NAT PROD, V71, P1; GAZIT Y, 1990, INSECT BIOCHEM, V20, P853, DOI 10.1016/0020-1790(90)90104-3; Gilon C, 1998, J MED CHEM, V41, P919, DOI 10.1021/jm970633x; GILON C, 1991, BIOPOLYMERS, V31, P745, DOI 10.1002/bip.360310619; GILON C, 1998, 24 EPS, P423; Gilon Chaim, 1997, Invertebrate Neuroscience, V3, P245, DOI 10.1007/BF02480381; HEINZERIAN P, 1987, AM J PHYSIOL, V252, pG439, DOI 10.1152/ajpgi.1987.252.3.G439; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V85, P219, DOI 10.1016/0742-8413(86)90077-0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HRUBY VJ, 1992, PROG BRAIN RES, V92, P215, DOI 10.1016/S0079-6123(08)61177-2; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; IMAI K, 1991, P JPN ACAD B-PHYS, V67, P98, DOI 10.2183/pjab.67.98; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KITAMURA A, 1990, AGR BIOL CHEM TOKYO, V54, P2495, DOI 10.1080/00021369.1990.10870317; KITAMURA A, 1989, BIOCHEM BIOPH RES CO, V163, P520, DOI 10.1016/0006-291X(89)92168-2; Kochansky JP, 1997, ARCH INSECT BIOCHEM, V35, P315, DOI 10.1002/(SICI)1520-6327(199705)35:3<315::AID-ARCH5>3.3.CO;2-O; KUNIYOSHI H, 1992, INSECT BIOCHEM MOLEC, V22, P399, DOI 10.1016/0965-1748(92)90078-S; KUNIYOSHI H, 1991, PEPTIDE CHEMISTRY 1990, P251; LAUFER R, 1986, J BIOL CHEM, V261, P257; LAUFER R, 1986, J MED CHEM, V29, P1284, DOI 10.1021/jm00157a029; MASLER EP, 1994, INSECT BIOCHEM MOLEC, V24, P829, DOI 10.1016/0965-1748(94)90111-2; MATSUMOTO S, 1992, BIOCHEM BIOPH RES CO, V182, P534, DOI 10.1016/0006-291X(92)91765-I; MATSUMOTO S, 1990, J INSECT PHYSIOL, V36, P427, DOI 10.1016/0022-1910(90)90060-S; Muller D, 1997, J ORG CHEM, V62, P411, DOI 10.1021/jo961580e; Nachman RJ, 1997, ANN NY ACAD SCI, V814, P73, DOI 10.1111/j.1749-6632.1997.tb46146.x; NACHMAN RJ, 1986, BIOCHEM BIOPH RES CO, V137, P936, DOI 10.1016/0006-291X(86)90315-3; NACHMAN RJ, 1993, ARCH INSECT BIOCHEM, V22, P181, DOI 10.1002/arch.940220115; NACHMAN RJ, 1991, P NATL ACAD SCI USA, V88, P4518, DOI 10.1073/pnas.88.10.4518; NAGASAWA H, 1994, ARCH INSECT BIOCHEM, V25, P261, DOI 10.1002/arch.940250403; Nakayama G R, 1998, Curr Opin Drug Discov Devel, V1, P85; PAPIRKRICHELI D, 1987, PAIN, V31, P263, DOI 10.1016/0304-3959(87)90041-8; Percy-Cunningham J.E., 1987, P27; RAINA AK, 1990, INSECT BIOCHEM, V20, P849, DOI 10.1016/0020-1790(90)90103-2; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; RAINA AK, 1993, ANNU REV ENTOMOL, V38, P329, DOI 10.1146/annurev.en.38.010193.001553; RAINA AK, 1984, SCIENCE, V225, P531, DOI 10.1126/science.225.4661.531; RAINA AK, 1992, INSECT BIOCHEM MOLEC, V22, P221, DOI 10.1016/0965-1748(92)90058-M; REVERO P, 1990, EUR J PHARMACOL, V175, P113; ROELOFS WL, 1974, PHEROMONES, P96; SCHOOFS L, 1991, GEN COMP ENDOCR, V81, P97, DOI 10.1016/0016-6480(91)90129-T; SCHOOFS L, 1990, PEPTIDES, V11, P427, DOI 10.1016/0196-9781(90)90038-7; SCHOOFS L, 1993, INSECT BIOCHEM MOLEC, V23, P859, DOI 10.1016/0965-1748(93)90104-Z; SCHOOFS L, 1993, COMP BIOCHEM PHYS C, V106, P103, DOI 10.1016/0742-8413(93)90260-R; SCHOOFS L, 1990, INSECT BIOCHEM, V20, P479, DOI 10.1016/0020-1790(90)90029-T; SCHOOFS L, 1992, INSECT BIOCHEM MOLEC, V22, P447, DOI 10.1016/0965-1748(92)90140-A; WAELBROECK M, 1985, ENDOCRINOLOGY, V116, P2643, DOI 10.1210/endo-116-6-2643; WOOL PJ, 1988, BRIT J CANCER, V57, P579; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x	62	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17573	17579		10.1074/jbc.274.25.17573	http://dx.doi.org/10.1074/jbc.274.25.17573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364192	hybrid			2022-12-25	WOS:000080974300028
J	Gerson, JH; Bobkova, E; Homsher, E; Reisler, E				Gerson, JH; Bobkova, E; Homsher, E; Reisler, E			Role of residues 311/312 in actin-tropomyosin interaction - In vitro motility study using yeast actin mutant E311A/R312A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL IMAGE-ANALYSIS; MUSCLE THIN-FILAMENTS; MYOSIN SUBFRAGMENT-1 COMPLEX; X-RAY-DIFFRACTION; SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN; ACTOMYOSIN SUBFRAGMENT-1; MUTATIONAL ANALYSIS; VERTEBRATE MUSCLE; ATP HYDROLYSIS	According to the Lorenz ct al, (Lorenz, M., Poole, K. J., Popp, D., Rosenbaum, G., and Holmes, K. C. (1995) J. Mol. Biol, 246, 108-119) atomic model of the actin-tropomyosin complex, actin residue Asp-311 (Glu-311 in yeast) is predicted to have a high binding energy contribution to actin-tropomyosin binding. Using the yeast actin mutant E311A/R312A in the in vitro motility assays, we have investigated the role of these residues in such interactions. Wild type (wt) yeast actin, like skeletal ar-actin, is fully regulated when complexed with tropomyosin (Tm) and troponin (Tn), Structure-function comparisons of the wt and E311A/R312A actins show no significant differences between them, and the unregulated F-actins slide at similar speeds in the in vitro motility assay. However, in the presence of Tm and Tn, the mutation increases both the sliding speed and the number of moving filaments at high pCa values, shifting the speed-pea curve nearly 0.5 pCa units to the left, Tm alone (no Tn) inhibits the motilities of both actins at low heavy meromyosin densities but potentiates only the motility of the mutant actin at high heavy meromyosin densities, Actin-Tm binding measurements indicate no significant difference between wt and E311A/R312A actin in Tm binding. These results implicate allosteric effects in the regulation of actomyosin function by tropomyosin.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Reisler, E (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	reisler@mbi.ucla.edu			NIAMS NIH HHS [R01 AR022031, AR30988, AR22031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988, R01AR022031] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; CARLIER MF, 1986, J BIOL CHEM, V261, P785; COOK RK, 1993, J BIOL CHEM, V268, P2410; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gerson JH, 1997, BIOPHYS J, V72, pMP180; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HASELGROVE JC, 1973, COLD SPRING HARB SYM, V37, P341, DOI 10.1101/SQB.1973.037.01.044; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Korman V, 1998, BIOPHYS J, V74, pA347; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; POOLEWILSON P, 1996, HEART FAILURE, P4; POPP D, 1987, J MOL BIOL, V197, P679, DOI 10.1016/0022-2836(87)90474-8; SELDEN LA, 1986, J MUSCLE RES CELL M, V7, P215, DOI 10.1007/BF01753554; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P245, DOI 10.1093/oxfordjournals.jbchem.a135049; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P219, DOI 10.1093/oxfordjournals.jbchem.a135048; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WAKABAYASHI T, 1981, J BIOCHEM-TOKYO, V90, P683, DOI 10.1093/oxfordjournals.jbchem.a133523; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; WERTMAN KF, 1992, GENETICS, V132, P337; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048	47	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17545	17550		10.1074/jbc.274.25.17545	http://dx.doi.org/10.1074/jbc.274.25.17545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364188	hybrid			2022-12-25	WOS:000080974300024
J	Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB				Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB			Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation; high throughput gene expression arrays; differentially expressed cDNAs	KINASE INHIBITOR P21; DNA CHIPS; INTERFERON; PROGRESSION; MDA-7; HYBRIDIZATION; ENCODES; COMPLEX	Abnormalities in differentiation are common occurrences in human cancers, Treatment-of human melanoma cells with the combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in a loss of tumorigenic potential that correlates with an irreversible suppression in proliferative ability and induction of terminal differentiation. It is hypothesized that this is associated with the differential expression of genes that may directly regulate cancer cell growth and differentiation. To define the relevant gene expression changes that correlate with and potentially control these important cellular processes a differentiation induction subtraction hybridization (DISH) scheme is being used,A temporally spaced subtracted differentiation inducer treated (TSS) cDNA library was constructed and differentially expressed DISH clones were isolated and evaluated using a high throughput microchip cDNA (Synteni) array screening approach, Verification of differential, gene expression for specific cDNAs was confirmed by Northern blotting. The temporal kinetics of regulation and the expression pattern of DISH genes were also evaluated by microchip cDNA array screening. Using this approach with 1000 DISH cDNA clones (similar to 10% of the DISH library) has resulted in the identification and cloning of both 26 known and 11 novel cDNAs of potential relevance to growth control and terminal differentiation in human melanoma cells.	Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; GenQuest Inc, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alama A, 1997, PHARMACOL RES, V36, P171, DOI 10.1006/phrs.1997.0227; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; GUARINI L, 1992, PIGM CELL RES, P123; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1997, ONCOGENE, V14, P473, DOI 10.1038/sj.onc.1200858; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KANG DC, 1998, IN PRESS INT J ONCOL; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; WAXMAN S, 1995, DIFFERENTIATION THER; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3546	3552		10.1038/sj.onc.1202715	http://dx.doi.org/10.1038/sj.onc.1202715			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376533				2022-12-25	WOS:000080850600013
J	Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A				Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A			Role of caspases and possible involvement of retinoblastoma protein during TGF beta-mediated apoptosis of human B lymphocytes	ONCOGENE			English	Article						B lymphocytes; apoptosis; TGF beta; caspases; retinoblastoma protein	PROGRAMMED CELL-DEATH; GROWTH FACTOR-BETA; S-PHASE ENTRY; CPP32-LIKE PROTEASES; TRANSFORMING GROWTH-FACTOR-BETA-1; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTION FACTOR; MAMMALIAN HOMOLOG; FAMILY PROTEASES; RAT HEPATOCYTES	In this study, we investigated the involvement of caspases in TGF beta-induced apoptosis in human B cells. Our results show that TGF beta-mediated nuclear fragmentation, observed in the Epstein-Barr virus-negative Burkitt's Lymphoma cell line BL41, was abolished in the presence of the tripeptide caspase inhibitor zVAD-fmk or the specific caspase-3 inhibitor DEVD-fmk. Other apoptotic manifestations such as cell shrinkage, surface phosphatidylserine expression and chromatin condensation were strongly inhibited by zVAD-fmk but only partially by DEVD-fmk. This suggests that other caspases in addition to caspase-3 control these apoptotis-associated features. Specific activation of caspase-3 during TGF beta-induced apoptosis was demonstrated by the DEVD-fmk-sensitive expression of the active p17 subunit of caspase-3 and by in vivo cleavage of PARP. In addition, TGP beta treatment of BL41 promoted the expression of both dephosphorylated and truncated forms of the retinoblastoma protein. Inhibition of caspase-3 activity abolished both nuclear fragmentation and expression of the truncated retinoblastoma protein, without modifying the G1 cell cycle arrest induced by TGF beta. Our data thus demonstrate that TGF beta-induced apoptosis of lymphoma B lymphocytes is dependent on caspase activation and involves caspase-dependent cleavage of the retinoblastoma protein.	IPSC, INSERM, U131, F-92140 Clamart, France; Ctr Claude Bernard CJF 95 2, F-92140 Clamart, France; Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Women & Infants Hospital Rhode Island	Vazquez, A (corresponding author), IPSC, INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.							Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; An B, 1996, CANCER RES, V56, P438; Anel A, 1997, J IMMUNOL, V158, P1999; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Berry DE, 1996, ONCOGENE, V12, P1809; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fan GS, 1996, ONCOGENE, V12, P1909; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KATO J, 1993, GENE DEV, V7, P331; KEHRL JH, 1986, J IMMUNOL, V137, P3855; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LOMO J, 1995, J IMMUNOL, V154, P1634; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang H, 1996, ONCOGENE, V13, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	58	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3511	3519		10.1038/sj.onc.1202718	http://dx.doi.org/10.1038/sj.onc.1202718			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376529				2022-12-25	WOS:000080850600009
J	Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD				Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD			Involvement of the adapter protein CRKL in integrin-mediated adhesion	ONCOGENE			English	Article						adhesion; integrins; BCR ABL; signal transduction; adapter proteins; CRKL	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; V-CRK; C-ABL; SIGNAL-TRANSDUCTION; CELLULAR PROTEINS; BCR/ABL ONCOGENE; SH3 DOMAIN; IN-VIVO	CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell Lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Bal F-CRKL, Ba/F-CRKL Delta SH2, and Ba/F-CRKL Delta SH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not Delta SH2- or Delta SH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta 1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta 1 integrins, nor did it spontaneously induce expression of the beta 1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167] Funding Source: Medline; NIDDK NIH HHS [DK560654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 1996, ONCOGENE, V12, P1981; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BELLIS SL, 1997, BIOCHEM J, V15, P375; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jacobsen K, 1996, BLOOD, V87, P73; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; WHITE GC, 1993, ADV EXP MED BIOL, V344, P187; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3343	3353		10.1038/sj.onc.1202689	http://dx.doi.org/10.1038/sj.onc.1202689			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362355				2022-12-25	WOS:000080589300005
J	Smith, FD; Oxford, GS; Milgram, SL				Smith, FD; Oxford, GS; Milgram, SL			Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; FILAMENT-BINDING PROTEIN; HIPPOCAMPAL-NEURONS; MEMBRANE; MECHANISMS; NEURABIN; SITES; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION	Signaling through D2 class dopamine receptors is crucial to correct brain development and function, and dysfunction of this system is implicated in major neurological disorders such as Parkinson's disease and schizophrenia. To investigate potential novel mechanisms of D2 receptor regulation, the third cytoplasmic loop of the D2 dopamine receptor was used to screen a rat hippocampal yeast two-hybrid library. Spinophilin, a recently characterized F-actin and protein phosphatase-1-binding protein with a single PDZ domain was identified as a protein that specifically associates with this region of D2 receptors, A direct interaction between spinophilin and the D2 receptor was confirmed in vitro using recombinant fusion proteins. The portion of spinophilin responsible for interacting with the D2 third cytoplasmic loop was narrowed to a region that does not include the actin-binding domain, the PDZ domain, or the coiled-coil, This region is distinct from the site of interaction with protein phosphatase-1, and both D2 receptors and protein phosphatase-1 may bind spinophilin at the same time. The interaction is not mediated via the unique 29-amino acid insert in D2(long); both D2(long) and D2(short) third cytoplasmic loops interact with spinophilin in vitro and in yeast two-hybrid assays, Expression of D2 receptors containing an extracellular hemagglutinin epitope in Madin-Darby canine kidney cells results in co-ocalization of receptor and endogenous spinophilin as determined by immunocytochemistry using antibodies directed against spinophilin and the HA tag. We hypothesize that spinophilin is important for establishing a signaling complex for dopaminergic neurotransmission through D2 receptors by linking receptors to downstream signaling molecules and the actin cytoskeleton.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R29DK50744] Funding Source: Medline; NINDS NIH HHS [NS18788] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018788] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; ARIANO MA, 1993, BRAIN RES, V609, P71, DOI 10.1016/0006-8993(93)90857-J; ARIANO MA, 1997, DOPAMINE RECEPTORS, P77; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Limbird LE, 1998, CELL, V93, P157, DOI 10.1016/S0092-8674(00)81568-8; MALEK D, 1993, FEBS LETT, V325, P215; Merkouris M, 1996, MOL PHARMACOL, V50, P985; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Nishi A, 1997, J NEUROSCI, V17, P8147; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Welsh GI, 1998, J NEUROCHEM, V70, P2139; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	33	170	177	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19894	19900		10.1074/jbc.274.28.19894	http://dx.doi.org/10.1074/jbc.274.28.19894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391935	hybrid, Green Published			2022-12-25	WOS:000081377300055
J	Kaiser, A; Brembeck, FH; Nicke, B; Wiedenmann, B; Riecken, EO; Rosewicz, S				Kaiser, A; Brembeck, FH; Nicke, B; Wiedenmann, B; Riecken, EO; Rosewicz, S			All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-CARCINOMA CELLS; THYROID-HORMONE RECEPTOR; HUMAN BREAST-CANCER; NUCLEAR RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL DISPLAY; ESTROGEN-RECEPTOR; FISSION YEAST; ALPHA; MITOSIS	In this study we used differential display reverse transcription-polymerase chain reaction to search for differentially expressed all-trans-retinoic acid (ATRA)-responsive genes in pancreatic carcinoma cells. We identified the kinesin-related protein HsEg5, which plays an essential role in spindle assembly and spindle function during mitosis, as a novel molecule involved in ATRA-mediated growth inhibition. Using Northern and Western blot analysis we demonstrated that ATRA significantly inhibits HsEg5 expression in various pancreatic carcinoma cell lines as well as in HaCat keratinocytes, Inhibition of HsEg5 expression by ATRA occurs at the posttranscriptional level. As a consequence, tumor cells synchronized in S-phase revealed a retarded progression through G(2)/M phase of the cell cycle indicating that HsEg5 inhibition results in a delayed progression through mitosis, Furthermore, a significant decrease of HsEg5 protein expression achieved by antisense transfection revealed a significant growth inhibition compared with control cells. Therefore, HsEg5 represents a novel molecule involved in ATRA-mediated growth inhibition, suggesting that vitamin A derivatives can interact with the bipolar spindle apparatus during mitosis.	Charite, Med Klin, S Hepatol & Gastroenterol, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Dept Gastroenterol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rosewicz, S (corresponding author), Charite, Med Klin, S Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburgerpl 1, D-13353 Berlin, Germany.	stefan.rosewicz@charite.de		Wiedenmann, Bertram/0000-0002-7890-2552				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURGER C, 1994, J CELL SCI, V107, P2047; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clairmont A, 1997, FEBS LETT, V419, P268, DOI 10.1016/S0014-5793(97)01468-3; DE LUCA LM, 1991, FASEB J, V5, P2924; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kaiser A, 1996, DIGESTION, V57, P149, DOI 10.1159/000201329; Kaiser A, 1997, GASTROENTEROLOGY, V113, P920, DOI 10.1016/S0016-5085(97)70188-4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LOPEZBARAHONA M, 1993, J BIOL CHEM, V268, P25617; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Manji SS, 1998, J CELL PHYSIOL, V176, P1; NELSON JA, 1986, MOL CELL BIOL, V6, P452, DOI 10.1128/MCB.6.2.452; Oridate N, 1996, ONCOGENE, V12, P2019; Rosewicz S, 1997, GASTROENTEROLOGY, V112, P532, DOI 10.1053/gast.1997.v112.pm9024307; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; VONMARSCHALL Z, 1999, IN PRESS BR J CANC; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Whitehead CM, 1996, ARTHRITIS RHEUM, V39, P1635, DOI 10.1002/art.1780391005; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZHENG ZS, 1990, CANCER RES, V50, P1201; ZHOU H, 1994, J BIOL CHEM, V269, P22433	46	17	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18925	18931		10.1074/jbc.274.27.18925	http://dx.doi.org/10.1074/jbc.274.27.18925			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383390	hybrid			2022-12-25	WOS:000081196300013
J	Wang, LH; Hayashi, H; Ebina, Y				Wang, LH; Hayashi, H; Ebina, Y			Transient effect of platelet-derived growth factor on GLUT4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; AFFECTING GLUCOSE-TRANSPORT; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; SIGNALING PATHWAYS; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; FACTOR TRIGGERS; PDGF RECEPTORS	We earlier developed a novel method to detect translocation of the glucose transporter (GLUT) directly and simply using c-MYC epitope-tagged GLUT (GLUTMYC). To define the effect of platelet-derived growth factor (PDGF) on glucose transport in 3T3-L1 adipocytes, we investigated the PDGF- and insulin-induced glucose uptake, translocation of glucose transporters, and phosphatidylinositol (PI) S-kinase activity in 3T3-L1, 3T3-L1GLUT4MYC, and 3T3-L1GLUT1MYC adipocytes, Insulin and PDGF stimulated glucose uptake by 9-10- and 5.5-6.5-fold, respectively, in both 3T3-L1 and 3T3-L1GLUT4MYC adipocytes. Exogenous GLUT4MYC expression led to enhanced PDGF-induced glucose transport. In 3T3-L1GLUT4MYC adipocytes, insulin and PDGF induced an 8- and 5-fold increase in GLUT4MYC translocation, respectively, determined in a cell-surface anti-c-MYC antibody binding assay. This PDGF-induced GLUT4MYC translocation was further demonstrated with fluorescent detection. In contrast, PDGF stimulated a a-fold increase of GLUT1MYC translocation and 2.5-fold increase of glucose uptake in 3T3-L1GLUT1MYC adipocytes. The PDGF-induced GLUT4MYC translocation, glucose uptake, and PI 3-kinase activity were maximal (100%) at 5-10 min and thereafter rapidly declined to 40, 30, and 12%, respectively, within 60 min, a time when effects of insulin were maximal. Wortmannin (0.1 mu M) abolished PDGF-induced GLUT4MYC translocation and glucose uptake in 3T3-L1GLUT4MYC adipocytes. These results suggest that PDGF can transiently trigger the translocation of GLUT4 and stimulate glucose uptake by translocation of both GLUT4 and GLUT1 in a PI 3-kinase dependent signaling pathway in 3T3-L1 adipocytes.	Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 7708503, Japan	Tokushima University	Ebina, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Genet, 3-18-15 Kuramoto-cho, Tokushima 7708503, Japan.			Hayashi, Hideki/0000-0003-4585-6542				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; ISHII K, 1994, BIOCHEM BIOPH RES CO, V205, P857, DOI 10.1006/bbrc.1994.2743; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUIN MJ, 1994, TRENDS ENDOCRIN MET, V5, P369; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YANG J, 1992, J BIOL CHEM, V267, P10393	45	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19246	19253		10.1074/jbc.274.27.19246	http://dx.doi.org/10.1074/jbc.274.27.19246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383432	hybrid			2022-12-25	WOS:000081196300055
J	Das, K; Lewis, RY; Scherer, PE; Lisanti, MP				Das, K; Lewis, RY; Scherer, PE; Lisanti, MP			The membrane-spanning domains of caveolins-1 and-2 mediate the formation of gaveolin hetero-oligomers - Implications for the assembly of caveolae membranes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PRIMARY BREAST-CANCER; IN-VIVO; MUTATIONAL ANALYSIS; PLASMA-MEMBRANE; SQUAMOUS-CELL; FREQUENT LOSS; EXPRESSION; HETEROZYGOSITY; FAMILY	The mammalian caveolin gene family consists of caveolins-1, -2, and -3. The expression of caveolin-3 is muscle-specific. In contrast, caveolins-1 and -2 are co-expressed, and they form a hetero-oligomeric complex in many cell types, with particularly high levels in adipocytes, endothelial cells, and fibroblasts. These caveolin hetero-oligomers are thought to represent the functional assembly units that drive caveolae formation in vivo. Here, we investigate the mechanism by which caveolins-1 and -2 form hetero-oligomers. We reconstituted this reciprocal interaction in vivo and in vitro using a variety of complementary approaches, including the generation of glutathione S-transferase fusion proteins and synthetic peptides. Taken together, our results indicate that the membrane-spanning domains of both caveolins-1 and -2 play a critical role in mediating their ability to interact with each other. This is the first demonstration that these unusual membrane-spanning regions found in the caveolin family play a specific role in protein-protein interactions.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; LAXMAN R, 1993, CANCER, V71, P1283, DOI 10.1002/1097-0142(19930215)71:4<1283::AID-CNCR2820710419>3.0.CO;2-I; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin JC, 1996, ONCOGENE, V13, P2001; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Matsuura K, 1998, ANTICANCER RES, V18, P453; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; OAKAHASHI S, 1995, CANCER RES, V55, P4114; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; Wang XL, 1998, INT J CANCER, V75, P671, DOI 10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.3.CO;2-6; XIU ZF, 1993, CHUNG HUA FU CHAN KO, V28, P91; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	52	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18721	18728		10.1074/jbc.274.26.18721	http://dx.doi.org/10.1074/jbc.274.26.18721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373486	hybrid			2022-12-25	WOS:000081056700078
J	Falck, J; Jensen, PB; Sehested, M				Falck, J; Jensen, PB; Sehested, M			Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase II alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; HEAT-SHOCK; CBF/NF-Y; C-MYB; NF-Y; PROMOTER; EXPRESSION; CDP/CUT; LOCALIZATION; STABILITY	Expression of DNA topoisomerase II alpha (topo II alpha) is cell cycle-regulated at both the transcriptional and the post- transcriptional levels. In order to identify cis-acting elements responsible for transcriptional regulation during the cell cycle, we investigated NIH/3T3 cells stably transfected with luciferase reporter plasmids containing various lengths of the human topo II alpha gene promoter. Serum-deprived cells expressed low levels of luciferase, and following serum-induced cell cycle reentry luciferase levels were gradually elevated 2-fold. During S phase, a steep S-fold increase in luciferase activity was seen, reaching its maximum approximately 22 h after serum addition. This pattern was observed with both a full-length (nucleotides (nt) -295 to +90] and a deletion (nt -90 to +90) promoter construct. In contrast, when testing a deletion construct (nt -51 to +90) lacking the first inverted CCAAT box (ICB1) the S phase-specific induction was absent. Mutation of ICB1 revealed that it had a repressive character, since luciferase levels rose rapidly to maximal levels immediately following serum addition. Furthermore, electrophoretic mobility shift assays demonstrated a marked decrease in ICB1 binding activity following serum addition. Together, this suggests a role of ICB1 in cell cycle-dependent repression of topo II alpha transcription.	Rigshosp, Dept Pathol, Lab Ctr, DK-2100 Copenhagen, Denmark; Rigshosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Sehested, M (corresponding author), Rigshosp, Dept Pathol, Lab Ctr, RH5444,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.							Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; Brandt TL, 1997, LEUKEMIA RES, V21, P711, DOI 10.1016/S0145-2126(97)00040-4; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FRASER DJ, 1995, MOL PHARMACOL, V47, P696; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Herzog CE, 1997, BIOCHEM BIOPH RES CO, V232, P608, DOI 10.1006/bbrc.1997.6267; HICKSON ID, 1996, ANTI-CANCER DRUG, V7, P19; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HSIANG YH, 1988, CANCER RES, V48, P3230; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kramer A, 1997, CANCER RES, V57, P5117; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mo YY, 1997, CANCER RES, V57, P5004; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18753	18758		10.1074/jbc.274.26.18753	http://dx.doi.org/10.1074/jbc.274.26.18753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373491	hybrid			2022-12-25	WOS:000081056700083
J	Okamoto, M; Schoch, S; Sudhof, TC				Okamoto, M; Schoch, S; Sudhof, TC			EHSH1/intersectin, a protein that contains EH and SH3 domains and binds to dynamin and SNAP-25 - A protein connection between exocytosis and endocytosis?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUBSTRATE EPS15; ACTIN CYTOSKELETON; SYNAPTOTAGMIN-I; RECEPTOR; INTERACTS; CLATHRIN; YEAST; ORGANIZATION; SYNAPTOJANIN; ADAPTER	In yeast two-hybrid screens for proteins that bind to SNAP-25 and may be involved in exocytosis, we isolated a protein called EHSH1 (for ER domain/SH3 domain-containing protein). Cloning of full-length cDNAs revealed that EHSH1 is composed of an N-terminal region with two EH domains, a central region that is enriched in lysine, leucine, glutamate, arginine, and glutamine (KLERQ domain), and a C-terminal region comprised of five SH3 domains. The third SH3 domain is alternatively spliced, Data bank searches demonstrated that EHSH1 is very similar to Xenopus and human intersectins and to human SH3P17. In addition, we identified expressed sequence tags that encode a second isoform of EHSH1, called EHSH2. EHSH1 is abundantly expressed in brain and at lower levels in all other tissues tested. In binding studies, we found that the central KLERQ domain of EHSH1 binds to recombinant or native brain SNAP-25 and SNAP-23, The C-terminal SH3 domains, by contrast, quantitatively interact with dynamin, a protein involved in endocytosis. Dynamin strongly binds to the alternatively spliced central SH3 domain (SH3C) and the two C-terminal SH3 domains (SH3D and SH3E) but not to the N-terminal SH3 domains (SH3A and SH3B), Immunoprecipitations confirmed that both dynamin and SNAP-25 are complexed to EHSH1 in brain, Our data suggest that EHSH1/intersectin may be a novel adaptor protein that couples endocytic membrane traffic to exocytosis. The ability of multiple SH3 domains in EHSH1 to bind to dynamin suggests that EHSH1 can cluster several dynamin molecules in a manner that is regulated by alternative splicing.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	T.Sudho@mednet.SWMED.edu	Schoch, Susanne/F-7741-2012					BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; Carbone R, 1997, CANCER RES, V57, P5498; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Harlow E., 1988, ANTIBODIES LAB MANUA; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Iannolo G, 1997, CANCER RES, V57, P240; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Palade GE, 1995, COLD SPRING HARB SYM, V60, P821, DOI 10.1101/SQB.1995.060.01.088; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaife RM, 1997, CELL SIGNAL, V9, P395, DOI 10.1016/S0898-6568(97)00041-7; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang GY, 1997, J CELL SCI, V110, P505; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	55	131	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18446	18454		10.1074/jbc.274.26.18446	http://dx.doi.org/10.1074/jbc.274.26.18446			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373452	hybrid			2022-12-25	WOS:000081056700044
J	Zhou, X; Park, SI; Moustafa, ME; Carlson, BA; Crain, PF; Diamond, AM; Hatfield, DL; Lee, BJ				Zhou, X; Park, SI; Moustafa, ME; Carlson, BA; Crain, PF; Diamond, AM; Hatfield, DL; Lee, BJ			Selenium metabolism in Drosophila - Characterization of the selenocysteine tRNA population	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA POPULATION; TRANSFER RNA<SER>SEC; MASS-SPECTROMETRY; MAMMALIAN-CELLS; GENE; UGA; CHROMOSOMES; ANTICODON; SYSTEM	The selenocysteine (Sec) tRNA population in Drosophila melanogaster is aminoacylated with serine, forms selenocysteyl-tRNA, and decodes UGA. The K-m of Sec tRNA and serine tRNA for seryl-tRNA synthetase is 6.67 and 9.45 nM, respectively. Two major bands of Sec tRNA were resolved by gel electrophoresis, Both tRNAs were sequenced, and their primary structures were indistinguishable and colinear with that of the corresponding single copy gene. They are 90 nucleotides in length and contain three modified nucleosides, 5-methylcarboxymethyluridine, N-6-isopentenyladenosine, and pseudouridine, at positions 34, 37, and 55, respectively. Neither form contains 1-methyladenosine at position 58 or 5-methylcarboxymethyl-2'-O-methyluridine which are characteristically found in Sec tRNA of higher animals. We conclude that the primary structures of the two bands of Sec tRNA resolved by electrophoresis are indistinguishable by the techniques employed and that See tRNAs in Drosophila may exist in different conformational forms. The Sec tRNA gene maps to a single locus on chromosome 2 at position 47E or F, To our knowledge, Drosophila is the lowest eukaryote in which the Sec tRNA population has been characterized to date.	Seoul Natl Univ, Inst Mol Biol & Genet, Genet Mol Lab, Seoul 151742, South Korea; NCI, Sect Mol Biol Selenium, Lab Basic Res, NIH, Bethesda, MD 20892 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Illinois, Dept Human Nutr & Dietet, Chicago, IL 60612 USA	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lee, BJ (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Med Genet Lab, Seoul 151742, South Korea.	imbglmg@snu.ac.kr	Moustafa, Mohamed E/E-9002-2018; Moustafa, Mohamed/AAM-2211-2021	Moustafa, Mohamed/0000-0003-1308-6221	NATIONAL CANCER INSTITUTE [R01CA081153, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81153] Funding Source: Medline; NIGMS NIH HHS [R01 GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alsina B, 1998, MOL GEN GENET, V257, P113, DOI 10.1007/s004380050630; AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Chittum HS, 1997, BIOCHEMISTRY-US, V36, P8634, DOI 10.1021/bi970608t; Chittum HS, 1997, BBA-MOL CELL RES, V1359, P25, DOI 10.1016/S0167-4889(97)00092-X; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; GREEN MR, 1985, BIOCHEM BIOPH RES CO, V129, P233, DOI 10.1016/0006-291X(85)91427-5; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1993, TRENDS GENET, V9, P69, DOI 10.1016/0168-9525(93)90215-4; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; Pardue M L, 1975, Methods Cell Biol, V10, P1, DOI 10.1016/S0091-679X(08)60727-X; PERLAKY S, 1998, 39 ANN DROS RES C WA; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Silberklang M, 1979, Methods Enzymol, V59, P58; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	31	11	11	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18729	18734		10.1074/jbc.274.26.18729	http://dx.doi.org/10.1074/jbc.274.26.18729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373487	hybrid, Green Published			2022-12-25	WOS:000081056700079
J	Feshchenko, EA; Shore, SK; Tsygankov, AY				Feshchenko, EA; Shore, SK; Tsygankov, AY			Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts	ONCOGENE			English	Article						Abl; Cbl; adhesion; morphology; transformation; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT P120(CBL); PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHOINOSITIDE 3-OH KINASE; INTEGRIN SIGNALING PATHWAY; SRC HOMOLOGY-3 DOMAIN; CRK ADAPTER PROTEINS; ACTIVATED T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR	The protooncogenic protein c-Cbl becomes tyrosine phosphorylated in normal cells in response to a variety of external stimuli, as well as in cells transformed by oncogenic protein tyrosine kinases. Tyrosine phosphorylation of c-Cbl upregulates its binding to multiple crucial signaling molecules. However, the biological consequences of c-Cbl-mediated signaling are insufficiently understood. To analyse the biological functions of c-Cbl, we overexpressed wild-type c-Cbl and its tyrosine phosphorylation-defective mutant form in v-Abl-transformed NIH3T3 fibroblasts. In this system, wild-type c-Cbl facilitated adhesion and spreading of v-Abl-transformed fibroblasts on the extracellular matrix, while reducing anchorage independence of these cells, as measured by their colony-forming efficiency in soft agar. Therefore, overexpression of wild-type c-Cbl exhibits an overall transformation-suppressing effect. By contrast, overexpression of a tyrosine phosphorylation-defective form of c-Cbl increases neither adhesion nor anchorage dependence of v-Abl-transformed fibroblasts. Analysis of the role of individual tyrosine phosphorylation sites of c-Cbl in these phenomena indicates that both phosphatidylinositol-3' kinase and the CrkL adaptor protein may be involved in the observed effects of c-Cbl. To summarize, the results presented in this report indicate that c-Cbl is involved in regulation of cell adhesion and cytoskeletal rearrangements, and that these effects of c-Cbl are dependent on its tyrosine phosphorylation.	Temple Univ, Sch Med, Dept Immunol & Microbiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Immunol & Microbiol, 3400 Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017		NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 1996, ONCOGENE, V12, P1981; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HAWLEY RG, 1994, GENE THER, V1, P136; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1996, ONCOGENE, V12, P2491; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LI PM, 1993, ONCOGENE, V8, P1731; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; NOBES CD, 1995, J CELL SCI, V108, P225; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; OKABE M, 1992, BLOOD, V80, P1330; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POWIS G, 1994, CANCER RES, V54, P2419; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHORE SK, 1994, J BIOL CHEM, V269, P5413; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1989, ONCOGENE, V4, P1411; Smit L, 1996, ONCOGENE, V13, P381; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	85	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3703	3715		10.1038/sj.onc.1202672	http://dx.doi.org/10.1038/sj.onc.1202672			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391678				2022-12-25	WOS:000081140200004
J	Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S				Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S			High incidence of allelic loss on chromosome 5 and inactivation of p15(INK4B) and p16(INK4A) tumor suppressor genes in oxystress-induced renal cell carcinoma of rats	ONCOGENE			English	Article						oxidative stress; renal cell carcinoma; loss of heterozygosity; p15(INK4B); p16(INK4A); methylation, rat	FERRIC NITRILOTRIACETATE; CARCINOGENESIS; MODEL; METHYLATION; MUTATIONS; CANCER; TSC2; RAS	Ferric nitrilotriacetate induces oxidative damage in renal proximal tubules, a consequence of Fenton-like reaction, that ultimately leads to a high incidence of renal cell carcinoma (RCC) in rats. In order to find common genetic alterations in this oxystress-induced carcinogenesis model, RCCs were produced in F1 hybrid rats between Wistar and Long-Evans strains and genomes were screened for loss of heterozygosity (LOH) with microsatellite polymorphic markers by PCR. Five consecutive markers on chromosome 5 (D5Mgh5, D5Mit9, D5Mgh6, D5Mit11 and D5Mit6) showed LOH in greater than or equal to 40% of the RCCs. As possible candidate tumor suppressor genes on chromosome 5, p15(INK4B) and p16(INK4A) were investigated for genetic alteration and aberrant methylation by Southern blot, PCR/SSCP/ sequencing and methylation-specific PCR. Genetic alteration (homozygous or hemizygous deletion with or without point mutation) or aberrant methylation were found in 30.7 and 53.8% of the RCC cases, respectively, which was proportionally associated with the histological nuclear grade and metastatic activity. Our data suggest that inactivation of p15 and p16 genes could be one of the major pathways responsible for oxystress-induced carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.		Toyokuni, Shinya/ABE-7714-2021; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; EBINA Y, 1986, J NATL CANCER I, V76, P107; Halliwell B, 1993, DNA FREE RADICALS; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HINO O, 1994, CANCER LETT, V83, P117, DOI 10.1016/0304-3835(94)90307-7; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; KNAPEK DF, 1995, CANCER RES, V55, P1607; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Schwerdtle RF, 1996, CANCER RES, V56, P2927; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; TOYOKUNI S, 1993, CARCINOGENESIS, V14, P223, DOI 10.1093/carcin/14.2.223; Toyokuni S, 1998, JPN J CANCER RES, V89, P814, DOI 10.1111/j.1349-7006.1998.tb00633.x	21	101	104	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3793	3797		10.1038/sj.onc.1202707	http://dx.doi.org/10.1038/sj.onc.1202707			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391689	Green Submitted			2022-12-25	WOS:000081140200015
J	Heuertz, RM; Tricomi, SM; Ezekiel, UR; Webster, RO				Heuertz, RM; Tricomi, SM; Ezekiel, UR; Webster, RO			C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; HEAT-SHOCK PROTEINS; SIGNAL-TRANSDUCTION; MAP KINASE; CELLULAR THERMORESISTANCE; HUMAN COMPLEMENT; PHOSPHORYLATION; ALVEOLITIS; RECEPTORS; FMLP	Serum levels of the acute-phase reactant, C-reactive protein (CRP), increase dramatically during acute inflammatory episodes. CRP inhibits migration of neutrophils toward the chemoattractant, f-Met-Leu-Phe (fMLP) and therefore acts as an anti-inflammatory agent, Since tyrosine kinases are involved in neutrophil migration and CRP has been shown to decrease phosphorylation of some neutrophil proteins, we hypothesized that CRP inhibits neutrophil chemotaxis via inhibition of MAP kinase activity. The importance of p38 MAP kinase in neutrophil movement was determined by use of the specific p38 MAP kinase inhibitor, SB203580. CRP and SB203580 both blocked random and fMLP-directed neutrophil movement in a concentration-dependent manner. Additionally, extracellular signal-regulated MAP kinase (ERK) was not involved in fMLP-induced neutrophil movement as determined by use of the MEK-specific inhibitor, PD98059. Blockade of ERK with PD98059 did not inhibit chemotaxis nor did it alter the ability of CRP or SB203580 to inhibit fMLP-induced chemotaxis, More importantly, CRP inhibited fMLP-induced p38 MAP kinase activity. in a concentration-dependent manner as measured by an in vitro kinase assay. Impressively, CRP-mediated inhibition of p38 MAP kinase activity correlated with CRP-mediated inhibition of fMLP-induced chemotaxis (r = -0.7144). These data show that signal transduction through p38 MAP kinase is necessary for neutrophil chemotaxis and that CRP intercedes through this pathway in inhibiting neutrophil movement.	St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Washington University (WUSTL)	Heuertz, RM (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, 3635 Vista Ave & Grand Blvd, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed N, 1996, AM J RESP CRIT CARE, V153, P1141, DOI 10.1164/ajrccm.153.3.8630558; Alvarez V, 1996, IMMUNOGENETICS, V44, P446, DOI 10.1007/BF02602806; BAN K, 1994, CARDIOVASC RES, V28, P1258, DOI 10.1093/cvr/28.8.1258; BUCHTA R, 1987, FEBS LETT, V211, P165, DOI 10.1016/0014-5793(87)81429-1; BUCHTA R, 1988, FEBS LETT, V237, P173, DOI 10.1016/0014-5793(88)80195-9; CLAUS DR, 1977, J IMMUNOL, V119, P187; Coffer PJ, 1998, BIOCHEM J, V329, P121; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DOBRINICH R, 1991, ARTHRITIS RHEUM-US, V34, P1031, DOI 10.1002/art.1780340813; Downey GP, 1998, J IMMUNOL, V160, P434; DUCLOS TW, 1981, CLIN EXP IMMUNOL, V43, P565; FOWLER AA, 1987, AM REV RESPIR DIS, V136, P1225, DOI 10.1164/ajrccm/136.5.1225; GANROT PO, 1969, SCAND J CLIN LAB INV, V24, P215, DOI 10.3109/00365516909080155; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HEUERTZ RM, 1993, AM J PATHOL, V142, P319; HEUERTZ RM, 1994, AM J PHYSIOL, V266, pL649, DOI 10.1152/ajplung.1994.266.6.L649; HOWARD T, 1994, BLOOD, V83, P231; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KEW RR, 1990, J LAB CLIN MED, V115, P339; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1981, J LAB CLIN MED, V97, P739; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LI JJ, 1989, J TRAUMA, V29, P1690, DOI 10.1097/00005373-198912000-00019; MALECH HL, 1977, J CELL BIOL, V75, P666, DOI 10.1083/jcb.75.3.666; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORLEY JJ, 1982, ANN NY ACAD SCI, V389, P406, DOI 10.1111/j.1749-6632.1982.tb22153.x; MORTENSEN RF, 1977, CELL IMMUNOL, V28, P59, DOI 10.1016/S0008-8749(77)80006-3; MORTENSEN RF, 1977, J IMMUNOL, V119, P1611; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARISH WE, 1976, CLIN ALLERGY, V6, P543, DOI 10.1111/j.1365-2222.1976.tb01939.x; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samols David, 1995, Arthritis and Rheumatism, V38, pS233; Schnyder B, 1998, BIOCHEM J, V331, P489, DOI 10.1042/bj3310489; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; VIGO C, 1985, J BIOL CHEM, V260, P3418; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; YASUI K, 1994, J IMMUNOL, V152, P5922; Zhong WJ, 1998, J IMMUNOL, V161, P2533; ZIGMOND SH, 1983, AM REV RESPIR DIS, V127, P290; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; Zu YL, 1998, J IMMUNOL, V160, P1982	50	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17968	17974		10.1074/jbc.274.25.17968	http://dx.doi.org/10.1074/jbc.274.25.17968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364245	hybrid			2022-12-25	WOS:000080974300081
J	de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED				de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED			P53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis	ONCOGENE			English	Article						human fibrosarcoma cells; transfection; stable expression; growth; tumorigenicity; UV-C irradiation	TRANSCRIPTION FACTOR EGR-1; FOCAL ADHESION KINASE; DAMAGE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; DNA-DAMAGE; INDUCIBLE APOPTOSIS; FIBROSARCOMA CELLS; GENE-EXPRESSION; PROTEIN-KINASE; C-JUN	The human fibrosarcoma cell line, HT1080, clone H-4, was used to determine if the transformation suppressive functions of p53 and Egr-1 have the same underlying mechanism. This cell Line expresses only mutant p53 and no detectable Egr-1, H4 clones stably expressing Egr-1 are less transformed in proportion to the level of Egr-1 expressed, acting through the induction of the TGF beta 1 gene. Here, H4 cells and the highest Egr-1 expressing clone mere transfected with a vector expressing normal human p53 to derive stable clones expressing p53. The expression of p53 in H4 cells inhibited transformed growth and reduced tumorigenicity. The effect of coexpression of both p53 and Egr-1 was additive, producing cell lines with 30% of normal growth rate and sevenfold reduced tumorigenicity compared with control lines. These results indicated that each factor may act independently by different pathways, although each additively increased the level of p21(WAF1) cell cycle inhibitor. However, exposure of the H4-derived cells to UV-C irradiation produced contrasting effects. Cell cycle analyses shelved that the presence of p53 was associated with loss of the G1 and S cells to apoptosis after irradiation. In contrast, the expression of Egr-1 increased entry into S/G2 phase of the cell cycle with Little apoptosis via a mechanism involving elevated FAK and low caspase activities. Apoptosis was observed only in the cell lines that expressed no Egr-1, especially those expressing wt-p53, and was preceded by high caspase activity. In summary, Egr-1 suppressed transformation and counteracted apoptosis by the coordinated activation of TGF beta 1, FN, p21 and FAK, leading to enhanced cell attachment and reduced caspase activity. In the doubly expressing cell line, the survival effect of Egr-1 was dominant over the apoptotic effect of p53.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; NW Hosp, Seattle, WA 98125 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Adamson, ED (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA76173, CA 67888, CA 63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA076173, R01CA067888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akamatsu H, 1996, CANCER RES, V56, P4541; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DelSal G, 1996, ONCOGENE, V12, P177; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dinkel A, 1997, J IMMUNOL, V159, P2678; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Globus RK, 1998, J CELL SCI, V111, P1385; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KEYSE SM, 1993, SEMIN CANCER BIOL, V4, P119; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN DY, 1991, STAT SINICA, V1, P1; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MERLO GR, 1994, ONCOGENE, V9, P443; Mohiuddin M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P427; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Planus E, 1997, J CELL SCI, V110, P1091; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	61	78	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3633	3642		10.1038/sj.onc.1202696	http://dx.doi.org/10.1038/sj.onc.1202696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380885				2022-12-25	WOS:000080891700009
J	Henics, T; Nagy, E; Oh, HJ; Csermely, P; von Gabain, A; Subjeck, JR				Henics, T; Nagy, E; Oh, HJ; Csermely, P; von Gabain, A; Subjeck, JR			Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MESSENGER-RNA; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; IDENTIFICATION; SEQUENCE; CELLS; HEAT-SHOCK-PROTEIN-70; DEGRADATION; LYMPHOCYTES	In this study, in vitro RNA binding by members of the mammalian 70-kDa heat shock protein (Hsp) family was examined. We show that Hsp/Hsc70 and Hsp110 proteins preferentially bound AU-rich RNA in vitro. Inhibition of RNA binding by ATP suggested the involvement of the N-terminal ATP-binding domain, By using deletion mutants of Hsp110 protein, a diverged Hsp70 family member, RNA binding was localized to the N-terminal ATP-binding domain of the molecule. The C-terminal peptide-binding domain did not bind RNA, but its engagement by a peptide substrate abrogated RNA binding by the N terminus of the protein. Interestingly, removal of the C-terminal alpha-helical structure or the alpha-loop domain unique to Hsp110 immediately downstream of the peptide-binding domain, but not both, resulted in considerably increased RNA binding as compared with the wild type protein. Finally, a 70 kDa activity was immunoprecipitated from RNA-protein complexes formed in vitro between cytoplasmic proteins of human lymphocytes and AU-rich RNA. These findings support the idea that certain heat shock proteins may act as RNA-binding entities in vivo to guide the appropriate folding of RNA substrates for subsequent regulatory processes such as mRNA degradation and/or translation.	Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Pecs, Sch Med, Dept Med Microbiol & Immunol, H-7643 Pecs, Hungary; Univ Pecs, Sch Med, Dept Clin Biochem, H-7643 Pecs, Hungary; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Semmelweis Univ, Dept Med Chem, H-1444 Budapest 8, Hungary	Vienna Biocenter (VBC); University of Pecs; University of Pecs; Roswell Park Cancer Institute; Semmelweis University	Henics, T (corresponding author), Vienna Bioctr, Inst Microbiol & Genet, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	THenics@intercell.co.at	Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659; Oh, Kelly/0000-0001-8203-5247	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BRIAN CF, 1995, EMBO J, V14, P2281; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DI YP, 1995, J CELL PHYSIOL, V165, P228, DOI 10.1002/jcp.1041650203; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENICS T, 1994, J BIOL CHEM, V269, P5377; Henics T, 1997, J CELL PHYSIOL, V173, P19, DOI 10.1002/(SICI)1097-4652(199710)173:1<19::AID-JCP3>3.3.CO;2-H; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruggero D, 1998, EMBO J, V17, P3471, DOI 10.1093/emboj/17.12.3471; Scandurro AB, 1997, KIDNEY INT, V51, P579, DOI 10.1038/ki.1997.83; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Soos H, 1998, PHYSIOL CHEM PHYS ME, V30, P163; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; WELCH WJ, 1982, HEAT SHOCK BACTERIA, P257; Wells DR, 1998, GENE DEV, V12, P3236, DOI 10.1101/gad.12.20.3236; YAMAMOTO T, 1987, J BIOL CHEM, V262, P7996; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	46	99	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17318	17324		10.1074/jbc.274.24.17318	http://dx.doi.org/10.1074/jbc.274.24.17318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358092	hybrid			2022-12-25	WOS:000080780400091
J	Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP				Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP			Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis	ONCOGENE			English	Article						HGF; c-met; MAPK; PI 3-kinase; motogenesis; mitogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; KIDNEY-CELLS REQUIRES; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; TRANSFORMATION; TRANSDUCTION; MOTILITY	HGF/NK2, a naturally occurring truncated HGF isoform, antagonizes the mitogenic and morphogenic activities of full length HGF, but stimulates cell scatter, or the motogenic response to HGF. We studied postreceptor signaling by these HGF isoforms in the human breast epithelial cell line 184B5, and in murine myeloid progenitor 32D cells transfected with c-Met, the human HGF receptor (32D/c-Met). HGF stimulated DNA synthesis in 184B5 and 32D/c-Met cells, while HGF/NK2 was mitogenically inactive, despite the ability of HGF/NK2 to stimulate c-Met autophosphorylation, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) in both cell systems. In 184B5 cells, HGF stimulated sustained MAPK activation, while activation by HGF/NK2 declined rapidly. In contrast, both isoforms activated MAPK with rapidly attenuated kinetics in 32D/c-Met cells. In both cell systems the increased motility observed in response to either HGF or HGF/NK2 treatment was more potently blocked by the PI3 kinase inhibitor wortmannin, than by PD98059, an inhibitor of MAPK kinase (MEK1). These data suggest that (1) alternative HGF isoforms signaling through c-Met generate both common and distinct biological responses, (2) the extent and duration of ligand-stimulated c-Met and MAPK activities are dependent on the cellular context and are not predictive of mitogenic signaling, and (3) in at least some HGF target cells, the activation of both MAPK and PI3K signaling pathways is insufficient for mitogenesis elicited through c-Met.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bldg 37,Room 1E24,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FALCO JP, 1988, ONCOGENE, V2, P573; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKUDA K, 1992, BLOOD, V79, P2880; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	45	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3399	3406		10.1038/sj.onc.1202683	http://dx.doi.org/10.1038/sj.onc.1202683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362361				2022-12-25	WOS:000080589300011
J	Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K				Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K			Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer	ONCOGENE			English	Article						mutation; RAD54; cancer	COMPARATIVE GENOMIC HYBRIDIZATION; NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; POSITIONAL CLONING; SYNDROME GENE; REPAIR; RECOMBINATION; SNF2; PROTEIN	Association of breast tumor susceptibility gene products BRCA1 and BRCA2 with the RAD51 recombination protein suggested that cancer could arise through defects in recombination, The identification of NBS1, responsible for Nijmegen breakage syndrome, from the MRE11/RAD50 recombination protein complex also supports this hypothesis. However, our mutation analysis revealed that known members of the RAD52 epistasis group are rarely mutated in human primary cancer. Here we describe the isolation of a novel member of the SNF2 superfamily, characterized with sequence motifs similar to those in DNA and RNA helicases. The gene, designated RAD54B, is significantly homologous to the RAD54 recombination gene. The expression of RAD54B was high in testis and spleen, which are active in meiotic and mitotic recombination. These findings suggest that RAD54B may play an active role in recombination processes in concert with other members of the RAD52 epistasis group. RAD54B maps to human chromosome 8q21.3-q22 in a region associated with cancer-related chromosomal abnormalities. Homozygous mutations at highly conserved positions of RAD54B were observed in human primary lymphoma and colon cancer.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Hiroshima 734, Japan; Univ Edinburgh, Western Gen Hosp, Mol Med Unit, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; University of Edinburgh; Kindai University (Kinki University); Hiroshima University	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 734, Japan.		Matsuura, Shinya/U-4182-2017	Matsuura, Shinya/0000-0001-5294-081X				Becker SA, 1996, CANCER RES, V56, P5092; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ElRifai W, 1996, CANCER RES, V56, P3230; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Klein HL, 1997, GENETICS, V147, P1533; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara M, 1997, GENETICS, V147, P1545; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	31	110	125	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3422	3426		10.1038/sj.onc.1202691	http://dx.doi.org/10.1038/sj.onc.1202691			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362364				2022-12-25	WOS:000080589300014
J	Crawford, HC; Fingleton, BM; Rudolph-Owen, LA; Goss, KJH; Rubinfeld, B; Polakis, P; Matrisian, LM				Crawford, HC; Fingleton, BM; Rudolph-Owen, LA; Goss, KJH; Rubinfeld, B; Polakis, P; Matrisian, LM			The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors	ONCOGENE			English	Article						beta-catenin; matrilysin; Tcf; APC; tumorigenesis	TRANSCRIPTION FACTOR LEF-1; IN-VIVO; COLORECTAL TUMORIGENESIS; SUPPRESSOR PROTEIN; SIGNALING ACTIVITY; EPITHELIAL-CELLS; COLON-CARCINOMA; GROWTH-FACTOR; MATRIX; APC	Matrilysin is a matrix metalloproteinase expressed in the tumor cells of greater than 80% of intestinal adenomas, The majority of these intestinal tumors are associated with the accumulation of beta-catenin, a component of the cadherin adhesion complex and, through its association with the T Cell Factor (Tcf) DNA binding proteins, a regulator in the Wnt signal transduction pathway. In murine intestinal tumors, matrilysin transcripts show striking overlap with the accumulation of beta-catenin protein, The matrilysin promoter is upregulated as much as 12-fold by beta-catenin in colon tumor cell lines in a manner inversely proportional to the endogenous levels of beta-catenin/Tcf complex and is dependent upon a single optimal Tcf-4 recognition site. Coexpression of the E-cadherin cytoplasmic domain blocked this induction and reduced basal promoter activity in every colon cancer cell line tested. Inactivation of the Tcf binding site increased promoter activity and overexpression of the Tcf factor, LEF-1, significantly downregulated matrilysin promoter activity, suggesting that beta-catenin transactivates the matrilysin promoter by virtue of its ability to abrogate Tcf-mediated repression. Because genetic ablation of matrilysin decreases tumor formation in multiple intestinal neoplasia (Min) mice, we propose that regulation of matrilysin production by beta-catenin accumulation is a contributing factor to intestinal tumorigenesis.	Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	Vanderbilt University	Matrisian, LM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA.		Crawford, Howard/A-2874-2008	Fingleton, Barbara/0000-0003-1132-0782; Goss, Kathleen/0000-0002-7379-5639; Rubinfeld, Bonnee/0000-0001-9861-6775	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA060867, F32CA067429] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60867, F32 CA67429, P30 CA68485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Borchers AH, 1997, J CANCER RES CLIN, V123, P13, DOI 10.1007/BF01212609; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Damsky CH, 1997, KIDNEY INT, V51, P1427, DOI 10.1038/ki.1997.195; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sparks AB, 1998, CANCER RES, V58, P1130; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takeuchi N, 1997, MOL CARCINOGEN, V19, P225; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1998, BIOL EXTRAC, P149; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY JP, 1994, CANCER RES, V54, P4805; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	49	589	611	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2883	2891		10.1038/sj.onc.1202627	http://dx.doi.org/10.1038/sj.onc.1202627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362259	Bronze			2022-12-25	WOS:000080125100011
J	Bencsits, E; Ebert, V; Tretter, V; Sieghart, W				Bencsits, E; Ebert, V; Tretter, V; Sieghart, W			A significant part of native gamma-aminobutyric acid(A) receptors containing alpha(4) subunits do not contain gamma or delta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTORS; RAT-BRAIN; ALLOSTERIC LIGANDS; MESSENGER-RNAS; PHARMACOLOGY; ALPHA-4-SUBUNIT; SUBTYPES; BINDING; CHANNEL; SYSTEM	Using a novel antibody directed against the alpha(4) subunit of gamma-aminobutyric acid(A) (GABA(A)) receptors, 5% of all [H-3]muscimol but only about 2% of all [H-3]Ro15-4513 binding sites present in brain membrane extracts could be precipitated. This indicated that part of the alpha(4) receptors containing [H-3]muscimol binding sites did not contain [H-3]Ro15-4513 binding sites. Immunoaffinity purification and Western blot analysis of alpha(4) receptors demonstrated that not only alpha(1), alpha(2), alpha(3), beta(1), beta(2), and beta(3) subunits but also gamma(1), gamma(2), gamma(3), and delta subunits can be colocalized with alpha(4) subunits in native GABA(A) receptors. Quantification experiments, however, indicated that only 7, 33, 4, or 7% of all alpha(4) receptors contained gamma(1), gamma(2), gamma(3), or delta subunits, respectively. These data not only explain the low percentage of [H-3]Ro15-4513 binding sites precipitated by the anti-alpha(4) antibody but also indicate that approximately 50% of the alpha(4) receptors did not contain gamma(1), gamma(2), gamma(3), or delta subunits. These receptors, thus, either are composed of alpha(4) and beta(1-3) subunits only, or additionally contain epsilon, pi, or so far unidentified GABA(A) receptor subunits.	Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria	University of Vienna	Sieghart, W (corresponding author), Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				Barnard EA, 1998, PHARMACOL REV, V50, P291; Benke D, 1997, J NEUROCHEM, V69, P806; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Ebert V, 1996, NEUROPHARMACOLOGY, V35, P1323, DOI 10.1016/S0028-3908(96)00062-7; FUCHS K, 1995, EUR J PHARM-MOLEC PH, V289, P87, DOI 10.1016/0922-4106(95)90172-8; Garret M, 1997, J NEUROCHEM, V68, P1382; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones A, 1997, J NEUROSCI, V17, P1350; KERN W, 1994, J NEUROCHEM, V62, P764; Khan ZU, 1996, NEUROPHARMACOLOGY, V35, P1315, DOI 10.1016/S0028-3908(96)00033-0; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; QUIRK K, 1995, EUR J PHARM-MOLEC PH, V290, P175, DOI 10.1016/0922-4106(95)00061-5; SIEGHART W, 1993, J NEUROCHEM, V60, P93, DOI 10.1111/j.1471-4159.1993.tb05826.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SLANY A, 1995, MOL PHARMACOL, V48, P385; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; TOGEL M, 1994, J BIOL CHEM, V269, P12993; Tretter V, 1997, J NEUROSCI, V17, P2728; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0	25	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19613	19616		10.1074/jbc.274.28.19613	http://dx.doi.org/10.1074/jbc.274.28.19613			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391897	hybrid			2022-12-25	WOS:000081377300017
J	Teuchert, M; Maisner, A; Herrler, G				Teuchert, M; Maisner, A; Herrler, G			Importance of the carboxyl-terminal FTSL motif of membrane cofactor protein for basolateral sorting and endocytosis - Positive and negative modulation by signals inside and outside the cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASLES-VIRUS; HEMAGGLUTININ PROTEINS; TARGETING SIGNAL; EPITHELIAL-CELLS; COATED VESICLES; BINDING-SITES; CD46; RECEPTOR; CLATHRIN; TRAFFICKING	Membrane cofactor protein (MCP), a widely distributed complement regulatory protein, is expressed on the basolateral surface of polarized epithelial cells, and it is not endocytosed. The carboxyl-terminal tetrapeptide (FTSL) is required for polarized surface expression. The ability of this tetrapeptide to serve as an autonomous sorting signal has been analyzed by adding this sequence motif to the C terminus of an apical membrane protein, the influenza A virus hemagglutinin (HA), The recombinant protein HA-FTSL retained the apical localization of the parental HA protein, Substitution of the complete cytoplasmic tail of MCP for the cytoplasmic tail of KA resulted in the targeting of the chimeric protein (HA/MCP) to the basolateral surface suggesting that the carboxyl-terminal FTSL motif is a weak sorting signal that requires additional targeting information from the membrane-proximal part of the cytoplasmic tail of MCP for redirecting an apical protein to the basolateral membrane domain, In contrast to the native HA, the HA-FTSL protein was subject to endocytosis, The basolateral HA/MCP was also found to be internalized and thus differed from the basolateral MCP, This result suggests that the carboxyl-terminal FTSL motif serves as an internalization signal and that in native MCP sorting information outside the cytoplasmic tail counteracts this endocytosis signal. Substitution of a tyrosine for the phenylalanine dramatically increased the internalization with most of the HA-YTSL protein being present intracellularly, Our results are consistent with the view that the interplay of multiple sorting signals and the modification of a well known targeting signal (YTSL) by amino acid exchange (FTSL) determine the constitutive expression of MCP on the basolateral surface of polarized epithelial cells.	Tierarztlichen Hsch Hannover, Inst Virol, D-30559 Hannover, Germany; Univ Marburg, Inst Virol, D-35037 Marburg, Germany	University of Veterinary Medicine Hannover, Foundation; Philipps University Marburg	Herrler, G (corresponding author), Tierarztlichen Hsch Hannover, Inst Virol, Bunteweg 17, D-30559 Hannover, Germany.							DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHULTZE B, 1991, J VIROL, V65, P6232, DOI 10.1128/JVI.65.11.6232-6237.1991; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K	23	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19979	19984		10.1074/jbc.274.28.19979	http://dx.doi.org/10.1074/jbc.274.28.19979			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391947	hybrid			2022-12-25	WOS:000081377300067
J	Elrod-Erickson, M; Pabo, CO				Elrod-Erickson, M; Pabo, CO			Binding studies with mutants of Zif268 - Contribution of individual side chains to binding affinity and specificity in the Zif268 zinc finger-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; RECOGNITION; SELECTION; PROTEINS; DESIGN; PHAGE; RULES	The Zif268 zinc finger-DNA complex has served as a model system for understanding how Cys,His, type zinc fingers recognize DNA. Structural studies of the Zif268-DNA complex revealed that residues at four positions in the cw helix of each zinc finger play key roles in recognition, but there has been no information about the precise contributions of individual residues. Here we report the results of binding studies involving five mutants of Zif268 that have changes in the base contacting residues of finger one. These studies let us evaluate the contributions that Arg(18) (position -1 of the alpha helix), Asp(20) (position 2), Glu(21) (position 3), and Arg(24) (position 6) make to the overall energy of DNA binding. Our results confirm the important role played by these arginines. By comparing the affinities of the wild type and mutant peptides for various sites, we also prove that Asp(20) and Glu(21) play important roles in determining binding site specificity.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Pabo, CO (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Choo Y, 1998, NUCLEIC ACIDS RES, V26, P554, DOI 10.1093/nar/26.2.554; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CORMACK B, 1997, CURRENT PROTOCOLS MO; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sambrook J., 2002, MOL CLONING LAB MANU; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	22	70	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19281	19285		10.1074/jbc.274.27.19281	http://dx.doi.org/10.1074/jbc.274.27.19281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383437	hybrid			2022-12-25	WOS:000081196300060
J	Loveland, KL; Herszfeld, D; Chu, B; Rames, E; Christy, E; Briggs, LJ; Shakri, R; de Kretser, DM; Jans, DA				Loveland, KL; Herszfeld, D; Chu, B; Rames, E; Christy, E; Briggs, LJ; Shakri, R; de Kretser, DM; Jans, DA			Novel low molecular weight microtubule-associated protein-2 isoforms contain a functional nuclear localization sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; LARGE T-ANTIGEN; CALMODULIN-BINDING PROTEINS; RAT TESTIS; IN-VITRO; BRAIN DEVELOPMENT; DNA-POLYMERASE; SITE FLANKING; IMPORT; TRANSPORT	Known high and low molecular weight (LMW) MAP2 protein isoforms result from alternative splicing of the MAP2 gene. Contrary to previous reports that MAP2 is neural-specific, we recently identified MAP2 mRNA and protein in somatic and germ cells of rat testis, and showed the predominant testicular isoform is LMW. Although cytoplasmic in neural tissue, MAP2 appeared predominantly nuclear in germ cells using immunohistochemistry. We sought to determine whether this unexpected localization was due to the inclusion of exon 10 within novel LMW MAP2 isoforms. Normally excluded from the LMW MAP2c, exon 10 harbors a putative CcN motif, comprising a nuclear localization sequence (NLS) flanked by regulatory phosphorylation sites for protein kinase CK2 and cdc2 kinase. Characterization of MAP2 mRNA in adult and immature brain and testis, by reverse transcriptase-polymerase chain reaction/Southern analysis and Northern blot, identified novel LMW forms containing exons 10 and 11, previously detected only in high molecular weight MAP2a and 2b. The MAP2 NLS targeted a large heterologous protein to the nucleus, as demonstrated using bacterially expressed MAP2-CcN-beta-galactosidase fusion protein and an in vitro nuclear import assay. Antibodies raised against the fusion protein produced a testicular immunohistochemical staining pattern correlating with MAP2 protein distribution in the nucleus of most germ cells, and precipitated both similar to 70-kDa and >220-kDa proteins recognized by the commercial MAP2-specific HMS monoclonal antibody, supporting our hypothesis of a novel LMW MAP2 isoform. These results demonstrate-the presence of a functional NLS in MAP2 and indicate that novel LMW MAP2 isoforms may be targeted to the nucleus in both neural and non-neuronal tissues.	Monash Med Ctr, Inst Reprod & Dev, Clayton, Vic 3168, Australia; John Curtin Sch Med Res, Dept Biochem & Mol Biol, Nucl Signalling Lab, Canberra, ACT 2601, Australia	Monash University; Australian National University; John Curtin School of Medical Research	Loveland, KL (corresponding author), Monash Med Ctr, Inst Reprod & Dev, 246 Clayton Rd, Clayton, Vic 3168, Australia.	kate.loveland@med.monash.edu.au	Briggs, Lyndall J/A-7549-2011; Loveland, Kate L/X-4404-2019	Loveland, Kate L/0000-0002-5750-8046; Jans, David/0000-0001-5115-4745				BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS RG, 1995, BIOCHEM SOC T, V23, P41, DOI 10.1042/bst0230041; CHARRIEREBERTRAND C, 1992, NEUROCHEM INT, V21, P535, DOI 10.1016/0197-0186(92)90085-6; Chung WJ, 1996, J NEUROCHEM, V66, P1273; DOLL T, 1993, J CELL SCI, V106, P633; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Forleo P, 1996, J MOL NEUROSCI, V7, P193, DOI 10.1007/BF02736840; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jiang MS, 1997, J BIOL CHEM, V272, P2421; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; KALCHEVA N, 1995, J NEUROCHEM, V65, P1472; KINDLER S, 1990, J BIOL CHEM, V265, P19679; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; LANGKOPF A, 1994, FEBS LETT, V354, P259, DOI 10.1016/0014-5793(94)01128-1; Loveland KL, 1996, J MOL ENDOCRINOL, V17, P61, DOI 10.1677/jme.0.0170061; Loveland KL, 1996, BIOL REPROD, V54, P896, DOI 10.1095/biolreprod54.4.896; Ludin B, 1996, J CELL SCI, V109, P91; MARECHAL D, 1988, ARCH INT PHYSIOL BIO, V96, P231, DOI 10.3109/13813458809075948; Matus Andrew, 1994, V13, P155; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; MELLO CM, 1992, J BIOMOL STRUCT DYN, V9, P791, DOI 10.1080/07391102.1992.10507956; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORIYA M, 1993, CELL TISSUE RES, V271, P441, DOI 10.1007/BF02913726; Munsie M, 1997, MOL REPROD DEV, V47, P19, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;19::AID-MRD3&gt;3.0.CO;2-T; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OHTA Y, 1989, J BIOL CHEM, V264, P16143; Pereira G, 1998, MOL BIOL CELL, V9, P775, DOI 10.1091/mbc.9.4.775; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shafit-Zagardo B, 1998, MOL NEUROBIOL, V16, P149, DOI 10.1007/BF02740642; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SURRIDGE CD, 1994, BIOCHEMISTRY-US, V33, P8051, DOI 10.1021/bi00192a009; Trejo R, 1997, MOL REPROD DEV, V48, P127, DOI 10.1002/(SICI)1098-2795(199709)48:1&lt;127::AID-MRD15&gt;3.0.CO;2-Y; TUCKER RP, 1988, DEV BIOL, V130, P423, DOI 10.1016/0012-1606(88)90338-7; VANCUROVA I, 1995, J CELL SCI, V108, P779; WANDOSELL F, 1984, CHROMOSOMA, V90, P68, DOI 10.1007/BF00352280; WANG Y, 1993, J CELL BIOL, V121, P257, DOI 10.1083/jcb.121.2.257; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	55	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19261	19268		10.1074/jbc.274.27.19261	http://dx.doi.org/10.1074/jbc.274.27.19261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383434	hybrid			2022-12-25	WOS:000081196300057
J	Lucas, LT; Gatehouse, D; Shuker, DEG				Lucas, LT; Gatehouse, D; Shuker, DEG			Efficient nitroso group transfer from N-nitrosoindoles to nucleotides and 2 '-deoxyguanosine at physiological pH - A new pathway for N-nitrosocompounds to exert genotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE TREATMENT; CHINESE CABBAGE; RAT STOMACH; DNA; 1-NITROSOINDOLE-3-ACETONITRILE; 2'-DEOXYOXANOSINE; ACID; INDOLE-3-ACETONITRILE; OLIGODEOXYNUCLEOTIDE; MUTAGENESIS	The endogenous formation of N-nitrosoindoles is of concern since humans are exposed to a variety of naturally occurring and synthetic indolic compounds. As part of a study to evaluate the genotoxicity of N-nitrosoindoles, the reactions of three model compounds with purine nucleotides and 2'-deoxyguanosine at physiological pH were investigated. The profiles of reaction products were identical for each of the N-nitrosoindoles and three distinct pathways of reaction could be discerned. These pathways were: (i) depurination to the corresponding purine bases, (ii) deamination, coupled with depurination, to give hypoxanthine and xanthine, and (iii) formation of the novel nucleotide 2'-deoxyoxanosine monophosphate and its corresponding depurination product oxanine in reactions with 2'-deoxyguanosine monophosphate, 2'-Deoxyoxanosine and oxanine were observed in reactions with S'-deoxyguanosine, Further studies showed that formation of all of these products could be rationalized by an initial transnitrosation step. These results suggest that, in contrast to many other genotoxic N-nitrosocompounds which are known to alkylate DNA, the genotoxicity of N-nitrosoindoles is likely to arise through transfer of the nitroso group to nucleophilic sites on the purine bases. All of the products resulting from transnitrosation by N-nitrosoindoles are potentially mutagenic. These findings reveal a new pathway for N-nitrosocompounds to exert genotoxicity.	Glaxo Wellcome Res & Dev Ltd, Med Safety & Evaluat Div, Ware SG12 0DP, Herts, England; Univ Leicester, MRC, Toxicol Unit, Biomonitoring & Mol Interact Sect, Leicester LE1 9HN, Leics, England	GlaxoSmithKline; University of Leicester	Shuker, DEG (corresponding author), Univ Leicester, MRC, Toxicol Unit, Biomonitoring & Mol Interact Sect, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	degs1@le.ac.uk						BARTSCH H, 1991, RELEVANCE HUMAN CANC, P1; BONNETT R, 1974, J CHEM SOC P1, V1, P962; CASTRO A, 1986, J CHEM SOC PERK T 2, P1165, DOI 10.1039/p29860001165; CROOKES MJ, 1998, J CHEM SOC CHEM COMM, P571; FURIHATA C, 1987, JPN J CANCER RES, V78, P432; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P413; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P1216; GATEHOUSE D, 1983, MUTAT RES, V124, P35, DOI 10.1016/0165-1218(83)90183-0; Glaser R, 1996, J AM CHEM SOC, V118, P10942, DOI 10.1021/ja961334k; KIRCHNER JJ, 1992, J AM CHEM SOC, V114, P4021, DOI 10.1021/ja00037a001; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MEYER TA, 1982, J CHEM SOC PERK T 2, P1383, DOI 10.1039/p29820001383; NAKAMURA H, 1981, J ANTIBIOT, V34, P1219, DOI 10.7164/antibiotics.34.1219; OCHIAI M, 1986, MUTAT RES, V172, P189, DOI 10.1016/0165-1218(86)90056-X; OHTA T, 1981, BIOCHEM BIOPH RES CO, V100, P52, DOI 10.1016/S0006-291X(81)80061-7; SHIMADA N, 1981, J ANTIBIOT, V34, P1216, DOI 10.7164/antibiotics.34.1216; Suzuki T, 1998, BIOCHEMISTRY-US, V37, P11592, DOI 10.1021/bi980971f; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P8013, DOI 10.1021/bi970166l; Suzuki T, 1996, J AM CHEM SOC, V118, P2515, DOI 10.1021/ja952550g; Suzuki T, 1997, Nucleic Acids Symp Ser, P313; VALIN N, 1985, MUTAT RES, V158, P159, DOI 10.1016/0165-1218(85)90079-5; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; WAKABAYASHI K, 1986, MUTAGENESIS, V1, P423, DOI 10.1093/mutage/1.6.423; WAKABAYASHI K, 1985, P JPN ACAD B-PHYS, V61, P190, DOI 10.2183/pjab.61.190; WAKABAYASHI K, 1989, CANCER SURV, V8, P385; WAKABAYASHI K, 1985, MUTAT RES, V143, P17, DOI 10.1016/0165-7992(85)90098-3; WAKABAYASHI K, 1987, RELEVANCE N NITROSO, P287; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YAMASHITA K, 1988, CARCINOGENESIS, V9, P1905, DOI 10.1093/carcin/9.10.1905	29	57	57	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18319	18326		10.1074/jbc.274.26.18319	http://dx.doi.org/10.1074/jbc.274.26.18319			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373435	hybrid			2022-12-25	WOS:000081056700027
J	Newton, TR; Patel, NM; Bhat-Nakshatri, P; Stauss, CR; Goulet, RJ; Nakashatri, H				Newton, TR; Patel, NM; Bhat-Nakshatri, P; Stauss, CR; Goulet, RJ; Nakashatri, H			Negative regulation of transactivation function but not DNA binding of NF-KB and AP-1 by I kappa B beta 1 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-BETA; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; ALPHA DEGRADATION; DEPENDENT TRANSCRIPTION; INDEPENDENT GROWTH; ESTROGEN-RECEPTOR; GENE-TRANSFER; P65 SUBUNIT	The transcription factor NF-kappa B regulates the expression of genes involved in cancer cell invasion, metastasis, angiogenesis, and resistance to chemotherapy, In normal cells NF-kappa B is maintained in the cytoplasm by protein-protein interaction with inhibitor I kappa Bs, In contrast, in cancer cells a substantial amount of NF-kappa B is in the nucleus and constitutively activates target genes, To understand the mechanisms of constitutive NF-kappa B activation, we have analyzed the function of I kappa B alpha and I kappa B beta in breast cancer cells, In most cases, constitutive NF-kappa B DNA binding correlated with reduced levels of either I kappa B alpha Or I kappa B beta isoforms, Overexpression of I kappa B alpha but not I kappa B beta 1 resulted in reduced constitutive DNA binding of NF-kappa B in MDA-MB-231 cells. Unexpectedly, I kappa B beta 1 overexpression moderately increased 12-O-tetradecanoylphorbol-13-acetate and interleukin-1-inducible NF-kappa B DNA binding, 12-O-Tetradecanoylphorbol-13-acetate and interleukin-1-induced transactivation by NF-kappa B, however, was lower in I kappa B beta 1-overexpressing cells. Mutants of I kappa B beta 1 lacking the C-terminal casein kinase II phosphorylation sites, which form a stable complex with DNA bound NF-kappa B without inhibiting its transactivation in other cell types, repressed the transactivation by NF-kappa B in MDA-MB-231 cells, Consistent with the results of transient transfections, the expression of urokinase plasminogen activator, an NF-kappa B target gene, was reduced in I kappa B beta 1-overexpressing cells. These results suggest that depending on the cell type, I kappa B beta 1 represses the expression of NF-kappa B-regulated genes by inhibiting either DNA binding or transactivation function of NF-kappa B.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakashatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CORNETTA K, 1994, CLIN EXP METASTAS, V12, P3, DOI 10.1007/BF01784328; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gilmore TD, 1996, ONCOGENE, V13, P1367; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERLOV C, 1991, ONCOGENE, V6, P1583; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	60	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18827	18835		10.1074/jbc.274.26.18827	http://dx.doi.org/10.1074/jbc.274.26.18827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373501	Green Published, hybrid			2022-12-25	WOS:000081056700093
J	Tsvetkov, PO; Protasevich, II; Gilli, R; Lafitte, D; Lobachov, VM; Haiech, J; Briand, C; Makarov, AA				Tsvetkov, PO; Protasevich, II; Gilli, R; Lafitte, D; Lobachov, VM; Haiech, J; Briand, C; Makarov, AA			Apocalmodulin finds to the myosin light chain kinase calmodulin target site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE COMPLEX; HIGH-AFFINITY; BINDING; CALCIUM; RECOGNITION; SIGNAL	The interaction of a 20-residue-long peptide derived from the calmodulin-binding domain of the smooth muscle myosin light chain kinase with calcium-free calmodulin (apocalmodulin) was studied using a combination of isothermal titration calorimetry and differential scanning calorimetry. We showed that: (i) a significant binding between apocalmodulin and the target peptide (RS20) exists in the absence of salt (K-a, = 10(6) M-1), (ii) the peptide interacts with the C-terminal lobe of calmodulin and adopts a partly helical conformation, and (iii) the presence of salt weakens the affinity of the peptide for apocalmodulin, emphasizing the importance of electrostatic interactions in the complex. Eased on these results and taking into account the work of Bayley et al. (Bayley, P. M,, Findlay, W,A,, and Martin, S. R, (1996) Protein Sci. 5, 1215-1228), we suggest a physiological role for apocalmodulin.	Univ Louis Pasteur Strasbourg 1, UMR CNRS, F-67401 Illkirch Graffenstaden, France; Univ Mediterranee, UPRESA CNRS 6032, F-13385 Marseille, France; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Aix-Marseille Universite; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Haiech, J (corresponding author), Univ Louis Pasteur Strasbourg 1, UMR CNRS, F-67401 Illkirch Graffenstaden, France.		Makarov, Alexander/P-5279-2016; haiech, jacques J/F-2890-2010	haiech, jacques/0000-0003-2908-8053				AFSHAR M, 1994, J MOL BIOL, V244, P554, DOI 10.1006/jmbi.1994.1752; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; GUIMARD L, 1994, ANAL BIOCHEM, V221, P118, DOI 10.1006/abio.1994.1387; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KILHOFFER MC, 1992, BIOCHIM BIOPHYS ACTA, V1160, P8, DOI 10.1016/0167-4838(92)90033-A; KILHOFFER MC, 1989, BIOCHEMISTRY-US, V28, P6086, DOI 10.1021/bi00440a053; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILOS M, 1988, J BIOL CHEM, V263, P9218; Privalov P L, 1986, Methods Enzymol, V131, P4; Protasevich I, 1997, BIOCHEMISTRY-US, V36, P2017, DOI 10.1021/bi962538g; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Yuan T, 1999, BIOCHEMISTRY-US, V38, P1446, DOI 10.1021/bi9816453	23	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18161	18164		10.1074/jbc.274.26.18161	http://dx.doi.org/10.1074/jbc.274.26.18161			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373414	hybrid			2022-12-25	WOS:000081056700006
J	Pickering, TJ; Garforth, S; Sayers, JR; Grasby, JA				Pickering, TJ; Garforth, S; Sayers, JR; Grasby, JA			Variation in the steady state kinetic parameters of wild type and mutant T5 5 '-3 '-exonuclease with pH - Protonation of Lys-83 is critical for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; FLAP ENDONUCLEASE-1; CRYSTAL-STRUCTURE; METAL-IONS; RNASE-H; EXONUCLEASE; MECHANISM; RESIDUES; IDENTIFICATION; 5'-EXONUCLEASE	T5 5'-3'-exonuclease is a member of a family of homologous 5'-nucleases essential for DNA replication and repair. We have measured the variation of the steady state parameters of the enzyme with pH, The log of the association constant of the enzyme and substrate is pH-independent between pH 5 and 7, but art higher PH, it decreases (gradient -0.91 +/- 0.1) with increasing pH. The log of the turnover number increases (gradient 0.9 +/- 0.01) with increasing pH until a pH-independent plateau is reached. The T5 5'-3'-exonuclease-catalyzed reaction requires the protonation of a single residue for substrate binding, whereas k(cat) depends on a single deprotonation as demonstrated by the bell-shaped dependence of log (k(cat)/K-m) on pH. To investigate the role of a conserved lysine (Lys-83), the pH profile of log (k(cat)/K-m) of a K83A mutant was determined and found to increase with pH (gradient 1.01 +/- 0.01) until a pH-independent plateau is reached. We therefore conclude that protonation of Lys-83 in the wild type protein facilitates DNA binding. The origin of the pH dependence of the k(cat) parameter of the wild type enzyme is discussed.	Univ Sheffield, Dept Chem, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England; Univ Sheffield, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Grasby, JA (corresponding author), Univ Sheffield, Dept Chem, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England.		Sayers, Jon R/AAP-6179-2020; Garforth, Scott/B-5701-2011; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Ceska TA, 1998, TRENDS BIOCHEM SCI, V23, P331, DOI 10.1016/S0968-0004(98)01259-6; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FOTHERGILL M, 1995, J AM CHEM SOC, V117, P11619, DOI 10.1021/ja00152a001; FRENKEL GD, 1971, J BIOL CHEM, V246, P4839; Garforth SJ, 1997, NUCLEIC ACIDS RES, V25, P3801, DOI 10.1093/nar/25.19.3801; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HALE SP, 1993, BIOCHEMISTRY-US, V32, P7479, DOI 10.1021/bi00080a020; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; HUHEEY JE, 1983, INORGANIC CHEM PRINC, P295; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JENCKS WP, 1976, HDB BIOCH MOL BIOL, P305; Kim CY, 1998, BIOPHYS J, V74, pA63; Kim Y, 1997, MOL CELLS, V7, P468; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PAUL AV, 1966, J BIOL CHEM, V241, P3441; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Williams NH, 1998, COMPREHENSIVE BIOL C, V1, P543	33	6	9	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17711	17717		10.1074/jbc.274.25.17711	http://dx.doi.org/10.1074/jbc.274.25.17711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364212	hybrid			2022-12-25	WOS:000080974300048
J	Ghiselli, G; Siracusa, LD; Iozzo, RV				Ghiselli, G; Siracusa, LD; Iozzo, RV			Complete cDNA cloning, genomic organization, chromosomal assignment, functional characterization of the promoter, and expression of the murine bamacan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE PROTEOGLYCANS; NUCLEAR-LOCALIZATION SIGNALS; TUMOR STROMA; PROTEIN; FAMILY; CELLS; TRANSCRIPTION; BIOSYNTHESIS; CONDENSATION	Bamacan is a chondroitin sulfate proteoglycan that abounds in basement membranes. To gain insights into the bamacan gene regulation and transcriptional control, we examined the genomic organization and identified the promoter region of the mouse bamacan gene. Secondary structure analysis of the protein reveals a sequential organization of three globular regions interconnected by two cu-helix coiled-coils. The N- and the C-terminal ends carry a P-loop and a DA box motif that can act cooperatively to bind ATP, These features as well as the high sequence homology with members of the SMC (structural maintenance of chromosome) protein family led us to conclude that bamacan is a member of this protein family. The gene comprises 31 exons and is driven by a promoter that is highly enriched in GC sequences and lacks TATA and CAAT boxes. The promoter is highly functional in transient cell transfection assays, and step-wise 5' deletions identify a strong enhancer element between -659 and -481 base pairs that includes Jun/Fos proto-oncogene-binding elements. Using backcrossing experiments we mapped the Barn gene to distal chromosome 19, a locus syntenic to human chromosome 10q25, Bamacan is differentially expressed in mouse tissues with the highest levels in testes and brain, Notably, bamacan mRNA levels are low in normal cells and markedly reduced during quiescence but are highly increased when cells resume growth upon serum stimulation. In contrast, in all transformed cells tested, bamacan is constitutively overexpressed, and its levels do not change with cell cycle progression. These results suggest that bamacan is involved in the control of cell growth and transformation,	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, 1020 Locust St,Room 249,JAH, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, P01CA021124, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA21124, R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; ARGESON AC, 1995, GENOMICS, V25, P29, DOI 10.1016/0888-7543(95)80106-V; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brix K, 1998, J CLIN INVEST, V102, P283, DOI 10.1172/JCI1614; Chang BHJ, 1998, METHODS, V15, P41, DOI 10.1006/meth.1998.0604; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; COUCHMAN JR, 1993, KIDNEY INT, V43, P79, DOI 10.1038/ki.1993.14; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; EDELHOFF S, 1994, ONCOGENE, V9, P665; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1987, HISTOCHEMISTRY, V88, P23, DOI 10.1007/BF00490162; IOZZO RV, 1995, LAB INVEST, V73, P157; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Johnson DG, 1998, FRONT BIOSCI, V3, pd447; KANDA H, 1993, ONCOGENE, V8, P3047; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MCCARTHY KJ, 1994, J HISTOCHEM CYTOCHEM, V42, P473, DOI 10.1177/42.4.8126374; MCCARTHY KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P401, DOI 10.1177/41.3.8429203; MCCARTHY KJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1479, DOI 10.1177/38.10.2401786; Poirier C, 1998, MAMM GENOME, V8, pS353, DOI 10.1007/s003359900664; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	40	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17384	17393		10.1074/jbc.274.24.17384	http://dx.doi.org/10.1074/jbc.274.24.17384			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358101	hybrid			2022-12-25	WOS:000080780400100
J	Wada, T; Long, JC; Zhang, D; Vik, SB				Wada, T; Long, JC; Zhang, D; Vik, SB			A novel labeling approach supports the five-transmembrane model of subunit a of the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATION; MUTAGENIC ANALYSIS; ALPHA-SUBUNIT; CROSS-LINKING; TOPOLOGY; MEMBRANE; SECTOR; F1F0-ATPASE; F1-ATPASE; MUTATIONS	Cysteine mutagenesis and surface labeling has been used to define more precisely the transmembrane spans of subunit a of the Escherichia coli ATP synthase, Regions of subunit a that are exposed to the periplasmic space have been identified by a new procedure, in which cells are incubated with polymyxin B nonapeptide (PMBN), an antibiotic derivative that partially permeabilizes the outer membrane of E. coli, along with a sulfhydryl reagent, 3-(N-maleimidylpropionyl) biocytin (MPB). This procedure permits reaction of sulfhydryl groups in the periplasmic space with MPB, but residues in the cytoplasm are not labeled, Using this procedure, residues 8, 27, 37, 127, 131, 230, 231, and 232 were labeled and so are thought to be exposed in the periplasm, Using inside-out membrane vesicles, residues near the end of transmembrane spans 1, 64, 67, 68, 69, and 70 and residues near the end of transmembrane spans 5, 260, 263, and 265 were labeled. Residues 62 and 257 were not labeled. None of these residues were labeled in PMBN-permeabilized cells. These results provide a more detailed view of the transmembrane spans of subunit a and also provide a simple and reliable technique for detection of periplasmic regions of inner membrane proteins in E, coli,	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [GM40508, R01 GM040508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CAIN BD, 1989, J BIOL CHEM, V264, P3292; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7	27	67	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17353	17357		10.1074/jbc.274.24.17353	http://dx.doi.org/10.1074/jbc.274.24.17353			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358096	hybrid			2022-12-25	WOS:000080780400095
J	Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR				Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR			Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids	ONCOGENE			English	Article						alternative lengthening of telomeres; immortalization; senescence; somatic cell hybridization; telomerase	HUMAN FIBROBLASTS; INDEFINITE DIVISION; IMMORTAL CELLS; DYNAMICS; COMPLEMENTATION; CANCER; LINES; IDENTIFICATION; CHROMOSOME-7; SENESCENCE	Some immortalized cell lines maintain their telomeres in the absence of detectable telomerase activity by an alternative (ALT) mechanism. To study how telomere maintenance is controlled in ALT cells, we have fused an ALT cell Line GM847 (SV40 immortalized human skin fibroblasts) with normal fibroblasts or with telomerase positive immortal human cell lines and have examined their proliferative potential and telomere dynamics. The telomeres in ALT cells are characteristically very heterogeneous in length, ranging from very short to very long, The ALT x normal hybrids underwent a rapid reduction in telomeric DIVA and entered a senescence-like state. Immortal segregants rapidly reverted to the ALT telomere phenotype. Fusion of ALT cells to telomerase-positive immortal cells in the same immortalization complementation group resulted in hybrids that appeared immortal and also exhibited repression of the ALT telomere phenotype. In these hybrids, which were all telomerase-positive, we observed an initial rapid loss of most long telomeres, followed either by gradual loss of the remaining long telomeres at a rate similar to the rate of telomere shortening in normal telomerase-negative cells, or by maintenance of shortened telomeres. These data indicate the existence of a mechanism of rapid telomere deletion in human cells. They also demonstrate that normal cells and at least some telomerase-positive immortal cells contain repressors of the ALT telomere phenotype.	Childrens Med Res Inst, Canc Res Grp, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Grp, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bryan TM, 1998, EXP CELL RES, V239, P370, DOI 10.1006/excr.1997.3907; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Katoh M, 1998, MOL CARCINOGEN, V21, P17, DOI 10.1002/(SICI)1098-2744(199801)21:1<17::AID-MC4>3.0.CO;2-M; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Moy EL, 1997, EXP GERONTOL, V32, P663, DOI 10.1016/S0531-5565(97)00092-2; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WHITAKER NJ, 1995, ONCOGENE, V11, P971	38	95	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3383	3390		10.1038/sj.onc.1202752	http://dx.doi.org/10.1038/sj.onc.1202752			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362359				2022-12-25	WOS:000080589300009
J	DeMali, KA; Balciunaite, E; Kazlauskas, A				DeMali, KA; Balciunaite, E; Kazlauskas, A			Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGF beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE C-GAMMA; TYROSINE-PHOSPHATASE; CELL-ADHESION; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHORYLATION SITES; DEPENDENT ACTIVATION; RAS; BINDING	Since the extracellular matrix (ECM) can promote platelet-derived growth factor (PDGF)-dependent responses, we hypothesized that the ECM mediates this effect by preventing the PDGF beta receptor (beta PDGFR) from associating with the negative regulator, RasGAP (the GTPase-activating protein of Ras). We found that binding of RasGAP to the wild-type beta PDGFR was decreased; the activation of Ras and Erk was enhanced, and [H-3]thymidine uptake was better in cells cultured on fibronectin than in cells cultured on polylysine. To investigate the mechanism by which culturing cells on fibronectin diminished the recruitment of RasGAP to the beta PDGFR, we focused on SHP-2 since it dephosphorylates the beta PDGFR at the phosphotyrosine required for binding of RasGAP. Culturing cells on fibronectin increased the amount of SHP-2 that associated with the beta PDGFR. Furthermore, cells expressing receptor mutants that failed to associate with SHP-8 were insensitive to fibronectin, The ECM enhances PDGF-dependent responses by increasing the association of SHP-2 with the beta PDGFR, which in turn decreases the time that RasGAP interacts with the receptor, Thus, fibronectin changes PDGF-dependent signaling and biological responses by altering the signal relay enzymes that are recruited to the receptor.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.			DeMali, Kris/0000-0003-0906-1371	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feldmann P, 1999, MOL CELL BIOL, V19, P1928; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; KAZLAUSKAS A, 1986, J CELL PHYSIOL, V126, P225, DOI 10.1002/jcp.1041260211; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WENNSTROM S, 1994, ONCOGENE, V9, P651; Woodard AS, 1998, J CELL SCI, V111, P469	43	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19551	19558		10.1074/jbc.274.28.19551	http://dx.doi.org/10.1074/jbc.274.28.19551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391888	hybrid			2022-12-25	WOS:000081377300008
J	Huang, CF; Li, LX; Krilis, SA; Chanasyk, K; Tang, YZ; Li, ZQ; Hunt, JE; Stevens, RL				Huang, CF; Li, LX; Krilis, SA; Chanasyk, K; Tang, YZ; Li, ZQ; Hunt, JE; Stevens, RL			Human tryptases alpha and beta/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; MERIONES-UNGUICULATUS; MONOCLONAL-ANTIBODY; COMPLEMENTARY-DNA; PERIPHERAL-BLOOD; SERINE PROTEASES; CLONING; EXPRESSION; TRANSCRIPTION; SPECIFICITY	Tryptases alpha and beta/II were expressed in insect cells to try to ascertain why human mast cells express these two nearly identical granule proteases, In contrast to that proposed by others, residue -3 in the propeptide did not appear to be essential for the three-dimensional folding, post-translational modification, and/or activation of this family of serine proteases, Both recombinant tryptases were functional and bound the active-site inhibitor diisopropyl fluorophosphate, However, they differed in their ability to cleave varied trypsin-susceptible chromogenic substrates, Structural modeling analyses revealed that tryptase alpha differs from tryptase beta/II in that it possesses an Asp, rather than a Gly, in one of the loops that form its substrate-binding cleft. A site-directed mutagenesis approach was therefore carried out to determine the importance of this residue. Because the D215G derivative of tryptase alpha exhibited potent enzymatic activity against fibrinogen and other tryptase beta/II-susceptible substrates, Asp(215) dominantly restricts the substrate specificity of tryptase alpha. These data indicate for the first time that tryptases alpha and beta/II are functionally different human proteases, Moreover, the variation of just a single amino acid in the substrate-binding cleft of a tryptase can have profound consequences in the regulation of its enzymatic activity and/or substrate preference.	Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ New S Wales, Dept Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Univ New S Wales, Sch Pathol, Randwick, NSW 2052, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of New South Wales Sydney; St George Hospital; University of New South Wales Sydney	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; HUANG R, 1993, SCAND J IMMUNOL, V38, P359, DOI 10.1111/j.1365-3083.1993.tb01738.x; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Li LX, 1998, J IMMUNOL, V161, P5079; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; NAWA Y, 1994, INT ARCH ALLERGY IMM, V104, P249, DOI 10.1159/000236673; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Ren S, 1997, J IMMUNOL, V159, P3540; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Svendsen L., 1972, THROMB RES, V1, P267, DOI 10.1016/0049-3848(72)90023-0; URATA H, 1993, J BIOL CHEM, V268, P24318; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; Wang ZM, 1998, BIOL CHEM, V379, P167, DOI 10.1515/bchm.1998.379.2.167; Wong GW, 1999, INT ARCH ALLERGY IMM, V118, P419, DOI 10.1159/000024152; XIA HZ, 1995, J IMMUNOL, V154, P5472	37	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19670	19676		10.1074/jbc.274.28.19670	http://dx.doi.org/10.1074/jbc.274.28.19670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391906	hybrid			2022-12-25	WOS:000081377300026
J	Langbein, L; Rogers, MA; Winter, H; Praetzel, S; Beckhaus, U; Rackwitz, HR; Schweizer, J				Langbein, L; Rogers, MA; Winter, H; Praetzel, S; Beckhaus, U; Rackwitz, HR; Schweizer, J			The catalog of human hair keratins I. Expression of the nine type I members in the hair follicle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; DIFFERENTIAL EXPRESSION; EPITHELIAL CYTOKERATINS; GENE; IDENTIFICATION; DISEASE; CELLS; MONILETHRIX; EPIDERMIS; SEQUENCE	The human type I hair keratin subfamily comprises nine individual members, which can be subdivided into three groups. Group A (hHa1, hHa3-I, hHa3-II, hHa4) and B (hHa7, hHa8) each contains structurally related hair keratins, whereas group C members hHa2, hHa5, and hHa6 represent structurally rather unrelated hair keratins. Antibodies produced against these individual hair keratins, first analyzed for specificity by one- dimensional Western blots of total hair keratins, were used to establish the two-dimensional catalog of the human type I hair keratin subfamily. The catalog comprises two different series of type I hair keratins: a strongly expressed, Coomassie-stainable series containing hair keratins hHa1, hHa3-I/II, hHa4, and hHa5, and a weakly expressed, immunodetectable series harboring hHa2, hHa6 hHa7, and hHa8. In situ hybridization and immunohistochemical expression studies on scalp follicles show that two hair keratins, hHa2 and hHa5, define the early stage of hair differentiation, i.e. hHa5 expression in hair matrix and hHa5/hHa2 coexpression in the early hair cuticle cells. Whereas cuticular differentiation proceeds without the expression of further type I hair keratins, matrix cells embark on the cortical pathway by sequentially expressing hHa1, hHa3-I/II, and hHa4, which are supplemented by hHa6 at an advanced stage of cortical differentiation, and hHa8, which is expressed heterogeneously in cortex cells. Thus, six type I hair keratins are involved in the terminal differentiation of anagen hairs. The expression of hHa7 is conspicuously different from that of the other hair keratins in that it does not occur in the large anagen follicles of terminal scalp hairs but only in central cortex cells of the rare and small follicle type that gives rise to vellus hairs.	German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Tumor Cell Regulat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Langbein, L (corresponding author), German Canc Res Ctr, Div Cell Biol, A0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	langbein@dkfz-heidelberg.de	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				BERTOLINO AP, 1988, J INVEST DERMATOL, V91, P541, DOI 10.1111/1523-1747.ep12476901; BERTOLINO AP, 1990, J INVEST DERMATOL, V94, P297, DOI 10.1111/1523-1747.ep12874436; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HERZOG F, 1994, J INVEST DERMATOL, V102, P165, DOI 10.1111/1523-1747.ep12371757; KAYTES PS, 1991, J INVEST DERMATOL, V97, P835, DOI 10.1111/1523-1747.ep12491511; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Mischke D, 1998, Subcell Biochem, V31, P71; MOLL I, 1994, CELL TISSUE RES, V277, P131, DOI 10.1007/s004410050140; MOLL R, 1984, DIFFERENTIATION, V28, P136, DOI 10.1111/j.1432-0436.1984.tb00277.x; MONTAGNA W, 1974, STRUCTURE FUNCTION S, P172; PARRY DAD, 1995, INTERMEDIATE FILAMEN, P145; POWELL B, 1992, DEVELOPMENT, V114, P417; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1994, J INVEST DERMATOL, V102, P171, DOI 10.1111/1523-1747.ep12371758; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; ROGERS MA, 1995, MOL BIOL REP, V20, P155, DOI 10.1007/BF00990548; SCHWEIZER J, 1989, EXP CELL RES, V184, P193, DOI 10.1016/0014-4827(89)90377-7; Schweizer Juergen, 1993, P33; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TOBIASCH E, 1992, DIFFERENTIATION, V50, P163, DOI 10.1111/j.1432-0436.1992.tb00671.x; TROJANOSKY SM, 1992, EUR J CLEL BIOL, V59, P127; Westgate GE, 1996, INT CONGR SER, V1111, P167; Winter H, 1998, J INVEST DERMATOL, V111, P955, DOI 10.1046/j.1523-1747.1998.00456.x; Winter H, 1997, J BIOL CHEM, V272, P32345, DOI 10.1074/jbc.272.51.32345; Winter H, 1997, HUM GENET, V101, P165, DOI 10.1007/s004390050607; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	39	196	199	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19874	19884		10.1074/jbc.274.28.19874	http://dx.doi.org/10.1074/jbc.274.28.19874			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391933	hybrid			2022-12-25	WOS:000081377300053
J	Grundhoff, AT; Kremmer, E; Turecin, O; Glieden, A; Gindorf, C; Atz, J; Mueller-Lantzsch, N; Schubach, WH; Grasser, FA				Grundhoff, AT; Kremmer, E; Turecin, O; Glieden, A; Gindorf, C; Atz, J; Mueller-Lantzsch, N; Schubach, WH; Grasser, FA			Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT MEMBRANE-PROTEIN; RBP-J-KAPPA; RNA-DEPENDENT ATPASE; BIOCHEMICAL-CHARACTERIZATION; HODGKINS-DISEASE; HELICASE GENE; POLYMERASE-II; EXPRESSION; PROMOTER; TRANSCRIPTION	The Epstein-Barr virus-encoded nuclear antigens EBNA2 and EBNA3C both interact with the cellular transcription factor RBP-JK and modulate the expression of several shared target genes, suggesting a tight cooperation in latently infected cells. In a survey for additional cellular factors that bind to EBNA2 as well as EBNA3C, we have isolated and characterized DP1031 a novel human member of the DEAD box family of putative ATP-dependent RNA helicases, The interaction with DP103 is mediated by amino acids (aa) 121-213 of EBNA2 and aa 534-778 of EBNA3C, regions that are not involved in binding of the viral proteins to RBP-JK, The DP103-cDNA encodes a protein of 824 aa that harbors all of the common DEAD box motifs, Monoclonal antibodies raised against DP103 detect a protein of 103 kDa in mammalian cells that resides in high molecular weight complexes in vivo. We have detected an ATPase activity intrinsic to or closely associated with DP103, By subcellular fractionation, we find DP103 in both a soluble nuclear fraction as well as in the insoluble skeletal fraction. Whereas the protein and its mRNA are uniformly expressed in all tested cell lines, we observed differential expression of the mRNA. in normal human tissues.	Univ Kliniken Saarlandes, Abt Virol, Inst Med Mikrobiol & Hyg, D-66421 Homburg, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Oncol, Seattle, WA 98108 USA	Universitatsklinikum des Saarlandes; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Grasser, FA (corresponding author), Univ Kliniken Saarlandes, Abt Virol, Inst Med Mikrobiol & Hyg, D-66421 Homburg, Germany.	graesser@med-rz.uni-sb.de		Grundhoff, Adam/0000-0003-0940-7045				AKAO Y, 1992, CANCER RES, V52, P6083; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; BARTEL PL, 1993, CELLULAR INTERACTION, P53; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GRASSER FA, 1994, BLOOD, V84, P3792, DOI 10.1182/blood.V84.11.3792.bloodjournal84113792; GRASSER FA, 1991, J VIROL, V65, P3779; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HILLE A, 1993, J MED VIROL, V39, P233, DOI 10.1002/jmv.1890390311; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KNUDSON DL, 1974, J VIROL, V14, P934, DOI 10.1128/JVI.14.4.934-944.1974; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; LAUX G, 1994, J VIROL, V68, P6947, DOI 10.1128/JVI.68.11.6947-6958.1994; LEROUX A, 1994, VIROLOGY, V205, P596, DOI 10.1006/viro.1994.1687; LING PD, 1995, J VIROL, V69, P1944, DOI 10.1128/JVI.69.3.1944-1950.1995; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; RANDAHL H, 1992, EUR J BIOCHEM, V207, P55, DOI 10.1111/j.1432-1033.1992.tb17019.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rhee JY, 1998, MOL CELLS, V8, P68; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	62	91	99	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19136	19144		10.1074/jbc.274.27.19136	http://dx.doi.org/10.1074/jbc.274.27.19136			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383418	hybrid			2022-12-25	WOS:000081196300041
J	Perez, RG; Soriano, S; Hayes, JD; Ostaszewski, B; Xia, WM; Selkoe, DJ; Chen, XH; Stokin, GB; Koo, EH				Perez, RG; Soriano, S; Hayes, JD; Ostaszewski, B; Xia, WM; Selkoe, DJ; Chen, XH; Stokin, GB; Koo, EH			Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR ACCUMULATION; ENDOPLASMIC-RETICULUM; LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; SORTING SIGNALS; NT2N CELLS; SURFACE; TRAFFICKING; MUTATION	It has long been assumed that the C-terminal motif, NPXY, is the internalization signal for beta-amyloid precursor protein (APP) and that the NPXY tyrosine (Tyr(743) by APP751 numbering, Tyr(682) in APP695) is required for APP endocytosis. To evaluate this tenet and to identify the specific amino acids subserving APP endocytosis, we mutated all tyrosines in the APP cytoplasmic domain and amino acids within the sequence GYENPTY (amino acids 737-743). Stable cell lines expressing these mutations were assessed for APP endocytosis, secretion, and turnover. Normal APP endocytosis was observed for cells expressing Y709A, G737A, and Y743A mutations. However, Y738A, N740A, and P741A or the double mutation of Y738A/P741A significantly impaired APP internalization to a level similar to that observed for cells lacking nearly the entire APP cytoplasmic domain (Delta C), arguing that the dominant signal for APP endocytosis is the tetrapeptide YENP, Although not an APP internalization signal, Tyr(743) regulates rapid APP turnover because half-life increased by 50% with the Y743A mutation alone. Secretion of the APP-derived proteolytic fragment, A beta, was tightly correlated with APP internalization, such that A beta secretion was unchanged for cells having normal APP endocytosis but significantly decreased for endocytosis-deficient cell lines. Remarkably, secretion of the A beta 42 isoform was also reduced in parallel with endocytosis from internalization-deficient cell lines, suggesting an important role for APP endocytosis in the secretion of this highly pathogenic A beta species.	Allegheny Univ Hlth Sci, Dept Psychiat, Pittsburgh, PA 15212 USA; Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, Pittsburgh, PA 15212 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Perez, RG (corresponding author), 125 George St, Turtle Creek, PA 15145 USA.	perez@pitt.edu	Perez, Ruth G./AAK-9844-2020; xia, weiming/E-5465-2016; Stokin, Gorazd Bernard/D-9480-2015; Perez, Ruth/A-7388-2009	xia, weiming/0000-0002-7463-3295; Stokin, Gorazd Bernard/0000-0001-8430-8755; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012376, R01AG006173, RF1AG006173, R37AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG012376, AG06173, AG12376] Funding Source: Medline; NINDS NIH HHS [NS01812] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GUENETTE S, 1998, NEUROBIOL AGING, V19, pS72; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jung SS, 1996, J NEUROSCI RES, V46, P336, DOI 10.1002/(SICI)1097-4547(19961101)46:3<336::AID-JNR7>3.3.CO;2-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P407; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Selkoe DJ, 1996, COLD SPRING HARB SYM, V61, P587; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yamazaki T, 1996, J CELL SCI, V109, P999; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	56	344	349	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18851	18856		10.1074/jbc.274.27.18851	http://dx.doi.org/10.1074/jbc.274.27.18851			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383380	hybrid			2022-12-25	WOS:000081196300003
J	Butz, S; Fernandez-Chacon, R; Schmitz, F; Jahn, R; Sudhof, TC				Butz, S; Fernandez-Chacon, R; Schmitz, F; Jahn, R; Sudhof, TC			The subcellular localizations of atypical synaptotagmins III and VI - Synaptotagmin III is enriched in synapses and synaptic plasma membranes but not in synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; PROTEINS; DOMAIN; ISOFORM; CELLS; BRAIN; CA2+; COMPONENTS; NEUREXINS	Multiple synaptotagmins are expressed in brain, but only synaptotagmins I and II have known functions in fast, synchronous Ca2+-triggered neurotransmitter release. Synaptotagmin III was proposed to regulate other aspects of synaptic vesicle exocytosis, particularly its slow component. Such a function predicts that synaptotagmin IU. should be an obligatory synaptic vesicle protein, as would also be anticipated from its high homology to synaptotagmins I and II. To test this hypothesis, we studied the distribution, developmental expression, and localization of synaptotagmin III and its closest homolog, synaptotagmin VI. We find that synaptotagmins III and VI are present in all brain regions in heterogeneous distributions and that their levels increase during development in parallel with synaptogenesis, Furthermore, we show by immunocytochemistry that synaptotagmin III is concentrated in synapses, as expected, Surprisingly, however, we observed that synaptotagmin III is highly enriched in synaptic plasma membranes but not in synaptic vesicles. Synaptotagmin VI was also found to be relatively excluded from synaptic vesicles. Our data suggest that synaptotagmins III and VI perform roles in neurons that are not linked to synaptic vesicle exocytosis but to other Ca2+-related nerve terminal events, indicating that the functions of synaptotagmins are more diverse than originally thought.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Max Planck Inst Biophys Chem, Abt Neurobiol, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Jahn, Reinhard/0000-0003-1542-3498; Fernandez-Chacon, Rafael/0000-0002-9845-9885				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Daly C, 1997, J NEUROSCI, V17, P2365; Dowling J. E., 1987, RETINA; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NAGY A, 1976, BRAIN RES, V109, P285, DOI 10.1016/0006-8993(76)90531-X; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Thompson CC, 1996, J NEUROSCI, V16, P7832; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859	40	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18290	18296		10.1074/jbc.274.26.18290	http://dx.doi.org/10.1074/jbc.274.26.18290			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373432	hybrid			2022-12-25	WOS:000081056700024
J	Cunningham, SA; Tran, TM; Arrate, MP; Brock, TA				Cunningham, SA; Tran, TM; Arrate, MP; Brock, TA			Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase - A real time kinetic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; LIGAND-BINDING; CRYSTAL-STRUCTURE; FLT-1 RECEPTOR; IN-VIVO; VEGF; IDENTIFICATION; DIMERIZATION; KDR	The kinase insert domain-containing receptor (KDR) tyrosine kinase mediates calcium mobilization in endothelial cells and plays a key role during physiological and pathological angiogenesis, To provide a detailed understanding of how KDR is activated, we analyzed the kinetics of ligand-receptor interaction using BIAcore. Both predimerized (KDR-Fc) and monomeric (KDR-cbu) receptors were examined with vascular endothelial cell growth factor (VEGF) homodimers and VEGF/placental growth factor (PIGF) heterodimers. VEGF binds to KDR-Fc with k(a) = 3.6 +/- 0.07e(6), k(d) = 1.54 +/- 0.19e(-4), and K-D = 37.1 +/- 4.9 pM. These values are similar to those displayed by monomeric KDR where k(a) = 5.23 +/- 1.4e(6), k(d) = 2.74 +/- 0.76e(-4), and KD = 51.7 +/- 5.8 pM were apparent. In contrast, VEGF/PIGF bound to KDR-Fc with k(a) = 7.3 +/- 1.6e(4), k(d) = 4.4 +/- 1.2e(-4), and K-D = 6 +/- 1.2 nM. Thus, the heterodimer displays a 160-fold reduced K-D for binding to predimerized KDR, which is mainly a consequence of a 50-fold reduction in k(a). We were unable to detect association between VEGF/PIGF and monomeric KDR. However, nanomolar concentrations of VEGF/ PIGF were able to elicit weak calcium mobilization in endothelial cells. This latter observation may indicate partial predimerization of KDR on the cell surface or facilitation of binding due to accessory receptors.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Integrat Biol Physiol & Pharmacol, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, Suite 1920,7000 Fannin, Houston, TX 77030 USA.	scunningham@tbc.com						Barleon B, 1997, J BIOL CHEM, V272, P10382; BIACORE AB, 1997, BIAEVALUATION; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COA Y, 1996, J BIOL CHEM, V271, P3154; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong TAT, 1999, CANCER RES, V59, P99; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; PARK JE, 1994, J BIOL CHEM, V269, P25646; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sugihara T, 1998, J BIOL CHEM, V273, P3033, DOI 10.1074/jbc.273.5.3033; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	41	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18421	18427		10.1074/jbc.274.26.18421	http://dx.doi.org/10.1074/jbc.274.26.18421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373449	hybrid			2022-12-25	WOS:000081056700041
J	Mathus, A; Bajaj, SP				Mathus, A; Bajaj, SP			Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa - Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	12th Symposium of the Protein-Society	JUL 25-29, 1998	SAN DIEGO, CALIFORNIA	Protein Soc			COAGULATION FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CA2+-BINDING SITE; FACTOR-X ACTIVATION; BLOOD-COAGULATION; HEMOPHILIA-B; TISSUE FACTOR; ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY	Previous studies revealed that cleavage at Arg-318-Ser-319 in the protease domain autolysis loop of factor Ma results in its diminished binding to factor VIIIa. Now, we have investigated the importance of adjacent surface-exposed helix 330-338 (162-170 in chymotrypsin numbering) of IX in its interaction with VIIIa, IXWT, eight point mutants mostly based on hemophilia B patients, and a replacement mutant (IXhelixVII in which helix 330-338 is replaced by that of factor VII) were expressed, purified, and characterized. Each mutant was activated normally by VIIa-tissue factor-Ca2+ or XIa-Ca2+, However, in both the presence and absence of phospholipid, interaction of each activated mutant with VIIIa was impaired. The role of IX EGF1 domain in binding to VIIIa was also examined, Two mutants (IXQ50P and IXPCEGF1, in which EGF1 domain is replaced by that of protein C) were used. Strikingly, interactions of the activated EGF1 mutants with VIIIa were impaired only in the presence of phospholipid. We conclude that helix 330 in Ma provides a critical binding site for VIIIa and that the EGF1 domain in this context primarily serves to correctly position the protease domain above the phospholipid surface for optimal interaction with VIIIa.	St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University	Bajaj, SP (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med, 3635 Vista Ave & Grand Blvd,POB 15250, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R55HL036365, R01HL036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED SS, 1995, BIOCHEM J, V310, P427; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BAJAJ SP, 1999, IN PRESS THROMB HAEM; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; Chang JL, 1998, J BIOL CHEM, V273, P12089, DOI 10.1074/jbc.273.20.12089; Chang JL, 1998, BLOOD, V92, p184A; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FRAZIER D, 1989, BLOOD, V74, P971; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LIN SW, 1990, J BIOL CHEM, V265, P144; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; LUDWIG M, 1992, BLOOD, V79, P1225; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mathur A, 1998, BLOOD, V92, p352A; MATHUR A, 1998, PROTEIN SCI S1, V7, P135; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SPITZER SG, 1990, BLOOD, V76, P1530; SPITZER SG, 1990, BIOCHEM J, V265, P219, DOI 10.1042/bj2650219; USHARANI P, 1985, J CLIN INVEST, V75, P76, DOI 10.1172/JCI111700; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	53	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18477	18486		10.1074/jbc.274.26.18477	http://dx.doi.org/10.1074/jbc.274.26.18477			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373456	hybrid			2022-12-25	WOS:000081056700048
J	Yohannan, J; Wienands, J; Coggeshall, KM; Justement, LB				Yohannan, J; Wienands, J; Coggeshall, KM; Justement, LB			Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ANTIGEN RECEPTOR; CD22-DEFICIENT MICE; NEGATIVE REGULATOR; PHOSPHATASE 1C; IG-BETA; ACTIVATION; KINASE; SYK; ASSOCIATION	The B cell-restricted transmembrane glycoprotein CD22 is rapidly phosphorylated on tyrosine in response to cross-linking of the B cell antigen receptor, thereby generating phosphotyrosine motifs in the cytoplasmic domain which recruit intracellular effector proteins that contain Src homology 2 domains. By virtue of its interaction with these effector proteins CD22 modulates signal transduction through the B cell antigen receptor. To define further the molecular mechanism by which CD22 mediates its co-receptor function, phosphopeptide mapping experiments were conducted to determine which of the six tyrosine residues in the cytoplasmic domain are involved in recruitment of the stimulatory effector proteins phospholipase C gamma (PLC gamma), phosphoinositide 3-kinase (PI3K), Grb2, and Syk. The results obtained indicate that the protein tyrosine kinase Syk interacts with multiple CD22-derived phosphopeptides in both immunoprecipitation and reverse Far Western assays. In contrast, the Grb2.Sos complex was observed to bind exclusively to the fourth phosphotyrosine motif ((YENV)-E-828) from CD22 and does so via a direct interaction based on Far Western and reverse Far Western blotting. Although both PLC gamma and PI3K were observed to bind to multiple phosphopeptides in precipitation experiments, subsequent studies using reverse Far Western blot analysis demonstrated that only the carboxyl-terminal phosphopeptide of CD22 ((YVTL)-V-868) binds directly to either one. This finding suggests that PLC gamma and PI3K may be recruited to CD22 either through a direct interaction with Tyr(868) Or indirectly through an association with one or more intermediate proteins.	Univ Alabama Birmingham, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Medical Branch Galveston; University System of Ohio; Ohio State University; Max Planck Society	Justement, LB (corresponding author), Univ Alabama Birmingham, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA.	louis.justement@ccc.uab.edu		Justement, Louis/0000-0001-7058-867X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Erickson LD, 1996, INT IMMUNOL, V8, P1121, DOI 10.1093/intimm/8.7.1121; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Methot N, 1996, MOL CELL BIOL, V16, P5328; Nadler MJS, 1997, J IMMUNOL, V159, P4233; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Stoddart A, 1997, INT IMMUNOL, V9, P1571, DOI 10.1093/intimm/9.10.1571; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; WIENANDS J, 1995, INT IMMUNOL, V7, P1701, DOI 10.1093/intimm/7.11.1701; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	47	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18769	18776		10.1074/jbc.274.26.18769	http://dx.doi.org/10.1074/jbc.274.26.18769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373493	hybrid			2022-12-25	WOS:000081056700085
J	Luo, Y; Zhou, Y; Cooperman, BS				Luo, Y; Zhou, Y; Cooperman, BS			Antichymotrypsin interaction with chymotrypsin - Intermediates on the way to inhibited complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SERPIN-PROTEASE COMPLEXES; REACTIVE CENTER LOOP; SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; PROTEINASE COMPLEX; SERINE PROTEINASE; MICHAELIS COMPLEX; HEPARIN-BINDING; HINGE REGION	Serpins form enzymatically inactive covalent complexes (designated E*I*) with their target proteinases, corresponding most likely to the acyl enzyme that resembles the normal intermediate in substrate turnover. Formation of E*I* involves large changes in the conformation of the reactive center loop (residues P17 to P9') and of the serpin molecule in general. The "hinge" region of the reactive center loop, including residues P10-P14, shows facile movement in and out of beta-sheet A, and this movement appears to be crucial in determining whether E*I* is formed (the inhibitor pathway) or whether I is rapidly hydrolyzed to I* (the substrate pathway). Here, we report stopped-flow and rapid quench studies investigating the pH dependence of the conversion of the alpha(1)-antichymotrypsin.alpha-chymotrypsin encounter complex, E.I, to E*I*. These studies utilize fluorescent derivatives of cysteine variants of cu,antichymotrypsin at the P11 and P13 residues. Our results demonstrate three identifiable intermediates, EIa, EIb, and EIc, between E.I and E*I* and permit informed speculation regarding the nature of these intermediates. Partitioning between inhibitor and substrate pathways occurs late in the process of E*I* formation, most likely from a species occurring between EIc and E*I*.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P9487; Bjork I, 1998, BIOCHEM J, V335, P701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrell R, 1997, THROMB HAEMOSTASIS, V78, P516; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; FINK AL, 1979, P NATL ACAD SCI USA, V76, P1566, DOI 10.1073/pnas.76.4.1566; FINK AL, 1976, BIOCHEMISTRY-US, V15, P1580, DOI 10.1021/bi00652a031; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gils A, 1998, BBA-PROTEIN STRUCT M, V1387, P291, DOI 10.1016/S0167-4838(98)00139-3; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Janciauskiene S, 1998, J BIOL CHEM, V273, P28360, DOI 10.1074/jbc.273.43.28360; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIEBERMAN J, 1995, NEUROBIOL AGING, V16, P747, DOI 10.1016/0197-4580(95)00056-K; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCALIA R, 1995, SHOCK, V4, P251, DOI 10.1097/00024382-199510000-00004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Shrikumar A, 1998, J BIOL CHEM, V273, P17459, DOI 10.1074/jbc.273.28.17459; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, ADV EXP MED BIOL, V425, P5; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; ZHONG JQ, 1996, THESIS U PENNSYLVANI	50	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17733	17741		10.1074/jbc.274.25.17733	http://dx.doi.org/10.1074/jbc.274.25.17733			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364215	hybrid			2022-12-25	WOS:000080974300051
J	Mitchell, RA; Metz, CN; Peng, T; Bucala, R				Mitchell, RA; Metz, CN; Peng, T; Bucala, R			Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF) - Regulatory role in cell proliferation and glucocorticoid action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; N-TERMINAL KINASE; NEURITE OUTGROWTH; CYCLIC-AMP; PHOSPHORYLATION; A(2); CALCIUM; FORSKOLIN; INDUCTION	Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory mediator with the unique ability to counter-regulate the inhibitory effects of glucocorticoids on immune cell activation. MIF is released from cells in response to glucocorticoids,certain pro-inflammatory stimuli, and mitogens and acts to regulate glucocorticoid action on the ensuing inflammatory response. To gain insight into the molecular mechanism of MIF action, we have examined the role of MIF in the proliferation and intracellular signaling events of the well characterized, NIH/3T3 fibroblast cell line. Both endogenously secreted and exogenously added MIFs stimulate the proliferation of NIH/3T3 cells, and this response is associated with the activation of the p44/p42 extracellular signal-regulated (ERK) mitogen-activated protein kinases (MAP). The MIF-induced activation of these kinases was sustained for a period of at least 24 h and was dependent upon protein kinase A activity. We further show that MIF regulates cytosolic phospholipase Az activity via a protein kinase A and ERK dependent pathway and that the glucocorticoid suppression of cytokine-induced cytoplasmic phospholipase A2 activity and arachidonic acid release can be reversed by the addition of recombinant MIF. These studies indicate that the sustained activation of p44/p42 MAP kinase and subsequent arachidonate release by cytoplasmic phospholipase A2 are important features of the immunoregulatory and intracellular signaling events initiated by MIF and provide the first insight into the mechanisms that underlie the pro-proliferative and inflammatory properties of this mediator.	Picower Inst Med Res, Manhasset, NY 10030 USA; Albany Med Coll, Dept Expt Pathol, Albany, NY 12208 USA	Northwell Health; Albany Medical College	Bucala, R (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 10030 USA.	rbucala@picower.edu		Christine, Metz/0000-0002-1013-1691	NIAID NIH HHS [1R01 AI42310-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042310] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Freeman EJ, 1998, AM J PHYSIOL-CELL PH, V274, pC282, DOI 10.1152/ajpcell.1998.274.1.C282; GALLI C, 1995, J NEUROSCI, V15, P1172; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Meinhardt A, 1996, ENDOCRINOLOGY, V137, P5090, DOI 10.1210/en.137.11.5090; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Spada A, 1997, HORM RES, V47, P235, DOI 10.1159/000185469; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240	45	379	412	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18100	18106		10.1074/jbc.274.25.18100	http://dx.doi.org/10.1074/jbc.274.25.18100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364264	hybrid			2022-12-25	WOS:000080974300100
J	Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G				Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G			Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas	ONCOGENE			English	Article						rat DMBA sarcoma; HGF receptor; Met gene amplification	MET PROTOONCOGENE PRODUCT; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; GENE AMPLIFICATION; SOLID TUMORS; HA-RAS; EXPRESSION; CANCER; CELLS	In the present study subcutaneous fibrosarcomas were induced by the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) in rats from F1 generation cross breedings of two different inbred strains. Comparative genomic hybridization (CGH) analysis, which allows detection of DNA sequence copy changes, was applied to one of the tumors and it was found that there were increased copy numbers of sequences at chromosome 4q12-q21 in this tumor. We have previously determined that the loci for the hepatocyte growth factor (Hgf) and hepatocyte growth factor receptor (Hgfr/Met), a protooncogene, are situated in this particular chromosome region, Using probes for the two genes in FISH (fluorescence in situ hybridization) and in Southern blots we found that the Hgfr/Met gene was amplified in five of the 19 sarcomas studied, and that the Hgf gene,vas coamplified in two of them. Northern and Western blots and tyrosine phosphorylation analysis showed that the HGF receptor was overexpressed and functional in all five tumors, as well as in two additional tumors. In summary, both amplification and overexpression of the Hgfr/Met gene was found in about 25% of DMBA-induced experimental rat sarcomas, and HGF receptor overexpression alone was seen in two additional tumors. Possibly this reflects an involvement in paracrine or autocrine stimulation of growth and invasiveness by HGF. Our finding could provide a rodent model system to increased knowledge about causality and therapy, which may be applicable to the sizeable fraction of human musculoskeletal tumors displaying MET overexpression.	Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden; Univ Gothenburg, Res Ctr Endocrinol & Metab, Gothenburg, Sweden; Univ Gothenburg, Dept Pathol, Gothenburg, Sweden; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; Lund University; Skane University Hospital	Helou, K (corresponding author), Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden.		Wallenius, Ville Raymond/C-5486-2014	Wallenius, Ville Raymond/0000-0001-8668-3196				BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Ferracini R, 1996, ONCOGENE, V12, P1697; FISCHER U, 1995, GENE CHROMOSOME CANC, V12, P63, DOI 10.1002/gcc.2870120111; GALEAZZI E, 1997, EUR ARCH OTO-RHINO-L, V1, pS138; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; Iwazawa T, 1996, JPN J CANCER RES, V87, P1134, DOI 10.1111/j.1349-7006.1996.tb03123.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LEVAN G, 1976, HEREDITAS, V83, P83; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO K, 1996, J BIOCH, V119, P519; MITELMAN F, 1972, SCIENCE, V176, P1340, DOI 10.1126/science.176.4041.1340; MITELMAN F, 1972, HEREDITAS-GENETISK A, V71, P325; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Naka T, 1997, MODERN PATHOL, V10, P832; NISSON PE, 1992, FOCUS, V14, P119; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; Wallenius VR, 1997, MAMM GENOME, V8, P661, DOI 10.1007/s003359900533; Yamanouchi K, 1995, LASER CHEM, V16, P1, DOI 10.1155/1995/74390; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	36	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3226	3234		10.1038/sj.onc.1202658	http://dx.doi.org/10.1038/sj.onc.1202658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359528				2022-12-25	WOS:000080523800005
J	Lee, Y; Shacter, E				Lee, Y; Shacter, E			Oxidative stress inhibits apoptosis in human lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDANT INJURY; ADENOSINE-TRIPHOSPHATE; ENDOTHELIAL-CELLS; DEATH; NECROSIS; BCL-2; DNA; ATP; OXYGEN	Apoptosis and necrosis are two forms of cell death that are induced under different conditions and that differ in morphological and biochemical features. In this report, we show that, in the presence of oxidative stress, human B lymphoma cells are unable to undergo apoptosis and die instead by a form of necrosis. This was established using the chemotherapy drug VP-16 or the calcium ionophore A23187 to induce apoptosis in Burkitt's lymphoma cell lines and by measuring classical markers of apoptotic death, including cell morphology, annexin V binding, DNA ladder formation, and caspase activation. In the presence of relatively low levels of H2O2 (75-100 mu M), VP-16 and A23187 were unable to induce apoptosis in these cells. Instead, the cells underwent non-apoptotic cell death with mild cytoplasmic swelling and nuclear shrinkage, similar to the death observed when they were treated with H2O2 alone. We found that H2O2 inhibits apoptosis by depleting the cells of ATP, The effects of H2O2 can be overcome by inhibitors of poly(ADP)-ribosylation, which also preserve cellular ATP levels, and can be mimicked by agents such as oligomycin, which inhibit ATP synthesis. The results show that oxidants can manipulate cell death pathways, diverting the cell away from apoptosis, The potential physiological ramifications of this finding will be discussed.	US FDA, Ctr Biol Evaluat & Res, Div Hematol Prod, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Shacter, E (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Hematol Prod, HFM-538,Bldg 29A,Rm 2A-11, Bethesda, MD 20892 USA.							BALLA G, 1990, J LAB CLIN MED, V116, P546; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BICKNELL GR, 1995, BIOCHEM BIOPH RES CO, V207, P40, DOI 10.1006/bbrc.1995.1150; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; BUTTKE TM, 1994, IMMUNOL TODAY, V17, P7; Ciolino HP, 1997, FREE RADICAL BIO MED, V22, P1277, DOI 10.1016/S0891-5849(96)00495-9; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Comelli M, 1998, FREE RADICAL BIO MED, V24, P924, DOI 10.1016/S0891-5849(97)00373-0; Eguchi Y, 1997, CANCER RES, V57, P1835; FADY C, 1995, J INTERF CYTOK RES, V15, P71, DOI 10.1089/jir.1995.15.71; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Halliwell B, 1988, FREE RADICALS BIOL M; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kass GEN, 1996, BIOCHEM J, V318, P749, DOI 10.1042/bj3180749; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Palomba L, 1996, FEBS LETT, V390, P91, DOI 10.1016/0014-5793(96)00634-5; Palomba L, 1996, EUR J PHARMACOL, V318, P167, DOI 10.1016/S0014-2999(96)00763-7; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Savill J, 1997, BRIT MED BULL, V53, P491; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRAUFSTATTER IU, 1985, J CLIN INVEST, V76, P1131, DOI 10.1172/JCI112068; SEARLE J, 1982, PATHOL ANNU, V17, P229; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STARKE PE, 1985, J BIOL CHEM, V260, P99; WATSON AJM, 1995, GASTROENTEROLOGY, V109, P472, DOI 10.1016/0016-5085(95)90335-6; WYLLIE AH, 1992, OXFORD TXB PATHOLOGY, P141	52	218	221	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19792	19798		10.1074/jbc.274.28.19792	http://dx.doi.org/10.1074/jbc.274.28.19792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391922	hybrid			2022-12-25	WOS:000081377300042
J	Powell, MD; Beard, WA; Bebenek, K; Howard, KJ; Le Grice, SFJ; Darden, TA; Kunkel, TA; Wilson, SH; Levin, JG				Powell, MD; Beard, WA; Bebenek, K; Howard, KJ; Le Grice, SFJ; Darden, TA; Kunkel, TA; Wilson, SH; Levin, JG			Residues in the alpha H and alpha I helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLUS-STRAND DNA; ALANINE-SCANNING MUTAGENESIS; ANGSTROM RESOLUTION; POLYMERASE DOMAIN; RIBONUCLEASE-H; CRYSTAL-STRUCTURE; TYPE-1; MUTATIONS; SEQUENCE	During retrovirus replication, reverse transcriptase (RT) must specifically interact with the polypurine tract (PPT) to generate and subsequently remove the RNA primer for plus-strand DNA synthesis. We have investigated the role that human immunodeficiency virus-1 RT residues in the alpha H and alpha I helices in the thumb subdomain play in specific RNase H cleavage at the 3'-end of the PPT; an in vitro assay modeling the primer removal step was used. Analysis of alanine-scanning mutants revealed that a subgroup exhibits an unusual phenotype in which the PPT is cleaved up to seven bases from its 3'-end. Further analysis of alpha H mutants (G262A, K263A, N265A, and W266A) with changes in residues in or near a structural motif known as the minor groove binding track showed that the RNase H activity of these mutants is more dramatically affected with PPT substrates than with non-PPT substrates. Vertical scan mutants at position 266 were all defective in specific RNase H cleavage, consistent with conservation of tryptophan at this position among lentiviral RTs, Our results indicate that residues in the thumb subdomain and the minor groove binding track in particular, are crucial for unique interactions between RT and the PPT required for correct positioning and precise RNase H cleavage.	NICHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Case Western Reserve Univ, Ctr AIDS Res, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Case Western Reserve University	Levin, JG (corresponding author), NICHD, Genet Mol Lab, NIH, Bldg 6B,Room 216, Bethesda, MD 20892 USA.	judith_levin@nih.gov	Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293	DIVISION OF BASIC SCIENCES - NCI [Z01BC010314] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52263] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; Bowman EH, 1996, J VIROL, V70, P1687, DOI 10.1128/JVI.70.3.1687-1694.1996; Brown P. O., 1997, P161; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gao HQ, 1998, J MOL BIOL, V277, P559, DOI 10.1006/jmbi.1998.1624; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; Hermann T, 1996, EUR J BIOCHEM, V242, P98, DOI 10.1111/j.1432-1033.1996.0098r.x; HONG H, 1991, GROWTH REGULAT, V1, P65; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Hughes SH, 1996, J VIROL, V70, P2679, DOI 10.1128/JVI.70.5.2679-2683.1996; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SMITH JS, 1992, J BIOL CHEM, V267, P15071; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; Telesnitsky A., 1997, P121; VARMUS H, 1989, MOBILE DNA, P53; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; Yusupova G, 1996, J MOL BIOL, V261, P315, DOI 10.1006/jmbi.1996.0463; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	59	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19885	19893		10.1074/jbc.274.28.19885	http://dx.doi.org/10.1074/jbc.274.28.19885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391934	hybrid			2022-12-25	WOS:000081377300054
J	Allan, BW; Garcia, R; Maegley, K; Mort, J; Wong, D; Lindstrom, W; Beechem, JM; Reich, NO				Allan, BW; Garcia, R; Maegley, K; Mort, J; Wong, D; Lindstrom, W; Beechem, JM; Reich, NO			DNA bending by EcoRI DNA methyltransferase accelerates base flipping but compromises specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; S-ADENOSYLMETHIONINE; TARGET BASE; METHYLASE; ENZYME; RECOGNITION; COFACTOR; BINDING; COMPLEX; MECHANISM	EcoRI DNA methyltransferase was previously shown to bend its cognate DNA sequence by 52 degrees and stabilize the target adenine in an extrahelical orientation. We describe the characterization of an EcoRI DNA methyltransferase mutant in which histidine 235 was selectively replaced with asparagine. Steady-state kinetic and thermodynamic parameters for the H235N mutant revealed only minor functional consequences: DNA binding affinity (K-D(DNA)) was reduced 10-fold, and k(cat) was decreased 30%. However, in direct contrast to the wild type enzyme, DNA bending within the mutant enzyme-DNA complexes was not observed by scanning force microscopy, The bending-deficient mutant showed enhanced discrimination against the methylation at nontarget sequence DNA. This enhancement of enzyme discrimination was accompanied by a change in the rate-limiting catalytic step. No presteady-state burst of product formation was observed, indicating that the chemistry step (or prior event) had become rate-limiting for methylation. Direct observation of the base flipping transition showed that the lack of burst kinetics was entirely due to slower base flipping. The combined data show that DNA bending contributes to the correct assembly of the enzyme-DNA complex to accelerate base flipping and that slowing the rate of this precatalytic isomerization can enhance specificity.	Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; Vanderbilt University; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.							Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Fersht A., 1985, ENZYME STRUCTURE MEC; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; HACKNEY DD, 1990, ENZYMES, V19, P1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sawa R., 1995, NATURE, V373, P487; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SMITH DW, 1992, NUCLEIC ACIDS RES, V20, P6091, DOI 10.1093/nar/20.22.6091; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645	33	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19269	19275		10.1074/jbc.274.27.19269	http://dx.doi.org/10.1074/jbc.274.27.19269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383435	hybrid			2022-12-25	WOS:000081196300058
J	Belting, M; Petersson, P				Belting, M; Petersson, P			Intracellular accumulation of secreted proteoglycans inhibits cationic lipid-mediated gene transfer - Co-transfer of glycosaminoglycans to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-PROMOTER SPERMINE; DNA-LIPOSOME COMPLEXES; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; ANTIPROLIFERATIVE ACTIVITY; CYSTIC-FIBROSIS; MAMMALIAN-CELLS; HUMAN-MELANOMA; IN-VITRO	Molecules secreted by potential target cells may interfere with cationic lipid-mediated gene transfer. This has been studied using human lung fibroblasts and human epidermoid lung cancer cells. Secreted cell medium components caused a substantial decrease both in the uptake of cationic lipid-DNA complexes (2-4-fold) and in reporter gene expression (100-1000-fold). Metabolic labeling of the cell medium showed that especially [S-35]sulfate-labeled macromolecules competed with DNA for binding to the cationic lipid. Release of DNA from the cationic lipid by cell medium components was demonstrated by an ethidium bromide intercalation assay. In the presence of the cationic lipid, the secreted macromolecules were internalized by the cells. By enzymatic digestions, it was shown that the competing macromolecules consist of chondroitin/dermatan sulfate and heparan sulfate proteoglycans and that the effects on transfection were mediated by the polyanionic glycosaminoglycan portion of the proteoglycan. Accordingly, pretreatment of cell medium with the polycationic peptide protamine sulfate abrogated the inhibitory effects on gene transfer. Fluorescence microscopy studies revealed that heparan sulfate, internalized as a complex with cationic lipids, accumulated in the cell nuclei. These results support the view that the lack of specificity of this type of gene transfer vehicle is a major hindrance to efficient and safe in vivo administration.	Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, S-22100 Lund, Sweden	Lund University	Belting, M (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, POB 94, S-22100 Lund, Sweden.		Petersson, Per/A-5740-2010; Petersson, Per/P-1878-2019	Petersson, Per/0000-0001-6697-0171; Petersson, Per/0000-0001-6697-0171; Belting, Mattias/0000-0003-1585-5434				Anderson WF, 1998, NATURE, V392, P25; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BELTING M, 1993, GLYCOCONJUGATE J, V10, P453, DOI 10.1007/BF00737966; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHENG F, 1992, GLYCOBIOLOGY, V2, P553, DOI 10.1093/glycob/2.6.553; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COHEN IR, 1994, CANCER RES, V54, P5771; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Escriou V, 1998, BBA-BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005-2736(97)00194-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu L, 1997, DISTRIB PARALLEL DAT, V5, P167, DOI 10.1023/A:1008641408566; LORIES V, 1987, J BIOL CHEM, V262, P854; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Nabel GJ, 1996, P NATL ACAD SCI USA, V93, P15388, DOI 10.1073/pnas.93.26.15388; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; QUAHABI AE, 1997, FEBS LETT, V414, P187; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reimer DL, 1997, J BIOL CHEM, V272, P19480, DOI 10.1074/jbc.272.31.19480; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P289, DOI 10.1042/bj2650289; SIE P, 1989, THROMB RES, V54, P63, DOI 10.1016/0049-3848(89)90337-X; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZHOU XH, 1991, BIOCHIM BIOPHYS ACTA, V1065, P8, DOI 10.1016/0005-2736(91)90003-Q	48	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19375	19382		10.1074/jbc.274.27.19375	http://dx.doi.org/10.1074/jbc.274.27.19375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383450	hybrid			2022-12-25	WOS:000081196300073
J	Beuret, N; Rutishauser, J; Bider, MD; Spiess, M				Beuret, N; Rutishauser, J; Bider, MD; Spiess, M			Mechanism of endoplasmic reticulum retention of mutant vasopressin precursor caused by a signal peptide truncation associated with diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPHYSIN-II GENE; CRYSTAL-STRUCTURE; INTERNAL SIGNAL; CLEAVAGE SITES; CELL-LINE; IDENTIFICATION; MUTATION; KINDREDS; SEQUENCE; SUBSTITUTION	Autosomal dominant neurohypophyseal diabetes insipidus is caused by mutations in the gene encoding the vasopressin precursor protein, prepro-vasopressin-neurophysin II. We analyzed the molecular consequences of a mutation (Delta G227) recently identified in a Swiss kindred that destroys the translation initiation codon, In COS-7 cells transfected with the mutant cDNA, translation was found to initiate at an alternative ATG, producing a truncated signal sequence that was functional for targeting and translocation but was not cleaved by signal peptidase, The mutant precursor was completely retained within the endoplasmic reticulum. The uncleaved signal did not affect folding of the neurophysin portion of the precursor, as determined by its protease resistance. However, formation of disulfide-linked aggregates indicated that it interfered with the formation of the disulfide bond in vasopressin, most likely by blocking its insertion into the hormone binding site of neurophysin. Preventing disulfide formation in the vasopressin nonapeptide by mutation of cysteine 6 to serine was shown to be sufficient to cause aggregation and retention. These results indicate that the Delta G227 mutation induces translation of a truncated signal sequence that cannot be cleaved but prevents correct folding and oxidation of vasopressin, thereby causing precursor aggregation and retention in the endoplasmic reticulum.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Kantonsspital, Dept Med, CH-6000 Luzern 16, Switzerland	University of Basel; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital	Spiess, M (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	spiess@ubaclu.unibas.ch		Spiess, Martin/0000-0001-7139-0550				BAYLIS PH, 1981, POSTGRAD MED J, V57, P36, DOI 10.1136/pgmj.57.663.36; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; Calvo B, 1998, J CLIN ENDOCR METAB, V83, P995, DOI 10.1210/jc.83.3.995; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Deeb R, 1996, BIOCHEMISTRY-US, V35, P864, DOI 10.1021/bi951947u; Ellermann M, 1939, ACTA PSYCH NEUROL, V14, P233, DOI 10.1111/j.1600-0447.1939.tb06638.x; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FORSSMAN H, 1945, ACTA MED SCANDINAV S, V159, P1; Gagliardi PC, 1997, J CLIN ENDOCR METAB, V82, P3643, DOI 10.1210/jc.82.11.3643; Gaupp R, 1941, Z GESAMTE NEUROL PSY, V171, P514, DOI 10.1007/BF02880551; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; HANHART E, 1940, HDB ERBBIOLOGIE ME 2, V4, P798; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; KAPLOWITZ PB, 1982, J PEDIATR-US, V100, P76, DOI 10.1016/S0022-3476(82)80238-2; LEVINGER EL, 1955, J CLIN ENDOCR METAB, V15, P547, DOI 10.1210/jcem-15-5-547; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Olias G, 1996, DNA CELL BIOL, V15, P929, DOI 10.1089/dna.1996.15.929; PEDERSEN EB, 1985, Q J MED, V57, P883; Rittig S, 1996, AM J HUM GENET, V58, P107; RITTIG S, 1993, VASOPRESSIN, P600; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; Ueta Y, 1996, J CLIN ENDOCR METAB, V81, P1787, DOI 10.1210/jc.81.5.1787; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287	42	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18965	18972		10.1074/jbc.274.27.18965	http://dx.doi.org/10.1074/jbc.274.27.18965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383395	hybrid			2022-12-25	WOS:000081196300018
J	Burke, JR; Witmer, MR; Zusi, FC; Gregor, KR; Davern, LB; Padmanabha, R; Swann, RT; Smith, D; Tredup, JA; Micanovic, R; Manly, SP; Villafranca, JJ; Tramposch, KM				Burke, JR; Witmer, MR; Zusi, FC; Gregor, KR; Davern, LB; Padmanabha, R; Swann, RT; Smith, D; Tredup, JA; Micanovic, R; Manly, SP; Villafranca, JJ; Tramposch, KM			Competitive, reversible inhibition of cytosolic phospholipase A(2) at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; SCOOTING MODE; CELL-LINE; CATALYSIS; MEMBRANES; MECHANISM; VESICLES; BINDING; PHOSPHORYLATION; ACTIVATION	Cytosolic phospholipase A(2) (cPL(2)) catalyzes the selective release of arachidonic acid from the sn-2 position of phospholipids and is believed to play a key cellular role in the generation of arachidonic acid. When assaying the human recombinant cPLA(2) using membranes isolated from [H-3] arachidonate-labeled U937 cells as substrate, 2-(2'-benzyl-4-chlorophenoxy)ethyl-dimethyl-n-octadecyl-ammonium chloride (compound 1) was found to inhibit the enzyme in a dose-dependent manner (IC50 = 5 mu M). It was over 70 times more selective for the cPLA(2) as compared with the human nonpancreatic se creted phospholipase A(2), and it did not inhibit other phospholipases, Additionally, it inhibited arachidonate production in N-formyl-methionyl-leucyl-phenylalanine-stimulated U937 cells. To further characterize the mechanism of inhibition, an assay in which the enzyme is bound to vesicles of 1,2-dimyristoyl-sn-glycero-3-phosphomethanol containing 6-10 mol % of 1-palmitoyl-2-[1-C-14]arachidonoyl-sn-glycero-3-phosphocholine was employed. With this substrate system, the dose-dependent inhibition could be defined by kinetic equations describing competitive inhibition at the lipid-water interface. The apparent equilibrium dissociation constant for the inhibitor bound to the enzyme at the interface (K-I(*app)) was determined to be 0.097 +/- 0.032 mol % versus an apparent dissociation constant for the arachidonate-containing phospholipid of 0.3 +/- 0.1 mol %. Thus, compound 1 represents a novel structural class of inhibitor of cPLA(2) that partitions into the phospholipid bilayer and competes with the phospholipid substrate for the active site. Shorter n-alkyl-chained (C-4, C-6, C-8) derivatives of compound 1 were shown to have even smaller K-I(*app) values. However, these short-chained analogs were less potent in terms of bulk inhibitor concentration needed for inhibition when using the [H-3]arachidonate-labaled U937 membranes as substrate. This discrepancy was reconciled by showing that these shorter-chained analogs did not partition into the [H-3]arachidonate-labeled U937 membranes as effectively as compound 1. The implications for in vivo efficacy that result from these findings are discussed.	Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Buffalo, NY 14213 USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Wallingford, CT 06492 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Burke, JR (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, POB 4000, Princeton, NJ 08543 USA.	burkej@bms.com						Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BASSOLINOKLIMAS D, 1993, BIOCHEMISTRY-US, V32, P12624, DOI 10.1021/bi00210a010; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; Burke JR, 1997, BIOCHEMISTRY-US, V36, P6854, DOI 10.1021/bi975006o; Burke JR, 1997, ARCH BIOCHEM BIOPHYS, V341, P177, DOI 10.1006/abbi.1997.9974; BURKE JR, 1995, BIOCHEMISTRY-US, V34, P15165, DOI 10.1021/bi00046a024; BURKE JR, 1995, J BIOL CHEM, V270, P274, DOI 10.1074/jbc.270.1.274; BURKE JR, IN PRSS ARCH BIOCH B; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1992, J BIOL CHEM, V267, P18342; GELB MH, 1992, BIOORG MED CHEM LETT, V2, P1335, DOI 10.1016/S0960-894X(00)80508-9; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HERBETTE LG, 1994, NEUROPHARMACOLOGY, V33, P241, DOI 10.1016/0028-3908(94)90015-9; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11319, DOI 10.1021/bi00093a008; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; MORING J, 1994, BIOPHYS J, V67, P2376, DOI 10.1016/S0006-3495(94)80724-6; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; PARASASSI T, 1995, BIOPHYS J, V68, P1895, DOI 10.1016/S0006-3495(95)80367-X; RAGHUPATHI R, 1987, FASEB J, V46, P1945; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TRAMPOSCH KM, 1992, BIOCHEM BIOPH RES CO, V189, P272, DOI 10.1016/0006-291X(92)91554-4; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; Verger R, 1980, Methods Enzymol, V64, P340; WHEATLEY WB, 1950, J AM CHEM SOC, V72, P5575, DOI 10.1021/ja01168a059; WHEATLEY WB, 1949, J AM CHEM SOC, V71, P64, DOI 10.1021/ja01169a018; Yu Lin, 1992, Bioorganic and Medicinal Chemistry Letters, V2, P1343; 1955, Patent No. 2703324	43	7	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18864	18871		10.1074/jbc.274.27.18864	http://dx.doi.org/10.1074/jbc.274.27.18864			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383382	hybrid			2022-12-25	WOS:000081196300005
J	Mouz, N; Di Guilmi, AM; Gordon, E; Hakenbeck, R; Dideberg, O; Vernet, T				Mouz, N; Di Guilmi, AM; Gordon, E; Hakenbeck, R; Dideberg, O; Vernet, T			Mutations in the active site of penicillin-binding protein PBP2x from Streptococcus pneumoniae - Role in the specificity for beta-lactam antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE; GENES; 2X; TRANSPEPTIDASE; CEPHALOSPORINS; IDENTIFICATION; PURIFICATION; RELATEDNESS; BACTERIA; CLONES	Penicillin-binding protein 2x (PBP2x) isolated from clinical beta-lactam-resistant strains of Streptococcus pneumoniae (R-PBP2x) have a reduced affinity for beta-lactam antibiotics. Their transpeptidase domain carries numerous substitutions compared with homologous sequences from beta-lactam-sensitive streptococci (S-PBP2x), Comparison of R-PBP2x sequences suggested that the mutation Gln(552) --> Glu is important for resistance development. Mutants selected in the laboratory with cephalosporins frequently contain a mutation Thr(550) --> Ala, The high resolution structure of a complex between S-PBP2x* and cefuroxime revealed that Gln(552) and Thr(550), which belong to strand beta 3, are in direct contact with the cephalosporin. We have studied the effect of alterations at positions 552 and 550 in soluble S-PBP2x (S-PBP2x*) expressed in Escherichia coli. Mutation Q552E lowered the acylation efficiency for both penicillin G and cefotaxime when compared with S-PBP2x*. We propose that the introduction of a negative charge in strand beta 3 conflicts with the negative charge of the beta-lactam. Mutation T550A lowered the acylation efficiency of the protein for cefotaxime but not for penicillin G, The in vitro data presented here are in agreement with the distinct resistance profiles mediated by these mutations in vivo and underline their role as powerful resistance determinants.	CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; Univ Kaiserslautern, Dept Microbiol, D-67663 Kaiserslautern, Germany	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern	Vernet, T (corresponding author), CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	vernet@ibs.fr	Vernet, Thierry/G-1118-2012	Gordon, Elspeth Jane/0000-0002-9876-8020				COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; DOWSON CG, 1989, MOL MICROBIOL, V3, P95, DOI 10.1111/j.1365-2958.1989.tb00108.x; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; Hakenbeck R, 1998, J BACTERIOL, V180, P1831, DOI 10.1128/JB.180.7.1831-1840.1998; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELL CM, 1993, FEMS MICROBIOL LETT, V106, P171; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; LAIBLE G, 1992, EUR J BIOCHEM, V207, P943, DOI 10.1111/j.1432-1033.1992.tb17128.x; MARTIN C, 1992, EMBO J, V11, P3831, DOI 10.1002/j.1460-2075.1992.tb05475.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Potgieter E, 1995, MICROB DRUG RESIST, V1, P35, DOI 10.1089/mdr.1995.1.35; Reichmann P, 1997, J INFECT DIS, V176, P1001, DOI 10.1086/516532; SIBOLD C, 1994, MOL MICROBIOL, V12, P1013, DOI 10.1111/j.1365-2958.1994.tb01089.x; Sifaoui F, 1996, ANTIMICROB AGENTS CH, V40, P152, DOI 10.1128/AAC.40.1.152; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; SOUGAKOFF W, 1989, GENE, V78, P339, DOI 10.1016/0378-1119(89)90236-9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; WISE EM, 1965, P NATL ACAD SCI USA, V54, P75, DOI 10.1073/pnas.54.1.75; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	30	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19175	19180		10.1074/jbc.274.27.19175	http://dx.doi.org/10.1074/jbc.274.27.19175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383423	hybrid			2022-12-25	WOS:000081196300046
J	Muren, EM; Suciu, D; Topping, TB; Kumamoto, CA; Randall, LL				Muren, EM; Suciu, D; Topping, TB; Kumamoto, CA; Randall, LL			Mutational alterations in the homotetrameric chaperone SecB that implicate the structure as dimer of dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; EXPORT; LIGANDS; SPECIFICITY; PEPTIDE	Variant forms of SecB with substitutions of aminoacyl residues in the region from 74 to 80 were analyzed with respect to their ability to bind a physiological ligand, precursor galactose-binding protein, and to their oligomeric states. SecBL75Q and SecBE77K are tetramers with affinity for ligand indistinguishable from that of the wild-type SecB, and thus the export defect exhibited by strains producing these variants must result from an effect on interactions between SecB and other components. SecBF74I is tetrameric but binds ligand with a lower affinity. Substitutions at positions 76, 78, and 80 cause a shift in the equilibrium so that the SecB tetramer dissociates into dimers. We conclude that the tetramer is a dimer of dimers and that the residues Cys(76), Val(78), and Gln(80) must be involved either directly or indirectly in forming the interface between dimers. These variant species are defective in binding ligand; however, because their oligomeric state is altered no conclusion can be drawn concerning the direct role of these residues in ligand binding.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Washington State University; Tufts University	Randall, LL (corresponding author), Washington State Univ, Dept Biochem & Biophys, POB 644660, Pullman, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36415, GM29298] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLIER DN, 1993, ADV PROTEIN CHEM, V44, P151, DOI 10.1016/S0065-3233(08)60567-7; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; KIMSEY HH, 1995, J BIOL CHEM, V270, P22831, DOI 10.1074/jbc.270.39.22831; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; Miller J. H., 1972, EXPT MOL GENETICS, P431; MORGAN DG, 1993, J BACTERIOL, V175, P133, DOI 10.1128/JB.175.1.133-140.1993; Randall LL, 1998, PROTEIN SCI, V7, P2384, DOI 10.1002/pro.5560071115; Randall LL, 1998, METHOD ENZYMOL, V290, P444, DOI 10.1016/S0076-6879(98)90037-4; Randall LL, 1998, PROTEIN SCI, V7, P1195, DOI 10.1002/pro.5560070514; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Smith VF, 1996, PROTEIN SCI, V5, P488; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; Topping TB, 1997, J BIOL CHEM, V272, P19314, DOI 10.1074/jbc.272.31.19314; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	20	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19397	19402		10.1074/jbc.274.27.19397	http://dx.doi.org/10.1074/jbc.274.27.19397			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383453	hybrid			2022-12-25	WOS:000081196300076
J	Navarro, P; Valverde, AM; Benito, M; Lorenzo, M				Navarro, P; Valverde, AM; Benito, M; Lorenzo, M			Activated Ha-ras induces apoptosis by association with phosphorylated Bcl-2 in a mitogen-activated protein kinase-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; NERVE GROWTH-FACTOR; BROWN ADIPOCYTES; INDUCED DIFFERENTIATION; GENE-EXPRESSION; CELL-LINES; IN-VITRO; INHIBITION; PATHWAY; FIBROBLASTS	Serum deprivation of Ha-ras-transformed brown adipocyte cell line resulted in a dramatic apoptotic cell death, as detected either by DNA laddering or by an increase in the percentage of hypodiploid cells or by nuclei condensation and fragmentation, as compared with immortalized cell line or primary fetal brown adipocytes, Moreover, transient transfection of immortalized brown adipocytes with a constitutively active ras gene (Ha-ras(lys12)) mimics the high rate of apoptosis detected in the transformed cell line. On the other hand, transient transfection of the dominant-negative construct of raf-l rescued serum-deprived Ha-ras-transformed brown adipocytes from apoptosis, decreasing the percentage of hypodiploid cells, the external display of phosphatidylserine, and the DNA laddering. However, inhibition of mitogen-activated protein kinase with PD098059 did not preclude apoptosis and in fact increased the rate of apoptosis observed in serum-deprived Ha-ras-transformed cells, indicating that the Ras/Raf-1 pathway induced apoptosis throughout a mitogen-activated protein kinase kinase 1 (MEK-1)-independent pathway. Furthermore, apoptosis in Ha-ras-transformed brown adipocytes is concurrent with an up-regulation in the expression of the pro-apoptotic protein Bcl-xS, the expression of the anti-apoptotic protein Bcl-2 being down-regulated. Finally, an association of Ras and Raf with phosphorylated Bcl-2 protein was demonstrated in immunoprecipitates from apoptotic cells. Thus, we propose a mechanism of apoptosis in Ha-ras-transformed adipocytes under serum deprivation involving Raf-1 association with phosphorylated Bcl-2, down-regulation of Bcl-2 expression, and up-regulation of Bcl-xS expression.	Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Lorenzo, M (corresponding author), Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain.		Benito, Manuel/J-5637-2014	Benito, Manuel/0000-0002-7218-406X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BENITO M, 1993, EXP CELL RES, V209, P248, DOI 10.1006/excr.1993.1308; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN CY, 1995, BIOCHEM BIOPH RES CO, V273, P16700; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DIJESO B, 1995, BIOCHEM BIOPH RES CO, V214, P819, DOI 10.1006/bbrc.1995.2360; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; JIMENEZ B, 1995, ONCOGENE, V10, P811; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; Lorenzo M, 1996, CELL GROWTH DIFFER, V7, P1251; LYONS AB, 1992, CYTOMETRY, V13, P809; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, BIOCHEM BIOPH RES CO, V234, P616, DOI 10.1006/bbrc.1997.6641; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V201, P500, DOI 10.1006/bbrc.1994.1730; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; Valverde AM, 1998, EXP CELL RES, V243, P274, DOI 10.1006/excr.1998.4154; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; WANG CY, 1995, MAT PROCESSING COMPU, V2, P129; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	35	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18857	18863		10.1074/jbc.274.27.18857	http://dx.doi.org/10.1074/jbc.274.27.18857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383381	hybrid			2022-12-25	WOS:000081196300004
J	Nishikawa, A; Nanda, A; Gregory, W; Frenz, J; Kornfeld, S				Nishikawa, A; Nanda, A; Gregory, W; Frenz, J; Kornfeld, S			Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PROTEIN RECOGNITION DETERMINANTS; LYSINE-BASED STRUCTURE; PROCATHEPSIN-D; OLIGOSACCHARIDES; RESIDUES; VARIANTS; MEDIATE	We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A, Gregory, W,, Frenz, J,, Cacia, J,, and Kornfeld, S, (1997) J, Biol, Chem. 272, 19408-19412), We now demonstrate that murine DNase I, which contains Lys(27) and Lys(74), is phosphorylated only 20.9% when expressed in the same COS-1 cell system. This difference is mostly due to the absence of three residues present in bovine DNase I (Tyr(54), Lys(124), and Ser(190)) along with the presence of a valine at position 23 that is absent in the bovine species. We show that Val(23) inhibits phosphorylation at the Asn(18) glycosylation site, whereas Tyr(54), Lys(124), and Ser(190) enhance phosphorylation at the Asn(106) glycosylation site. Tyr(54) and Ser(190) are widely separated from each other and from Asn(106) on the surface of DNase I, indicating that residues present over a broad area influence the interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase which is responsible for the formation of mannose 6-phosphate residues on lysosomal enzymes.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Okayama Univ Sci, Dept Biochem, Okayama 700, Japan; Genentech Inc, S San Francisco, CA 94080 USA	Washington University (WUSTL); Okayama University of Science; Roche Holding; Genentech	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.		Nishikawa, Atsushi/E-6766-2013	Nishikawa, Atsushi/0000-0003-4325-1160	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CACIA J, 1995, GLYCOBIOLOGY, V4, P99; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; Pan CQ, 1998, J BIOL CHEM, V273, P18374, DOI 10.1074/jbc.273.29.18374; Pan CQ, 1998, J BIOL CHEM, V273, P11701, DOI 10.1074/jbc.273.19.11701; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; Schierau A, 1999, J BIOL CHEM, V274, P3651, DOI 10.1074/jbc.274.6.3651; SINICROPI D, 1994, ANAL BIOCHEM, V222, P351, DOI 10.1006/abio.1994.1502; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; WORRALL AF, 1990, J BIOL CHEM, V265, P21889	23	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19309	19315		10.1074/jbc.274.27.19309	http://dx.doi.org/10.1074/jbc.274.27.19309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383441	hybrid			2022-12-25	WOS:000081196300064
J	Ron, D; Napolitano, EW; Voronova, A; Vasquez, NJ; Roberts, DN; Calio, BL; Caothien, RH; Pettiford, SM; Wellik, S; Mandac, JB; Kauvar, LM				Ron, D; Napolitano, EW; Voronova, A; Vasquez, NJ; Roberts, DN; Calio, BL; Caothien, RH; Pettiford, SM; Wellik, S; Mandac, JB; Kauvar, LM			Direct interaction in T-cells between theta PKC and the tyrosine kinase p59fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; C-THETA; ANTIGEN RECEPTOR; BINDING-PROTEIN; ACTIVATION; FYN; FAMILY; PHOSPHORYLATION; LYMPHOCYTES	The protein kinase C (PKC) family has been clearly implicated in T-cell activation as have several nonreceptor protein-tyrosine kinases associated with the T-cell receptor, including p59fyn. This report demonstrates that theta PKC and p59fyn specifically interact in vitro, in the yeast two-hybrid system, and in T-cells, Further indications of direct interaction are that p59fyn potentiates theta PKC catalytic activity and that theta PKC is a substrate for tyrosine phosphorylation by p59fyn. This interaction may account for the localization of theta PKC following T-cell activation, pharmacological disruption of which results in specific cell-signaling defects. The demonstration of a physical interaction between a PKC and a protein-tyrosine kinase expands the class of PKC-anchoring proteins (receptors for activated C kinases (RACKs)) and demonstrates a direct connection between these two major T-cell-signaling pathways.	Telik Inc, S San Francisco, CA 94080 USA		Kauvar, LM (corresponding author), Telik Inc, S San Francisco, CA 94080 USA.							Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; Entschladen F, 1997, J IMMUNOL, V159, P3203; Fusaki N, 1996, J IMMUNOL, V156, P1369; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kauvar LM, 1998, J CHROMATOGR B, V715, P93, DOI 10.1016/S0378-4347(98)00045-0; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; MarieCardine A, 1995, EUR J IMMUNOL, V25, P3290, DOI 10.1002/eji.1830251214; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; Meller N, 1996, MOL CELL BIOL, V16, P5782; Mochly-Rosen D, 1998, FASEB J, V12, P35; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; RIGLEY K, 1995, J IMMUNOL, V154, P1136; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; Szamel M, 1998, J IMMUNOL, V160, P2207; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	43	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19003	19010		10.1074/jbc.274.27.19003	http://dx.doi.org/10.1074/jbc.274.27.19003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383400	hybrid			2022-12-25	WOS:000081196300023
J	Sugita, S; Janz, R; Sudhof, TC				Sugita, S; Janz, R; Sudhof, TC			Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; LONG-TERM POTENTIATION; TYROSINE KINASE INHIBITORS; NEUROTRANSMITTER RELEASE; SYNAPTOPHYSIN; RAB3A; DEFINES; SYNAPTOPORIN; HIPPOCAMPUS; PP60(C-SRC)	Synaptogyrins constitute a family of synaptic vesicle proteins of unknown function. With the full-length structure of a new brain synaptogyrin isoform, we now show that the synaptogyrin family in vertebrates includes two neuronal and one ubiquitous isoform. All of these synaptogyrins are composed of a short conserved N-terminal cytoplasmic sequence, four homologous transmembrane regions, and a variable cytoplasmic C-terminal tail that is tyrosine-phosphorylated. The localization, abundance, and conservation of synaptogyrins suggest a function in exocytosis, To test this, we employed a secretion assay in PC12 cells expressing transfected human growth hormone (hGH) as a reporter protein, When Ca2+-dependent hGH secretion from PC12 cells was triggered by high K+ or alpha-latrotoxin, co-transfection of all synaptogyrins with hGH inhibited hGH exocytosis as strongly as co-transfection of tetanus toxin light chain. Synaptophysin I, which is distantly related to synaptogyrins, was also inhibitory but less active. Inhibition was independent of the amount of hGH expressed but correlated with the amount of synaptogyrin transfected. Inhibition of exocytosis was not observed with several other synaptic proteins, suggesting specificity. Analysis of the regions of synaptogyrin required for inhibition revealed that the conserved N-terminal domain of synaptogyrin is essential for inhibition, whereas the long C-terminal cytoplasmic tail is largely dispensable. Our results suggest that synaptogyrins are conserved components of the exocytotic apparatus, which function as regulators of Ca2+-dependent exocytosis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Janz, Roger/0000-0002-9872-0596; Sugita, Shuzo/0000-0002-9182-873X	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABE K, 1993, BRAIN RES, V621, P167, DOI 10.1016/0006-8993(93)90315-E; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHUNG S, 1995, J BIOL CHEM, V269, P32717; ESHKIND LG, 1995, CELL TISSUE RES, V282, P423, DOI 10.1007/s004410050493; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Graham ME, 1997, J NEUROCHEM, V69, P2369; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MARQUEZE-POUEY B, 1991, J NEUROSCI, V11, P3388; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELLER RH, 1995, NEURON, V14, P893; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WICKPW, 1993, J BIOL CHEM, V268, P10988; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	40	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18893	18901		10.1074/jbc.274.27.18893	http://dx.doi.org/10.1074/jbc.274.27.18893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383386	hybrid			2022-12-25	WOS:000081196300009
J	Liu, Y; Emeson, RB; Samuel, CE				Liu, Y; Emeson, RB; Samuel, CE			Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-DELTA VIRUS; DSRNA BINDING DOMAIN; PROTEIN-KINASE PKR; UNWINDING ACTIVITY; MOLECULAR-CLONING; MESSENGER-RNA; HUMAN-CELLS; IN-VITRO; 2 FORMS; GLUR-B	The interferon-inducible RNA-specific adenosine deaminase (ADAR1) is an RNA editing enzyme implicated in the site-selective deamination of adenosine to inosine in cellular pre-mRNAs. The pre-mRNA for the rat serotonin-2C receptor (5-HT2CR) possesses four editing sites (A, B, C, and D), which undergo A-to-I nucleotide conversions that alter the signaling function of the encoded G-protein-coupled receptor. Measurements of 5-HT2CR pre-mRNA editing in vitro revealed site-specific deamination catalyzed by ADAR1, Three splice site variants, ADAR1-a, -b, and -c, all efficiently edited the A site of 5-HT2CR pre-mRNA, but the D site did not serve as an efficient substrate for any of the ADAR1 variants. Mutational analysis of the three double-stranded (ds) RNA binding motifs present in ADAR1 revealed a different relative importance of the individual dsRNA binding motifs for deamination of the A site of 5-HT2CR and synthetic dsRNA substrates. Quantitative reverse transcription-polymerase chain reaction analyses demonstrated that the 5-HT2CR pre-mRNA was most highly expressed in the choroid plexus of rat brain. However, ADAR1 and the related deaminase ADAR2 showed significant expression in all regions of the brain examined, including cortex, hippocampus, olfactory bulb, and striatum, where the 5-HT2CR pre-mRNA was extensively edited.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Vanderbilt University	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.			Emeson, Ronald/0000-0002-4585-1648	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12520] Funding Source: Medline; NINDS NIH HHS [NS-35891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Belcher SM, 1997, MOL BRAIN RES, V52, P130, DOI 10.1016/S0169-328X(97)00252-0; Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Canton H, 1996, MOL PHARMACOL, V50, P799; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; CATTANEO R, 1992, CURR TOP MICROBIOL, V176, P63; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Gerber A, 1997, RNA, V3, P453; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; HOYER D, 1994, PHARMACOL REV, V46, P157; Hurst SR, 1995, RNA, V1, P1051; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; Liu Y, 1998, METHODS, V15, P199, DOI 10.1006/meth.1998.0624; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Lodish H., 1995, MOL CELL BIOL; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	58	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18351	18358		10.1074/jbc.274.26.18351	http://dx.doi.org/10.1074/jbc.274.26.18351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373439	hybrid			2022-12-25	WOS:000081056700031
J	Mason, RP; Jacob, RF; Walter, MF; Mason, PE; Avdulov, NA; Chochina, SV; Igbavboa, U; Wood, WG				Mason, RP; Jacob, RF; Walter, MF; Mason, PE; Avdulov, NA; Chochina, SV; Igbavboa, U; Wood, WG			Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ETHANOL-CONSUMPTION; ALZHEIMERS-DISEASE; PHOSPHOLIPID-MEMBRANES; APOLIPOPROTEIN-E; X-RAY; PROTEIN; BRAIN; CALCIUM; NEUROTOXICITY; CHOLESTEROL	The effects of soluble and aggregated amyloid P-peptide (AP) on cortical synaptic plasma membrane (SPM) structure were examined using small angle x-ray diffraction and fluorescence spectroscopy approaches, Electron density profiles generated from the x-ray diffraction data demonstrated that soluble and aggregated A beta(1-40) peptides associated with distinct regions of the SPM, The width of the SPM samples, including surface hydration, was 84 Angstrom at 10 degrees C, Following addition of soluble A beta(1-40), there was a broad increase in electron density in the SPM hydrocarbon core +/-0-15 Angstrom from the membrane center, and a reduction in hydrocarbon core width by 6 Angstrom. By contrast, aggregated A beta(1-40) contributed electron density to the phospholipid headgroup/hydrated surface of the SPM +/-24-37 Angstrom from the membrane center, concomitant with an increase in molecular volume in the hydrocarbon core, The SPM interactions observed for A beta(1-40) were reproduced in a brain lipid membrane system, In contrast to A beta(1-40), aggregated A beta(1-42) intercalated into the lipid bilayer hydrocarbon core +/-0-12 Angstrom from the membrane center. Fluorescence experiments showed that both soluble and aggregated A beta(1-40) significantly increased SPM bulk and protein annular fluidity, Physico chemical interactions of AP with the neuronal membrane may contribute to mechanisms of neurotoxicity, independent of specific receptor binding.	MCPHU, Sch Med, Dept Med, Membrane Biophys Lab, Pittsburgh, PA 15212 USA; MCPHU, Sch Med, Dept Biochem, Pittsburgh, PA 15212 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55417 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Mason, RP (corresponding author), Allegheny Univ Hosp, 320 E North Ave,15ST, Pittsburgh, PA 15212 USA.				NIAAA NIH HHS [AA10806] Funding Source: Medline; NIA NIH HHS [AG11056] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010806] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; AVDULOV NA, 1994, ALCOHOL CLIN EXP RES, V18, P53, DOI 10.1111/j.1530-0277.1994.tb00880.x; AVDULOV NA, 1995, ALCOHOL CLIN EXP RES, V19, P886, DOI 10.1111/j.1530-0277.1995.tb00963.x; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harris ME, 1996, J NEUROCHEM, V67, P277; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HERBETTE L, 1985, BIOCHIM BIOPHYS ACTA, V817, P103, DOI 10.1016/0005-2736(85)90073-2; Hertel C, 1997, P NATL ACAD SCI USA, V94, P9412, DOI 10.1073/pnas.94.17.9412; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; LUO YQ, 1995, BRAIN RES, V681, P65, DOI 10.1016/0006-8993(95)00282-U; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; MASON RP, 1989, BIOPHYS J, V55, P769, DOI 10.1016/S0006-3495(89)82875-9; Mason RP, 1996, BIOCHEM BIOPH RES CO, V222, P78, DOI 10.1006/bbrc.1996.0699; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MOODY MF, 1963, SCIENCE, V142, P1173, DOI 10.1126/science.142.3596.1173; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; OYAMA Y, 1995, JPN J PHARMACOL, V68, P77, DOI 10.1254/jjp.68.77; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PRADIER L, 1992, STRUCTURE BIOL MEMBR, P1047; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shin RW, 1997, J NEUROSCI, V17, P8187; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAHARA Y, 1992, BIOCHEMISTRY-US, V31, P8747, DOI 10.1021/bi00152a010; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; WOOD WG, 1995, BRAIN RES, V683, P36; WOOD WG, 1989, J NEUROCHEM, V52, P1925, DOI 10.1111/j.1471-4159.1989.tb07278.x; WOOD WG, 1990, BIOCHIM BIOPHYS ACTA, V1025, P243, DOI 10.1016/0005-2736(90)90103-U; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; YOUNG HS, 1992, BIOPHYS J, V61, P1244, DOI 10.1016/S0006-3495(92)81933-1	50	120	121	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18801	18807		10.1074/jbc.274.26.18801	http://dx.doi.org/10.1074/jbc.274.26.18801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373497	hybrid			2022-12-25	WOS:000081056700089
J	Wilke, RA; Mehta, RP; Lupardus, PJ; Chen, YM; Ruoho, AE; Jackson, MB				Wilke, RA; Mehta, RP; Lupardus, PJ; Chen, YM; Ruoho, AE; Jackson, MB			Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NERVE-TERMINALS; LUNG-CANCER; CLONING; EXPRESSION; CARCINOMA; K+; HALOPERIDOL; MECHANISMS; INHIBITION	Recent work has indicated that sigma receptor ligands can modulate potassium channels. However, the only sigma receptor characterized at the molecular level has a novel structure unlike any other receptor known to modulate ion channels. This 26-kDa protein has a hydropathy profile suggestive of a single membrane-spanning domain, with no apparent regions capable of G-protein activation or protein phosphorylation, In the present study patch clamp techniques and photoaffinity labeling were used in DMS-114 cells (a tumor cell line known to express sigma receptors) to investigate the role of the 26-kDa protein in ion channel modulation and probe the mechanism of signal transduction, The sigma receptor Ligands N-allylnormetazocine (SKF10047), ditolyl-guanidine, and (+/-)-2-(N-phenylethyl-N-propyl)-amino-5-hy- droxytetralin all inhibited voltage-activated potassium current (I-K). Iodoazidococaine (IAC), a high affinity sigma receptor photoprobe, produced a similar inhibition in I-K, and when cell homogenates were illuminated in the presence of IAC, a protein with a molecular mass of 26 kDa was covalently labeled. Photolabeling of this protein by IAC was inhibited by SKF10047 with half-maximal effect at 7 mu M. SKF10047 also inhibited I-K with a similar EC50 (14 mu M). Thus, physiological responses to sigma receptor ligands are mediated by a protein with the same molecular weight as the cloned sigma receptor. This indicates that ion channel modulation is indeed mediated by this novel protein. Physiological responses were the same when cells were perfused internally with either guanosine 5'-O-(2-thiodiphosphate) or GTP, indicating that signal transduction is independent of G-proteins, These results demonstrate that ion channels can be modulated by a receptor that does not have seven membrane-spanning domains and does not employ G-proteins, Sigma receptors thus modulate ion channels by a novel transduction mechanism.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [5-T32CA09614-10] Funding Source: Medline; NINDS NIH HHS [NS30016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BIELEFELDT K, 1992, J PHYSIOL-LONDON, V458, P41, DOI 10.1113/jphysiol.1992.sp019405; BOWEN WD, 1993, ASPECTS SYNAPTIC TRA, P113; Breitwieser GE, 1996, J MEMBRANE BIOL, V152, P1, DOI 10.1007/s002329900080; Brent PJ, 1996, BIOCHEM BIOPH RES CO, V219, P219, DOI 10.1006/bbrc.1996.0208; DeVita VT, 1997, CANC PRINCIPLES PRAC; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Johnson BE, 1997, AM J RESP CRIT CARE, V156, P1669, DOI 10.1164/ajrccm.156.5.96-10075; KAHOUN JR, 1992, P NATL ACAD SCI USA, V89, P1393, DOI 10.1073/pnas.89.4.1393; KAHOUN JR, 1992, MULTIPLE SIGMA PCP R, P273; Kebabian JW, 1997, DRUG DISCOV TODAY, V2, P333, DOI 10.1016/S1359-6446(97)01075-1; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MORIO Y, 1994, BRAIN RES, V637, P190, DOI 10.1016/0006-8993(94)91232-7; MORTON ME, 1994, FASEB J, V8, P884, DOI 10.1096/fasebj.8.11.8070639; PANCRAZIO JJ, 1993, ANTICANCER RES, V13, P1231; PETTENGILL OS, 1980, CANCER-AM CANCER SOC, V45, P906, DOI 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RAMAMOORTHY JD, 1995, ENDOCRINOLOGY, V136, P924, DOI 10.1210/en.136.3.924; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SANGUINETTI MC, 1996, NATURE, V80, P384; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Seth P, 1997, BIOCHEM BIOPH RES CO, V241, P535, DOI 10.1006/bbrc.1997.7840; Seth P, 1998, J NEUROCHEM, V70, P922; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; Soriani O, 1998, J PHARMACOL EXP THER, V286, P163; SU TP, 1993, CRIT REV NEUROBIOL, V7, P187; TRUSSELL LO, 1987, J NEUROSCI, V7, P3306; WALKER JM, 1993, ASPECTS SYNAPTIC TRA, P91; Wilke RA, 1998, J PHARMACOL EXP THER, V284, P542; Wilke RA, 1999, J PHYSIOL-LONDON, V517, P391, DOI 10.1111/j.1469-7793.1999.00391.x; WU XZ, 1991, J PHARMACOL EXP THER, V257, P351	37	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18387	18392		10.1074/jbc.274.26.18387	http://dx.doi.org/10.1074/jbc.274.26.18387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373444	hybrid			2022-12-25	WOS:000081056700036
J	Brady, ME; Ozanne, DM; Gaughan, L; Waite, I; Cook, S; Neal, DE; Robson, CN				Brady, ME; Ozanne, DM; Gaughan, L; Waite, I; Cook, S; Neal, DE; Robson, CN			Tip60 is a nuclear hormone receptor coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; ANDROGEN RECEPTOR; HUMAN GENES; PROTEIN; BINDING; YEAST; DEACETYLASE; SPECIFICITY	The androgen receptor (AR) is a member of the nuclear hormone receptor superfamily, Recent work in this field has been focused upon defining the mechanisms of transcriptional control exacted by members of this superfamily. Using a COOH-terminal region of the human AR in a yeast two-hybrid screen, we have identified Tip60 as an AR-interacting protein. In this report, we show that Tip60, which was originally identified as a coactivator for the human immunodeficiency virus TAT protein, can enhance AR-mediated transactivation in a ligand-dependent manner in LNCaP and COS-1 cell lines. In addition, our experiments show that Tip60 can also enhance transactivation through the estrogen receptor and progesterone receptor in a ligand-dependent manner; thus identifying Tip60 as a nuclear hormone receptor coactivator, Our studies also demonstrate that Tip60 co-immunoprecipitates with the full-length AR in vitro and that, in our system, Tip60 enhances transactivation to levels observed with the coactivators steroid receptor coactivator 1, p300, and CREB-binding protein. The importance of such proteins in enhancing nuclear hormone receptor-mediated transcriptional activation is widely accepted, and this work suggests that Tip60 may have an equally important role to play.	Newcastle Univ, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Newcastle Univ, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	c.n.robson@newcastle.ac.uk		Neal, David/0000-0002-6033-5086				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Betts AM, 1997, FEBS LETT, V405, P328, DOI 10.1016/S0014-5793(97)00209-3; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Conneely OM, 1989, GENE REGULATION STER, V4, P220; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; ING NH, 1992, J BIOL CHEM, V267, P17617; James P, 1996, GENETICS, V144, P1425; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	47	208	210	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17599	17604		10.1074/jbc.274.25.17599	http://dx.doi.org/10.1074/jbc.274.25.17599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364196	hybrid			2022-12-25	WOS:000080974300032
J	Hoshinoso, M; Sone, M; Fukata, M; Kurodad, S; Kaibuchi, K; Nabeshima, Y; Hama, C				Hoshinoso, M; Sone, M; Fukata, M; Kurodad, S; Kaibuchi, K; Nabeshima, Y; Hama, C			Identification of the stef gene that encodes a novel guanine nucleotide exchange factor specific for Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; SIGNALING MOLECULES; SMALL GTPASES; RHO; CELL; RAS; INVASION; DOMAINS	The Rho family GTPases are involved in a variety of cellular events by changing the organization of actin cytoskeletal networks in response to extracellular signals. However, it is not clearly known how their activities are spatially and temporally regulated. Here we report the identification of a novel guanine nucleotide exchange factor for Rad, STEF, which is related in overall amino acid sequence and modular structure to mouse Tiam1 and Drosophila SIF proteins. STEF protein contains two pleckstrin homology domains, a PDZ domain and a Dbl homology domain. The in vitro assay showed that STEF protein specifically enhanced the dissociation of GDP from Rac1 but not that from either RhoA or Cdc42. Expression of a truncated STEF protein in culture cells induced membrane ruffling with altered actin localization, which implies that this protein also activates Rad in vivo. The stef transcript was observed in restricted parts of mice, including cartilaginous tissues and the cortical plate of the central nervous system during embryogenesis. These findings suggested that STEF protein participates in the control of cellular events in several developing tissues, possibly changing the actin cytoskeletal network by activating Rad.	NCNP, Natl Inst Neurosci, Dept Mol Genet, Kodaira, Tokyo 1878502, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 6068501, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Inheritance & Variat Grp, Kyoto 6190237, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 332, Japan	National Center for Neurology & Psychiatry - Japan; Kyoto University; Osaka University; Nara Institute of Science & Technology; Hiroshima University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Hoshinoso, M (corresponding author), NCNP, Natl Inst Neurosci, Dept Mol Genet, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.		Sone, Masaki/Q-9058-2019; Fukata, Masaki/AAZ-2476-2021	Fukata, Masaki/0000-0001-5200-9806				Allen WE, 1997, J CELL SCI, V110, P707; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; ANDO S, 1992, J BIOL CHEM, V267, P25709; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KIKUCHI A, 1992, ONCOGENE, V7, P289; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; WHITEHEAD AP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	39	92	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17837	17844		10.1074/jbc.274.25.17837	http://dx.doi.org/10.1074/jbc.274.25.17837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364228	hybrid			2022-12-25	WOS:000080974300064
J	Liang, Y; Annan, RS; Carr, SK; Popp, S; Mevissen, M; Margolis, RK; Margolis, RU				Liang, Y; Annan, RS; Carr, SK; Popp, S; Mevissen, M; Margolis, RK; Margolis, RU			Mammalian homologues of the Drosophila slit protein are ligands of the heparan sulfate proteoglycan glypican-1 in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CHONDROITIN SULFATE; EXTRACELLULAR PROTEIN; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; IDENTIFICATION; CLONING; GROWTH; MOTIF; EGF	an affinity matrix in which a recombinant glypican-Fc fusion protein expressed in 293 cells was coupled to protein A-Sepharose, we have isolated from rat brain at least two proteins that were detected by SDS-polyacrylamide gel electrophoresis as a single 200-kDa silver-stained band, from which 16 partial peptide sequences were obtained by nano-electrospray tandem mass spectrometry. Mouse expressed sequence tags containing two of these peptides were employed for oligonucleotide design and synthesis of probes by polymerase chain reaction and enabled us to isolate from a rat brain cDNA library a 4.1-kilobase clone that encoded two of our peptide sequences and represented the N-terminal portion of a protein containing a signal peptide and three leucine-rich repeats. Comparisons with recently published sequences also showed that our peptides were derived from proteins that are members of the Slit/MEGF protein family, which share a number of structural features such as N-terminal leucine-rich repeats and C-terminal epidermal growth factor-like motifs, and in Drosophila Slit is necessary for the development of midline glia and commissural axon pathways. All of the five known rat and human Slit proteins contain 1523-1534 amino acids, and our peptide sequences correspond best to those present in human Slit-1 and Slit-2. Binding of these ligands to the glypican-Fc fusion protein requires the presence of the heparan sulfate chains, but the interaction appears to be relatively specific for glypican-Fc insofar as no other identified heparin-binding proteins were isolated using our affinity matrix. Northern analysis demonstrated the presence of two mRNA species of 8.6 and 7.5 kilobase pairs using probes based on both N- and C-terminal sequences, and in situ hybridization histochemistry showed that these glypican-1 ligands are synthesized by neurons, such as hippocampal pyramidal cells and cerebellar granule cells, where we have previously also demonstrated glypican-1 mRNA and immunoreactivity, Our results therefore indicate that Slit family proteins are functional ligands of glypican-1 in nervous tissue and suggest that their interactions may be critical for certain stages of central nervous system histogenesis.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	New York University; GlaxoSmithKline; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Margolis, RU (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.		Carr, Steven A./AAH-8366-2019		NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; ANNAN RS, 1996, P 44 ASMS C MASS SPE, P702; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Engel M, 1996, J COMP NEUROL, V366, P34; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GOWDA DC, 1989, J BIOL CHEM, V264, P11436; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; PILIA G, 1996, NAT GENET, V12, P225; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Ziegler J, 1997, ANAL BIOCHEM, V250, P257, DOI 10.1006/abio.1997.2248	39	102	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17885	17892		10.1074/jbc.274.25.17885	http://dx.doi.org/10.1074/jbc.274.25.17885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364234	hybrid			2022-12-25	WOS:000080974300070
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; LUNG-CANCER; FACTOR BINDING-PROTEIN-3; NUCLEAR TRANSPORT; GENE-EXPRESSION; CARCINOMA CELLS; UP-REGULATION; INHIBITION; LINES; FIBROBLASTS	Neither retinoic acid receptor-beta (RAR beta) nor insulinlike growth factor-binding protein-3 (IGFBP-3) is expressed in breast cancer cell line MCF-7. The expression of both proteins can be induced in response to all-trans-retinoic acid (atRA). By using an RAR alpha-selective antagonist (Ro 41-5253), we demonstrated that RAR beta expression was induced by atRA through an RAR alpha-dependent signaling pathway and that RAR beta induction was correlated with IGFBP-3 induction. However, MCF-7 cells transfected with sense RAR beta cDNA expressed IGFBP-3 even in the presence of the RAR alpha-selective antagonist Ro 41-5253. On the other hand, antisense RAR beta cDNA transfection of MCF-7 cells blocked atRA-induced IGFBP-3 expression, indicating that RAR beta is directly involved in the mediation of IGFBP-3 induction by atRA. Induction of IGFBP-3 expression by atRA occurs at the transcriptional level, as measured by nuclear run-on assays. Finally, we showed that atRA-induced IGFBP-3 is functionally active in modulating the growth-promoting effect of IGF-I. These experiments indicate that RAR alpha and RAR beta, both individually and together, are important in mammary gland homeostasis and breast cancer development. By linking IGFBP-3 to RAR beta, our experiments define the signal intersection between the retinoid and IGF systems in cell growth regulation and explain why loss of RAR beta might be critical in breast cancer carcinogenesis/progression.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; AGADIR A, 1994, CELL MOL BIOL, V40, P263; ALBISTON AL, 1995, ENDOCRINOLOGY, V136, P696, DOI 10.1210/en.136.2.696; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan K, 1997, ENDOCRINE, V7, P95, DOI 10.1007/BF02778072; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; Gebauer G, 1998, ANTICANCER RES, V18, P1191; GERBERT JF, 1991, ONCOGENE, V6, P1859; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gucev ZS, 1996, CANCER RES, V56, P1545; HIGUCHI T, 1991, CANCER RES, V51, P3958; Hong Waun Ki, 1994, P597; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HU L, 1991, CANCER RES, V51, P3972; Hung Huynh, 1995, Progress in Growth Factor Research, V6, P495, DOI 10.1016/0955-2235(95)00036-4; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Oh Y, 1998, BREAST CANCER RES TR, V47, P283, DOI 10.1023/A:1005911319432; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; ROMANS SD, 1992, CANCER RES, V56, P2235; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; WRAIGHT CJ, 1995, J INVEST DERMATOL, V105, P602, DOI 10.1111/1523-1747.ep12323716; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6	47	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18005	18010		10.1074/jbc.274.25.18005	http://dx.doi.org/10.1074/jbc.274.25.18005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364250	hybrid			2022-12-25	WOS:000080974300086
J	Shieh, RC; Chang, JC; Kuo, CC				Shieh, RC; Chang, JC; Kuo, CC			K+ binding sites and interactions between permeating K+ ions at the external pore month of an inward rectifier K+ channel (Kir2.1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PHEOCHROMOCYTOMA CELLS; POTASSIUM CHANNEL; XENOPUS OOCYTES; CA2+ CHANNEL; RECTIFICATION; IRK1; MEMBRANE; MECHANISM; STARFISH; RESIDUE	The arginine at position 148 is highly conserved in the inward rectifier K+ channel family, Increases of external pH decrease the single-channel conductance in mutant R148H of the Kir2.1 channel (arginine is mutated into histidine) but not in the wild type channel. Moreover, in 100 mM external K+, varying external pH induced biphasic changes of open channel noise, which peaks at around pH 7.4 in the R148H mutant but not in the wild type channel. The maximum single-channel conductances are higher in the wild type channel and R148H mutant at pH 6.0 than those in the B148H mutant at pH 7.4. However, the maximal conductance is achieved with much lower external [K+] for the latter. Interestingly, the single-channel conductances and open channel noise of the wild type channel at pH 6.0 and the R148H mutant at pH 6.0 and 7.4 become the same in [K+] = 10 mM, These results indicate that the residue at position 148 is accessible to the external H+ and probably is involved in the formation of two K+ binding sites in the external pore mouth, Effective repulsion between permeating K+ ions in this area requires a positive charge at position 148, and such K+-K+ interaction is the essential mechanism underlying high K+ conduction rate through the Kir2.1 channel pore.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Univ Hosp, Dept Neurol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Physiol, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Shieh, RC (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Yen Chiu Yuan Rd,Sect 2, Taipei 11529, Taiwan.			Kuo, Chung-Chin/0000-0001-8208-6829				COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kubo Y, 1996, RECEPTOR CHANNEL, V4, P73; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; Shieh RC, 1996, J PHYSIOL-LONDON, V494, P363, DOI 10.1113/jphysiol.1996.sp021498; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; Stampe P, 1998, J GEN PHYSIOL, V112, P475, DOI 10.1085/jgp.112.4.475; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	20	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17424	17430		10.1074/jbc.274.25.17424	http://dx.doi.org/10.1074/jbc.274.25.17424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364171	hybrid			2022-12-25	WOS:000080974300007
J	Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A				Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A			Effect of p21(waf1/cip1) transgene on radiation induced apoptosis in T cells	ONCOGENE			English	Article						p21(waf1); transgenic mice; radiation; apoptosis; p53	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; DNA-REPLICATION; CDK INHIBITOR; CYCLE ARREST; IN-VIVO; POTENTIAL MEDIATOR; HUMAN FIBROBLASTS; S-PHASE; P21	The cyclin kinase inhibitor p21(WAF1/Cip1) is upregulated by the tumor suppressor p53. While p21 is central for the G-1 arrest mediated by p53, it is still unclear if p21 also functions as a downstream effector of p53 dependent apoptosis. Apoptosis induced by DNA damage but not dexamethasone is p53 dependent in thymocytes. To investigate the physiological role of p21 in apoptosis, we have generated transgenic mice in which the p21 transgene is targeted for restricted expression in the T cell lineage. Thymocytes from p21 transgenic mice were hypersensitive to cell death induced by DNA damaging agents such as ionizing radiation and UV, but not be dexamethasone. Irradiated p21 transgenic thymocytes had approximately twofold more apoptotic cells as compared to irradiated age matched littermate control mice. Radiation induced death is comparable in thymocytes from p21 + Bcl2 + double transgenic mice and age matched littermate controls, indicating that the Bcl2 transgene rescues the radiation hypersensitivity imposed by p21. However, thymocytes from p53-/- mice even when they expressed the p21 transgene, were resistant to death induced by radiation. Together these results show that thymocytes from p21 transgenic mice are hypersensitive to radiation induced programmed cell death and suggest that the radiation hypersensitivity of p21 transgenic thymocytes involves p53 dependent pathway and signals in addition to p21.	Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); La Jolla Institute for Immunology; Sanford Burnham Prebys Medical Discovery Institute	Fotedar, A (corresponding author), Inst Biol Struct JP Ebel, 41 Ave Martyrs, F-38027 Grenoble 1, France.				NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, ONCOGENE, V12, P2155; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; JACKSON FH, 1904, P LOND MATH SOC, V3, P1; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; LOWE SW, 1993, NATURE, V362, P837; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	49	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3652	3658		10.1038/sj.onc.1202693	http://dx.doi.org/10.1038/sj.onc.1202693			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380888				2022-12-25	WOS:000080891700012
J	Rosenberger, SF; Gupta, A; Bowden, GT				Rosenberger, SF; Gupta, A; Bowden, GT			Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription	ONCOGENE			English	Article						okadaic acid; p38 MAPK; SB 203580; AP-1	ACTIVATED PROTEIN-KINASE; PROMOTER-INDUCED TRANSFORMATION; EPIDERMAL-CELL LINES; MOUSE JB6 CELLS; TUMOR PROMOTER; C-JUN; SUBSTRATE-SPECIFICITY; RESPONSE ELEMENT; RETINOIC ACID; PHOSPHORYLATION	By performing in vitro kinase assays we found in papilloma producing 308 mouse keratinocytes that okadaic acid elevated activities of extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs). This okadaic acid mediated activation of MAP kinases correlated with increased AP-1 binding to a consensus TPA responsive element (TRE) and elevated TRE dependent transcription. To determine the role of p38 MAP kinases in these processes we employed the specific p38 MAP kinase inhibitor SB 203580. Using orthophosphate labeling we showed a decrease in phosphorylation of MAPK activated protein kinase-2 (MAPKAP-K2) indicating reduced activity of p38 MAPKs utilizing this kinase as substrate. In contrast, we found the SB 203580 raised activities of ERK-1/2 and JNKs. Electrophoretic mobility shift assays revealed an increase in TRE binding activity in response to SB 203580 most likely resulting from increased expression of the major TRE binding components JunD and FosB as indicated by Western blot analyses. Increased TRE DNA binding failed to lead to increased transactivation correlating with the inability of SB 203580 to increase phosphorylation of these AP-1 proteins. These data indicate that SB 203580 sensitive p38 MAP kinases are not involved in okadaic acid mediated increases in TRE DNA binding and transactivation.	Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Bowden, GT (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA 23074, CA 40584] Funding Source: Medline; NIEHS NIH HHS [P30-ESO 6694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040584, P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Daum G, 1998, FEBS LETT, V427, P271, DOI 10.1016/S0014-5793(98)00448-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JJ, 1996, CANCER RES, V56, P483; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang HL, 1996, ONCOGENE, V13, P2639; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3626	3632		10.1038/sj.onc.1202695	http://dx.doi.org/10.1038/sj.onc.1202695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380884				2022-12-25	WOS:000080891700008
J	Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D			Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase inhibitors; pocket proteins	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; TGF-BETA; P21; P27(KIP1); P107; PHOSPHORYLATION; SUPPRESSION	One prominent effect of IFNs is their cell growth-inhibitory activity. The mechanism behind this Inhibition of proliferation is still not fully understood. In this study, the effect of IFN-alpha treatment on cell cycle progression has been analysed in three lymphoid cell lines, Daudi, U-266 and H9, Examination of the growth-arrested cell populations shows that Daudi cells accumulate in a G0-like state, whereas U-266 cells arrest later in G1, H9 cells are completely resistant to IFN-alpha's cell growth-inhibitory effects. The G0/G1-phase arrest is preceded by a rapid induction of the ca clin-dependent kinase inhibitors (CKIs), p21 and p15, In parallel, the activities of the G1 Cdks are significantly reduced. In addition to p21/p15 induction, IFN-alpha regulates the expression of another CKI, p27, presumably by a post-transcriptional mechanism. In the G1 Cdk-complexes, there is first an increased binding of p21 and p15 to their respective kinases. At longer exposure times, when Cdk-bound p15 and p21 decline, p27 starts to accumulate. Furthermore, we found that IFN-alpha not only suppresses the phosphorylation of pRb, but also alters the phosphorylation and expression of the other pocket proteins p130 and p107. These data suggest that induction of p21/p15 is involved in the primary IFN-alpha response inhibiting G1 Cdk activity, whereas increased p27 expression is part of a second set of events which keep these Cdks in their inactive form. Moreover, elevated levels of p27 correlated with a dissociation of cyclin E/Cdk2-p130 or p107 complexes to yield cyclin E/Cdk2-p27 complexes. In resistant H9 cells, which possess a homozygous deletion of the p15/p16 genes and lack p21 protein expression, IFN-alpha causes no detectable changes in p27 expression and, furthermore, no effects are observed on either pocket proteins in this cell line. Taken together, these data suggest that the early decline in G1 Cdk activity, subsequent changes in phosphorylation of pocket proteins, and G1/G0 arrest following IFN-alpha treatment, is not primarily due to loss of the G1 kinase components, but result from the inhibitory action of CKIs on these complexes.	Karolinska Hosp & Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.							APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER E, 1988, INTERFERON OTHER REG; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; GERDES J, 1984, J IMMUNOL, V133, P1710; Grander D, 1997, EUR J HAEMATOL, V59, P129; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEIDEN T, 1990, ANTICANCER RES, V10, P1555; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KACZMAREK L, 1986, LAB INVEST, V54, P365; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Palmero I, 1996, CANCER SURV, V27, P351; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PINES J, 1995, BIOCHEM J, V308, P687; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	51	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2798	2810		10.1038/sj.onc.1202609	http://dx.doi.org/10.1038/sj.onc.1202609			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362250				2022-12-25	WOS:000080125100002
J	Ilagan, JG; Cvekl, A; Kantorow, M; Piatigorsky, J; Sax, CM				Ilagan, JG; Cvekl, A; Kantorow, M; Piatigorsky, J; Sax, CM			Regulation of alpha A-crystallin gene expression - Lens specificity achieved through the differential placement of similar transcriptional control elements in mouse and chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSGENIC MICE; C-JUN; B-CRYSTALLIN; DNA-BINDING; PROMOTER; PROTEIN; AP-1; ACTIVATION	The lens-preferred mouse alpha A-crystallin gene contains a conserved stretch (proximal element 2, +24/+43) in its 5'-noncoding region that we have previously shown binds nuclear proteins of lens and non-lens cells. The 5'-half of this sequence (PE2A, +25/+32) has consensus binding sites for AP-1 and other transcription factors. We show here by deletion experiments that PE2A is important for activity of the mouse alpha A-crystallin promoter and mediates phorbol ester and c-Jun responsiveness of this promoter in transfected lens cells. In vitro protein binding studies suggest that AP-1 complexes are capable of binding to PE2A. Our findings suggest that PE2A plays a role in mouse alpha A-crystallin gene expression through AP-1-mediated regulatory mechanisms. We propose that the mouse and chicken alpha A-crystallin genes are expressed with lens specificity using a similar assortment of transcription factors but with a different physical arrangement of their respective cis-elements within the promoter region. A fundamental role for AP-1 in lens-preferred expression of crystallin genes is consistent with the idea that a redox-sensitive mechanism is a selective force for recruiting lens crystallins.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Sax, CM (corresponding author), Univ Maryland, Univ Coll, SFSC Bldg,Rm 4224B,Univ Blvd Adelphi Rd, College Pk, MD 20742 USA.		Cvekl, Ales/B-2427-2013					ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; CHEPELINSKY AB, 1988, MOL BIOL EYE GENES V, P215; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Earle WR, 1943, J NATL CANCER I, V4, P165; ERRINGTON LH, 1985, BIOL CELL, V54, P101, DOI 10.1111/j.1768-322X.1985.tb00385.x; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Graw J, 1997, BIOL CHEM, V378, P1331; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KANTOROW M, 1993, J MOL BIOL, V230, P425, DOI 10.1006/jmbi.1993.1160; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; Klok EJ, 1998, J BIOL CHEM, V273, P17206, DOI 10.1074/jbc.273.27.17206; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Leenders WPJ, 1997, MECH DEVELOP, V67, P193, DOI 10.1016/S0925-4773(97)00121-4; McDermott JB, 1997, INVEST OPHTH VIS SCI, V38, P951; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Ogino H, 1996, Tanpakushitsu Kakusan Koso, V41, P1050; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RINAUDO JA, 1995, J CELL BIOCHEM, V58, P237, DOI 10.1002/jcb.240580212; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SAX CM, 1995, NUCLEIC ACIDS RES, V23, P442, DOI 10.1093/nar/23.3.442; SAX CM, 1990, MOL CELL BIOL, V10, P6813, DOI 10.1128/MCB.10.12.6813; SAX CM, 1990, DEV BIOL, V139, P56, DOI 10.1016/0012-1606(90)90278-Q; Sax CM, 1997, GENE, V185, P209, DOI 10.1016/S0378-1119(96)00643-9; Scheier B, 1996, MOL CELL ENDOCRINOL, V123, P187, DOI 10.1016/S0303-7207(96)03922-6; SOMMER B, 1988, J BIOL CHEM, V263, P15666; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; TOMAREV SI, 1994, J MOL EVOL, V39, P134; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; Vacchiano E, 1996, EXP EYE RES, V63, P753, DOI 10.1006/exer.1996.0169; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; YASUDA K, 1988, MOL BIOL EYE GENES V, P205	54	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19973	19978		10.1074/jbc.274.28.19973	http://dx.doi.org/10.1074/jbc.274.28.19973			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391946	hybrid			2022-12-25	WOS:000081377300066
J	Jeltsch, A; Christ, F; Fatemi, M; Roth, M				Jeltsch, A; Christ, F; Fatemi, M; Roth, M			On the substrate specificity of DNA methyltransferases - Adenine-N-6 DNA methyltransferases also modify cytosine residues at position N-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-MODIFICATION SYSTEM; CRYSTAL-STRUCTURE; TARGET BASE; METHYLATION; SEQUENCE; BINDING; DOMAINS; FOKI; ACID; MISMATCHES	Methylation of DNA is important in many organisms and essential in mammals, Nucleobases can be methylated at the adenine-N-6, cytosine-N-4, or cytosine-C-5 atoms by specific DNA methyltransferases. We show here that the M.EcoRV, M.EcoRI, and Escherichia coli dam methyltransferases as well as the N- and C-terminal domains of the M.KokI enzyme, which were formerly all classified as adenine-N-6 DNA methyltransferases, also methylate cytosine residues at position N-4. Kinetic analyses demonstrate that the rate of methylation of cytosine residues by M.EcoRV and the M.FokI enzymes is reduced by only 1-2 orders of magnitude in relation to methylation of adenines, This result shows that although these enzymes methylate DNA in a sequence specific manner, they have a low substrate specificity with respect to the target base, This unexpected finding has implications on the mechanism of adenine-N-6 DNA methyltransferases, Sequence comparisons suggest that adenine-N-6 and cytosine-N-4 methyltransferases have changed their reaction specificity at least twice during evolution, a model that becomes much more likely given the partial functional overlap of both enzyme types. In contrast, methylation of adenine residues by the cytosine-N-4 methyltransferase M.BamHI was not detectable. On the basis of our results, we suggest that adenine-N-6 and cytosine-N-4 methyltransferases should be grouped into one enzyme family.	Inst Biochem, Fachbereich Biol, D-35392 Giessen, Germany		Jeltsch, A (corresponding author), Inst Biochem, Fachbereich Biol, Heinrich Buff Ring 58, D-35392 Giessen, Germany.		Christ, Frauke/H-7513-2018; Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290; Christ, Frauke/0000-0001-9580-3874				Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Cal S, 1997, J BIOL CHEM, V272, P490; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Heitman J, 1993, Genet Eng (N Y), V15, P57; HELTSCH A, 1999, IN PRESS J MOL EVOL; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jeltsch A, 1999, J MOL BIOL, V285, P1121, DOI 10.1006/jmbi.1998.2389; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LANDRY D, 1989, GENE, V77, P1, DOI 10.1016/0378-1119(89)90353-3; Leismann O, 1998, EUR J BIOCHEM, V251, P899, DOI 10.1046/j.1432-1327.1998.2510899.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MASHHOON N, 1994, BIOCHEMISTRY-US, V33, P7113, DOI 10.1021/bi00189a014; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NOYERWEIDNER M, 1993, DNA METHYLATION MOL; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Serva S, 1998, NUCLEIC ACIDS RES, V26, P3473, DOI 10.1093/nar/26.15.3473; SUGISAKI H, 1989, J BIOL CHEM, V264, P5757; SUGISAKI H, 1981, GENE, V16, P73; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	46	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19538	19544		10.1074/jbc.274.28.19538	http://dx.doi.org/10.1074/jbc.274.28.19538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391886	hybrid			2022-12-25	WOS:000081377300006
J	Rojo, EE; Guiard, B; Neupert, W; Stuart, RA				Rojo, EE; Guiard, B; Neupert, W; Stuart, RA			N-terminal tail export from the mitochondrial matrix - Adherence to the prokaryotic "positive-inside" rule of membrane protein topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; CHARGED RESIDUES; ESCHERICHIA-COLI; INTERMEMBRANE SPACE; C-TERMINI; TRANSLOCATION; OXA1P; ATP	Export of N-terminal tails of mitochondrial inner membrane proteins from the mitochondrial matrix is a membrane potential-dependent process, mediated by the Oxa1p translocation machinery. The hydrophilic segments of these membrane proteins, which undergo export, display a characteristic charge profile where intermembrane space-localized segments bear a net negative charge, whereas those remaining in the matrix ha ve a net positive one. Using a model protein, preSu9(1-112)-dihydrofolate reductase (DHFR), which undergoes Oxa1p-mediated N-tail export, we demonstrate here that the net charge of N- and C-flanking regions of the transmembrane domain play a critical role in determining the orientation of the insertion process. The N-tail must bear a net negative charge to be exported to the intermembrane space. Furthermore, a net positive charge of the C-terminal region supports this N-tail export event. These data provide experimental evidence that protein export in mitochondria adheres to the "positive-inside" rule, described for sec-independent sorting of membrane proteins in prokaryotes, We propose here that the importance of a charge profile reflects a need for specific protein-protein interactions to occur in the export reaction, presumably at the level of the Oxa1p export machinery.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Univ Paris 06, CNRS, Ctr Mol Genet, F-91190 Gif Sur Yvette, France	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Stuart, RA (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.							ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; GAVEL Y, 1992, FEBS LETT, V268, P41; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Sambrook J., 2002, MOL CLONING LAB MANU; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x	27	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19617	19622		10.1074/jbc.274.28.19617	http://dx.doi.org/10.1074/jbc.274.28.19617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391898	hybrid			2022-12-25	WOS:000081377300018
J	Caccuri, AM; Antonini, G; Ascenzi, P; Nicotra, M; Nuccetelli, M; Mazzetti, AP; Federici, G; Lo Bello, M; Ricci, G				Caccuri, AM; Antonini, G; Ascenzi, P; Nicotra, M; Nuccetelli, M; Mazzetti, AP; Federici, G; Lo Bello, M; Ricci, G			Temperature adaptation of glutathione S-transferase P1-1 - A case for homotropic regulation of substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POSITIVE COOPERATIVITY; MUTATION; PI; MECHANISM; ENZYME; TRANSCARBAMOYLASE; FLEXIBILITY; CYS-47; SKIN	Human glutathione S-transferase P1-1 (GST P1-1) is a homodimeric enzyme expressed in several organs as well as in the upper layers of epidermis, playing a role against carcinogenic and toxic compounds. A sophisticated mechanism of temperature adaptation has been developed by this enzyme. In fact, above 35 degrees C, glutathione (GSH) binding to GST P1-1 displays positive cooperativity, whereas negative cooperativity occurs below 25 degrees C. This binding mechanism minimizes changes of GSH affinity for GST P1-1 because of temperature fluctuation. This is a likely advantage for epithelial skin cells, which are naturally exposed to temperature variation and, incidentally, to carcinogenic compounds, always needing efficient detoxifying systems. As a whole, GST P1-1 represents the first enzyme which displays a temperature-dependent homotropic regulation of substrate (e.g. GSH) binding.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; IRCCS Bambin Gesu, Osped Pediat, I-00165 Rome, Italy; Univ Rome Tre, Dept Biol, I-00146 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Sapienza University Rome; IRCCS Bambino Gesu; Roma Tre University	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		CACCURI, ANNA MARIA/AFU-2643-2022	Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; BRAXTON BL, 1994, J BIOL CHEM, V269, P47; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; Coletta M, 1998, BIOCHEMISTRY-US, V37, P2873, DOI 10.1021/bi9713613; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; Habig W H, 1981, Methods Enzymol, V77, P398; HALPRIN KM, 1967, J INVEST DERMATOL, V48, P149, DOI 10.1038/jid.1967.24; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hochachka P. W., 1984, BIOCH ADAPTATION; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lo Bello M, 1998, J MOL BIOL, V284, P1717; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; Segel I.H., 1975, ENZYME KINETICS; SHIMIZU K, 1995, VIRCHOWS ARCH, V425, P589; Somero GN, 1996, NEWS PHYSIOL SCI, V11, P72; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; TAKETA K, 1965, J BIOL CHEM, V240, P651	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19276	19280		10.1074/jbc.274.27.19276	http://dx.doi.org/10.1074/jbc.274.27.19276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383436	hybrid			2022-12-25	WOS:000081196300059
J	O'Brien, CA; Gubrij, I; Lin, SC; Saylors, RL; Manolagas, SC				O'Brien, CA; Gubrij, I; Lin, SC; Saylors, RL; Manolagas, SC			STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-kappa B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D-3 or parathyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; BONE-MARROW CULTURES; IN-VIVO; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; IL-6 RECEPTOR; GROWTH ARREST; GENE-TRANSFER	Interleukin (IL)-6-type cytokines stimulate osteoclastogenesis by activating gp130 in stromal/osteoblastic cells and may mediate some of the osteoclastogenic effects of other cytokines and hormones. To determine whether STAT3 is a downstream effector of gp130 in the osteoclast support function of stromal/osteoblastic cells and whether the gp130/STAT3 pathway is utilized by other osteoclastogenic agents, we conditionally expressed dominant negative (dn)-STAT3 or dn-gp130 in a stromal/osteoblastic cell line (UAMS-32) that supports osteoclast formation. Expression of either dominant negative protein abolished osteoclast formation stimulated by IL-6 + soluble IL-6 receptor, oncostatin M, or IL-1 but not by parathyroid hormone or 1,25-dihydroxyvitamin D-3. Because previous studies suggested that IL-B-type cytokines may stimulate osteoclastogenesis by inducing expression of the tumor necrosis factor-related protein, receptor activator of NF-kappa B ligand (RANKL), we conditionally expressed RANKL in UAMS-32 cells and found that this was sufficient to stimulate osteoclastogenesis, Moreover, dn-STAT3 blocked the ability of either IL-6 + soluble IL-6 receptor or oncostatin M to induce RANKL, These results establish that STAT3 is essential for gp130-mediated osteoclast formation and that the target of STAT3 during this process is induction of RANKL, In addition, this study demonstrates that activation of the gp130 STAT3 pathway in stromal/osteoblastic cells mediates the osteoclastogenic effects of IL-1, but not parathyroid hormone or 1,25-dihydroxyvitamin D-3.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Pediat Hematol Oncol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Cent Arkansas Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	O'Brien, CA (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, 4301 W Markham St,Mail Slot 587, Little Rock, AR 72205 USA.		O'Brien, Charles A./AAL-5078-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR045241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [1R29AR45241-01] Funding Source: Medline; NIA NIH HHS [P01 AG13918-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Aubin Jane E., 1993, P1; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Boyle WJ, 1998, BONE, V23, pS189; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990; Devlin RD, 1998, J BONE MINER RES, V13, P393, DOI 10.1359/jbmr.1998.13.3.393; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREY A, 1997, J BONE MINER RES  S1, V12, pS112; Grignani F, 1998, CANCER RES, V58, P14; GUBRIJ I, 1998, BONE, V23, pS216; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAPETEIN A, 1996, J BIOL CHEM, V271, P5961; Kim GS, 1997, J BONE MINER RES, V12, P896, DOI 10.1359/jbmr.1997.12.6.896; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kumanogoh A, 1997, P NATL ACAD SCI USA, V94, P2478, DOI 10.1073/pnas.94.6.2478; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAJORS J, 1990, CURR TOP MICROBIOL, V157, P50; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Manolagas Stavros C., 1996, P701; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; OBRIEN CA, 1998, BONE, V23, pS149; Piekorz RP, 1998, BBA-MOL CELL RES, V1402, P313, DOI 10.1016/S0167-4889(98)00024-X; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Pollock JH, 1996, J BONE MINER RES, V11, P754; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; SAITO M, 1992, J IMMUNOL, V148, P4066; Saylors RL, 1998, MOL GENET METAB, V63, P198, DOI 10.1006/mgme.1997.2665; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; SUDA T, 1988, EXP HEMATOL, V16, P891; Suda Tatsuo, 1996, P87; TAKEDA S, 1997, J BONE MINER RES, V12, pS110; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	60	236	241	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19301	19308		10.1074/jbc.274.27.19301	http://dx.doi.org/10.1074/jbc.274.27.19301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383440	hybrid			2022-12-25	WOS:000081196300063
J	Pak, M; Hoskins, JR; Singh, SK; Maurizi, MR; Wickner, S				Pak, M; Hoskins, JR; Singh, SK; Maurizi, MR; Wickner, S			Concurrent chaperone and protease activities of ClpAP and the requirement for the N-terminal ClpA ATP binding site for chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; SPECIFICITY COMPONENT; MUTATIONAL ANALYSIS; DEPENDENT PROTEASE; ACTIVATED ATPASE; MU-TRANSPOSASE; HSP104; PROTEOLYSIS	ClpA, a member of the Clp/Hsp100 family of ATPases, is both an ATP-dependent molecular chaperone and the regulatory component of ClpAP protease. We demonstrate that chaperone and protease activities occur concurrently in ClpAP complexes during a single round of RepA binding to ClpAP and ATP-dependent release. This result was substantiated with a ClpA mutant, ClpA(K220V), carrying an amino acid substitution in the N-terminal ATP binding site. ClpA(K220V) is unable to activate RepA, but the presence of ClpP or chemically inactivated ClpP restores its ability to activate RepA. The presence of ClpP simultaneously facilitates degradation of RepA ClpP must remain bound to ClpA(K220V) for these effects, indicating that both chaperone and proteolytic activities of the mutant complex occur concurrently. ClpA(K220V) itself is able to form stable complexes with RepA in the presence of a poorly hydrolyzed ATP analog, adenosine 5'-O-(thiotriphosphate), and to release RepA upon exchange of adenosine 5'-O-(thiotriphosphate) with ATP. However, the released RepA is inactive in DNA binding, indicating that the N-terminal ATP binding site is essential for the chaperone activity of ClpA. Taken together, these results suggest that substrates bound to the complex of the proteolytic and ATPase components can be partitioned between release/reactivation and translocation/degradation.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2D19,37 Convent Dr,MSC37-4255, Bethesda, MD 20892 USA.	wickners@dc37a.nci.nih.gov						Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WOO KM, 1992, J BIOL CHEM, V267, P20429	40	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19316	19322		10.1074/jbc.274.27.19316	http://dx.doi.org/10.1074/jbc.274.27.19316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383442	hybrid			2022-12-25	WOS:000081196300065
J	Poupon, V; Begue, B; Gagnon, J; Dautry-Varsat, A; Cerf-Bensussan, N; Benmerah, A				Poupon, V; Begue, B; Gagnon, J; Dautry-Varsat, A; Cerf-Bensussan, N; Benmerah, A			Molecular cloning and characterization of MT-ACT48, a novel mitochondrial Acyl-CoA thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; LONG-CHAIN; MEDIATED ENDOCYTOSIS; PROTEIN THIOESTERASE; TRANSPORT VESICLES; COENZYME-A; EH-DOMAIN; EPS15; PURIFICATION; EXPRESSION	While characterizing Eps15 partners, we identified a 48-kDa polypeptide (p48) which was precipitated by Eps15-derived glutathione S-transferase fusion proteins. A search in a murine expressed sequence tag data base with N-terminal microsequences of p48 led to the identification of two complete cDNA clones encoding two isoforms of a 439-amino acid protein sharing 95% nucleic and amino acid identity. Northern blot and immunoblotting studies showed that p48 was ubiquitously expressed. A significant homology (19% identity and 40% similarity) between p48 and rat brain cytosolic acyl-CoA thioesterase was observed in an 80-amino acid C-terminal domain, retrieved from proteins from human, nematode, and plants. The thioesterase function of p48 was further demonstrated against long chain acyl-CoAs in a spectrophotometric assay. Furthermore, data obtained from sequence analysis showed that p48 contained a mitochondrial targeting signal, cleaved in mature protein as assessed by microsequencing. The mitochondrial localization of both endogenous and transfected p48 was confirmed by confocal microscopy. These results indicate that p48, called MT-ACT48 (mitochondrial acyl-CoA thioesterase of 48 kDa), defines a novel family of mitochondrial long chain acyl CoA thioesterases.	Fac Necker Enfants Malad, INSERM, F-75756 Paris 15, France; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble, France; Inst Pasteur, Unite Biol Interact Cellulaires, CNRS, URA 1960, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benmerah, A (corresponding author), Fac Necker Enfants Malad, INSERM, CJF 97-10,156 Rue Vaugirard, F-75756 Paris 15, France.		Cerf-Bensussan, nadine/H-9505-2017; Gagnon, Jean/C-3136-2008; benmerah, alexandre/H-3742-2017; Begue, Bernadette/I-2744-2017	Cerf-Bensussan, nadine/0000-0003-0665-1245; Gagnon, Jean/0000-0002-0177-824X; benmerah, alexandre/0000-0003-0188-8016; Begue, Bernadette/0000-0002-1228-9978				Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; Carbone R, 1997, CANCER RES, V57, P5498; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Engberg ST, 1997, BIOCHEM J, V323, P525, DOI 10.1042/bj3230525; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Iannolo G, 1997, CANCER RES, V57, P240; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sambrook J., 2002, MOL CLONING LAB MANU; SRERE PA, 1959, BIOCHIM BIOPHYS ACTA, V33, P313, DOI 10.1016/0006-3002(59)90118-0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; Yamada J, 1997, BIOCHEM BIOPH RES CO, V232, P198, DOI 10.1006/bbrc.1997.6246	34	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19188	19194		10.1074/jbc.274.27.19188	http://dx.doi.org/10.1074/jbc.274.27.19188			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383425	hybrid			2022-12-25	WOS:000081196300048
J	Schwenzer, R; Siemienski, K; Liptay, S; Schubert, G; Peters, N; Scheurich, P; Schmid, RM; Wajant, H				Schwenzer, R; Siemienski, K; Liptay, S; Schubert, G; Peters, N; Scheurich, P; Schmid, RM; Wajant, H			The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappa B and c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; SIGNAL-TRANSDUCING PROTEINS; RING FINGER PROTEIN; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; INTERACTING PROTEIN; CONTAINS 2; T-CELLS; CD40; MEMBER	To understand how the TNF receptor-associated factor 1 (TRAF1) is transcriptionally regulated, in vitro DNA binding assays, promoter-reporter gene assays, and RNase protection assays were performed with the human TRAF1 gene. Binding of NF-kappa B to three of five putative binding sites within the human TRAF1 promoter was found in electrophoretic mobility shift assay studies, and analysis of TRAF1 gene promoter luciferase constructs confirmed the functional importance of these elements. Moreover, triggering of TNF-R1, CD40, and the interleukin-l receptor resulted in transcription of the TRAF1 gene, whereas receptors that are not activators or only poor activators of NF-kappa B in HeLa cells failed to show a significant TRAF1 induction. Because it has been shown that members of the TRAF family are involved in activation of NF-kappa B and the c-Jun N-terminal kinase (JNK) by the interleukin-1 receptor and members of the TNF receptor superfamily, a role of TRAF1 in receptor cross-talk and/or feedback regulation of activated receptor signaling complexes can be suggested. In fact, we found that TNF-induced activation of JNK is prolonged in transfectants overexpressing TRAF1, whereas overexpression of a deletion mutant of TRAF1 in which the N-terminal part had been replaced by the green fluorescent protein interfered with TNF-induced activation of NF-kappa B and JNK.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Ulm, Chirurg Klin 1, D-89081 Ulm, Germany	University of Stuttgart; Ulm University	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Aizawa S, 1997, J BIOL CHEM, V272, P2042; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siemienski K, 1997, GENE, V195, P35, DOI 10.1016/S0378-1119(97)00147-9; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	50	148	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19368	19374		10.1074/jbc.274.27.19368	http://dx.doi.org/10.1074/jbc.274.27.19368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383449	hybrid			2022-12-25	WOS:000081196300072
J	Thomas, VH; Yang, YS; Rice, KG				Thomas, VH; Yang, YS; Rice, KG			In vivo ligand specificity of E-selectin binding to multivalent sialyl Lewis(x) N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; P-SELECTIN; MYELOID CELLS; IN-VIVO; GLYCOPROTEIN LIGAND; ENZYMATIC-SYNTHESIS; ANIMAL LECTINS; O-GLYCANS; EXPRESSION; ADHESION	The in vivo specificity for E-selectin binding to a panel of N-linked oligosaccharides containing a clustered array of one to four sialyl Lewis(x) (SLe(x); NeuAc alpha 2-3Gal[Fuc alpha 1-3]beta 1-4G1cNAc) determinants was studied in mice. Following intraperitoneal dosing with lipopolysaccharide, radioiodinated tyrosinamide N-linked oligosaccharides were dosed i.v. and analyzed for their pharmacokinetics and biodistribution, Specific targeting was determined from the degree of SLe(x) oligosaccharide targeting relative to a sialyl oligosaccharide control. Oligosaccharides targeted the kidney with the greatest selectivity after a 4-h induction period following lipopolysaccharide dosing. Unique pharmacokinetic profiles were identified for SLe(x) biantennary and triantennary oligosaccharides but not for monovalent and tetraantennary SLe(x) oligosaccharides or sialyl oligosaccharide controls. Biodistribution studies established that both SLe(x) biantennary and triantennary oligosaccharides distributed to the kidney with 2-3-fold selectivity over sialyl oligosaccharide controls, whereas monovalent and tetraantennary SLe(x) oligosaccharides failed to mediate specific kidney targeting. Simultaneous dosing of SLe(x) biantennary or triantennary oligosaccharide with a mouse anti-E-selectin monoclonal antibody blocked kidney targeting, whereas co-administration with anti-P-selectin monoclonal antibody did not significantly block kidney targeting. The results suggest that SLe(x) biantennary and triantennary are N-linked oligosaccharide ligands for E-selectin and implicate E-selectin as a bivalent receptor in the murine kidney endothelium.	Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Rice, KG (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.				NIAID NIH HHS [AI33189] Funding Source: Medline; NIGMS NIH HHS [GM48049] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048049, R29GM048049] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENET LZ, 1979, J PHARM SCI, V68, P1071, DOI 10.1002/jps.2600680845; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHIU MH, 1995, J BIOL CHEM, V270, P24024, DOI 10.1074/jbc.270.41.24024; CHIU MH, 1994, J BIOL CHEM, V269, P16195; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DEFREES SA, 1995, J AM CHEM SOC, V117, P66, DOI 10.1021/ja00106a008; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; Eppihimer MJ, 1997, AM J PHYSIOL-HEART C, V273, pH1903, DOI 10.1152/ajpheart.1997.273.4.H1903; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; FRIES JWU, 1993, AM J PATHOL, V143, P725; HASEGAWA T, 1994, DRUG METAB DISPOS, V22, P8; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Henseleit U, 1996, J PATHOL, V180, P317; HEWETT JA, 1993, PHARMACOL REV, V45, P381; Konstantopoulos K, 1997, J CLIN INVEST, V100, pS19; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEE YC, 1983, J BIOL CHEM, V258, P199; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Lin CH, 1995, BIOORGAN MED CHEM, V3, P1625, DOI 10.1016/0968-0896(95)00150-6; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; RIEGELMAN S, 1980, J PHARMACOKINET BIOP, V8, P509, DOI 10.1007/BF01059549; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Thomas VH, 1998, CARBOHYD RES, V306, P387, DOI 10.1016/S0008-6215(97)10098-2; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WAGNER J. G., 1975, FUNDAMENTALS CLIN PH, Vfirst, P57; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yoshida M, 1997, ANN NY ACAD SCI, V811, P493, DOI 10.1111/j.1749-6632.1997.tb52031.x	39	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19035	19040		10.1074/jbc.274.27.19035	http://dx.doi.org/10.1074/jbc.274.27.19035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383404	hybrid			2022-12-25	WOS:000081196300027
J	Guo, CY; Wang, Y; Brautigan, DL; Larner, JM				Guo, CY; Wang, Y; Brautigan, DL; Larner, JM			Histone H1 dephosphorylation is mediated through a radiation-induced signal transduction pathway dependent on ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; CHINESE-HAMSTER CELLS; S-PHASE CHECKPOINTS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CHROMATIN STRUCTURE; POTENT INHIBITOR; GENE-PRODUCT; OVARY CELLS; PHOSPHORYLATION	Ionizing radiation is known to activate multiple signal transduction pathways, but the targets of these pathways are poorly understood. Phosphorylation of histone Ill is thought to have a role in chromatin condensation/ decondensation, and we asked whether ionizing radiation (IR) would alter H1 phosphorylation. Our data demonstrate that low doses of IR result in a dramatic, but transient, dephosphorylation of H1 isoforms, The in vivo IR-induced dephosphorylation of H1 is completely blocked by wortmannin and is abrogated in ataxia telangiectasia cells. Furthermore, we measured radiation-induced inhibition of cyclin dependent kinase activity and activation of histone H1 phosphatase activity. Both activities were affected by radiation-induced signals in an ATM dependent manner. Thus, the rapid IR-induced dephosphorylation of H1 involves a pathway including ATM and a wortmannin-sensitive step leading to both inhibition of cyclin-dependent kinase activities as well as activation of H1 phosphatase(s).	Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Dept Radiat Oncol, Box 383, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA 72622] Funding Source: Medline; NIGMS NIH HHS [GM 56362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GURLEY LR, 1971, BIOCHEMISTRY-US, V10, P1588, DOI 10.1021/bi00785a013; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; HARPER JW, 1993, CELL, V75, P805; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; Jung M, 1997, CANCER RES, V57, P24; Larner JM, 1997, CANCER SURV, V29, P25; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LIU VF, 1995, STEM CELLS, V13, P117; LU MJ, 1994, CHROMOSOMA, V103, P111; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PASCHAL B, 1998, CELL BIOL LAB HDB, V2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18715	18720		10.1074/jbc.274.26.18715	http://dx.doi.org/10.1074/jbc.274.26.18715			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373485	hybrid			2022-12-25	WOS:000081056700077
J	Kwon, G; Xu, G; Marshall, CA; McDaniel, ML				Kwon, G; Xu, G; Marshall, CA; McDaniel, ML			Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta(12,14)-prostaglandin J(2) and aminoguanidine - A role for peroxisome proliferator-activated receptor gamma activation and iNOS expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; SIGNAL-TRANSDUCTION; GLUCOSE-TOLERANCE; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; PPAR-GAMMA; PHAS-I	Recent studies have identified a beta-cell insulin receptor that functions in the regulation of protein translation and mitogenic signaling similar to that described for insulin-sensitive cells. These findings have raised the novel possibility that beta-cells may exhibit insulin resistance similar to skeletal muscle, liver, and fat. To test this hypothesis, the effects of tumor necrosis factor-alpha (TNF alpha), a cytokine proposed to mediate insulin resistance by interfering with insulin signaling at the level of the insulin receptor and its substrates, was evaluated. TNF alpha inhibited p70(s6k) activation by glucose-stimulated beta-cells of the islets of Langerhans in a dose- and time-dependent manner, with maximal inhibition observed at similar to 20-50 ng/ml, detected after 24 and 48 h of exposure. Exogenous insulin failed to prevent TNF alpha-induced inhibition of p70(s6k), suggesting a defect in the insulin signaling pathway. To further define mechanisms responsible for this inhibition and also to exclude cytokine-induced nitric oxide (NO) as a mediator, the ability of exogenous or endogenous insulin +/- inhibitors of nitric-oxide synthase (NOS) activity, aminoguanidine or N-monomethyl-L-arginine, was evaluated. Unexpectedly, TNFa and also interleukin 1 (IL-1)-induced inhibition of p70(s6k) was completely prevented by inhibitors that block NO production. Western blot analysis verified inducible NOS (MOS) expression after TNF alpha exposure. Furthermore, the ability of IL-1 receptor antagonist protein, IRAP, to block TNF alpha-induced inhibition of p70(s6k) indicated that activation of intra-islet macrophages and the release of IL-1 that induces iNOS expression in beta-cells was responsible for the inhibitory effects of TNF alpha. This mechanism was confirmed by the ability of the peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) to attenuate TNF alpha-induced insulin resistance by down-regulating MOS expression and/or blocking IL-1 release from activated macrophages. Overall, TNF alpha-mediated insulin resistance in beta-cells is characterized by a global inhibition of metabolism mediated by NO differing from that proposed for this proinflammatory cytokine in insulin-sensitive cells.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu			NIDDK NIH HHS [DK55024, DK06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK055024, R01DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1995, DIABET ANN, V9, P265; CORBETT JA, 1996, NITRIC OXIDE PRINCIP, P177; DeFronzo RA, 1997, DIABETES REV, V5, P177; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KHAN CR, 1997, CELL, V88, P561; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LEE MK, 1994, DIABETES, V43, P1435, DOI 10.2337/diabetes.43.12.1435; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Ma ZM, 1997, J BIOL CHEM, V272, P17827, DOI 10.1074/jbc.272.28.17827; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Peraldi P, 1997, J ENDOCRINOL, V155, P219, DOI 10.1677/joe.0.1550219; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Prigeon RL, 1998, J CLIN ENDOCR METAB, V83, P819, DOI 10.1210/jc.83.3.819; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	44	67	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18702	18708		10.1074/jbc.274.26.18702	http://dx.doi.org/10.1074/jbc.274.26.18702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373483	hybrid			2022-12-25	WOS:000081056700075
J	LaPlante, SR; Cameron, DR; Aubry, N; Lefebvre, S; Kukolj, G; Maurice, R; Thibeault, D; Lamarre, D; Llinas-Brunet, M				LaPlante, SR; Cameron, DR; Aubry, N; Lefebvre, S; Kukolj, G; Maurice, R; Thibeault, D; Lamarre, D; Llinas-Brunet, M			Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; SERINE-PROTEASE; CLEAVAGE PRODUCTS; CRYSTAL-STRUCTURE; PEPTIDE; POLYPROTEIN; PROTEINASE; INHIBITORS; CONFORMATION; PRECURSOR	The interactions of the NS3 protease domain with inhibitors that are based on N-terminal cleavage products of peptide substrates were studied by NMR methods. Transferred nuclear Overhauser effect experiments showed that these inhibitors bind the protease in a well defined, extended conformation. Protease-induced line-broadening studies helped identify the segments of inhibitors which come into contact with the protease. A comparison of the NMR data of the free and protease-bound states suggests that these ligands undergo rigidification upon complexation. This work provides the first structure of an inhibitor when bound to NS3 protease and should be valuable for designing more potent inhibitors.	Boehringer Ingelheim Canada Ltd, Dept Chem, Bio Mega Res Div, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Bio Mega Res Div, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	LaPlante, SR (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Chem, Bio Mega Res Div, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	slaplante@lav.boehringer-ingelheim.com		Cameron, Dale/0000-0001-6274-2913				BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Bodanszky M., 1993, PEPTIDE CHEM; Briand J, 1995, J BIOMOL NMR, V6, P347; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Ingallinella P, 1998, BIOCHEMISTRY-US, V37, P8906, DOI 10.1021/bi980314n; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kwong AD, 1998, ANTIVIR RES, V40, P1, DOI 10.1016/S0166-3542(98)00043-6; LaPlante SR, 1998, ANGEW CHEM INT EDIT, V37, P2729, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2729::AID-ANIE2729>3.0.CO;2-4; LaPlante SR, 1998, BIOCHEMISTRY-US, V37, P9793, DOI 10.1021/bi980555v; LaPlante SR, 1999, J AM CHEM SOC, V121, P2974, DOI 10.1021/ja983904h; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P2719, DOI 10.1016/S0960-894X(98)00480-6; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; LYERLA JR, 1974, TOP CARBON 13 NMR SP, V1, P79; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLGAR L, 1989, MECH PROTEASE ACTION; REED KE, 1998, RB8 STUD HEMATOL, V62, P1; SCHECHTER J, 1970, PHIL T R SOC LONDO B, V257, P249; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Steinkuhler C, 1996, J VIROL, V70, P6694; STEWART JM, 1984, SOLID PHASE PEPTIDE, P149; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Urbani A, 1997, J BIOL CHEM, V272, P9204; Yan YW, 1998, PROTEIN SCI, V7, P837; [No title captured]	36	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18618	18624		10.1074/jbc.274.26.18618	http://dx.doi.org/10.1074/jbc.274.26.18618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373473	hybrid			2022-12-25	WOS:000081056700065
J	Mikami, T; Kusakabe, T; Suzuki, N				Mikami, T; Kusakabe, T; Suzuki, N			Tandem organization of medaka fish soluble guanylyl cyclase alpha(1) and beta(1) subunit genes - Implications for coordinated transcription of two subunit genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE; MOLECULAR-CLONING; ORYZIAS-LATIPES; RAT LUNG; ACTIVITY REQUIRES; ENZYME SUBUNITS; BLOOD-PRESSURE; MESSENGER-RNA; 2 SUBUNITS	We determined the complete nucleotide sequences of the a, subunit gene (OIGCS-alpha(1)) and the beta(1) subunit gene (OlGCS-beta(1)) of medaka fish soluble guanylyl cyclase, In the genome, OlGCS-alpha(1) and OlGCS-beta(1) are organized in tandem. The two genes are only 986 base pairs apart and span approximately 34 kilobase pairs in the order of OlGCS-alpha(1) and OlGCS-beta(1). The nucleotide sequence of a large part of the 5'-upstream region of OlGCS-alpha(1) is complimentarily conserved in that of OlGCS-beta(1). To analyze the promoter activity of each gene, a fusion gene construct in which the 5'-upstream region was fused with the green fluorescent protein gene was injected into medaka fish 2-cell embryos. When the fusion gene containing the OlGCS-alpha(1) upstream region was injected, green fluorescent protein fluorescence was detected in the embryonic brain. The 5'-upstream region of OlGCS-beta(1) alone was insufficient for the reporter gene expression in the embryos. When the OlGCS-alpha(1) upstream region was located upstream of the OlGCS-beta(1)-green fluorescence protein fusion gene, the reporter gene was expressed in the brain and trunk region of the embryos. These results suggest that the 5'-upstream region of OlGCS-alpha(1) can affect the expression of OlGCS-beta(1). It is therefore possible that the expression of OlGCS-alpha(1) and OlGCS-beta(1) is coordinated.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Suzuki, N (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.		Kusakabe, Takehiro/H-7178-2012	Kusakabe, Takehiro/0000-0002-8325-3665				Azam M, 1998, HYPERTENSION, V32, P149, DOI 10.1161/01.HYP.32.1.149; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FAISST S, 1991, NUCLEIC ACIDS RES, V18, P6573; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GIUILI G, 1993, HUM GENET, V91, P257; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; IWAMATSU T, 1983, J EXP ZOOL, V228, P83, DOI 10.1002/jez.1402280109; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; Mikami T, 1998, EUR J BIOCHEM, V253, P42, DOI 10.1046/j.1432-1327.1998.2530042.x; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PAPAPETROPOULOS A, 1995, HYPERTENSION, V26, P696, DOI 10.1161/01.HYP.26.4.696; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Savchenko A, 1997, NATURE, V390, P694, DOI 10.1038/37803; Scholz NL, 1998, J NEUROBIOL, V34, P208, DOI 10.1002/(SICI)1097-4695(19980215)34:3<208::AID-NEU2>3.0.CO;2-6; Seimiya M, 1997, J BIOL CHEM, V272, P23407, DOI 10.1074/jbc.272.37.23407; SHIMOUCHI A, 1993, AM J PHYSIOL, V265, P6456; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Truman JW, 1996, DEVELOPMENT, V122, P3949; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; Wedel BJ, 1998, TRENDS ENDOCRIN MET, V9, P213, DOI 10.1016/S1043-2760(98)00061-7; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18567	18573		10.1074/jbc.274.26.18567	http://dx.doi.org/10.1074/jbc.274.26.18567			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373466	hybrid			2022-12-25	WOS:000081056700058
J	Allay, E; Veigl, M; Gerson, SL				Allay, E; Veigl, M; Gerson, SL			Mice over-expressing human O(6)alkylguanine-DNA alkyltransferase selectively reduce O(6)methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea	ONCOGENE			English	Article						Big Blue lacI mice; mutation frequency; hMGMT mice; N-methyl-N-nitrosourea induced lymphoma	INDUCED THYMIC LYMPHOMAS; TRANSGENIC MICE; DNA ALKYLTRANSFERASE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HUMAN-FIBROBLASTS; EXCISION-REPAIR; CELLS; PROTECTS; GENE; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE	While it is well known that MNU induces thymic lymphomas in the mouse, it remains unclear which premutagenic lesions are responsible for lymphomagenic transformation. One lesion thought to play a critical role is O(6)methylguanine [O(6)mG] which initiates G:C to A:T transition mutations in K-ras and other oncogenes, O(6)alkylguanine-DNA alkyltransferase (AGT), encoded by the methylguanine methyltransferase gene [MGMT], removes the methyl group thereby preventing the mutation from occurring, When overexpressed in the thymus, MGMT protects mice from MNU-induced thymic lymphomas, To determine whether MGMT overexpression reduced G:C to A:T mutation frequency after MNU, Big Blue(TM) IacI and MGMT+/Big Blue(TM) mice were treated with MNU and analysed for mutations in the lacI and K-ras genes. The incidence of MNU-induced lymphomas was 84% in Big Blue(TM) lacI mice compared to 14% in MGMT+Big Blue(TM) lad mice. Sixty-two per cent of the lymphomas had a GGT to GAT activating mutation in codon 12 of K-I ns consistent with O(6)mG adduct-mediated paint mutagenesis, LacI mutation frequency in thymus of MNU treated Big Blue(TM) mice was 45-fold above background whereas it was ii-fold above background in MNU treated MGMT+/Big Blue(TM) mice, Most IacI mutations were G:C to A:T transitions, implicating O(6)mG even in the MGMT+ mice. No mutations were attributable to chromosomal aberrations or rearrangements, Thus, O(6)mG adducts account for the carcinogenic effect of MNU and MGMT overexpression is selectively able to reduce O(6)methylguanine adducts below a carcinogenic threshold. Other adducts are mutagenic but appear to contribute much less to malignant transformation or oncogene activation.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA.				NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali RB, 1998, MOL CELL BIOL, V18, P1660, DOI 10.1128/MCB.18.3.1660; Becker K, 1996, CANCER RES, V56, P3244; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; COROMINAS M, 1991, CANCER RES, V51, P5129; de Boer JG, 1998, MUTAGENESIS, V13, P109; Dobo KL, 1998, CARCINOGENESIS, V19, P755, DOI 10.1093/carcin/19.5.755; DOMORADZKI J, 1985, CARCINOGENESIS, V6, P1823, DOI 10.1093/carcin/6.12.1823; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; DOSANJH MK, 1993, CARCINOGENESIS, V14, P1915, DOI 10.1093/carcin/14.9.1915; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LIU LL, 1994, CANCER RES, V54, P4648; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; MORIWAKI S, 1991, CANCER RES, V51, P6219; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Nivard MJM, 1996, MUTAT RES-FUND MOL M, V352, P97, DOI 10.1016/0027-5107(96)00011-5; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Sitaram A, 1997, MOL CELL BIOL, V17, P564, DOI 10.1128/MCB.17.2.564; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TREY JE, 1989, CANCER RES, V49, P1899; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	25	41	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3783	3787		10.1038/sj.onc.1202697	http://dx.doi.org/10.1038/sj.onc.1202697			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391687				2022-12-25	WOS:000081140200013
J	Bossy-Wetzel, E; Green, DR				Bossy-Wetzel, E; Green, DR			Caspases induce cytochrome c release from mitochondria by activating cytosolic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CELL-FREE SYSTEM; SIGNALING COMPLEX; FUNCTIONS DOWNSTREAM; PROTEASE ACTIVATION; NECROSIS-FACTOR; CD95 FAS/APO-1; DEATH DOMAIN; BCL-X(L); BCL-2	We investigated the ability of caspases (cysteine proteases with aspartic acid specificity) to induce cytochrome c release from mitochondria. When Jurkat cells were induced to undergo apoptosis by Fas receptor ligation, cytochrome c was released from mitochondria, an event that was prevented by the caspase inhibitor, zVAD-fmk (zVal-Ala-Asp-CR2F). Purified caspase-8 triggered rapid cytochrome c release from isolated mitochondria in vitro. The effect was indirect, as the presence of cytosol was required, suggesting that caspase-8 cleaves and activates a cytosolic substrate, which in turn is able to induce cytochrome c release from mitochondria, The cytochrome c releasing activity was not blocked by caspase inhibition, but was antagonized by Bcl-2 or Bcl-xL. Caspase-8 and caspase-3 cleaved Bid, a proapoptotic Bcl-2 family member, which gains cytochrome c releasing activity in response to caspase cleavage. However, caspase-6 and caspase-7 did not cleave Bid, although they initiated cytochrome c release from mitochondria in the presence of cytosol. Thus, effector caspases may cleave and activate another cytosolic substrate (other than Bid), which then promotes cytochrome c release from mitochondria. Mitochondria significantly amplified the caspase-8 initiated DEVD-specific cleavage activity. Our data suggest that cytochrome c release, initiated by the action of caspases on a cytosolic substrates, may act to amplify a caspase cascade during apoptosis.	La Jolla Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), La Jolla Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hasegawa J, 1996, CANCER RES, V56, P1713; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZY, 1996, OPT REV, V3, P47, DOI 10.1007/s10043-996-0047-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	278	281	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17484	17490		10.1074/jbc.274.25.17484	http://dx.doi.org/10.1074/jbc.274.25.17484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364179	hybrid			2022-12-25	WOS:000080974300015
J	Jin, DY; Giordano, V; Kibler, KV; Nakano, H; Jeang, KT				Jin, DY; Giordano, V; Kibler, KV; Nakano, H; Jeang, KT			Role of adapter function in oncoprotein-mediated activation of NF-kappa B - Human T-cell leukemia virus type i tax interacts directly with I kappa B kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; IKK-ALPHA; PROTEIN; BETA; ASSOCIATION; LYMPHOCYTES; COMPLEX; P16(INK4A); REPRESSOR; INDUCTION	Mechanisms by which the human T-cell leukemia virus tyre I Tax oncoprotein activates NF-kappa B remain incompletely understood. Although others have described an interaction between Tax and a holo-I kappa B kinase (IKK) complex, the exact details of protein-protein contact are not fully defined. Here we show that Tax binds to neither IKK-alpha nor IKH-beta but instead complexes directly with IKK-gamma, a newly characterized component of the IKK complex. This direct interaction with IKK-gamma correlates with Tax-induced I kappa B-alpha phosphorylation and NF-kappa B activation, Thus, our findings establish IKK-gamma as a key molecule for adapting an oncoprotein-specific signaling to IKK-alpha and IKK-beta.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Juntendo University; Japan Science & Technology Agency (JST)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kjeang@niaid.nih.gov	Jeang, Kuan-Teh/A-2424-2008	Nakano, Hiroyasu/0000-0003-4843-1427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, J BIOMED SCI, V6, P115, DOI 10.1007/BF02256442; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REID RL, 1993, ONCOGENE, V8, P3029; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	193	196	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17402	17405		10.1074/jbc.274.25.17402	http://dx.doi.org/10.1074/jbc.274.25.17402			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364167	hybrid			2022-12-25	WOS:000080974300003
J	Xu, GG; Gao, ZY; Borge, PD; Wolf, BA				Xu, GG; Gao, ZY; Borge, PD; Wolf, BA			Insulin receptor substrate 1-induced-inhibition of endoplasmic reticulum Ca2+ uptake in beta-cells - Autocrine regulation of intracellular Ca2+ homeostasis and insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC-ISLETS; TYROSINE PHOSPHORYLATION; MYOINOSITOL 1,4,5-TRISPHOSPHATE; TARGETED DISRUPTION; ISOLATED ORGANELLES; CA-2+ MOBILIZATION; PLASMA-MEMBRANE; GLUCOSE SENSOR; RAT INSULINOMA	To understand the role of the insulin receptor pathway in beta-cell function, we have generated stable beta-cells (beta IRS1-A) that overexpress by S-fold the insulin receptor substrate-1 (IRS-1) and compared them to vector-expressing controls. IRS-1 overexpression dramatically increased basal cytosolic Ca2+ levels from 81 to 278 nM, but it did not affect Ca2+ response to glucose. Overexpression of the insulin receptor also caused an increase in cytosolic Ca2+. Increased cytosolic Ca2+ was due to inhibition of Ca2+ uptake by the endoplasmic reticulum, because endoplasmic reticulum Ca2+ uptake and content were reduced in beta IRS1-A cells. Fractional insulin secretion was significantly increased 2-fold, and there was a decrease in beta IRS1-A insulin content and insulin biosynthesis. Steady-state insulin mRNA levels and glucose-stimulated ATP were unchanged. High IFS-1 levels also reduced beta-cell proliferation. These data demonstrate a direct link between the insulin receptor signaling pathway and the Ca2+-dependent pathways regulating insulin secretion of beta-cells. We postulate that during regulated insulin secretion, released insulin binds the beta-cell insulin receptor and activates IRS-1, thus further increasing cytosolic Ca2+ by reducing Ca2+ uptake. We suggest the existence of a novel pathway of autocrine regulation of intracellular Ca2+ homeostasis and insulin secretion in the beta-cell of the endocrine pancreas.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wolf, BA (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 230 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049814, P30DK019525, R01DK043354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19525, DK43354, DK49814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Avruch J, 1998, NATURE, V391, P846, DOI 10.1038/35998; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLCA JR, 1982, J BIOL CHEM, V257, P7223; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P6947, DOI 10.1073/pnas.92.15.6947; Gao ZY, 1998, EUR J NEUROSCI, V10, P2416, DOI 10.1046/j.1460-9568.1998.00252.x; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Guest PC, 1997, BIOCHEM J, V323, P445, DOI 10.1042/bj3230445; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HENQUIN JC, 1992, ENDOCRINOLOGY, V131, P127, DOI 10.1210/en.131.1.127; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEVY J, 1994, AM J MED, V96, P260, DOI 10.1016/0002-9343(94)90152-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacLennan DH, 1997, ANN NY ACAD SCI, V834, P175, DOI 10.1111/j.1749-6632.1997.tb52249.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PRENTKI M, 1984, J BIOL CHEM, V259, P4054; PRENTKI M, 1984, J BIOL CHEM, V259, P118; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THIES RS, 1989, J BIOL CHEM, V264, P12820; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; VARADI A, 1995, BBA-BIOMEMBRANES, V1236, P119, DOI 10.1016/0005-2736(95)00103-A; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	52	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18067	18074		10.1074/jbc.274.25.18067	http://dx.doi.org/10.1074/jbc.274.25.18067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364259	hybrid			2022-12-25	WOS:000080974300095
J	Merzendorfer, H; Huss, M; Schmid, P; Harvey, WR; Wieczorek, H				Merzendorfer, H; Huss, M; Schmid, P; Harvey, WR; Wieczorek, H			A novel insect V-ATPase subunit M9.7 is glycosylated extensively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; POLYMERASE CHAIN-REACTION; MANDUCA-SEXTA MIDGUT; VACUOLAR-TYPE ATPASE; PLASMA-MEMBRANE; SECONDARY-STRUCTURE; ESCHERICHIA-COLI; PROTON PUMP; ENDOPLASMIC-RETICULUM; POLYACRYLAMIDE GELS	Plasma membrane V-ATPase isolated from midgut and Malpighian tubules of the tobacco hornworm, Manduca sexta, contains a novel prominent 20-kDa polypeptide. Based on N-terminal protein sequencing, we cloned a corresponding cDNA. The deduced hydrophobic protein consisted of 88 amino acids with a molecular mass of only 9.7 kDa. Immunoblots of the recombinant 9.7-kDa polypeptide, using a monoclonal antibody to the 20-kDa polypeptide, confirmed that the correct cDNA had been cloned. The 20-kDa polypeptide is glycosylated, as deduced from lectin staining. Treatment with N-glycosidase A resulted in the appearance of two additional protein bands of 16 and 10 kDa which both were immunoreactive to the 20-kDa polypeptide-specific monoclonal antibody. Thus, extensive N-glycosylation of the novel V-0 subunit M9.7 accounts for half of its molecular mass observed in SDS-polyacrylamide gel electrophoresis. M9.7 exhibits some similarities to the yeast protein Vma21p which resides in the endoplasmic reticulum and is required for the assembly of the V-0 complex. However, as deduced from immunoblots as well as from activities of the V-ATPase and endoplasmic reticulum marker enzymes in different membrane preparations, M9.7 is, in contrast to the yeast polypeptide, a constitutive subunit of the mature plasma membrane V-ATPase of M. sexta.	Univ Osnabruck, Dept Biol, Sect Anim Physiol, D-49069 Osnabruck, Germany; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA	University Osnabruck; State University System of Florida; University of Florida	Wieczorek, H (corresponding author), Univ Osnabruck, Dept Biol, Sect Anim Physiol, D-49069 Osnabruck, Germany.							ARAI H, 1988, J BIOL CHEM, V263, P8796; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; AZUMA M, 1995, FEBS LETT, V361, P153, DOI 10.1016/0014-5793(95)00146-Z; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEGG JCS, 1982, ANAL BIOCHEM, V127, P389, DOI 10.1016/0003-2697(82)90192-0; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FERRERAS M, 1993, ANAL BIOCHEM, V213, P206, DOI 10.1006/abio.1993.1410; FROHLICH DR, 1994, J MOL EVOL, V38, P476, DOI 10.1007/BF00178847; GRAF R, 1994, J BIOL CHEM, V269, P3767; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HAWKES R, 1982, ANAL BIOCHEM, V123, P143, DOI 10.1016/0003-2697(82)90634-0; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HSU DKW, 1995, FEBS LETT, V371, P127, DOI 10.1016/0014-5793(95)00867-9; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; Ludwig J, 1998, J BIOL CHEM, V273, P10939, DOI 10.1074/jbc.273.18.10939; Merzendorfer H, 1997, J EXP BIOL, V200, P225; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROST B, 1995, PROTEIN SCI, V4, P521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; SCHNEPPE B, 1991, FEBS LETT, V292, P145, DOI 10.1016/0014-5793(91)80853-U; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	47	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17372	17378		10.1074/jbc.274.24.17372	http://dx.doi.org/10.1074/jbc.274.24.17372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358099	hybrid			2022-12-25	WOS:000080780400098
J	Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D				Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D			Cyclin D-1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma	ONCOGENE			English	Article						cyclin D-1; p16; head and neck cancer	IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; ESTROGEN-RECEPTOR; FREQUENT LOSS; LUNG CANCERS; EXPRESSION; D1; PROTEIN; OVEREXPRESSION; PROGRESSION	Progression through the G(1) phase of the cell cycle is mediated by phosphorylation of the retinoblastoma protein (pRb) resulting in the release of essential transcription factors such as E2F-1. The phosphorylation of pRb is regulated positively by cyclin D-1/CDK4 and negatively by CDK inhibitors, such as p16 (CDKN2/MTS-1/INK4A), The p16/cyclin D-1/Rb pathway plays a critical role in tumorigenesis and many tumor types display a high frequency of inactivation of at least one component of this pathway. In order to determine the overall contribution of these three components to progression of head and neck squamous cell carcinoma (HNSCC), we examined p16 inactivation, cyclin D-1 amplification, and pRb expression in 23 primary HNSCC tumors and five cell lines, p16 inactivation was detected in 19/23 (83%) primary tumors by detailed genetic analysis and was confirmed by immunohistochemistry (MC), Absence of Ph protein expression indicative of pRb inactivation was identified in 2/23 (9%) tumors, In this set of tumors, there was a perfect inverse correlation between p16 and pRb inactivation, Using fluorescence in situ hybridization (FISH) cyclin D-1 amplification was identified in 4/5 (80%) cell lines and 4/11 (36%) primary tumors. However, 2/4 cell lines and all four primary tumors with cyclin D-1 amplification contained a concomitant alteration of p16, Therefore 21/23 (91%) of primary HNSCC contained at least one alteration in the p16/cyclin D-1/Rb pathway. Although p16 and Rb alteration are apparently exclusive, cyclin D-1 amplification occurs concomitantly with the loss of p16 suggesting an additional role for this amplification in HNSCC.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21287 USA; Yamaguchi Univ, Dept Otolaryngol, Ube, Yamaguchi 755, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yamaguchi University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.							Andl T, 1998, CANCER RES, V58, P5; BRODEUR GM, 1998, GENETIC BASIS HUMAN, P161; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1997, CANCER RES, V57, P4497; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JARES P, 1994, CANCER RES, V54, P4813; Jenkins RB, 1997, CANCER RES, V57, P524; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simpson JF, 1997, AM J PATHOL, V151, P161; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOO GH, 1994, CANCER RES, V54, P4603; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	30	68	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3541	3545		10.1038/sj.onc.1202837	http://dx.doi.org/10.1038/sj.onc.1202837			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376532				2022-12-25	WOS:000080850600012
J	Chiloeches, A; Paterson, HF; Marais, R; Clerk, A; Marshall, CJ; Sugden, PH				Chiloeches, A; Paterson, HF; Marais, R; Clerk, A; Marshall, CJ; Sugden, PH			Regulation of Ras-GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester - Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MUSCLE CELL HYPERTROPHY; CARDIAC MYOCYTES; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; ANGIOTENSIN-II; TRANSDUCTION PATHWAYS; DEPENDENT PATHWAYS; BINDING DOMAIN	The small G protein Ras has been implicated in hypertrophy of cardiac myocytes. We therefore examined the activation (GTP loading) of Ras by the following hypertrophic agonists: phorbol la-myristate 13-acetate (PMA), endothelin-l (ET-1), and phenylephrine (PE). All three increased Ras GTP loading by 10-15-fold (maximal in 1-2 min), as did bradykinin. Other G protein-coupled receptor agonists (e.g. angiotensin II, carbachol, isoproterenol) were less effective. Activation of Ras by PMA, ET-1, or PE was reduced by inhibition of protein kinase C (PKC), and that induced by ET-1 or PE was partly sensitive to pertussis toxin, 8-(4-Chlorophenylthio)-cAMP (CPT-cAMP) did not inhibit Ras GTP loading by PMA, ET-1, or PE, The association of Ras with c-Raf protein was increased by PMA, ET-1, or PE, and this was inhibited by CPT-cAMP. However, only PMA and ET-1 increased Ras-associated mitogen-activated protein kinase kinase 1-activating activity, and this was decreased by PKC inhibition, pertussis toxin, and CPT-cAMP. PMA caused the rapid appearance of phosphorylated (activated) extracellular signal-regulated kinase in the nucleus, which was inhibited by a microinjected neutralizing anti-Ras antibody. We conclude that PKC- and G(i)-dependent mechanisms mediate the activation of Ras in myocytes and that Ras activation is required for stimulation of extracellular signal-regulated kinase by PMA.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Cardiac Med, Natl Heart & Lung Inst, London SW3 6LY, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci Mol Pathol, London SW7 2AZ, England	Imperial College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Sugden, PH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Cardiac Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	p.sugden@ic.ac.uk	Chiloeches, Antonio/Z-5993-2019	Marais, Richard/0000-0001-7484-4183; Clerk, Angela/0000-0002-5658-0708; Antonio, Chiloeches Galvez/0000-0001-7162-330X				Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGOYEVITCH MA, 1993, AM J PHYSIOL, V265, pC1247, DOI 10.1152/ajpcell.1993.265.5.C1247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; CLERK A, 1995, AM J PHYSIOL-HEART C, V269, pH1087, DOI 10.1152/ajpheart.1995.269.3.H1087; CLERK A, 1994, J BIOL CHEM, V269, P32848; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; Fuller SJ, 1998, BIOCHEM J, V335, P241, DOI 10.1042/bj3350241; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GSCHWENDT M, 1993, BIOCHEM BIOPH RES CO, V194, P571, DOI 10.1006/bbrc.1993.1858; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEIMER GV, 1974, J CLIN PATHOL, V27, P254, DOI 10.1136/jcp.27.3.254; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HilalDandan R, 1997, AM J PHYSIOL-HEART C, V272, pH130, DOI 10.1152/ajpheart.1997.272.1.H130; HILALDANDAN R, 1994, MOL PHARMACOL, V45, P1183; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOZERI O, 1992, ONCOGENE, V7, P2259; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	78	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19762	19770		10.1074/jbc.274.28.19762	http://dx.doi.org/10.1074/jbc.274.28.19762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391918	hybrid			2022-12-25	WOS:000081377300038
J	Xu, JH; Tse, FW				Xu, JH; Tse, FW			Brefeldin A increases the quantal size and alters the kinetics of catecholamine release from rat adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; REGULATED EXOCYTOSIS; TRANSMITTER RELEASE; ORGANELLE STRUCTURE; SYNAPTIC VESICLES; PHOSPHOLIPASE-D; IN-VITRO; FUSION; ARF; INHIBITION	The fungal metabolite, brefeldin A (BFA), is known to inhibit guanine nucleotide exchange on the ADP-ribosylating factors that are involved in vesicle membrane trafficking. Here, we investigated the action of BFA on Ca2+-regulated exocytosis in single rat adrenal chromaffin cells. Incubation of chromaffin cells with BFA (1 or 10 mu M) for 2 h effectively disrupted the Golgi membranes but did not affect the pattern of catecholamine release triggered by high extracellular K+, which was monitored with carbon fiber amperometry along with cytosolic Ca2+ measurement. The BFA treatment, however, increased the mean quantal size of catecholamine-containing vesicles and the occurrence of amperometric events with a "foot" or "stand alone" signal (which reflects sluggish or incomplete dilation of the fusion pore). To examine whether BFA altered the Ca2+-dependence of exocytosis, we employed the whole-cell recording technique in conjunction with the capacitance measurement to measure exocytosis evoked from the entire cell during voltage-gated Ca2+ entry. Our results suggested that BFA treatment did not alter either the initial rate of capacitance increase or the total amount of capacitance increase. Therefore, in chromaffin cells, BFA treatment affects Ca2+-regulated exocytosis predominantly by increasing the quantal size and by slowing the fusion kinetics of some vesicles.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Tse, FW (corresponding author), Univ Alberta, Dept Pharmacol, 9-70 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Tse, Frederick/C-3449-2013	Xu, Jianhua/0000-0003-0084-8856				BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow Robert H., 1995, P245; Cleves AE, 1997, NEUROCHEM RES, V22, P933, DOI 10.1023/A:1022462523315; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; Fischer TA, 1997, AM J PHYSIOL-HEART C, V272, pH958, DOI 10.1152/ajpheart.1997.272.2.H958; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; HERRINGTON J, 1994, PULSE CONTROL, V5; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lim W, 1997, PFLUG ARCH EUR J PHY, V435, P34, DOI 10.1007/s004240050481; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Loirand G, 1997, AM J PHYSIOL-CELL PH, V273, pC816, DOI 10.1152/ajpcell.1997.273.3.C816; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; Pothos EN, 1998, J NEUROSCI, V18, P5575; Pothos EN, 1998, J NEUROSCI, V18, P4106; ROBINSON IM, 1995, P NATL ACAD SCI USA, V92, P2474, DOI 10.1073/pnas.92.7.2474; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TSE A, 1995, PFLUG ARCH EUR J PHY, V430, P645, DOI 10.1007/BF00386158; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZIZI M, 1991, J BIOL CHEM, V266, P18443	38	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19095	19102		10.1074/jbc.274.27.19095	http://dx.doi.org/10.1074/jbc.274.27.19095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383412	hybrid			2022-12-25	WOS:000081196300035
J	Kelly, JD; Inga, A; Chen, FX; Dande, P; Shah, D; Monti, P; Aprile, A; Burns, PA; Scott, G; Abbondandolo, A; Gold, B; Fronza, G				Kelly, JD; Inga, A; Chen, FX; Dande, P; Shah, D; Monti, P; Aprile, A; Burns, PA; Scott, G; Abbondandolo, A; Gold, B; Fronza, G			Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYMERASE-BETA; NUCLEOTIDE INCORPORATION; FUNCTIONAL ASSAY; CELL-LINES; IN-VITRO; GLYCOSYLASE; MUTAGENESIS; ALKYLATION; DEFICIENT	Me-lex, a methyl sulfonate ester appended to a neutral N-methylpyrrolecarboxamide-based dipeptide, was synthesized to preferentially generate N-3-methyladenine (3-MeA) adducts which are expected to be cytotoxic rather than mutagenic DNA lesions. In the present study, the sequence specificity for DNA alkylation by Me-lex was determined in the p53 cDNA through the conversion of the adducted sites into single strand breaks and sequencing gel analysis. In order to establish the mutagenic and lethal properties of Me-lex lesions, a yeast expression vector harboring the human wild-type p53 cDNA was treated in vitro with Me-lex, and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter. The results showed that: 1) more than 99% of the lesions induced by Me-lex are 3-MeA; 2) the co-addition of distamycin quantitatively inhibited methylation at all minor groove sites; 3) Me-lex selectively methylated A's that are in, or immediately adjacent to, the lex equilibrium binding sites; 4) all but 6 of the 33 independent mutations were base pair substitutions, the majority of which (17/33; 52%) were AT-targeted; 5) AT --> TA transversions were the predominant mutations observed (13/33; 39%); 6) 13 out of 38 (39%) independent mutations involved a single lex-binding site encompassing positions A(600-602), and 9 occurred at position 602 which is a real Me-lex mutation hotspot (n = 9, p < 10(-6), Poisson's normal distribution). A hypothetical model for the interpretation of mutational events at this site is proposed. The present work is the first report on mutational properties of Me-lex. Our results suggest that 3-MeA is not only a cytotoxic but also a premutagenic lesion which exerts this unexpected property in a strict sequence-dependent manner.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 69198 USA; Natl Canc Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Leeds; University of Genoa	Gold, B (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA.	bgold@MAIL.UNMC.EDU; fronzagi@hp380.ist.unige.it	Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Inga, Alberto/AAC-3815-2022	Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Inga, Alberto/0000-0002-8767-1637	NCI NIH HHS [CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; CHAUDHURI I, 1991, CARCINOGENESIS, V12, P2283, DOI 10.1093/carcin/12.12.2283; CHURCH KM, 1990, BIOCHEMISTRY-US, V29, P6827, DOI 10.1021/bi00481a011; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; Dinglay S, 1998, MUTAT RES-DNA REPAIR, V407, P109, DOI 10.1016/S0921-8777(97)00065-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Efrati E, 1997, J BIOL CHEM, V272, P2559; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HENRYAMAR M, 1993, HEMATOL ONCOL CLIN N, V7, P369, DOI 10.1016/S0889-8588(18)30246-6; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; Kelly JD, 1998, CHEM RES TOXICOL, V11, P1481, DOI 10.1021/tx9801763; KONAKAHARA T, 1988, BIOCHEMISTRY-US, V27, P8606, DOI 10.1021/bi00423a015; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lawley P.D, 1984, ACS MONOGR SER, V182; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; MARSELOS M, 1991, CARCINOGENESIS, V12, P1751, DOI 10.1093/carcin/12.10.1751; Mehta P, 1996, CHEM RES TOXICOL, V9, P939, DOI 10.1021/tx960007n; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; ZHANG Y, 1993, BIOCHEMISTRY-US, V32, P7954, DOI 10.1021/bi00082a017	35	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18327	18334		10.1074/jbc.274.26.18327	http://dx.doi.org/10.1074/jbc.274.26.18327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373436	hybrid			2022-12-25	WOS:000081056700028
J	Muller, S; Alving, K; Peter-Katalinic, J; Zachara, N; Gooley, AA; Hanisch, FG				Muller, S; Alving, K; Peter-Katalinic, J; Zachara, N; Gooley, AA; Hanisch, FG			High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; IN-VIVO; ANTIBODIES; SPECIFICITY; CLONING; ANTIGEN; SITES; CDNA; SEQUENCE; CHAINS	The site-specific O-glycosylation of MUC1 tandem repeat peptides from secretory mucin of T47D breast cancer cells was analyzed. After affinity isolation on immobilized BC3 antibody, MUC1 was partially deglycosylated by enzymatic treatment with alpha-sialidase/beta-galactosidase and fragmented by proteolytic cleavage with the Arg-C-specific endopeptidase clostripain, The PAP20 glycopeptides were isolated by reversed phase high pressure liquid chromatography and subjected to the structural analyses by quadrupole time-of-flight electrospray ionization mass spectrometry and to the sequencing by Edman degradation. All five positions of the repeat peptide were revealed as O-glycosylation targets in the tumor cell, including the Thr within the DTR moth, The degree of substitution was estimated to average 4.8 glycans per repeat, which compares to 2.6 glycosylated sites per repeat for the mucin fi om milk (Miiller, S,, Goletz, S,, Packer, N,, Gooley, A A, Lawson, A M,, and Hanisch, F,-G, (1997) J, Biol Chem, 272, 24780-24793), In addition to a modification by glycosylation, the immunodominant DTR motif on T47D-MUC1 is altered by amino acid replacements (PAPGSTAPAAHGVTSAPESR), which were revealed in about 50% of PAP20 peptides, The high incidence of these replacements and their detection also in other cancer cell Lines imply that the conserved tandem repeat domain of MUC1 is polymorphic with respect to the peptide sequence.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Macquarie Univ, Ctr Analyt Biotechnol, Sydney, NSW 2109, Australia	University of Cologne; University of Munster; Macquarie University	Hanisch, FG (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	franz.hanisch@uni-koeln.de						Alving K, 1998, J MASS SPECTROM, V33, P1124, DOI 10.1002/(SICI)1096-9888(1998110)33:11<1124::AID-JMS734>3.0.CO;2-H; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Cao Y, 1998, TUMOR BIOL, V19, P88, DOI 10.1159/000056509; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hanisch FG, 1998, TUMOR BIOL, V19, P111, DOI 10.1159/000056511; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1992, CANCER RES, V52, P3138; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Harrison MJ, 1998, EUR J BIOCHEM, V256, P119, DOI 10.1046/j.1432-1327.1998.2560119.x; Ho S B, 1991, Semin Cancer Biol, V2, P389; Hull S R, 1989, Cancer Commun, V1, P261; Karsten U, 1998, CANCER RES, V58, P2541; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; Petrarca C, 1996, EUR J CANCER, V32A, P2155, DOI 10.1016/S0959-8049(96)00254-7; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG YC, 1992, J BIOL CHEM, V267, P2728; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; ZACHARA NE, 1998, IN PRESS MUCIN METHO	33	139	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18165	18172		10.1074/jbc.274.26.18165	http://dx.doi.org/10.1074/jbc.274.26.18165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373415	hybrid			2022-12-25	WOS:000081056700007
J	Sun, LQ; Cairns, MJ; Gerlach, WL; Witherington, C; Wang, L; King, A				Sun, LQ; Cairns, MJ; Gerlach, WL; Witherington, C; Wang, L; King, A			Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; CORONARY ANGIOPLASTY; DNA ENZYME; EXPRESSION; INDUCTION	A small catalytic DNA molecule targeting c-myc RNA was found to be a potent inhibitor of smooth muscle cell (SMC) proliferation. The catalytic domain of this molecule was based on that previously derived by in vitro selection (Santoro, S, W,, and Joyce, G, F, (1997) Proc. Natl, Acad. Sci. U.S.A. 94, 4262-4266) and is known as the "10-23" general purpose RNA-cleaving deoxyribozyme, In addition to inhibiting SMC proliferation at low concentration, this molecule (targeting the translation initiation region of c-myc RNA) was found to efficiently cleave its full-length substrate in vitro and downregulate c-myc gene expression in smooth muscle cells. The serum nuclease stability of this molecule was enhanced without substantial loss of kinetic efficiency by inclusion of a 3'-3'-internucleotide inversion at the 3'-terminal. The extent of SMC suppression was found to be influenced by the length of the substrate binding arms. This correlated to some extent with catalytic activity in both the short substrate under multiple turnover conditions and the full-length substrate under single turnover conditions, with the 9 + 9 base arm molecule producing the greatest activity.	Johnson & Johnson Res Labs, Sydney, NSW 2001, Australia	Johnson & Johnson	Sun, LQ (corresponding author), Johnson & Johnson Res Labs, 74 MacLachlan Ave, Sydney, NSW 2112, Australia.			Cairns, Murray/0000-0003-2490-2538; King, Andrew/0000-0003-0481-3490				AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BANSKOTA NK, 1989, MOL ENDOCRINOL, V3, P1183, DOI 10.1210/mend-3-8-1183; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Field AK, 1998, ANTIVIR RES, V37, P67; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; Libby P, 1992, J Vasc Surg, V15, P916; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; Ortigao J F, 1992, Antisense Res Dev, V2, P129; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SHI Y, 1993, CIRCULATION, V88, P1190, DOI 10.1161/01.CIR.88.3.1190; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Sun LQ, 1997, MOL BIOTECHNOL, V7, P241, DOI 10.1007/BF02740815; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641	19	98	122	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17236	17241		10.1074/jbc.274.24.17236	http://dx.doi.org/10.1074/jbc.274.24.17236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358082	hybrid			2022-12-25	WOS:000080780400081
J	Vallar, L; Melchior, C; Plancon, S; Drobecq, H; Lippens, G; Regnault, V; Kieffer, N				Vallar, L; Melchior, C; Plancon, S; Drobecq, H; Lippens, G; Regnault, V; Kieffer, N			Divalent cations differentially regulate integrin alpha(IIb) cytoplasmic tail binding to beta(3) and to calcium- and integrin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; SURFACE-PLASMON RESONANCE; SIGNAL-TRANSDUCTION; GLANZMANN THROMBASTHENIA; SELECTIVE BINDING; STRUCTURAL MODEL; LIGAND-BINDING; CELL-ADHESION; GROWTH-FACTOR; DOMAIN	We have used recombinant or synthetic alpha(IIb) and beta(3) integrin cytoplasmic peptides to study their in vitro complexation and ligand binding capacity by surface plasmon resonance. alpha(.)beta heterodimerization occurred in a 1:1 stoichiometry with a weak K-D in the micromolar range. Divalent cations were not required for this association but stabilized the alpha(.)beta complex by decreasing the dissociation rate. alpha(.)beta complexation was impaired by the R995A substitution or the KVGFFKR deletion in alpha(IIb) but not by the beta(3) S752P mutation. Recombinant calcium-and integrin-binding protein (CIB), an alpha(IIb)-specific ligand, bound to the alpha(IIb) cytoplasmic peptide in a Ca2+- or Mn2+-independent, one-to-one reaction with a K-D value of 12 mu M. In contrast, in vitro liquid phase binding of CIB to intact alpha(IIb)beta(3) occurred preferentially with Mn2+-activated alpha(IIb)beta(3) conformers, as demonstrated by enhanced coimmunoprecipitation of CIB with PAC-1-captured Mn2+-activated alpha(IIb)beta(3), suggesting that Mn2+ activation of intact alpha(IIb)beta(3) induces the exposure of a GIB-binding site, spontaneously exposed by the free alpha(IIb) peptide. Since CIB did not stimulate PAC-1 binding to inactive alpha(IIb)beta(3) nor prevented activated alpha(IIb)beta(3) occupancy by PAC-1, we conclude that CIB does not regulate alpha(IIb)beta(3) inside-out signaling, but rather is involved in an alpha(IIb)beta(3) post-receptor occupancy event.	Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CNRS, L-1511 Luxembourg, Luxembourg; Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CRP Sante, L-1511 Luxembourg, Luxembourg; Inst Biol Lille, Lab Biol RMN, F-59000 Lille, France; Fac Med, CNRS, UMR 7563, Hematol Lab, F-54500 Vandoeuvre Nancy, France	University of Luxembourg; Luxembourg Institute of Health; University of Luxembourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine	Kieffer, N (corresponding author), Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CNRS, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.		Regnault, Veronique/H-9138-2016; REGNAULT, Veronique/AAY-1711-2020	REGNAULT, Veronique/0000-0001-6418-5022; Drobecq, Herve/0000-0002-4081-1575; Vallar, Laurent/0000-0002-4404-1010; Lippens, Guy/0000-0002-8236-0901				Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1997, BLOOD S1, V90, P572; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; KIEFFER N, 1986, J BIOL CHEM, V261, P5854; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOUNS WC, 1992, BLOOD, V80, P2539; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEISNER TM, 1997, THROMB HAEMOSTASIS S, V6; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SACKS DB, 1995, BIOCHEM J, V312, P197, DOI 10.1042/bj3120197; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SRIRAMARAO P, 1993, J BIOL CHEM, V268, P22036; STEINER B, 1989, J BIOL CHEM, V264, P13102; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Zage PE, 1998, CELL ADHES COMMUN, V5, P335, DOI 10.3109/15419069809010780	51	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17257	17266		10.1074/jbc.274.24.17257	http://dx.doi.org/10.1074/jbc.274.24.17257			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358085	hybrid			2022-12-25	WOS:000080780400084
J	El-Husseini, AE; Vincent, SR				El-Husseini, AE; Vincent, SR			Cloning and characterization of a novel RING finger protein that interacts with class V myosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BINDING PROTEIN; GROWTH CONES; DOMAIN; MOTIF; GENE; EXPRESSION; FAMILY; ALPHA; FOLD	We have identified a novel protein (BERP) that is a specific partner for the tail domain of myosin V, Class V myosins are a family of molecular motors thought to interact via their unique C-terminal tails with specific proteins for the targeted transport of organelles. BERP is highly expressed in brain and contains an N-terminal RING finger, Followed by a B-box zinc finger, a coiled-coil (RBCC domain), and a unique C-terminal beta-propeller domain. A yeast two-hybrid screening indicated that the C-terminal beta-propeller domain mediates binding to the tail of the class V myosin myr6 (myosin Vb), This interaction was confirmed by immunoprecipitation, which also demonstrated that BERP could associate with myosin Va, the product of the dilute gene. Like myosin Va, BERP is expressed in a punctate pattern in the cytoplasm as well as in the neurites and growth cones of PC12 cells. We also found that the RBCC domain of BERP is involved in protein dimerization. Stable expression of a mutant form of BERP lacking the myosin-binding domain but containing the dimerization domain resulted in defective PC12 cell spreading and prevented neurite outgrowth in response to nerve growth factor. Our studies present a novel interaction for the beta-propeller domain and provide evidence for a role for BERP in myosin V-mediated cargo transport.	Univ British Columbia, Dept Psychiat, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Vincent, SR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	svincent@unixg.ubc.ca	Vincent, Steven R/D-2996-2012					BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Evans LL, 1997, J CELL SCI, V110, P439; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fucini P, 1997, NAT STRUCT BIOL, V4, P223, DOI 10.1038/nsb0397-223; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; McNellis TW, 1996, PLANT CELL, V8, P1491, DOI 10.1105/tpc.8.9.1491; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; Palmer S, 1997, P NATL ACAD SCI USA, V94, P12030, DOI 10.1073/pnas.94.22.12030; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Peirs P, 1997, EUR J BIOCHEM, V244, P604, DOI 10.1111/j.1432-1033.1997.00604.x; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wu XF, 1997, J CELL SCI, V110, P847; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	41	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19771	19777		10.1074/jbc.274.28.19771	http://dx.doi.org/10.1074/jbc.274.28.19771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391919	hybrid			2022-12-25	WOS:000081377300039
J	Luchoomun, J; Hussain, MM				Luchoomun, J; Hussain, MM			Assembly and secretion of chylomicrons by differentiated Caco-2 cells - Nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; RAT SMALL-INTESTINE; APOLIPOPROTEIN-B SECRETION; FATTY-ACID UPTAKE; EICOSAPENTAENOIC ACID; PLURONIC L-81; OLEIC-ACID; MONOCLONAL-ANTIBODIES; LIPID TRANSPORT; RAPID METHOD	To develop a cell culture model for chyclomicron (CM) assembly, the apical media of differentiated Caco-2 cells were supplemented with oleic acid (OA) together with either albumin or taurocholate (TC), The basolateral media were subjected to sequential density gradient ultracentrifugations to obtain large CM, small CM, and very low density lipoproteins (VLDL), and the distribution of apoB in these fractions was quantified. In the absence of OA, apoB was secreted as VLDL/LDL size particles. Addition of OA (greater than or equal to 0.8 mM) with TC, but not with albumin, resulted in the secretion of one-third of apoB as CM. Lipid analysis revealed that half of the secreted phospholipids (PL) and triglycerides (TG) were associated with CM. In CM, TG were 7-11-fold higher than PL indicating that CM were TG-rich particles. Secreted CM contained apoB100, apoB48, and other apolipoproteins, Secretion of large CM was specifically inhibited by Pluronic L81, a detergent known to inhibit CM secretion in animals. These studies demonstrate that differentiated Caco-2 cells assemble and secrete CM in a manner similar to enterocytes in vitro. Next, experiments were performed to identify the sources of lipids used for lipoprotein assembly. Cells were labeled with [H-3]glycerol for 12 h, washed, and supplemented with OA, TC, and [C-14] glycerol for various times to induce CM assembly and to radiolabel nascent lipids, TG and PL were extracted from cells and media and the association of preformed and nascent lipids with lipoproteins was determined. All the lipoproteins contained higher amounts of preformed PL compared with nascent PL. VLDL contained equal amounts of nascent and preformed TG, whereas CM contained higher amounts of nascent TG even when nascent TG constituted a small fraction of the total cellular pool. These studies indicate that nascent TG and preformed PL are preferentially used for CM assembly and provide a molecular explanation for the in vivo observations that the fatty acid composition of TG, but not PL, of secreted CM reflects the composition of dietary fat. It is proposed that in the intestinal cells the preformed PL from the endoplasmic reticulum bud off with apoB as primordial particles and the assembly of larger lipoproteins is dependent on the synthesis and delivery of nascent TG to these particles.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Sch Med, Philadelphia, PA 19129 USA	Drexel University	Hussain, MM (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Biochem, Sch Med, 2900 Queen Lane, Philadelphia, PA 19129 USA.				NHLBI NIH HHS [HL-22633] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046900, R56DK046900, R29DK046900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ANDERSON LJ, 1989, J LIPID RES, V30, P1819; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; DASHTI N, 1990, J LIPID RES, V31, P113; DASHTI N, 1991, PROG LIPID RES, V30, P219, DOI 10.1016/0163-7827(91)90018-Z; DOLE VP, 1962, PHYSIOL REV, V42, P674, DOI 10.1152/physrev.1962.42.4.674; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; FIELD FJ, 1988, J LIPID RES, V29, P1427; FIELD FJ, 1995, PROG LIPID RES, V34, P185, DOI 10.1016/0163-7827(95)00005-K; FIELD FJ, 1994, J LIPID RES, V35, P749; FRASER R, 1970, J LIPID RES, V11, P60; FRASER R, 1968, Q J EXP PHYSIOL CMS, V53, P390, DOI 10.1113/expphysiol.1968.sp001984; GANTZ D, 1990, J LIPID RES, V31, P163; GEDDEDAHL A, 1995, J LIPID RES, V36, P535; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GLICKMAN RM, 1972, J CLIN INVEST, V51, P356, DOI 10.1172/JCI106821; Hamilton JA, 1998, J LIPID RES, V39, P467; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; HUGHES TE, 1988, J BIOL CHEM, V263, P3425; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; Karpe F, 1996, METHOD ENZYMOL, V263, P95; KAYDEN HJ, 1963, J CLIN INVEST, V42, P1373, DOI 10.1172/JCI104821; Kim E, 1998, J LIPID RES, V39, P703; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MINDHAM MA, 1992, J LIPID RES, V33, P1084; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; OCKNER RK, 1969, J CLIN INVEST, V48, P2079, DOI 10.1172/JCI106174; OCKNER RK, 1969, J CLIN INVEST, V48, P2367, DOI 10.1172/JCI106203; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; RANHEIM T, 1994, BBA-LIPID LIPID MET, V1212, P295, DOI 10.1016/0005-2760(94)90203-8; RANHEIM T, 1992, J LIPID RES, V33, P1281; RANHEIM T, 1994, BIOCHEM J, V303, P155, DOI 10.1042/bj3030155; REDGRAVE TG, 1975, ATHEROSCLEROSIS, V22, P389, DOI 10.1016/0021-9150(75)90019-2; RENNER F, 1986, J LIPID RES, V27, P72; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1991, J LIPID RES, V32, P293; TSO P, 1980, AM J PHYSIOL, V239, pG348, DOI 10.1152/ajpgi.1980.239.5.G348; TSO P, 1986, AM J PHYSIOL, V250, pG715, DOI 10.1152/ajpgi.1986.250.6.G715; TSO P, 1987, BIOCHIM BIOPHYS ACTA, V922, P304, DOI 10.1016/0005-2760(87)90053-1; TSO P, 1984, AM J PHYSIOL, V247, pG599, DOI 10.1152/ajpgi.1984.247.6.G599; TSO P, 1982, AM J PHYSIOL, V242, pG408, DOI 10.1152/ajpgi.1982.242.4.G408; TSO P, 1984, AM J PHYSIOL, V247, pG32, DOI 10.1152/ajpgi.1984.247.1.G32; TSO P, 1981, AM J PHYSIOL, V241, pG487, DOI 10.1152/ajpgi.1981.241.6.G487; van Greevenbroek MMJ, 1996, ATHEROSCLEROSIS, V121, P139, DOI 10.1016/0021-9150(95)05712-9; van Greevenbroek MMJ, 1998, J LIPID RES, V39, P173; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WHYTE M, 1963, J LIPID RES, V4, P322; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673	57	151	155	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19565	19572		10.1074/jbc.274.28.19565	http://dx.doi.org/10.1074/jbc.274.28.19565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391890	hybrid			2022-12-25	WOS:000081377300010
J	Sugiyama, H; Savill, JS; Kitamura, M; Zhao, L; Stylianou, E				Sugiyama, H; Savill, JS; Kitamura, M; Zhao, L; Stylianou, E			Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappa B in primary glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-TRANSFER; ACTIVATION; PHOSPHORYLATION; EXPRESSION; INHIBITION; DISEASE; DEATH; INTERLEUKIN-1	Recent data have implicated nuclear factor kappa B (NF-kappa B) in the prevention of apoptosis in transformed cell lines exposed to tumor necrosis factor alpha (TNF-alpha). However, it is obscure whether NF-kappa B plays an anti-apoptotic role in nontransformed cells, and it is not clear whether NF-kappa B inhibits apoptosis triggered by other mediators. We investigated the effect of specific inhibition of NF-kappa B on cytokine-induced apoptosis of glomerular mesangial cells, which is important in determining the outcome of glomerulonephritis. Cultured rat mesangial cells were stably transfected with the dominant negative mutant inhibitor of NF-kappa B (I kappa B alpha M), I kappa B alpha M was resistant to stimulus-dependent degradation and suppressed NF-kappa B activation induced by TNF-alpha (10 ng/ml) or IL-1 beta (10 ng/ml), I kappa B alpha M significantly sensitized mesangial cells to TNF-alpha-induced apoptosis in a dose- and time-dependent manner but had no significant effects on the level of apoptosis in the presence of proinflammatory or apoptosis-inducing stimuli including Fas ligand, IL-1 alpha, IL-1 beta, hydrogen peroxide, lipopolysaccharide, cycloheximide, or serum deprivation, Moreover, I kappa B alpha M-mediated sensitization to TNF-alpha overcame the protective effect of mesangial cell survival factors present in serum, which usually inhibit killing of mesangial cells by the proapoptotic stimuli used. These data show that inhibition of NF-kappa B selectively sensitizes primary adult glomerular mesangial cells to TNF-induced apoptosis but not to other mediators of cell death including the Fas ligand.	Univ Nottingham Hosp, Sch Med & Surg Sci, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England; Royal Infirm, Dept Clin & Surg Sci Internal Med, Ctr Inflammat Res, Edinburgh EH3 9YW, Midlothian, Scotland; Univ London Univ Coll, Sch Med, Rayne Inst, Dept Med, London WC1E 6JJ, England	University of Nottingham; Royal Infirmary of Edinburgh; University of London; King's College London; University College London; UCL Medical School	Sugiyama, H (corresponding author), Univ Nottingham Hosp, Sch Med & Surg Sci, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England.		Sugiyama, Hitoshi/B-2252-2011	Sugiyama, Hitoshi/0000-0002-4127-6471				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; COHEN L, 1998, SCIENCE, V395, P292; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; DIAMOND JR, 1992, AM J KIDNEY DIS, V19, P292, DOI 10.1016/S0272-6386(13)80013-3; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUESDON F, 1995, BIOCHEM J, V307, P287, DOI 10.1042/bj3070287; Guijarro C, 1996, NEPHROL DIAL TRANSPL, V11, P990; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Jobson TM, 1998, J CLIN INVEST, V101, P2650, DOI 10.1172/JCI1876; KITAMURA M, 1994, J CLIN INVEST, V94, P497, DOI 10.1172/JCI117361; Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mooney A, 1997, J IMMUNOL, V159, P3949; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Sandau K, 1997, J IMMUNOL, V158, P4938; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; SAVILL J, 1996, KIDNEY INT S54, V49, P14; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; Sugiyama H, 1996, J AM SOC NEPHROL, V7, P2357; Sugiyama H, 1996, KIDNEY INT, V49, P103, DOI 10.1038/ki.1996.14; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yokoo T, 1997, J IMMUNOL, V159, P2886; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123	41	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19532	19537		10.1074/jbc.274.28.19532	http://dx.doi.org/10.1074/jbc.274.28.19532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391885	hybrid			2022-12-25	WOS:000081377300005
J	Sun, CH; Tai, JH				Sun, CH; Tai, JH			Identification and characterization of a ran gene promoter in the protozoan pathogen Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CYST WALL PROTEIN; POLYMERASE-II; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; CONSENSUS SEQUENCE; FIREFLY LUCIFERASE; HIGHER EUKARYOTES; BINDING-PROTEIN; TRANSCRIPTION	The promoter elements that regulate transcription initiation in Giardia lamblia are poorly understood. In this report, the promoter of the Giardia ran gene was studied using a luciferase expression plasmid pRANluc+ to monitor transcription efficiency. An AT-rich sequence spanning -51/-20 relative to the translation start site of the ran gene was identified and was found to be required for efficient luciferase expression by deletion and mutation mapping of pRANluc+. The -51/-20 sequence was also sufficient for promoter activity as revealed from studies on a 32-base pair synthetic promoter derived from this region. Deletion mapping of the synthetic promoter revealed two minimal promoter elements, -51/-42 and -30/-20, sufficient for 6- and 30-fold luciferase expression above background, respectively. The transcription start sites on luc+ messenger RNA were determined by the position of the synthetic promoter in the luciferase expression plasmids as shown by primer extension experiments. Results from electrophoretic mobility shift assays revealed multiple DNA-protein complexes upon binding of nuclear proteins with either DNA strand but not the double-stranded DNA derived from the ran promoter. Our results delineate the first promoter sequence of the Giardia gene (ran), which provides an excellent model for future studies on transcription regulation in this protozoan parasite.	Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Tai, JH (corresponding author), Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei, Taiwan.	bmtai@ccvax.sinica.edu.tw	Tai, Jung-Hsiang/S-7019-2018; Shin, Jerry/AAO-2515-2021	SUN, CHIN-HUNG/0000-0002-8604-8085				ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ALONSO RA, 1992, MOL BIOCHEM PARASIT, V50, P95, DOI 10.1016/0166-6851(92)90247-H; Bemark M, 1998, J BIOL CHEM, V273, P18881, DOI 10.1074/jbc.273.30.18881; BROWN SD, 1994, MOL BIOCHEM PARASIT, V65, P109, DOI 10.1016/0166-6851(94)90120-1; Bruderer T, 1996, MOL BIOCHEM PARASIT, V77, P225, DOI 10.1016/0166-6851(96)02605-9; CHEN LM, 1994, J BIOL CHEM, V269, P17297; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; EY PL, 1993, MOL BIOCHEM PARASIT, V58, P247, DOI 10.1016/0166-6851(93)90046-Z; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hetsko ML, 1998, EXP PARASITOL, V88, P172, DOI 10.1006/expr.1998.4246; HILARIO E, 1995, BIOCHIM BIOPHYS ACTA, V128, P94; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KIRKMASON KE, 1989, MOL BIOCHEM PARASIT, V36, P87, DOI 10.1016/0166-6851(89)90204-1; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MOWATT MR, 1994, EXP PARASITOL, V78, P85, DOI 10.1006/expr.1994.1008; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NOHRIA A, 1992, MOL BIOCHEM PARASIT, V56, P27, DOI 10.1016/0166-6851(92)90151-9; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; SINGER SM, 1998, MOL BIOCHEM PARASIT, V92, P123; Smith MW, 1998, MOL BIOCHEM PARASIT, V95, P267, DOI 10.1016/S0166-6851(98)00113-3; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Upcroft J, 1998, BIOESSAYS, V20, P256, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;256::AID-BIES9&gt;3.0.CO;2-P; VANHAMME L, 1995, MOL CELL BIOL, V15, P5598; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEE J, 1995, P NATL ACAD SCI USA, V92, P5615, DOI 10.1073/pnas.92.12.5615; YEE J, 1992, J BIOL CHEM, V267, P7539; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; YU DC, 1995, MOL CELL BIOL, V15, P4867; Yu DC, 1996, MOL BIOCHEM PARASIT, V83, P81, DOI 10.1016/S0166-6851(96)02752-1	44	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19699	19706		10.1074/jbc.274.28.19699	http://dx.doi.org/10.1074/jbc.274.28.19699			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391910	hybrid			2022-12-25	WOS:000081377300030
J	Bernard, C; Berthault, MF; Saulnier, C; Ktorza, A				Bernard, C; Berthault, MF; Saulnier, C; Ktorza, A			Neogenesis vs. apoptosis as main components of pancreatic beta cell mass changes in glucose-infused normal and mildly diabetic adult rats	FASEB JOURNAL			English	Article						pancreas plasticity; streptozotocin; chronic hyperglycemia	ENDOCRINE PANCREAS; NEWBORN RATS; B-CELLS; GROWTH; PROLIFERATION; STREPTOZOTOCIN; REGENERATION; PREGNANCY; INDUCTION; MELLITUS	We have investigated in adult rats made mildly diabetic by a low dose of streptozotocin (35 mg/kg; STZ rats) and in nondiabetic rats (ND rats) the mechanisms leading to adaptive changes in the beta cell mass, during glucose infusion and several days after stopping infusion. As early as 24 h of glucose infusion, the beta cell mass was maximally increased in ND and STZ rats. In both groups, this increase was due mainly to a rapid activation of neogenesis of new endocrine cells rather than to an increase in beta cell proliferation. Seven days after stopping glucose infusion, the beta cell mass returned to basal values in both groups as a result of stimulation of beta cell apoptosis and a decrease in beta cell replication rate. In glucose-infused ND rats, changes in the beta cell mass were correlated to insulin secretion, whereas in STZ rats, insulin secretion in response to glucose was still impaired whatever the beta cell mass. In conclusion, the data stress the impressive plasticity of the endocrine pancreas of adult rats. They also show that changes in beta cell mass in ND and STZ rats resulted from a disruption in the balance between neogenesis and apoptosis.	Univ Paris 07, Lab Physiopathol Nutr, CNRS ESA 7059, F-75251 Paris, France	UDICE-French Research Universities; Universite Paris Cite	Bernard, C (corresponding author), Univ Paris 07, Lab Physiopathol Nutr, CNRS ESA 7059, Tour 23-33 Ler Etage,2 Pl Jussieu, F-75251 Paris, France.							Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BONNERWEIR S, 1981, METABOLISM, V30, P914, DOI 10.1016/0026-0495(81)90071-8; CANTENYS D, 1981, VIRCHOWS ARCH B, V35, P109; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; COLES HSR, 1993, DEVELOPMENT, V118, P777; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; GU DL, 1993, DEVELOPMENT, V118, P33; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; KRORZA A, 1981, DIABETOLOGIA, V21, P569; Laybutt DR, 1997, AM J PHYSIOL-ENDOC M, V273, pE1, DOI 10.1152/ajpendo.1997.273.1.E1; LIPSETT M, 1998, PANCREATIC DUCTUL S1, V47, pA257; MARYNISSEN G, 1983, J DEV PHYSIOL, V5, P373; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; Movassat J, 1997, DIABETES, V46, P1445, DOI 10.2337/diabetes.46.9.1445; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; ROSENBERG L, 1992, TRANSPLANT P, V24, P1027; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; THIBAULT C, 1993, DIABETOLOGIA, V36, P589, DOI 10.1007/BF00404066; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WESTERMARK P, 1978, DIABETOLOGIA, V15, P417, DOI 10.1007/BF01219652	31	109	113	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1195	1205		10.1096/fasebj.13.10.1195	http://dx.doi.org/10.1096/fasebj.13.10.1195			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385610				2022-12-25	WOS:000081264800008
J	Everts, V; Korper, W; Jansen, DC; Steinfort, J; Lammerse, I; Heera, S; Docherty, AJP; Beertsen, W				Everts, V; Korper, W; Jansen, DC; Steinfort, J; Lammerse, I; Heera, S; Docherty, AJP; Beertsen, W			Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone	FASEB JOURNAL			English	Article						MMP activity; cathepsin K; proteinase inhibitor; cysteine proteinase	GELATINASE-A MMP-2; CATHEPSIN-K; CYSTEINE-PROTEINASES; RESORBING COMPARTMENT; MOLECULAR-CLONING; COLLAGENASE; INHIBITORS; TISSUE; PYCNODYSOSTOSIS; IDENTIFICATION	Data in the literature suggest that site-specific differences exist in the skeleton with respect to digestion of bone by osteoclasts. Therefore, we investigated whether bone resorption by calvarial osteoclasts (intramembranous bone) differs from resorption by long bone osteoclasts (endochondral bone). The involvement of two major classes of proteolytic enzymes, the cysteine proteinases (CPs) and matrix metalloproteinases (MMPs), was studied by analyzing the effects of selective low molecular weight inhibitors of these enzymes on bone resorption. Mouse tissue explants (calvariae and long bones) as well as rabbit osteoclasts, which had been isolated from both skeletal sites and subsequently seeded on bone slices, were cultured in the presence of inhibitors and resorption was analyzed. The activity of the CP cathepsins B and K and of MMPs was determined biochemically (CPs and MMPs) and enzyme histochemically (CPs) in explants and isolated osteoclasts. We show that osteoclastic resorption of calvarial bone depends on activity of both CPs and MMPs, whereas long bone resorption depends on CPs, but not on the activity of MMPs. Furthermore, significantly higher levels of cathepsin B and cathepsin K activities were expressed by long bone osteoclasts than by calvarial osteoclasts. Resorption of slices of bovine skull or cortical bone by osteoclasts isolated from long bones was not affected by MMP inhibitors, whereas resorption by calvarial osteoclasts was inhibited. Inhibition of CP activity affected the resorption by the two populations of osteoclasts in a similar way. We conclude that this is the first report to show that significant differences exist between osteoclasts of calvariae and long bones with respect to their bone resorbing activities. Resorption by calvarial osteoclasts depends on the activity of CPs and MMPs, whereas resorption by long bone osteoclasts depends primarily on the activity of CPs. We hypothesize that functionally different subpopulations of osteoclasts, such as those described here, originate from different sets of progenitors.	Univ Amsterdam, Dept Cell Biol & Histol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Periodontol, Acad Ctr Dent, NL-1100 DE Amsterdam, Netherlands; Celltech, Slough, Berks, England	University of Amsterdam; Academic Medical Center Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Celltech Group Ltd	Everts, V (corresponding author), Univ Amsterdam, Dept Cell Biol & Histol, Acad Med Ctr, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Beertsen, Wouter/B-5308-2013	Beertsen, Wouter/0000-0001-5698-5986				Aibe K, 1996, BIOL PHARM BULL, V19, P1026; Amling M, 1996, J BONE MINER RES, V11, P36, DOI 10.1002/jbmr.5650110107; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; Beekman B, 1996, FEBS LETT, V390, P221, DOI 10.1016/0014-5793(96)00665-5; BLAVIER L, 1995, J CELL SCI, V108, P3649; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; Creemers LB, 1998, MATRIX BIOL, V17, P35, DOI 10.1016/S0945-053X(98)90072-5; DEBARI K, 1995, CALCIFIED TISSUE INT, V56, P566, DOI 10.1007/BF00298591; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1993, J CELL SCI, V106, P1071; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; Everts V, 1998, J BONE MINER RES, V13, P1420, DOI 10.1359/jbmr.1998.13.9.1420; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FULLER K, 1995, J CELL SCI, V108, P2221; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GREENSPAN A, 1991, SKELETAL RADIOL, V20, P561, DOI 10.1007/BF01106087; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; HORTON MA, 1985, CANCER RES, V45, P5663; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JANAKIDEVI K, 1988, ANAL BIOCHEM, V172, P78, DOI 10.1016/0003-2697(88)90413-7; Johnson MR, 1996, GENOME RES, V6, P1050, DOI 10.1101/gr.6.11.1050; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Matayoshi A, 1996, P NATL ACAD SCI USA, V93, P10785, DOI 10.1073/pnas.93.20.10785; Mizoguchi I, 1997, ANAT EMBRYOL, V196, P291, DOI 10.1007/s004290050098; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; Sato T, 1997, J CELL SCI, V110, P589; SCOTT CK, 1991, CALCIFIED TISSUE INT, V49, P349, DOI 10.1007/BF02556258; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; van Noorden C.J.F., 1992, MICROSCOPY HDB, V26; VANNOORDEN CJF, 1991, BIOCHEM BIOPH RES CO, V178, P178, DOI 10.1016/0006-291X(91)91796-F	45	137	139	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1219	1230		10.1096/fasebj.13.10.1219	http://dx.doi.org/10.1096/fasebj.13.10.1219			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385612	Bronze			2022-12-25	WOS:000081264800010
J	Song, DK; Im, YB; Jung, JS; Suh, HW; Huh, SO; Song, JH; Kim, YH				Song, DK; Im, YB; Jung, JS; Suh, HW; Huh, SO; Song, JH; Kim, YH			Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system	FASEB JOURNAL			English	Article						norepinephrine; sympathetic nervous system; liver; spleen	C-REACTIVE PROTEIN; ACUTE-PHASE RESPONSE; CARDIOVASCULAR RISK-FACTORS; INTRACEREBROVENTRICULAR INJECTION; IMMOBILIZATION STRESS; IMMUNE-RESPONSES; UNSTABLE ANGINA; DISEASE; RAT; MODULATION	Accumulating evidence suggests that plasma levels of interleukin 6 (IL-6), a major cytokine stimulating the synthesis of acute-phase proteins, are intimately regulated by the central nervous system. Nicotine, one of the major drugs abused by humans, has been shown to affect immunological functions. In the present study, effects of intracerebroventricular (i.c.v.) injection of nicotine on plasma IL-6 levels were investigated in mice. Nicotine administered i.c.v. dose-dependently increased plasma IL-6 levels; the lowest effective dose was 0.3 ng/mouse and the maximal effect was attained with the dose of 105 ng/mouse. The nicotine (105 ng/mouse, i.c.v.)-induced plasma IL-6 levels peaked at 3 h and approached basal levels 6 h after injection. Mecamylamine, a nicotinic receptor antagonist, blocked nicotine-induced plasma IL-6 levels. Depletion of peripheral norepinephrine with 6-hydroxydopamine [100 mg/kg, intraperitoneal (i.p.)] inhibited the nicotine-induced plasma IL 6 levels by 57%, whereas central norepinephrine depletion with 6-hydroxydopamine (50 mu g/mouse, i.c.v.) had no effect. Pretreatment with prazosin (alpha(1)-adrenergic antagonist; 1 mg/kg, i.p.), yohimbine (alpha(2)-adrenergic antagonist; 1 mg/kg, i.p.), and ICI-118,551 (beta(2)-adrenergic antagonist; 2 mg/kg, i.p.), but not with betaxolol (beta(1)-adrenergic antagonist; 2 mg/kg, i.p.), inhibited nicotine-induced plasma IL-6 levels. Among the peripheral organs, including the pituitary, adrenals, heart, lung, liver, spleen, and lymph nodes, nicotine (105 ng/mouse, i.c.v.) increased IL-6 mRNA expression only in the liver and spleen, which was inhibited by peripheral norepinephrine depletion. These results suggest that stimulation of central nicotinic receptors induces plasma IL-6 levels and IL-6 mRNA expression in the liver and spleen via the peripheral sympathetic nervous system, alpha(1)-, alpha(2)-, and beta(2)-adrenoreceptors being involved.	Hallym Univ, Coll Med, Dept Pharmacol, Inst Nat Med, Kangwon Do 200702, South Korea	Hallym University	Song, DK (corresponding author), Hallym Univ, Coll Med, Dept Pharmacol, Inst Nat Med, Kangwon Do 200702, South Korea.	dksong@sun.hallym.ac.kr						BILLIAR TR, 1992, ARCH SURG-CHICAGO, V127, P31; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS I, 1985, CLIN CHIM ACTA, V153, P9, DOI 10.1016/0009-8981(85)90133-0; deMaat MPM, 1996, ATHEROSCLEROSIS, V121, P185, DOI 10.1016/0021-9150(95)05716-1; DERIGGI D, 1994, STAT PROBABIL LETT, V19, P1, DOI 10.1016/0167-7152(94)90061-2; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739, DOI 10.1152/ajpregu.1993.265.4.R739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; FAULKNER CB, 1995, INFECT IMMUN, V63, P4084, DOI 10.1128/IAI.63.10.4084-4090.1995; Felten S Y, 1998, Adv Pharmacol, V42, P583; Finck BN, 1997, AM J PHYSIOL-REG I, V272, pR1880, DOI 10.1152/ajpregu.1997.272.6.R1880; Fu YT, 1997, ENDOCRINOLOGY, V138, P1935, DOI 10.1210/en.138.5.1935; Fu YT, 1998, J PHARMACOL EXP THER, V284, P1188; Geng YM, 1996, J IMMUNOL, V156, P2384; Geng YM, 1995, TOXICOL APPL PHARM, V135, P268, DOI 10.1006/taap.1995.1233; GOTTSCHALL PE, 1992, NEUROENDOCRINOLOGY, V56, P935, DOI 10.1159/000126328; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hirano Toshio, 1998, P197; Huang QH, 1997, AM J PHYSIOL-REG I, V273, pR731, DOI 10.1152/ajpregu.1997.273.2.R731; Kitamura H, 1997, BIOCHEM BIOPH RES CO, V238, P707, DOI 10.1006/bbrc.1997.7368; Komaki Gen, 1994, Neuroimmunomodulation, V1, P127, DOI 10.1159/000097146; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; LEMAY LG, 1990, PHYSIOL BEHAV, V47, P957, DOI 10.1016/0031-9384(90)90024-X; Li XY, 1998, J NEUROSCI, V18, P1904; Limbird, 1996, GOODMAN GILMANS PHAR, P557; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MADDEN KS, 1995, ANNU REV PHARMACOL, V35, P417, DOI 10.1146/annurev.pharmtox.35.1.417; MATTA SG, 1987, J PHARMACOL EXP THER, V243, P217; MATTA SG, 1992, J PHARMACOL EXP THER, V260, P1285; MATTA SG, 1990, ENDOCRINOLOGY, V127, P1646, DOI 10.1210/endo-127-4-1646; McAllister-Sistilli CG, 1998, PSYCHONEUROENDOCRINO, V23, P175, DOI 10.1016/S0306-4530(97)00080-2; Mendall MA, 1997, HEART, V78, P273, DOI 10.1136/hrt.78.3.273; Mendall MA, 1996, BRIT MED J, V312, P1061; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; NAITOH Y, 1988, BIOCHEM BIOPH RES CO, V155, P1459, DOI 10.1016/S0006-291X(88)81305-6; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rosecrans JA, 1998, PSYCHONEUROENDOCRINO, V23, P95, DOI 10.1016/S0306-4530(97)00073-5; Sato S, 1996, INT J EPIDEMIOL, V25, P521, DOI 10.1093/ije/25.3.521; Song DK, 1999, J NEUROCHEM, V72, P1625, DOI 10.1046/j.1471-4159.1999.721625.x; Song DK, 1996, EUR J PHARMACOL, V316, P165, DOI 10.1016/S0014-2999(96)00666-8; Song DK, 1998, J PHARMACOL EXP THER, V287, P144; Sopori ML, 1998, PSYCHONEUROENDOCRINO, V23, P189, DOI 10.1016/S0306-4530(97)00076-0; Soszynski D, 1996, NEUROENDOCRINOLOGY, V63, P459, DOI 10.1159/000127072; SUAUDEAU C, 1995, NEUROPHARMACOLOGY, V34, P101, DOI 10.1016/0028-3908(94)00109-6; Takaki Atsushi, 1994, Neuroimmunomodulation, V1, P335, DOI 10.1159/000097185; TAPPIA PS, 1995, CLIN SCI, V88, P485, DOI 10.1042/cs0880485; TEREBUH PD, 1992, AM J PATHOL, V140, P649; VANGOOL J, 1990, CLIN IMMUNOL IMMUNOP, V57, P200, DOI 10.1016/0090-1229(90)90034-N; VANLOON GR, 1989, PROG BRAIN RES, V79, P217; YOKOTANI K, 1987, JPN J PHARMACOL, V45, P288, DOI 10.1254/jjp.45.288; ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523	54	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1259	1267		10.1096/fasebj.13.10.1259	http://dx.doi.org/10.1096/fasebj.13.10.1259			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385616				2022-12-25	WOS:000081264800014
J	Brand, M; Yamamoto, K; Staub, A; Tora, L				Brand, M; Yamamoto, K; Staub, A; Tora, L			Identification of TATA-binding protein-free TAF(II)-containing complex subunits suggests a role in nucleosome acetylation and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; TFIID COMPLEX; POLYMERASE-II; ADA-COMPLEX; TRANSCRIPTION; GCN5; DISTINCT; CORE; TAFS; ACTIVATION	Recently we identified a novel human (h) multiprotein complex, called TATA-binding protein (TBP)-free TAF(II)containing complex (TFTC), which is able to nucleate RNA polymerase II transcription and can mediate transcriptional activation. Here we demonstrate that TFTC, similar to other TBP-free TAF(II), complexes (yeast SAGA, hSTAGA, and hPCAF) contains the acetyltransferase hGCN5 and is able to acetylate histones in both a free and a nucleosomal context. The recently described TRRAP cofactor for oncogenic transcription factor pathways was also characterized as a TFTC subunit, Furthermore, we identified four other previously uncharacterized subunits of TFTC: hADA3, hTAF(II)150, hSPT3, and hPAF65 beta. Thus, the polypeptide composition of TFTC suggests that TFTC is recruited to chromatin templates by activators to acetylate histones and thus may potentiate initiation and activation of transcription.	Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,CU Strasbourg, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,CU Strasbourg, BP 163, F-67404 Strasbourg, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				BELLARD M, 1989, METHOD ENZYMOL, V170, P317; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	33	166	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18285	18289		10.1074/jbc.274.26.18285	http://dx.doi.org/10.1074/jbc.274.26.18285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373431	hybrid			2022-12-25	WOS:000081056700023
J	Brosh, RM; Orren, DK; Nehlin, JO; Ravn, PH; Kenny, MK; Machwe, A; Bohr, VA				Brosh, RM; Orren, DK; Nehlin, JO; Ravn, PH; Kenny, MK; Machwe, A; Bohr, VA			Functional and physical interaction between WRN helicase and human replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; WERNER-SYNDROME PROTEIN; NUCLEOTIDE EXCISION-REPAIR; SYNDROME GENE-PRODUCT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SYNDROME CELLS; BLOOMS-SYNDROME; CALF THYMUS; EXONUCLEASE	The human premature aging disorder Werner syndrome (WS) is associated with a large number of symptoms displayed in normal aging. The WRN gene product, a DNA helicase, has been previously shown to unwind short DNA duplexes (less than or equal to 53 base pairs) in a reaction stimulated by single-stranded DNA-binding proteins. We have studied the helicase activity of purified WRN protein on a variety of DNA duplex substrates to characterize the unwinding properties of the enzyme in greater detail. WRN helicase can catalyze unwinding of long duplex DNA substrates up to 849 base pairs in a reaction dependent on human replication protein A (hRPA). Escherichia coli SSB and bacteriophage T4 gene 32 protein (gp32) completely failed to stimulate WRN helicase to unwind long DNA duplexes indicating a specific functional interaction between WRN and hRPA. So far, there have been no reports of any physical interactions between WRN helicase and other proteins. In support of the functional interaction, we demonstrate a direct interaction between WRN and hRPA by coimmunoprecipitation of purified proteins. The physical and functional interaction between WRN and hRPA suggests that the two proteins may function together in vivo in a pathway of DNA metabolism such as replication, recombination, or repair.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA; Aarhus Univ, DK-8000 Aarhus C, Denmark; Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Brosh, RM (corresponding author), NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Nehlin, Jan O./AAR-8721-2020	Nehlin, Jan O./0000-0001-6038-5027				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P1128, DOI 10.1093/nar/22.7.1128; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THOMMES P, 1992, J BIOL CHEM, V267, P6063; Watt PM, 1996, GENETICS, V144, P935; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YAN H, 1995, SCIENCE, V269, P1883, DOI 10.1126/science.7569932; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	53	245	247	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18341	18350		10.1074/jbc.274.26.18341	http://dx.doi.org/10.1074/jbc.274.26.18341			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373438	hybrid			2022-12-25	WOS:000081056700030
J	Kuno, K; Terashima, Y; Matsushima, K				Kuno, K; Terashima, Y; Matsushima, K			ADAMTS-1 is an active metalloproteinase associated extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; VENOM METALLOPROTEINASE; CONVERTING-ENZYME; MOLECULAR-CLONING; FAMILY PROTEIN; DISINTEGRIN; PRECURSOR; DOMAIN; FURIN	Cellular disintegrin and metalloproteinases (ADAMs) are a family of genes with a sequence similar to the snake venom metalloproteinases and disintegrins. ADAMTS-1 is a unique ADAM family protein with respect to the presence of thrombospondin type I motifs and the capacity to bind to the extracellular matrix. Because ADAMTS-1 has a potential zinc-binding motif in the metalloproteinase domain, we examined in this study whether ADAMTS-1 is an active metalloproteinase by means of the proteinase trapping mechanism of alpha(2)-macroglobulin. We found that the soluble type of ADAMTS-1 protein is able to form a covalent-binding complex with alpha(2)-macroglobulin. Furthermore, the point mutation within the zinc-binding motif of ADAMTS-1 protein eliminates its capacity to bind to alpha(2)-macroglobulin. These data demonstrate that the metalloproteinase domain of ADAMTS-1 is catalytically active. In addition, we showed that the removal of the pro-domain from the ADAMTS-1 precursor is impaired in the furin-deficient cell line, LoVo, and that the processing ability of the cells is restored by the co-expression of the furin cDNA. These data provide evidence that the ADAMTS-1 precursor is processed in vivo by furin endopeptidase in the secretory pathway. Consequently, ADAMTS-1 is an active metalloprotease that is associated with the extracellular matrix. This study strongly suggests that ADAMTS-1 may play a role in the inflammatory process through its protease activity.	Kanazawa Univ, Canc Res Inst, Dept Mol Pharmacol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 113, Japan	Kanazawa University; University of Tokyo	Kuno, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pharmacol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		KUNO, Kouji/D-8439-2015					ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEILEIN UAO, 1994, DEV GROWTH DIFFER, V36, P49; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1994, ANN NY ACAD SCI, V737, P172, DOI 10.1111/j.1749-6632.1994.tb44311.x; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447	37	127	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18821	18826		10.1074/jbc.274.26.18821	http://dx.doi.org/10.1074/jbc.274.26.18821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373500	hybrid			2022-12-25	WOS:000081056700092
J	Timson, DJ; Trayer, HR; Smith, KJ; Trayer, IP				Timson, DJ; Trayer, HR; Smith, KJ; Trayer, IP			Size and charge requirements for kinetic modulation and actin binding by alkali 1-type myosin essential light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; SUBFRAGMENT-1 ISOENZYMES; TROPONIN COMPLEX; HEAVY-CHAIN; AMINO-ACID; CONTRACTION; SPECTROSCOPY; EXPRESSION; POLYMERASE; RESONANCE	The alkali 1-type isoforms of myosin essential light chains from vertebrate striated muscles have an additional 40 or so amino acids at their N terminus compared with the alkali 2-type. Consequently two light chain isoenzymes of myosin subfragment-1 can be isolated. Using synthesized peptide mimics of the N-terminal region of alkali 1-type essential light chains, we have found by H-1 NMR that the major actin binding region occurred in the N-terminal four residues, APKK.... These results were confirmed by mutating this region of the human atrial essential light chain, resulting in altered actin-activated MgATPase kinetics when the recombinant light chains were hybridized into rabbit skeletal subfragment 1. Substitution of either Lys(3) or Lys(4) with Ala resulted in increased K-m and k(cat) and decreased actin binding las judged by chemical cross-linking. Replacement of Lys4 with Asp reduced actin binding and increased K-m and k(cat) still further. Alteration of Ala(1) to Val did not alter the kinetic parameters of the hybrid subfragment 1 or the essential light chain's ability to bind actin, Furthermore, we found a significant correlation between the apparent K-m for actin and the k(cat) for MgATP turnover for each mutant hybrid, strengthening our belief that the binding of actin by alkali I-type essential light chains results directly in modulation of the myosin motor.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Trayer, IP (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.		Timson, David/I-4014-2019	Timson, David/0000-0002-0985-8818				ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ANDREEV OA, 1995, BIOCHEMISTRY-US, V34, P14829, DOI 10.1021/bi00045a025; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARNOLD HH, 1988, EUR J BIOCHEM, V178, P53, DOI 10.1111/j.1432-1033.1988.tb14428.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRANK G, 1974, EUR J BIOCHEM, V44, P317; HENRY GD, 1985, EUR J BIOCHEM, V148, P75, DOI 10.1111/j.1432-1033.1985.tb08809.x; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; JIANG H, 1994, MOL CELL BIOCHEM, V135, P1, DOI 10.1007/BF00925956; LEVINE BA, 1979, CHEM MACROMOLECULES, V24, P77; LOWEY S, 1993, J BIOL CHEM, V268, P20414; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sweeney H. L., 1995, BIOPHYS J, V68, p112S; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; Timson DJ, 1998, EUR J BIOCHEM, V255, P654, DOI 10.1046/j.1432-1327.1998.2550654.x; Timson DJ, 1997, FEBS LETT, V400, P31, DOI 10.1016/S0014-5793(96)01314-2; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; TRAYER IP, 1991, PEPTIDES PROBES MUSC, P56; UENO H, 1984, J BIOCHEM-TOKYO, V96, P895, DOI 10.1093/oxfordjournals.jbchem.a134908; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, FEBS LETT, V49, P320, DOI 10.1016/0014-5793(75)80776-9; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	37	36	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18271	18277		10.1074/jbc.274.26.18271	http://dx.doi.org/10.1074/jbc.274.26.18271			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373429	hybrid			2022-12-25	WOS:000081056700021
J	Low, W; Smith, A; Ashworth, A; Collins, M				Low, W; Smith, A; Ashworth, A; Collins, M			JNK activation is not required for Fas-mediated apoptosis	ONCOGENE			English	Article						caspase; CD95; FADD; M3/6; IL-3	N-TERMINAL KINASE; STRESS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; HUMAN T-CELLS; SIGNALING COMPLEX; PROTEIN-KINASES; SURFACE-ANTIGEN; CD95 FAS/APO-1; JURKAT CELLS; JUN KINASE	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3. Fas-mediated apoptosis was prevented by expression of dominant negative FADD but not inhibited by IL-3. To investigate the role of JNK activation in this process, we examined cells overexpressing a JNK-specific phosphatase M3/6. M3/6 prevented Pas stimulation of JNK, but did not affect Pas-mediated caspase activation or cell death, demonstrating that JNK activation is not required for these processes.	UCL, Dept Immunol, London W1P 6DB, England; Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Collins, M (corresponding author), UCL, Dept Immunol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cahill MA, 1996, ONCOGENE, V13, P2087; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; delPeso L, 1997, SCIENCE, V278, P687; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faris M, 1998, J IMMUNOL, V160, P134; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rudel T, 1998, J IMMUNOL, V160, P7; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	43	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3737	3741		10.1038/sj.onc.1202702	http://dx.doi.org/10.1038/sj.onc.1202702			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391681				2022-12-25	WOS:000081140200007
J	Hou, ZL; Cashel, M; Fromm, HJ; Honzatko, RB				Hou, ZL; Cashel, M; Fromm, HJ; Honzatko, RB			Effecters of the stringent response target the active site of Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; IDENTIFICATION; 5'-PHOSPHATE; HYDANTOCIDIN; HADACIDIN; BINDING; MG2+; GDP	Guanosine 5'-diphosphate 3'-diphosphate (ppGpp), a pleiotropic effector of the stringent response, potently inhibits adenylosuccinate synthetase from Escherichia coli as an allosteric effector and/or as a competitive inhibitor with respect to GTP. Crystals of the synthetase grown in the presence of IMP, hadacidin, NO3- and Mg2+, then soaked with ppGpp, reveal electron density at the GTP pocket which is consistent with guanosine 5'-diphosphate 2':3'-cyclic monophosphate. Unlike ligand complexes of the synthetase involving IMP and GDP, the coordination of Mg2+ in this complex is octahedral with the side chain of Asp(13) in the inner sphere of the cation. The cyclic phosphoryl group interacts directly with the side chain of Lys(49) and indirectly through bridging water molecules with the side chains of Asn(295) and Arg(305). Th, synthetase either directly facilitates the formation of the cyclic nucleotide or scavenges trace amounts of the cyclic nucleotide from solution. Regardless of its mode of generation, the cyclic nucleotide binds far more tightly to the active site than does ppGpp. Conceivably, synthetase activity in vivo during the stringent response may be sensitive to the relative concentrations of several effecters, which together exercise precise control over the de novo synthesis of AMP.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	Iowa State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Honzatko, RB (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CASHEL M, 1969, J BIOL CHEM, V245, P2039; CHOE JY, 1999, IN PRESS BIOCHEMISTR; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; DONG Q, 1990, J BIOL CHEM, V265, P6235; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GALLANT J, 1971, J BIOL CHEM, V246, P5812; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KACKZA EA, 1962, BIOCHEMISTRY-US, V1, P340; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAPPER RD, 1973, J AM CHEM SOC, V95, P2880, DOI 10.1021/ja00790a025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; Lipmann F, 1976, Prog Nucleic Acid Res Mol Biol, V17, P1, DOI 10.1016/S0079-6603(08)60063-X; MARKHAM DG, 1977, ARCH BIOCHEM BIOPHYS, V184, P24; MARKHAM GD, 1978, J BIOL CHEM, V253, P6184; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; PAO CC, 1981, BIOCHIM BIOPHYS ACTA, V677, P358, DOI 10.1016/0304-4165(81)90247-6; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; SAENGER W, 1984, PRINCIPLES NUCL ACID, P167; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STAYTON MM, 1979, J BIOL CHEM, V254, P2579; TYAGI AK, 1980, CANCER RES, V40, P4390; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000	31	35	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17505	17510		10.1074/jbc.274.25.17505	http://dx.doi.org/10.1074/jbc.274.25.17505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364182	hybrid			2022-12-25	WOS:000080974300018
J	Wang, Q; Mullah, BK; Robishaw, JD				Wang, Q; Mullah, BK; Robishaw, JD			Ribozyme approach identifies a functional association between the G protein beta(1)gamma(7) subunits in the beta-adrenergic receptor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNIT; LIPID MODIFICATIONS; CDNA CLONES; SPECIFICITY; TRANSDUCTION; INCREASES; RHODOPSIN; BINDING; BRAIN	The complex role that the heterotrimeric G proteins play in signaling pathways has become increasingly apparent with the cloning of countless numbers of receptors, G proteins, and effecters. However, in most cases, the specific combinations of alpha and beta gamma subunits comprising the G proteins that participate in the most common signaling pathways, such as beta-adrenergic regulation of adenylyl cyclase activity, are not known. The extent of this problem is evident in the fact that the identities of the beta gamma subunits that combine with the alpha subunit of G(s) are only now being elucidated almost 20 years after its initial purification. In a previous study, we described the first use of a ribozyme strategy to suppress specifically the expression of the gamma(7) subunit of the G proteins, thereby identifying a specific role of this protein in coupling the beta-adrenergic receptor to stimulation of adenylyl cyclase activity in HEK 293 cells, In the present study, we explored the potential utility of a ribozyme approach directed against the gamma(7) subunit to identify functional associations with a particular beta and alpha(s) subunit of the G protein in this signaling pathway. Accordingly, HEK 293 cells were transfected with a ribozyme directed against the gamma(7) subunit, and the effects of this manipulation on levels of the beta and alpha(s) subunits were determined by immunoblot analysis. Among the five beta alpha(s) subunits detected in these cells, only the beta(1) subunit was coordinately reduced following treatment with the ribozyme directed against the gamma(7) subunit, thereby demonstrating a functional association between the beta(1) and gamma(7) subunits, The mechanism for coordinate suppression of the beta(1) subunit was due to a striking change in the half-life of the beta(1) monomer versus the beta(1) heterodimer complexed with the gamma(7) subunit, Neither the 52- nor 45-kDa subunits were suppressed following treatment with the ribozyme directed against the gamma(7) subunit, thereby providing insights into the assembly of the G(s) heterotrimer, Taken together, these data show the utility of a ribozyme approach to identify the role of not only the gamma subunits but also the beta subunits of the G proteins in signaling pathways.	Penn State Univ, Henry Hood MD Res Program, Coll Med, Weis Ctr Res, Danville, PA 17822 USA; Appl Biosyst Inc, Foster City, CA 94404 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Thermo Fisher Scientific; Applied Biosystems	Robishaw, JD (corresponding author), Penn State Univ, Henry Hood MD Res Program, Coll Med, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	jrobishaw@psghs.edu			NIGMS NIH HHS [GM58191, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058191, R29GM039867, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DUZIC E, 1992, J BIOL CHEM, V267, P24045; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FOSTER KA, 1991, MOL CELL BIOCHEM, V104, P63; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MOHR E, 1995, P NATL ACAD SCI USA, V92, P4377, DOI 10.1073/pnas.92.10.4377; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONG OC, 1997, GENOMICS, V15, P101; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RAY K, 1994, GENE, V149, P337, DOI 10.1016/0378-1119(94)90172-4; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Taylor JM, 1996, J BIOL CHEM, V271, P3336; Ueda H, 1997, J CELL SCI, V110, P1503; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	50	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17365	17371		10.1074/jbc.274.24.17365	http://dx.doi.org/10.1074/jbc.274.24.17365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358098	hybrid			2022-12-25	WOS:000080780400097
J	Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C				Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C			Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis	ONCOGENE			English	Article						HPCs; PML; RB; erythropoiesis	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ZINC FINGER GENE; RAR-ALPHA; ERYTHROID-DIFFERENTIATION; RETINOBLASTOMA PROTEIN; RECEPTOR-ALPHA; HUMAN CYTOMEGALOVIRUS; BINDING DOMAINS; HOXB GENES	The expression of the PML gene was investigated in purified early hematopoietic progenitor cells (HPCs) induced to unilineage erythroid or granulocytic differentiation. PML mRNA and protein, while barely detectable in quiescent HPCs, are consistently induced by growth factor stimulation through the erythroid or granulocytic lineage. Thereafter, PML is downmodulated in late granulocytic maturation, whereas it is sustainably expressed through the erythroid pathway. In functional studies, PML expression was inhibited by addition of antisense oligomers targeting PML mRNA (alpha-PML). Interestingly, early treatment (day 0 HPCs) with cr-PML reduced the number of both erythroid and granulocytic colonies, whereas late treatment (day 5 culture) reduced erythroid, but not granulocytic, clonogenesis. These findings suggest that PML is required for early hematopoiesis and erythroid, but not granulocytic maturation. The pattern of PML expression in normal hematopoiesis mimics that of retinoblastoma pRb 105. Combined treatment of HPCs with alpha-PML and alpha-Rb oligomers inhibited both PML and Rb protein expression and completely blocked erythroid colony development. Furthermore, PML and pRb 105 were co-immunoprecipitated in cellular lysates derived from erythroid precursors indicating that this functional interaction may have a biochemical basis. These results suggest a key functional role of PML in early hematopoiesis and late erythropoiesis: the latter phenomenon may be related to the molecular and functional interaction of PML with pRb 105.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Dept Clin Med, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Jefferson University; Istituto Superiore di Sanita (ISS); University of Perugia; IRCCS European Institute of Oncology (IEO)	Peschle, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Puglisi, Rossella/M-7120-2017; valtieri, mauro/H-1044-2016; Testa, Ugo/J-6472-2016; Grignani, Francesco/AAC-2565-2022; Labbaye, Catherine/J-9930-2016	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Puglisi, Rossella/0000-0003-1680-1032; valtieri, mauro/0000-0002-9139-6754; Testa, Ugo/0000-0001-7900-8942; Labbaye, Catherine/0000-0003-1255-4396				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He DL, 1997, CANCER RES, V57, P1868; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LABBAYE C, 1994, BLOOD, V83, P651; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NEVINS JR, 1992, SCIENCE, V258, P424; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; VALTIERI M, 1989, BLOOD, V74, P460; VALTIERI M, 1991, BLOOD, V77, P1181; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109	58	21	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3529	3540		10.1038/sj.onc.1202682	http://dx.doi.org/10.1038/sj.onc.1202682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376531				2022-12-25	WOS:000080850600011
J	Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ				Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ			Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts	ONCOGENE			English	Article						Myc; Bcl-2; apoptosis; etoposide; mitochondrial; membrane potential	PROGRAMMED CELL-DEATH; MITOCHONDRIAL PERMEABILITY TRANSITION; C-MYC; INTRACELLULAR CALCIUM; OUTER-MEMBRANE; PROTEIN; LOCALIZATION; ONCOPROTEIN; HOMEOSTASIS; GENERATION	Bcl-2 is a key inhibitor of a broad range of apoptotic pathways, yet neither the mechanism of action nor the role of Bcl-2 subcellular localization are well understood. The subcellular localization of Bcl-2 includes the mitochondrial membrane as well as the contiguous membrane of the endoplasmic reticulum and nuclear envelope. Most studies suggest that the ability of Bcl-2 to confer cell survival is dependent upon its localization to the mitochondria, In this manuscript, we show that Bcl-2 targeted to the endoplasmic reticulum can inhibit Myc-, but not etoposide-induced apoptosis in the Rat-1 fibroblast cell line. By contrast, wild type Bcl-2 can inhibit apoptosis triggered by either death agonist, We further show both Myc and etoposide trigger disruption of mitochondrial membrane potential (MMP) and induce poly-ADP ribose polymerase (PARP) cleavage, but release of calcium was not evident. Bcl-2 abrogates apoptosis at or upstream of MMP depletion showing that Bcl-2 does not have to reside at the mitochondria to prevent apoptosis, These results further elucidate the biochemical events associated with Myc- and etoposide-induced apoptosis and significantly advance our understanding of Bcl-2 function.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Mol Biol, Toronto, ON M5G 2M9, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University; McMaster University	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Penn, Linda/0000-0001-8133-5459; Andrews, David/0000-0002-9266-7157; Hedley, David/0000-0003-1323-2655; Leber, Brian/0000-0001-5502-1480				AKAO Y, 1994, CANCER RES, V54, P2468; Backway KL, 1997, CANCER RES, V57, P2446; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3520	3528		10.1038/sj.onc.1202716	http://dx.doi.org/10.1038/sj.onc.1202716			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376530				2022-12-25	WOS:000080850600010
J	Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV				Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV			Constitutive activation of stimulatory guanine nucleotide binding protein (G(s)alpha QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells	ONCOGENE			English	Article						G(s)alpha; invasiveness; tumorigenicity; prostate cancer	INTESTINAL-PEPTIDE RECEPTORS; RAT VENTRAL PROSTATE; NEUROENDOCRINE DIFFERENTIATION; COUPLED RECEPTORS; ADENYLYL-CYCLASE; GROWTH; KINASE; CARCINOMA; EXPRESSION; TUMORS	An abnormal stimulation of cAMP signaling cascade has been implicated in various human carcinomas, Since the agents activating G(s)alpha-mediated signaling pathways have been shown to increase in vitro proliferation of prostate cancer cells, present studies examined the G(s)alpha-mediated signaling in tumorigenicity and invasiveness of PC-3M prostate cancer cells. PC-3M cells were stably transfected with plasmids containing either wild type (G(s)alpha-WT) or constitutively active (gsp mutant of G(s)alpha or G(s)alpha-QL) CDNAs. The stable transfectants were then tested for: (1) colony formation in soft agar; (2) cell migration and penetration of basement matrix in an in vitro invasion assay; and (3) the ability to form tumors and metastases in nude mice. PC-3M cells expressing G(s)alpha-QL protein displayed 15-fold increase in their ability to migrate and penetrate the basement membrane as compared to parental PC-3M cells or those expressing G(s)alpha-WT. G(s)alpha-QL transfectants also displayed a dramatically greater rate of growth in soft agar, and greater tumorigenicity and metastasis forming ability when orthotopically implanted in nude mice. All mice receiving PC-3M cells produced primary tumors within 5 weeks after implantation. However, the cells expressing G(s)alpha-QL displayed a significantly faster tumor growth as assessed by prostate weight (greater than 20-fold as compared to PC-3M cells), and produced metastases in kidneys, 12 mph nodes, blood vessels, bon el mesentery and intestine. Interestingly, expression of G(s)alpha-WT reduced the ability of PC-3M cells to form tumors in nude mice. These results suggest that persistent activation of G(s)alpha-mediated signaling cascade can dramatically accelerate tumorigenesis and metastasizing ability of prostate cancer cells.	Univ Kansas, Med Ctr, Dept Urol Surg, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Shah, GV (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.		Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45044, R01 DK045044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDUL M, 1994, ANTICANCER RES, V14, P1215; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BANERJEE A, 1992, CANCER RES, V52, P6297; CARMENA MJ, 1995, PROSTATE, V27, P204, DOI 10.1002/pros.2990270405; Chen CL, 1996, J STEROID BIOCHEM, V58, P489, DOI 10.1016/0960-0760(96)00069-6; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COHEN MK, 1994, CANCER, V74, P1899, DOI 10.1002/1097-0142(19941001)74:7<1899::AID-CNCR2820740712>3.0.CO;2-U; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; DREWS RT, 1992, MOL CELL ENDOCRINOL, V87, P125, DOI 10.1016/0303-7207(92)90240-7; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GUP DI, 1990, J UROLOGY, V143, P179, DOI 10.1016/S0022-5347(17)39906-8; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; HUANG ZY, 1994, CHUNG HUA I HSUEH TS, V74, P23; JUARRANZ MG, 1994, GEN PHARMACOL-VASC S, V25, P509, DOI 10.1016/0306-3623(94)90207-0; KADMON D, 1991, J UROLOGY, V146, P358, DOI 10.1016/S0022-5347(17)37793-5; KILLAM AL, 1995, EUR J PHARMACOL, V273, P7, DOI 10.1016/0014-2999(94)00613-C; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LEPOR H, 1984, J UROLOGY, V132, P397, DOI 10.1016/S0022-5347(17)49636-4; LOGOTHETIS C, 1992, J CELL BIOCHEM, V16, pH128; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MIRAYLOPEZ R, 1992, J BIOL CHEM, V267, P23063; MUCA C, 1994, ONCOGENE, V9, P3647; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Newling DWW, 1996, EUR UROL, V29, P69; NEWLING DWW, 1992, PROSTATE, P139; Rayford W, 1997, PROSTATE, V30, P160, DOI 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q; REUBI JC, 1995, J NUCL MED, V36, P1846; SEGAL NH, 1994, ARCH PATHOL LAB MED, V118, P616; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SHINTANI Y, 1995, ENDOCR J, V42, P331, DOI 10.1507/endocrj.42.331; Solano RM, 1996, ENDOCRINOLOGY, V137, P2815, DOI 10.1210/en.137.7.2815; SOLANO RM, 1994, NEUROPEPTIDES, V27, P31, DOI 10.1016/0143-4179(94)90014-0; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TANAKA K, 1995, CANCER RES, V55, P2927; VANWEERDEN WM, 1993, CELL PROLIFERAT, V26, P67, DOI 10.1111/j.1365-2184.1993.tb00007.x; Wu GA, 1996, UROLOGY, V47, P376, DOI 10.1016/S0090-4295(99)80456-7; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZEIGER MA, 1993, SURGERY, V114, P458	42	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3376	3382		10.1038/sj.onc.1202690	http://dx.doi.org/10.1038/sj.onc.1202690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362358				2022-12-25	WOS:000080589300008
J	Zhan, QM; Antinore, MJ; Wang, XW; Carrier, F; Smith, ML; Harris, CC; Forance, AJ				Zhan, QM; Antinore, MJ; Wang, XW; Carrier, F; Smith, ML; Harris, CC; Forance, AJ			Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45	ONCOGENE			English	Article						g2 checkpoint; UV radiation; Cdc2; cyclin B1; Gadd45	CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; GROWTH ARREST; G(2) DELAY; HELA-CELLS; P53; G(1); PROGRESSION; IRRADIATION; DISRUPTION	Recently Gadd45, a p53-regulated stress protein, has been implicated in the activation of a G2/M checkpoint after damage by UV radiation and alkylating agents, While inhibitory phosphorylation of Cdc2 and suppression of cyclin B1 levels are known to be involved in GZ delays after genotoxic stress, Gadd45 has non been found to directly inhibit the activity of Cdc2/Cyclin B1 complex, while it had no appreciable effect on Cdk2/ Cyclin E activity even at very high levels of Gadd45, In contrast, p21(Cip1/Waf1) is an universal cdk/cyclin inhibitor and inhibited both of the cyclin complexes tested here, Gadd45 was also able to physically interact with Cdc2, but not Cyclin B1, Addition of Gadd45 to immunoprecipitated Cdc2/Cyclin B1 in vitro led to a dissociation of this complex, and thus may represent a new checkpoint mechanism whereby Cdc2/Cyclin B1 can be inhibited, With the use of an antisense approach, reduced Gadd45 expression attenuated the suppression of Cdc2/Cyclin B1 activity in UV-irradiated human cells. Taken together, these results implicate Gadd45 in the control of G2/M cell cycle progression after certain stresses.	NCI, Biol Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Forance, AJ (corresponding author), NCI, Biol Chem Lab, Div Basic Sci, NIH, Bldg 37,Room 5C09, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Fornace, Albert J/A-7407-2008; Carrier, France/C-3063-2008	Wang, Xin Wei/0000-0001-9735-606X; Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAN SJ, 1995, CANCER RES, V55, P1649; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kao GD, 1997, CANCER RES, V57, P753; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Khan SH, 1998, CANCER RES, V58, P396; KILPATRICK KE, 1995, HYBRIDOMA, V14, P355, DOI 10.1089/hyb.1995.14.355; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWELL SN, 1995, CANCER RES, V55, P1643; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Smith ML, 1996, ONCOGENE, V13, P2255; STEWART N, 1995, ONCOGENE, V10, P109; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wang X. W., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P201; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG WW, 1994, CANCER GENE THER, V1, P1	34	377	397	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2892	2900		10.1038/sj.onc.1202667	http://dx.doi.org/10.1038/sj.onc.1202667			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362260				2022-12-25	WOS:000080125100012
J	Craig, AWB; Zirngibl, R; Greer, P				Craig, AWB; Zirngibl, R; Greer, P			Disruption of coiled-coil domains in Fer protein-tyrosine kinase abolishes trimerization but not kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NUCLEOTIDE-SEQUENCE; SIGNALING PATHWAY; TRANSCRIPT FERT; BCR-ABL; V-FPS; GENE; RECEPTOR; FAMILY; SRC	The protein-tyrosine kinase Fer and the highly homologous proto-oncoprotein Fps/Fes are implicated in signaling from a variety of growth factor and cytokine receptors. Here we examine the molecular basis of Fer kinase activation with an emphasis on the role of oligomerization. We show that Fer forms trimers in vivo and that disruption of either the first or second coiled-coil domain abolishes oligomerization, suggesting a cooperative interaction between these two domains. Although Fps/Fes also forms homotypic oligomers, probably via homologous coiled-coil domains, no heterotypic interactions were observed between Fer and Fps/ Fes. Incorporation of catalytically inactive Fer peptides into the oligomeric complex caused only mild reduction of wild type Fer kinase activity, suggesting that kinase-inactive Fer would not behave as a potent dominant negative. Although oligomerization of Fer can potentiate autophosphorylation in trans at three major phosphorylation sites, these residues can likely also be phosphorylated in cis. In contrast, the testis-specific FerT isomer does not oligomerize and is able to autophosphorylate in cia at two of the same three residues autophosphorylated in Fer. These results suggest that although oligomerization potentiates autophosphorylation in trans, this is apparently not necessary for Fer activation.	Queens Univ, Canc Res Lab, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Greer, P (corresponding author), Queens Univ, Canc Res Lab, Botterell Hall,Rm A309, Kingston, ON K7L 3N6, Canada.		Craig, Andrew/G-2312-2017; Zirngibl, Ralph/AHB-0565-2022; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ALCALAY M, 1990, ONCOGENE, V5, P267; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARE A, 1994, ONCOGENE, V9, P739; Cole LA, 1999, PROTEIN ENG, V12, P155, DOI 10.1093/protein/12.2.155; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUANG CC, 1984, J VIROL, V50, P125, DOI 10.1128/JVI.50.1.125-131.1984; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; Lowenthal RM, 1997, INT J HEMATOL, V65, P319; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Saylor P, 1998, BIOCHEMISTRY-US, V37, P17875, DOI 10.1021/bi981775b; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sirotkin H, 1997, GENOMICS, V41, P75, DOI 10.1006/geno.1997.4627; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tong Q, 1997, J BIOL CHEM, V272, P9043; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	52	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19934	19942		10.1074/jbc.274.28.19934	http://dx.doi.org/10.1074/jbc.274.28.19934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391941	hybrid			2022-12-25	WOS:000081377300061
J	Dong, ZW; Zhong, Q; Chen, PL				Dong, ZW; Zhong, Q; Chen, PL			The Nijmegen breakage syndrome protein is essential for Mre11 phosphorylation upon DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-LINE; REPAIR; RECOMBINATION; COMPLEX; YEAST; BINDING; KINASE; RAD50; BRCA1	The Nijmegen breakage syndrome (NBS), a chromosomal instability disorder, is characterized in part by cellular hypersensitivity to ionizing radiation. Repair of DNA double-strand breaks by radiation is dependent on a multifunctional complex containing Rad50, Mre11, and the NBS1 gene product, p95 (NBS protein, nibrin). The role of p95 in these repair processes is unknown. Here it is demonstrated that Mre11 is hyperphosphorylated in a cell cycle-independent manner in response to treatment of cells with genotoxic agents including gamma irradiation. This response is abrogated in two independently established NBS cell lines that have undetectable levels of the p95 protein. NBS cells are also deficient for radiation-induced nuclear foci containing Mre11, while those with Rad51 are unaffected. An analysis of the kinetic relationship between Mre11 phosphorylation and the appearance of its radiation-induced foci indicates that the former precedes the latter. Together, these data suggest that specific phosphorylation of Mre11 is induced by DNA damage, and p95 is essential in this process, perhaps by recruiting specific kinases.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X				ALANI E, 1989, GENETICS, V122, P47; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, CANCER RES, V56, P3168; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Goggins M, 1996, CANCER RES, V56, P5360; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Tomlinson GE, 1998, CANCER RES, V58, P3237; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	21	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19513	19516		10.1074/jbc.274.28.19513	http://dx.doi.org/10.1074/jbc.274.28.19513			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391882	hybrid			2022-12-25	WOS:000081377300002
J	Hedin, KE; Bell, MP; Huntoon, CJ; Karnitz, LM; McKean, DJ				Hedin, KE; Bell, MP; Huntoon, CJ; Karnitz, LM; McKean, DJ			G(i) proteins use a novel beta gamma- and Ras-independent pathway to activate extracellular signal-regulated kinase and mobilize AP-1 transcription factors in jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CELL ANTIGEN RECEPTOR; MAP KINASE; COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASES; ALPHA-SUBUNIT; EGF RECEPTOR; IN-VITRO	Receptors coupled to pertussis toxin (PTX)-sensitive G(i) proteins regulate T lymphocyte cytokine secretion, proliferation, and chemotaxis, yet little is known about the molecular mechanisms of G(i) protein signaling in mammalian lymphocytes. Using the Jurkat T lymphocyte cell line, we found that a stably expressed G(i) protein-coupled receptor (the delta-opioid receptor (DOR1)) stimulates MEK-1 and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) and transcriptional activity by an ERK target, Elk-1, via a mechanism requiring a PTX-sensitive Gi protein. Levels of beta-adrenergic receptor kinase-1 C-terminal fragment that inhibited signaling by G(i) protein beta gamma subunits in these cells had no effect on DOR1 stimulation of either MEK-1 or Elk-1-dependent transcription, indicating that this pathway is independent of beta gamma, Analysis of this beta gamma-independent pathway indicates a role for a herbimycin A-sensitive tyrosine kinase. Unlike beta gamma-mediated pathways, the py-independent pathway was insensitive to RasN17, inhibitors of phosphatidylinositol 3-kinase (PI 3-kinase), and constitutive PI 3-kinase activity. The beta gamma-independent pathway regulates downstream events, since blocking it abrogated both Elk-1-dependent transcription and mobilization of the mitogenic transcription factor, AP-1, in response to DOR1 signaling. These results characterize a novel, Ras- and PI 3-kinase-independent pathway for ERK activation by Gi protein signaling that is distinct from ERK activation by beta gamma and may therefore be mediated by the ai subunit.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Hedin, KE (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, GUGG-3, Rochester, MN 55905 USA.			Hedin, Karen/0000-0003-1010-923X				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HEDIN KE, 1995, IMMUNOLOGY, V84, P183; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCKEAN DJ, 1994, J EXP MED, V180, P1321, DOI 10.1084/jem.180.4.1321; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sharp BM, 1996, P NATL ACAD SCI USA, V93, P8294, DOI 10.1073/pnas.93.16.8294; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Taub DD, 1996, J IMMUNOL, V156, P2095; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3	60	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19992	20001		10.1074/jbc.274.28.19992	http://dx.doi.org/10.1074/jbc.274.28.19992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391949	hybrid			2022-12-25	WOS:000081377300069
J	van Dalen, A; Killian, A; de Kruijff, B				van Dalen, A; Killian, A; de Kruijff, B			Delta psi stimulates membrane translocation of the C-terminal part of a signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER-MEMBRANE; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; LEADER PEPTIDASE; PLASMA-MEMBRANE; PURIFIED COMPONENTS; SECRETORY PROTEINS; MODEL MEMBRANES; AMINO TERMINUS	For several proteins in Escherichia coli it has been shown that the protonmotive force (pmf) dependence of translocation can be varied with the signal sequence composition, suggesting an effect of the pmf on the signal sequence. To test this possibility, we analyzed the effect of the membrane potential on translocation of the signal sequence. For this purpose, a precursor peptide was used (SP+7), corresponding to the signal sequence of PhoE with the first seven amino acids of the mature part that can be processed by purified leader peptidase, Translocation was studied in pure lipid vesicles containing leader peptidase, with its active site inside the vesicles. In the presence of a positive inside Delta Psi the amount of processing of SP+7 was significantly higher than without a Delta Psi, indicating that the translocation of the cleavage region is stimulated by Delta Psi. Replacement of the helix-breaking glycine residue at position -10 in the signal sequence for a leucine abolished the effect of Delta Psi on the translocation of the cleavage region. It is concluded that Delta Psi directly acts on the wild type signal sequence by stimulating the translocation of its C terminus. We propose that Delta Psi acts on the signal sequence by stretching it into a transmembrane orientation.	Univ Utrecht, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, Biomembrane Inst, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Dalen, A (corresponding author), Univ Utrecht, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, Biomembrane Inst, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	a.vandalen@chem.uu.nl	Killian, J. Antoinette/I-3001-2016	Killian, J. Antoinette/0000-0001-8010-3816				AKITA M, 1990, J BIOL CHEM, V265, P8164; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; BATENBURG AM, 1988, J BIOL CHEM, V263, P4202; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CHUPIN V, 1995, BIOCHEMISTRY-US, V34, P11617, DOI 10.1021/bi00036a038; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Demel R A, 1974, Methods Enzymol, V32, P539; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; GELLER B, 1993, J BIOL CHEM, V268, P9442; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KUHN A, 1990, J STRUCT BIOL, V104, P38, DOI 10.1016/1047-8477(90)90055-H; KUSTERS R, 1994, J BIOL CHEM, V269, P1560; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LU HM, 1991, J BIOL CHEM, V266, P9977; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nouwen N, 1996, MOL MICROBIOL, V19, P1205, DOI 10.1111/j.1365-2958.1996.tb02466.x; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; OHNOIWASHITA Y, 1984, BIOCHEMISTRY-US, V23, P6178, DOI 10.1021/bi00320a044; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; vanKlompenburg W, 1995, MOL MEMBR BIOL, V12, P349, DOI 10.3109/09687689509072437; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; WATTS C, 1981, CELL, V25, P347, DOI 10.1016/0092-8674(81)90053-2	50	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19913	19918		10.1074/jbc.274.28.19913	http://dx.doi.org/10.1074/jbc.274.28.19913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391938	hybrid			2022-12-25	WOS:000081377300058
J	Zhou, Q; Ruiz-Lozano, P; Martone, ME; Chen, J				Zhou, Q; Ruiz-Lozano, P; Martone, ME; Chen, J			Cypher, a striated muscle-restricted PDZ and LIM domain-containing protein, binds to alpha-actinin-2 and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HEART-FAILURE; MOTIF; RIL; DIFFERENTIATION; RECOGNITION; HOMEODOMAIN; ELEGANS; NEURONS; PSD-95	We have cloned and characterized a novel striated muscle-restricted protein (Cypher) that has two mRNA splice variants, designated Cypher1 and Cypher2. Both proteins contain an amino-terminal PDZ domain. Cypher1, but not Cypher2, contains three carboxyl-terminal LIM domains and an amino acid repeat sequence that exhibits homology to a repeat sequence found in the largest subunit of RNA polymerase II. cypher1 and cypher2 mRNAs exhibited identical expression patterns. Both are exclusively expressed in cardiac and striated muscle in embryonic and adult stages. By biochemical assays, we have demonstrated that Cypher1 and Cypher2 bind to a-actinin-a via their PDZ domains. This interaction has been further confirmed by immunohistochemical studies that demonstrated co-localization of Cypher and a-actinin at the Z-lines of cardiac muscle. We have also found that Cypher1 binds to protein kinase C through its LIM domains. Phosphorylation of Cypher by protein kinase C has demonstrated the functional significance of this interaction. Together, our data suggest that Cypher1 may function as an adaptor in striated muscle to couple protein kinase C-mediated signaling, via its LIM domains, to the cytoskeleton (cu-actinin-a) through its PDZ domain.	Univ Calif San Diego, Sch Med, Dept Med, Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Chen, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, Salk Program Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Chen, Ju/E-5579-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; JONES WK, 1994, DEV DYNAM, V200, P117, DOI 10.1002/aja.1002000204; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIESS M, 1995, ONCOGENE, V10, P61; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LUMSDEN A, 1995, CURR BIOL, V5, P491, DOI 10.1016/S0960-9822(95)00100-X; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	32	190	197	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19807	19813		10.1074/jbc.274.28.19807	http://dx.doi.org/10.1074/jbc.274.28.19807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391924	hybrid			2022-12-25	WOS:000081377300044
J	Benlagha, K; Guglielmi, P; Cooper, MD; Lassoued, K				Benlagha, K; Guglielmi, P; Cooper, MD; Lassoued, K			Modifications of Ig alpha and Ig beta expression as a function of B lineage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASES; IMMUNOGLOBULIN GENE REARRANGEMENT; CHAIN ALLELIC EXCLUSION; PSEUDO-LIGHT-CHAIN; HUMAN PRE-B; LYMPHOCYTES-B; CROSS-LINKING; HEAVY-CHAIN; MB-1 GENE	Transcription of the mb1 and B29 genes is initiated when lymphoid progenitors enter the B cell differentiation pathway, and their transmembrane Ig alpha and Ig beta products constitute essential signaling components of pre B and B cell antigen receptors. We analyzed Ig alpha/Ig beta biosynthesis, heterogeneity, and molecular interactions as a function of human B lineage differentiation in cell lines representative of the pro-B, pre-B, and B cell stages. All B lineage representatives produced a 36-kDa Ig beta form and three principal Ig alpha forms, transient 33/40-kDa species and a mature 44-kDa glycoprotein. Deglycosylation revealed a major Ig alpha core protein of 25 kDa and a minor 21-kDa Ig alpha protein, apparently the product of an alternatively spliced mRNA. In pro-B cells, the Ig alpha and Ig beta molecules existed primarily in separate unassembled pools, exhibited an immature glycosylation pattern, did not associate with surrogate Light chain proteins, and were retained intracellularly. Their unanticipated association with the Lyn protein-tyrosine kinase nevertheless suggests functional potential for the Ig alpha/Ig beta molecules in pro-B cells. Greater heterogeneity of the Iglu and Ig beta molecules in pre-B and B cell Lines was attributable to increased glycosylation complexity. Finally, the Ig alpha/Ig beta heterodimers associated with fully assembled IgM molecules as a terminal event in B cell receptor assembly.	Hop St Louis, Inst Hematol, Immunopathol Lab, F-75475 Paris 10, France; Inst Genet Mol, F-34293 Montpellier, France; Univ Alabama, Howard Hughes Med Inst, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Dept Pathol & Microbiol, Birmingham, AL 35294 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Lassoued, K (corresponding author), Hop St Louis, Inst Hematol, Immunopathol Lab, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Benlagha, Kamel/I-5035-2016; Benlagha, Kamel/GLQ-8342-2022	benlagha, kamel/0000-0002-3251-9195	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039816, R37AI039816] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39816] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; Brouns GS, 1996, J BIOL CHEM, V271, P19272, DOI 10.1074/jbc.271.32.19272; BROUNS GS, 1995, INT IMMUNOL, V7, P359, DOI 10.1093/intimm/7.3.359; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHEN CH, 1990, AVIAN CELLULAR IMMUN, P1; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, J IMMUNOL, V149, P2857; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; FINLEY HW, 1982, BLOOD, V60, P1305; FREIDRICH J, 1993, J IMMUNOL, V150, P2814; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; HA HJ, 1992, J IMMUNOL, V148, P1526; HASHIMOTO S, 1995, MOL IMMUNOL, V32, P651, DOI 10.1016/0161-5890(95)00023-8; HASHIMOTO S, 1993, J IMMUNOL, V150, P491; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KIYOTAKI M, 1987, J IMMUNOL, V138, P4150; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; Koyama M, 1997, INT IMMUNOL, V9, P1767, DOI 10.1093/intimm/9.11.1767; KOYAMA M, 1995, IMMUNOL LETT, V47, P151, DOI 10.1016/0165-2478(95)00071-X; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; KUWAHARA K, 1993, BIOCHEM BIOPH RES CO, V197, P1563, DOI 10.1006/bbrc.1993.2656; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassoued K, 1996, J EXP MED, V183, P421, DOI 10.1084/jem.183.2.421; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MARUYAMA S, 1985, J IMMUNOL, V135, P192; MASON DY, 1991, J IMMUNOL, V147, P2474; MATSUO T, 1993, J IMMUNOL, V150, P3766; MULLER B, 1992, EUR J IMMUNOL, V22, P1621, DOI 10.1002/eji.1830220641; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NUSSENZWEIG MC, 1988, J EXP MED, V167, P1969, DOI 10.1084/jem.167.6.1969; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PULVERTAFT RJV, 1964, LANCET, V1, P238; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; VASILE S, 1994, MOL IMMUNOL, V31, P419, DOI 10.1016/0161-5890(94)90061-2; VENTIKARAMAN AR, 1991, NATURE, V352, P777; WIENANDS J, 1991, EUR J IMMUNOL, V21, P2373, DOI 10.1002/eji.1830211012; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOUN HY, 1994, J IMMUNOL, V153, P5127; YU LM, 1992, J IMMUNOL, V148, P633	62	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19389	19396		10.1074/jbc.274.27.19389	http://dx.doi.org/10.1074/jbc.274.27.19389			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383452	hybrid			2022-12-25	WOS:000081196300075
J	Febbraio, M; Abumrad, NA; Hajjar, DP; Sharma, K; Cheng, WL; Pearce, SFA; Silverstein, RL				Febbraio, M; Abumrad, NA; Hajjar, DP; Sharma, K; Cheng, WL; Pearce, SFA; Silverstein, RL			A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MACROPHAGE SCAVENGER RECEPTORS; ADIPOCYTE MEMBRANE-PROTEIN; PPAR-GAMMA ACTIVATORS; SR-BI; PREADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPOSITION; APOPTOTIC THYMOCYTES; EXPRESSION CLONING; BINDING-PROPERTIES	A null mutation in the scavenger receptor gene CD36 was created in mice by targeted homologous recombination. These mice produced no detectable CD36 protein, were viable, and bred normally. A significant decrease in binding and uptake of oxidized low density lipoprotein was observed in peritoneal macrophages of null mice as compared with those from control mice. CD36 null animals had a significant increase in fasting levels of cholesterol, nonesterified free fatty acids, and triacylglycerol. The increase in cholesterol was mainly within the high density lipoprotein fraction, while the increase in triacylglycerol was within the very low density lipoprotein fraction. Null animals had lower fasting serum glucose levels when compared with wild type controls. Uptake of H-3-labeled oleate was significantly reduced in adipocytes from null mice. However, the decrease was limited to the low ratios of fatty acid:bovine serum albumin, suggesting that CD36 was necessary for the high affinity component of the uptake process. The data provide evidence for a functional role for CD36 in lipoprotein/fatty acid metabolism that was previously underappreciated.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Cornell University; Cornell University; Cornell University; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Febbraio, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058559, P50HL056987, R01HL042540] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P0 HL56987, 2R01 HL42540, 1R29 HL58559-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ASHKENAS J, 1993, J LIPID RES, V34, P983; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCOLO G, 1973, CLIN CHEM, V19, P476; Calvo D, 1998, J LIPID RES, V39, P777; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DOI T, 1993, J BIOL CHEM, V268, P2126; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FADOK VA, 1992, J IMMUNOL, V148, P2207; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1992, BLOOD, V80, P1105; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HARMON CM, 1992, BIOCHEM SOC T, V20, P811, DOI 10.1042/bst0200811; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; Huh HY, 1996, BLOOD, V87, P2020; Hwang EH, 1998, J NUCL MED, V39, P1681; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RICHIERI GV, 1995, J LIPID RES, V36, P229; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Ryeom SW, 1996, J CELL SCI, V109, P387; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCANES CG, 1994, COMP BIOCHEM PHYS C, V107, P243, DOI 10.1016/1367-8280(94)90047-7; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI DOI 10.1177/000456326900600108; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WANTANABE K, 1998, JPN CIRC J, V62, P541; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	97	622	641	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19055	19062		10.1074/jbc.274.27.19055	http://dx.doi.org/10.1074/jbc.274.27.19055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383407	hybrid			2022-12-25	WOS:000081196300030
J	Giovanni, A; Wirtz-Brugger, F; Keramaris, E; Slack, R; Park, DS				Giovanni, A; Wirtz-Brugger, F; Keramaris, E; Slack, R; Park, DS			Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F center dot DP, in B-amyloid-induced neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; DNA-DAMAGING AGENTS; RETINOBLASTOMA PROTEIN; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; PC12 CELLS; PROMOTE SURVIVAL; BETA-PEPTIDE; EXPRESSION; INHIBITORS	Previous evidence by others has indicated that a variety of cell cycle-related molecules are up-regulated in brains of Alzheimer's disease patients. The significance of this increase, however, is unclear. Accordingly, we examined the obligate nature of cyclin-dependent kinases and select downstream targets of these kinases in death of neurons evoked by B-amyloid (AB) protein. We present pharmacological and molecular biological evidence that cyclin dependent kinases, in particular Cdk4/6, are required for such neuronal death. In addition, we demonstrate that the substrate of Cdk4/6, pRb/ p107, is phosphorylated during AB treatment and that one target of pRb/p107, the E2F.DP complex, is required for AB-evoked neuronal death. These results provide evidence that cell cycle elements play a required role in death of neurons evoked by AB and suggest that these elements play an integral role in Alzheimer's disease-related neuronal death.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Hoechst Marion Roussel, Neurosci, Bridgewater, NJ 08807 USA	University of Ottawa	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835				BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Berry DE, 1996, ONCOGENE, V12, P1809; BURDICK D, 1992, J BIOL CHEM, V267, P546; Busser J, 1998, J NEUROSCI, V18, P2801; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COTMAN CW, 1994, BETA AMYLOID ITS CON, P305; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Fan GS, 1996, ONCOGENE, V12, P1909; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARK RJ, 1995, J NEUROSCI, V15, P6239; McShea A, 1997, AM J PATHOL, V150, P1933; NEVINS JR, 1992, SCIENCE, V258, P424; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLUHA W, 1996, MOL CELL BIOL, V16, P1334; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RUSH DK, 1992, NEUROBIOL AGING, V13, P591, DOI 10.1016/0197-4580(92)90061-2; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Vincent I, 1997, J NEUROSCI, V17, P3588; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	42	210	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19011	19016		10.1074/jbc.274.27.19011	http://dx.doi.org/10.1074/jbc.274.27.19011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383401	hybrid			2022-12-25	WOS:000081196300024
J	Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS				Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS			Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THALASSEMIC ERYTHROCYTES; PLASMODIUM-FALCIPARUM; RODENT MALARIA; QUINOLINE ANTIMALARIALS; DRUG ACCUMULATION; IN-VITRO; CHLOROQUINE; HEMATIN; MECHANISM; POLYMERIZATION	Endoperoxide antimalarials based on the ancient Chinese drug Qinghaosu (artemisinin) are currently our major hope in the fight against drug-resistant malaria. Rational drug design based on artemisinin and its analogues is slow as the mechanism of action of these antimalarials is not clear. Here we report that these drugs, at least in part, exert their effect by interfering with the plasmodial hemoglobin catabolic pathway and inhibition of heme polymerization. In an in vitro experiment we observed inhibition of digestive vacuole proteolytic activity of malarial parasite by artemisinin, These observations were further confirmed by ex vivo experiments showing accumulation of hemoglobin in the parasites treated with artemisinin, suggesting inhibition of hemoglobin degradation. We found artemisinin to be a potent inhibitor of heme polymerization activity mediated by Plasmodium yoelii lysates as well as Plasmodium falciparum histidine-rich protein II. Interaction of artemisinin with the purified malarial hemozoin in vitro resulted in the concentration-dependent breakdown of the malaria pigment. Our results presented here may explain the selective and rapid toxicity of these drugs on mature, hemozoin-containing, stages of malarial parasite. Since artemisinin and its analogues appear to have similar molecular targets as chloroquine despite having different structures, they can potentially bypass the quinoline resistance machinery of the malarial parasite, which causes sublethal accumulation of these drugs in resistant strains.	Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, New Delhi 110067, India; Cent Drug Res Inst, Div Biochem, Lucknow 226001, Uttar Pradesh, India; RML Avadh Univ, Dept Biochem, Faizabad 224001, Uttar Pradesh, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Chauhan, VS (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, Aruna Asaf Ali Marg,POB 10504, New Delhi 110067, India.	virender@icgeb.res.in	Pandey, Amit V/AAO-6442-2020; Pandey, Amit V/A-7223-2008; Chauhan, Virander S./K-5276-2019	Pandey, Amit V/0000-0001-8331-5902; Pandey, Amit V/0000-0001-8331-5902; 				Adams PA, 1996, BIOCHEM J, V318, P25, DOI 10.1042/bj3180025; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bohle DS, 1997, J BIOL CHEM, V272, P713, DOI 10.1074/jbc.272.2.713; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; CAILLARD V, 1992, EXP PARASITOL, V75, P449, DOI 10.1016/0014-4894(92)90258-C; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Fitch CD, 1996, MOL BIOCHEM PARASIT, V82, P261, DOI 10.1016/0166-6851(96)02744-2; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GEARY TG, 1989, AM J TROP MED HYG, V40, P240, DOI 10.4269/ajtmh.1989.40.240; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Grigorov M, 1997, J CHEM INF COMP SCI, V37, P124, DOI 10.1021/ci9601168; HIEN TT, 1993, LANCET, V341, P603; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Ignatushchenko MV, 1997, FEBS LETT, V409, P67, DOI 10.1016/S0014-5793(97)00405-5; Jefford CW, 1996, HELV CHIM ACTA, V79, P1475, DOI 10.1002/hlca.19960790520; KAMCHONWONGPAISAN S, 1994, J CLIN INVEST, V93, P467, DOI 10.1172/JCI116994; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P238, DOI 10.4269/ajtmh.1999.60.238; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B; Mohapatra PK, 1996, INDIAN J MED RES, V104, P284; Newton P, 1999, ANNU REV MED, V50, P179, DOI 10.1146/annurev.med.50.1.179; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Paitayatat S, 1997, J MED CHEM, V40, P633, DOI 10.1021/jm960767v; PANDEY AV, 1995, BIOMED RES-TOKYO, V16, P115, DOI 10.2220/biomedres.16.115; Pandey AV, 1999, ANAL BIOCHEM, V268, P159, DOI 10.1006/abio.1998.2997; Pandey AV, 1997, FEBS LETT, V402, P236, DOI 10.1016/S0014-5793(96)01536-0; Pandey AV, 1998, CURR SCI INDIA, V75, P911; Pandey AV, 1997, MOL BIOCHEM PARASIT, V90, P281, DOI 10.1016/S0166-6851(97)00161-8; Pandey AV, 1999, J PHARMACEUT BIOMED, V20, P203, DOI 10.1016/S0731-7085(99)00021-7; Pandey AV, 1996, FEBS LETT, V393, P189, DOI 10.1016/0014-5793(96)00881-2; PETERS W, 1986, ANN TROP MED PARASIT, V80, P483, DOI 10.1080/00034983.1986.11812054; Platel DFN, 1999, MOL BIOCHEM PARASIT, V98, P215, DOI 10.1016/S0166-6851(98)00170-4; Ridley RG, 1997, ANN TROP MED PARASIT, V91, P559, DOI 10.1080/00034989760932; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHERR L, 1995, AIDS CARE, V7, P85; SHUKLA KL, 1995, J MOL GRAPHICS, V13, P215, DOI 10.1016/0263-7855(94)00001-9; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; Vattanaviboon P, 1998, MOL PHARMACOL, V53, P492, DOI 10.1124/mol.53.3.492; WELLEMS TE, 1992, NATURE, V355, P108, DOI 10.1038/355108a0; YANG YZ, 1993, BIOCHEM PHARMACOL, V46, P336, DOI 10.1016/0006-2952(93)90425-V	59	200	207	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19383	19388		10.1074/jbc.274.27.19383	http://dx.doi.org/10.1074/jbc.274.27.19383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383451	hybrid			2022-12-25	WOS:000081196300074
J	Allgayer, H; Wang, H; Gallick, GE; Crabtree, A; Mazar, A; Jones, T; Kraker, AJ; Boyd, DD				Allgayer, H; Wang, H; Gallick, GE; Crabtree, A; Mazar, A; Jones, T; Kraker, AJ; Boyd, DD			Transcriptional induction of the urokinase receptor gene by a constitutively active Src - Requirement of an upstream motif (-152/-135) bound with Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; CELL-LINE; POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; TUMOR PROMOTERS; GROWTH-FACTOR; COLON-CANCER; A431 CELLS; C-JUN; EXPRESSION	Since c-src overexpression increases colonic cell invasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colon cancers, the present study was undertaken: 1) to determine if a constitutively active Src regulates urokinase receptor expression and 2) to identify required cis-elements and trans-acting factors. SW480 colon cancer cells transfected with an expression plasmid (c-srcY527F) encoding a constitutively active Src protein manifested increased urokinase receptor gene expression and Src activity. Treatment of the src transfectants with a Src-inhibitor (PD173955) reduced urokinase receptor protein levels and laminin degradation. Inasmuch as we recently implicated an upstream region of the urokinase receptor promoter (-152/-135) in constitutive urokinase receptor expression, we determined its role for the induction by src, Whereas the activity of a CAT reporter driven by this region was stimulated by c-srcY527F, the u-PAR promoter mutated at the Spl-binding motif in the -152/-135 region was not. Nuclear extracts from the src transfectants demonstrated increased Spl binding to region -152/-135 compared with those from SW480 cells. Finally, endogenous urokinase receptor protein amounts in 10 colon cancers and corresponding normal colon correlated with Src specific activity. These data suggest that urokinase receptor gene expression is regulated by Src partly via increased Spl binding.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@notes.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906, R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [P01 DE11906, R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Barvian M. R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P176; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CASEY JR, 1994, BLOOD, V84, P1151; CONESE M, 1994, J BIOL CHEM, V269, P17886; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Ishidoh K, 1997, BIOCHEM BIOPH RES CO, V238, P665, DOI 10.1006/bbrc.1997.7349; JONES TR, 1998, Patent No. 121230; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KARIKO K, 1993, CANCER RES, V53, P3109; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Pories SE, 1998, GASTROENTEROLOGY, V114, P1287, DOI 10.1016/S0016-5085(98)70435-4; QUATTRONE A, 1995, CANCER RES, V55, P90; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xing RH, 1997, CANCER RES, V57, P3585; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	55	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18428	18437		10.1074/jbc.274.26.18428	http://dx.doi.org/10.1074/jbc.274.26.18428			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373450	hybrid			2022-12-25	WOS:000081056700042
J	Yamazaki, T; Hamano, Y; Tashiro, H; Itoh, K; Nakano, H; Miyatake, S; Saito, T				Yamazaki, T; Hamano, Y; Tashiro, H; Itoh, K; Nakano, H; Miyatake, S; Saito, T			CAST, a novel CD3 epsilon-binding protein transducing activation signal for interleukin-2 production in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-BETA-CHAIN; ANTIGEN RECEPTOR; TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; CD3 COMPLEX; GRB2; MICE; PHOSPHOPROTEIN; EXPRESSION; CLONING	Antigen recognition through T cell receptor (TCR)CD3 complex transduces signals into T cells, which regulate activation, function, and differentiation of T cells. The TCR-CD3 complex is composed of two signaling modules represented by CD3 zeta and CD3 epsilon. Signaling through CD3 zeta has been extensively analyzed, but that via CD3 epsilon, which is also crucial in immature thymocyte development, is still not clearly understood. We isolated cDNA encoding a novel CD3 epsilon-binding protein CAST. CAST specifically interacts in vivo and in vitro with CD3 epsilon but not with CD3 zeta or FcR gamma via a unique membrane-proximal region of CD3 epsilon. CAST is composed of 512 amino acids including a single tyrosine and undergoes tyrosine phosphorylation upon TCR stimulation. Overexpression of two dominant-negative types of CAST, a minimum CD3 epsilon-binding domain and a tyrosine-mutant, strongly suppressed NFAT activation and interleukin-2 production. These results demonstrate that CAST serves as a component of preformed TCR complex and transduces activation signals upon TCR stimulation and represents a new signaling pathway via the CD3 epsilon-containing TCR signaling module.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan	Chiba University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Saito, Takashi/C-9684-2009	Saito, Takashi/0000-0001-9495-3547; Nakano, Hiroyasu/0000-0003-4843-1427				AOE T, 1994, INT IMMUNOL, V6, P1671, DOI 10.1093/intimm/6.11.1671; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSRELO XR, 1992, NATURE, V356, P68; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fusaki N, 1996, J IMMUNOL, V156, P1369; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KUWABARA I, 1994, J IMMUNOL, V152, P2148; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Levelt CN, 1995, IMMUNITY, V3, P667, DOI 10.1016/1074-7613(95)90056-X; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5450; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Takase K, 1997, J IMMUNOL, V159, P741; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	39	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18173	18180		10.1074/jbc.274.26.18173	http://dx.doi.org/10.1074/jbc.274.26.18173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373416	hybrid			2022-12-25	WOS:000081056700008
J	Yamin, R; Malgeri, EG; Sloane, JA; McGraw, WT; Abraham, CR				Yamin, R; Malgeri, EG; Sloane, JA; McGraw, WT; Abraham, CR			Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; CULTURED-CELLS; DISEASE BRAIN; CATHEPSIN-D; RAT-BRAIN; MONOCLONAL-ANTIBODIES; THIMET OLIGOPEPTIDASE; LIPOPROTEIN RECEPTOR; ENDOPEPTIDASE 24.15; PRECURSOR PROTEIN	We have investigated the functional relationship between metalloendopeptidase EC 3.4.24.15 (MP24.15) and the amyloid precursor protein involved in Alzheimer's disease (AD) and discovered that the enzyme promotes A beta degradation. We show here that conditioned medium (CM) of MP24.15 antisense-transfected SKNMC neuroblastoma has significantly higher levels of A beta, Furthermore, synthetic-A beta degradation was increased or decreased following incubation with CM of sense or antisense-transfected cells, respectively, Soluble A beta 1-42 was degraded more slowly than soluble A beta 1-40, while aggregated A beta 1-42 showed almost no degradation. Pretreatment of CM with serine proteinase inhibitors 4-(2-aminoethyl)benzenesulfonyl fluoride and diisopropyl fluorophosphate completely inhibited A beta degradation. Additionally, alpha(1)-antichymotrypsin (ACT), a serpin family inhibitor tightly associated with plaques and elevated in AD brain, blocked up to 60% of A beta degradation. Interestingly, incubation of CM of MP24.15-overexpressing cells with ACT formed an SDS-resistant ACT complex, suggesting an ACT-serine proteinase interaction. Recombinant MP24.15 alone did not degrade A beta, C-14-Diisopropyl fluorophosphate-radiolabeled CM from MP24.15-overexpressing cells contained increased levels of several active serine proteinases, suggesting that MP24.15 activates one or more A beta-degrading serine proteases. Thus, ACT may cause A beta accumulation by inhibiting an A beta-degrading enzyme or by direct binding to A beta, rendering it degradation-resistant. Identification of the A beta-degrading enzyme and MP24.15's role in its activation is underway. Pharmacological modulation of either enzyme may provide a means of regulating A beta in the brain.	Boston Univ, Sch Med, Dept Biochem & Med, Boston, MA 02118 USA	Boston University	Abraham, CR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K-6, Boston, MA 02118 USA.			Abraham, Carmela/0000-0002-6649-1960; Sloane, Jacob/0000-0003-0028-3031	NIA NIH HHS [AG00001, AG09905] Funding Source: Medline; NINDS NIH HHS [NS07152] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009905] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; Bai JPF, 1996, J PHARM PHARMACOL, V48, P1180, DOI 10.1111/j.2042-7158.1996.tb03917.x; Banks WA, 1996, NEUROTOXICOL TERATOL, V18, P671, DOI 10.1016/S0892-0362(96)00084-0; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; Brown AM, 1996, J NEUROCHEM, V66, P2436; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Christie RH, 1996, AM J PATHOL, V148, P399; Conn KJ, 1996, J NEUROCHEM, V66, P2011; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1993, PEPTIDES, V14, P593, DOI 10.1016/0196-9781(93)90150-F; Du YS, 1997, J NEUROCHEM, V69, P299; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; ICHAI C, 1994, J NEUROCHEM, V62, P645; Janciauskiene S, 1998, J BIOL CHEM, V273, P28360, DOI 10.1074/jbc.273.43.28360; KATZMAN R, 1994, ALZHEIMER DIS; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOJ A, 1985, ACUTE PHASE RESPONSE; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matsumoto A, 1996, NEUROSCI LETT, V220, P159, DOI 10.1016/S0304-3940(96)13235-3; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; Mentlein R, 1998, J NEUROCHEM, V70, P721; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; Narita M, 1997, J NEUROCHEM, V69, P1904; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PAPASTOITSIS G, 1994, BIOCHEMISTRY-US, V33, P192, DOI 10.1021/bi00167a025; POTTER H, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P275; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TARASCON JM, 1995, Patent No. 5424205; THOMPSON A, 1995, BIOCHEM BIOPH RES CO, V213, P66, DOI 10.1006/bbrc.1995.2099; Thompson A, 1997, MOL BRAIN RES, V48, P206, DOI 10.1016/S0169-328X(97)00091-0; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; Waters SM, 1997, ANN NY ACAD SCI, V814, P30, DOI 10.1111/j.1749-6632.1997.tb46142.x; WISNIEWSKI HM, 1994, NEUROPATH APPL NEURO, V20, P192; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	51	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18777	18784		10.1074/jbc.274.26.18777	http://dx.doi.org/10.1074/jbc.274.26.18777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373494	hybrid			2022-12-25	WOS:000081056700086
J	Alejo, A; Andres, G; Vinuela, E; Salas, ML				Alejo, A; Andres, G; Vinuela, E; Salas, ML			The African swine fever virus prenyltransferase is an integral membrane trans-geranylgeranyl-diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN FARNESYLTRANSFERASE; DELTA-ANTIGEN; PURIFICATION; PRODUCT; ISOPRENYLATION; PRENYLATION; SEPARATION; BINDING; RELEASE	previous study, it was shown that the protein encoded by the gene B318L of African swine fever virus (ASFV) is a trans-prenyltransferase that catalyzes in vitro the condensation of farnesyl diphosphate and isopentenyl diphosphate to synthesize geranylgeranyl diphosphate and longer chain prenyl diphosphates (Alejo, A., Yanez, R. J., Rodriguez, J. M., Vinuela, II., and Salas, M. L. (1997) J. Biol. Chem. 272, 9417-9423), To investigate the in vivo function of the viral enzyme, we have determined, in this work, its subcellular localization and activity in cell extracts, Two systems were used in these studies: cells infected with ASFV and cells infected with a recombinant pseudo-Sindbis virus carrying the complete B318L gene. In this latter system, the trans-prenyltransferase was found to colocalize with the endoplasmic reticulum marker protein-disulfide isomerase, whereas in cells infected with ASFV, the viral enzyme was present in cytoplasmic viral assembly sites, associated with precursor viral membranes derived from the endoplasmic reticulum. In addition, after subcellular fractionation, the viral enzyme partitioned into the membrane fraction. Extraction of membrane proteins with alkaline carbonate and Triton X-114 indicated that the ASFV enzyme behaved as an integral membrane protein. The membrane enzyme synthesized predominantly all-trans-geranylgeranyl diphosphate from farnesyl diphosphate and isopentenyl diphosphate, These results indicate that the viral B318L protein is a trans-geranylgeranyl-diphosphate synthase, being the only enzyme of this type that is known to have a membrane localization.	Autonomous Univ Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, ML (corresponding author), Autonomous Univ Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Andres, German/E-2632-2016; Alejo, Ali/AAF-1477-2020	Andres, German/0000-0003-0265-5409; Alejo, Ali/0000-0002-1613-6063				Alejo A, 1997, J BIOL CHEM, V272, P9417, DOI 10.1074/jbc.272.14.9417; Andres G, 1997, J VIROL, V71, P2331; Andres G, 1998, J VIROL, V72, P8988; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; Costa J. V., 1990, Molecular Biology of Iridoviruses., P247; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; ERICSSON J, 1993, J BIOL CHEM, V268, P832; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; Garcia-Escudero R, 1998, J VIROL, V72, P3185; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Otto JC, 1996, J BIOL CHEM, V271, P4569; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rouiller I, 1998, J VIROL, V72, P2373, DOI 10.1128/JVI.72.3.2373-2387.1998; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; Tschantz WR, 1997, J BIOL CHEM, V272, P9989; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	38	17	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18033	18039		10.1074/jbc.274.25.18033	http://dx.doi.org/10.1074/jbc.274.25.18033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364254	Green Published, hybrid			2022-12-25	WOS:000080974300090
J	McGee, AW; Bredt, DS				McGee, AW; Bredt, DS			Identification of an intramolecular interaction between the SH3 and guanylate kinase domains of PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS VULVAR INDUCTION; NITRIC-OXIDE SYNTHASE; TUMOR SUPPRESSOR GENE; POSTSYNAPTIC DENSITY; TYROSINE KINASE; PDZ DOMAINS; PROTEIN; FAMILY; DLG; LOCALIZATION	Postsynaptic density-95 (PSD-95/SAP-90) is a member of the membrane-associated guanylate kinase (MAGUK) family of proteins that assemble protein complexes at synapses and other cell junctions. MAGUKs comprise multiple protein-protein interaction motifs including PDZ, SH3 and guanylate kinase (GK) domains, and these binding sites mediate the scaffolding function of MAGUK proteins, Synaptic binding partners for the PDZ and GK domains of PSD-95 have been identified, but the role of the SH3 domain remains elusive. We now report that the SH3 domain of PSD-95 mediates a specific interaction with the GK domain. The GK domain lacks a poly-proline motif that typically binds to SH3 domains; instead, SH3/GK binding is a bi-domain interaction that requires both intact motifs. Although isolated SH3 and GK domains can bind in trans, experiments with intact PSD-95 molecules indicate that intramolecular SH3/GK binding dominates and prevents intermolecular associations. SH3/GK binding is conserved in the related Drosophila MAGUK protein DLG but is not detectable for Caenorhabditis elegans LIN-2. Many previously identified genetic mutations of MAGUKs in invertebrates occur in the SH3 or GK domains, and all of these mutations disrupt intramolecular SH3/GK binding.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Neurosci Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Bredt, David/J-4872-2012		NIGMS NIH HHS [R01 GM36017] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	23	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17431	17436		10.1074/jbc.274.25.17431	http://dx.doi.org/10.1074/jbc.274.25.17431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364172	hybrid			2022-12-25	WOS:000080974300008
J	Obrietan, K; Impey, S; Smith, D; Athos, J; Storm, DR				Obrietan, K; Impey, S; Smith, D; Athos, J; Storm, DR			Circadian regulation of cAMP response element-mediated gene expression in the Suprachiasmatic nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR ANTAGONISTS; C-FOS TRANSCRIPTION; CREB PHOSPHORYLATION; MESSENGER-RNA; GROWTH-FACTOR; BIOLOGICAL CLOCK; DROSOPHILA-MELANOGASTER; MEMBRANE DEPOLARIZATION; SOMATOSTATIN GENE; JUNB PROMOTER	A program of stringently-regulated gene expression is thought to be a fundamental component of the circadian clock Although recent work has implicated a role for E-box-dependent transcription in circadian rhythmicity, the contribution of other enhancer elements has yet to be assessed. Here, we report that cells of the supra-chiasmatic nuclei (SCN) exhibit a prominent circadian oscillation in cAMP response dement (CRE)-mediated gene expression. Maximal reporter gene expression occurred from late-subjective night to mid-subjective day. Cycling of CRE-dependent transcription was not observed in other brain regions, including the supraoptic nucleus and piriform cortex. Levels of the phospho-active form of the transcription factor CREB (P-CBEB) varied as a function of circadian time, peak P-CREB levels occurred during the mid- to late-subjective night. Furthermore, photic stimulation during the subjective might, but not during the subjective day, triggered a marked increase in CRE-mediated gene expression in the SCN. Reporter gene experiments showed that activation of the p44/42 mitogen-activated protein kinase signaling cascade is required for Ca2+-dependent stimulation of CRE-mediated transcription in the SCN. These findings reveal the CREB/CRE transcriptional pathway to be circadian-regulated within the SCN, and raise the possibility that this pathway provides signaling information essential for normal clock function.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, D-429 Hlth Sci Bldg,Box 357280, Seattle, WA 98195 USA.	dstorm@u.washington.edu			NIMH NIH HHS [F32 MH 11857-01] Funding Source: Medline; NINDS NIH HHS [NS 37056] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037056] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Amato SF, 1996, J IMMUNOL, V157, P146; Ban Y, 1997, J NEUROSCI, V17, P3920; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CARD JP, 1981, J NEUROSCI, V1, P1289; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; COLWELL CS, 1991, BRAIN RES, V554, P105, DOI 10.1016/0006-8993(91)90177-W; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1990, J BIOL CHEM, V265, P10274; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Ding JM, 1997, J NEUROSCI, V17, P667; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GLASS JD, 1993, AM J PHYSIOL, V265, pR504, DOI 10.1152/ajpregu.1993.265.3.R504; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAMADA T, 1993, AM J PHYSIOL, V265, pR1199, DOI 10.1152/ajpregu.1993.265.5.R1199; Hannibal J, 1997, J NEUROSCI, V17, P2637, DOI 10.1523/jneurosci.17-07-02637.1997; Hastings MH, 1996, PROG BRAIN RES, V111, P147, DOI 10.1016/S0079-6123(08)60406-9; Honma S, 1996, AM J PHYSIOL-REG I, V271, pR579, DOI 10.1152/ajpregu.1996.271.3.R579; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Iwasaki Y, 1997, ENDOCRINOLOGY, V138, P5266, DOI 10.1210/en.138.12.5266; KALSBEEK A, 1995, BRAIN RES, V682, P75, DOI 10.1016/0006-8993(95)00324-J; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; KYRIACOU CP, 1980, P NATL ACAD SCI-BIOL, V77, P6729, DOI 10.1073/pnas.77.11.6729; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; LIOU SY, 1986, BRAIN RES BULL, V16, P527, DOI 10.1016/0361-9230(86)90182-6; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; PARDY K, 1992, J BIOL CHEM, V267, P21746; PIGGINS HD, 1995, J NEUROSCI, V15, P5612; PROSSER RA, 1994, MOL BRAIN RES, V25, P151, DOI 10.1016/0169-328X(94)90292-5; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shinohara K, 1998, NEUROREPORT, V9, P137, DOI 10.1097/00001756-199801050-00027; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tentler JJ, 1997, MOL ENDOCRINOL, V11, P859, DOI 10.1210/me.11.7.859; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VANDENPOL AN, 1993, NEUROSCIENCE, V56, P793, DOI 10.1016/0306-4522(93)90128-3; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANG J, 1994, MOL CELL NEUROSCI, V5, P97, DOI 10.1006/mcne.1994.1011; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	74	230	234	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17748	17756		10.1074/jbc.274.25.17748	http://dx.doi.org/10.1074/jbc.274.25.17748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364217	hybrid			2022-12-25	WOS:000080974300053
J	Shi, Y; Ratnayake, DB; Okamoto, K; Abe, N; Yamamoto, K; Nakayama, K				Shi, Y; Ratnayake, DB; Okamoto, K; Abe, N; Yamamoto, K; Nakayama, K			Genetic analyses of proteolysis, hemoglobin finding, and hemagglutination of Porphyromonas gingivalis - Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE LYS-GINGIPAIN; CYSTEINE PROTEINASE; ARG-GINGIPAIN; BACTEROIDES-GINGIVALIS; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS; BINDING PROTEIN; ENCODING GENES	Porphyromonas gingivalis produces arginine-specific cysteine proteinase (Arg-gingipain, RGP) and lysine-specific cysteine proteinase (Lys-gingipain, KGP) in the extracellular and cell-associated forms. Two separate genes (rgpA and rgpB) and a single gene (kgp) have been found to encode RGP and KGP, respectively. We constructed rgpA rgpB kgp triple mutants by homologous recombination with cloned rgp and kgp DNA interrupted by drug resistance gene markers. The triple mutants showed no RGP or KGP activity in either cell extracts or culture supernatants. The culture supernatants of the triple mutants grown in a rich medium had no proteolytic activity toward bovine serum albumin or gelatin derived from human type I collagen. Moreover, the mutants did not grow in a defined medium containing bovine serum albumin as the sole carbon/energy source. These results indicate that the proteolytic activity of P, gingivalis toward bovine serum albumin and gelatin derived from human type I collagen appears to be attributable to RGP and KGP. The hemagglutinin gene hagA of P. gingivalis possesses the adhesin domain regions responsible for hemagglutination and hemoglobin binding that are also located in the C-terminal ;regions of rgpA and kgp. A rgpA kgp hagA triple mutant constructed in this study exhibited no hemagglutination using sheep erythrocytes or hemoglobin binding activity, as determined by a solid-phase binding assay with horseradish peroxidase-conjugated human hemoglobin, indicating that the adhesin domains seem to be particularly important for P. gingivalis cells to agglutinate erythrocytes and bind hemoglobin, leading to heme acquisition.	Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Nakayama, K (corresponding author), Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, 3-1-1, Fukuoka 8128582, Japan.							Aduse-Opoku J, 1998, INFECT IMMUN, V66, P1594, DOI 10.1128/IAI.66.4.1594-1600.1998; AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; AMANO A, 1995, FEMS MICROBIOL LETT, V134, P63, DOI 10.1111/j.1574-6968.1995.tb07915.x; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; Booth V, 1997, J PERIODONTAL RES, V32, P54, DOI 10.1111/j.1600-0765.1997.tb01382.x; Curtis MA, 1996, INFECT IMMUN, V64, P2532, DOI 10.1128/IAI.64.7.2532-2539.1996; FELDHAUS MJ, 1991, J BACTERIOL, V173, P4540, DOI 10.1128/JB.173.14.4540-4543.1991; FLETCHER HM, 1995, INFECT IMMUN, V63, P1521, DOI 10.1128/IAI.63.4.1521-1528.1995; FUJIMURA S, 1995, FEMS IMMUNOL MED MIC, V10, P109; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; GMUR R, 1988, ORAL MICROBIOL IMMUN, V3, P181, DOI 10.1111/j.1399-302X.1988.tb00007.x; Haffajee A D, 1994, Periodontol 2000, V5, P78, DOI 10.1111/j.1600-0757.1994.tb00020.x; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; ISOGAI H, 1988, ARCH ORAL BIOL, V33, P479, DOI 10.1016/0003-9969(88)90028-3; Kadowaki T, 1998, J BIOL CHEM, V273, P29072, DOI 10.1074/jbc.273.44.29072; KATO T, 1992, J BACTERIOL, V174, P3889, DOI 10.1128/jb.174.12.3889-3895.1992; Kelly CG, 1997, CLIN EXP IMMUNOL, V110, P285; KISHORE AR, 1992, J MED MICROBIOL, V37, P341, DOI 10.1099/00222615-37-5-341; Kuboniwa M, 1998, BIOCHEM BIOPH RES CO, V249, P38, DOI 10.1006/bbrc.1998.8958; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepine G, 1996, ORAL MICROBIOL IMMUN, V11, P65, DOI 10.1111/j.1399-302X.1996.tb00339.x; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; Milner P, 1996, FEMS MICROBIOL LETT, V140, P125, DOI 10.1016/0378-1097(96)00159-0; MILOLAJCZYKPAWL.J, 1998, BIOL CHEM H-S, V379, P205; Nakayama K, 1996, J BACTERIOL, V178, P2818, DOI 10.1128/jb.178.10.2818-2824.1996; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; OGAWA T, 1994, INFECT IMMUN, V62, P3305, DOI 10.1128/IAI.62.8.3305-3310.1994; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; OKUDA K, 1981, CURR MICROBIOL, V6, P7, DOI 10.1007/BF01566718; PARK Y, 1993, INFECT IMMUN, V61, P4139, DOI 10.1128/IAI.61.10.4139-4146.1993; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; PROGULSKEFOX A, 1995, ORAL MICROBIOL IMMUN, V10, P311, DOI 10.1111/j.1399-302X.1995.tb00160.x; SHAH HN, 1987, CURR MICROBIOL, V15, P241, DOI 10.1007/BF01589374; Shibata Y, 1999, J BIOL CHEM, V274, P5012, DOI 10.1074/jbc.274.8.5012; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; SLOTS J, 1978, INFECT IMMUN, V19, P254, DOI 10.1128/IAI.19.1.254-264.1978; Watanabe-Kato T, 1998, MICROB PATHOGENESIS, V24, P25, DOI 10.1006/mpat.1997.0170; YOSHIMURA F, 1984, J BACTERIOL, V160, P949, DOI 10.1128/JB.160.3.949-957.1984	44	286	298	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17955	17960		10.1074/jbc.274.25.17955	http://dx.doi.org/10.1074/jbc.274.25.17955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364243	hybrid			2022-12-25	WOS:000080974300079
J	Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A				Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A			The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel and nuclear co-regulators	ONCOGENE			English	Article						oncogene; coactivator; chromatin; gene regulation; signal transduction	CANDIDATE PROTOONCOGENE BCL-3; DNA-BINDING; B PROTEINS; TRANSCRIPTIONAL ACTIVATION; P50 HOMODIMERS; HUMAN GENES; IN-VIVO; BRCA1; ENCODES; PHOSPHORYLATION	The proto-oncoprotein Bcl-3 is a member of the I kappa B family and is present predominantly in the nucleus. To gain insight into specific nuclear functions of Bcl-3 we have isolated proteins that interact with its ankyrin repeat domain. Using the yeast two-hybrid-system we identified four novel binding partners of Bcl-3 in addition to NF-kappa B p50 and p52, previously known to associate with Bcl-3. The novel Bcl-3 interactors Jab1, Pirin, Tip60 and Bard1 are nuclear proteins which also bind to other transcription factors including c-Jun, nuclear factor I (NFI), HIV-1 Tat or the tumor suppressor and Polll holoenzyme component Brca1, respectively. Bcl-3, p50, and either Bard1, Tip60 or Pirin are sequestered into quarternary complexes on NF-kappa B DSA binding sites, whereas Jab1 enhances p50-Bcl-3-DNA complex formation. Furthermore, the histone acetylase Tip60 enhances Bcl-3-p50 activated transcription through an NF-kappa B binding site, indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappa B driven gene expression, These data implicate Bcl-3 as an adaptor between NF-kappa B p50/p52 and other transcription regulators and suggest that its gene activation function may at least in part be due to recruitment of the Tip60 histone actetylase.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 078, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Asahikawa Medical College	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Ansieau, Stephane/I-6195-2016; Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; ANSIEAU, Stephane/0000-0003-0989-2108; Heissmeyer, Vigo/0000-0002-2263-8545				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	42	256	267	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3316	3323		10.1038/sj.onc.1202717	http://dx.doi.org/10.1038/sj.onc.1202717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362352				2022-12-25	WOS:000080589300002
J	Anthony, ML; Zhao, M; Brindle, KM				Anthony, ML; Zhao, M; Brindle, KM			Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; INTRACELLULAR ACIDIFICATION; DNA FRAGMENTATION; LEUKEMIA-CELLS; CDP-CHOLINE; DEATH; FARNESOL; ACTIVATION; CHOLINEPHOSPHOTRANSFERASE	Induction of apoptosis in HL-60 cells, using a variety of cytotoxic drugs, resulted, in all cases, in inhibition of CDP-choline:1,2-diacylglycerol choline phosphotransferase, leading to an accumulation of its substrate, CDP-choline, and inhibition of phosphatidylcholine biosynthesis. Incubation of the cells with phosphatidylcholine reduced the number displaying an apoptotic morphology following drug treatment, and this was inversely related to the degree to which the drugs inhibited phosphatidylcholine biosynthesis. Inhibition of choline phosphotransferase by two of the drugs, farnesol and chelerythrine, was shown to be due to direct inhibition of the enzyme, while inhibition by the other drugs, etoposide and camptothecin, could be explained by the intracellular acidification that followed induction of apoptosis.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd,Old Addenbrookes Site, Cambridge CB2 1GA, England.	k.m.brindle@bioc.cam.ac.uk						Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Chen Q, 1997, J CELL SCI, V110, P379; Chmura SJ, 1997, CANCER RES, V57, P4340; CHU AJ, 1994, INT J BIOCHEM, V26, P189, DOI 10.1016/0020-711X(94)90144-9; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Furlong IJ, 1997, J CELL SCI, V110, P653; GONG JP, 1993, J CELL PHYSIOL, V157, P263; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; Ishaque A, 1997, GENET ENG BIOTECHNOL, V17, P85; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; JARVIS WD, 1994, CANCER RES, V54, P1707; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kleuser B, 1998, CANCER RES, V58, P1817; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P100, DOI 10.1016/S0005-2760(97)00097-0; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MELNYKOVYCH G, 1992, BIOCHEM BIOPH RES CO, V186, P543, DOI 10.1016/S0006-291X(05)80842-3; Miquel K, 1996, BIOCHEM BIOPH RES CO, V225, P869, DOI 10.1006/bbrc.1996.1265; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Pardhasaradhi BVV, 1997, FEBS LETT, V411, P67, DOI 10.1016/S0014-5793(97)00665-0; Park HJ, 1996, EUR J CANCER, V32A, P540, DOI 10.1016/0959-8049(95)00606-0; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SUIDAN HS, 1993, J NEUROSCI, V13, P1190; TANIGUCHI S, 1986, J BIOCHEM-TOKYO, V100, P485, DOI 10.1093/oxfordjournals.jbchem.a121737; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VOZIYAN PA, 1993, BIOCHEM J, V295, P757, DOI 10.1042/bj2950757; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Williams SNO, 1998, MAGNET RESON MED, V40, P411, DOI 10.1002/mrm.1910400311; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOSHIDA A, 1993, BIOCHEM BIOPH RES CO, V196, P927, DOI 10.1006/bbrc.1993.2338	55	119	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19686	19692		10.1074/jbc.274.28.19686	http://dx.doi.org/10.1074/jbc.274.28.19686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391908	hybrid			2022-12-25	WOS:000081377300028
J	Mozzherin, DJ; Tan, CK; Downey, KM; Fisher, PA				Mozzherin, DJ; Tan, CK; Downey, KM; Fisher, PA			Architecture of the active DNA polymerase delta center dot proliferating cell nuclear antigen center dot template-primer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; REPLICATION INVITRO; ENZYMOLOGIC MECHANISM; AUXILIARY PROTEIN; CATALYTIC SUBUNIT; IN-VITRO; CIS-SYN; PURIFICATION; BINDING; ALPHA	The relative positions of components of the DNA-dependent DNA polymerase delta (pol delta) proliferating cell nuclear antigen (PCNA) DNA complex were studied. We have shown that pol delta incorporates nucleotides close to a template biotin-streptavidin complex located 5' (downstream) to the replicating complex in the presence or absence of PCNA. PCNA-dependent synthesis catalyzed by pol delta was nearly totally (95%) inhibited by a biotin streptavidin complex located at the 3'-end of a template with a 15-mer primer (upstream of the replicating complex), but was only partially inhibited with a 19-mer primer. With either primer, PCNA-independent synthesis was not affected by the biotin streptavidin complex. Quantification of results with primers of varying length suggested that pol delta interacts with between 8 and 10 nucleotides of duplex DNA immediately proximal to the 3'-OH primer terminus. Using UV photocross-linking, we determined that the 125-kDa subunit of pol delta, but not the 50-kDa subunit, interacted with a photosensitive residue of a substrate oligonucleotide, Interaction apparently takes place through the C terminus of p125, Based on these results, we conclude that PCNA is located "behind" pol delta in the polymerization complex during DNA synthesis and that only the large subunit of pol delta (two-subunit form) interacts directly with DNA. A detailed model of the enzymatically active complex is proposed.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem, Miami, FL 33101 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Miami; University of Miami	Fisher, PA (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	paul@pharm.sunysb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26206] Funding Source: Medline; NIEHS NIH HHS [ES-04068] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1994, PROG NUCLEIC ACID RE, V47, P371, DOI 10.1016/S0079-6603(08)60257-3; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hindges R, 1997, BIOL CHEM, V378, P345; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Latham GJ, 1997, J BIOL CHEM, V272, P31685, DOI 10.1074/jbc.272.50.31685; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; NG L, 1991, J BIOL CHEM, V266, P11699; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740	35	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19862	19867		10.1074/jbc.274.28.19862	http://dx.doi.org/10.1074/jbc.274.28.19862			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391931	hybrid			2022-12-25	WOS:000081377300051
J	Ramjaun, AR; Philie, J; de Heuvel, E; McPherson, PS				Ramjaun, AR; Philie, J; de Heuvel, E; McPherson, PS			The N terminus of amphiphysin II mediates dimerization and plasma membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CLATHRIN-COATED PITS; SH3 DOMAIN; NERVE-TERMINALS; DEPENDENT DEPHOSPHORYLATION; SPLICE VARIANTS; BINDING-SITE; DYNAMIN; PROTEIN; BRAIN	Amphiphysin I and II are nerve terminal-enriched proteins containing SH3 domains that interact with dynamin and synaptojanin. The amphiphysins may function in synaptic vesicle endocytosis by targeting synaptojanin and dynamin to emerging endocytic buds through SH3 domain-independent interactions with clathrin and AP2, We have recently identified and cloned several amphiphysin II splice variants that differentially incorporate clathrin-binding domains. To determine whether these domains function in membrane targeting, we used immunofluorescence to examine the potential localization of amphiphysin II variants to clathrin-coated pits on plasma membranes purified from transfected COS-7 cells. Full-length amphiphysin II targets to the plasma membrane where it partially co-localizes with clathrin. However, splice variants and deletion constructs lacking clathrin-binding domains still target to the plasma membrane, and removal of clathrin from the membrane does not affect amphiphysin II distribution. Surprisingly, plasma membrane targeting was dependent on the presence of a 31-amino acid alternatively spliced sequence at the N terminus of amphiphysin II, a result confirmed using subcellular fractionation, In binding assays, the 31-amino acid sequence was also found to facilitate amphiphysin dimerization mediated through the N terminus, Taken together, these data support a role for the N terminus of amphiphysin II in membrane targeting during endocytosis.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.	mcpm@musica.mcgill.ca						Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Slepnev VI, 1998, MOL BIOL CELL, V9, p197A; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	43	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19785	19791		10.1074/jbc.274.28.19785	http://dx.doi.org/10.1074/jbc.274.28.19785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391921	hybrid			2022-12-25	WOS:000081377300041
J	Ancellin, N; Hla, T				Ancellin, N; Hla, T			Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SWISS 3T3 FIBROBLASTS; LYSOPHOSPHATIDIC ACID; CELLULAR-RESPONSES; KINASE ACTIVATION; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; CELLS; PROLIFERATION; PATHWAYS	Sphingosine 1-phosphate (SPP) is a potent lipid mediator released upon cellular activation. In this report, pharmacological properties of the three G-protein-coupled receptors (GPCRs) for SPP, EDG-1, -3, and -5 are characterized using a Xenopus oocyte expression system, which lacks endogenous SPP receptors. Microinjection of the EDG-3 and EDG-5 but not EDG-1 mRNA conferred SPP-responsive intracellular calcium transients; however, the EDG-5 response was quantitatively much less. Go-expression of EDG-1 receptor with the chimeric G(alpha qi) protein conferred SPP responsiveness. G(alpha qi) or G(alpha q) co-injection also potentiated the EDG-5 and EDG-3 mediated responses to SPP. These data suggest that SPP receptors couple differentially to the G(q) and G(i) pathway. All three GPCRs were also activated by sphingosylphosphorylcholine, albeit at higher concentrations. None of the other related sphingolipids tested stimulated or blocked SPP-induced calcium responses. However, suramin, a polycyclic anionic compound, selectively antagonized SPP-activated calcium transients in EDG-3 expressing oocytes with an IC50 of 22 mu M, suggesting that it is an antagonist selective for the EDG-3 GPCR isotype. We conclude that the three SPP receptors signal differentially by coupling to different G-proteins. Furthermore, because only EDG-3 was antagonized by suramin, variations in receptor structure may determine differences in antagonist selectivity. This property may be exploited to synthesize receptor subtype-specific antagonists.	Univ Connecticut, Ctr Hlth, Sch Med, Dept Physiol,Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Sch Med, Dept Physiol,Ctr Vasc Biol, MC-3505,263 Farmington Ave, Farmington, CT 06030 USA.	hla@sun.uchc.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL54710] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BARNARD EA, 1987, NEUROCHEMISTRY PRACT, P243; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA T, 1999, IN PRESS BIOCH PHARM; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Klingler C, 1998, CELL SIGNAL, V10, P65, DOI 10.1016/S0898-6568(97)00077-6; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOCHEM, V121, P969; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	40	222	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18997	19002		10.1074/jbc.274.27.18997	http://dx.doi.org/10.1074/jbc.274.27.18997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383399	hybrid			2022-12-25	WOS:000081196300022
J	Lange, H; Kispal, G; Lill, R				Lange, H; Kispal, G; Lill, R			Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; FRIEDREICHS-ATAXIA; MOLECULAR-BIOLOGY; PROTEIN IMPORT; TRANSLOCATION; FERROCHELATASE; ACCUMULATION; HOMOLOG; IDENTIFICATION	The import of metals, iron in particular, into mitochondria is poorly understood. Iron in mitochondria is required for the biosynthesis of heme and various iron-sulfur proteins. We have developed an in vitro assay to follow the uptake of iron into isolated yeast mitochondria. By measuring the incorporation of iron into porphyrin by ferrochelatase in the matrix, we were able to define the mechanism of iron import. Iron uptake is driven energetically by a membrane potential across the inner membrane but does not require ATP, Only reduced iron is functional in generating heme, Iron cannot be preloaded in the mitochondrial matrix but rather has to be transported across the inner membrane simultaneously with the synthesis of hems, suggesting that ferrochelatase receives iron directly from the inner membrane, Transport of iron is inhibited by manganese but not by zinc, nickel, and copper ions, explaining why in vivo these ions are not incorporated into porphyrin. The inner membrane proteins Mmt1p and Mmt2p proposed to be involved in mitochondrial iron movement are not required for the supply of ferrochelatase with iron. Iron transport can be reconstituted efficiently in a membrane potential-dependent fashion in proteoliposomes that were formed from a detergent extract of mitochondria. Our biochemical analysis of iron import into yeast mitochondria provides the basis for the identification of components involved in transport.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Pecs, Sch Med, Inst Biochem, H-7624 Pecs, Hungary	Philipps University Marburg; University of Pecs	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.			Lill, Roland/0000-0002-8345-6518; Lange, Heike/0000-0002-8222-3448				ABBAS A, 1993, J BIOL CHEM, V268, P8541; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CEDERBAUM AI, 1972, J BIOL CHEM, V247, P4593; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; EGYED A, 1982, BIOCH PHYSL IRON, P103; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; KISPAL G, 1988, J BIOL CHEM, V263, P11145; KLAUSNER RD, 1994, FEBS LETT, V355, P109, DOI 10.1016/0014-5793(94)01111-7; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KONOPKA K, 1980, EUR J BIOCHEM, V107, P433; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; Labbe-Bois Rosine, 1994, V11, P413; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Reissbrodt R, 1997, J BACTERIOL, V179, P4538, DOI 10.1128/jb.179.14.4538-4544.1997; Sambrook J., 2002, MOL CLONING LAB MANU; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STRICKLAND EH, 1965, BIOCHIM BIOPHYS ACTA, V104, P596, DOI 10.1016/0304-4165(65)90367-3; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	46	131	136	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18989	18996		10.1074/jbc.274.27.18989	http://dx.doi.org/10.1074/jbc.274.27.18989			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383398	hybrid			2022-12-25	WOS:000081196300021
J	Meuller, J; Rydstrom, J				Meuller, J; Rydstrom, J			The membrane topology of proton-pumping Escherichia coli transhydrogenase determined by cysteine labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE ALPHA-HELICES; POLYMERASE CHAIN-REACTION; RHODOSPIRILLUM-RUBRUM; BETA-SUBUNIT; AMINO-ACID; PROTEINS; ENZYME; PREDICTION	The membrane topology of proton-pumping nicotinamide-nucleotide transhydrogenase from Escherichia coli was determined by site-specific chemical labeling, A His-tagged cysteine-free transhydrogenase was used to introduce unique cysteines in positions corresponding to potential membrane loops. The cysteines mere reacted with fluorescent reagents, fluorescein 5-maleimide or 2-[(4'-maleimidyl)anilino]naphthalene-6-sulfonic acid, in both intact cells and inside-out vesicles. Labeled transhydrogenase was purified with a small-scale procedure using a metal affinity resin, and the amount of labeling was measured as fluorescence on UV-illuminated acrylamide gels. The difference in labeling between intact cells and inside-out vesicles was used to discriminate between a periplasmic and a cytosolic location of the residues. The membrane region was found to be composed of 13 helices (four in the alpha-subunit and nine in the beta-subunit), with the C terminus of the alpha-subunit and the N terminus of the beta-subunit facing the cytosolic and periplasmic sides, respectively. These results differ from previous models with regard to both number of helices and the relative location and orientation of certain helices. This study constitutes the first in which all transmembrane segments of transhydrogenase have been experimentally determined and provides an explanation for the different topologies of the mitochondrial and E. coli transhydrogenases.	Univ Gothenburg, Dept Chem, Div Biochem & Biophys, S-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-40530 Gothenburg, Sweden	University of Gothenburg; Chalmers University of Technology	Rydstrom, J (corresponding author), Univ Gothenburg, Dept Chem, Div Biochem & Biophys, Medicinaregatan 9C,POB 462, S-40530 Gothenburg, Sweden.		Rydström, Jan/A-7683-2010					AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; Bizouam T, 1997, BBA-BIOENERGETICS, V1322, P19, DOI 10.1016/S0005-2728(97)00065-0; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; CLARKE DM, 1985, J BACTERIOL, V162, P367, DOI 10.1128/JB.162.1.367-373.1985; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; GLAVAS NA, 1995, BIOCHEM BIOPH RES CO, V214, P230, DOI 10.1006/bbrc.1995.2279; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P47; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kimura T, 1997, J BIOL CHEM, V272, P580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Meuller J, 1997, BIOCHEM J, V324, P681, DOI 10.1042/bj3240681; Moore DD, 1995, GLOB MOB SURV; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROST B, 1995, PROTEIN SCI, V4, P521; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P17020; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	38	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19072	19080		10.1074/jbc.274.27.19072	http://dx.doi.org/10.1074/jbc.274.27.19072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383409	hybrid			2022-12-25	WOS:000081196300032
J	Resendes, MC; Dobransky, T; Ferguson, SSG; Rylett, RJ				Resendes, MC; Dobransky, T; Ferguson, SSG; Rylett, RJ			Nuclear localization of the 82-kDa form of human choline acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; GENE-EXPRESSION; MESSENGER-RNA; RAT-BRAIN; IN-VIVO; PROTEIN; CELLS; ACETYLCHOLINE; ENZYME; IDENTIFICATION	Choline acetyltransferase is the enzyme catalyzing synthesis of the neurotransmitter acetylcholine in cholinergic neurons. In human, transcripts encoding two forms of the enzyme with apparent molecular masses of 69 and 82 kDa are found in brain and spinal cord; the 82-kDa form differs from the 69-kDa enzyme only in terms of a 118-amino acid extension on its amino terminus. Using green fluorescent protein-tagged choline acetyltransferase, we show that the 82-kDa enzyme is targeted to nuclei of cells, whereas the 69-kDa protein is found in cytoplasm. Expression of site-directed and deletion mutants of the 82-kDa isoform reveals that the extended amino terminus contains a nuclear localization signal in the first nine amino acids which targets the protein to nucleus. This represents the first report of a neurotransmitter-synthesizing enzyme that is localized to the cell nucleus.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada; John P Robarts Res Inst, Neurodegenerat Dis Grp, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.		Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; BADAMCHIAN M, 1986, NEUROCHEM INT, V9, P409, DOI 10.1016/0197-0186(86)90083-5; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; Chatterjee S, 1997, EXP CELL RES, V236, P346, DOI 10.1006/excr.1997.3746; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HERSH LB, 1984, J BIOL CHEM, V259, P1253; IRAURRALDE E, 1998, RNA NY, V4, P351; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LIND GJ, 1995, INVEST OPHTH VIS SCI, V36, P1492; Misawa H, 1997, MOL BRAIN RES, V44, P323, DOI 10.1016/S0169-328X(96)00231-8; MISAWA H, 1992, J BIOL CHEM, V267, P20392; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Moroianu J, 1997, CRIT REV EUKAR GENE, V7, P61, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.40; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ODA Y, 1992, MOL BRAIN RES, V16, P287, DOI 10.1016/0169-328X(92)90237-6; Oda Y, 1996, MOL BRAIN RES, V38, P135, DOI 10.1016/0169-328X(95)00280-6; Pahud G, 1998, EUR J NEUROSCI, V10, P1644, DOI 10.1046/j.1460-9568.1998.00177.x; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RYLETT RJ, 1993, J NEUROCHEM, V61, P1388, DOI 10.1111/j.1471-4159.1993.tb13632.x; SALEM N, 1994, EUR J NEUROSCI, V6, P737, DOI 10.1111/j.1460-9568.1994.tb00985.x; SCHMIDT BM, 1993, J NEUROCHEM, V61, P1774, DOI 10.1111/j.1471-4159.1993.tb09815.x; SLEMMON JR, 1991, MOL BRAIN RES, V9, P245; TUCEK S, 1993, PROG BIOPHYS MOL BIO, V60, P59, DOI 10.1016/0079-6107(93)90013-A; WU DH, 1994, J NEUROCHEM, V62, P1653	31	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19417	19421		10.1074/jbc.274.27.19417	http://dx.doi.org/10.1074/jbc.274.27.19417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383456	hybrid			2022-12-25	WOS:000081196300079
J	Rachubinski, RA; Marcus, SL; Capone, JP				Rachubinski, RA; Marcus, SL; Capone, JP			The p56(lck)-interacting protein p62 stimulates transcription via the SV40 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-INDEPENDENT LIGAND; MURINE PERITONEAL-MACROPHAGES; UBIQUITOUS NUCLEAR PROTEINS; A170 STRESS PROTEIN; BINDING-PROTEIN; SH2 DOMAIN; MAMMALIAN-CELLS; INVITRO BINDING; GENE; ELEMENTS	p62 is a recently identified ubiquitin-binding, cytosolic phosphoprotein that interacts with several signal transduction molecules including the tyrosine kinase p56(lck) and the protein kinase C-zeta, p62 is therefore suggested to serve an important role in signal transduction in the cell, although the physiological function of p62 remains undefined. Here we demonstrate by transient transfection assays that p62 stimulates the transcription of reporter genes linked to the simian virus 40 (SV40) enhancer. A putative p62-responsive element was localized to the B domain of the distal 72-base pair repeat of the SV40 enhancer. p62 was unable to bind this element in vitro, nor was it able to activate transcription when directly tethered to a promoter, suggesting that p62 stimulates transcription via an indirect mechanism. Stimulation of transcription mediated by p62 was dependent on its amino-terminal region, which is also necessary for interaction with cell surface signaling molecules. These findings indicate that p62 may link extracellular signals directly to transcriptional responses, and identify the SV40 enhancer as a downstream target for signal transduction pathways in which p62 participates.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	McMaster University; University of Alberta	Capone, JP (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	caponej@fhs.csu.mcmaster.ca						ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lee YH, 1998, FEBS LETT, V438, P297, DOI 10.1016/S0014-5793(98)01323-4; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; Marcus SL, 1996, J BIOL CHEM, V271, P27197, DOI 10.1074/jbc.271.44.27197; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yanagawa T, 1997, BIOCHEM BIOPH RES CO, V241, P157, DOI 10.1006/bbrc.1997.7783; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	33	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18278	18284		10.1074/jbc.274.26.18278	http://dx.doi.org/10.1074/jbc.274.26.18278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373430	hybrid			2022-12-25	WOS:000081056700022
J	Liao, WC; Haimovitz-Friedman, A; Persaud, RS; McLoughlin, M; Ehleiter, D; Zhang, N; Gatei, M; Lavin, M; Kolesnick, R; Fuks, Z				Liao, WC; Haimovitz-Friedman, A; Persaud, RS; McLoughlin, M; Ehleiter, D; Zhang, N; Gatei, M; Lavin, M; Kolesnick, R; Fuks, Z			Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; DEPENDENT PROTEIN-KINASE; CELL-CYCLE CHECKPOINT; EPSTEIN-BARR-VIRUS; DOUBLE-STRAND BREAKS; ATM-DEFICIENT MICE; IONIZING-RADIATION; MAMMALIAN-CELLS; SPHINGOLIPID BIOSYNTHESIS; CHROMOSOMAL-ABERRATIONS	DNA double-stranded breaks (dsb) activate surveillance systems that identify DNA damage and either initiate repair or signal cell death. Failure of cells to undergo appropriate death in response to DNA damage leads to misrepair, mutations, and neoplastic transformation. Pathways linking DNA dsb to reproductive or apoptotic death are virtually unknown. Here we report that metabolic incorporation of I-125-labeled 5-iodo-2'deoxyuridine, which produces DNA dsb, signaled de novo ceramide synthesis by post-translational activation of ceramide synthase (CS) and apoptosis. CS activation was obligatory, since fumonisin B1, a fungal pathogen that acts as a specific CS inhibitor, abrogated DNA damage-induced death. X-irradiation yielded similar results. Furthermore, inhibition of apoptosis using the peptide caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone did not affect CS activation, indicating this event is not a consequence of induction of apoptosis. ATM, the gene mutated in ataxia telangiectasia, isa member of the phosphatidylinositol 3-kinase family that constitutes the DNA damage surveillance/repair system. Epstein-Barr virus-immortalized B cell lines from six ataxia telangiectasia patients with different mutations exhibited radiation-induced CS activation, ceramide generation, and apoptosis, whereas three lines from normal patients failed to manifest these responses. Stable transfection of wild type ATM cDNA reversed these events, whereas antisense inactivation of ataxia telangiectasia-mutated gene product in normal B cells conferred the ataxia telangiectasia phenotype. We propose that one of the functions of ataxia telangiectasia-mutated gene product is to constrain activation of CS, thereby regulating DNA damage-induced apoptosis.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Lavin, Martin/F-5961-2014	Lavin, Martin/0000-0002-5940-4769	NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AllalunisTurner J, 1997, RADIAT RES, V147, P284, DOI 10.2307/3579334; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEDFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457, DOI 10.1016/0360-3016(91)90320-4; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHARLTON DE, 1986, RADIAT RES, V107, P163, DOI 10.2307/3576804; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garzotto M, 1998, CANCER RES, V58, P2260; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Haimovitz-Friedman, 1996, Semin Radiat Oncol, V6, P273, DOI 10.1016/S1053-4296(96)80023-3; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOFER KG, 1975, INT J RADIAT BIOL, V28, P225, DOI 10.1080/09553007514550991; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; KASSIS AI, 1982, RADIAT RES, V90, P362, DOI 10.2307/3575714; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1993, ONCOGENE, V8, P3307; KINSELLA TJ, 1987, INT J RADIAT ONCOL, V13, P733, DOI 10.1016/0360-3016(87)90292-6; Krisch R E, 1978, Curr Top Radiat Res Q, V12, P355; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEMOTTE PK, 1984, CANCER RES, V44, P1337; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTIN RF, 1981, SCIENCE, V213, P896, DOI 10.1126/science.7256283; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; RADFORD IR, 1985, INT J RADIAT BIOL, V48, P555, DOI 10.1080/09553008514551611; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Telatar M, 1996, AM J HUM GENET, V59, P40; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; Vidair CA, 1996, CANCER RES, V56, P4116; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; YASUI LS, 1986, INT J RADIAT BIOL, V49, P601; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; ZHANG N, 1998, ONCOGENE, V58, P2260; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	73	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17908	17917		10.1074/jbc.274.25.17908	http://dx.doi.org/10.1074/jbc.274.25.17908			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364237	hybrid			2022-12-25	WOS:000080974300073
J	Maekawa, T; Bernier, F; Sato, M; Nomura, S; Singh, M; Inoue, Y; Tokunaga, T; Imai, H; Yokoyama, M; Reimold, A; Glimcher, LH; Ishii, S				Maekawa, T; Bernier, F; Sato, M; Nomura, S; Singh, M; Inoue, Y; Tokunaga, T; Imai, H; Yokoyama, M; Reimold, A; Glimcher, LH; Ishii, S			Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; TRANSCRIPTION FACTORS; GENE-EXPRESSION; BINDING PROTEIN; CDNA CLONES; CRE-BP1; ANGIOGENESIS; HYPOXIA; FAMILY; CREB	Mouse null mutants of transcription factor ATF-2 were generated by the gene targeting method. They died shortly after birth and displayed symptoms of severe respiratory distress with lungs filled with meconium, These features are similar to those of a severe type of human meconium aspiration syndrome. The increased expression of the hypoxia inducible genes suggests that hypoxia occurs in the mutant embryos and that it may lead to strong gasping respiration with: consequent aspiration of the amniotic fluid containing meconium. A reduced number of cytotrophoblast cells in the mutant placenta was found and may be responsible for an insufficient supply of oxygen prior to birth. Using the cDNA subtraction and microarray-based expression monitoring method, the expression level of the platelet-derived growth factor receptor a gene, which plays an important role in the proliferation of trophoblasts, was found to be low in the cytotrophoblasts of the mutant placenta. In addition, ATF-S can trans-activate the PDGF receptor a gene promoter in the co-transfection assay. These results indicate the important role of ATF-S in the formation of the placenta and the relationship between placental anomalies and neonatal respiratory distress. The ATF-S null mutants should enhance our understanding of the mechanism of severe neonatal respiratory distress.	RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0600815, Japan; Natl Inst Anim Ind, Inashiki, Ibaraki 3050901, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1940031, Japan; Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	RIKEN; Osaka University; Hokkaido University; National Agriculture & Food Research Organization - Japan; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Bernier, Francois/AAP-2174-2020; Bernier, Francois/V-7150-2018; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478	NIAID NIH HHS [AI32412] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032412] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFINK GB, 1995, ONCOGENE, V10, P1667; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BLOCK MF, 1981, OBSTET GYNECOL, V57, P37; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Floros J, 1998, ANNU REV PHYSIOL, V60, P365, DOI 10.1146/annurev.physiol.60.1.365; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENOUGH A, 1995, EARLY HUM DEV, V41, P183, DOI 10.1016/0378-3782(95)01625-D; GUPTA S, 1995, SCIENCE, V267, P339; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KATZ VL, 1992, AM J OBSTET GYNECOL, V166, P171, DOI 10.1016/0002-9378(92)91856-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; NOMURA N, 1993, J BIOL CHEM, V268, P4259; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKEDA J, 1991, ONCOGENE, V6, P1009; Thureen PJ, 1997, AM J OBSTET GYNECOL, V176, P967, DOI 10.1016/S0002-9378(97)70387-9; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; VANDAM H, 1997, EMBO J, V14, P31798; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	31	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17813	17819		10.1074/jbc.274.25.17813	http://dx.doi.org/10.1074/jbc.274.25.17813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364225	hybrid			2022-12-25	WOS:000080974300061
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SMOOTH-MUSCLE; ADENYLYL-CYCLASE; DEPENDENT PHOSPHORYLATION; PHOSPHOLIPASE C-BETA-3; KINASE-A; INHIBITION; MEMBRANES; PATHWAY; CELLS	We have shown recently that the 37-amino acid intracellular domain of the single-transmembrane, natriuretic peptide clearance receptor, NPR-C, which is devoid of kinase and guanylyl cyclase activities, activates selectively G(i1) and G(i2) in gastric and tenia coli smooth muscle. In this study, we have used synthetic peptide fragments of the N-terminal, C-terminal, and middle regions of the cytoplasmic domain of NPR-C to identify the G protein-activating sequence. A 17-amino acid peptide of the middle region (Arg(469)-Arg(485)), denoted Peptide 4, which possesses two N-terminal arginine residues and a C-terminal B-B-X-X-B motif (where B and X are basic and non-basic residues, respectively) bound selectively to G(i1) and G(i2), activated phospholipase C-beta 3 via the py subunits, inhibited adenylyl cyclase, :and induced smooth muscle contraction, in similar fashion to the selective NPR-C ligand, cANP4-23, A similar sequence (Peptide 3), but with a partial C-terminal motif, lead minimal activity. Sequences which possessed either the N-terminal basic residues (Peptide 1) or the C-terminal B-B-X-X-B motif (Peptide 2) were inactive. Peptide 2, however, inhibited G; protein activation and cellular responses mediated by the stimulatory Peptide 4 and by cANP4-23, suggesting that the B-B-X-X-B motif mediated binding but not activation of G protein, thus causing Peptide 2 to act as a competitive inhibitor of G protein activation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Murthy, KS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, POB 980711, Richmond, VA 23298 USA.				NIDDK NIH HHS [DK28300, DK15564] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564, R01DK028300] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; Bianciotti LG, 1998, BIOCHEM BIOPH RES CO, V247, P123, DOI 10.1006/bbrc.1998.8753; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAI LJ, 1993, AM J PHYSIOL, V265, pF592, DOI 10.1152/ajprenal.1993.265.4.F592; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; JAMISON RL, 1992, AM J KIDNEY DIS, V20, P519, DOI 10.1016/S0272-6386(12)70269-X; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; Murthy KS, 1996, MOL PHARMACOL, V50, P870; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V275, pC1409, DOI 10.1152/ajpcell.1998.275.6.C1409; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Teng BO, 1998, GASTROENTEROLOGY, V114, pA846, DOI 10.1016/S0016-5085(98)83447-1; Teng BQ, 1998, AM J PHYSIOL-GASTR L, V275, pG342, DOI 10.1152/ajpgi.1998.275.2.G342; UHING RJ, 1986, J BIOL CHEM, V261, P2140	31	86	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17587	17592		10.1074/jbc.274.25.17587	http://dx.doi.org/10.1074/jbc.274.25.17587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364194	hybrid			2022-12-25	WOS:000080974300030
J	Tate, CG; Whiteley, E; Betenbaugh, MJ				Tate, CG; Whiteley, E; Betenbaugh, MJ			Molecular chaperones stimulate the functional expression of the cocaine-sensitive serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; DEPENDENT REDUCTASE ERP57; N-LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; P-GLYCOPROTEIN; INSECT CELLS; NOREPINEPHRINE TRANSPORTER; BACULOVIRUS EXPRESSION; CALNEXIN P88; CALRETICULIN	The serotonin transporter (SERT) is an N-glycosylated integral membrane protein that is predicted to contain 12 transmembrane regions. SERT is the major binding site in the brain for antidepressant drugs, and it also binds amphetamines and cocaine. The ability of various molecular chaperones to interact with a tagged version of SERT (Myc-SERT) was investigated using the baculovirus expression system. Overexpression of Myc-SERT using the baculovirus system led to substantial quantities of inactive transporter, together with small amounts of fully active and, therefore, correctly folded molecules. The high levels of inactive Myc-SERT probably arose because folding was rate-limiting due, perhaps, to insufficient molecular chaperones. Therefore, Myc-SERT was co-expressed with the endoplasmic reticulum (ER) molecular chaperones calnexin, calreticulin and immunoglobulin heavy chain binding protein (BiP), and the foldase, ERp57, The expression of functional Myc-SERT, as determined by an inhibitor binding assay, was enhanced nearly 3-fold by co-expressing calnexin, and to a lesser degree on co-expression of calreticulin and BiP, Go-expression of ERp57 did not increase the functional expression of Myc-SERT. A physical interaction between Myc-SERT-calnexin and Myc-SERT-calreticulin was demonstrated by co-immunoprecipitation. These associations were inhibited in vivo by deoxynojirimycin, an inhibitor of N-glycan precusor trimming that is known to prevent the calnexin/calreticulin-N-glycan interaction. Functional expression of the unglycosylated SERT mutant, SERT-QQ, was also increased on co-expression of calnexin, suggesting that the interaction between calnexin and SERT is not entirely dictated by the N-glycan, SERT is the first member of the neurotransmitter transporter family whose folding has been shown to be assisted by the molecular chaperones calnexin, calreticulin, and BiP.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	MRC Laboratory Molecular Biology; Johns Hopkins University	Tate, CG (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659; Tate, Christopher/0000-0002-2008-9183				ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Lenhard T, 1997, BIOCHEM BIOPH RES CO, V238, P823, DOI 10.1006/bbrc.1997.7395; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PIND S, 1994, J BIOL CHEM, V269, P12784; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Possee RD., 1992, BACULOVIRUS EXPRESSI; QIAN Y, 1995, J NEUROSCI, V15, P1261; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Smith J, 1996, BIOTECHNIQUES, V20, P1082; SMITH JM, 1990, COMPUT APPL BIOSCI, V6, P93; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; TATE CG, 1994, J BIOL CHEM, V269, P26303; Tate CG, 1998, METHOD ENZYMOL, V296, P443; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG JB, 1995, J NEUROCHEM, V64, P1416; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WORRALL DM, 1994, BIOCHEM J, V297, P425, DOI 10.1042/bj2970425; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	56	73	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17551	17558		10.1074/jbc.274.25.17551	http://dx.doi.org/10.1074/jbc.274.25.17551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364189	hybrid			2022-12-25	WOS:000080974300025
J	Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC				Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC			Mutational analysis of p73 and p53 in human cancer cell lines	ONCOGENE			English	Article						p73; mutation; deletion	TUMOR-SUPPRESSOR GENE; RAS MUTATIONS; LUNG-CANCER; COLORECTAL-CANCER; CARCINOMAS; FREQUENT; PROTEIN; EXPRESSION; INHIBITOR; KINASES	p73 is a candidate tumor suppressor gene with substantial DNA and protein homology to the p53 tumor suppressor gene. We have investigated two hypotheses: (a) p73 is mutated in diverse types of human cancer, and (b) p73 is functionally redundant with p53 in carcinogenesis so that mutations would be exclusive in these two genes. The entire coding region and intronic splice junctions of p73 were examined in 54 cancer cell lines. Three lung cancer cell lines contained mutations that affected the amino acid sequence. One amino acid substitution was in a region with homology to the specific DNA binding region of p53 and two microdeletions were outside the region of homology. Two of the cell lines with p73 mutations also carried p53 mutations. Although our results are inconsistent with the two hypotheses tested, p73 mutations may contribute infrequently to the molecular pathogenesis of human lung cancer.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Room 2CD5, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODNER SM, 1992, ONCOGENE, V7, P743; CAAMANO J, 1993, AM J PATHOL, V142, P1131; EL DW, 1993, CELL, V75, P817; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 1996, CANCER RES, V56, P2130; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEHMAN TA, 1991, CANCER RES, V51, P4090; Mai M, 1998, CANCER RES, V58, P2347; METCALF RA, 1992, CANCER RES, V52, P2610; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEINADO MA, 1993, INT J ONCOL, V2, P123; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUGGERI B, 1992, ONCOGENE, V7, P1503; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SOMERS KD, 1992, CANCER RES, V52, P5997; Takahashi H, 1998, CANCER RES, V58, P2076; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3415	3421		10.1038/sj.onc.1202677	http://dx.doi.org/10.1038/sj.onc.1202677			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362363				2022-12-25	WOS:000080589300013
J	Prendergast, GC				Prendergast, GC			Myc and Myb: are the veils beginning to lift?	ONCOGENE			English	Article						transformation; apoptosis; transcription; oncogene; proliferation; cell cycle			Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.								0	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					2914	2915		10.1038/sj.onc.1202784	http://dx.doi.org/10.1038/sj.onc.1202784			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378687				2022-12-25	WOS:000080387800001
J	Kim, YG; Lowenhaupt, K; Schwartz, T; Rich, A				Kim, YG; Lowenhaupt, K; Schwartz, T; Rich, A			The interaction between Z-DNA and the Zab domain of double-stranded RNA adenosine deaminase characterized using fusion nucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOKI CLEAVAGE DOMAIN; RESTRICTION-ENDONUCLEASE; BINDING DOMAIN; EDITING ENZYME; Z-ALPHA	Zab is a structurally defined protein domain that binds specifically to DNA in the Z conformation. It consists of amino acids 133-368 from the N terminus of human double-stranded RNA adenosine deaminase, which is implicated in RNA editing. Zab contains two motifs with related sequence, Z alpha and Z beta. Z alpha alone is capable of binding Z-DNA with high affinity, whereas Z beta alone has little DNA binding activity. Instead, Z beta modulates Z alpha binding, resulting in increased sequence specificity for alternating (dCdG)(n) as compared with (dCdA/ dTdG)(n). This relative specificity has previously been demonstrated with short oligonucleotides. Here we demonstrate that Zab can also bind tightly to (dCdGr)(n) stabilized in the Z form in supercoiled plasmids, Binding was assayed by monitoring cleavage of the plasmids using fusion nucleases, in which Z-DNA-binding peptides from the N terminus of double-stranded RNA adenosine deaminase are linked to the nuclease domain of FokI, A fusion nuclease containing Z alpha shows less sequence specificity, as well as less conformation specificity, than one containing Zab, Further, a construct in which Z beta has been replaced in Zab with Z alpha, cleaves Z-DNA regions in supercoiled plasmids more efficiently than the wild type but with little sequence specificity. We conclude that in the Zab domain, both Z alpha and Z beta contact DNA, Z alpha contributes contacts that produce conformation specificity but not sequence specificity. In contrast, Z beta contributes weakly to binding affinity but discriminates between sequences of Z-DNAs.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	cbeckman@mit.edu	Schwartz, Thomas/ABA-1770-2021	Schwartz, Thomas/0000-0001-8012-1512; /0000-0002-8187-6498				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANIFORD DB, 1983, J BIOMOL STRUCT DYN, V1, P593, DOI 10.1080/07391102.1983.10507467; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; Kim YG, 1998, BIOL CHEM, V379, P489, DOI 10.1515/bchm.1998.379.4-5.489; Kim YG, 1997, GENE, V203, P43, DOI 10.1016/S0378-1119(97)00489-7; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J	20	27	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19081	19086		10.1074/jbc.274.27.19081	http://dx.doi.org/10.1074/jbc.274.27.19081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383410	hybrid			2022-12-25	WOS:000081196300033
J	Wanner, GA; Mica, L; Wanner-Schmid, E; Kolb, SA; Hentze, H; Trentz, O; Ertel, T				Wanner, GA; Mica, L; Wanner-Schmid, E; Kolb, SA; Hentze, H; Trentz, O; Ertel, T			Inhibition of caspase activity prevents CD95-mediated hepatic microvascular perfusion failure and restores Kupffer cell clearance capacity	FASEB JOURNAL			English	Article						liver failure; apoptosis; hepatic microcirculation; cysteine protease	MULTIPLE ORGAN FAILURE; FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; INDUCED LIVER-INJURY; TNF-ALPHA; HEPATOCYTE APOPTOSIS; MOUSE HEPATOCYTES; SIGNALING COMPLEX; CD95 FAS/APO-1; SOLUBLE FORM	Using a murine model, we studied the effect of agonistic anti-CD95 antibodies (aCD95) on sinusoidal lining cells and a potential protection by caspase inhibition. C3H/HeN mice were intravenously administered aCD95 (10 mu g/mouse) or unspecific IgG (control) in the presence or absence of the caspase inhibitor z-VAD-fmk, Analysis of hepatic microcirculation using intravital fluorescence microscopy revealed severe (P<0.01) sinusoidal perfusion failure and reduced (P<0.05) phagocytic activity of Kupffer cells (KC) within 2 h. Transmission electron micrographs demonstrated loss of integrity of sinusoidal endothelial cells as early as 1 h after aCD95 application, whereas histological manifestation of hepatocellular apoptosis and hemorrhagic necrosis was most pronounced at 6 h, Blocking of caspase activity attenuated (P<0.01) both hepatic microvascular perfusion failure and KC dysfunction, Accordingly, full protection of the liver from apoptotic damage and intact microarchitecture was observed in histological sections after z-VAD-fmk treatment. Mortality rate was 40% 6 h after aCD95 administration, whereas all animals survived in the z-VAD-fmk group (P<0.05), The activation of caspases through CD95 may primarily lead to damage of sinusoidal endothelial cells and hepatic microvascular perfusion failure. Moreover, reduced phagocytic capacity of KC may contribute to accumulation of toxic metabolites released by dying cells at the local site of inflammation, further aggravating liver injury.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Konstanz	Ertel, T (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Raemistr 100, CH-8091 Zurich, Switzerland.	guido.wanner@chi.usz.ch						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; BAUER I, 1995, SHOCK, V4, P324, DOI 10.1097/00024382-199511000-00003; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Gao WS, 1998, HEPATOLOGY, V27, P1652, DOI 10.1002/hep.510270626; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Ksontini R, 1998, J IMMUNOL, V160, P4082; Ksontini Riadh, 1997, Surgical Forum, V48, P58; Lawson JA, 1998, HEPATOLOGY, V28, P761, DOI 10.1002/hep.510280324; Leist M, 1998, Rev Physiol Biochem Pharmacol, V133, P109; LEIST M, 1995, AM J PATHOL, V146, P1220; LIVINGSTON DH, 1995, ANN MED, V27, P13, DOI 10.3109/07853899509031931; MACPHEE PJ, 1993, PROGR APPL MICR, V19, P52; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MENGER MD, 1993, PROGR APPL MICR, V19, P106; Muschen M, 1998, HEPATOLOGY, V27, P200, DOI 10.1002/hep.510270131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; POST S, 1992, HEPATOLOGY, V16, P803, DOI 10.1002/hep.1840160329; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; RUFF MC, 1992, NATURE, V356, P397; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shakil AO, 1997, J VIRAL HEPATITIS, V4, P107, DOI 10.1111/j.1365-2893.1997.tb00170.x; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; Suzuki A, 1998, P SOC EXP BIOL MED, V217, P450; Takehara T, 1998, HEPATOLOGY, V27, P1643, DOI 10.1002/hep.510270625; TAKEI Y, 1995, J GASTROEN HEPATOL, V10, pS65, DOI 10.1111/j.1440-1746.1995.tb01802.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vollmar B, 1997, J LEUKOCYTE BIOL, V62, P710, DOI 10.1002/jlb.62.6.710; Vollmar B, 1996, SHOCK, V6, P434, DOI 10.1097/00024382-199612000-00008; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	53	51	51	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1239	1248		10.1096/fasebj.13.10.1239	http://dx.doi.org/10.1096/fasebj.13.10.1239			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385614				2022-12-25	WOS:000081264800012
J	Evans, TC; Benner, J; Xu, MQ				Evans, TC; Benner, J; Xu, MQ			The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNPROTECTED PEPTIDES; CHEMICAL LIGATION; AUTOPROTEOLYSIS; MODULATION; SUPPORT; ELEMENT	Mini-inteins derived from Synechocystis sp. (Ssp DnaB intein) and Mycobacterium xenopi (Mxe GyrA intein) that have been modified to cleave peptide bonds at their C and N termini, respectively, were cloned in-frame to the N and C termini of a target protein. Peptide bond cleavage of the modified inteins generated an N-terminal cysteine and a C-terminal thioester on the same protein, These complementary reactive groups underwent intra- or intermolecular condensation to generate circular or polymeric protein species with a new peptide bond at the site of ligation, Three cyclic peptides, BBP, an organ specific localization peptide; RGD, an inhibitor of platelet aggregation; and CDR-H3/C2, which inhibits HIV-1 replication, were isolated using the two-intein system. BBP, RGD, and CDR-H3/C2 had masses of 977.1, 1119.9, and 2098.6 g/mol, respectively, as determined by matrix-assisted laser desorption-time of flight mass spectrometry, which agreed well with the values of 977.2, 1120.3, and 2098.3 g/mol, respectively, predicted for the cyclic species. This system was used to cyclize proteins as large as 395 amino acids. Furthermore, multimers of thioredoxin were formed upon concentration of the reactive species, indicating the potential to form novel biomaterials based on fibrous proteins.	New England Biolabs Inc, Beverly, MA 01915 USA		Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	xum@neb.com	Wood, David W/B-2992-2012					Camarero JA, 1998, J PEPT RES, V51, P303; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cotton GJ, 1999, J AM CHEM SOC, V121, P1100, DOI 10.1021/ja983804b; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; Holford M, 1998, STRUCTURE, V6, P951, DOI 10.1016/S0969-2126(98)00097-5; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; SOUTHWORTH MW, 1999, IN PRESS BIOTECHNIQU; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388; YAMAMOTO Y, 1995, CHEM LETT, P11, DOI 10.1246/cl.1995.11; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y	28	117	137	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18359	18363		10.1074/jbc.274.26.18359	http://dx.doi.org/10.1074/jbc.274.26.18359			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373440	hybrid			2022-12-25	WOS:000081056700032
J	Johnson, BW; Boise, LH				Johnson, BW; Boise, LH			Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-alpha-induced cell death in a Bcl-2 cleavage-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; CD95 FAS/APO-1; PROTEIN; ACTIVATION; PHOSPHORYLATION; RELEASE; DOMAIN	The ability of proteins of the Bcl-2 family to either induce or inhibit apoptosis is dependent on both cell type and the apoptotic stimulus. We have shown in the murine pro-B cell line FL5.12 that Bcl-2 is incapable of inhibiting tumor necrosis factor alpha (TNF alpha)-induced cell death and is cleaved during this process. One potential explanation for this observation is that caspase activation directly or indirectly inhibits Bcl-2 function. It has been suggested that caspase cleavage of Bcl-2 is responsible for its inability to block certain cell deaths. Consistent with Bcl-2 cleavage being a caspase-mediated event, this cleavage is inhibitable by 50 mu M CBZ-Val-Ala-Asp-fluoromethylketone (zVAD-fmk). Furthermore, Bcl-2 can cooperate with the caspase inhibitor zVAD-fmk in a dose-dependent manner to block TNF alpha-induced cell death. Overexpression of Bcl-2 results in a 10-fold decrease in the amount of zVAD-fmk required to inhibit TNF alpha-induced apoptosis. However, cleavage-defective mutants (D31A and D34A) show no enhanced viability relative to wild-type Bcl-2 in response to TNF alpha-induced cell death and also show the same cooperativity with zVAD-fmk. These results suggest that Bcl-2 cleavage is not important for the inhibition of TNF alpha-induced cell death but do not preclude an involvement in a post-commitment phase of apoptosis.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA; Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Miami, FL 33101 USA	University of Miami; University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.		Boise, Lawrence/AAD-2314-2019					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Fang GF, 1998, CANCER RES, V58, P3202; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hawkins C J, 1997, Semin Immunol, V9, P25, DOI 10.1006/smim.1996.0052; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; REED JC, 1996, MECH LYMPHOCYTE ACTI, V6; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18552	18558		10.1074/jbc.274.26.18552	http://dx.doi.org/10.1074/jbc.274.26.18552			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373464	hybrid			2022-12-25	WOS:000081056700056
J	Kumar, S; Talis, AL; Howley, PM				Kumar, S; Talis, AL; Howley, PM			Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-C; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTION FACTOR TFIIH; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; E6 ONCOPROTEIN; COMPLEX-FORMATION; HUMAN HOMOLOGS; BINDING-SITES	The human papilloma virus E6-associated protein (E6AP) functions as a ubiquitin protein ligase (E3) in the E6-mediated ubiquitination of p53. E6AP is also an E3 in the absence of E6, but its normal cellular substrates have not yet been identified. Here we report the identification of HHR23A, one of the human homologues of the yeast DNA repair protein Rad23, as an E6-independent target of E6AP, HHR23A binds E6AP and is ubiquitinated in. vitro in an E6AP dependent manner. Ubiquitinated forms of endogenous HHR23A are detectable in mammalian cells. Overexpression of wild-type E6AP in vivo enhances the ubiquitination of HHR23A, whereas a dominant negative E6AP mutant inhibits HHR23A ubiquitination. Although HHR23A is a stable protein in nonsynchronized cells, its levels are regulated in a cell cycle-dependent manner, with specific degradation occurring during S phase. The S phase degradation of HHR23A could be blocked in vivo by dominant negative E6AP, providing direct evidence for the involvement of E6AP in the regulation of HHR23A. Consistent with a role of the HHR23 proteins in DNA repair, UV-induced DNA damage inhibited HHR23A degradation. Although the precise role of HHR23 proteins in DNA repair and cell cycle progression remains to be elucidated, our data suggest that E6AP-mediated ubiquitination of HHR23A may have important implications in DNA repair and cell cycle progression.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Howley, PM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R01CA064888] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; BOULIKAS T, 1996, ANTICANCER RES, V16, P673; CLEAVER JE, 1989, XERODERMA PIGMENTOSU, P2949; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUKURA T, 1997, NAT GENET, V15, P1; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1990, J BIOL CHEM, V265, P3685; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; VanderSpek PJ, 1996, GENOMICS, V31, P20, DOI 10.1006/geno.1996.0004; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	55	163	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18785	18792		10.1074/jbc.274.26.18785	http://dx.doi.org/10.1074/jbc.274.26.18785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373495	hybrid			2022-12-25	WOS:000081056700087
J	Lam, MHC; House, CM; Tiganis, T; Mitchelhill, KI; Sarcevic, B; Cures, A; Ramsay, R; Kemp, BE; Martin, TJ; Gillespie, MT				Lam, MHC; House, CM; Tiganis, T; Mitchelhill, KI; Sarcevic, B; Cures, A; Ramsay, R; Kemp, BE; Martin, TJ; Gillespie, MT			Phosphorylation at the cyclin-dependent kinases site (Thr(85)) of parathyroid hormone-related protein negatively regulates its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SV40 T-ANTIGEN; NUCLEOLAR LOCALIZATION; GROWTH-FACTORS; EXPRESSION; PEPTIDE; IDENTIFICATION; TRANSPORT; SEQUENCE; CHONDROCYTES	Parathyroid hormone-related protein (PTHrP) is expressed by a wide variety of cells and is considered to act as a secreted factor; however, evidence is accumulating for it to act in an intracrine manner. We have determined that PTHrP localizes to the nucleus at the G(1) phase of the cell cycle and is transported to the cytoplasm when cells divide. PTHrP contains a putative nuclear localization sequence (NLS) (residues 61-94) similar to that of SV40 T-antigen, which may be implicated in the nuclear import of the molecule. We identified that Thr(85) immediately prior to the NLS of PTHrP was phosphorylated by CDC2-CDK2 and phosphorylation was cell cycle-dependent. Mutation of Thr(85) to Ala(85) resulted in nuclear accumulation of PTHrP, while mutation to GIu(85) to mimic a phosphorylated residue resulted in localization of PTHrP to the cytoplasm. Combined, the data demonstrate that the intracellular localization of PTHrP is phosphorylation- and cell cycle-dependent, and such control further supports a potential intracellular role (10, 34, 35) for PTHrP.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Peter Maccallum Cancer Center	Gillespie, MT (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	m.gillespie@medicine.unimelb.edu.au	Kemp, Bruce E/L-2633-2014; Ramsay, Robert G/C-3291-2015; Tiganis, Tony/AAV-3495-2020; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Ramsay, Robert G/0000-0001-5003-0433; Tiganis, Tony/0000-0002-8065-9942; Kemp, Bruce/0000-0001-6735-5082; Sarcevic, Boris/0000-0002-8063-1050; Gillespie, Matthew/0000-0001-6543-8909				AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; Goltzman D, 1992, J Endocrinol Invest, V15, P43; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; HEATH JK, 1995, BIOCHEM J, V307, P159, DOI 10.1042/bj3070159; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LI X, 1994, J BIOL CHEM, V269, P6263; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POON RYC, 1995, CURR BIOL, V5, P1243; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RANKIN W, 1995, BONE, V16, pS205; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613	37	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18559	18566		10.1074/jbc.274.26.18559	http://dx.doi.org/10.1074/jbc.274.26.18559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373465	hybrid			2022-12-25	WOS:000081056700057
J	Palma, E; Maggi, L; Barabino, B; Eusebi, F; Ballivet, M				Palma, E; Maggi, L; Barabino, B; Eusebi, F; Ballivet, M			Nicotinic acetylcholine receptors assembled from the alpha 7 and beta 3 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED HUMAN-CELLS; XENOPUS-LAEVIS OOCYTES; NEURONAL ALPHA(7); CHANNEL DOMAIN; FORMS; 5-HYDROXYTRYPTAMINE; MUTATION; MUTANTS; AGONIST; NACHRS	Intracellular recordings were performed in voltage-clamped Xenopus oocytes upon injection with a mixture of cDNAs encoding the beta 3 and mutant alpha 7 ((L247T)alpha 7) neuronal nicotinic acetylcholine receptor (nAChR) subunits. The expressed receptors maintained sensitivity to methyllycaconitine and to alpha-bungarotoxin but exhibited a functional profile strikingly different from that of the homomeric (L247T)alpha 7 receptor, The heteromeric (L247T)alpha 7 beta 3 nAChR had a lower apparent affinity and a faster rate of desensitization than L247Ta7 nAChR, exhibited nonlinearity in the I-V relationship, and was inhibited by 5-hydroxytryptamine, much like wild type alpha 7 ((WT)alpha 7) nAChR. Single channel recordings in cell-attached mode revealed unitary events with a slope conductance of 19 picosiemens and a lifetime of 5 ms, both values being much smaller than those of the homomeric receptor channel. Upon injection with a mixture of (WT)alpha 7 and beta 3 cDNAs, clear evidence was obtained for the plasma membrane assembly of heteromeric nAChRs, although ACh could not activate these receptors. It is concluded that beta 3, long believed to be an orphan subunit, readily co-assembles with other subunits to form heteromeric receptors, some of which may be negative regulators of cholinergic function.	Univ Rome La Sapienza, Ist Pasteur, Fondaz Cenci Bolognetti, I-00158 Rome, Italy; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00158 Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Lab Biofis, I-00158 Rome, Italy; Univ Geneva, Dept Biochim, CH-1211 Geneva 4, Switzerland	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Geneva	Ballivet, M (corresponding author), Biochem Sci 2,30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Palma, Eleonora/A-2775-2010; maggi, laura/H-2535-2012	Palma, Eleonora/0000-0001-6026-927X; maggi, laura/0000-0002-0566-0433	Telethon [222/BI] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALBUQUERQUE EX, 1995, SEMIN NEUROSCI, V7, P91, DOI 10.1006/smns.1995.0011; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; Bertrand S, 1997, NEUROREPORT, V8, P3591, DOI 10.1097/00001756-199711100-00034; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CRABTREE G, 1997, SOC NEUR ABSTR, V23, P157; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; Fucile S, 1997, NEUROREPORT, V8, P2433, DOI 10.1097/00001756-199707280-00005; Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GARCIACOLUNGA J, 1995, P NATL ACAD SCI USA, V92, P2919, DOI 10.1073/pnas.92.7.2919; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; Jones S, 1997, J PHYSIOL-LONDON, V504, P603, DOI 10.1111/j.1469-7793.1997.603bd.x; LINDBLADH M, 1995, VEG HIST ARCHAEOBOT, V4, P153; MATTER JM, 1995, J NEUROSCI, V15, P5910; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; Palma E, 1997, P NATL ACAD SCI USA, V94, P1539, DOI 10.1073/pnas.94.4.1539; Palma E, 1996, P NATL ACAD SCI USA, V93, P11231, DOI 10.1073/pnas.93.20.11231; Palma E, 1997, P NATL ACAD SCI USA, V94, P9915, DOI 10.1073/pnas.94.18.9915; Ragozzino D, 1997, EUR J NEUROSCI, V9, P480, DOI 10.1111/j.1460-9568.1997.tb01625.x; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Sivilotti LG, 1997, J PHYSIOL-LONDON, V500, P123, DOI 10.1113/jphysiol.1997.sp022004; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; Williams BM, 1998, NAT NEUROSCI, V1, P557, DOI 10.1038/2792; WILLOUGHBY JJ, 1993, NEUROSCI LETT, V155, P136, DOI 10.1016/0304-3940(93)90691-D; Wonnacott S., 1993, METHODS NEUROSCI, P263	39	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18335	18340		10.1074/jbc.274.26.18335	http://dx.doi.org/10.1074/jbc.274.26.18335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373437	Green Published, hybrid			2022-12-25	WOS:000081056700029
J	Van Hermelen, V; Reynisdottir, S; Cianflone, K; Degerman, E; Hoffstedt, J; Nilsell, K; Sniderman, A; Arner, P				Van Hermelen, V; Reynisdottir, S; Cianflone, K; Degerman, E; Hoffstedt, J; Nilsell, K; Sniderman, A; Arner, P			Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; HUMAN ADIPOCYTES; ALTERNATIVE PATHWAY; IN-VIVO; ANTILIPOLYTIC AGENTS; INDUCED LIPOLYSIS; KINASE-C; REESTERIFICATION; METABOLISM	The effects of acylation-stimulating protein (ASP) and insulin on free fatty acid (FFA) release from isolated human fat cells and the signal transduction pathways to induce these effects were studied. ASP and insulin inhibited basal and norepinephrine-induced FFA release by stimulating fractional FFA re-esterification (both to the same extent) and by inhibiting FFA produced during lipolysis (ASP to a lesser extent than insulin). Protein kinase C inhibition influenced none of the effects of ASP or insulin. Phosphatidylinositol S-kinase inhibition counteracted the effects of insulin but not of ASP. Phosphodiesterase 3 (PDE3) activity was stimulated by ASP and insulin, whereas PDE4 activity was slightly increased by ASP only. Selective PDES inhibition reversed the effects of both ASP and insulin on fractional FFA re-esterification and lipolysis. Selective PDE4 inhibition slightly counteracted the ASP but not the effect of insulin on fractional FFA re-esterification and did not prevent the action of ASP or insulin on lipolysis. Thus, ASP and insulin play a major role in regulating FFA release from fat cells as follows: insulin by stimulating fractional FFA re-esterification and inhibiting lipolysis and ASP mainly by stimulating fractional FFA re-esterification. For both ASP and insulin these effects on FFA release are mediated by PDES, and for ASP PDE4 might also be involved. The signaling pathway preceding PDE is not known for ASP but involves phosphatidylinositol 3-kinase for insulin.	Huddinge Univ Hosp, MK Div, Ctr Metab & Endocrinol, Karolinska Inst,Dept Med, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Res Ctr, Dept Surg, S-14186 Huddinge, Sweden; McGill Univ, Royal Victoria Hosp, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signalling, S-22100 Lund, Sweden	Karolinska Institutet; Karolinska Institutet; McGill University; Royal Victoria Hospital; Lund University	Arner, P (corresponding author), Huddinge Univ Hosp, MK Div, Ctr Metab & Endocrinol, Karolinska Inst,Dept Med, M63, S-14186 Huddinge, Sweden.	peter.arner@medhs.ki.se		Arner, Peter/0000-0002-6208-6220				ARNER P, 1991, INT J OBESITY, V15, P327; ARNER P, 1974, BIOCHIM BIOPHYS ACTA, V369, P209, DOI 10.1016/0005-2760(74)90252-5; ARNER P, 1995, INT J OBESITY, V19, P435; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BALDO A, 1995, J LIPID RES, V36, P1415; BODEN G, 1993, DIABETES, V42, P1588, DOI 10.2337/diabetes.42.11.1588; BROOKS B, 1982, FEBS LETT, V146, P327, DOI 10.1016/0014-5793(82)80945-9; CAMPBELL PJ, 1994, AM J PHYSIOL, V266, pE600, DOI 10.1152/ajpendo.1994.266.4.E600; CAMPBELL PJ, 1992, AM J PHYSIOL, V263, pE1063; Cianflone K, 1997, CLIN BIOCHEM, V30, P301, DOI 10.1016/S0009-9120(97)00011-8; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; EDENS NK, 1990, J LIPID RES, V31, P1423; ENGFELDT P, 1983, J CLIN ENDOCR METAB, V56, P501, DOI 10.1210/jcem-56-3-501; Enoksson S, 1998, DIABETOLOGIA, V41, P560, DOI 10.1007/s001250050947; FRAYN KN, 1994, AM J PHYSIOL, V266, pE308, DOI 10.1152/ajpendo.1994.266.3.E308; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; HAGSTROMTOFT E, 1995, DIABETES, V44, P1170, DOI 10.2337/diabetes.44.10.1170; HELLMER J, 1989, ANAL BIOCHEM, V177, P132, DOI 10.1016/0003-2697(89)90027-4; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KATHER H, 1988, J BIOL CHEM, V263, P8803; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Large V, 1997, INT J OBESITY, V21, P78, DOI 10.1038/sj.ijo.0800368; LEIBEL RL, 1985, AM J PHYSIOL, V248, pE140, DOI 10.1152/ajpendo.1985.248.1.E140; LEIBEL RL, 1985, AM J CLIN NUTR, V42, P198, DOI 10.1093/ajcn/42.2.198; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; LINDGREN S, 1991, BIOCHEM PHARMACOL, V42, P545, DOI 10.1016/0006-2952(91)90317-X; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; LONNQVIST F, 1989, INT J OBESITY, V13, P137; LOW GK, 1961, J BIOL CHEM, V236, P1631; MANGANIELLO VC, 1971, J BIOL CHEM, V246, P2195; MARCUS C, 1987, J CLIN INVEST, V79, P1812, DOI 10.1172/JCI113022; Maslowska M, 1997, J LIPID RES, V38, P1; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; NASLUND B, 1993, J LIPID RES, V34, P633; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RICHELSEN B, 1992, MOL CELL ENDOCRINOL, V85, P73, DOI 10.1016/0303-7207(92)90126-Q; RODBELL M, 1964, J BIOL CHEM, V239, P375; Saleh J, 1998, J LIPID RES, V39, P884; SCHREIBER RD, 1978, J EXP MED, V148, P1722, DOI 10.1084/jem.148.6.1722; SHECHTER Y, 1984, ENDOCRINOLOGY, V115, P1787, DOI 10.1210/endo-115-5-1787; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Steinberg D, 1963, Biochem Soc Symp, V24, P111; Steinberg D, 1965, HANDB PHYSIOL, P335; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; VanHarmelen V, 1997, INT J OBESITY, V21, P972, DOI 10.1038/sj.ijo.0800504; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; WALSH MJ, 1989, J SURG RES, V46, P470, DOI 10.1016/0022-4804(89)90162-5; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; Zierath JR, 1998, DIABETOLOGIA, V41, P1343, DOI 10.1007/s001250051075	53	129	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18243	18251		10.1074/jbc.274.26.18243	http://dx.doi.org/10.1074/jbc.274.26.18243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373426	hybrid			2022-12-25	WOS:000081056700018
J	Lamprecht, C; Mueller, CR				Lamprecht, C; Mueller, CR			D-site binding protein transactivation requires the proline- and acid-rich domain and involves the coactivator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ADENOVIRUS E1A; BZIP PROTEIN; GENE; DBP; PROMOTER; EXPRESSION; FAMILY	The D-site binding protein (DBP) is a member of the proline- and acid-rich (PAR) domain subfamily of basic/ leucine zipper proteins and is involved in transcriptional regulation in the liver. Deletion analysis of the DBP protein was carried out in an effort to define the function of the conserved PAR domain. Internal deletions of the protein, i.e. removing portions of the PAR domain, resulted in a substantial loss in transactivation of a high affinity DBP reporter construct when assayed in Rep G2 cells. These same sequences conferred significant transactivation to GAL4 DNA binding domain fusion proteins, indicating that this region acts as part of an independent activation domain comprised of sequences in both the amino terminus and in the PAR domain of DBP. The coexpression of full-length expression constructs for both DBP and hepatic leukemia factor resulted in a dramatic increase in activation mediated by the GAL4-DBP fusion proteins, suggesting the involvement of a regulated coactivator in this process. DBP transactivation appears to be a p300-dependent process, as a 12 S E1A expression construct disrupted DBP-mediated transactivation, and a p300 expression vector, but not a CREB binding protein vector, was able to restore DBP transactivation. These results suggest that the PAR domain is required for DBP activation, which occurs through a regulated, p300-dependent process.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Newcombe K, 1998, BIOCHEM BIOPH RES CO, V245, P633, DOI 10.1006/bbrc.1998.8467; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; PICKETTS DJ, 1994, BLOOD, V84, P2992; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; Shutler G, 1996, GENOMICS, V34, P334, DOI 10.1006/geno.1996.0295; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847	25	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17643	17648		10.1074/jbc.274.25.17643	http://dx.doi.org/10.1074/jbc.274.25.17643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364202	hybrid			2022-12-25	WOS:000080974300038
J	Sala-Newby, GB; Skladanowski, AC; Newby, AC				Sala-Newby, GB; Skladanowski, AC; Newby, AC			The mechanism of adenosine formation in cells - Cloning of cytosolic 5 '-nucleotidase-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 5'-NUCLEOTIDASE; PIGEON HEART; DOG HEART; PURIFICATION; ENZYMES; NUCLEOTIDES; EXPRESSION; INHIBITORS; METABOLITE; CDNA	Adenosine increases blood flow and decreases excitatory nerve firing. In the heart, it reduces rate and force of contraction and preconditions the heart against injury by prolonged ischemia. Based on indirect kinetic arguments, an AMP-selective cytosolic 5'-nucleotidase designated cN-I has been implicated in adenosine formation during ATP breakdown. The molecular identity of cN-I is unknown, although an IMP/GMP-selective cytosolic 5'-nucleotidase (cN-II) and an ecto-5'-nucleotidase (e-N) have been cloned. We utilized the high abundance of cN-I in pigeon heart to purify a 40-kDa subunit for partial protein sequencing and subsequent cDNA cloning. We obtained a full-length clone encoding a novel 40-kDa peptide, unrelated to cN-II or e-N, that was most abundant in heart, brain, and breast muscle. Immunolocalization in heart showed a striated cytoplasmic location, suggesting association with contractile elements. Transient expression in COS-7 cells, generated a 5'-nucleotidase that catalyzed adenosine formation from AMP, which was increased during ATP catabolism, In conclusion, the cloning and expression of cN-I provides definitive evidence of its ability to produce adenosine during ATP breakdown.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Med Univ Gdansk, Dept Biochem, PL-80211 Gdansk, Poland	University of Bristol; Fahrenheit Universities; Medical University Gdansk	Newby, AC (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	A.Newby@bris.ac.uk	Skladanowski, Andrzej C. C/B-4687-2010	Skladanowski, Andrzej C. C/0000-0003-3408-1147				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; COHEN MV, 1995, J MOL CELL CARDIOL, V27, P1527, DOI 10.1016/S0022-2828(95)90293-7; DARVISH A, 1993, AM J PHYSIOL, V264, pH1528; DARVISH A, 1993, HYPERTENSION, V21, P906, DOI 10.1161/01.HYP.21.6.906; Darvish A, 1996, CIRCULATION, V94, P722; DAVIS LG, 1995, BASIC METHODS MOL BI, P143; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; GORDON EL, 1986, J BIOL CHEM, V261, P5496; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; NEWBY AC, 1990, NEWS PHYSIOL SCI, V5, P67; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; NEWBY AC, 1981, BIOCHEM PHARMACOL, V30, P2611, DOI 10.1016/0006-2952(81)90589-X; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; POSNETT DN, 1989, METHOD ENZYMOL, V178, P739; Ralevic V, 1998, PHARMACOL REV, V50, P413; RICHARDSON PJ, 1987, NATURE, V327, P232, DOI 10.1038/327232a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHRADER J, 1990, CIRCULATION, V81, P389, DOI 10.1161/01.CIR.81.1.389; Skladanowski AC, 1996, AM J PHYSIOL-HEART C, V270, pH1493, DOI 10.1152/ajpheart.1996.270.4.H1493; SKLADANOWSKI AC, 1990, BIOCHEM J, V268, P117, DOI 10.1042/bj2680117; SKLADANOWSKI AC, 1991, ROLE ADENOSINE ADENI, P289; SMOLENSKI RT, 1990, J CHROMATOGR-BIOMED, V527, P414, DOI 10.1016/S0378-4347(00)82125-8; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1657, DOI 10.1177/27.12.392001; SUZUKI K, 1993, J BIOCHEM-TOKYO, V113, P607, DOI 10.1093/oxfordjournals.jbchem.a124090; TRUONG VL, 1988, BIOCHEM J, V253, P117, DOI 10.1042/bj2530117; YAMAZAKI Y, 1991, BIOCHEMISTRY-US, V30, P1503, DOI 10.1021/bi00220a009; YOKOTA R, 1995, AM J PHYSIOL-HEART C, V268, pH1149, DOI 10.1152/ajpheart.1995.268.3.H1149	31	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17789	17793		10.1074/jbc.274.25.17789	http://dx.doi.org/10.1074/jbc.274.25.17789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364222	hybrid			2022-12-25	WOS:000080974300058
J	Schwandner, R; Dziarski, R; Wesche, H; Rothe, M; Kirschning, CJ				Schwandner, R; Dziarski, R; Wesche, H; Rothe, M; Kirschning, CJ			Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; BACTERIAL PEPTIDOGLYCAN; CD14-DEPENDENT PATHWAY; STAPHYLOCOCCUS-AUREUS; SOLUBLE PEPTIDOGLYCAN; DROSOPHILA TOLL; LIPOPOLYSACCHARIDE; CD14; BINDING; GENE	The Life-threatening complications of sepsis in humans are elicited by infection with Gram-negative as well as Gram-positive bacteria. Recently, lipopolysaccharide (LPS), a major biologically active agent of Gram-negative bacteria, was shown to mediate cellular activation by a member of the human Toll-like receptor family, Toll-like receptor (TLR) 2. Here we investigate the mechanism of cellular activation by soluble peptidoglycan (sPGN) and lipoteichoic acid (LTA), main stimulatory components of Gram-positive bacteria, Like LPS, sPGN and LTA bind to the glycosylphosphatidylinositol-anchored membrane protein CD14 and induce activation of the transcription factor NF-kappa B in host cells like macrophages. We show that whole Gram-positive bacteria, sPGN and LTA induce the activation of NF-kappa B in HEK293 cells expressing TLR2 but not in cells expressing TLR1 or TLR4. The sPGN- and LTA-induced NF-kappa B activation was not inhibited by polymyxin B, an antibiotic that binds and neutralizes LPS. Coexpression together with membrane CD14 enhances sPGN signal transmission through TLR2. In contrast to LPS signaling, activation of TLR2 by sPGN and LTA does not require serum. These findings identify TLR2 as a signal transducer for sPGN and LTA in addition to LPS.	Tularik Inc, San Francisco, CA 94080 USA; Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Kirschning, CJ (corresponding author), DeveloGen AG, Rudolf Wissel Str 28, D-37079 Gottingen, Germany.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; Bernardo J, 1998, INFECT IMMUN, V66, P28, DOI 10.1128/IAI.66.1.28-35.1998; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; Downey J. S., 1998, FRONT BIOSCI, V3, pd468; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; FERNANDEZ C, 1983, SCAND J IMMUNOL, V18, P265, DOI 10.1111/j.1365-3083.1983.tb00867.x; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; Fischer W, 1997, EUR J BIOCHEM, V244, P913, DOI 10.1111/j.1432-1033.1997.00913.x; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P3484, DOI 10.1128/IAI.59.10.3484-3491.1991; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hattor Y, 1997, BIOCHEM BIOPH RES CO, V233, P375, DOI 10.1006/bbrc.1997.6462; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Tominaga K, 1997, MOL IMMUNOL, V34, P1147, DOI 10.1016/S0161-5890(97)00145-4; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vogel G, 1998, SCIENCE, V281, P1942, DOI 10.1126/science.281.5385.1942; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	38	1372	1434	1	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17406	17409		10.1074/jbc.274.25.17406	http://dx.doi.org/10.1074/jbc.274.25.17406			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364168	hybrid			2022-12-25	WOS:000080974300004
J	Zhi, N; Ohashi, N; Rikihisa, Y				Zhi, N; Ohashi, N; Rikihisa, Y			Multiple p44 genes encoding major outer membrane proteins are expressed in the human granulocytic ehrlichiosis agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC MULTIGENE FAMILY; ANAPLASMA-MARGINALE; ANTIGENIC VARIATION; NEISSERIA-GONORRHOEAE; RECOMBINANT PROTEIN; SURFACE PROTEIN-2; HUMORAL RESPONSE; NEW-YORK; CLONING; IDENTIFICATION	Human granulocytic ehrlichiosis (HGE) is caused by infection with an obligatory intracellular bacterium, the HGE agent. We previously cloned a gene encoding HGE agent 44-kDa major outer membrane protein and designated it p44, In this study, we (i) identified five different mRNAs that are transcribed from p44-homologous genes in the HGE agent cultivated in HL-60 cells; (ii) cloned genes corresponding to the mRNAs from the genomic DNA of the HGE agent; (iii) showed that the genes being expressed were not clustered in the HGE agent genome; (iv) estimated that a minimum copy number of the p44-homologous genes in the genome is 18; (v) detected two different P44-homologous proteins expressed by the HGE agent; and (vi) demonstrated existence of antibodies specific to the two proteins in sera from patients with HGE. These findings showed that p44 multigenes have several active expression sites and the expression is regulated at transcriptional level, suggesting a potentially unique mechanism for generating the diversity in major antigenic outer membrane proteins of the HGE agent. Characterization of p44-homologous genes expressed by the HGE agent in a tissue culture would assist in understanding a role of the p44 multigene family in pathogenesis and immune response in HGE.	Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Rikihisa, Y (corresponding author), Ohio State Univ, Coll Vet Med, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.				NIAID NIH HHS [R01 AI40934] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040934] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asanovich KM, 1997, J INFECT DIS, V176, P1029, DOI 10.1086/516529; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; Dumler JS, 1996, J INFECT DIS, V173, P1027, DOI 10.1093/infdis/173.4.1027; French DM, 1998, INFECT IMMUN, V66, P1200, DOI 10.1128/IAI.66.3.1200-1207.1998; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Ijdo JW, 1997, J INFECT DIS, V176, P687, DOI 10.1086/514091; Ijdo JW, 1998, INFECT IMMUN, V66, P3264, DOI 10.1128/IAI.66.7.3264-3269.1998; Kim HY, 1998, J CLIN MICROBIOL, V36, P3278, DOI 10.1128/JCM.36.11.3278-3284.1998; Murphy CI, 1998, INFECT IMMUN, V66, P3711, DOI 10.1128/IAI.66.8.3711-3718.1998; OBERLE SM, 1993, GENE, V136, P291, DOI 10.1016/0378-1119(93)90482-I; Ohashi N, 1998, J CLIN MICROBIOL, V36, P2671, DOI 10.1128/JCM.36.9.2671-2680.1998; Ohashi N, 1998, INFECT IMMUN, V66, P132, DOI 10.1128/IAI.66.1.132-139.1998; PALMER GH, 1994, INFECT IMMUN, V62, P3808, DOI 10.1128/IAI.62.9.3808-3816.1994; PALMER GH, 1988, INFECT IMMUN, V56, P1526, DOI 10.1128/IAI.56.6.1526-1531.1988; Pusterla N, 1997, J CLIN MICROBIOL, V35, P2307, DOI 10.1128/JCM.35.9.2307-2309.1997; Pusterla N, 1998, J CLIN MICROBIOL, V36, P2035, DOI 10.1128/JCM.36.7.2035-2037.1998; RIKIHISA Y, 1992, J CLIN MICROBIOL, V30, P143, DOI 10.1128/JCM.30.1.143-148.1992; Rikihisa Y, 1997, J INFECT DIS, V175, P210, DOI 10.1093/infdis/175.1.210; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; Sambrook J., 2002, MOL CLONING LAB MANU; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; StGeme JW, 1996, J BACTERIOL, V178, P6281, DOI 10.1128/jb.178.21.6281-6287.1996; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zhi N, 1997, J CLIN MICROBIOL, V35, P2606, DOI 10.1128/JCM.35.10.2606-2611.1997; Zhi N, 1998, J CLIN MICROBIOL, V36, P1666, DOI 10.1128/JCM.36.6.1666-1673.1998	33	91	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17828	17836		10.1074/jbc.274.25.17828	http://dx.doi.org/10.1074/jbc.274.25.17828			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364227	hybrid			2022-12-25	WOS:000080974300063
J	Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E				Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E			MBP1: a novel mutant p53-specific protein partner with oncogenic properties	ONCOGENE			English	Article						mutant p53; MBP1; fibulin; gain of function	CELL-LINES; FUNCTION MUTATIONS; 2-HYBRID SYSTEM; P53 PROTEIN; WILD-TYPE; GENE; GROWTH; RAS; CANCER; YEAST	Using a least two-hybrid screening strategy with a common tumour-derived p53 mutant as bait, we identified several mutant p53-interacting partners including the known proteins wild-type (nt) p53, hUBC9 and GBP/PIAS1. In addition, a novel protein partner was identified which we have termed MBP1, for Mutant p53-binding Protein 1. MBP1 is a new member of the emerging fibulin gene family, which currently comprises fibulin-1, fibulin-2 and S1-5. Expression of MBP1 mRNA is differentially regulated both temporally during development of the mouse embryo and in a tissue-specific manner within the adult. Specific interaction between MBP1 and mutant p53 was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells. MBP1 displayed the following order of binding specificity towards different p53 forms: H175 > G281 > H273 greater than or equal to W248 > wt p53. Thus, MBP1 appears to bind preferentially to p53 mutants of the 'structural' rather than 'contact' class, reflecting a potential bias towards those mutants having a significant alteration in conformation from that assumed by wt p53. We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed. Furthermore, MBP1 may play a role in determining if a 'gain of function' effect is seen with certain p53 mutants.	Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; IGBMC, F-67404 Illkirch, France; ExonHit Therapeut, F-75013 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm)	Conseiller, E (corresponding author), Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, 13 Quai Jules Guesde,BP14, F-94403 Vitry, France.			Gallagher, William/0000-0002-4307-5999				Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Delahunty M, 1995, Connect Tissue Res, V31, P283, DOI 10.3109/03008209509010824; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLAY C, 1995, METHOD ENZYMOL, V255, P389; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSIAO M, 1994, AM J PATHOL, V145, P702; IWABUCHI K, 1993, ONCOGENE, V8, P1693; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nelson Vanessa, 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P695; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Toh H, 1992, Mediators Inflamm, V1, P223, DOI 10.1155/S0962935192000346; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	51	54	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3608	3616		10.1038/sj.onc.1202937	http://dx.doi.org/10.1038/sj.onc.1202937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380882				2022-12-25	WOS:000080891700006
J	Takahashi, M; Shibata, H; Shimakawa, M; Miyamoto, M; Mukai, H; Ono, Y				Takahashi, M; Shibata, H; Shimakawa, M; Miyamoto, M; Mukai, H; Ono, Y			Characterization of a novel giant scaffolding protein, CG-NAP, that anchors multiple signaling enzymes to centrosome and the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; ZIPPER-LIKE SEQUENCES; KINASE-C; PKN; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION; DOMAIN; CELLS	A novel 450-kDa coiled-coil protein, CG-NAP (centrosome and Golgi localized PKN-associated protein), was identified as a protein that interacted with the regulatory region of the protein kinase PKN, having a catalytic domain homologous to that of protein kinase C. CG-NAP contains two sets of putative RII (regulatory subunit of protein kinase A)-binding motif, Indeed, CG-NAP tightly bound to RII alpha in HeLa cells. Furthermore, CG-NAP was coimmunoprecipitated with the catalytic subunit of protein phosphatase 2A (PP2A), when one of the B subunit of PP2A (PR130) was exogenously expressed in COS7 cells. CG-NAP also interacted with the catalytic subunit of protein phosphatase 1 in HeLa cells. Immunofluorescence analysis of HeLa cells revealed that CG-NAP was localized to centrosome throughout the cell cycle, the midbody at telophase, and the Golgi apparatus at interphase, where a certain population of PKN and RII alpha were found to be accumulated. These data indicate that CG-NAP serves as a novel scaffolding protein that assembles several protein kinases and phosphatases on centrosome and the Golgi apparatus, where physiological events, such as cell cycle progression and intracellular membrane traffic, may be regulated by phosphorylation state of specific protein substrates.	Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe 6578501, Japan	Kobe University; Kobe University	Ono, Y (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Nada Ku, 1-1 Rokkodai Cho, Kobe 6578501, Japan.			Mukai, Hideyuki/0000-0002-0167-8695				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHOI KY, 1994, CELL, V78, P499; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOXEY SJ, 1994, CELL, V76, P639; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Kawamata T, 1998, J NEUROSCI, V18, P7402; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lin JW, 1998, J NEUROSCI, V18, P2017; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Mukai H, 1996, P NATL ACAD SCI USA, V93, P10195, DOI 10.1073/pnas.93.19.10195; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; SHU HB, 1995, J CELL SCI, V108, P2955; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	43	204	207	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17267	17274		10.1074/jbc.274.24.17267	http://dx.doi.org/10.1074/jbc.274.24.17267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358086	hybrid			2022-12-25	WOS:000080780400085
J	Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S				Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S			cbl-3: a new mammalian cbl family protein	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTOONCOGENE C-CBL; PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; V-CBL; NEGATIVE REGULATOR; POINT MUTATIONS; TYROSINE KINASE; ONCOGENE; MOTIF; ACTIVATION	We have cloned a new human gene, cbl-3, which encodes a protein with marked homology to the cbl family of proteins. The predicted protein encoded by this gene retains the conserved phosphotyrosine binding domain (PTB) in the N-terminal and the zinc finger but is significantly shorter (MW 52.5 kDa) than the other mammalian cbl proteins. The protein lacks the extensive proline rich domain and leucine zipper seen in c-cbl and cbl-b and structurally most resembles the C. elegans and Drosophila cbl proteins. The gene is ubiquitously expressed with highest expression in the aerodigestive tract, prostate, adrenal gland, and salivary gland. The protein is phosphorylated and recruited to the EGFR upon EGF stimulation and inhibits EGF stimulated MAP kinase activation. In comparison to the other mammalian cbl proteins (e.g. cbl-b), cbl-3 interacts with a restricted range of proteins containing Src Homology 3 regions, An alternatively spliced form of the cbl-3 protein was also identified which deletes a critical region of the PTB domain and which does not interact with the EGFR nor inhibit EGF stimulated MAP kinase activation. These data demonstrate that cbl-3, a novel mammalian cbl protein, is a regulator of EGFR mediated signal transduction.	Bethesda Naval Hosp, Dept Genet, Med Branch, NCI, Bethesda, MD 20889 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lipkowitz, S (corresponding author), NCI, Dept Genet, Med Branch, Natl Naval Med Ctr, Bldg 8,Room 5101, Bethesda, MD 20889 USA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	43	94	101	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3365	3375		10.1038/sj.onc.1202753	http://dx.doi.org/10.1038/sj.onc.1202753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362357				2022-12-25	WOS:000080589300007
J	Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC				Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC			C-CAM1 expression: Differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells	ONCOGENE			English	Article						C-CAM; tumor suppression; morphometric analysis; prostate carcinoma; cytokeratin expression; TGF-beta	RAT HEPATOCELLULAR CARCINOMAS; ANTIGEN GENE FAMILY; MOLECULE C-CAM; ADHESION MOLECULE; BILIARY GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLORECTAL CARCINOMAS; MEDIATED CYTOLYSIS; LIVER DEVELOPMENT; GROWTH INHIBITOR	Studies in rat prostate and liver have suggested that C-CAM1 is involved in the formation and maintenance of histotypic associations in tissues and possibly tumors. Most recently, C-CAM1 has been shown to suppress tumorigenicity of prostate and colon carcinoma cells. However, the mechanisms whereby C-CAM1 suppresses growth and the relationship of this activity to its proposed role in histotypic interactions remain largely unknown. In the present study, we have analysed the growth, phenotypic, morphological and ultrastructural characteristics of four human PC-3 prostate carcinoma cell lines transduced with C-CAM1 retrovirus. We report that three of four lines regained their tumorigenic phenotype in vivo while maintaining high levels of C-CAM1 expression and a growth retarded phenotype in vitro. These findings suggested that high levels of C-CAM1 expression were negatively influencing recovery during reconstitution after freezing or during the latency period after subcutaneous injection and that loss of suppression resulted from changes in expression of other molecules required for full disclosure of C-CAM1 mediated growth inhibition. Results from Northern blot and immunofluorescence analyses of tumor nodules demonstrated that C-CAM1 decreased rather than enhanced phenotypic differentiation and induced ultrastructural and morphological changes that occurred independently of tumor suppression.	Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center	Hixson, DC (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Med Oncol, 593 Eddy St, Providence, RI 02903 USA.				NCI NIH HHS [CA42714] Funding Source: Medline; NIEHS NIH HHS [T32 ESO7272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barrack ER, 1997, PROSTATE, V31, P61; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BECK BN, 1982, TRANSPLANTATION, V33, P118, DOI 10.1097/00007890-198202000-00003; BECKER A, 1986, EUR J CELL BIOL, V39, P417; BRUMMER J, 1995, ONCOGENE, V11, P1649; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Denhez F, 1990, GROWTH FACTORS, V3, P139, DOI 10.3109/08977199009108276; DUNSFORD HA, 1989, CANCER RES, V49, P4887; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; FARIS RA, 1991, CANCER RES, V51, P1308; Foty RA, 1997, CANCER RES, V57, P5033; Goldman R. D., 1990, CELLULAR MOL BIOL IN, P3; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1983, CANCER RES, V43, P3874; HIXSON DC, 1984, EXP CELL RES, V152, P402, DOI 10.1016/0014-4827(84)90641-4; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; KUNG JT, 1988, J IMMUNOL, V140, P3727; LAKE JP, 1991, J IMMUNOL, V147, P1121; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEO O, 1988, J IMMUNOL, V141, P37; LIEBERMAN M, ANDERSONS PATHOLOGY; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Marceau N, 1995, BIOCHEM CELL BIOL, V73, P619, DOI 10.1139/o95-068; MARCEL M, 1992, B CANC, V79, P347; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Miyaki M, 1995, ONCOGENE, V11, P2547; MOWERY J, 1991, HEPATOLOGY, V13, P47; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perry KT, 1997, UROLOGY, V49, P151, DOI 10.1016/S0090-4295(96)00426-8; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANG J, 1993, CANCER RES, V55, P1152; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; STITZ L, 1986, J IMMUNOL, V136, P4674; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257; THOMPSON NL, 1990, J CELL BIOL, V11, pA156; Turbide C, 1997, CANCER RES, V57, P2781; WILLIAMS MA, 1997, QUANTITATIVE METHODS, V6, P5; Yang YM, 1997, AM J PATHOL, V150, P693	65	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3261	3276		10.1038/sj.onc.1202666	http://dx.doi.org/10.1038/sj.onc.1202666			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359532				2022-12-25	WOS:000080523800009
J	Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y				Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y			Isolation and characterization of mammalian homologues of Caenorhabditis elegans lin-7: localization at cell-cell junctions	ONCOGENE			English	Article						lin-7; cadherin; cell-cell junction	SYNAPTIC VESICLE EXOCYTOSIS; FILAMENT-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; VULVAR INDUCTION; EPITHELIAL-CELLS; PDZ DOMAIN; TIGHT JUNCTION; MOLECULAR ARCHITECTURE; RECEPTOR LOCALIZATION; BASOLATERAL MEMBRANE	In Caenorhabditis elegans, the vulval induction is mediated by the let-23 receptor tyrosine kinase (RTK)/ Ras signaling pathway. The precise localization of the let-23 RTK at the epithelial junctions is essential for the vulval induction, and requires three genes including lin-2, -7, and -10. The mammalian homologue of lin-2 has been identified as a protein interacting with a neuronal adhesion molecule, neurexin, and named CASK. CASK has recently been reported to interact with syndecans and an actin-binding protein, band 4.1, at epithelial and synaptic junctions, and to play central roles in the formation of cell-cell junctions. The product of C. elegans lin-7 directly interacts with let-23 RTK and localize it at epithelial junctions. Here, we report three rat homologues of lin-7 ubiquitously expressed in various tissues, These homologues are accumulated at the junctional complex region in cultured Madin-Darby canine kidney cells, and are also localized at the synaptic junctions in neurons. The mammalian homologues of lin-7 may be implicated in the formation of cell-cell junctions.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Reuver SM, 1998, J CELL SCI, V111, P1071; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SAKISAKA T, 1999, IN PRESS ONCOGENE, V18; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tsukita S, 1997, SOC GEN PHY, V52, P69; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	47	42	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2811	2817		10.1038/sj.onc.1202652	http://dx.doi.org/10.1038/sj.onc.1202652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362251				2022-12-25	WOS:000080125100003
J	Singh, RP; Dhawan, P; Golden, C; Kapoor, GS; Mehta, KD				Singh, RP; Dhawan, P; Golden, C; Kapoor, GS; Mehta, KD			One-way cross-talk between p38(MAPK) and p42/44(MAPK) - Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE ACTIVATION; NERVE GROWTH-FACTOR; MAP KINASE; C-JUN; SIGNAL-TRANSDUCTION; CYTOKINE BIOSYNTHESIS; CELLULAR STRESSES; P38; APOPTOSIS	In this paper, we report that SB202190 alone, a specific inhibitor of p38(MAPK), induces low density lipoprotein (LDL) receptor expression (6-8-fold) in a sterol-sensitive manner in HepG2 cells. Consistent with this finding, selective activation of the p38(MAPK) Signaling pathway by expression of MKK6b(E), a constitutive activator of p38(MAPK), significantly reduced LDL receptor promoter activity. Expression of the p38(MAPK) alpha-isoform had a similar effect, whereas expression of the p38(MAPK) beta II-isoform had no significant effect on LDL receptor promoter activity. SB202190-dependent increase in LDL receptor expression was accompanied by induction of p42/44(MAPK), and inhibition of this pathway completely prevented SB202190-induced LDL receptor expression, suggesting that p38(MAPK) negatively regulates the p42/44(MAPK) cascade and the responses mediated by this kinase, Cross-talk between these kinases appears to be one-way because modulation of p42/44(MAPK) activity did not affect p38(MAPK) activation by a variety of stress inducers. Taken together, these findings reveal a hitherto unrecognized one-way communication that exists between p38(MAPK) and p42/44(MAPK) and provide the first evidence that through the p42/44(MAPK) Signaling cascade, the p38(MAPK) alpha-isoform negatively regulates LDL receptor expression, thus representing a novel mechanism of fine tuning cellular levels of cholesterol in response to a diverse set of environmental cues.	Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Mehta, KD (corresponding author), Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, Slot 516,4301 W Markham, Little Rock, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; GOEDERT M, 1997, EMBO J, V16, P3663; Graves JD, 1998, J IMMUNOL, V161, P168; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; KUMAR A, 1997, J LIPID RES, V38, P4220; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mehta KD, 1996, J BIOL CHEM, V271, P33616, DOI 10.1074/jbc.271.52.33616; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIA Z, 1995, SCIENCE, V270, P126	59	149	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19593	19600		10.1074/jbc.274.28.19593	http://dx.doi.org/10.1074/jbc.274.28.19593			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391894	hybrid			2022-12-25	WOS:000081377300014
J	Xia, Y; Uhlin, BE				Xia, Y; Uhlin, BE			Mutational analysis of the PapB transcriptional regulator in Escherichia coli - Regions important for DNA binding and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN H-NS; MINOR-GROOVE; CRYSTAL-STRUCTURE; ALPHA-HELICES; EXPRESSION; CLONING; PLASMID; COMPLEX; OPERON; DOMAIN	PapB transcriptional regulator in the control of pop operon expression in Escherichia coli. There are PapB homologous proteins encoded by many fimbrial gene systems that are involved in the regulation of fimbriae-adhesin production, and previous studies suggested that PapB binds DNA through minor groove contact. Both deletion and alanine-scanning mutagenesis were used to identify functionally important regions of the PapB protein. Mutations altering Arg(61) or Cys(65) caused deficiency in DNA binding, indicating that these residues are critical for PapB binding to DNA Alanine substitutions at positions 35-36, 53-56, and 74-76 resulted in mutants that were impaired in oligomerization. All these amino acid residues are conserved among the PapB homologous proteins, suggesting their importance in the whole family of regulatory proteins, The transcriptional efficiency of all the mutants was clearly reduced as compared with that of wild-type PapB. Taken together, we have localized regions in the PapB protein that are involved in DNA binding and oligomerization, and our results show that both functions are required for its activity as a transcriptional regulator.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden	Umea University	Uhlin, BE (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.		Uhlin, Bernt Eric/AAO-6292-2021	Uhlin, Bernt Eric/0000-0002-2991-8072				BAGA M, 1985, EMBO J, V4, P3887, DOI 10.1002/j.1460-2075.1985.tb04162.x; BAILONE A, 1978, VIROLOGY, V84, P547, DOI 10.1016/0042-6822(78)90273-8; BECKETT D, 1993, BIOCHEMISTRY-US, V32, P9073, DOI 10.1021/bi00086a012; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAGBERG B, 1992, J BACTERIOL, V174, P7606, DOI 10.1128/JB.174.23.7606-7612.1992; FORSMAN K, 1989, EMBO J, V8, P1271, DOI 10.1002/j.1460-2075.1989.tb03501.x; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; FRIEDRICH MJ, 1993, MOL MICROBIOL, V8, P543, DOI 10.1111/j.1365-2958.1993.tb01599.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gibbs C.S., 1991, METHODS COMPANION ME, V3, P165; GORANSSON M, 1984, EMBO J, V3, P2885, DOI 10.1002/j.1460-2075.1984.tb02225.x; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Maniatis T., 1982, MOL CLONING LAB MANU; Martin C, 1996, MOL MICROBIOL, V21, P281, DOI 10.1046/j.1365-2958.1996.00651.x; MCGOVERN V, 1994, BIOCHIMIE, V76, P1019, DOI 10.1016/0300-9084(94)90026-4; Miller J.H., 1972, EXPT MOL GENETICS; MORSCHHAUSER J, 1993, MOL GEN GENET, V238, P97; NORQVIST A, 1993, INFECT IMMUN, V61, P2434, DOI 10.1128/IAI.61.6.2434-2444.1993; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROOSENDAAL B, 1989, MOL GEN GENET, V215, P250, DOI 10.1007/BF00339725; SAUER RT, 1995, NAT STRUCT BIOL, V2, P7, DOI 10.1038/nsb0195-7; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SILHAVY TJ, 1984, EXPT GENE FUSION; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TARASEVICIENE L, 1994, J BIOL CHEM, V269, P12167; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; Xia Y, 1998, MOL MICROBIOL, V30, P513, DOI 10.1046/j.1365-2958.1998.01080.x; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zeng XG, 1997, GENE, V185, P245, DOI 10.1016/S0378-1119(96)00652-X	44	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19723	19730		10.1074/jbc.274.28.19723	http://dx.doi.org/10.1074/jbc.274.28.19723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391913	hybrid			2022-12-25	WOS:000081377300033
J	Chaudhary, PM; Eby, MT; Jasmin, A; Hood, L				Chaudhary, PM; Eby, MT; Jasmin, A; Hood, L			Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; KAPPA-B ACTIVATION; CELL-DEATH; INDUCED APOPTOSIS; JNK ACTIVATION; TNF RECEPTOR-1; FAS; FADD; INTERACTS	Caspase-8 is the most proximal caspase in the caspase cascade and possesses a prodomain consisting of two homologous death effector domains (DEDs). We have discovered that caspase-8 and its homologs can physically interact with tumor necrosis factor receptor-associated factor family members and activate the c-Jun N-terminal kinase (JNK, or stress-activated protein kinase) pathway. This ability resides in the DED-containing prodomain of these proteins and is independent of their role as cell death proteases. A point mutant in the first DED of caspase-8 can block JNK activation induced by several death domain receptors, Inhibition of JNK activation blocks apoptosis mediated by caspase-10, Mach-related inducer of toxicity/cFLIP, and Fas/CD95, thereby suggesting a cooperative role of this pathway in the mediation of caspase-induced apoptosis.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Chaudhary, Preet/E-1970-2018					Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	41	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19211	19219		10.1074/jbc.274.27.19211	http://dx.doi.org/10.1074/jbc.274.27.19211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383428	hybrid			2022-12-25	WOS:000081196300051
J	Strassheim, D; May, LG; Varker, KA; Puhl, HL; Phelps, SH; Porter, RA; Aronstam, RS; Noti, JD; Williams, CL				Strassheim, D; May, LG; Varker, KA; Puhl, HL; Phelps, SH; Porter, RA; Aronstam, RS; Noti, JD; Williams, CL			M-3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; SMOOTH-MUSCLE MYOSIN; CELL LUNG-CARCINOMA; CADHERIN-MEDIATED ADHESION; OPERATED CALCIUM INFLUX; STRESS FIBER FORMATION; HAMSTER OVARY CELLS; GUINEA-PIG; TYROSINE PHOSPHORYLATION; CLOSTRIDIUM-BOTULINUM	Although muscarinic acetylcholine receptors (mAChR) regulate the activity of smooth muscle myosin, the effects of mAChR activation on cytoplasmic myosin have not been characterized. We found that activation of transfected human M-3 mAChR induces the phosphorylation of myosin light chains (MLC) and the formation of myosin-containing stress fibers in Chinese hamster ovary (CHO-m3) cells. Direct activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (PMA) also induces myosin light chain phosphorylation and myosin reorganization in CHO-m3 cells. Conventional (alpha), novel (delta), and atypical (iota) PKC isoforms are activated by mAChR stimulation or PMA treatment in CHO-m3 cells, as indicated by PKC translocation or degradation. mAChR-mediated myosin reorganization is abolished by inhibiting conventional PKC isoforms with Go6976 (IC50 = 0.4 mu M), calphostin C (IC50 = 2.4 mu M), or chelerythrine (IC50 = 8.0 mu M) Stable expression of dominant negative RhoA(Asn-19) diminishes, but does not abolish, mAChR-mediated myosin reorganization in the CHO-m3 cells. Similarly, mAChR-mediated myosin reorganization is diminished, but not abolished, in CHO-m3 cells which are multi-nucleate due to inactivation of Rho with C3 exoenzyme, Expression of dominant negative RhoA(Asn-19) Or inactivation of RhoA with C3 exoenzyme does not affect PMA-induced myosin reorganization. These findings indicate that the PKC-mediated pathway of myosin reorganization (induced either by M-3 mAChR activation or PMA treatment) can continue to operate even when RhoA activity is diminished in CHO-m3 cells. Conventional PKC isoforms and RhoA may participate in separate but parallel pathways induced by M-3 mAChR activation to regulate cytoplasmic myosin, Changes in cytoplasmic myosin elicited by M-3 mAChR activation may contribute to the unique ability of these receptors to regulate cell morphology, adhesion, and proliferation.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA; Guthrie Res Inst, Neurobiol Lab, Sayre, PA 18840 USA; Guthrie Res Inst, Mol Biol Lab, Sayre, PA 18840 USA; Guthrie Clin, Dept Surg, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA.	cwilliam@inet.guthrie.org	STRASSHEIM, DEREK/AHB-1158-2022	Puhl, Henry/0000-0003-3095-7201				Akopov SE, 1998, AM J PHYSIOL-HEART C, V275, pH930, DOI 10.1152/ajpheart.1998.275.3.H930; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; Bremerich DH, 1997, AM J PHYSIOL-LUNG C, V273, pL775, DOI 10.1152/ajplung.1997.273.4.L775; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chang ZL, 1997, BIOCHEM PHARMACOL, V54, P833, DOI 10.1016/S0006-2952(97)00250-5; CHOI OH, 1994, J BIOL CHEM, V269, P536; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; Croxton TL, 1998, AM J PHYSIOL-LUNG C, V275, pL748, DOI 10.1152/ajplung.1998.275.4.L748; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; DETJEN K, 1995, P NATL ACAD SCI USA, V92, P10929, DOI 10.1073/pnas.92.24.10929; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1988, ADV SEC MESS PHOSPH, V21, P95; IKEBE M, 1987, J BIOL CHEM, V262, P9569; JARVINEN M, 1987, EUR J CELL BIOL, V44, P238; JIAN X, 1994, J NEUROBIOL, V25, P1310, DOI 10.1002/neu.480251011; KAMM KE, 1989, J BIOL CHEM, V264, P21223; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOKUBU K, 1995, EUR J PHARM-MOLEC PH, V290, P19, DOI 10.1016/0922-4106(95)90012-8; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KREISBERG JI, 1997, AM J PHYSIOL, V251, pC505; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Lucius C, 1998, J PHYSIOL-LONDON, V506, P83, DOI 10.1111/j.1469-7793.1998.083bx.x; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Puhl HL, 1997, BIOCHEM PHARMACOL, V53, P1107, DOI 10.1016/S0006-2952(97)00089-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Quigley RL, 1998, CHEST, V114, P839, DOI 10.1378/chest.114.3.839; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Satoh M, 1998, GEN PHARMACOL, V30, P103, DOI 10.1016/S0306-3623(97)00083-9; Savineau JP, 1997, FUNDAM CLIN PHARM, V11, P289, DOI 10.1111/j.1472-8206.1997.tb00841.x; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Shafer SH, 1999, EXP CELL RES, V248, P148, DOI 10.1006/excr.1998.4385; SingerLahat D, 1996, BIOCHEM PHARMACOL, V51, P495, DOI 10.1016/0006-2952(95)02226-0; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; STEPHENS EV, 1993, ONCOGENE, V8, P19; Takuwa Y, 1996, JPN HEART J, V37, P793; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; Tokman MG, 1997, CANCER RES, V57, P1785; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VUORI K, 1993, J BIOL CHEM, V268, P21459; WHITNEY G, 1995, J VASC SURG, V22, P37, DOI 10.1016/S0741-5214(95)70086-2; WILLIAMS CL, 1989, IN VITRO CELL DEV B, V25, P397; WILLIAMS CL, 1993, J CELL BIOL, V121, P643, DOI 10.1083/jcb.121.3.643; WILLIAMS CL, 1986, J EXP MED, V164, P1043, DOI 10.1084/jem.164.4.1043; WILLIAMS CL, 1991, CELL REGUL, V2, P373, DOI 10.1091/mbc.2.5.373; WOODS A, 1992, J CELL SCI, V101, P277; Yoshimura Y, 1997, Int J Urol, V4, P62, DOI 10.1111/j.1442-2042.1997.tb00142.x; Yuhan R, 1997, GASTROENTEROLOGY, V113, P1873, DOI 10.1016/S0016-5085(97)70006-4	78	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18675	18685		10.1074/jbc.274.26.18675	http://dx.doi.org/10.1074/jbc.274.26.18675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373480	hybrid			2022-12-25	WOS:000081056700072
J	Tasheva, ES; Funderburgh, ML; McReynolds, J; Funderburgh, JL; Conrad, GW				Tasheva, ES; Funderburgh, ML; McReynolds, J; Funderburgh, JL; Conrad, GW			The bovine mimecan gene - Molecular cloning and characterization of two major RNA transcripts generated by alternative use of two splice acceptor sites in the third exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR; OSTEOINDUCTIVE FACTOR; MESSENGER-RNAS; LUMICAN GENE; CORE PROTEIN; ORGANIZATION; ISOFORMS; BONE	Mimecan is a proteoglycan expressed by many connective tissues. It was originally isolated in a truncated form as a bone-associated glycoprotein, osteoglycin, and was considered an osteoinductive factor. Recently, we demonstrated that the full-length translation product of the cDNA encoding mimecan is a corneal keratan sulfate proteoglycan present in other tissues without keratan sulfate chains. We also described multiple mimecan mRNA transcripts generated by differential splicing and alternative polyadenylation, In this study, we isolated genomic clones and determined the genomic organization of the bovine mimecan gene. The gene is spread over >33 kilobases of continuous DNA sequence and contains eight exons, The newly discovered first exon, identified by 5'-rapid amplification of cDNA ends, consists of a 5'-untranslated region and is enriched in C + G nucleotides. Two transcription initiation sites starting at the first and at the second exons were determined by primer extension. Molecular characterization shows that alternatively spliced RNA isoforms are generated by the use of two distinct splice acceptor sites in the third exon situated 278 base pairs apart. We determined a partial genomic structure of the human mimecan gene and demonstrated two alternatively spliced RNA transcripts that are generated likewise. Despite the diversity of mimecan transcripts, the primary structure of the core protein is encoded from exons 3 to 8 and remains unchanged, indicating its functional importance. Using ribonuclease protection assay, we analyzed the patterns of spliced RNA expressed in cultured bovine keratocytes. We demonstrated that their expression is differentially modulated in a temporal manner by basic fibroblast growth factor.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Tasheva, ES (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.				NEI NIH HHS [EY00952, EY09368] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DASH JR, 1993, CONNECT TISSUE RES, V30, P11; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Garcia F, 1998, GENOMICS, V50, P69, DOI 10.1006/geno.1998.5315; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Iwata Y, 1998, BIOCHEM J, V331, P959, DOI 10.1042/bj3310959; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KISS I, 1989, J BIOL CHEM, V264, P8126; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MOUNT S, 1982, NUCLEIC ACIDS RES, V19, P459; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAITTA B, 1992, J BIOL CHEM, V267, P6188; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shanahan CM, 1997, ARTERIOSCL THROM VAS, V17, P2437, DOI 10.1161/01.ATV.17.11.2437; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; Tasheva ES, 1999, DNA SEQUENCE, V10, P67, DOI 10.3109/10425179909033939; Tasheva ES, 1998, GENE, V218, P63, DOI 10.1016/S0378-1119(98)00390-4; TASHEVA ES, 1993, LEUKEMIA, V7, P318; Tasheva ES, 1997, J BIOL CHEM, V272, P32551, DOI 10.1074/jbc.272.51.32551; Tzanakakis GN, 1997, BIOCHIMIE, V79, P323, DOI 10.1016/S0300-9084(97)80026-0; UJITA M, 1995, GENE, V158, P237, DOI 10.1016/0378-1119(95)00070-M; VASSART G, 1985, MOL CELL ENDOCRINOL, V40, P89, DOI 10.1016/0303-7207(85)90162-5; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	47	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18693	18701		10.1074/jbc.274.26.18693	http://dx.doi.org/10.1074/jbc.274.26.18693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373482	hybrid			2022-12-25	WOS:000081056700074
J	Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D				Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D			p53-dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with P-32 ortho-phosphate in human fibroblasts	ONCOGENE			English	Article						p53; metabolic labelling; DNA damage; phosphorylation; cell cycle	DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DAMAGE; INDUCTION; ACTIVATION; SENESCENCE; EXPRESSION; ANTIBODIES	The tumour suppressor gene p53 plays a major role in the cellular response to DNA damage, mediating growth arrest and/or apoptosis. Phosphorylation of the protein occurs at numerous sites in vivo and is likely to be a major mechanism for modulation of its activity as a transcriptional transactivator. Not surprisingly, therefore, p53 has been intensively studied by P-32 metabolic labelling. Here we show however, using normal human fibroblasts, that typical labelling conditions induce (i) a p53-dependent inhibition of DNA synthesis and (ii) an increase in the cellular content of p53 protein detectable by the phosphorylation-sensitive antibody DO-1 but not by antibody DO-12. These data demonstrate for the first time that P-32 labelling is sufficient to induce biologically-significant, p53-mediated cellular response and strongly suggest that it perturbs the phosphorylation state of p53 which it is being used to measure. This highlights the need to re-evaluate earlier data by nonradioactive approaches using phospho-specific antibodies.	Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Cardiff University; University of Dundee	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales.			Jones, Christopher/0000-0002-5447-8187				Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; BRADY MAW, 1990, IN SITU HYBRIDIZATIO; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CRAIG AL, 1998, 9 P53 WORKSH CRET, P102; DOVER R, 1994, J CELL SCI, V107, P1181; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS T, 1998, 9 P53 WORKSH CRET, P52; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Shaw P, 1996, ONCOGENE, V12, P921; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie FS, 1996, ONCOGENE, V12, P1077; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3788	3792		10.1038/sj.onc.1202733	http://dx.doi.org/10.1038/sj.onc.1202733			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391688				2022-12-25	WOS:000081140200014
J	Akasaki, T; Koga, H; Sumimoto, H				Akasaki, T; Koga, H; Sumimoto, H			Phosphoinositide 3-kinase-dependent and -independent activation of the small GTPase Rac2 in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; PROTEIN-KINASE-C; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SUPEROXIDE PRODUCTION; DEPENDENT ACTIVATION; GDP/GTP EXCHANGE; RHO-GTPASES	The small GTPase Rac participates in various cellular events such as cytoskeletal reorganization. It has remained, however, largely unknown about intracellular signaling pathways for Rac activation because of the lack of a simple and reliable assay to estimate the activation. Here we describe a novel method to detect the GTP-bound, active Rac in cells by pulling it down with the Rac-binding domain of the protein kinase PAK. Experiments using this method reveal that stimulation of human neutrophils with the G(i)-coupled receptor agonists N-formyl-methionyl-leucyl-phenylalanine (fMLP) and leukotriene B-4 (LTB4) leads to a rapid and transient increase in the GTP-bound state of Rac2, whereas phorbol myristate acetate (PMA) causes a slow but more sustained activation of Rac2. Pretreatment of cells with pertussis toxin results in defective activation of Rac2 in response to fMLP and LTB4, indicating that coupling of the receptors to G(i) plays a crucial role in the activation. Furthermore, the phosphoinositide 3-kinase (PI3K) inhibitors wortmannin and LY294002 block Rac2 activation elicited by the receptor agonists, but not that by PMA. Thus the G(i)-coupled receptors likely mediate Rac2 activation via PI3K, whereas PMA activates Rac2 in a PI3K-independent manner.	Kyushu Univ, Grad Sch Med Sci, Dept Biol & Mol Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Biol & Mol Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OKADA T, 1994, J BIOL CHEM, V269, P3563; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1984, BIOCHIM BIOPHYS ACTA, V803, P271, DOI 10.1016/0167-4889(84)90117-4; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WATSON F, 1991, J BIOL CHEM, V266, P7432; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776	43	153	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18055	18059		10.1074/jbc.274.25.18055	http://dx.doi.org/10.1074/jbc.274.25.18055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364257	hybrid			2022-12-25	WOS:000080974300093
J	Liu, SCH; Wang, Q; Lienhard, GE; Keller, SR				Liu, SCH; Wang, Q; Lienhard, GE; Keller, SR			Insulin receptor substrate 3 is not essential for growth or glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-CELLS; PROTEIN; MICE; PHOSPHATASE; ADIPOCYTES; IRS-1; SHP-2; GENE; EXPRESSION; DISRUPTION	The insulin receptor substrates (IRS) 1 and 2 are required for normal growth and glucose homeostaisis in mice. To determine whether IRS-3, a recently cloned member of the IRS family, is also involved in the regulation of these, we have generated mice with a targeted disruption of the IRS-3 gene and characterized them. Compared with wild-type mice, the IRS-3-null mice showed normal body weight throughout development, normal blood glucose levels in the fed and fasted state and following an oral glucose bolus, and normal fed and fasted plasma insulin levels. IRS-3 is most abundant in adipocytes and is tyrosine-phosphorylated in response to insulin in these cells. Therefore, isolated adipocytes were analyzed for changes in insulin effects, Insulin-stimulated glucose transport in the adipocytes from the IRS-3-null mice was the same as in wild-type cells. The extent of tyrosine phosphorylation of IRS-1/2 following insulin stimulation was similar in adipocytes from IRS-3-null and wild-type mice, and the insulin-induced association of tyrosine-phosphorylated IRS-1/2 with phosphatidylinositol 3-kinase and SHP-2 was not detectably increased by IRS-3 deficiency. Thus, IRS-3 was not essential for normal growth, glucose homeostasis, and glucose transport in adipocytes, and in its absence no significant compensatory augmentation of insulin signaling through IRS-1/2 was evident.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Lienhard, GE (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1998, DIABETES, V47, pA66; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CUSHMAN SW, 1978, J LIPID RES, V19, P269; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DOLE VP, 1956, J CLIN INVEST, V19, P269; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ross SA, 1998, BIOCHEM BIOPH RES CO, V247, P487, DOI 10.1006/bbrc.1998.8821; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; White MF, 1998, RECENT PROG HORM RES, V53, P119; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	30	126	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18093	18099		10.1074/jbc.274.25.18093	http://dx.doi.org/10.1074/jbc.274.25.18093			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364263	hybrid			2022-12-25	WOS:000080974300099
J	Sekimata, M; Kabuyama, Y; Emori, Y; Homma, Y				Sekimata, M; Kabuyama, Y; Emori, Y; Homma, Y			Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BINDING-PROTEIN; IN-VIVO; ACTIN; RAS; 5-KINASE; CALCIUM; RELEASE; DOMAIN	We recently cloned a novel signaling molecule, p122, that shows a GTPase-activating activity specific for Rho and the ability to enhance the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of phospholipase C delta 1 in vitro. Here we analyzed the in vivo function of p122, Microinjection of the GTPase-activating domain of p122 suppressed the formation of stress fibers and focal adhesions induced by lysophosphatidic acid, suggesting a GTPase-activating activity for Rho as in in vitro. Transfection of p122 also induced the disassembly of stress fibers and the morphological rounding of various; adherent cells. Analyses using deletion and point mutants demonstrated that the GTPase-activating domain of p122 is responsible for the morphological changes and detachment and that arginine residues at positions 668 and 710 and a lysine residue at position 706 in the GTPase-activating domain are essential. Using Fluo-3-based Ca2+ microscopy, we found that p122 evoked a rapid elevation of intracellular Ca2+ levels, suggesting that p122 stimulates the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of phospholipase C delta 1. These results demonstrate that p122 synergistically functions as a GTPase-activating protein specific for Rho and an activator of phospholipase C delta 1 in vivo and induces morphological changes and detachment through cytoskeletal reorganization.	Fukushima Med Coll, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan; Univ Tokyo, Fac Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan	Fukushima Medical University; University of Tokyo	Homma, Y (corresponding author), Fukushima Med Coll, Inst Biomed Sci, Dept Biomol Sci, 1 Hikariga Oka, Fukushima 9601295, Japan.							Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PerezTerzic C, 1997, CELL CALCIUM, V21, P275, DOI 10.1016/S0143-4160(97)90115-9; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Tribioli C, 1996, P NATL ACAD SCI USA, V93, P695, DOI 10.1073/pnas.93.2.695; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	30	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17757	17762		10.1074/jbc.274.25.17757	http://dx.doi.org/10.1074/jbc.274.25.17757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364218	hybrid			2022-12-25	WOS:000080974300054
J	Murakami, A; Thurlow, J; Dickson, C				Murakami, A; Thurlow, J; Dickson, C			Retinoic acid-regulated expression of fibroblast growth factor 3 requires the interaction between a novel transcription factor and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-2; BINDING PROTEIN; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; MOUSE; FAMILY; DIFFERENTIATION; PROMOTER	fgf-3 shows a complex spatial-temporal pattern of transcription during mouse development, and the gene product appears to be an important intercellular signaling molecule. Here we show that the major enhancer, which is obligatory for transcription, is composed of three elements with different properties. Both functional analyses in undifferentiated and differentiated F9 cells and characterization of DNA-protein complexes in vitro have identified the sequence motifs GTGACT(C), ATTGT, and GATA as the key transcription factor binding sites. The GTGACT(C) motif, while not essential, is required for full enhancer activity. However, binding at ATTGT is crucial for transcriptional activity and is required for cooperative binding at the proximal GATA site. The GATA binding site mediates the retinoic acid/ dibutyryl cyclic AMP stimulation of transcription and correlates with the binding of Gata-4 which is induced by retinoic acid in differentiating F9 cells. The ATTGT and GATA motifs are inactive when placed separately on a minimal thymidine kinase (TK) promoter, but together they act as a strong retinoic acid-regulated enhancer. In undifferentiated F9 cells, gata-4 expression stimulates the fgf-3 promoter, whereas in differentiated F9 cells already expressing gata-4, no further increase in promoter activity was observed.	Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England; Kyoto Univ, Inst Virus Res, Dept Virol Oncol, Sakyo Ku, Kyoto 6068507, Japan	Cancer Research UK; Kyoto University	Dickson, C (corresponding author), Imperial Canc Res Fund, Lincolns Inn Fields, POB 123, London WC2A 3PX, England.	C.Dickson@icrf.icnet.uk						ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bielinska M, 1997, MECH DEVELOP, V65, P43, DOI 10.1016/S0925-4773(97)00053-1; BIELINSKA M, 1995, BIOCHEM J, V307, P183, DOI 10.1042/bj3070183; Brown T., 1997, CURRENT PROTOCOLS MO; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO LC, 1991, EMBO J, V10, P1187; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jiang YM, 1998, DEV GENET, V22, P263, DOI 10.1002/(SICI)1520-6408(1998)22:3<263::AID-DVG8>3.0.CO;2-4; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wang CY, 1996, MOL CELL BIOL, V16, P712; WANG SY, 1994, J BIOL CHEM, V269, P607; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J	40	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17242	17248		10.1074/jbc.274.24.17242	http://dx.doi.org/10.1074/jbc.274.24.17242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358083	hybrid			2022-12-25	WOS:000080780400082
J	Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ				Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ			Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells	ONCOGENE			English	Article						MAP kinases; TPCK; apoptosis; c-Raf-1; Bcl-2	INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; DNA FRAGMENTATION; KINASE ACTIVATION; LEUKEMIA-CELLS; T-LYMPHOCYTES; CANCER CELLS; RAF-1; INVOLVEMENT	The mechanism of Taxol-induced apoptosis was investigated in MCF-7 human breast carcinoma cells, Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases, The serine protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) effectively blocked apoptosis, but N-p-tosyl-L-lysine chloromethyl ketone (TLCK), another serine protease inhibitor, was without effect. TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment. The serine protease inhibitor did not alter JNK activity, but it enhanced Taxol-induced activation of ERK1/2 Treatment of cells with the inhibitor of MEK activation, PD98059, prevented Taxol-induced ERK activation both in the presence and absence of TPCK, but did not influence survival of either Taxol- or Taxol plus TPCK-treated cells. In addition, PD98059 had no effect on c-Raf-1 or Bcl-2 phosphorylation, Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation, In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes.	NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NCI, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; BAKER ME, 1977, NATURE, V269, P810, DOI 10.1038/269810a0; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dong Z, 1997, AM J PATHOL, V151, P1205; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Guyton KZ, 1996, CANCER RES, V56, P3480; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Huang Y, 1997, APOPTOSIS, V2, P199, DOI 10.1023/A:1026420616484; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR N, 1981, J BIOL CHEM, V256, P435; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Sebestyen A, 1997, ANTICANCER RES, V17, P2609; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TUDELA J, 1986, INT J BIOCHEM, V18, P285, DOI 10.1016/0020-711X(86)90121-7; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON WE, 1989, J BIOL CHEM, V264, P17777; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	61	73	76	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3431	3439		10.1038/sj.onc.1202685	http://dx.doi.org/10.1038/sj.onc.1202685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376521				2022-12-25	WOS:000080850600001
J	Wang, S; Nath, N; Adlam, M; Chellappan, S				Wang, S; Nath, N; Adlam, M; Chellappan, S			Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function	ONCOGENE			English	Article						Rb; E2F; cell cycle; transformation; tumor suppression	CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE-PRODUCT; HISTONE DEACETYLASE; VIRAL ONCOPROTEINS; DEPENDENT KINASES; BREAST-CANCER; REPRESS TRANSCRIPTION; BINDING PROTEIN; MESSENGER-RNA	The retinoblastoma tumor suppressor protein and its family members, p107 and p130, are major regulators of the mammalian cell cycle. They exert their growth suppressive effects at least in part by binding the E2F family of transcription factors and inhibiting their transcriptional activity. Agents that disrupt the interaction between Rb family proteins and E2F promote cell proliferation. Here we describe the characterization of a novel interaction between Rb family proteins and a potential tumor suppressor protein, prohibitin. Prohibitin physically interacts with all three Rb family proteins in vitro and in vivo, and was very effective in repressing E2F-mediated transcription. Prohibitin could inhibit the activity of E2Fs 1, 2, 3, 4 and 5, but could not affect the activity of promoters lacking an E2F site. Surprisingly, prohibitin-mediated repression of E2F could not be reversed by adenovirus E1A protein. A prohibitin mutant that could not bind to Rb was impaired in its ability to repress E2F activity and inhibit cell proliferation. We believe that prohibitin is a novel regulator of E2F activity that responds to specific signaling cascades.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA	Columbia University; Columbia University	Chellappan, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COBRINIK D, 1996, CURR TOP MICROBIOL I, V208, P32; CORBEIL HB, 1995, ONCOGENE, V11, P909; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Franklin D.S., 1993, J CELL BIOCHEM, V17D, P159; GRANA X, 1995, ONCOGENE, V11, P211; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JIANG H, 1995, IN PRESS ONCOGENE, V11; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNAIEF JL, 1994, CELL, V79, P119; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; Kohn KW, 1998, ONCOGENE, V16, P1065, DOI 10.1038/sj.onc.1201608; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; MEYERSON M, 1992, GENE DEV, V6, P1874; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QIN XQ, 1995, MOL CELL BIOL, V15, P742; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; SATO T, 1992, CANCER RES, V52, P1643; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUTHERLAND RL, 1995, ACTA ONCOL, V34, P651, DOI 10.3109/02841869509094043; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, SCIENCE, V243, P934; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhang YH, 1996, MOL CELL DIFFER, V4, P297	81	194	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3501	3510		10.1038/sj.onc.1202684	http://dx.doi.org/10.1038/sj.onc.1202684			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376528				2022-12-25	WOS:000080850600008
J	Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G				Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G			Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex	ONCOGENE			English	Article						cyclin B1 promoter; muscle differentiation; CCAAT-binding factor NF-Y	RNA POLYMERASE-II; DEPENDENT REGULATION; MAMMALIAN-CELLS; BREAST-CANCER; FISSION YEAST; S-PHASE; EXPRESSION; PROTEIN; PROMOTER; KINASE	The observation that cyclin B1 protein and mRNAs are down-regulated in terminally differentiated (TD) C2C12 cells, suggested us to investigate the transcriptional regulation of the cyclin B1 gene in these cells. Transfections of cyclin B1 promoter constructs indicate that two CCAAT boxes support ca clin BI promoter activity in proliferating cells. EMSAs demonstrate that both CCAAT boxes are recognized by the trimeric NF-Y complex in proliferating but not in TD cells. Transfecting a dominant-negative mutant of NF-YA me provide evidence that NF-Y is required for maximal promoter activity. Addition of recombinant NF-YA to TD C2C12 nuclear extracts restores binding activity in vitro, thus indicating that the loss of NF-YA in TD cells is responsible for the lack of the NF-Y binding to the CCAAT boxes, Consistent with this, we found that the IVF-YA protein is absent in TD C2C12 cells. In conclusion, our data demonstrate that NF-Y is required for cyclin B1 promoter activity. We also demonstrate that cyclin B1 expression is regulated at the transcriptional level in TD C2C12 cells and that the switch-off of cyclin B1 promoter activity in differentiated cells depends upon the loss of a functional NF-Y complex. In particular the loss of NF-YA protein is most likely responsible for its inactivation.	Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, I-00158 Rome, Italy; Univ Milan, Dipartimento Genet & Biol Microganismi, I-20133 Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan	Piaggio, G (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, Via Messi Oro 156, I-00158 Rome, Italy.		Fontemaggi, Giulia/K-9702-2016; CENCIARELLI, CARLO/AAC-1603-2019; Piaggio, Giulia/J-7214-2018; Manni, Isabella/ABH-6460-2020; Piaggio, Giulia/AAD-7336-2022	Fontemaggi, Giulia/0000-0001-8332-8842; CENCIARELLI, CARLO/0000-0001-7480-4608; Piaggio, Giulia/0000-0003-2114-1892; Manni, Isabella/0000-0003-4823-0596; 	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Farina A, 1996, ONCOGENE, V13, P1287; Fromm L, 1996, ONCOGENE, V12, P69; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEYHYDE J, 1992, GENOMICS, V13, P1018, DOI 10.1016/0888-7543(92)90015-K; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HWANG A, 1995, J BIOL CHEM, V270, P28419; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; Osada S, 1996, J BIOL CHEM, V271, P3891; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; Sambrook J., MOL CLONING LAB MANU; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHAO JZ, 1995, NEUROSCI LETT, V190, P49, DOI 10.1016/0304-3940(95)11497-K; ZORBAS H, 1992, J BIOL CHEM, V267, P8478; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	45	97	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2818	2827		10.1038/sj.onc.1202472	http://dx.doi.org/10.1038/sj.onc.1202472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362252				2022-12-25	WOS:000080125100004
